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There has been a resurgence in interest in lysosomes based on exciting new discov-
eries over the past decade. Lysosomal function was observed microscopically in the
late 19th century, and lysosomes were purified in the 1950s by the group of Chris-
tian De Duve [1]. During the same period, accumulation of undigested material in
cells was observed in pathological examination of tissues from patients with a variety
of diseases [2–4]. With the biochemical and morphological characterization of lyso-
somes, the linkage of the accumulated material with these organelles led to significant
insights into the functional importance of lysosomes.
In the second half of the 20th century, there were groundbreaking studies of the
biology and biochemistry of lysosomes [5–9]. These studies were linked closely with
rapid developments in understanding fundamental cellular biological processes such
as secretion and endocytosis. As a result, an increasingly detailed picture emerged of
the biogenesis of lysosomes and their functional role in digesting internalized cargo
[10,11]. As understanding of lysosomal function increased, mechanism-based strate-
gies for treating lysosomal diseases emerged. These included substrate reduction
therapies (e.g., for Gaucher disease) [12,13] and enzyme replacement therapies [14].
While there continued to be advances in basic cell biology and biochemistry,
as well as in new therapeutic modalities, many investigators had a sense that the
exciting era of discovery in lysosome biology was ending in the early 2000s. As an
example, the Gordon Conference on “Lysosomes,” which for many years was one
of the premier meetings on membrane traffic, changed its name to “Lysosomes and
Endocytosis” in 2004.
Several related areas of investigation have blossomed over the past decade, and





biochemistry. One of these areas is autophagy. This process for lysosomal digestion
of cytoplasmic organelles had been known for decades, but there were few handles
on how to study it. With genetic studies leading to identification of key molecular
components in the formation of autophagosomes and their subsequent fusion with
lysosomes, it became possible to analyze this process in detail. As a result, autophagy
is now recognized as playing a key role in processes including maintenance of
organelle integrity, catabolism of lipid droplets, and responses to stress [15,16]. Addi-
tionally, autophagy is essential for the survival and proliferation of some cancer cells,
making it a novel target for development of therapies [17,18]. Furthermore, genetic
and molecular biological data accentuate the broad importance of the lysosome
in aging and age-related diseases, including cardiovascular and neurodegenerative
diseases, which make improving lysosome function an attractive target.
One of the most exciting recent developments has been the recognition that
lysosomes are key regulators of signaling processes that regulate metabolism. The
elucidation of the mTOR signaling pathways has shown that hydrolytic activity in
lysosomes is used by the cell to sense nutrient status [19]. Among other activities,
mTOR regulates autophagy to enhance the availability of new molecular building
blocks when lysosomal production of catabolites is reduced. In another related
area, it was recognized a few years ago that there is a coordinated transcriptional
regulation of the genes involved in lysosome biogenesis [20,21].
Along with these basic science developments, there have been important advances
in the understanding of lysosomal storage disorders and in newmethods for treatment.
In some cases, this is beginning to turn these devastating diseases into conditions that
can be managed. At the same time, there is increasing recognition that drugs used
for various purposes can interact with lysosomal processes. A dramatic example of
this is the discovery of mTOR as amechanistic target for the immunosuppressive drug
rapamycin [22]. Many pharmacological drugs in widespread use can affect lysosomal
function [23–26], and it is important to understand the impact of these effects.
With all of these interrelated advances in understanding of lysosome biology, it
seemed worthwhile to assemble an updated and integrated book on lysosomes. There
are several notable earlier books on lysosomes, and a few of them will be cited here
with apologies to the authors whose contributions may have been overlooked. Eric
Holtzman [27] wrote a classic monograph that is still worth reading for its historical
background and insights into the role of lysosomes in biology. This was followed a
few years later by a book by Brian Storrie and Robert Murphy [28]. A book by Paul
Saftig [29] focused on the basic biology and function of lysosomes. There have been
several excellent books on lysosomal storage disorders, including one by Fran Platt
and Steven Walkley [30]. More recently, there was a book emphasizing methods for
the study of lysosomes [31].
The current book is intended for a broad audience of researchers interested in
multiple facets of lysosome biology. Chapters 1–7 and 12 cover fundamental roles of
lysosomes in physiological processes; Chapters 8–11 discusses involvement of lyso-
somes in various pathological conditions; Chapters 13–20 focus on the contribution of




as a target for drug discovery, toxicity, and special pharmacokinetics attributed to
lysosomal accumulation and sequestration
We thank all contributors who provided their chapters despite other pressing
responsibilities. We also thank our editors for their diligent effort and David B. Iaea
for the cover illustration.
We hope that the broad scope, which includes both basic science and clinical appli-
cations, can promote a productive interchange among scientists working across the
spectrum of lysosomal studies and nurture drug development efforts targeting lyso-
some pathways. Ultimately, discovery of new drugs that could improve lysosomal
function will benefit multiple therapeutics areas.
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Late endosomes and lysosomes (LE/Ly) are the main digestive organelles of
eukaryotic cells. They contain a variety of enzymes and accessory proteins [1] that
are capable of the hydrolysis of many biological molecules. The LE/Ly are main-
tained at an acidic pH, and most lysosomal enzymes are acid hydrolases with acidic
pH optima. Substrates are delivered to LE/Ly either by endocytic processes (e.g.,
receptor-mediated endocytosis, pinocytosis, and phagocytosis) or by autophagic
processes in which autophagosomes containing cellular content fuse with the LE/Ly.
The history of lysosomal studies has been discussed in several publications [2–5].
The study of lysosomal digestion began in the late 19th century with microscopic
observations of cells ingesting material. In the same period, physicians began to see
abnormal storage of material in pathology specimens from patients with unusual ill-
nesses. In the 1950s and 1960s, lysosomes were purified by differential centrifugation
techniques, and the linkage was established between these organelles and the micro-
scopic observations of storage material in what then became known as lysosomal
storage diseases. These discoveries were followed by contributions from many labo-
ratories that have led to a fairly detailed understanding of the biogenesis, composition,
and function of lysosomal organelles.
There have been several recent advances in our understanding of lysosomal func-
tion. In particular, we now have a much better understanding of the mechanisms
underlying the regulation of lysosome formation (see Chapters 2 and 7). In addition,
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2 LYSOSOMES: AN INTRODUCTION
while autophagy has been known for many years, there have been dramatic increases
in our understanding of its molecular mechanisms in the past decade (see Chapter 2).
A brief note about nomenclature may be useful. As with other organelles, the
acidic digestive organelles are heterogeneous and undergo rapid changes due to vari-
ous membrane trafficking processes. Several years ago, a definition was proposed [6]
in which the organelles that were actively receiving new lysosomal enzymes from
the trans-Golgi network would be called late endosomes, while more mature acidic
digestive organelles would retain the name lysosomes. This distinction remains use-
ful in describing two broad groups of acidic digestive organelles, but it does lead to
some semantic difficulties. For example, in many cells, digestion of endocytosed pro-
teins by lysosomal hydrolases occurs mainly in the late endosomes. Thus, “lysosomal
digestion” is nearly complete before the endocytosed material can enter “lysosomes.”
In addition, even within the same cell there can be significant differences in the prop-
erties (size, morphology, enzyme content, substrate content, etc.) in organelles that
are broadly grouped as late endosomes or lysosomes. These difficulties arise because
of the intrinsically dynamic nature of these organelles, which are rapidly exchanging
membrane and lumenal content with each other and with other organelles. Unfortu-
nately, a completely accurate and descriptive terminology may not be possible.
1.1 HISTORICAL BACKGROUND
The study of lysosomes began with the microscopic observations summarized by
Metchnikoff [7] in the late 19th century. He and his contemporaries reported their
direct microscopic analysis on the uptake of foreign particles into cells, and the subse-
quent digestion of these particles. In some cases, Metchnikoff observed that ingested
pieces of litmus would change from blue to red, implying an acid environment sur-
rounding the ingested particles. Metchnikoff emphasized that aspects of phagocytic
uptake were evolutionarily conserved from single cell organisms through leukocytes
obtained from mammals.
One of the ongoing themes in studies of lysosomes is that there is a dynamic
interplay between the study of diseases and the contributions of basic science. In
parallel with the developments in the cell biology of digestion of internalized mate-
rial, there were descriptions beginning in the 19th century of various storage diseases
in which cellular accumulations of material were observed upon pathological exami-
nation of tissues from patients with a variety of diseases [3]. These included Gaucher,
Tay–Sachs [8], and Niemann–Pick diseases among others. Many of these storage dis-
orders were recognized to have a hereditary component, and several of themwere also
recognized to lead to accumulation of certain molecular species, especially lipids.
The modern era of lysosome study began with the purification of lysosomes
by Christian de Duve and his colleagues in the 1950s, and a review of these
discoveries presents many of the important details [5]. De Duve’s laboratory sought
to understand the localization of glucose-6-phosphatase in liver fractions as part of
study of the mechanisms of insulin action. Among the phosphatase activities that




could only be observed when membranes were disrupted. At first they considered
that this might suggest a mitochondrial localization, but improved centrifugation
techniques led to separation of the acid phosphatase fraction from the mitochondria.
In 1955, they published a paper describing isolation of particles that contained five
enzyme activities with acidic pH optima [9]. Alex Novikoff had also been working
on the distribution of various enzymes in cells. After visiting de Duve’s laboratory,
Novikoff carried out the first electron microscopic studies of the newly isolated
organelles. To do this, he would carry fresh samples from the de Duve laboratory
in Belgium to the new electron microscope available in the laboratory of Albert
Claude in Paris [10]. He observed that the fractions were enriched in dense bodies
about 370 nm in length, and he also noted that they resembled in many ways similar
structures observed in hepatocytes [11]. Working independently, Straus [12] isolated
“droplets” from rat kidneys and showed that these were enriched in acid phosphatase
and other enzymes [13]. Straus also showed that similar, but larger, droplets were
observed after intraperitoneal injection of egg white and reported that the injected
protein could be found in these droplets. This linked the degradative organelles with
the uptake of extracellular material.
After the discovery of lysosomes by de Duve and his coworkers, the idea that
lysosomal defects might be the underlying cause of the storage diseases began to be
considered. The clear demonstration of association of these storage disorders with
lysosomes was first made by Hers [14,15] when the defect in a glycogen storage
disease was shown to be a deficiency in the lysosomal enzyme acid maltase. This
was followed by the association of several of the storage disorders, now classified as
lysosomal storage disorders, with a deficiency in specific enzymes.
Work from Neufeld and others [16] showed that enzymes secreted by one cell
could be added to the culture medium of a cell lacking a particular enzyme and
correct the storage defect. It was found, however, that enzymes secreted from I-cell
disease fibroblasts could not correct the enzyme deficiencies in other cells. This and
other observations led to the hypothesis that there must be a tag of some type on
lysosomal enzymes and there must be receptors on the surface of cells that could
selectively endocytose the tagged enzymes [4]. Shortly thereafter, it was found
that the uptake of β-glucuronidase could be inhibited by mannose-6-phosphate
and that the uptake of the enzyme could also be blocked by pretreatment with a
phosphatase [17]. Mannose-6-phosphate glycoconjugates were then identified on
many lysosomal enzymes.
The cation-independent mannose-6-phosphate receptor was first isolated from
bovine liver in 1981 [18], and the sequence of the human receptor was determined
in 1988 [19]. It was found to be identical to an independently identified receptor for
insulin-like growth factor II (IGF-II) [20]. A second mannose-6-phosphate receptor
(the cation-dependent mannose-6-phosphate receptor) was identified in 1985 [21].
In 1978, Ohkuma and Poole [22], whowere colleagues of de Duve, used the uptake
of fluorescein–dextran into lysosomes to measure the pH of these organelles accu-
rately based on the pH dependence of fluorescein fluorescence. They also showed
that lysosomal acidification required ATP and that weak bases could increase the pH
of these organelles. Most of the lysosomal hydrolases have acidic pH optima, and it
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seems likely that this pH dependence is protective for events that lead to disruption
of lysosomes since the enzymes will have greatly reduced activity at cytoplasmic or
extracellular pH.
From the 1980s to the present, there has been an explosive growth in the number
of studies of various aspects of lysosome biology, and many aspects of lysosomal
biogenesis and function are becoming well understood. It is particularly gratifying
that understanding of the basic biochemistry and cell biology is leading to therapies
for several of the lysosomal storage disorders. In addition, understanding of endocytic
targeting to digestive organelles is leading to development of very selectively targeted
delivery of therapeutic agents. Many of these studies are summarized in the chapters
of this book.
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2.1 INTRODUCTION
Lysosomes degrade biological components acquired by endocytosis, the major
cellular pathway for internalization of extracellular material, and macroautophagy,
the main system in the cell for turnover of organelles and large cytoplasmic protein
aggregates. Endocytosis starts with the formation of an endocytic vesicle that buds
from the plasmamembrane and fuses with an early endosome (EE). EEs subsequently
mature into late endosomes (LEs), which eventually fusewith lysosomes (Figure 2.1).
Proteins not destined for degradation return to the plasma membrane directly from
EEs or via specialized recycling endosomes (REs). Macroautophagy begins with the
sequestration of parts of the cytoplasm by a cistern known as the phagophore or iso-
lation membranes, which expands into a double membrane vesicle called autophago-
some. The autophagosome fuses with LEs and/or lysosomes to form an amphisome
or an autolysosome, respectively (Figure 2.1). Autolysosomes are generally larger
and more irregularly shaped than lysosomes, with a highly variable content in which
sometimes remnants of cytoplasmic components, for example ribosomes or mito-
chondria, are seen (Figure 2.2; [1]). While the onset of autophagy is independent of
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Figure 2.1 Schematic drawing depicting the endocytic and autophagy pathways to the lyso-
somes. ALR, autolysosome reformation; CMA, chaperone-mediated autophagy; ILV, intralu-
minal vesicle; MVB, multivesicular body; PAS, phagophore assembly site. (See color plate













Figure 2.2 Gallery of electron micrographs providing characteristic examples of endolyso-
somal compartments. From (a) to (d) a sequence of early-to-late endolysosomal intermediates
is shown. Arrows in (a) and (b) point to the bilayered flat clathrin coat harboring protein
machinery involved in intraluminal vesicle (ILV) formation. Early endosomes (EE) and late
endosomes (LE) contain an increasing number of ILVs. Lysosomes (LY) show typical mem-
brane lamella. Pictures were taken from distinct cell models: (a) embryonic zebrafish, (b)
human prostate cancer (PC3) cell, (c) activated mouse B cell, (d) HeLa cell. ER, endoplasmic
reticulum; M, mitochondrion; RE, recycling endosome. Bar = 200 nm. (a–c). Courtesy of Ann
deMazière, Department of Cell Biology, UniversityMedical Center, Utrecht, The Netherlands.
endocytosis, the formation of autophagosomes requiresmembranes derived fromREs
and completion of the autophagy process, which is characterized by the degradation
and recycling to the cytoplasm of the encapsulated material, requires lysosomes.
This intimate connection is the reason behind the recognition that lysosome-related
disorders (LSDs) often affect both endocytosis and macroautophagy and abnormal-
ities in lysosomal functioning become more prominent under starvation conditions.
Over the past decades, important progress has been made to reveal the molecules and
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membrane compartments that underlie endocytosis and autophagy. In this chapter, we
give an overview of these two major degradative intracellular pathways and highlight
the emerging cross talks between them, in healthy and diseased conditions.
2.2 PATHWAYS TO THE LYSOSOMES
2.2.1 Biosynthetic Transport Routes to the Lysosome
Lysosomes contain more than 50 different hydrolytic enzymes involved in substrate
degradation and more than 150 lysosomal membrane proteins (LMPs) involved in
lysosome stability and regulation of the interior lysosomal milieu [2,3]. After synthe-
sis in the endoplasmic reticulum (ER), lysosomal proteins traverse the Golgi complex
to enter the trans-Golgi network (TGN),where themajority of the enzymes are directly
sorted to the endolysosomal system.Most of the soluble lysosomal enzymes are mod-
ified in the Golgi complex with mannose-6-phosphate (M6P) residues, which in the
TGN bind to a M6P receptor (MPR), that is, the 300 kDa cation-independent M6P
receptor (CI-MPR) or the 46 kDa cation-dependent M6P receptor (CD-MPR) [4].
MPRs with or without their cargo [5] enter clathrin-coated vesicles that travel directly
from the TGN to the EEs. This sorting step requires the heterotetrameric adaptor pro-
tein complex (AP)-1 and the Golgi-localized, γ-ear-containing, Arf-binding (GGA)
protein family, which recognize specific motifs in the cytosolic tail of the MPRs and
catalyze the recruitment of clathrin [6–8]. These clathrin-coated vesicles can also be
used for the sorting of LMPs from TGN to EEs [9,10].
In addition, a clathrin-independent transport route has recently been discovered
that delivers LMPs, but notMPRs, directly from the TGN to LE [11,12]. VPS41, orig-
inally identified as part of the yeast HOPS tethering complex, and the SNARE (solu-
ble N-ethylmaleimide-sensitive factor attachment protein receptors) protein VAMP7
are required for fusion of these TGN-derived carriers with LEs, but the signals that
sort LMPs into this pathway are still unresolved. Newly synthesized lysosomal hydro-
lases and LMPs that escape sorting in the TGN enter a default pathway to the plasma
membrane, where they can subsequently be targeted to lysosomes via endocytosis.
Low levels of the MPRs at the plasma membrane thereby mediate the endocytosis of
these secreted hydrolases [13].
2.2.2 Endocytic Pathways to the Lysosome
There are several distinct subtypes of endocytic vesicles that bud from the plasma
membrane and mediate entry into the cell. These differ by cargo and machinery
proteins and include dynamin- and/or clathrin-dependent and independent pathways
[14]. The commonly accepted model is that endocytic vesicles subsequently
fuse with each other or directly with preexisting EEs, a network of dynamically
interacting compartments at the cell’s periphery [15]. RAB GTPases are small
monomeric G proteins that can switch between an active (GTP-bound) and an
inactive (GDP-bound) state, which provide not only the means to spatially and
temporally control intracellular traffic and signaling but also organelle identity.
 
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EE-localized RAB5 is considered the master regulator of the endocytic pathway,
which exerts its action by attracting a variety of effectors proteins [16]. While most
EEs are positive for Rab5 and its effector EEA1, subpopulations of EEs with a
specific function exist, for example, EEs that lack EEA1 but contain RAB5 and
APPL1 or APPL2, two RAB5 effectors that act as intermediates in signaling between
the plasma membrane and the nucleus [17].
EEs have a mild pH of 5.9–6.8 and a complex structure consisting of a vacuo-
lar body with an approximate diameter of 100–500 nm, from which tubular mem-
brane domains emerge (Figure 2.2a and b). These tubules generate membrane car-
riers that fuse with either the plasma membrane (the so-called fast or direct recy-
cling pathway), the REs (the so-called slow or indirect recycling pathway), the TGN
[18,19], or the LEs [20,21]. Internalized cargo proteins destined for degradation in
lysosomes, such as the epidermal growth factor receptor (EGFR) and growth hor-
mone receptor (GHR), are retained in the EE vacuole by their incorporation into
intraluminal vesicles (ILVs) that form through the budding of the endosomal limiting
membrane (Figure 2.1). ILV formation starts in the EEs and continue in LEs. The pro-
cess of cargo selection and ILV formation generally involves the ubiquitin-dependent
ESCRT (endosomal sorting complexes required for transport) complexes, and also
other mechanisms have been described (for recent review, see Ref. [22]). Hrs and
STAM, two components of the ESCRT complex are localized to a characteristic bilay-
ered, flat clathrin coat that forms patches on the EE vacuole [23]. Cargoes destined
for lysosomal degradation, such as EGFR and GHR, are concentrated in this coat
via interaction between ubiquitin residues appended to them and ubiquitin-binding
domains in Hrs and STAM, whereas recycling proteins are not [24] implicating a role
for clathrin in retention and concentration of proteins prior to their sorting into ILVs.
Of note, the process of ILV formation is different from the process of microautophagy
occurring at the lysosome.
EEs mature into LEs through a mechanism that involves multiple rounds of
membrane fusion and fission during which the protein and lipid composition of the
EEs change and they acquire more ILVs. This results in globular-shaped LEs with
an approximate diameter of 250–1000 nm and a pH of ∼5–6. They also contain
numerous ILVs and for this reason they are often also termed multivesicular bodies
(MVBs) (Figure 2.2c). During the EE to LE maturation, Rab5 is replaced by Rab7
and the phosphoinositides phosphatidylinositol-3-phosphate (PI3P) is converted
into phosphatidylinositol-3,5-biphosphate [25,26]. The RAB5/RAB7 switch also
requires a cytosolic complex formed by SAND1/Mon1 and Ccz1, which depends on
PI3P concentrations [27] and acts as the activating guanosine exchange factor (GEF)
for RAB7 [28,29]. For a detailed list of the changes accompanying the EE to LE
switch, see the reviews [2,30].
LEs can fuse with other LEs (homotypic fusion) or with lysosomes (heterotypic
fusion). Lysosomes are vacuoles with an approximate diameter of 200–1000 nm and
a pH of 4.5–5 (Figure 2.2d). The shape and content of lysosomes are more heteroge-
neous (Figure 2.2d) than that of LEs and depend on the type and amount of cargo,
degree of degradation and also on the cell type. Degradation of cargo starts in LEs
but is optimal in lysosomes. Glycoproteins, oligosaccharides, and also lipid bilayers
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and DNA/RNA are degraded in lysosomes into basic metabolites, including amino
acids and sugars, which are then released into the cytosol through lysosomal mem-
brane transporters. Here they can be used for either de novo synthesis of cellular
constituents or as a source of energy [31].
REs are generated as tubules with a 60–100 nm diameter that can extend over a
distance of several micrometers, a pH of ∼6.4, which form from the nonclathrin-
coated areas of the main EE vacuole (Figure 2.2a). In some cells, REs associate into
an endosomal recycling compartment that is typically located near the microtubule-
organizing center in the perinuclear area (reviewed by Ref. [22]). REs are generally
defined by the presence of RAB4 [32,33], RAB11 [34–36], the RAB11-FIP family of
RAB11-interacting proteins, and the SNAREs cellubrevin/VAMP3 and syntaxin 13.
Members of the large protein family of sorting nexins (SNXs) have been attributed
to distinct recycling pathways emerging from REs [37]. SNXs can detect and/or
induce membrane curvature and, thus, mediate the formation of tubules. REs consist
of (a network of) branched tubules with multiple (clathrin-coated) buds [38], which
form exits from which cargo proteins can travel to distinct cellular destinations [19].
While most pathways emerging from REs divert from the degradative track, RE can
also be an intermediate station en route to the lysosomes. The adaptor protein AP-3
is associated with an RE exit that transports LMPs from REs to LEs/lysosomes
[20,21]. Hence, LMPs that reach REs can via this AP3-mediated exit be transported
back toward the main degradative pathway to the lysosomes.
2.2.3 Autophagy Pathways to the Lysosome
Lysosomes are not only reached by endocytosis but also by autophagic processes.
Three autophagic transport pathways deliver cytoplasmic components for turnover
in the lysosome: chaperone-mediated autophagy (CMA), microautophagy and
macroautophagy (Figure 2.1). CMA is devoted to the transport of specific cytoplas-
mic proteins, while microautophagy and macroautophagy also deliver other cellular
constituents, including large protein complexes, aggregates, and organelles.
Proteins destined for degradation by CMA possess a KFERQ motif or pseudo-
KFERQ sequences, which are generated through regulated posttranslational modi-
fications such as phosphorylation and acetylation [39]. Recognition of these motifs
by the cytosolic chaperone HSC70 leads to substrate recruitment onto the surface of
lysosomes. There, the targeted substrates bind to monomeric LAMP-2A, triggering
the assembly of this LMP into a high-molecular-weight complex, which mediates
translocation of the associated protein into the lysosomal lumen, an event that also
requires the intralysosomal form of HSC70 [39]. CMA is thus directly dependent on
the function of LMPs, providing an example for the intricate relationship between the
endocytic and the autophagy pathways at the molecular level.
Microautophagy is generally described as a process that involves the selection
of a specific cargo at the lysosomal limiting membrane, followed by an inward
invagination and a pinching-off event, which lead to the sequestration of the cargo
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Macroautophagy, hereafter referred to as autophagy, is the most widely studied
form of autophagy and characterized by the sequestration of cytoplasmic cargoes
by autophagosomes (Figure 2.1). This type of autophagy is used for the degrada-
tion of a wide range of substrates, which differ in origin and size. Upon autophagy
induction, the conserved factors involved in this pathway, the autophagy-related (Atg)
proteins, assemble at a specialized site that has been named the phagophore assem-
bly site or the preautophagosomal structure (PAS). The precise ultrastructure of the
PAS is not known, but it is considered the organizational center of the autophagy
machinery. At the PAS, the ATG proteins together with specific SNAREs, putatively
mediate the biogenesis of the phagophore (Figure 2.3) by orchestrated fusion of
Golgi-, RE-, and plasma membrane-derived membranes [42–44]. The ATG proteins
are also involved in the subsequent elongation of the phagophore into an autophago-
some, a process that requires acquisition of extra membranes. The frequent proximity
and contact points between the growing phagophores and the ER have led to the
hypothesis that lipids necessary for membrane elongation can directly transfer from
the ER to nascent autophagosomes [45–47]. By contrast, the involvement of ER
exit sites (ERES) in autophagy has underlined the possibility that vesicular traffic
could also play a critical role [48,49]. Growing phagophores are also often detected
adjacent to the ER–mitochondria contact sites [50,51], explaining how mitochondria
could also be involved in supplying membranes, possibly by direct lipid transfer [52].
Complete autophagosomes fuse with LEs or lysosomes to enable cargo degradation
(Figure 2.3). Like for the endocytic cargo, the resulting metabolites are transported
into the cytoplasm by lysosomal membrane transporters. Moreover, this flux of amino
acids provides a feedback mechanism to stop autophagy and restore lysosome forma-





Figure 2.3 Electron micrograph showing the three main intermediates of macroautophagy:
phagophore, autophagosome and autolysosome. Picture taken from Akt knockdown human
prostate cell (PC3) [41]. ER, endoplasmic reticulum. Bar= 200 nm. Courtesy of Ann de Maz-
ière, Department of Cell Biology, University Medical Center, Utrecht, The Netherlands.
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2.2.4 The ATG Proteins: The Key Regulators of Autophagy
The central actors of the autophagy process are the ATG genes. Based on their
organization in complexes and interactions, the ATG genes have been divided
into five functional clusters that compose the core autophagy machinery [53,54]
(Figure 2.4). Autophagosome biogenesis is initiated by the ULK/ATG1 complex,
composed of the ULK1 or ULK2 kinase, ATG13, FIP200, and ATG101. Activation
of the ULK complex and subsequent translocation from the cytosol to the PAS,
possibly from REs, triggers the assembly of the rest of the autophagy machinery.
Several signaling cascades regulating autophagy, including the one centered around
mTOR, modulate the kinase activity of the ULK complex [55]. In particular,
phosphorylation of the subunits of the ULK/ATG1 complex leads to recruitment of
the autophagy-specific class III phosphatidylinositol 3-kinase (PtdIns3K) complex
to the PAS [56,57]. This complex is formed by VPS34, p150, BECLIN1/ATG6, and






































Figure 2.4 Schematic overview of the distinct Atg complexes required for autophagy. The
ULK and PtsIns3K complex and the ATG9 cycling system are key in the organization of the
PAS and biogenesis of the phagophore. The two ubiquitin-like systems appear to be mostly
involved into the elongation of the phagophore into an autophagosome. WIPIs is a protein
family with four members, that is, WIPI1-4. LC3/ATG* is composed of six proteins: LC3A–C
and GABARAPL1–3. There are also four isoforms of ATG4, that is, ATG4A–D.
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also regulate PtdIns3K complex localization and activity [53,54]. The generation of
phosphatiylinositol-3-phosphate (PtdIns3P) at the PAS also triggers the recruitment
of WIPI (WD-repeat protein interacting with phosphoinositides) proteins and
DFCP1, two other proteins that mediate the formation of the phagophore and
associate to membrane through binding PtdIns3P [53,54]. In this context, it is
interesting to note that RAB5 can bind VPS34 and Beclin1 subunits of the PtdIns3K
complex and that this interaction is relevant to the regulation of autophagy [58].
Another protein essential for the initial steps of autophagosome formation is the
transmembrane protein ATG9, which together with ATG2 and members of the WIPI
protein family, at least WIPI4, forms a second functional cluster [53,54]. ATG9 local-
izes to different compartments of the endolysosomal system, that is, REs, TGN, LE,
and plasma membrane, and dynamically associates with the PAS [44,59,60]. While
the precise function of ATG9 is still unknown, it has been proposed that it is required
to provide some of the initial membranes that organize the PAS [61,62]. Together
with the ULK and PtdIns3K complexes, ATG9 is therefore considered a key factor
in generating the phagophore.
The subsequent elongation and closure of the phagophore cistern is driven by
two ubiquitin-like conjugation systems: ATG7/ATG10/ATG5/ATG12 and ATG7/
ATG3/ATG8. In the first, the E1-like ATG7 and the E2-like ATG10 enzymes cova-
lently link the ubiquitin-like protein ATG12 to ATG5. The ATG12–ATG5 conjugate
subsequently associates toATG16L1 [53,54]. TheATG12–ATG5/ATG16L1 complex
then recruits the second ubiquitin-like conjugation system to the PAS [53,54] by con-
jugating phosphatidylethanolamine (PE) to members of the LC3 (or ATG8) protein
family (LC3A, LC3B, LC3C, GABARAP-L1, GABARAP-L2, and GABARAP-L3)
[63]. All the members of this protein family are posttranslationally processed at their
C-terminus by ATG4 to generate the nonlipidated LC3-I form. Upon autophagy
induction, LC3-I is conjugated to PE on both the inner and outer membranes of the
growing phagophore through the action of ATG7, the E2-like enzyme ATG3 and the
ATG12–ATG5/ATG16L1 complex. The lipidated form of LC3, known as LC3-II,
is a multitask factor. Together with the ATG5–ATG12/ATG16L1 complex, LC3-II
is thought to form a protein coat that drives the formation of autophagosomes,
possibly by deforming membranes [64]. Moreover, LC3-II appears to have fusogenic
properties [65,66] that could be essential for sealing the growing phagophore and/or
the subsequent fusion of autophagosomes with lysosomes [67,68]. Finally, LC3-II is
involved in microtubule-dependent transport of autophagosomes toward lysosomes
by interacting with microtubules and motor proteins [69].
Under starvation conditions, the autophagy pathway is a nonselective process for
bulk degradation of cytoplasmic components. However, there are numerous situa-
tions in which cells can use autophagy to specifically eliminate unwanted structures,
including damaged or superfluous organelles, and invadingmicroorganisms [70]. The
selective types of autophagy rely on autophagy receptors, which mediate the specific
sequestration of cargo into autophagosomes. Autophagy receptors simultaneously
bind to both the cargo and the pool of LC3-II present at the internal surface of the
growing autophagosome [70,71]. The interaction between LC3 and the autophagy
receptors is in most cases mediated through a specific amino acid sequence in the
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autophagy receptors: the LC3-interacting region (LIR) or Atg8-interacting motif
(AIM) [70,71]. The binding of autophagy receptors to the cargo, in contrast, involves
either the recognition of a specific determinant (e.g., in case of yeast Atg32 and
mammalian NIX with mitochondria) or the interaction between an ubiquitin-binding
domain present within the autophagy receptors (e.g., p62/SQSTM1 and NBR1) with
ubiquitin moieties conjugated to the cargo.
2.3 FUSION AND FISSION BETWEEN THE ENDOLYSOSOMAL
AND AUTOPHAGY PATHWAYS
Cross talk between the endocytic and autophagic pathways occurs at many levels:
transcriptional regulation, protein sharing, and compartmental connections. A center
stage in the regulation of these interactions is taken by the transcription factor EB
(TFEB) and the mTORC1 complex. For recent reviews hereon, we refer to Ref. [72]
and Chapter 7 of this book. Here we focus on the fusion and fission events between
compartments of the endolysosomal system and autophagic membranes, respectively.
2.3.1 Recycling Endosomes and Autophagosome Biogenesis
An interaction between endocytic vesicles, ATG proteins, and REs occur at an early
stage of autophagosome biogenesis. In particular, plasma membrane–associated
ATG9 can enter clathrin-coated vesicles to travel to EEA1-positive EEs [44]. By
contrast, cytoplasmic ATG16L associates with a distinct pool of clathrin-coated
endocytic vesicles, which fuse between themselves and with Rab11-positive REs
thus bypassing EEA1-positive EEs [43,73], which very likely are also positive for
ULK1 [74]. The membrane deforming PX-BAR protein SNX18 facilitates delivery
of ATG16L1 to the REs [75]. ATG9-positive recycling tubules emerging from
EEA1-positive EEs can subsequently fuse with ATG16L1/RAB11 positive REs,
which bring together these two proteins, a step that appears to be critical to initiate
phagophore formation. The SNARE critical for the fusion of ATG9 and ATG16L1
positive membranes is VAMP3, which is present on REs. Knockdown of VAMP3
results in the accumulation of ATG9 in EEs and a decrease in autophagosome
formation [44]. Several studies have shown that vesicles derived from REs are
recruited to the site where autophagosomes are formed [44,74], a process that
is increased upon autophagy induction [74,76]. Overexpression of the putative
RabGAP TBC1D14, which associates to ULK1, impairs autophagosome formation
while Rab11 depletion blocks autophagy [74]. The Rab substrate for TBC1D14 is
still unknown. It binds activated RAB11 but is not a GAP for RAB11. Altogether,
these data show that membrane traffic from EEs to REs is involved in autophagosome
formation and that REs can probably serve as a membrane source and key regulator
for the early stages of autophagosome biogenesis.
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2.3.2 Autophagosome Fusion with Late Endosomes and Lysosomes
When complete, autophagosomes first fuse with LE to form amphisomes and then
with lysosomes, thus generating autolysosomes [1]. In addition, lysosomes can fuse
directly with an autophagosome to also form autolysosomes. The relevance of amphi-
somes is underlined by the fact that disruption of LE homeostasis, for example, by
deleting ESCRT complex subunits, leads to the accumulation of autophagosomes and
impairs the progression of autophagy [77]. Efficient fusion between lysosomes and
autophagosomes requires the coordinated transport of these two organelles to the
perinuclear area [78,79]. Starvation causes an increase in the intracellular pH, which
induces lysosome relocalization to the perinuclear area [79,80]. Under the same con-
ditions, mTORC1 inhibition triggers the formation of autophagosomes, which are
transported to the same region of the cell by an interaction with microtubules [69].
The molecular mechanism regulating fusion of autophagosomes with lysosomes
has not yet been fully established, but some key players are identified. Importantly,
all the factors that have been involved so far in the RAB7-dependent fusion of LEs
with lysosomes have also been shown to be essential for autolysosome formation.
In both yeast and mammalian cells, impairment or deletion of Rab7 results in the
accumulation of autophagosomes, indicating that this Rab GTPase is required for
autophagosome–LE/lysosome fusion [81–83]. The hexameric homotypic fusion and
protein sorting (HOPS) complex is a downstream effector of Rab7 involved in mem-
brane tethering [84–86]. Recent studies in Drosophila and mammalian cells showed
that loss of each of the six HOPS subunits results in the accumulation of autophago-
somes and a block in the degradation of the autophagic cargo [84,86]. Moreover, the
GEF of RAB7, the SAND1/Mon1 and Ccz1 complex, is also essential for fusion of
autophagosomes with the vacuole at least in yeast [87].
More than 30 SNAREs safeguard fusion specificity and drive the fusion process in
mammalian cells. Several SNAREs located in the endolysosomal system have been
shown to be involved in the fusion of yeast autophagosomes with vacuoles, but until
lately no SNAREs were found on autophagosomes. It was shown in both Drosophila
and mammalian cells that upon starvation the SNARE SYNTAXIN17 redistributes
in part from an ER/mitochondria onto autophagosomes [88,89]. The recruitment of
SYNTAXIN17 to autophagosomes is reduced by mutations in the two glycine-rich
transmembrane motifs that appear to regulate the solubility of this protein [89], but
it is still unclear how the translocation of syntaxin 17 is spatially and temporarily
regulated. On the autophagosome, SYNTAXIN17 binds and recruits the HOPS com-
plex and associates with the lysosomal SNAREs SNAP-29 and VAMP8 to carry out
its fusogenic function [86,88,89]. Depletion of SYNTAXIN17 results in the accumu-
lation of autophagosomes, underscoring its importance in autolysosome biogenesis
[86,88]. Interestingly, SYNTAXIN17 was originally localized to the smooth ER and
implicated in the dynamics of this compartment in steroidogenic cells [90]. At least
in partial agreement with this original observation, a subpopulation of SYNTAXIN17
also binds ATG14L and recruits it to ER–mitochondria contact sites, where it has been
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proposed to be important for autophagosome formation [51].Whether SYNTAXIN17
is also present in isolation membranes remains a subject of debate [51,91].
Besides these classical fusion machinery proteins, more unexpected proteins are
also important for the fusion between autophagosome and lysosome. For example,
in patients suffering from Danon disease, the LAMP-2 deficiency causes an accumu-
lation of autophagosomes leading to cardiomyopathy and myopathy [92]. Similarly,
pancreatitis due to the depletion of LAMP-2 from a combination of alcohol exposure
and endotoxemia correlates with the accumulation of autophagosomes and a rela-
tive paucity of autolysosomes [93]. How LAMP-2 participates in the fusion between
autophagosomes and lysosomes is unclear.
2.3.3 Autophagic Lysosomal Reformation
Cells under sustained starvation lose their lysosomes (an event accompanied by the
formation of autolysosomes) within 4 h but show a restored lysosome population
after 8 h [94]. An important source for these de novo formed lysosomes is a
process called autophagic lysosomal reformation (ALR) ([94]; Figure 2.1). The
onset of ALR is accompanied by the generation of long tubules that extend in a
microtubule-dependent manner from autolysosomes. Interestingly, these tubules
are positive for LAMP-1 but are nonacidic and lack lysosomal enzymes, such as
cathepsin D, which remains segregated in the vacuolar body of autolysosomes.
The LAMP-positive tubules detach from the autolysosome through vesiculation
and form globular compartments that have been named protolysosomes. It has
been hypothesized that these catabolically inactive organelles are involved in the
reformation of lysosomes.
The ALR process is regulated by mTOR. After prolonged starvation, the trans-
port of metabolites from autolysosomes to the cytoplasm results in the restoration
of mTOR activity, which not only attenuates autophagy but also induces the gen-
eration of the LAMP-1-positive tubules from autolysosomes [94]. For example, in
Drosophila, the sugar transporter activity of Spinster is required to restore nutri-
ent levels and reactivation of mTOR [95]. Interestingly, also fibroblasts from LSD
patients (e.g., Pompe and Niemann–Pick diseases) show impaired mTOR reactiva-
tion and no ALR [94]. Thus, mTOR via ALR links the nutrient status of a cell to
the induction or cessation of autophagy, and in addition controls the number of lyso-
somes. This feedback mechanism is therefore important to prevent autophagic cell
death by prolonged autophagy [96] and seems to play a relevant role in the patho-
physiology of LSDs.
The generation of reformation tubules from autolysosomes requires dissoci-
ation of RAB7 and the concomitant recruitment of clathrin [94,97]. This latter
event is triggered by conversion of phosphatidylinositol-4-phosphate (PI4P) into
phosphatidylinositol-4,5-biphosphate (PI4,5P2), which recruits the clathrin adaptor
AP2 that in turn mediates the association of clathrin. The GTPase DYNAMIN2 is
also recruited to the reformation tubules and its depletion prevents the fission of
protolysosomes from the reformation tubules [98]. Intriguingly, PtdIns(4,5)P2, AP2,




endocytosis of transmembrane proteins from the plasma membrane. In normal
growth conditions, these molecules are localized at the plasma membrane and not on
lysosomes. It is rather unexpected, but highly interesting, that the same machinery
appears to regulate different clathrin-mediated sorting events depending on the nutri-
tional status of the cell. In contrast to clathrin-mediated endocytosis, the recruitment
of AP2 to autolysosomes does not seem to require transmembrane proteins, such as
LAMP-1, which contains an AP2 binding motif, but just PI(4,5)P2 [97]. This raises
the question how sorting of lysosomal enzymes and LMPs is achieved during ALR.
One clue is provided by the study of Sridhar et al. [99]. The synthesis of PI4P is
under control of four different phosphatidylinositol 4-kinases (PI4Ks) in mammalian
cells. A particular pool of one of the PI4K isoforms, PI4KIIIβ, associates with the
lysosomal membrane. In PI4KIIIβ knockdown cells, the absence of PI4KIIIβ and
PI4P leads to the constitutive formation of tubules from the surface of lysosomes.
Notably, these tubules also contain cathepsin D and LC3 in addition to LAMP-1 and
LAMP-2, and recruitment of clathrin and AP2 to lysosomes is markedly increased.
These data show that in control cells PI4KIIIβ prevents tubule formation from
lysosomes, but during ALR is required for retention of lysosomal enzymes in the
autolysosomal lumen. How PI4P and PI4,5P2 prevent lysosomal enzymes to enter
the lysosomal reformation tubules is a question that still remains unanswered.
Over time, protolysosomes formed during ALR acquire a novel set of lysosomal
enzymes and become functionally active. The molecular pathways underlying the
refueling of protolysosomes are still unknown. For example, it remains to be estab-
lished whether the MPRs are required. Alternative transport routes might involve
yet undiscovered pathways of lysosomal enzyme transport and/or fusion between
protolysosomes and LE or lysosomes. The process of protolysosome biogenesis
is seemingly reminiscent to the formation of a temporary hybrid organelle upon
fusion between LEs and lysosomes, from which small, dense lysosomes can reform,
possibly to avoid an excessive expansion of the lysosome volume. In this case,
however, the reformed lysosomes contain lysosomal enzymes and are functionally
active [100,101].
2.4 DISEASES
2.4.1 Lysosome-Related Disorders (LSDs)
To date, almost 60 different inherited LSDs are known. LSDs are caused bymutations
in genes encoding for proteins that directly affect lysosomal functioning, includ-
ing lysosomal hydrolases and LMPs. Specific examples of LSDs are discussed in
Chapter 11. Although most LSDs have a defect in the (optimal) functioning of just
one specific protein, accumulation of nondegraded material in the lysosome inte-
rior severely disturbs numerous functions of this organelle, including completion of
the final stages of autophagy (i.e., autophagosome fusion and autophagosomal cargo
degradation). Accordingly, a growing number of studies are highlighting that numer-
ous LSDs display an impairment in the autophagic flux [102]. Thus, lysosomal dys-
functioning and defects in autophagy are intrinsically linked and a common feature of
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LSDs. Strikingly, the pathology of most LSDs also involves neurodegeneration [103],
probably because the impairment in autophagy causes an accumulation of cytoplas-
mic aggregates [104].
2.4.2 Lysosomes in Neurodegeneration and Its Links to Autophagy
The pathophysiological connection between the endolysosomal system and
autophagy is not limited to LSDs. This is particularly relevant in neurodegenerative
diseases such as Alzheimer’s, Parkinson’s, and Huntington’s diseases, amyotrophic
lateral sclerosis (ALS), and ataxias, which are caused or accompanied by an aggre-
gation of aberrant proteins (detailed discussion in Chapter 9). This is also underlined
by the observation that upregulation of autophagy can decrease the effects of toxic
aggregates [105].
Recently, it was proposed that the genes such as SNCA, LRRK2, and GBA
associated with the Lewy bodies typical of Parkinson’s disease (PD) all affect
lysosomal functioning [106]. In addition, forms of PD caused by mutations in VPS35
or ATP31A2, a gene involved in recycling from endosomes and in acidification of
the lysosome, respectively, may very likely also result from the disruption of the
autophagy–endolysosomal system [106]. The direct intracerebral delivery of agents
that enhance the activity of Aβ degrading enzymes is considered one of the most
promising approaches for future AD treatment [107].
In Alzheimer’s disease (AD), impairment of lysosomal proteolysis is among the
earliest pathogenic events [108] and progression of the disease is accompanied by
a continuum of pathological changes that ultimately lead to the massive accumula-
tion of LEs, lysosomes, autolysosomes, and autophagosomes [109–112] (reviewed
in Ref. [113]). Mutations in PS1, the major causative gene for early-onset familial
AD, directly impair lysosome proteolysis [112,114]. An extra copy of APP, another
gene leading to familial AD, triggers an abnormal activation of RAB5 [113]. Finally,
high-dietary LDL cholesterol and overexpression of the APOE E4 allele of APOE,
a mediator of neuronal cholesterol transport and major risk factor for late onset of
AD, also result in aberrant RAB5 activation [115]. The picture that emerges is that
mutations causing an early onset of AD impair lysosomal proteolysis and functions,
which in turn result in the accumulation of autophagosomes and/or autolysosomes
with undigested material, which contribute to the pathogenesis worsening.
2.4.3 Autophagy-Related Diseases
Because of the central role of autophagy in cell and organismal physiology, hereditary
genetic disorders caused by a mutation of an ATG gene are extremely rare. Not sur-
prisingly, the diseases reported so far caused by a mutation in one of the ATG genes
are either de novo mutations or generating a hypomorph allele.
2.4.3.1 Crohn’s Disease Crohn’s disease (CD) is a chronic form of inflammatory
bowel disease that can affect any part of the gastrointestinal tract. It is a complex




development of the disease [116]. More than 90 distinct genomic susceptibility
loci have been identified to be associated with an increased risk of CD. Those
include three genes that are linked to autophagy: NOD2, ATG16L1, and IRGM. The
coding polymorphism in ATG16L1 (i.e., T300A) appears to lead to a decrease in
selective types of autophagy resulting in altered cytokine signaling and reduced
antibacterial defense [117]. The NOD2 protein is an intracellular sensor for bacteria
and positively regulates autophagy in response to bacterial infections [118,119].
Cells carrying loss-of-function variants of NOD2 that have been associated with an
increased susceptibility for CD display defects in antibacterial autophagy [118,119].
Similarly, the human immunity-related GTPase IRGM is required for IFN-γ-induced
autophagy that controls infections [120]. The polymorphism in IRGM alters a
binding site for miR-196 and causes deregulation of IRGM-dependent removal of
intracellular pathogens [121]. Recently, additional genes linked to autophagy such
as ULK1, MTMR3, and LKKR2 have been associated to CD [122–124].
2.4.3.2 Vici Syndrome The Vici syndrome is a rare, hereditary multisystem
disorder characterized by callosal agenesis, cataracts, cardiomyopathy, combined
immunodeficiency, and hypopigmentation. A major causative gene for this syn-
drome is EPG5 [125], the human homolog of Caenorhabditis elegans epg-5, which
encodes a protein with a key role in autophagy in multicellular organisms [126].
EPG5 is a 2579-amino acid protein with no obvious known domains, which is
involved in the late steps of autophagy because knockdown in mammalian cells
leads to an accumulation of nondegradative autolysosomes, whereas overexpression
accelerates autophagic catabolism [126]. Similarly, skeletal muscle tissues and
fibroblasts from Vici syndrome patients display an accumulation of autophagosomes
caused by an impairment in either the fusion of these carriers with lysosomes
or in cargo breakdown [125]. The histopathological features are also consistent
with an autophagy defect, as autophagic vacuoles containing abnormal material,
such as aberrant mitochondria, are prominent [125]. This symptomology is in
part recapitulated in the knockout mice [127]. Interestingly, EPG5 is probably not
exclusively involved in autophagy but rather in multiple pathways terminating at the
lysosome because phagolysosome formation is also defective in the absence of epg-5
in C. elegans [128] and degradation of endocytosed surface receptors is impaired in
EPG5 knockdown cells [127]. The mechanism of function and interacting partners
of EPG5 still need to be revealed.
2.4.3.3 Neurodegeneration with Brain Iron Accumulation (NBIA) NBIA dis-
eases comprise a set of single-gene disorders that manifest a range of neurological
phenotypes, with a common feature of high iron levels in basal ganglia. Recently,
it has been revealed that de novo mutations in WDR45/WIPI4 are associated with
NBIA [129–132]. Wdr45 is one of the four human homologs of yeast Atg18, and
studies inC. elegans,Drosophila melanogaster, and human cell lines have shown that
this protein is essential for autophagy and interacts with Atg2’s counterparts in these
organisms [133–136]. Indeed, cells from NBIA patients carrying a WDR45 muta-
tion display a defect in autophagy [129]. However, it remains unclear whether this
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defect actually causes NBIA disorders since other genes mutated in NBIA (PANK2,
C19orf12, and PLA2G6) are not involved in autophagy and Atg18 has additional
cellular functions in yeast [137–139].
2.4.3.4 Hereditary Spastic Paraparesis (HSP) Hereditary spastic paraparesis
(HSP) is a group of clinically and genetically heterogeneous neurodegenerative
disorders that is characterized by progressive spasticity and hyperreflexia of the
lower limbs due to the axonal degeneration of the corticospinal tracts. There are
hereditary forms of HSP caused by mutations in genes that are linked to autophagy.
The first is a point mutation in TECPR2, which leads to a truncated version of
the protein that is rapidly degraded by the proteasome [140]. While the precise
function of TECPR2 is unknown, this protein interacts with all the members of the
LC3 protein family, and when knocked down, autophagy is impaired [134,140].
However in patient skin fibroblasts the autophagy defect is not very prominent,
possibly because TECPR2 is principally expressed in human brains, the tissue
affected most by the pathology [140]. Another protein found mutated in HSP
patients is spastizin (or FYVE-CENT), a PtdIns3P-binding protein that in addition
to a cytosolic distribution also localizes to EEs, ER, microtubules, transport vesicles,
and the midbodies formed during cell division [141–143]. Spastizin binds to the
PtsIns3K complex that contains UVRAG and RUBICON, but not ATG14L, via an
interaction with BECLIN1 [142,144]. This PtsIns3K complex has been implicated
in the maturation of autophagosomes through its involvement in LE biogenesis
[145]. In neuronal and nonneuronal cells carrying the HSP spastizin mutant forms
or lacking this protein, autophagosome maturation is compromised even if the
UVRAG- and Rubicon-containing PtsIns3K complex is still assembled [144]. The
accumulation of immature autophagosomes is also observed in fibroblasts from
patient.
2.4.3.5 Cancer Autophagy can function in both tumor suppression and tumor pro-
gression [146]. Monoallelic deletion of BECLIN1 frequently occurs in human breast,
ovarian, and prostate tumors [147,148]. In support to this, clinical studies have asso-
ciated poor prognosis and aggressive tumor phenotypes with aberrant expression of
Beclin1 in tumor tissue [149,150]. The sequence and the expression of other core
ATG proteins such as ULK1/Atg1, ATG2B, ATG5, GABARAP/Atg8 ATG12, and
ATG16L1, and autophagy-associated proteins such as UVRAG and BIF-1 have also
been found to be altered in several cancers [151]. For a deeper discussion of this topic,
see Chapter 13.
2.5 CONCLUDING REMARKS
It is becoming increasingly clear that the endocytic and autophagy pathways are
intrinsically interconnected at many organizational and regulatory stages, both in
health and disease. In principle, any defects in the endocytic pathway could also




lysosomal functions could regulate autophagy and vice versa how autophagy could
modulate lysosomal functioning [153]. For example, a block of the endolysosomal
maturation may trigger autophagy to correct cellular defects [154]. Solving this
type of questions will yield important insights for the development of therapeutic
approaches to treat autophagy–lysosome-related diseases.
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3.1 INTRODUCTION
Multivesicular endosomes/bodies (MVBs) are endosomes that contain small
intraluminal vesicles (ILVs) within their lumen. They were first identified in studies
following the trafficking of internalized epidermal growth factor receptor (EGFR),
where EGF-stimulated EGFR was found to accumulate on the ILVs of MVBs (see
Figure 3.1) before delivery to the lysosome for degradation [1,2]. Proteins, such as
transferrin receptor, destined for recycling to the plasma membrane, remain on the
limiting membrane of the MVB before return to the cell surface [3]. MVBs were
shown to undergo a gradual maturation process involving accumulation of ILVs,
sorting of lysosomally directed proteins onto the ILVs and the gradual removal of
recycling proteins via tubular extensions [4–6]. When all the recycling proteins
have been removed, the MVB fuses directly with the lysosome and the contents
are degraded [4,7]. At the time of these studies, it was already clear that MVBs
would have a role in downregulating signaling through delivering activated receptor
tyrosine kinases (RTKs) for degradation. The demonstration that RTKs remain
active after endocytosis [8–10], suggesting the possibility of a more acute role for
sorting onto ILVs of MVBs in regulating RTK signaling because sequestration on
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Figure 3.1 Electron micrograph of an MVB. Hela cells were stimulated with EGF in
the presence of anti-EGFR 10 nm gold conjugate and prepared for transmission electron
microscopy. The image shows an MVB with EGFR (gold particles) localized on the ILVs. The
MVB-containing discrete ILVs are readily distinguished from the electron-dense lysosome that
contains characteristic multilamellar membranous whorls. Scale bar = 200 nm.
ILVs removes the catalytic domain of the receptor from the cytosol and therefore
limits its ability to interact with downstream signaling molecules.
During the last two decades, two major sets of discoveries have transformed the
interest and activity in the field of MVB biology. The first is the identification of
molecular mechanisms regulating ILV cargo sorting and ILV formation and the sec-
ond is the discovery that fusion with the lysosome is not the only possible fate of an
MVB. Identification of molecular components of the MVB sorting machinery was an
important prerequisite for establishing the role of that sorting in regulating signaling.
However, the machinery was initially elusive, partly because ILV formation within
MVBs involves budding away from the cytosol and so has the reverse topology
and is differently regulated compared with other better characterized budding
events in the cell that are mediated by coat proteins such as clathrin. The best
established machinery regulating both cargo sorting onto ILVs and ILV formation
is the endosomal sorting complex required for transport (ESCRT) machinery, but
there are multiple populations of MVBs and ILVs within them [11–13] and ESCRT-
independent mechanisms of ILV formation also exist. Studies analyzing the effects
of interfering with components of the ILV sorting machinery on signaling have
revealed that sorting onto ILVs can have both negative and positive effects on
signaling. As expected, sorting onto ILVs generally has negative effects on RTK
signaling, presumably because the kinase domain and signaling proteins associated
with it are sequestered from the cytoplasm. Less expected is the demonstration
that inhibitors of signaling pathways can also be sequestered onto ILVs of MVBs,
thereby enhancing certain signaling pathways.
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A second major discovery is that fusion with the lysosome is not the only poten-
tial fate of MVBs. In specialized cell types, they are on the biosynthetic pathway
of lysosome-related organelles, such as melanosomes, and in many cell types they
can also fuse with the cell surface and release the ILVs, now termed exosomes, into
the extracellular space. The role of exosomes in mediating intercellular communica-
tion between cells of the immune system has been well established but more recently
attention has focused on the role of exosomes in mediating intercellular signaling.
Release of the contents of MVBs into the extracellular space opens up the possibility
of sorting onto ILVs providing a means of signaling to neighboring or even distant
cells. The relationship between ILVs destined for the lysosome and those destined
for release from the cell and how they are segregated is not clear.
Many studies have analyzed the effects of inhibiting endocytosis on signal
transduction and revealed that, although many signaling pathways can be activated
from the plasma membrane, some require endocytosis for maximal activation. In this
review, we do not examine the role of endocytosis per se but, rather, focus on the role
ofMVBs.We review the ways in which sorting onto ILVs ofMVBs can downregulate
intracellular signaling, taking the canonical RTK, EGF receptor, as an example. We
then examine the evidence for a role of sequestration of inhibitory factors on ILVs
in the upregulation of signaling, focusing on the role of sequestration of glycogen
synthase kinase (GSK3) in upregulating Wnt signaling. Finally, we review how
sorting onto ILVs and the subsequent release of those ILVs as exosomes can promote
intercellular signaling, taking long-range signaling of Notch ligands as an example.
3.2 DOWNREGULATION OF SIGNALING BY SORTING ONTO ILVs
Ligand-stimulated EGFR tyrosine kinase signaling can promote cell survival, pro-
liferation, differentiation, or motility, depending upon the cellular context. Overex-
pressed EGFR or EGFR carrying activating mutations are a feature of many human
cancers and so the EGFR is a target for cancer therapeutics. Ligand binding to the
EGFR kinase promotes receptor dimerization, activation of the RTK activity and
trans-autophosphorylation of the receptor, and generates sites for the recruitment of
phosphotyrosine-binding domain (PTB)-containing components of signaling path-
ways. Ligand-stimulated EGFRs are endocytosed via a number of different mecha-
nisms and a proportion of endocytosed EGFR is delivered to the lysosome via sorting
onto the ILVs of MVBs.
EGF receptors are sorted onto ILVs via the ESCRT machinery, which has
recently been extensively reviewed elsewhere [14–16]. It consists of a series of
protein complexes, ESCRT0-III, and accessory proteins, components of which bind
ubiquitinated cargo and sort them into domains on the perimeter membrane of the
MVB. ESCRTs also promote membrane invagination and ultimately the budding
of the ILV, which is accompanied by vacuolar protein sorting-associated protein 4
(Vps4)-mediated release of ESCRT components from the MVB-limiting membrane.




RTK signaling in cultured cells [17–19]. Furthermore, enhanced EGFR signaling
and MAP kinase signaling has been reported in ESCRT-mutant cells in Drosophila
tissues [20,21]. One complication of studies interfering with the ESCRT machinery
is that ESCRT-mutant cells can activate a powerful apoptosis program [22,23].
However, when proapoptotic signaling is prevented, a major overproliferation is
observed in ESCRT-mutant cells [24], supporting the notion that sorting onto the
ILVs downregulates signaling.
As suggested earlier, a complication in the interpretation of this type of study is that
ESCRT components havemultiple functions in addition to sorting ubiquitinated cargo
onto ILVs. These include the promotion of recycling, which has been demonstrated
for certain G protein-coupled receptors [25], abscission during cytokinesis [26,27]
and they also have a role in handling of microRNAs [24,28]. An alternative approach
that allows the role of the ESCRT machinery in regulating sorting of EGFR onto
ILVs to be distinguished from other ESCRT roles is to analyze ligand-stimulated
signaling by an EGFR that is deficient in ubiquitination and so cannot engage the
ESCRTmachinery. This receptor is efficiently endocytosed [29], but rather than being
sorted onto ILVs the receptor is recycled and signaling via the ERK MAP kinase
pathway is prolonged [30].
Does sorting onto ILVs play a major/direct role in regulating signaling from the
EGFR by removal of the catalytic domain of the EGFR from the cytosol or is the main
role of sequestration on ILVs in signal modulation the prevention of recycling? The
demonstration that some EGFR signaling pathways, such as the ERK MAP kinase
pathway, are unaffected by inhibition of endocytosis [31] suggests that for these path-
ways inhibition of EGFR return to the plasma membrane may be the main role of the
ESCRT machinery in their regulation. For other pathways, such as the B/AKT path-
way, where endocytosis is required for their sustained activation [31], implying that
they signal from the perimeter membrane of endosomes, sequestration on ILVs may
directly regulate their potency.
Endocytosis has been shown to regulate the ability of EGFR to interact with tyro-
sine phosphatases that downregulate EGFR signaling by removing sites for recruit-
ment of PTB domain-containing proteins [32]. EGFR on the perimeter membrane of
MVBs comes into contact with a protein tyrosine phosphatase, PTP1B, on the cyto-
plasmic face of the ER via membrane contacts that form between the MVB perimeter
membrane and the ER [33]. This interaction must occur before sorting of EGFR onto
ILVs and so it is possible that the EGFR is already dephosphorylated before ILV
targeting. PTP1B both dephosphorylates the EGFR and promotes its sorting onto
ILVs, possibly through dephosphorylation of components of the ESCRT machinery
[33,34]. Thus, a combination of dephosphorylation, followed by rapid sequestration
onto ILVs to prevent rephosphorylation, could serve to dampen signaling at the level
of the MVB (illustrated in Figure 3.2).
It is important to note that signaling proteins downstream of the EGFR kinase
may be sequestered on ILVs along with the EGFR. Dephosphorylation of the EGFR
before sorting onto ILVs may trigger dissociation of PTB domain-containing com-
ponents of signaling pathways that associate with autophosphorylated EGFR. Alter-
natively sequestration of components of signaling pathways along with the EGFR
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Figure 3.2 Downregulation of EGFR signaling by sorting onto ILVs. (a) EGFRs at the cell
surface dimerize on ligand binding and are internalized into early endosomes where sorting
of ligand–receptor complexes destined for lysosomal degradation onto ILVs begins (“early”
MVBs). EGFR-containing ILVs accumulate in the maturing MVB and when all recycling
proteins have been removed the “late” MVB fuses with the lysosome and the contents are
degraded. (b) Signaling from the EGFR tyrosine kinase on the limiting membrane of the MVB
is dampened by a combination of dephosphorylation and sequestration away from the cytosol
on ILVs. Ubiquitination-dependent interaction with Hrs, and subsequent recruitment of the
ESCRTmachinery, concentrates EGFR on theMVB-limiting membrane where both the EGFR
and ESCRTs can potentially interact with ER-localized PTP1B via direct membrane contacts
between the ER and MVBs. ESCRTs then promote sequestration of EGFR on ILVs of MVBS,
which ultimately fuse with the lysosome, ensuring signal termination. (See color plate section
for the color representation of this figure.)
could contribute to downregulation of signaling. In addition, signals propagated from
the EGFR may continue after the EGFR itself has been degraded or sequestered on
ILVs. An ERK MAP kinase-containing signaling complex forms on the perimeter
membrane of late endosomes [35], but the importance of ILV sorting in regulation of
signaling from this complex is not clear.
Finally, the importance of sequestration of EGFR and downstream signaling
proteins away from the cytosol in directly regulating signaling begs the question
of whether or not this is an irreversible process. Back fusion of ILVs with the
perimeter membrane has been demonstrated for ILVs bearing Semliki Forest
virus [36] and anthrax toxin [37] in a mechanism involving Alix and the lipid,




carried in a separate population of MVBs to those that label for LBPA [11] and
whether EGFR-containing ILVs can back fuse remains to be established.
3.3 UPREGULATION OF SIGNALING BY SORTING ONTO ILVs
In contrast to EGFR signaling, where many (though not all) signaling pathways
downstream of the receptor are activated from the plasma membrane, endocytosis
is required for Wnt signaling. Wnt signaling is ultimately mediated through the
stabilization of β-catenin [39]. In the absence of Wnt signaling, β-catenin levels are
kept low through GSK3-mediated phosphorylation, which targets β-catenin for ubiq-
uitination and degradation by the proteasome. Wnt signaling inhibits GSK3 activity,
allowing newly synthesized β-catenin to escape phosphorylation and ubiquitination.
Accumulated β-catenin can then enter the nucleus and coactivate transcription of
Wnt-responsive genes. The means whereby Wnt signaling inhibits GSK activity are
controversial but one proposed mechanism involves the sequestration of GSK3 on
the ILVs of MVBs, rendering it inaccessible to newly translated β-catenin [40]. Thus,
sequestration of GSK3 on the ILVs results in β-catenin evading GSK3-mediated
phosphorylation and resulting ubiquitination and degradation and instead being
transported to the nucleus where it activates transcription of target genes.
When Wnt ligands bind to their Frizzled (Fz) receptors and low-density
lipoprotein-related protein (LRP) coreceptors on the plasma membrane, disheveled
(Dvl) proteins are recruited to the complex. This results in the recruitment of
Axin, which, in unstimulated cells, is in an inhibitory complex with adenomatous
polyposis coli (APC), casein kinase 1 (CK1) and GSK3 that targets β-catenin for
degradation by facilitating the GSK3-mediated phosphorylation of β-catenin and
resulting recruitment of the E3 ubiquitin ligase. Dvl polymers activate the phos-
phorylation of LRP5/6 by CK1, which creates docking sites for Axin, enhancing
its recruitment, together with other components of the signalosome. A complex
series of homo- and hetero-oligomerization events and phosphorylations by the
two kinases, CK1 and GSK3, lead to the formation of a large protein complex, the
Wnt signalosome. One proposed mechanism of GSK3 inhibition within this protein
complex is the generation of a pseudosubstrate for GSK3 in the phosphorylated
cytoplasmic domain of LRP5/6 that prevents GSK3 phosphorylating other proteins
[41,42]. However, several groups have shown that the Wnt signaling complex is
endocytosed. The mechanism of internalization is unclear since dependence on
clathrin [43] and caveolin [44] have both been reported. A recent study indicated that
internalization of the Wnt signaling complex was dependent upon dissociation of a
p120-catenin/cadherin complex [45]. In all these studies, interfering with endocytosis
of the Wnt signalosome, albeit in different ways, inhibited Wnt signaling.
Focusing on the role of MVBs in Wnt signaling, the finding that a proportion
of GSK3 and other components of the Wnt signaling complex becomes protease
resistant in digitonin-permeabilized but not Triton-permeabilized cells suggested
that GSK3 became sequestered from the cytosol and immunoEM confirmed that
the endocytosed protein became sequestered on the ILVs of MVBs [40]. This
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sequestration was inhibited by depletion of the ESCRT0 component, Hrs, or
expression of dominant negative Vps4, implicating the ESCRT machinery in the
sorting of GSK3 onto ILVs [40]. Importantly, Hrs depletion/Vps4 mutant expression
inhibited Wnt-stimulated β-catenin stabilization, suggesting that one mechanism of
GSK3 inhibition is sequestration of GSK3 away from cytosolic substrates, allowing
newly synthesized β-catenin to escape phosphorylation, accumulate in the cytosol
and subsequently be transported to the nucleus (illustrated in Figure 3.3). Support
for the idea of sequestration of GSK3 in MVBs as a mechanism of Wnt signaling
came from the recent demonstration that dissociation of the p120-catenin/cadherin
complex was necessary for sequestration of GSK3 within MVBs andWnt-stimulated
β-catenin stabilization [45].
The above scheme (Figure 3.3) suggests that sequestration of GSK3 onto ILVs
must be very efficient and if it is sequestered onto the same ILVs as activated EGFR,
the normal destination of those MVBs would be fusion with the lysosome and degra-
dation. However, total cellular levels of GSK3 did not change on Wnt signaling [40],
suggesting either that it is only a small proportion of the GSK3 that is active and there-
fore sequestered onto ILVs and subsequently degraded or that the GSK3-containing
ILVs can back fuse with the limiting membrane and thus escape lysosomal degra-
dation. Alternatively, GSK3 could be sequestered in a population of MVBs distinct
from those that are delivered to the lysosome and degraded.
Many questions remain about the molecular regulation of the sorting of the Wnt
signaling complex on to the ILVs of MVBs. GSK3 is sorted onto ILVs in a complex
with LRPs, Fx, Dvl, Axin, and CK1 in a manner that appears dependent on compo-
nents of the ESCRTmachinery. However, it is not known whether any components of
the Wnt complex become ubiquitinated, providing a potential means of engaging the
ESCRT machinery. Furthermore, the relationship between the MVBs that sequester
the Wnt signaling complex and those that sequester-activated RTKs such as EGFR is
not clear.
Finally, the demonstration that an inhibitory protein, such as GSK, can be
sequestered on ILVs to activate signaling raises questions about the interpretation
of studies where the functions of ESCRT machinery in signal regulation have been
investigated. Depletion of components of the ESCRT machinery may have effects
on the availability of a range of signaling regulators in addition to the one that is the
target of the study.
3.4 INTERCELLULAR SIGNALING DEPENDENT ON SORTING
ONTO ILVs
The first demonstration that release of ILVs into the extracellular space as exosomes
was not simply a means of getting rid of unwanted material from the cell came from
studies showing that exosomes from B lymphocytes could present antigen [46].
Since then the role of exosomes in the immune system has been extensively studied
and more recently a plethora of roles have been attributed to exosomes, including the



















































































































































Figure 3.3 Upregulation of Wnt signaling by sorting onto ILVs. In resting cells, cytosolic
β-catenin levels are kept low through the activity of an inhibitory complex that contains GSK3,
which phosphorylates β-catenin, promoting its ubiquitination and proteosomal degradation.
When Wnt ligands bind Frizzled receptors (Fz) and LRP coreceptors at the cell surface, a
multiprotein complex is recruited that includes disheveled (Dvl), the scaffold protein, Axin,
the kinases, CK1γ, and β-catenin ESCRT-dependent sequestration of the Wnt signaling com-
plex onto the ILVs of MVBs prevents GSK3-mediated phosphorylation of newly synthesized
β-catenin, allowing cytosolic β-catenin levels to rise, leading to its transport to the nucleus to
activate transcription of Wnt target genes. The lack of sequestration of the Wnt signaling com-
plex onto ILVs in the absence of Hrs renders GSK3 able to phosphorylate newly synthesized
β-catenin, leading to ubiquitination and degradation, thus preventing β-catenin-mediated tran-
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transported in the extracellular environment, forming spatial and temporal gradients,
orchestrating morphogenesis during development and adult tissue homeostasis.
The main families of such molecules, Hedgehog, Wnts, Notch ligands, TGF-β,
EGF and FGF have all been found associated with exosomes [47]. Here we focus
on the membrane-associated Notch ligands, delta/serrate/Lag2 (DSL), which until
recently were thought to activate the transmembrane protein, Notch, solely via direct
cell:cell contact between the signal-sending (DSL-producing) cell and the signal-
receiving (Notch-expressing) cell. Notch activation triggers S2 proteolysis of the
extracellular domain of Notch and then the S3 γ-secretase cleavage of the Notch intra-
cellular domain, which can then shuttle to the nucleus, bind transcriptional cofactors,
and activate the transcription of target genes. The trafficking of Notch ligands, Notch
regulators, and Notch itself to promote and inhibit Notch signaling via the canonical
pathway and the ligand-independent Deltex-dependent pathway is complex. This is
particularly so during asymmetric cell division, when regulators of Notch signaling
are partitioned unequally between daughter cells (reviewed by Furthauer and
Gonzalez-Gaitan [48]). In this chapter, we focus on the canonical pathway and on
the potential importance of Notch signaling via exosomes and therefore the sorting
of ligand and receptor within MVBs in both the signal-sending cell and the signal-
receiving cell.
A number of studies have demonstrated that endocytosis of the DSL family
of Notch ligands by the signal-sending cell is necessary to activate Notch in the
signal-receiving cell [49–52]. One proposal is that the DSL ligand is activated in
endosomes and so must be endocytosed and recycled to plasma membrane lipid
microdomains to be able to stimulate Notch [53]. Another proposal is that Delta and
Notch on the signal-sending and signal-receiving cells, respectively, interact and
endocytosis of Delta by the signal-sending cell “pulls” on Notch, altering its physical
conformation, promoting S2 cleavage of the extracellular domain, which may be
internalized with Delta in the signal-sending cell [54,55]. This creates a substrate for
the subsequent S3 cleavage and release of the Notch intracellular domain for nuclear
translocation and transcriptional activation in the signal-receiving cell. The finding
of the Notch ligand, Delta-like Notch ligand DLL-4, associated with exosomes from
tumor cells and endothelial cells suggests another possibility [56,57]. Endocytosis of
Delta could be required for sorting onto ILVs before subsequent release as exosomes.
One pathway of DSL ligand endocytosis requires ubiquitination and interaction with
Epsin [58,59]. As described earlier, ubiquitination could allow engagement of the
ESCRT machinery and sorting onto ILVs of MVBs. The formation of ILVs that
are subsequently released as exosomes has been proposed to be regulated by an
ESCRT-independent mechanism involving sphingomyelinase-mediated formation
of the cone-shaped lipid ceramide [60], which can promote membrane curvature.
However, ESCRT components are present on exosomes [61] and recently depletion
of ESCRT components was shown to impact on exosome formation [62–64].
ESCRTs have frequently been found to have a negative impact on Notch signaling,
but this is largely due to effects on ligand-independent Notch trafficking [65–68]
where delivery of Notch to the limiting membrane of late endosomes is required




In this case, cleavage and/or release of the Notch intracellular domain is inhibited
by targeting onto the ILVs of MVBs. Whether the ESCRT machinery has a role in
targeting of DSL ligands to ILVs for release as exosomes is not clear.
Once targeted to ILVs the MVB must move to and fuse with the plasma mem-
brane of the signal-sending cell before release of exosomes. A number of members
of the Rab family of low-molecular-weight GTPases have been implicated in this pro-
cess, including Rabs 11 [69,70], 35 [71], and Rab27a and b [72]. Like most secretory
events, fusion of MVBs with the plasma membrane is also regulated by calcium [69]
and SNAREs (soluble NSF attachment protein receptors) [70] and a role for pH and
the vacuolar ATPase [73] has also recently been reported. There appears to be some
specificity in the fusion machinery, probably depending on the cell type and cargo
and the specific machinery required for release of DSL-containing exosomes has not
been reported.
What happens when exosomes reach the signal-receiving cell? Delta-like 4 (Dll4)-
containing exosomes can elicit both stimulation and inhibition of Notch signaling in
endothelial cells, promoting endothelial sprout formation and inhibiting angiogene-
sis, respectively [56,74]. The trafficking events that underlie this signaling upon the
arrival of signal-bearing exosomes at the receiving cell are not clear. Both Dll4 and
Notch are internalized in the signal-receiving cell in a manner that depends on Notch
expression by the receiving cell [56]. Could this occur following fusion of exosomes
at the cell surface? Microvesicles bearing the oncogenic EGFR mutant EGFRVlll
have been shown to transfer oncogenic mutant receptor and signaling capacity to
nonexpressing cells, suggesting fusion of exosomes at the plasma membrane [75].
Whether these microvesicles are bona fide exosomes is not clear. Exosomal fusion
with the plasma membrane [76,77], macropinocytosis [78], endocytosis [79], and
phagocytosis [80] have all been reported to occur upon arrival of exosomes at the
receiving cell. Exosome fate may depend on cargo and cell type, and whether the
function is exosome clearance, such as occurs upon macropinocytic uptake of exo-
somes by microglia followed by exosome degradation [78], or whether the func-
tion is antigen presentation, transfer of microRNAs, or modulation of signaling in
the receiving cell. Fusion of exosomes at the signal-receiving cell surface would
deliver Dll4 to the same membrane as Notch, allowing interaction in the “cis” con-
formation. Cis interaction between Notch and Notch ligands in the same cell could
inhibit Notch signaling through competing for trans-ligand–Notch interactions or
through promoting Notch endocytosis. Dll4-containing exosomes caused a marked
depletion of Notch from the receiving cell surface and ultimately Notch degrada-
tion [56]. Conceivably, the selective sorting of either Notch or Notch ligand onto the
ILV would allow Notch–Delta interaction in the transconformation (see Figure 3.4).
If conditions within the MVB were favorable for S2 cleavage, retention of Notch
on the limiting membrane could potentially allow S3 cleavage of the intracellular
domain of Notch, release into the cytosol and nuclear transport. If Notch were sorted
onto the ILV, then S3 cleavage would release the intracellular domain into the ILV
and back fusion would be required for release into the cytosol. If exosomes do not
fuse at the cell surface and the entire exosome is endocytosed, then, as shown in
Figure 3.4, there could be the intriguing situation of a readymade MVB formed
 
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Figure 3.4 Intercellular Notch signaling mediated by ligand-bearing exosomes. Exosomes
containing the Notch ligand, Delta, are released from the signal-sending cell and bind to Notch
on the cell surface of the signal-receiving cell. Both Notch and Delta are endocytosed by the
signal-receiving cell, but it is unclear how. In the left-hand panel, Delta-bearing exosomes fuse
at the cell surface and then Delta and Notch on the same membrane are endocytosed. (i) Delta
is selectively sorted onto the ILVs of MVBs where it can bind Notch on the MVB-limiting
membrane. Conditions in the MVB may be favorable for S2 and then S3 cleavage releasing
the Notch intracellular domain that can then traffic to the nucleus. (ii) Notch is selectively tar-
geted to the ILV where it can bind Delta on the limiting membrane of the MVB. In this case,
if S2 and S3 cleavage occurs, the intracellular domain of Notch would be sequestered within
the ILV and would require back fusion of the ILV with the limiting membrane for release into
the cytosol and traffic to the nucleus. (iii) Both Notch and Delta are sorted onto ILVs and this
serves to target both proteins to the lysosome for degradation. In the right-hand panel, the
exosomes are endocytosed forming an MVB where the limiting membrane is derived from
the signal-receiving cell and the ILVs are derived from the signal-sending cell. In this case,
Delta–Notch interactions could be continued after endocytosis. In all cases, the ultimate desti-
nation of the MVB in the signal-receiving cell that contains Delta and Notch, with or without
the Notch intracellular domain, is likely to be the lysosome. (See color plate section for the




immediately after internalization with no requirement for MVB sorting machinery.
The signal-receiving cell would contain MVBs with the limiting membrane from the
signal-receiving cell but the ILVs within the lumen of the MVB would have come
from a different (the signal-sending) cell. DII4 on the ILVs could continue to inter-
act with Notch on the perimeter membrane of the MVB in the “trans” conformation
leading either to Notch cleavage and release of the intracellular domain or delivery
to the lysosome for degradation.
Clearly, much remains to be resolved, both with respect to the molecular mecha-
nisms regulating sorting of cell fate determining molecules onto ILVs that are subse-
quently released as exosomes and the fate of those exosomes at the receiving cell.
3.5 CONCLUSION
ESCRT-dependent sorting onto the ILVS of MVBs plays a major role in downreg-
ulating signaling from RTKs by promoting delivery of the RTK to the lysosome for
degradation. Sorting onto ILVs also sequesters the RTK and possibly downstream sig-
naling molecules away from the cytoplasm and so may also have a more direct role in
signal downregulation. ESCRT-depending sorting onto the ILVs of MVBs can also
play a role in upregulating signaling by sequestering inhibitory molecules, such as
GSK3, from their cytoplasmic substrates, such as β-catenin. Sorting of cell fate deter-
mining signaling molecules, such as Notch ligands, onto ILVs and their subsequent
release as exosomes may allow short- or long-range signaling to other cells.
There is a major gap in our understanding of the relationship between the MVBs
and the ILVs within them that regulate signaling in different ways. Do they all use
the same mechanism of cargo sorting onto ILVs and ILV formation? Sorting of
RTKs onto ILVs via ubiquitin-dependent engagement of the ESCRT machinery has
been well established. The sorting of the Wnt signalosome appears to depend on the
ESCRT machinery but the means whereby this machinery is engaged is not clear.
Both ESCRT-dependent and -independent mechanisms have been proposed for
sorting onto ILVs that are subsequently released as exosomes. The mechanisms that
sort cell fate determining molecules into ILVs are not clear. Furthermore, several
studies have indicated that different mechanisms of ILV formation can occur on the
same membrane. If this is the case, then how are ILVs with different fates segregated?
Another major question is how reversible is sorting of signaling cargo onto ILVs?
This is very difficult to address experimentally but is of particular importance in
cases where inhibitory molecules are sequestered from the cytoplasmic targets on
ILVs. A final major question relating to ILV fate is what happens to exosomes
bearing cell fate determining molecules on arrival at the signal-receiving cell?
The requirement for high-resolution techniques to visualize ILVs, the multiple
roles of the ESCRT and other MVB sorting machineries, and cross talk between
signaling pathways are among the challenges faced by those analyzing the role
of ILV formation in regulating signaling. However, recent discoveries point to a
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4.1 SUMMARY
Mitochondrial autophagy or “self-eating” is a catabolic process of mitochondrial
degradation by lysosomes. In contrast to nonselective autophagy (discussed in
Chapter 2), mitophagy is the selective elimination of dysfunctional or unwanted
mitochondria during periods of stress or during regulated development [1,2]. Given
the fundamental role of mitochondria in energy production, signaling, and cellular
survival, mitophagy emerged as a central mechanism in regulating mitochondrial
homeostasis and quality control in health and disease [3,4].
4.2 MITOCHONDRIAL SIGNIFICANCE
Since the initial discovery ofmitochondria in the 19th century, accumulating evidence
continues to reshape our views of mitochondrial functions and their vital role in man-
aging various cellular processes such as metabolic homeostasis, energy production,
stress response, and cell death [5].
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Mitochondria are relatively small in size with a diameter of about 0.5–1 μm and a
length that can be up to 5 μm [6], but depending on the cell type and cellular state this
number varies significantly. Mitochondrial shape may vary from spheres to filamen-
tous structures, but they are always composed of two enclosed membranes [6,7]. The
two membranes (outer and inner) have different biochemical and physical character-
istics that define their functions, with the outer membrane forming a partial selective
barrier toward the cytoplasm while the inner membrane (where the major enzymatic
machinery resides) forms long invaginations called “cristae” enclosing the matrix [7].
Each mitochondrion is formed by approximately 1500 distinct proteins [8]. These
proteins are mainly encoded by nuclear DNA, and only 13 proteins are encoded by
mitochondrial DNA [9]. Hence, specific mitochondrial functions are largely defined
by the cell type these organelles reside in.
Mitochondria have numerous basic functions and they play a central role in energy
metabolism through adenosine-5′-triphosphate (ATP) synthesis [10]. Mitochondria
have also additional functions that are fundamental for cellular homeostasis such as
calcium storage, release, and buffering [11]. Calcium has an intrinsic role in mod-
ulating mitochondrial ATP production. In addition, calcium plays an important role
in controlling the function of many proteins and enzymes and therefore has a critical
impact on numerous biological pathways such as neurotransmitter release, autophagy,
and apoptosis [11,12]. In addition to their ability to buffer calcium, mitochondria
play a central role in reactive oxygen species (ROS) homeostasis [13]. ROS (such
as hydrogen peroxide, superoxide anion, and hydroxyl radical) are an essential com-
ponent of different signaling pathways but can also damage the cellular machinery.
Mitochondria are the main source of intracellular ROS [14].
Overall, mitochondrial dysfunction may affect several aspects of cellular life rang-
ing from functional failures to apoptosis and cell death. Keeping mitochondria at their
optimal functionality and integrity is critical for cellular survival [15,16]. Mitochon-
drial defects may arise from various origins such as mutated proteins or damaged
mitochondrial components due to oxidative stress, all of which may affect mitochon-
drial structure and/or function. Consequently, if mitochondria become dysfunctional,
multiple restoration mechanisms can be triggered, including mitophagy and lysoso-
mal degradation. Here, defective mitochondria or, by virtue of mitochondrial fission,
parts of mitochondria are eliminated and the mitochondrial pool remains healthy,
protecting against several disorders that are associated with abnormal mitochondria
[15,17] (more discussion in Chapter 9).
4.3 HISTORY OF MITOPHAGY
In 1955, ChristianDeDuve discovered different cytoplasmic granules containing acid
hydrolases using a new scheme of cellular fractionation, where he referred to these
granules as “lysosomes” to implicate their enrichment in hydrolytic enzymes [18].
Shortly thereafter, the first lysosomal engulfment of mitochondria was observed by
Clark in 1957 using electron microscopy, where he described “large cytoplasmic
bodies” that include “altered mitochondria” surrounded by dense membranes [19].
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Similarly, Ashford and Porter in 1962 noticed upon glucagon treatment of
hepatocytes promoting autophagy, a significant increase in the number of lysosomes
that contain mitochondria “in various stages of breakdown or hydrolysis” [20]. How-
ever, the term “autophagy” of mitochondria was only introduced and described in
1963 [21], wheremitochondria are first sequestered bymembrane structures (prelyso-
some), then acid hydrolases are added to form an active “lysosome” andmitochondria
are degraded to form a “postlysosomal body” [22]. Later, in 2005, Lemasters [23] pro-
posed the term “mitophagy” based on similarities to the peroxisomal autophagy (pex-
ophagy), suggesting the selective removal of cytoplasmic organelles by autophagy.
One example of selective autophagy is “pexophagy,” where yeast grown on
methanol as a sole source of carbon and energy has a significant increase in peroxiso-
mal mass required for specialized metabolic pathways. Once methanol-rich media is
withdrawn, selective autophagy of excess peroxisomes takes place while the turnover
rate of other organelles remains unaffected [24]. This indicates that autophagy of
cytoplasmic organelles is a selective process that vigorously adapts to metabolic
needs. Similarly, oxidative stress may damage mitochondrial membranes and
cause nonspecific pore opening, the mitochondrial permeability transition (MPT),
uncoupling of oxidative phosphorylation and consequently bioenergetic failure [25].
When severe, MPT activates caspases and apoptosis [26], whereas under mild stress,
MPT pore formation induces autophagy, which selectively eliminates damaged
mitochondria [27]. Furthermore, starvation induces autophagy in yeast and cytoplas-
mic organelles degradation. However, mutation in the yeast mitochondrial outer-
membrane protein Uth1p, which is the first gene identified to control autophagy,
significantly inhibits mitochondrial degradation while elimination of other cytosolic
components occurs normally [28]. Hence, mitophagy is a selective degradation
process of damaged organelles that promotes the maintenance of a healthy pool of
mitochondria and sustains the bioenergetic capacity of the cell.
4.4 MECHANISMS OF MITOPHAGY
Once mitochondria are targeted for elimination, autophagy is induced and degrada-
tion of dysfunctional or unwantedmitochondria is initiated. However, it was proposed
that an early response mechanism exists, where an initial quality control pathway
precedes the clearance of damaged mitochondria by autophagy. Indeed, mild stress
induces the biogenesis of mitochondrial vesicles enriched for oxidized proteins and
targeted for degradation by the lysosome [29]. This first line of defense operates at an
early stage before the recruitment of the full blown autophagic machinery. This mech-
anism would be part of the quality control system that specifically removes damaged
mitochondrial components via vesicular carriers and lysosomal degradation without
the need to eliminate the entire organelle at once. Nonetheless, if this initial quality
control intervention becomes overwhelmed and mitochondria are irreversibly dam-
aged, autophagy is triggered and targeted mitochondria are eliminated [30].
Interestingly, an important observation that precedes mitophagy is mitochondrial
fragmentation [31], a process that may in part also overlap with the production of
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mitochondrial vesicles destined for degradation. In order to sustain cellular needs and
function, mitochondria are highly dynamic organelles undergoing constant fission
and fusion events. This dynamic process helps mitochondria mix their content,
preserve their integrity, and keep their physiological homeostasis balanced [32,33].
While mitochondrial length can reach up to 5 μm, autophagosomes do not exceed
1 μm causing sterical problems for their capacity to engulf mitochondria during
autophagy [34]. Furthermore, when mitochondria undergo fission events, it gives rise
to mitochondria with a different membrane potential spectrum, where the daughter
organelle with lower membrane potential are unlikely to fuse again with “healthy
mitochondria” and are then degraded by autophagy [35]. However, mitochondrial
fission per se is not enough to induce mitophagy, suggesting the involvement of
other signals that trigger mitophagy in parallel or upstream of fission [34].
Once initiated, autophagy can be divided into two major steps: induction of the
general autophagic machinery (described in Chapter 2) and priming of targeted mito-
chondria for autophagic recognition and degradation (discussed below). Mitophagy
begins with engulfment of the targeted organelle by a double-membrane structure
(autophagosome), these membranes may originate from different sources such as
the plasma membrane [36], Golgi [37], endoplasmic reticulum (ER) [38], and even
mitochondria themselves [39]. Next, autophagosomes fuse with lysosomes for degra-
dation and formation of the “autolysosome.” More than 30 autophagy-related genes
(Atg) have been discovered in yeast, and most of these are well conserved across
species. Nonetheless, the exact mechanism of autophagy (as well as mitophagy) or
how it is regulated at specific cellular compartments (e.g., in neurons at the synapse)
is not yet fully understood and remains to be elucidated.
4.4.1 Mitophagy in Yeast
Mitophagy exists inmammalian cells [19], but themolecular mechanisms and genetic
pathways were initially identified in yeast. The first genetic factor discovered to be
involved in mitophagy was Uth1p, a member of the SUN family. This protein is
mostly localized to the outer mitochondrial membrane (OMM) and is required for
degradation of dysfunctional mitochondria during starvation [28]. Another compo-
nent required for stationary-phase mitophagy is Aup1p, a member of the protein
phosphatase family localized to the intermembrane space [40].
Further screening of mitophagy modulators revealed dozens of new genes. One
important outcome was the identification of the 60-kDa OMM protein Atg32 that
harbors its carboxy terminal in the intermembrane space while the amino terminal
faces toward the cytosol [41,42]. Atg32 is required for selective autophagy during
high respiration growth, but not during starvation, and is highly expressed under
oxidizing conditions, reflecting its importance for mitochondrial quality control.
Interestingly, under mitophagy-inducing conditions, Atg32 can interact with Atg11,
known to recruit organelles into autophagosomes via Atg8 (also referred to as LC3),
or directly with Atg8 through its WXXL-like Atg8-binding motif, thereby recruiting
mitochondria to autophagosomes and initiating selective mitochondrial degrada-
tion [41,42] (Figure 4.1). Numerous other genes have been linked to mitophagy but
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Figure 4.1 Summary of mitophagy in yeast and mammalian cells. Mitochondria require
specific targeting signals to recruit the autophagic machinery and mediate autophagosome for-
mation and lysosomal degradation. (See color plate section for the color representation of this
figure.)
with different levels of necessity, which might indicate the existence of multiple
mitophagy pathways for different purposes that remain to be uncovered [43].
4.4.2 Mitophagy in Mammals
During early stages of embryogenesis, mitophagy is needed in fertilized oocytes to
eliminate paternal mitochondria [44,45]. Upon oocyte fertilization, autophagy is acti-
vated and autophagosomes are formed, causing the selective degradation of paternal
mitochondria at lysosomes (Figure 4.1). When autophagy is blocked, paternal mito-
chondria are fragmented and fusion incompetent inhibiting their capacity to fuse with
maternal mitochondria [45]. Mitochondrial DNA is mostly maternally inherited [46]
and the evolutionary benefit and molecular mechanism of this selective autophagy of
paternal mitochondria remains elusive.
Another type of selective mitochondrial elimination is mitophagy during red blood
cell maturation [47] (Figure 4.1). As mature red blood cells (erythrocytes) lack mito-
chondria, autophagy efficiently eliminates those organelles throughout their matu-
ration, and it is proposed that this elimination is necessary for the red blood cell
function in oxygen transport. During the red blood cell terminal differentiation phase,
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expression of the OMMNIP3-like protein X (NIX) is significantly increased [48] and
NIX knockout mice suffer from anemia and maintain residual mitochondria in their
erythrocytes, reducing their survival [49]. It is proposed that NIX plays an essential
role in red blood cell mitophagy by integrating mitochondria into autophagosomes
and subsequently lysosomal degradation of unwanted mitochondria [50]. This pro-
cess is mediated by NIX binding to the microtubule-associated protein light chain 3
(LC3; the Atg8 yeast homologue) via its WXXL-like motif facing the cytosol as NIX
lacking WXXL-like motif does not rescue mitophagy in NIX-deficient cells [51,52].
Although the mechanism of mitophagy induction in red blood cell maturation is not
yet discovered, other players that affect this process are identified such as ULK1
and ATG7, key components of the autophagic cascade required for mitochondrial
degradation [53,54].
Mitophagy is also induced under hypoxic conditions to eliminate mitochondria
that might cause oxidative stress by increasing ROS levels and altering oxygen home-
ostasis [55] (Figure 4.1). NIX and its homologue Bnip3 (both share a BH3 domain)
localize to the OMM and their expression is highly increased under hypoxic con-
ditions by the hypoxia-inducible factor-1 (HIF-1). High Bnip3 levels affect the Bcl2
and Beclin1 interaction and have been linked to Atg5-dependent autophagy via nucle-
ation of preautophagosomal membranes mediated by Beclin1 [55]. In addition to NIX
and Bnip3, FUNDC1 is another OMM protein that directly interacts with LC3 and
facilitates mitochondrial engulfment by autophagosomes and lysosomal degradation
under hypoxic conditions [56].
NIX is required for mitophagy in red blood cells during their differentiation;
however, depolarization of mitochondria with uncouplers such as carbonilcyanide
p-trifluoromethoxyphenylhydrazone (FCCP) rescues mitophagy in NIX-deficient
cells [49]. Therefore, dissipating mitochondrial membrane potential triggers alterna-
tive mitophagy pathways that are NIX-independent. Indeed, dissipating the electro-
chemical gradient across the inner mitochondrial membrane using acute treatment of
the mitochondrial uncoupler carbonyl cyanide m-chlorophenyl hydrazone (CCCP)
leads to mitochondrial depolarization and autophagy initiation [57] (Figure 4.1).
Under steady conditions, PINK1 a serine/threonine kinase that maintains electron
transport chain function in mitochondria [58–61] is constitutively cleaved by the
mitochondrial-processing protease (MPP) followed by the presenilin-associated
rhomboid-like protease (PARL). But upon dissipation of themitochondrial membrane
potential by CCCP, PINK1 processing is inhibited causing its accumulation on the
OMM [62–65]. PINK1 accumulation triggers the relocalization of Parkin, a cytosolic
E3 ubiquitin ligase, to mitochondria [57,63]. Accumulation of PINK1 alone is suffi-
cient to relocalize Parkin, as PINK1 targeted to other cytoplasmic components such
as peroxisomes or lysosomes also recruits Parkin to the respective organelles [66].
Once autophagy is initiated, Parkin interacts with autophagy factors, for example,
Ambra1, known to activate class III PI3K required for phagophore formation [67].
To selectively degrade mitochondria, these organelles are labeled with ubiquitin.
Indeed, several mitochondrial targets have been identified to be ubiquitinated in a




by the E2 ubiquitin conjugating enzyme Ube2a. The absence of E2 activity blocks
CCCP-inducedmitophagy because ubiquitin is not transferred to Parkin and to Parkin
substrates, and Parkin cannot relocalize to defective mitochondria anymore [72]. Pro-
teomic analyses identified OMMproteins such asMiro, Mitofusin, hFis1, and Tom70
[60,71,73,74] to be modified with lysine 48-linked polyubiquitin chains, suggesting a
possible involvement of proteasome-dependent degradation pathways. Alternatively,
other mitochondrial targets such as the OMM protein VDAC are modified with lysine
63-linked polyubiquitin chains and this is necessary for mitophagy initiation. There-
fore, both types of ubiquitin linkage (via K48 and K63) are mediated by Parkin and
required for mitophagy [43,70–72,75].
Followingmitochondrial ubiquitination, adaptor proteins such as ubiquitin-binding
adaptor protein 62 (p62/SQSTRM1) or histone deacetylase 6 (HDAC6) are required
for the autophagic machinery recruitment to the targeted organelles. p62 links
mitochondria to the autophagic machinery by binding both ubiquitin and LC3, which
initiates the formation of autophagosomes and subsequently fusion with lysosomes
for degradation [68,70].
4.5 CONCLUSION
Although mitophagy is a defined type of selective autophagy and expected to be con-
served among eukaryotes, homologues of several key components involved in yeast
mitophagy have not yet been characterized in mammalian systems. One potential
explanation for such distinction is the purpose of mitophagy in each system. In yeast,
for instance, mitophagy is involved in cell adaptation to diverse nutritional conditions,
while in mammalian cells their role could vary during specific conditions such as
developmental processes (e.g., maturation of red blood cells), starvation, or elimina-
tion of damaged mitochondria. Indeed, while dissipation of mitochondrial membrane
potential seems a critical trigger for mitophagy in many mammalian cells, it has
no effect on yeast cells. This distinction suggests that mitophagy senses mitochon-
drial depolarization for its initiation in mammalian cells versus growth conditions in
yeast. Furthermore, mitophagy activates distinct molecular pathways depending on
cell types in response to variable conditions affecting cell homeostasis. Accumula-
tion of damaged mitochondria and defective lysosomal degradation has been linked
to numerous human disorders such as neurodegeneration and cancer (discussed in
Chapters 9 and 10). While some aspects of mitophagy are revealed, future discover-
ies will shed light on understanding the fine complexity and necessity of this system
in cellular life and disease etiology.
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5.1 INTRODUCTION
It has long been recognized that lysosomes serve as the degradative machinery within
the cell where larger molecules, such as proteins and polysaccharides, are catabolized
into their basic components. In addition to their role in intracellular degradation,
lysosomes can be trafficked to the cell periphery where they release their lumenal
contents into the extracellular space by fusing with the plasma membrane. Lysosome
exocytosis occurs in a large variety of cell types and is used to regulate a number of
biologically important processes. While these processes are diverse, several common
themes have emerged regarding the functions of lysosome exocytosis. Thus, the role
of lysosomes in cellular biology has been expanded, and, in addition to the conven-
tional view that lysosomes are terminal compartments of the endocytic pathway, it is
now accepted that lysosomes behave as regulated secretory vesicles.
5.2 FUNCTIONS OF LYSOSOME EXOCYTOSIS
Lysosomes are acidic organelles that participate not only in intracellular degrada-
tion but also in a wide variety of other cellular functions. Ca2+-triggered fusion of
lysosomes and other intracellular vesicles with the plasma membrane is a highly con-
served phenomenon. Once considered a pathway exclusive to specialized secretory
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cells, we now know that Ca2+-regulated exocytosis is a ubiquitous cellular process
[1]. Investigations of regulated exocytosis in nonspecialized cells, such as fibroblasts
and epithelial cells have identified conventional lysosomes as the major intracellular
compartment capable of reacting to Ca2+ by fusing with the plasma membrane [2].
The capacity to sense Ca2+ rises and respond by lysosome exocytosis is a process
present in a large number of cell types and serves a variety of effector functions [3].
5.2.1 Specialized Lysosome-Related Organelles
Lysosome-related organelle is a term used to describe the modified lysosomal
vesicles found in specialized secretory cells [4–6]. The usage and definition of
the term “lysosome-related organelle” can vary greatly. Some prefer to call most
secretory organelles related to lysosomes “secretory lysosomes,” including lytic
granules of CD8-positive cytotoxic T lymphocytes (CTLs), melanosomes, platelet
dense granules, azurophil granules of neutrophils, and the ruffled border secretory
vesicles of osteoclasts [1,7,8]. Others use the term “lysosome-related organelle”
to encompass these secretory organelles [9,10]. In this chapter, we refer to such
organelles as “lysosome-related organelles.” A key distinction between conventional
lysosomes and lysosome-related organelles originated from the mistaken belief
that conventional lysosomes were unable to undergo exocytic events. However,
it is now understood that conventional lysosomes can also undergo secretion in a
wide variety of cell types. Similar to conventional lysosomes, lysosome-related
organelles have an acidic lumen and contain high concentrations of lysosomal acid
hydrolases. However, unlike conventional lysosomes, which are multivesicular [4,6],
lysosome-related organelles have a heterogeneous morphology and contain a dense
core that holds specialized mediators specifically destined for secretion. Examples of
such contents include melanin in melanocytes, proinflammatory mediators serotonin
and histamine in mast cells, and perforin and granzyme in CTLs [11–13]. Further,
lysosome-related organelles contain unique surface proteins that are specifically
required for secretion and are not used during conventional lysosome exocytosis.
For instance, the exocytic regulator Rab27a and its effector proteins are used by the
majority of secretory cells but are not present on conventional lysosomes [6,14]. Exo-
cytosis of lysosome-related organelles has been studied extensively and may provide
insights into the molecular machinery regulating conventional lysosome exocytosis.
Exocytosis of lysosome-related organelles results in the release of their contents
into the extracellular space, where they perform a number of effector functions. One
of the best studied examples is the Ca2+-dependent degranulation and target cell
killing by CTLs [15]. CTLs function to kill tumor cells or virally infected cells by
making an intimate contact with the target cell called the immunological synapse [16].
CTLs secrete contents contained in lysosome-related organelles, such as perforin and
granzyme A, into the immunological synapse where these proteins elicit cytotoxic
effects on the infected cell [17]. Actin depletion at the immunological synapse initi-
ates events leading to lysosome-related organelle exocytosis, and integrins are used
to seal the contact area thereby containing the secreted lysosomal contents [16,18].
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Lysosome-related organelles can be exocytosed by a large variety of cell types in
addition to CTLs and perform a number of other biologically important functions.
Exocytosis and/or shedding of melanosome-rich packages containing melanin from
the tips of melanocyte dendrites is required for their delivery to the extracellular
space prior to their uptake by keratinocytes, where they protect nuclear DNA from
light-induced damage in the skin [19,20]. Blood clotting relies on lysosome-related
organelle exocytosis of platelet dense granules [21]. Mast cells exocytose histamine
and other proinflammatory molecules from specialized secretory granules that
are responsible for allergic and antiparasitic responses [22]. The exocytosis of
lysosome-related organelles regulates many diverse processes and is therefore of
considerable physiological importance in the context of disease and homeostasis.
5.2.2 Lysosome Exocytosis for Membrane Repair
The discovery that exocytosis of conventional lysosomes occurred in nonspecialized
cells, such as fibroblasts and epithelial cells, arose during the study of cellular wound
repair. Bacterial toxins, such as Streptolysin-O, create pores in the plasma membrane
of cells, which must be sealed to avoid cellular necrosis or apoptosis. Ca2+ influx
through plasmamembrane wounds triggers a rapid repair response that is essential for
cell survival. Calcium ionophores can induce the secretion of predocked conventional
lysosomes in many different cell types [3] and pore-forming toxins in the presence of
extracellular calcium cause lysosome exocytosis in a variety of cells [2]. Interfering
with the exocytosis of lysosomes inhibits the ability of cells to reseal plasma mem-
brane wounds, establishing these organelles as important mediators of plasma mem-
brane repair [23]. Originally, it was thought that lysosomal exocytosis functioned to
promote resealing of thewound solely by providing a source of newmembrane. In this
scenario, resealing is mediated by the addition of intracellular lysosomal membrane
to the cell surface through exocytosis [24,25]. The additional membrane provided
by Ca2+-dependent exocytosis also results in a decrease in plasma membrane ten-
sion that is required for bilayer resealing [26–28]. However, it is now appreciated
that the delivery of lysosomal contents also plays a role in wound healing. In partic-
ular, acid sphingomyelinase, a lysosomal hydrolase, promotes membrane repair by
converting membrane sphingomyelin into ceramide. The generation of ceramide pro-
motes endocytosis and clearance of membrane lesions [29]. In human patients and
murine models, mutations in the genes required for lysosome exocytosis-mediated
plasma membrane repair cause muscular degenerative diseases, thus highlighting the
importance of understanding cellular wound healing [30–32].
Plasmamembrane repair mechanisms are also important in infection as they can be
hijacked to evade host defenses. After attachment of the parasite Trypanosoma cruzi
to the cell, lysosomes surrounding the area fuse with the nascent parasitic vacuole and
provide a source of membrane that promotes parasite internalization [33,34]. Inhibi-
tion of lysosome exocytosis or acid sphingomyelinase blocks the entry of T. cruzi into
cells [33,34]. Mycobacterium tuberculosis infection of cells also induces lesions in
the plasma membrane. Macrophages use lysosome exocytosis in an attempt to repair
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these lesions butM. tuberculosis can interfere with this repair mechanism to promote
macrophage necrosis and evade host defenses [35].
5.2.3 Lysosome Exocytosis as a Source of Membrane
In addition to providing a source of new membrane during cellular wound heal-
ing, lysosome exocytosis to the nascent phagosome provides membrane to facilitate
phagocytosis. This is of particular importance to promote efficient phagocytosis of
large particles, allowing the phagosome to surround the particle and close [36,37].
The nervous system is also thought to rely on lysosome exocytosis to provide a source
of membrane for neuron dendrite growth. Neurons are specialized cells that require
extension and branching of long processes, called dendrites, in order to make con-
nections with other neurons. Recent studies have suggested that lysosome exocytosis
occurs at the tips of newly forming dendrites, which may provide a source of mem-
brane to promote the extension of these protrusions [38].
5.2.4 Lysosome Exocytosis for Extracellular Degradation
Perhaps not surprisingly, akin to their function within the cell, lysosomes can aid
degradation of moieties outside of the cell. This occurs in cases where the target to be
degraded cannot be internalized by standard endocytic or phagocytic mechanisms.
The best-studied example transpires during bone remodeling. Osteoclasts are
multinucleated cells of hematopoietic origin that degrade the bone matrix. They
secrete lysosomal contents onto areas of bone that are destined for remodeling and
resorption [39]. Osteoclasts confine the area of degradation by forming an intimate
contact with the region of bone to be remodeled. This contact is facilitated by a
filamentous actin (F-actin) ring and adhesion molecules, called integrins, that form
a sealing zone [40]. Lysosomal contents are secreted into the contact zone and are
confined to this area. Lysosome exocytosis also delivers vacuolar ATPases to the
sealing zone [41]. Vacuolar ATPases pump protons from the cell into the contact area,
which causes acidification and greater activity of lysosomal enzymes that function
more efficiently at low pH. Interestingly, the osteoclast forms elaborate membrane
protrusions in the contact area called a ruffled border. As in wound repair, lysosome
exocytosis is thought to provide the extra source of membrane required to form the
ruffled border. The ruffled border can be extensive and provides a large surface area
for the release of protons and hydrolases and the uptake of catabolized material [42].
During this process, the osteoclast is polarized, and lysosome exocytosis is thought
to be a driving force to generate and maintain cell polarity [43].
Lysosome exocytosis-mediated bone remodeling plays an important role in skele-
tal pathologies. Recently, it was found that mice with impaired osteoclast lysosome
exocytosis have lower bone mineral density, known as osteopenia, due to defective
remodeling and bone formation [44]. The impaired exocytosis prevents osteoclast
secretion of lysosomal enzymes required to degrade and remodel bone (in particu-
lar cathepsin K). Interestingly, osteoclasts have both lysosome-related organelles and
conventional lysosomes. The lysosome-related organelles contain cathepsin K, which
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degrades type I collagen, the major component of bone matrix and is the main lyso-
somal hydrolase used to degrade bone [45]. Osteoclasts also have a second distinct
population of lysosomes, which lack cathepsin K but contain cathepsin D. Upon bind-
ing of bone matrix proteins and osteoclast integrins, lysosome-related organelles fuse
with the plasma membrane and initiate bone resorption [46]. However, cathepsin D,
which is not thought to play a role in bone remodeling [47], is not released during
the stimulatory event, suggesting that these lysosomes may serve a more conven-
tional role in degradation within the cell [46]. Future studies are needed to examine
lysosome heterogeneity in other types of secretory cells.
An additional example of lysosome exocytosis functioning to degrade extracellu-
lar species occurs during macrophage catabolism of aggregated lipoproteins. During
atherosclerosis, low-density lipoproteins (LDLs) become aggregated and retained in
the arterial wall [48,49]. Macrophages engage the LDL aggregates forming a stable
contact zone into which lysosomal contents are secreted [50] (Figure 5.1). Again,
lysosomal enzymes are confined to the area of degradation by local actin polymer-
ization that restricts passage of molecules from the extracellular compartment to the
outside environment [51]. As in osteoclasts, vacuolar ATPases pump protons into
the extracellular compartment, and an acidic pH allows activity of lysosomal acid
hydrolases delivered by exocytosis. Akin to the ruffled border in osteoclasts, exten-
sivemembrane ruffling is observed inmacrophage contact areas with aggregated LDL
10nm
Figure 5.1 Lysosome exocytosis is required for extracellular degradation. Electron micro-
graph of a macrophage digesting aggregated LDL, labeled with colloidal gold, sequestered in
deep membrane invaginations (arrow). During atherogenesis, macrophages make an extracel-
lular degradative compartment to catabolize aggregated LDL. Formation of the compartment
is likely aided by extensive plasma membrane ruffling at contact sites (asterisks). Lysosomal
enzymes are delivered to the contact area through exocytosis and the compartment is acidified
by plasma membrane vacuolar ATPase, allowing activity of lysosomal enzymes. This process
promotes extracellular degradation of aggregated LDL prior to uptake of partially digested
material and ensuing foam cell formation. Portions of aggregated LDL that have not been
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(Figure 5.1). The membrane required to form this ruffled border may be provided by
lysosome exocytosis. The interaction results in the hydrolysis of LDL cholesteryl
esters and transfer of free cholesterol to the macrophage with subsequent foam cell
formation, a key event in atherogenesis.
5.2.5 Lysosome Exocytosis and Delivery of Proteins to the Cell Surface
In the same way that lysosome exocytosis delivers vacuolar ATPases to the ruffled
border in osteoclasts and macrophages, in dendritic cells, fusion of an intracel-
lular compartment with the plasma membrane delivers major histocompatibility
complex class II (MHCII) to their surface [52]. These MHC class II compartments
(MIICs) are thought to be either a lysosome-related organelle or a conventional late
endosome/lysosome (discussed in depth in Chapter 12). Dendritic cells sample the
local environment by endocytosis of antigens, in an effort to identify pathogens and
initiate an immune response. MHCII, which is present in dendritic cell MIICs, is
important in antigen presentation. Endocytosed antigens are delivered to lysosomes
but are only partially degraded [53] because dendritic cell lysosomes are less acidic
than lysosomes in most cells, thus dampening the activity of many lysosomal
hydrolases [54]. Partially degraded peptides are then loaded onto MHCII, and this
complex is presented on the cell surface. Delivery of the MHCII–antigen complex
occurs by fusion of tubular MIICs with the plasma membrane during the process of
dendritic cell maturation [52]. Cell surface presentation is important for recognition
by other leukocytes, such as T lymphocytes, which then become activated and
initiate an immune response [55].
5.3 MECHANISMS OF LYSOSOME EXOCYTOSIS
Despite its importance in a wide range of processes, current understanding of the
molecular machinery regulating conventional lysosome exocytosis is limited. How-
ever, recent studies have begun to unravel the mechanisms governing exocytosis of
specialized lysosome-related organelles, and many of the key proteins involved are
now known. Consideration of proteins involved in lysosome-related organelle exo-
cytosis may provide important insights into the regulatory machinery likely to be
involved in more general lysosome exocytosis.
There are two main types of exocytosis that occur within the cell. The first is
regulated exocytosis. In this process, cells exhibit polarized exocytosis secondary to
an extracellular stimulatory signal. The regulated exocytosis of lysosomes involves
integration of major cytoarchitectural changes with precisely timed and often targeted
vesicular transport to the extracellular space. The second type of exocytosis is consti-
tutive exocytosis. Molecules such as growth factors and cytokines that are required
in the extracellular space for tissue homeostasis can be secreted constitutively. Such
molecules are synthesized and trafficked through the trans-Golgi network and pack-
aged into vesicles distinct from lysosomes and lysosome-related organelles, which
then fuse with the plasma membrane in a constant manner [56]. In unstimulated
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fibroblasts, epithelial cells, and macrophages, constitutive lysosome exocytosis
occurs at a low frequency, though the rate is slightly higher in macrophages, for
reasons that are not known [2]. This is because in general, lysosome exocytosis is
a regulated process that requires a specific stimulus to induce exocytosis [4,57].
Very little is known regarding the purpose of constitutive exocytosis of lysosomes.
Therefore, we limit our discussion to stimulus-induced exocytosis of lysosomes.
In resting cells, levels of intracellular calcium are strictly maintained. However,
upon stimulation, cell surface receptor-mediated signaling leads to an increase in
intracellular calcium. This stimulates regulated exocytosis of lysosomes (Figure 5.2).
While lysosome exocytosis is predominately regulated by calcium, other factors can
also stimulate exocytosis, such as the depletion of membrane cholesterol [58].
5.3.1 Maturation of Lysosomes and Lysosome-Related Organelles
While the steps regulating lysosome maturation have been the subject of much



















Figure 5.2 Schematic of mechanisms involved in lysosome exocytosis. Lysosomes acquire
lysosomal hydrolases from late endosomes. Signaling through ligation of cell surface receptors
induces microtubule-dependent movement of lysosomes toward the plasma membrane. Local
depolymerization of cortical actin can promote docking of lysosomes at the plasma membrane
in some systems. While in other cell types, tethering of lysosomes to cortical actin appears
to be necessary for exocytosis to occur. Engagement of vesicular membrane-associated and
target membrane-associated SNAREs occurs with the help of accessory proteins, such as cal-
cium sensing synaptotagmins. The binding of SNAREsmakes lysosome fusionwith the plasma
membrane more energetically favorable and influx of calcium stimulates exocytosis to occur.
This releases lysosomal hydrolases and other secretory products into the extracellular envi-
ronment where they mediate various effector functions. (See color plate section for the color
representation of this figure.)
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not well understood. By contrast, the maturation of lysosome-related organelles
prior to fusion with the plasma membrane has been studied in detail (discussed in
depth in Chapter 12). A critical maturation step is the fusion of exocytic vesicles
with immature lysosome-related organelles [60]. Exocytic vesicles are formed from
the fusion of late endosomes and recycling endosomes [61] and deliver proteins
necessary for fusion with the plasma membrane [60]. In mast cells and melanosomes,
lysosome-related organelles maturation can be visualized by the progressive buildup
of secretory cargo in these organelles [11,62,63].
5.3.2 Transport of Lysosomes to the Plasma Membrane
An early step in the process of lysosome exocytosis is their transport to the plasma
membrane. Rab GTPases are a family of evolutionary conserved small GTPases that
are important regulators of intracellular trafficking [56,64]. Members of the Rab
GTPase family have been shown to control regulated exocytosis of lysosome-related
organelles that are secreted in response to external stimuli. Rab GTPases are
typically present on the lysosome-related organelle, and upon stimulation of the cell,
they become activated and bind to a discrete set of effector proteins. Rab effector
proteins are involved in both the transport of lysosomes to the plasma membrane via
microtubules and actin as well as their docking at the membrane prior to exocytosis.
5.3.2.1 Microtubules in Lysosome Transport Lysosomes and secretory vesicles
in many cell types are transported within the cell through interaction with the micro-
tubule network [33,65,66]. The spatial targeting of lysosomes is regulated through
association with the microtubule motor proteins kinesin and dynein. Kinesins and
dyneins can bind tomicrotubules by their heavy chains and to lysosomes by their light
chains [67]. The heavy chains are responsible for the motor activity and move pro-
cessively along microtubules in a manner that requires ATP hydrolysis [67]. Micro-
tubules emerge from a structure called the microtubule-organizing center (MTOC),
which is the major site of microtubule nucleation within the cell [68]. Kinesin heavy
chains move along microtubules toward the plus end (the end distal to the MTOC),
while dynein heavy chains move toward the minus end (the end proximal to the
MTOC), transporting lysosomes with them. Lysosome dispersion within the cell and
anterograde/retrograde transport of lysosomes toward the cell periphery/interior is
therefore dependent on kinesin and dynein.
Several studies have attempted to characterize the interaction of kinesin/dynein
light chains with lysosomes. Kinesin light chain interaction with lysosomes is thought
to occur due to binding to the lysosomal proteins SifA, kinesin-interacting protein
and the small GTPase Arl8 in its GTP-bound active form [69]. Dynein light chains
can interact with Rab7-interacting lysosomal protein (RILP), which binds the small
GTPase Rab7 in its active GTP-bound form in fibroblast-like Rat2 cells [70]. In
this way, active Rab7 and RILP regulate lysosome minus end transport by recruit-
ing dynein motors to lysosomes [71]. Dynein is known to interact with the accessory
protein dynactin, which is required for minus end transport. Overexpression of the
dynamitin (p50) subunit of dynactin disrupts dynein/dynactin complex formation and
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redistributes lysosomes to the cell periphery in HeLa cells [72]. Therefore, it seems
that under resting conditions in the cell, this “tug of war” between kinesin and dynein
regulates lysosome distribution within the cell.
In CTLs, the MTOC polarizes toward the cell to be killed, so minus end transport
allows lysosome-related organelles to be trafficked toward the target cell [73]. This
function requires Rab7 and the effector RILP, which interact with dynein and couple
lysosome-related organelles to minus end transport [74]. The adaptor protein AP-3
has also been implicated in promoting minus end microtubule-dependent transport of
lysosome-related organelles in CTLs [75], and consistent with this, depletion of AP-3
in HEK293T cells causes lysosomes to accumulate at the cell periphery [76]. How-
ever, AP-3 does not localize to lysosome-related organelles; therefore, it is likely that
AP-3 does not interact directly with the dynein/dynactin complex but rather regulates
the sorting of cargoes important for minus end transport [75,76].
Exogenous factors can also influence lysosome distribution and transport. Choles-
terol is known to regulate lysosome distribution, and its depletion redistributes lyso-
somes to the cell periphery [58]. However, the role of microtubules in this process
has not been evaluated. Cholesterol regulation of organelle distribution was recently
suggested to be mediated by cholesterol binding to the Rab7 effector Orp1-like, in
late endosomes [77], and this may also be true for lysosomes. In live cell experiments,
macrophage lysosomesmake tubular structures that extend radially and are dependent
on microtubules [78,79]. Formation of tubular lysosomes can be stimulated by exoge-
nous factors, such as lipopolysaccharide and phorbol-12-myristate 13-acetate, and
their formation is dependent on dynein, kinesin, Rab7, RILP, FYCO1, Arl8, and SKIP
[80,81]. Tubular lysosomes were also found to be motile more often than punctuate
lysosomes [80], suggesting a link between microtubule-dependent motility of lyso-
somes and their morphology. Interestingly, in some cell types, microtubules appear
to be less important in lysosome secretion [82]. This perhaps suggests that in certain
circumstances, lysosomes in close proximity to the plasma membrane do not require
microtubule transport and can be selectively exocytosed.
Rab7 is a protein known to be associated with the lysosome [71]. Rab7 func-
tion has been characterized in the endocytic pathway, where it promotes late
endosome/lysosome fusion. However, it also induces microtubule-based motility of
lysosomes within the cell. It is presumably through this aspect of Rab7 function that it
plays a role in lysosome-related organelles exocytosis in CTLs [74]. This is supported
by the fact that in CTLs, as discussed above, Rab7 interacts with the effector RILP that
recruits the microtubule motor protein dynein [74]. Rab7 also likely plays a role in
lysosome-related organelle exocytosis from osteoclasts [43,83]. Further, Rab7-GTP
is known to interact with Rac1, so it has been suggested that this interaction may
promote switching of microtubule to actin-based transport of lysosomes [84].
5.3.2.2 Cortical Actin in Lysosome Exocytosis The role of cortical actin in exo-
cytosis has been debated in recent years. Some studies suggest that F-actin is required
to tether lysosome-related organelles close to the plasma membrane prior to exocy-
tosis while others find that F-actin creates a barrier that requires remodeling prior
to exocytosis. In melanocytes, cortical actin seems to play an important role in the
 

72 LYSOSOME EXOCYTOSIS AND MEMBRANE REPAIR
peripheral distribution of melanosomes prior to exocytosis. Microtubule-based trans-
port of melanosomes is followed by their peripheral tethering to cortical actin due
to the actions of the Rab27a/Melanophilin/Myosin Va complex [85,86]. This is a
requirement for pigment transfer as deficiency of any protein in this complex leads
to pigment dilution in the skin of mice and humans [87–92]. Similarly, melanosome
secretion from retinal pigment epithelium, the color producing cell in the eye, requires
a Rab27a/MyRIP/Myosin VIIa complex to perform tethering to cortical actin prior to
exocytosis [93]. Melanocytes are not the only cell types to use this tethering function.
In neural PC12 cells, Rab27a and MyRIP link secretory granules to F-actin and this
interaction has been proposed to control the motion of granules to exocytic sites [94].
While some lysosome-related organelles show a requirement for peripheral teth-
ering to cortical actin prior to exocytosis, there is also evidence that cortical actin
acts as a barrier to lysosome secretion and must be remodeled to allow exocytosis
to occur (Figure 5.2). Actin depolymerization prior to stimulation with a calcium
ionophore increased apical lysosome exocytosis from Madin–Darby canine kidney
epithelial cells [82]. Depolymerization of F-actin also increased lysosome exocytosis
from NRK cells in response to calcium, while F-actin stabilization using phalloidin
reduced lysosome exocytosis in this system [95]. Further, entry of T. cruzi into cells,
which is dependent on lysosome exocytosis, is enhanced under conditions where actin
is depolymerized [33]. F-actin depolymerization prior to stimulation also increases
granule exocytosis from mast cells [66,96,97]. These studies support a barrier func-
tion for F-actin in exocytosis, in which actin polymerization slows the transport of
lysosome-related organelles [98,99]. Recently, the secretory machinery itself was
proposed to remodel F-actin in the local environment of secretory granules, thereby
promoting exocytosis. The Rab27 effector synaptotagmin-like protein 1 (Slp1) was
found to recruit RhoA-GAP GMIP and inhibit RhoA signaling on secretory gran-
ules. In neutrophils, this promotes remodeling of F-actin around secretory granules
allowing them to traverse cortical actin prior to exocytosis in neutrophils [99]. Further
studies are needed to determine the mechanisms by which the secretory machinery
in other cell types is able to overcome this F-actin barrier prior to exocytosis as well
as if and when actin remodeling is necessary.
5.3.3 Tethering of Lysosomes to the Plasma Membrane
Currently, the Rab GTPases regulating lysosome exocytosis remain largely
uncharacterized, though their role in exocytosis of lysosome-related organelles
has been intensively studied (Table 5.1). Several “secretory” Rab GTPases have
been identified, including Rab27 and Rab3, which are related through amino
acid sequence similarity. Many studies have focused on the role of Rab27 and
Rab3 as they are expressed in a variety of different cell types. Rab27a regulates
exocytosis of lysosome-related organelles from CD8 positive CTLs [12]. While
Rab27a-deficient ashen CTLs polarize correctly to the site of contact with the target
cell, lysosome-related organelles do not dock with the plasma membrane, suggesting
a role for Rab27a in this process. CD4-positive T helper lymphocytes typically
use mechanisms distinct from CTLs to kill target cells, but there have been reports
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TABLE 5.1 Summary of Secretion Machinery Used by Different Cell Types for
Exocytosis of Various Secretory Organelles
Cell Type Organelle Proteins Regulating
Secretion
References
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TABLE 5.1 (Continued)
Cell Type Organelle Proteins Regulating
Secretion
References




































of CD4-positive lysosome-related organelle-mediated cytotoxicity in response to
certain pathogens [103,138,139]. Rab27a is important for lysosome-related organelle
exocytosis in CD4-positive T lymphocytes as well [140]. Mast cells use both Rab27a
and its related isoform Rab27b in conjunction with Munc13-4 to promote secretory
granule exocytosis [97,102,115]. In Rab27a/b double knockout mast cells, granules
exhibited more prominent long-range movements than in wild-type cells. This was
inhibited by nocodazole treatment, which disrupts microtubules, suggesting that
Rab27 may promote plasma membrane docking of granules and in its absence,
granules remain associated with microtubules [102]. Using Munc13-4 (FQL>AAA)
and Munc13-4 (Δ280-285) mutants that specifically disrupt the Munc13-4/Rab27
association, it was shown that this interaction is required for stimulation-induced
granule docking at the plasma membrane [115].
Rab27 and Munc13-4 have also been found to play a role in exocytic events
in NK cells, platelets, and neutrophils [98,116,124–128,133,141–143]. While the
rudimentary details about how Rab27/Munc13-4 function to promote exocytosis in
NK cells and platelets are known, the exact mechanisms remain to be determined. It
is likely that in these cell types, Rab27/Munc13-4 functions in much the same way
that they do in mast cells. In addition to Rab27 and Munc13-4, recent studies have
suggested a role for the effector Slp1 in neutrophil granule exocytosis. In neutrophils
isolated from Slp1 knockout mice or in cells treated with Slp1 blocking antibod-
ies, azurophilic granule secretion is inhibited [99,126]. Slp1 can bind to plasma
membrane phospholipids, particularly phosphoinositide 3,4,5 triphosphate (PIP3).
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This may suggest that Slp1 promotes exocytosis by recruiting Rab27-positive
granules to membrane microdomains rich in PIP3 and allowing them to dock there
prior to calcium-dependent exocytosis. Consistent with this, HL-60 neutrophil-like
cells that were downregulated for Slp1 displayed increased LAMP-3-positive granule
velocity and displacement, suggestive of greater microtubule-based transport and
decreased granule docking at the plasma membrane [126].
Rab3, which exists in four isoforms (Rab3a, 3b, 3c, and 3d), is related to Rab27
in terms of structure [64]. Rab3a has been implicated in the regulation of exocyto-
sis from sperm cells called spermatids [136]. Spermatids contain one large acidic
dense-core granule that is related to a lysosome, called an acrosome. Upon contact
with an oocyte during the process of fertilization, the acrosome is exocytosed [144].
This releases digestive enzymes onto the oocyte and helps the spermatid to break
through the hard shell of the oocyte [145]. This process is similar to that described
previously for osteoclast bone resorption and macrophage degradation of aggregated
LDL. Acrosome exocytosis is regulated by both Rab27 and Rab3. A sequential model
of action has been proposed in which Rab27 recruits a guanine nucleotide exchange
factor for Rab3 that allows Rab3a to become activated [119]. Rab3d is thought to
regulate exocytosis from other granulocyte cell types, such as eosinophils [146] and
mast cells [101,110,134,147], though much less is known about their regulation.
5.3.4 Lysosome Fusion with the Plasma Membrane
Recent work has demonstrated a key role for Soluble NSF Attachment REceptor
(SNARE) proteins in membrane fusion events within the cell. SNARE proteins are
expressed on each of the membranes destined to fuse. They each contain at least one
α-helical domain that can bind to specific α-helical domains of other SNAREproteins.
These helices form a specific and stable four-helix bundle and induce energetically
favorable conditions to allow membrane fusion events to take place (Figure 5.2).
The vesicular SNARE (v-SNARE) VAMP-7 and the target SNAREs (t-SNAREs)
syntaxin 4 and SNAP-23 are involved in lysosome exocytosis in response to wound-
ing in NRK cells [112]. In platelets, SNAP-23, syntaxin 2, and syntaxin 4 were
found to be involved in exocytosis of conventional lysosomes [114]. For the exocyto-
sis of lysosome-related organelles, additional SNAREs have been implicated. These
include VAMP-2 and VAMP-8 for lysosome-related organelles in CTLs [121,122],
VAMP-4 and VAMP-7 in NK cells [129], VAMP-7 and VAMP-8 in mast cell granule
exocytosis [108,109], and Syntaxin 11 in platelets, neutrophils, NK cells, and CTLs
[148–150] (Table 5.1). Recent work has indicated that lytic granules in NK cells do
not fuse completely with the plasmamembrane [100]. This type of exocytosis is often
referred to as “kiss-and-run” and is also known to occur in the context of adrenal
chromaffin cell granule release [151,152]. Similarly, in NK cells, “kiss-and-run” exo-
cytosis may promote reclamation of lytic granule membrane and proteins; however,
the factors influencing incomplete fusion of lysosome-related organelles with the
plasma membrane are not well understood.
 

76 LYSOSOME EXOCYTOSIS AND MEMBRANE REPAIR
5.3.5 Calcium-Dependent Exocytosis
Lysosome exocytosis in many cell types has been shown to be calcium dependent.
The protein Synaptotagmin VII (Syt VII) is thought to function as a calcium
sensor for the exocytosis of lysosomes. Syt VII is important for calcium-dependent
exocytosis of lysosomes in fibroblasts [104] and mediates cell invasion by T. cruzi
that is dependent on calcium-regulated exocytosis of lysosomes [105]. It is also
required for plasma membrane repair in response to scratch-induced wounding of
NRK cells [23] and to repairM. tuberculosis-induced plasma membrane lesions [35].
In addition, Syt VII regulates calcium-dependent lysosome exocytosis at the rear
of the cell. This can facilitate cell detachment and efficient migration of T cells
and neutrophils [106], lysosome exocytosis in osteoclasts [44], and to nascent
phagosomes in macrophages [37]. Lysosomes are the major vesicular compartment
to exocytose in response to calcium in astrocytes [107], which is important for
ATP release [111], and Syt VII is required for lysosome exocytosis as a source of
membrane to promote neurite outgrowth [38]. The relationship between Syt VII
and SNARE proteins in lysosome exocytosis has not been fully characterized, but
one study found that calcium influx into wounded NRK cells stimulates formation
of a complex consisting of SNAP-23/Syntaxin 4/VAMP7, which interacts with
Syt VII [112]. This would allow Syt VII to confer calcium sensitivity to the
SNARE fusion machinery (Figure 5.2). Another regulator of lysosome exocytosis
is transcription factor EB, which can promote the fusion of lysosomes with the
plasma membrane. The overexpression of transcription factor EB raises intracellular
Ca2+ levels through the activation of the lysosomal Ca2+ channel MCOLN1 [113].
Interestingly, a recent study found a pool of lysosomes that can be exocytosed in
response to cholesterol depletion in the plasma membrane independently of Syt
VII and that this exocytosis occurred more efficiently in the absence of Ca2+ [58].
This suggests the existence of a distinct pool of lysosomes that may utilize different
secretory proteins to undergo exocytosis in a calcium-independent manner.
5.4 CONCLUSION
Lysosome exocytosis plays an important role in diverse biological processes such as
plasma membrane repair following mechanical or bacterial cellular damage, immune
responses, parasite entry into cells, bone remodeling, phagocytosis of large parti-
cles, and extracellular degradation of disease-associated substrates. While significant
progress has been made in understanding how lysosome exocytosis is regulated in
various physiological systems, there is much yet to be learned. Parallels can be drawn
between the exocytic regulation of conventional lysosomes and lysosome-related
organelles. This is likely to serve as a template to guide future studies attempting to
understand lysosome exocytosis in different cell types and systems.While our current
understanding of the secretory machinery regulating lysosome exocytosis is limited,
it is clear that elucidation of such mechanisms will have direct significance for human
health. Discoveries may offer new strategies and drug targets for the prevention and
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6.1 INTRODUCTION
Many of the acid hydrolases in late endosomes and lysosomes (LE/Ly) participate
in the breakdown of lipids. Lipids are delivered to lysosomes by endocytic uptake
of lipoproteins, as components of the lipid bilayer involved in vesicle transport, by
autophagy, and by cytoplasmic lipid transport proteins. Lipids can leave lysosomes by
vesicle transport, by export to cytoplasmic lipid transport proteins, or by lysosome
secretion. For several reasons, specialized mechanisms are required for hydrolysis
of lipids in LE/Ly. First, the membrane integrity of the LE/Ly must be maintained
even as some of the lipid components that were once part of its limiting bilayer are
hydrolyzed, so the outer limiting membrane must be protected from hydrolysis even
as extensive lipid hydrolysis is taking place. Second, many of the lipid components
are highly insoluble in water, so mechanisms must be employed to allow enzymatic
access to cleavage sites. In some cases (e.g., cholesterol), special mechanisms are
required to solubilize the hydrophobic products of hydrolysis. The mechanisms used
by LE/Ly to hydrolyze lipids and some of the disease states that occur when these
mechanisms fail are discussed in this chapter. The role of lysosomes in responding
to nutrient status is also discussed.
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6.2 ENDOCYTIC UPTAKE OF LIPOPROTEINS
Probably the best characterized example of lysosomal digestion of lipids is the hydrol-
ysis of cholesteryl esters that are present in the core of low-density lipoprotein (LDL)
particles taken into the cell by receptor-mediated endocytosis [1–3] (Figure 6.1). LDL
receptors are expressed on the surface of most nucleated mammalian cells, and they
bind LDL particles, which are derived from larger lipoproteins, very low-density


















Figure 6.1 Schematic diagram of lipoprotein and lipid droplet degradation by lysosomes.
Low-density lipoproteins (LDLs) bind to receptors on the surface of cells and are rapidly inter-
nalized via clathrin-coated pits. The contents of the clathrin-coated pits are delivered to sorting
endosomes, which are transient organelles with an internal pH of about 6.2. The low pH causes
LDL to dissociate from its receptor, and the empty receptors are rapidly exported from the
sorting endosome in narrow diameter tubules. The receptors return to the cell surface either
directly or after passing through an intermediate organelle, the endocytic recycling compart-
ment (ERC). The sorting endosomes mature into late endosomes, which are somewhat more
acidic and have lysosomal enzymes that have been delivered from the trans-Golgi network.
Membrane invaginations at the surface of the late endosomes create internal vesicles that are
enriched in BMP. Lysosomal enzymes, which are activated by the low pH, and these digest the
internalized LDL. Membrane lipids in the bilayer are mainly digested on the internal vesicles,
which protects the limiting membrane against leakage. Lipid droplets can be surrounded by
phagophores to create an autophagosome, which fuses with late endosomes or lysosomes to
create a digestive autolysosome. Figure created by David B. Iaea. (See color plate section for
the color representation of this figure.)
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a nonlysosomal enzyme, lipoprotein lipase, which is held on the surface of certain
endothelial cells by a GPI-anchored receptor, GPIHBP1 [4–6]. The lipase hydrolyzes
the triacylglycerides in the core of VLDL, leaving smaller cholesteryl ester-rich LDL
particles that circulate throughout the body but not the central nervous system. LDL
receptors, which bind the circulating LDL, are internalized via clathrin-coated pits
and delivered to early sorting endosomes, which maintain an internal pH of about 6.2
[7,8]. This pH is sufficiently acidic to cause dissociation of LDL from its receptor, and
the LDL receptors then are free to recycle while the LDL remains in the early sort-
ing endosome as it matures into a late endosome (LE) [7,9]. Unless retained in the
sorting endosomes by a signal, most membrane components are returned to the cell
surface. This is accomplished by an iterative process in which newly formed vesicles
that are pinched off from the surface continue to fuse with a sorting endosome for
several minutes [7,10]. During this time, narrow diameter tubules, which have a high
surface-to-volume ratio, repeatedly pinch off from the sorting endosome and deliver
the membrane components (and a small amount of the volume) back to the surface
either directly or through an intermediate compartment called the endocytic recycling
compartment (ERC) [10–12].
In the LE, the LDL begins to encounter lysosomal enzymes that have been deliv-
ered from the trans-Golgi network [13]. The lysosomal proteases digest the protein
components, and a single enzyme, lysosomal acid lipase, digests the cholesteryl
esters and triacylglycerides in the core of lipoproteins [14]. This releases cholesterol
and a fatty acid from the cholesteryl esters and glycerol and fatty acids from the
triacylglycerides. (Deficiencies in lysosomal acid lipase lead to Wollman disease or
cholesteryl ester storage disease [14].) Cholesterol is highly insoluble in water, so
it needs to be bound to transport proteins when it is not in a bilayer. In the LE/Ly, a
soluble protein called NPC2 serves this role [15]. It now appears that NPC2 delivers
the cholesterol to an LE/Ly membrane protein, NPC1, which helps to shuttle the
cholesterol to the limiting membrane of the LE/Ly [16–18]. The itinerary of choles-
terol after insertion into the limiting membrane is uncertain, but it may be transported
by one or more cytoplasmic sterol-binding proteins and delivered to other organelles
[19,20]. Homozygous defects in either NPC1 or NPC2 cause Niemann–Pick C
disease, which is characterized by abnormal accumulation of cholesterol and other
lipids in LE/Ly. β-Cyclodextrins can chelate cholesterol and facilitate its exchange
among membranes. When delivered into the LE/Ly, β-cyclodextrins can bypass
the requirement for both NPC1 and NPC2, suggesting that delivery of sterol to the
limiting membrane of the LE/Ly is the essential role of these proteins [20]. Clinical
trials for treatment of NPC patients with β-cyclodextrins have been initiated [21].
Some LE are also described as multivesicular bodies (MVBs) because their lumen
is filled with small vesicles and inward budding tubules. The internal vesicles are
formed by the invagination of the limiting membrane into the lumen of the LE under
the control of a set of proteins called the endosomal sorting complexes required
for transport (ESCRT) complex [22]. These inward invaginations are enriched in
proteins that had been mono-ubiquitinated, and their inclusion in these structures
helps prevent their recycling. The internal vesicles are highly enriched in an unusual
lipid, bis(monoacylglycero)phosphate (BMP) (also called lysobisphosphatidic acid in
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some older publications), a negatively charged glycerophospholipid with an unusual
sn-1;sn-1′ structural configuration, that is present at very low levels elsewhere in
the cell [23,24]. Under some circumstances, these internal vesicles containing BMP
could hold some of the cholesterol that is released by the action of lysosomal acid
lipase, but typically these vesicles become enriched in ceramide following hydrol-
ysis of sphingomyelin (SM) by acid sphingomyelinase. The ceramide can displace
cholesterol from lipid bilayers [25], so normally these internal membranes would be
expected to have low cholesterol content.
In peripheral cells (i.e., outside the central nervous system), the cholesterol derived
from LDL uptake provides some of the cholesterol used by cells for incorporation
into lipid bilayers. Excess cholesterol is esterified by acyl-coA-cholesterol acyltrans-
ferase (ACAT), an ER-associated enzyme, and the cholesteryl esters are stored in
cytoplasmic lipid droplets [26]. Some cholesterol is effluxed from the plasma mem-
brane, mainly by delivery to high-density lipoproteins (HDLs) [27]. Small amounts
of cholesterol are converted into oxysterols, which play regulatory roles in cells by
binding to oxysterol-binding proteins and to some nuclear receptors [28,29].
Most cells can also synthesize cholesterol, so the total cholesterol in a cell is a bal-
ance between uptake and synthesis versus export and conversion to oxysterols (or bile
salts in the liver). The major regulator of total cell cholesterol is the SREBP2 tran-
scriptional regulator [30]. SREBP2 is a membrane protein with two transmembrane
domains. In conditions of high cholesterol, SREBP2 is retained in the ER by binding
to SCAP and Insig [31]. When cholesterol levels are reduced, SCAP and SREBP2 are
released from Insig, and they are transported to the Golgi apparatus via COP-II trans-
port vesicles. In the Golgi, SREBP2 is cleaved sequentially by two endoproteases,
releasing a cytoplasmic fragment that is translocated into the nucleus, where it acti-
vates transcription of several genes involved in the synthesis of cholesterol. SREBP2
also activates the transcription of the LDL receptor, so it can simultaneously increase
cholesterol uptake and synthesis by cells.
Two important cell types for lipid metabolism are hepatocytes and macrophages.
Hepatocytes are the key cells in mammals for regulation of lipoproteins and choles-
terol. Dietary cholesterol is packaged in intestinal cells into large lipoproteins called
chylomicrons that contain ApoB48 and other apolipoproteins, including ApoE. These
particles are enriched in triacylglycerides and to a lesser extent cholesteryl esters.
After being acted on by lipoprotein lipase, the chylomicron remnants are internalized
by hepatocytes by binding to a variety of receptors [32,33], and they are hydrolyzed in
LE/Ly as described earlier. Some of the fatty acids and cholesterol are reesterified and
packaged into VLDL particles, which are large lipoproteins containing ApoB100
and other apolipoproteins including ApoE. The core of the VLDL is also mainly
triacylglycerides with some cholesteryl esters. Similar to chylomicrons, the VLDL
is acted on by lipoprotein lipase, hydrolyzing the triacylglycerides and leaving a
cholesteryl ester-enriched LDL particle, which can be taken up by many cell types as
described earlier. When overall cholesterol levels are in balance, LDL receptors on
the hepatocyte play a major role in clearing LDL from the circulation by endocytosis
into hepatocytes. Since cholesterol is not catabolized, the main pathway for clear-
ance from the body is conversion to bile salts in hepatocytes and excretion [34]. In
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conditions of excess LDL cholesterol, the hepatic LDL receptors are downregulated,
and LDL levels in the circulation rise due to reduced hepatic uptake.
Recently, it has been found that a circulating protein, proprotein convertase sub-
tilisin/kexin type 9 (PCSK9), promotes downregulation of LDL receptors in certain
tissues, including liver [35]. PCSK9 binds to the LDL receptor and redirects it from
its normal recycling itinerary toward lysosomal degradation by a mechanism that is
not well understood at present. Antibody therapies to inactivate PCSK9 have recently
been approved for treatment of elevated LDL in some individuals [36].
Some LDL percolates through the endothelium, especially in areas of high shear
stress, and this LDL can accumulate in the wall of blood vessels. Macrophages nor-
mally clear this LDL and digest it by lysosomal hydrolases. Excess cholesterol in
the macrophages is effluxed to HDL and can return to the liver. Under conditions of
elevated LDL cholesterol, the cellular cholesterol load in the macrophages is beyond
the capacity of the efflux system, and the excess cholesterol is esterified by ACAT
and stored as lipid droplets. Under conditions of extreme cholesterol loading, the
macrophages become filled with lipid droplets that are enriched in cholesteryl esters,
and these macrophage foam cells can eventually die as a consequence of the lipid
loading [37–39].
6.3 LIPID METABOLISM IN LATE ENDOSOMES AND LYSOSOMES
Lipids are brought into LE/Ly by vesicle transport, and LE/Ly are a significant site
for the catabolism of these lipids. It should be noted, however, that breakdown and
remodeling of lipids occur in many membranes of the cell, and this contributes to the
variation in lipid composition among membrane organelles [40]. Much of our knowl-
edge about the various lipid degrading enzymes in LE/Ly was initiated by studies of
patients with lysosomal storage diseases, as discussed later in this section. Most lipid
degradation products that are formed in LE/Ly are subsequently used by the cell to
create new lipids. For example, in human fibroblasts, it was found that 90% of the
sphingoid base incorporated into glucosylceramide was recycled after degradation of
sphingolipids, and only 10% was newly synthesized [41]. Fatty acids released from
LE/Ly following lipid hydrolysis are also used for energy production.
Hydrolysis of membrane lipids in lysosomes presents a special problem because it
is essential to maintain the integrity of the limiting membrane while allowing efficient
degradation of lipids delivered to the LE/Ly. Protection of the limiting membrane is
achieved by having a dense enzyme-resistant glycocalyx composed of the glycocon-
jugates of lysosomal membrane proteins – the lysosomal integral membrane proteins
(LIMPs) and lysosome-associated membrane proteins (LAMPs) [42,43]. The invagi-
nated membranes and internal vesicles formed by the ESCRT complexes lack this
glycocalyx, and they are sites of lipid hydrolysis as well as the degradation of inte-
gral membrane proteins. The special properties of these internal vesicles have been
described in detail in several reviews [43–45].
Glycerolipids can be cleaved by several lysosomal phospholipases, including
isoenzymes of acid phospholipase A2 (group XV PLA2), which have broad speci-
ficity and some preference for phosphatidylcholine and phosphatidylethanolamine
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[43,46]. Sphingomyelin (SM) and glycosphingolipids (GSLs), which have phos-
phorylcholine or glycoconjugates attached to the hydroxyl group of ceramide,
have more complex degradation mechanisms [44,45]. The degradation of the GSLs
begins with stepwise removal of monosaccharides from the terminal ends of the
glycoconjugates. These ends of the glycoconjugates protrude into the aqueous phase
and are easily reached by the acid hydrolases in the LE/Ly. However, the last few
sugars (i.e., those closest to the membrane) can only be removed with the assistance
of sphingolipid activator proteins (saposins or SAPs) that solubilize the glycolipids
and present them to acid hydrolases. Four saposins, SAP A–D, are derived by pro-
teolytic hydrolysis of a precursor protein, prosaposin, which is delivered to LE/Ly
by the mannose-6-phoshate receptor system. Another soluble activator protein, the
GM2-activator protein (GM2-AP), is essential for the degradation of ganglioside
GM2 by β-hexosaminidase A [47]. GM2-AP selectively extracts gangliosides such as
GM1 and GM2 frommembranes and presents them in the aqueous phase to the active
sites of acid hydrolases. The GM2-AP is an essential component of the enzymatic
complex. Lack of GM2-AP leads to a lysosomal storage disorder with accumulation
of the GM2 ganglioside. GM2-AP and other activator proteins are sometimes called
“liftases” because they have no enzymatic activity of their own, but they pull the lipid
substrates out of the bilayer and present them to the hydrolases that cleave them [48].
SAPs A–D are small, highly homologous, protease-resistant proteins that are sol-
uble in the lumen of LE/Ly. They are homologous to other lipid-binding proteins,
including some of the pore-forming lipid-binding proteins released by bacteria. The
saposins have positively charged surfaces that can interact with negatively charged
membranes. One of the key features of the internal vesicles in LE is that they are
highly enriched in BMP, which retains a negative charge even in the acid environ-
ment inside LE/Ly [49,50]. It has been estimated that more than half of the lipids
in some of the internal vesicles are BMP [51]. This negatively charged lipid pro-
vides a favorable docking platform for the saposins [49]. Although all four of the
saposins are able to extract lipids from membrane bilayers, they differ in their speci-
ficity for presenting sphingolipids to acid hydrolases as seen by the differences in
the lipids that accumulate when different saposins are defective in human lysosomal
storage diseases [45]. Degradation of sphingomyelin by acid sphingomyelinase does
not require an activator protein because acid sphingomyelinase has a SAP homology
domain, which carries out the same function [45].
The important role of the anionic lipid BMP has implications for understanding
some drug-induced effects on sphingolipid breakdown (see Chapter 20). It is known
that many amphiphilic weak bases can cause accumulation of phospholipids, sph-
ingolipids, and cholesterol in LE/Ly [52]. Because the uncharged species of a weak
base can cross amembrane by passive diffusionmuchmore rapidly than the positively
charged form, weak bases will accumulate in acidic organelles such as LE/Ly since
it is the uncharged species that equilibrates across the membrane (see Chapter 18). In
acidic organelles, the fraction of molecules in the protonated, positively charged form
is increased. An amphiphilic weak base (i.e., one with a hydrophobic portion in addi-
tion to the titratable weak base – usually an amine) will also partition into membrane
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bilayers. When these positively charged weak bases associate with the internal vesi-
cles in LE/Ly, they neutralize the negative charge imparted by BMP. This causes the
saposins and acid sphingomyelinase to dissociate from the internal vesicles in the
LE/Ly. When released from the internal vesicles, these proteins are more susceptible
to proteolytic degradation, further reducing their activity [43].
An interesting aspect of this is the pH dependence of enzymes involved in sph-
ingolipid hydrolysis. The pH of endolysosomal organelles drops from early sorting
endosomes (pH≈ 6.2) to LEs (pH≈ 5.5) to lysosomes (pH 5.0 or below) [7,53].
These pH changes alter the activity of enzymes involved in sphingolipid catabolism.
The enzymes acid sphingomyelinase and glucosylceramide-β-glucosidase, which
produce ceramide from sphingomyelin and glucosylceramide, respectively, have pH
optima near pH 5.5 [45]. This favors ceramide production at the pH found in LEs.
In contrast, acid ceramidase, which converts ceramide into sphingosine, has a pH
optimum near 4.0, and at pH 5.5 it actually favors the reverse reaction converting
sphingosine to ceramide. These reactions all keep ceramide relatively high in the
LE/MVBs. The ceramide competes with cholesterol for sites in the lipid bilayer
because both of these lipids have small headgroups that need to be shielded from
the aqueous phase [25]. High ceramide on internal membranes in MVBs may help
to deliver cholesterol to NPC2 by reducing the stability of the cholesterol in the
bilayer (i.e., increasing its chemical activity coefficient) [49,54]. Sphingosine has a
positive charge and would neutralize the negative charges from BMP as discussed
above. This would promote dissociation of saposins and acid sphingomyelinase
from internal membranes and slow down sphingolipid catabolism.
As described in Chapter 11, many lysosomal storage diseases are associated with
abnormal lipid accumulation. It has been noted that several of these disorders with
different primary deficiencies lead to a similar spectrum of lipid accumulation [55].
Thus, several disorders lead to accumulation of sphingolipids and cholesterol in the
storage organelles. This similar lipid profile arising from different primary causes can
be understood in terms of the general properties of lipid biophysics and the biochem-
istry of lipid degradation. For example, Niemann–Pick disease type C arises from
recessive mutations in genes encoding NPC1 and NPC2 [56]. As expected, choles-
terol levels are increased in the LE/Ly of cells with homozygous defects in either the
NPC1 or NPC2 genes. However, these cells also accumulate sphingomyelin, other
sphingolipids, and BMP. In neuronal cells, the accumulation of gangliosides is partic-
ularly evident [57]. Studies of the biophysics of membranes have demonstrated that
sphingomyelin and cholesterol have an energetically favorable association in lipid
bilayers [58], so the increased cholesterol may stabilize sphingomyelin and slow its
degradation by acid sphingomyelinase. Ceramide, the product of sphingomyelinase,
would displace cholesterol from membranes, so the cholesterol:sphingomyelin inter-
actions would be mutually reinforcing [25]. In fact, when acid sphingomyelinase
levels are increased in the LE/Ly of Niemann–Pick C mutant cells, the cholesterol
storage in these organelles is greatly reduced [59]. The same cholesterol:sphingolipid
interactions would lead to increased cholesterol content in LE/Ly of cells with defects
in acid sphingomyelinase or in GSL hydrolysis.
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6.4 AUTOPHAGY AND LYSOSOMAL LIPID TURNOVER
Autophagy, which is discussed in Chapter 2, plays important roles in lipid degrada-
tion in lysosomes. In this process, portions of the cytoplasm, including organelles,
are engulfed by membranes to form sealed autophagosomes. Lysosomes fuse with
the autophagosomes to form autophagolysosomes, which digest the contents of the
autophagosomes. As with other catabolic processes in lysosomes, the breakdown
products are then released back into the cell and can be reused.
Autophagy may play an important role in the synthesis of BMP. The biosyn-
thetic route to production of BMP is unknown, but potential precursors include
phosphatidylglycerol (PG) and cardiolipin [49]. Studies with mutant cells lacking
the ability to synthesize PG in the ER strongly implicate this as the main precursor
for BMP. Cardiolipin is found almost exclusively in mitochondria. There is not a
major lipid vesicle transport pathway directly from the ER directly to the LE/Ly,
and there is no vesicle transport from mitochondria to LE/Ly. Thus, it is not clear
how either PG or cardiolipin would be delivered to LE/Ly in sufficient abundance
to serve as an adequate precursor pool for production of BMP. One possibility is
that these lipids are delivered to lysosomes by autophagy of ER segments or of
mitochondria (mitophagy) [49]. Another possibility is that PG is transported from
the ER to LE/Ly at membrane contact sites, which have been observed between
these organelles and are recognized to play important roles in many aspects of lipid
transport between organelles.
In the past few years, it has been shown that autophagy of lipid droplets and lyso-
somal breakdown of the cholesteryl ester and triacylglycerides in their cores is an
important component of the catabolism of lipid droplets. It had long been thought that
breakdown of the neutral lipids in the core of lipid droplets was carried out exclusively
by cytoplasmic enzymes with pH optima near 7 [60]. Recent studies have shown that
a significant amount of the catabolism of lipid droplets in hepatocytes [60] and in
macrophages [61,62] follows sequestration of the lipid droplets in autophagosomes
and subsequent fusion with lysosomes. The cholesteryl esters and triacylglycerides
are then hydrolyzed by lysosomal acid lipase, the enzyme that is also responsible for
breakdown of these lipids when delivered to LE/Ly in the core of lipoproteins.
The balance between formation and breakdown of lipid droplets in hepatocytes is
important for the overall metabolic regulation of the organism. In the presence of high
glucose after a meal, fatty acids are synthesized and stored as TGs in lipid droplets.
During periods of fasting, these lipid droplets are utilized to provide fatty acids for
gluconeogenesis to produce glucose, which is the main energy source for the brain.
Thus, the formation and breakdown of these lipid droplets in hepatocytes must be
under tight regulatory control, which is only partially understood at present. Inhi-
bition of autophagy in hepatocytes by 3-methyladenine led to a significant increase
in stored TGs in the cells [60]. There was a further increase upon inhibition of all
lipolysis, indicating that autophagy was only one component of TG turnover. The
association of lipid droplets with autophagic membranes could be observed by both
optical and electron microscopies [60]. Treatment with rapamycin, which releases
the inhibition of autophagy by mTOR, leads to a decrease in lipid droplets and in the
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amount of TG in the cells. Starvation increased the association of lipid droplets with
autophagosomes, indicating that the rates of autophagic flux of lipid droplets can be
metabolically regulated.
Macrophages are another cell type in which the formation and breakdown of
lipid droplets play an important role in normal physiology and in disease [39].
Macrophages ingest cholesterol deposited in lipoproteins in the wall of blood
vessels. Some of this cholesterol is exported to HDLs and returned to the liver,
where it can be converted into bile salts or repackaged into lipoproteins. Excess
cholesterol in the macrophages is esterified by ACAT and stored in lipid droplets.
As in the liver, the prevailing view had long been that the cholesteryl ester in lipid
droplets was hydrolyzed by neutral hydrolases in the cytoplasm, although the relative
importance of specific neutral cholesteryl ester hydrolases has remained uncertain.
Recently, it was shown that autophagy of lipid droplets and lysosomal hydrolysis of
their cholesteryl esters by lysosomal acid lipase plays a significant role in releasing
cholesterol contained in lipid droplets [61,62]. The cholesterol can then be shuttled
out of the lysosomes by NPC2 and NPC1 as described earlier and delivered to
various cellular compartments including the plasma membrane, where it can be
exported from the cell onto HDL carriers.
6.5 LYSOSOMAL LIPID HYDROLYSIS AND METABOLIC
REGULATION
Recent studies have started to elucidate mechanistic links between nutrient sensing
and the regulation of lysosomal lipid catabolism (Chapter 7). Transcriptional factors
such as transcription factor EB (TFEB; see Chapter 7) regulate lysosome biogen-
esis and autophagy, including the autophagy of lipid droplets. Under conditions of
nutrient abundance, the mechanistic target of rapamycin complex 1 (mTORC1) is
activated at the lysosomal surface, and this stimulates lipogenesis through the SREBP
transcription factors and adipogenesis through the PPARγ transcription factors. The
activation of mTORC1 also inhibits autophagy. Conversely, low levels of amino acids
in the lysosomes cause inactivation of mTORC1, with decreases of lipid synthe-
sis and increased autophagy. The stimulated autophagy includes lipophagy, leading
to hydrolysis of triacylglycerides by lysosomal acid lipase in autophagolysosomes.
This provides a source of fatty acids for both energy production and synthesis of
phospholipids.
TFEB is a member of the microphthalmia-associated transcription factor (MITF)
family. Under the condition of nutrient abundance, it is mainly held in the cytoplasm
due to phosphorylation of key serine residues by active mTORC1. When nutrient
levels are reduced, mTORC1 is inactivated, and the lack of phosphorylation allows
TFEB to enter the nucleus. TFEB stimulates the synthesis of proteins involved in
lysosome biogenesis and autophagy. The main regulators of mTORC1 activation are
amino acids in the lumen of the organelles. It is unclear whether lipid catabolism
in lysosomes can also influence mTORC1 signaling directly. In addition, it remains
unclear how lipophagy is regulated beyond the transcriptional regulation discussed
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here. It seems likely that molecules recruited to the surface of lipid droplets can regu-
late lipophagy, but such regulatory mechanisms are not well characterized at present.
6.6 SUMMARY
There has been enormous progress in elucidating mechanisms of lipid catabolism in
LE/Ly. Many of the important pathways of lysosomal lipid metabolism have been
elucidated by analysis of the metabolic defects in inherited lysosomal storage disor-
ders. Basic biochemical and genetic studies of cells from these patients have revealed
surprisingly complex and interrelated mechanisms for lipid breakdown. One unique
feature of lipid breakdown in LE/Ly is the important role for internal vesicle mem-
branes that are enriched in BMP, a lipid that is found almost exclusively in these
organelles. Restricting lipid hydrolysis mainly to these internal membranes helps to
preserve the integrity of the limiting membrane. Often, the accumulation of one lipid,
due to a defective hydrolytic enzyme, leads to accumulation of several other lipids
and to expansion of the internal membranes. These accumulations can be understood
in terms of the biophysical association of certain lipids such as cholesterol and sphin-
golipids, which will mutually stabilize each other in the bilayer in a way that partially
protects them from extraction. In recent years, it has become apparent that autophagy
plays an important role in the turnover of lipids in lipid droplets. This means that
lysosomal turnover is important in the digestion of cholesteryl esters and triacylglyc-
erides in the core of the droplets. It seems likely that there will be further discoveries
linking the biology of the LE/Ly to regulatory mechanisms governing lipid synthesis
and degradation.
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7.1 LYSOSOME
Lysosome is the main digestive compartment of the cell. This organelle degrades a
wide variety of structurally diverse substances, such as proteins, glycosaminoglycans
(GAGs), nucleic acids, oligosaccharides, and complex lipids into their building
blocks, which are either recycled in biosynthetic pathways or further degraded to
generate energy (Figure 7.1). Numerous functions, including the turnover of cellular
proteins, autophagy, cholesterol homeostasis, downregulation of surface receptors,
release of endocytosed nutrients, inactivation of pathogenic organisms, repair of the
plasma membrane, and bone remodeling, have been shown to depend on normal
lysosomal function. The lysosome is delimited by a single-layer lipid membrane. An
acidic internal pH is maintained by an ATP-dependent proton pump. Lysosomal pro-
teins include acidic hydrolases, soluble accessory proteins, and lysosomal membrane
proteins, for most of which the precise function is unknown. Lysosomal biogenesis
involves maturation of the early endosome to form a multivesicular body (i.e., late
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Figure 7.1 Central role of lysosomes in key cellular processes. (See color plate section for
the color representation of this figure.)
endosome) followed by fusion to lysosomes and by lysosome reformation [1].
Lysosomal hydrolases are imported into lysosomes by a mannose-6-phosphate
(M6P) trafficking pathway that involves binding to the M6P receptors. Other
proteins are transported to lysosomes by alternative receptors such as the lysosomal
integral membrane protein LIMP-2 and sortilin. Cellular and foreign material to be
degraded can reach the lysosome via endocytosis, phagocytosis, autophagy, or direct
transport. Autophagy is a lysosomal degradation pathway with a crucial role in health
and disease. A growing number of intracellular substrates such as polyubiquitinated
proteins, protein aggregates, and dysfunctional organelles are degraded, and their
components recycled, by autophagy. During autophagy, a double-membrane vesicle
(autophagosome AV) originates in the proximity of the ER and targets cytosolic
cargoes to lysosomes. A crucial step of the autophagic pathway is fusion of the
autophagosome with the lysosome. A schematic view of lysosome biogenesis and of
the autophagic pathway is depicted in Figure 7.1.
7.2 THE TRANSCRIPTIONAL REGULATION OF LYSOSOMAL
FUNCTION
The cell has developed strategies to facilitate the coordination of complex functions,
such as cellular clearance, by concentrating these processes in specialized organelles.
As the degradative requirements of the cell vary depending upon tissue type, age, and
environmental conditions, it was reasonable to expect the existence of systems that
allow regulation of lysosomal function. This hypothesis led to the discovery of a gene
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Figure 7.2 Systems biology approach used to discover the CLEAR network. The clear net-
work is inferred by integrating the coexpression analysis of microarray data and promoter
analysis. Pattern discovery analysis of the promoter regions of the known lysosomal genes
resulted in the identification of a palindromic 10-base preferentially located at 200 bp from
the transcription start site. The CLEAR consensus sequence overlaps that of the E-box (CAN-
NTG), a known target site for basic helix–loop–helix transcription factors. (See color plate
section for the color representation of this figure.)
regulatory network (CLEAR: Coordinated Lysosomal Enhancement AndRegulation)
that controls lysosomal biogenesis and function [2]. The coordinated regulation of
lysosomal genes was discovered using both coexpression and promoter analyses. The
latter resulted in the identification of a palindromic sequence of 10 bases, preferen-
tially located at 200 bp from the transcription start site. This sequence, named the
CLEAR consensus sequence, overlaps with that of the E-box, a known target for
basis helix–loop–helix transcription factors (Figure 7.2).
Members of the microphthalmia–transcription factor E (MiT/TFE) subfamily of
bHLH factors were found to bind sequences identical to the CLEAR consensus. The
MiT/TFE subfamily is composed of four members in humans: MITF, TFE3, TFEB,
and TFEC [3]. All members of the family share a similar structure and are capable
of homo- or heterodimerizing with each other in order to bind to DNA and activate
transcription. MiTF and TFEC have a restricted pattern of expression in specific cell
types (MiTF: melanocytes, osteoclasts, mast cells, macrophages, NK cells, B cells
and heart; TFEC, cells of myeloid origin), while TFEB and TFE3 have a ubiquitous
pattern of expression [3–7].
TFEB binds to CLEAR sites and positively regulates the expression of lysoso-
mal genes. TFEB overexpression in cells increases the number of lysosomes and
enhances the degradative capabilities of the cells, as a result of an induction of lyso-
somal gene expression [2]. A detailed analysis on TFEB target genes in HeLa cells,
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using promoter, transcriptome, and ChIP-seq analyses, identified 471 TFEB direct
targets representing the essential components of the CLEAR network in this cell type,
which include genes regulating the full spectrum of lysosomal catabolism, includ-
ing degradation of proteins, glycosaminoglycans, sphingolipids, and glycogen [8].
This analysis also revealed that the CLEAR network is involved in the regulation of
lysosome-associated processes, including autophagy, exo- and endocytosis, phago-
cytosis, and immune response. These data suggested that the function of the CLEAR
network, and TFEB, may extend beyond the regulation of lysosomal function and
impact other important cellular processes related to cellular catabolism [8]. Recent
studies suggest that the CLEAR network may be remarkably different in different
tissues and cell types. For instance, in liver, TFEB regulates genes involved in lipid
catabolism [9].
TFEB overexpression was also shown to induce autophagy by increasing the
number of autophagosomes and enhancing lysosome-to-autophagosome fusion and
degradation of long-lived proteins, which are known autophagy substrates [10].
TFEB also has a direct impact on lysosomal exocytosis, a process by which
lysosomes secrete their content into the extracellular matrix by fusing with the
plasma membrane through a Ca2+-regulated mechanism [11,12]. TFEB regulates
different aspects of this process including docking of lysosomes to the plasma
membrane and fusion of lysosomes to the plasma membrane via the calcium channel
mucolipin-1 [13].
Other members of the MiT/TFE family, such as TFE3, have been shown to have a
function similar to that of TFEB (and similar regulation as described in the following
section). In fact, both TFE3 and MITF have been shown to increase the expres-
sion of lysosomal and autophagic genes and to stimulate lysosomal biogenesis and
autophagy [14,15]. More studies are necessary to determine the functional redun-
dancy of this family of transcription factors and the physiological relevance of each.
7.3 TFEB SUBCELLULAR REGULATION IS REGULATED
BY ITS PHOSPHORYLATION
In most cell types, TFEB is located in the cytoplasm under normal nutrient con-
ditions. However, in response to certain stimuli, such as starvation, TFEB translo-
cates from the cytoplasm to the nucleus [2,16]. The translocation of TFEB to the
nucleus is mediated by the phosphorylation status of two particular serines, Ser142
and Ser211. When these two serines are phosphorylated, TFEB is located predomi-
nantly in the cytoplasm, while when they are unphosphorylated it is mainly nuclear.
Mutations of either of these serines into alanines, preventing their phosphorylation,
result in a nuclear, and constitutively active, TFEB [16–19]. ERK2 kinase was found
to phosphorylate TFEB S142 and consequently its inhibition leads to TFEB nuclear
translocation [16]. The mTOR complex 1 (mTORC1) kinase complex is also able to
phosphorylate TFEB and plays a critical role in determining TFEB subcellular local-
ization and activity [17–20]. mTORC1 phosphorylates both TFEB S142 and S211
[16,19]. When S211 is phosphorylated, TFEB binds to several isoforms of the 14-3-3
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protein family and this binding retains TFEB in the cytoplasm [17,18]. This mech-
anism is also shared by other members of the bHLH family of transcription factors,
such as MITF and TFE3, which are closely related to TFEB [7,18].
Interestingly, the transcriptional response of TFEB to nutrients is mediated by
an autoregulatory feedback loop in which TFEB regulates its own expression in a
starvation-dependent manner [9]. Thus, the regulation of TFEB activity by nutrients
involves a rapid, phosphorylation-dependent, post-transcriptional switch, which is
responsible for the nuclear translocation of TFEB and a transcriptional autoregulatory
component for a slower, more sustained, response.
While the role of the kinases that phosphorylate TFEB has been studied by sev-
eral groups [17–19,21], the phosphatase(s) involved in its dephosphorylation have
remained elusive for some time. Presumably, kinases and phosphatases would have
an opposite effect of TFEB subcellular localization, the former promoting a cyto-
plasmic, while the latter a nuclear localization. A high content (HC) screening of
a phosphatase siRNA library using a cellular assay based on cytoplasm-to-nucleus
shuttling of TFEB during starvation was used to identify phosphatases that dephos-
phorylate TFEB, thus promoting its nuclear translocation. This approach led to the
identification of calcineurin, a calcium-dependent serine–threonine phosphatase [22],
which binds and dephosphorylates TFEB [23]. Calcineurin inhibition, either by phar-
macologic or genetic approaches, suppresses TFEB activity even during starvation.
Conversely, calcineurin overexpression and constitutive activation have the opposite
effect. Interestingly, the effect of calcineurin on TFEB subcellular localization over-
rides that of mTORC1, as the inhibition of both calcineurin andmTOR activities leads
to a cytoplasmic localization of TFEB [23].
7.4 A LYSOSOME-TO-NUCLEUS SIGNALING MECHANISM
The discovery that the mTORC1 kinase complex, a master growth regulator that
is stimulated by nutrients and growth factors, exerts its activity on the lysosomal
surface has shed new light on the role of the lysosome in signaling processes
[24,25]. The lysosomal localization of mTORC1 suggests that the lysosome acts as
a link between the regulation of anabolic and catabolic processes. Growth factors,
hormones, amino acids, glucose, stress, and oxygen are the major activators of
mTORC1, which in turn positively regulates protein, mRNA and lipid biosynthesis,
and ATP production [24,26,27]. When nutrients are present, mTORC1 is activated,
promotes anabolic process and inhibits autophagy through the direct phosphorylation
and inhibition of the kinase complex ULK1–Atg13–FIP200 (unc-51-like kinase
1/mammalian autophagy-related gene 13/focal adhesion kinase family-interacting
protein of 200 kDa) [28–30], which is required to induce autophagosome biogenesis
[31,32]. When mTORC1 is inhibited, by either starvation or drugs, autophagy is
stimulated. mTORC1 is part of a complex signaling machinery that sits on the
lysosomal surface. This machinery includes the Rag GTPases proteins, which
regulate mTORC1 subcellular localization [26] and Rheb GTPases, responsible for
mTORC1 activation [26]. Rag GTPases are activated by nutrients, in particular,
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amino acids, and are responsible for the translocation of mTORC1 to the lysosomal
surface. Upon starvation, the tuberous sclerosis complex (TSC1/2) maintains Rheb in
its GDP-bound status, thereby blocking the activation of mTORC1 [33]. mTORC1 is
further regulated by additional lysosome-associated proteins that include Ragulator,
which is responsible for both the subcellular localization of the Rags and regulation
of their nucleotide-binding state [25]. The sensing of amino acids by the lysosomal
proton pump v-ATPase is necessary to activate the Ragulator complex that exerts a
GEF activity toward the Rag proteins, thus promoting the translocation of mTORC1
to the lysosomal surface [25]. Additional GTPase-activating protein (GAP) com-
plexes, such as GATOR1 and folliculin-FNIP1/2, promote the GTPase activity of Rag
proteins [34,35]. More recently, an additional component of the lysosomal amino
acid machinery that controls mTORC1 has been described, SLC38A9, a member of
the solute carrier (SLC) family. SLC38A9 is a transmembrane protein that associates
with the lysosomal Rag-Ragulator complex. SLC38A9 overexpression renders
mTORC1 insensitive to amino acid depletion, thus active during starvation [36,37].
Interestingly, the cytoplasmic form of TFEB is found both free in the cytosol and
anchored to the lysosomal surface, where it interacts with mTORC1 [19]. Cellular
conditions that alter lysosomal function such as stress and lysosomal inhibition lead
to mTORC1 inactivation and induce TFEB nuclear translocation [17–19]. Thus, the
lysosome controls its own biogenesis by sending a signal to the nucleus via TFEB.
Lysosomal Ca2+ release plays a crucial role in the activation of calcineurin, the
phosphatase that dephosphorylates TFEB [23]. This process is mediated by the cal-
cium channel mucolipin-1 (MCOLN1), also known as transient receptor potential cal-
cium channel MucoLipin subfamily member 1 (TRPML1), which is localized on the
lysosomal surface. Inhibition or downregulation of MCOLN1 significantly reduced
cytoplasm-to-nucleus shuttling of TFEB after starvation [23]. Interestingly, the induc-
tion of autophagy and lysosomal biogenesis via TFEB requires MCOLN1-mediated
calcineurin activation, thus linking lysosomal calcium signaling to autophagy reg-
ulation [23]. Together these findings identify the lysosome as a central hub for the
signaling pathways that regulate cellular homeostasis (Figure 7.3).
7.5 TFEB AND CELLULAR CLEARANCE IN HUMAN DISEASE
Lysosomal dysfunction is a major contributor to the pathogenesis of a significant
number of human diseases, including neurodegenerative disorders, disorders of
lipid and glucose metabolism, infectious diseases, bone diseases, and disorders
of the immune system. Even aging has been associated to decline in lysosomal
function [38]. Therefore, boosting lysosomal activity and pathways related to
cellular clearance could have a significant impact on a number of human conditions.
Therapeutic strategies aimed at rescuing and/or enhancing lysosomal and autophagic
function may impact lysosomal storage disorders (LSDs) as well as common
neurodegenerative diseases.
The function of TFEB, and the associated CLEAR network, has a direct impact on
each step associated with cellular clearance: regulation of cargo delivery of substrates
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Figure 7.3 Model depicting Ca2+-mediated regulation of TFEB. This figure illustrates how
transcription factor TFEB is induced by starvation andmediates the starvation response. TFEB,
in adequate nutrition condition, is phosphorylated by mTORC1 on the lysosomal surface. This
keeps TFEB inactive by cytosolic sequestration. During starvation, mTORC1 is released from
the lysosomal surface and becomes inactive while a calcium-dependent serine–threonine phos-
phatase, calcineurin, dephosphorylates TFEB. Thus, TFEB can no longer be phosphorylated
by mTORC1 and its dephosphorylation promotes its nuclear translocation, where it induces
its own transcription. Therefore, starvation regulates TFEB activity through a dual mechanism
that involves a posttranslational modification (phosphorylation) and a transcriptional autoreg-
ulatory loop. Once in the nucleus, TFEB regulates the expression of genes involved in the
lysosomal–autophagy pathway. (See color plate section for the color representation of this
figure.)
by inducing autophagosome biogenesis and autophagosome–lysosome fusion, pro-
motion of substrate degradation by increasing the levels of lysosomal enzymes, induc-
tion of lysosomal exocytosis with the consequent release of storage material outside
the cells (Figure 7.4). The major impact that TFEB has on cellular clearance identifies
this pathway as a possible therapeutic target for a variety of diseases (Figure 7.5).
7.5.1 Lysosomal Storage Disorders
LSDs are characterized by progressive accumulation of undigested macromolecules
within the cell due to lysosomal dysfunction. LSDs include nearly 50 different
inherited disorders, each sharing a genetic defect that renders the lysosomal system
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Figure 7.4 TFEB activation on cellular mechanisms that lead to cellular clearance. TFEB
controls lysosomal biogenesis, autophagosome biogenesis, autophagosome–lysosome fusion,
and lysosomal exocytosis. The concerted action of these processes leads to cellular clearance.





































Figure 7.5 Diseases that respond to TFEB-mediated clearance. The major impact that TFEB
has on cellular clearance identifies this pathway as a possible therapeutic target for a variety
of diseases. (See color plate section for the color representation of this figure.)
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dysfunctional and unable to degrade specific materials normally processed within
the cell. As a consequence, many tissues and organ systems are affected, including
brain, viscera, bone, and cartilage, with early-onset central nervous system (CNS)
dysfunction predominating. The clinical features of these disorders vary widely.
Most are fatal within the first two decades of life following many years of worsening
disease. The progressive nature of phenotype development is one of the hallmarks
of LSDs.
Viral-mediated gene transfer of TFEB in mouse models of LSDs, including mul-
tiple sulfatase deficiency (MSD) and Pompe disease, resulted in clearance lysosomal
storage, in spite of the differences in the nature of accumulating substrates (e.g.,
glycogen in Pompe disease and GAG accumulation in MSD and MPSIIIA) [13,39].
Other secondary effects of storage, such as inflammation and apoptosis, were also
reduced. The proposed mechanism of cellular clearance is through the induction of
lysosomal exocytosis, as a way to empty the cells from the unwanted storage of undi-
gested substrates. Interestingly, the clearance effect mediated by TFEB required a
functional autophagic pathway [39].
7.5.2 Neurodegenerative Disorders
A series of experimental evidences indicate that lysosomal and autophagy dysfunc-
tion are associated to the disease pathogenesis of common neurodegenerative disor-
ders such as Parkinson’s disease (PD), Alzheimer’s disease (AD), and Huntington’s
disease (HD) [40,41]. Therefore, several studies addressed whether boosting lyso-
somal and autophagic function through TFEB overexpression could arrest or delay
disease progression in several models of common neurodegenerative disorders.
TFEB overexpression resulted in beneficial effects in two mouse models of
PD, one pharmacologically induced [42] and the other obtained by α-synuclein
overexpression. In both models, AAV-mediated TFEB overexpression had beneficial
effects, significantly reducing death of dopaminergic neurons [42,43]. Clearance
of α-synuclein oligomers and significant neuroprotection was also observed [43].
Interestingly, inhibition of TFEB expression, by the overexpression of a microRNA
known to target TFEB, exacerbated the toxicity of α-synuclein [43].
TFEB was also shown to effectively reduce neurofibrillary tangle pathology and
improve behavioral and synaptic defects as well as neurodegeneration in a mouse
model of AD, induced by the overexpression of tau. TFEB was shown to specifically
target hyperphosphorylated and misfolded tau species [44], and not influence the lev-
els of wild-type soluble tau. Similar results were also obtained in a mouse model of
HD, in which TFEBwas shown to be the downstream effector of the ability of PGC1α
to promote cellular clearance and decrease neurotoxicity in this disease model [45].
Finally, TFEB function was found to be inhibited in a mouse model of X-linked
spinal and bulbar muscular atrophy (SBMA), due to polyglutamine-expanded andro-
gen receptor (polyQ-AR). PolyQ-AR was shown to interfere with TFEB function,
while normal AR induces TFEB activation. TFEB overexpression rescued metabolic
and autophagic flux defects in SBMA cell lines [46].
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The fact that TFEB overexpression has such a strong impact on the phenotype
of a wide variety of neurodegenerative diseases further strengthens the link between
neurodegenerative disorders and lysosomal-autophagic dysfunction.
7.5.3 Metabolic Syndrome
There is accumulating evidence that the lysosomal-autophagic pathway directly
influences lipid metabolism. In fact, in a process known as macrolipophagy [47,48],
lipid droplets are transported to lysosomes via autophagic vesicles, where they are
hydrolyzed into free fatty acids (FFAs) and glycerol. The link is further strengthened
by evidence indicating that autophagy levels in the liver directly influence the pheno-
type of genetically induced obese mice and that anomalies in lysosomal lipases, such
as seen in Wolman disease, can lead to severe intracellular fat accumulation. Upon
starvation, the organism induces a starvation response that includes the degradation
of lipids to produce energy. One of the immediate responders to starvation is
TFEB, which translocates to the nucleus upon nutrient deprivation and activates the
expression of target genes.
In the liver, TFEB exerts an integrated control on cellular lipid metabolism by acti-
vating genes involved in several steps of lipid breakdown, such as lipophagy, fatty acid
oxidation, and ketogenesis [9]. This effect is mediated by a TFEB-dependent activa-
tion of PGC1α and PPARα, keymediators of the lipid catabolism during the starvation
response [9,49,50]. Interestingly, when mice overexpress TFEB, they are leaner and
show increased levels of lipid catabolism as well as increased energy expenditure.
Most importantly, when TFEB was overexpressed in mouse models of obesity, both
genetically and diet induced, it rescued the effects of metabolic syndrome [9].
7.5.4 Cancer, Inborn Errors of Metabolism, Immunity, and Longevity
The activation of the autophagic/lysosomal pathway has also been shown to have
beneficial effects in other disorders and disease conditions. For instance, the overex-
pression of TFEB in the liver of a mouse model of α1-antitrypsin (ATZ) deficiency
resulted in the clearance of mutated protein aggregates and rescue of liver fibrosis
phenotype. Once again in this case, the increase in ATZ degradation was accompa-
nied by an increase in the autophagic flux, decreased liver fibrosis, and decreased
apoptosis, which are the key features of the disease [51].
Using alternative animal models, such as Caenorhabditis elegans, TFEB was
shown to have a direct effect on the transcription of cytoprotective, antimicrobial,
and autophagy genes, suggesting that TFEB has an important role in host response
to infection and innate immunity [52].
Gene fusions caused by chromosomal translocations that involve either TFE3 or
TFEB are associated with a specific type of renal cell carcinoma (RCC); however,
the molecular mechanisms underlying the renal-specific tumorigenesis of these
genes remain largely unclear. Determining which pathways are most important





Finally, of particular interest is the recent finding that TFEB promotes longevity in
C. elegans [53], suggesting that modulation of lysosomal function may even prevent
aging and prolong lifespan [52].
To date, therapeutic strategies for disorders due to intracellular accumulation
of storage material have been tailored to the specific gene or disease, significantly
increasing the costs of preclinical investigation. The global enhancement of cellular
clearance as the basis for a new therapeutic approach may overcome this major
limitation and set the basis to develop therapies for a large number of disorders.
More need to be understood on this mechanism to be able to fine-tune its activity, to
understand potential unwanted effects, and maximize its benefits.
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8.1 INTRODUCTION
The organelles of the endocytic pathway comprise early endosomes, late endosomes,
lysosomes, and hybrid organelles between the last two. As explained in the earlier
chapters, pH decreases and degradative potential increases along the endocytic path-
way. This supports the function of the late endocytic compartments (hereafter referred
to as lysosomes), which is degradation of cargo, delivered either by endocytosis,
phagocytosis, or autophagy [1]. However, more than 60 different hydrolases packed
in vesicles lined by a single phospholipid bilayer pose a threat if released into the
cytosol as realized already by de Duve [2–4] when characterizing these organelles.
Nevertheless, the lysosomal membrane seems sturdy and lysosomal membrane per-
meabilization (LMP) takes place either as a result of a direct insult to lysosomes or in
response to stress signaling [4]. In either case, LMP interferes with the degradative
function of the endocytic pathway. Moreover, in the event of considerable perme-
abilization, the luminal hydrolases are released into the cytosol. On the one hand,
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these hydrolases can generate mediators that signal programmed cell death; on the
other hand, the extensive LMP can lead to widespread hydrolysis in the cytoplasm,
which causes nonprogrammed cell necrosis. Herein, LMP is discussed in the con-
text of cell death together with the agents that cause it. In addition to exogenous
compounds that directly destabilize lysosomal membrane, the endogenous signaling
events that lead to LMP are described. Finally, cell death signaling downstream of
LMP is summarized.
8.2 CELL DEATHMODALITIES
In multicellular organisms, cell death process has evolved into an array of regulated
signaling pathways that can respond to external and internal signals and limit their
potentially harmful consequences for the sake of preserving the homeostasis of the
organism. Based on the ultrastructure, cell death is apoptotic or nonapoptotic. Apop-
totic cells show chromatin and cytoplasm condensation, membrane blebbing, and
apoptotic body formation. Nonapoptotic cell death is characterized by oncosis (dilata-
tion of the ER and the nuclear envelope, swelling of the cytosol), which leads to the
loss of plasma membrane integrity. Based on biochemical criteria, additional types
of cell death were identified. At the highest level of classification, cell death can be
programmed and nonprogrammed, also termed accidental. While nonprogrammed
cell death is a consequence of a catastrophic event and can only be prevented with
the removal of the stressor, programmed cell death is “characterized” with a spe-
cific biochemical pathway [3,4]. Apoptosis and programmed necrosis represent two
morphologically distinct types of programmed cell death.
Biochemically, apoptosis is characterized by activation of the executioner
caspases-3 and -7. Depending on the upstream signaling, apoptosis can be extrinsic
or intrinsic, but the principles of the activation of the pathway-specific “initiator
caspases” are similar. Extrinsic apoptosis is initiated upon binding of cognate ligands
(TNF-α, TRAIL, FasL, or CD95L) to death receptors on the plasma membrane.
This leads to receptor conformational changes and the assembly of the multiprotein
platform termed death-inducing signaling complex (DISC), which mediates the
initiator caspase-8 activation. Activated caspase-8 can proteolytically activate
executioner caspases or recruits the intrinsic apoptotic pathway via the cleavage
of the BCL-2 protein family member BID. In the intrinsic pathway, the critical
event is mitochondrial outer membrane permeabilization (MOMP). The integrity
of the mitochondrial outer membrane (MOM) is regulated by BCL-2 proteins
[5,6]. MOMP enables translocation of proapoptotic factors into the cytosol. Among
them, cytochrome c and cytosol-resident apoptotic peptidase activating factor
(APAF1) form the apoptosome, which serves as a platform for the activation of the
initiator capsase-9. Activated caspase-9 then proteolytically activates the executioner
caspases-3 and -7, which degrade several cellular components thereby causing cell
demise [7,8].
Programmed necrosis includes necroptosis and pyroptosis. Similarly to the
extrinsic apoptosis, necroptosis is initiated by ligation of the same death receptors;
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however, the multiprotein complex that is assembled is different and thereby it
mediates a different biological response. In addition to death receptors, necroptosis
can also be initiated by pattern-recognition receptors, which include toll-like recep-
tors (TLRs) either on the plasma membrane or in the endosomal limiting membrane.
The executioner mechanisms of necroptosis are complex and include generation of
ROS and activation of hydrolytic enzymes, which collectively affect mitochondrial,
lysosomal, and plasma membrane integrity [9]. Pyroptosis is a proinflammatory cell
death pathway and characteristic for cells that can express caspase-1, most notably
macrophages. Pyroptosis stimuli, which include viral DNA and RNA, intracellular
bacteria, and crystalline material accumulated in endosomes, activate NOD-like
receptors (NLRs). This leads to the assembly of the inflammasome, which serves as
a platform for caspase-1 activation. Caspase-1 activation depends on potassium or
chloride ion efflux and calcium mobilization; however, they alone are not sufficient
for caspase-1 activation. Cell demise in pyroptosis seems to be largely mediated by
the proteolytic activity of caspase-1, which either directly degrades structural and
functional elements or proteolytically activates other hydrolases [10].
8.3 LYSOSOMAL MEMBRANE PERMEABILIZATION (LMP)
AND CELL DEATH
In the context of cell death, LMP commonly refers to the permeabilization of the
limiting membrane of lysosomes, late endosomes, and hybrid organelles between
these two, as they all harbor hydrolases, which can promote cell death [11]. LMP
can contribute to different cell death pathways. Actually, the same exogenous com-
pound can initiate different cell death modalities depending on the intensity of the
stimulus and cell death signaling machinery of the affected cell. In general, it was
postulated that limited LMP initiates signaling that leads to or amplifies apoptosis,
whereas extensive LMP results in general proteolysis/hydrolysis and causes nonpro-
grammed (accidental) necrosis [12–16]. The intensity of the stimulus determines the
extent of the LMP and its reversibility. Minor destabilization would enable the loss
of ion gradients, including the proton gradient, which would cause the loss of acidic
pH in the lumen of the endosomes and lysosomes [17]. This would in turn affect
the activity of luminal hydrolases whose stability and/or activity depends on acidic
environment. If minor destabilization is transient, then the degradative potential of
endosomes could be restored and the cell saved from more severe consequences,
which can take place if luminal hydrolases are released into the cytosol. However,
this requires larger membrane lesions to allow the translocation of lysosomal hydro-
lases (25–80 kDa) into the cytosol. It was recently shown that upon such considerable
destabilization of the lysosomal membrane cellular and tissue homeostasis depends
on the sequestration of damaged lysosomes by autophagy [18].
Signaling events both upstream and downstream of LMP are poorly understood.
As described below proteolytic activation of proapoptotic messengers and general-
ized proteolysis seem the most important mechanism through which LMP promotes
cell death. An indirect effect of LMP and consequent loss of lysosomal degradative
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capacity is also the interruption of the autophagic flux. By sequestering bulk cyto-
plasm or specifically damaged organelles, autophagy removes damaged organelles
and provides metabolites that can fuel glycolysis. This aspect of autophagymay influ-
ence the ability of cells to overcome the stress and avoid cell death [15,19].
8.3.1 Mechanisms of LMP
8.3.1.1 Characteristics of the Lysosomal Membranes The inner leaflet of
the lysosomal membrane is lined by a thick glycocalyx, which is composed of
the carbohydrate parts of lysosomal integral membrane proteins (LIMPs) and
lysosome-associated membrane proteins (LAMPs) and protects the limiting mem-
brane from the degradative enzymes [20]. Compared to the plasma membrane, the
lysosomal limiting membrane contains less cholesterol and sphingolipids, but the
content of cholesterol is still higher than that in the intracellular membranes of other
organelles [21]. However, the lipid composition of the limiting membrane differs
considerably from the intralysosomal membrane of intraluminal vesicles, which start
forming by ESCRT-dependent sorting already early in the endocytic pathway [22]
and represent the platform for membrane degradation [23]. The intralysosomal
membranes are characterized by the increased content of negatively charged lipid
bis(monoacylglycero)phosphate (BMP) and to a lesser extent phosphatidylinositol
and dolichol phosphate [23]. These negative charges facilitate the adhesion of the
soluble positively charged hydrolases and activator proteins [24]. Cholesterol is
almost absent from intralysosomal membranes and sphingomyelin is progressively
degraded to ceramide by the acid sphingomyelinase (SMase) [23]. Changes in
its lipid composition can sensitize the lysosomal membrane to LMP [25]. Sphin-
gomyelin and cholesterol form liquid ordered phase, which represents the so-called
membrane rafts and give the membrane stability [21]. SMase, which degrades
sphingosine to ceramide, sensitizes lysosomes to damage, including oxidative
injury, by reducing sphingomyelin content [26]. Accumulation of ceramide perturbs
the mechanical integrity of membranes, which can lead to increased membrane
permeability or even membrane rupture [27]. On the other hand, ceramidase can
degrade ceramide to sphingosine, which can also affect membrane permeability by
rigidifying lipid acyl chains [28] and was shown to be associated with increased risk
for LMP [29]. In addition, sphingosine would act as a cationic amphiphile and induce
lipidosis by neutralizing the negative charge of BMP and displacing lysosomal
proteins from membranes [23]. In contrast to pH 4.5, at pH 5.5, ceramide catalyzes
the reverse reaction, which maintains low level of sphingosine in endosomes [30].
Another factor suggested to participate in sphingomyelin metabolism is Hsp70,
which was found to exhibit a protective effect on the lysosomal membrane that
was associated with its role as an essential cofactor for lysosomal sphingomyelin
metabolism [31,32]. Depletion of cholesterol by adding methyl cyclodextrin to cell
culture sensitized lysosomes to osmotic stress or membranolytic action exerted
by Gly-Phe-β-naphthylamide [33]. This is possibly due to decreased mechanical
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rigidity of the membrane as well as increased permeability to water, potassium ions,
and protons [21,34,35]. Moreover, increased content of cholesterol was identified as
a protective factor against LMP [36].
8.3.1.2 Selective Targeting of the Lysosomal Membrane Selective permeabiliza-
tion of the lysosomal membrane entails lysosomal localization of the causative agents
or the susceptible factor. The former applies mostly to compounds applied externally
(exogenous factors) and the latter to internal signaling. Selective accumulation of
exogenous compounds can be achieved by several routes. Membrane-nonpermeable
compounds can be taken up by endocytosis and transferred along the endocytic path-
way to accumulate in its late compartments. Membrane-permeable compounds can
diffuse throughout the cell, but in order to be retained and to accumulate inside the
endocytic organelles, they need to be modified in the lumen in such a way to become
impermeable. Lysosomotropic amines are thus made impermeable by protonation in
the acidic lysosomal lumen [37], whereas esterified compounds are retained in the
lysosomes by de-esterification carried out by luminal hydrolases [38,39]. However,
additional enzymatic modifications could be involved in other types of compounds.
Mediators that can transmit cellular stress signals into LMP are mostly localized in
the limiting membrane and their modification destabilizes membrane in such a way
that the membrane permeability increases. Lysosomal membranes are particularly
prone to ROS-mediated damage, because of the lysosomal iron content, which can
produce intralysosomal ROS in the Fenton reaction [40]. The initial burst of ROSmay
be generated inside lysosomes [41] or outside, for example, by destabilizedmitochon-
dria [42]. However, hardly any of these accumulation mechanisms is entirely specific
for lysosomes, and, therefore, one has to be aware that LMP might not be the only
consequence of the treatment with a particular LMP-inducing compound [43].
The two main mechanisms of LMP include direct membranolytic activity and
osmotic lysis (Figure 8.1).
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Figure 8.1 Mechanisms of LMP.
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8.3.1.3 Direct Membrane Lysis Direct membranolytic activity is usually asso-
ciated with detergents. These amphiphilic molecules partition between the water
phase and the phospholipid bilayer. With their increasing concentration, a point
is reached at which the membranes are solubilized and mixed micelles consisting
of membrane lipids and detergent molecules are formed [44]. Lysosomotropic
amines with linear-chain hydrocarbon “tails” induce LMP due to detergent activity.
They include O-methyl-serine dodecylamide hydrochloride (MSDH) [13] and
N-dodecylimidazole [45–47]. Lipofuscin, which is generated in lysosomes by oxida-
tive polymerization of protein and lipid residues, may be an endogenous compound
with membranolytic activity on lysosomal membranes [48]. In particular, long-lived
postmitotic cells are prone to accumulation of this nondegradable compound, as they
cannot dilute it by cell division [49].
Apart from lipid detergents, also peptides can exert membranolytic activity, as
demonstrated by antimicrobial peptides, in particular, amphipathic α-helical peptides.
Initially, these accumulate at the bilayer surface like a carpet. In the next step, pep-
tide accumulation leads to thinning of the bilayer, which in turn leads to conditions
allowing a localized collapse of the lipid bilayer by the formation of discrete pores or
simply a detergent-like disintegration of the bilayer structure [50]. Upon intralysoso-
mal oligomerization also certain dipeptide methyl esters and β-naphthylamides exert
membranolytic properties [51].
8.3.1.4 Osmotic Lysis If lysosomal membrane permeability to otherwise nonper-
meable solutes increases, the net influx of solutes will increase the osmolarity in the
lumen and cause an influx of water, which may lead to osmotic lysis. Such increased
permeability could bemediated by increased transient water defects of themembrane.
These act as mobile free volumes that can carry small molecules and ions across
the membrane. Their frequency can be increased by the modification of membrane
lipids [52] or the incorporation of external perturbants [53,54]. Another example is
membrane lipids that can be modified by ROS-mediated lipid peroxidation or enzy-
matically [52]. Lipid peroxidation oxidizes functional groups in lipid tails, which
causes their conformational change so that the oxidized tails bend toward the water
phase and the oxygen atoms form hydrogen bonds with water and the polar lipid
headgroup. Membrane lipids are also modified by lipases, including cytosolic phos-
pholipase 2 (cPLA2), phospholipase C (PLC), SMase, and ceramidase [28,55,56].
Arachidonic acid generated by cPLA2 and phosphatide acid generated mainly by
phospholipase D both increase lysosomal permeability to potassium ions and pro-
tons [56,57]. In addition, detergents at sublytic concentrations can act as external
perturbants that affect membrane permeability [58].
Increased permeability for small solutes and even larger molecules can also be
mediated by pore-forming proteins. These proteins are long enough to transverse
the length of the hydrophobic core of the membrane. Notable examples include
complement membrane attack complex [59], perforin [60], and BAX and BAK
molecules [61].
Rather than increasing osmotic pressure across the lysosomal membrane by
changing permeability to small solutes, compounds themselves can directly build
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up osmotic pressure. This is true for compounds that accumulate inside lysosomes
after being modified to become impermeable. Lysosomotropic amines, such as
chloroquine or ammonium chloride, mediate the so-called “proton sponge effect,”
which is underlined with the rise in pH and the increase in the lysosomal volume.
However, the osmotic lysis is not commonly observed [47,62]. This is in contrast
to dipeptide methyl esters, such as LeuLeuOMe, or dipeptide-β-naphthylamides,
such as Gly-Phe-β-naphthylamide, which were among the first compounds that were
shown to destabilize lysosomal membranes. However, they are also oligomerized
by lysosomal enzymes, in particular, cathepsin C, and comparison with lysoso-
motropic amines indicates that efficient permeabilization of lysosomal membranes
by dipeptide methyl esters or β-naphthylamides is mediated largely by detergent-like
properties of oligopeptides [38,39,51].
8.3.2 Upstream of LMP: Direct Insult Versus Molecular Signaling
Historically, the role of LMP in cell death signaling has been demonstrated with
exogenous compounds, which directly target the lysosomal membrane or osmotic
stability (Figure 8.1). Among best-studied compounds that induce apoptosis via
LMP are dipeptide methyl esters [63–65]. LeuLeuOMe has even been tested in
clinical trials for ex vivo purging of perforin-positive T cells in order to prevent
a graft-versus-host disease after allogeneic bone marrow transplantation [66,67].
Another group of agents that can induce LMP-triggered apoptosis are lysoso-
motropic detergents [13,46,47]. However, when added to cells, these compounds
can destabilize the plasma membrane and impair its barrier function causing
necrotic cell death even below the critical micelle concentration [13,45,68,69].
Natural compounds include quinolone antibiotics ciprofloxacin and norfloxacin.
Norfloxacin triggers ROS-mediated LMP after UV light activation [70]. Similarly,
aminoglycoside antibiotic gentamicin [41] and covalent conjugates between the
photosensitizer chlorin(e6) and hyperbranched poly(ether-ester) (HPEE) [71] also
trigger LMP by local generation of ROS. These compounds present candidates for
therapeutic agents that would induce cell death specifically in targeted cells, for
example, cancer cells [72], as also discussed in Chapter 10.
Crystalline materials, such as aluminum hydroxide (alum), silicon dioxide
(silica), uric acid, and asbestos, permeabilize phagolysosomal membranes and
induce pyroptosis. However, the uptake of these small crystals is limited to cells that
can phagocytose these particulate compounds, most notably macrophages [73,74].
The exact mechanism of phagosomal membrane destabilization is not known, but
it was shown that ROS are generated by a NADPH oxidase upon phagocytosis of
asbestos or silica particles [74]. The current understanding of the immunogenic
effect of alum adjuvants is that it mediates cell death, which transiently induces the
release of endogenous danger signals and proinflammatory cytokines. These in turn
activate antigen-presenting cells and thereby increase the immune response to the
antigen [75]. To date, there is no report that LMP could initiate necroptosis.
As mentioned, LMP can occur also as a consequence of molecular signaling that
was initiated outside the endocytic pathway (Figure 8.2). The paramount question
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Figure 8.2 Molecular events upstream and downstream of LMP. Most exogenous com-
pounds cause LMP as a consequence of direct targeting of the lysosomal membrane or osmotic
stability. In contrast, LMP can also occur in consequence of cell death signaling. The most
likely factors that mediate LMP downstream ofMOMP activation are ROS and increased intra-
cellular calcium concentration linked to activation of several lipases, which collectively affect
the osmotic stability of lysosomes. Downstream of LMP, the best-studied effector mechanism
is the proteolytic activity of lysosomal cathepsins that translocate to the cytosol. In the case of
moderate LMP, cell response is dominated by the proteolytic activation of BID and degrada-
tion of antiapoptotic BCL-2 proteins and caspase inhibitors. Extensive LMP can cause general
proteolysis and thereby necrosis.
is whether LMP occurs early or late in the signaling cascade, so to say upstream or
downstream of the point that irreversibly commits the cell to death.Most data indicate
that LMP, unless a consequence of a direct insult on lysosomal membranes, amplifies
cell death signaling beyond the point of no return represented by mitochondria desta-
bilization, in apoptosis, pyroptosis, or necroptosis, and contributes to the execution
phase of cell death [9,76–80].
The critical regulators of mitochondrial integrity are the BCL-2 proteins and it is
the interactions between its antiapoptotic and proapoptotic members that regulate the
integrity of outer mitochondrial membrane in response to several stress modalities.
The effector proteins BAX and BAK can homooligomerize in the outer mitochondrial
membrane and thereby form pores through which proapoptotic agents, including
cytochrome c, are released into the cytosol. Stress affects the transcriptional and
posttranscriptional modulation of BH3-only proapoptotic proteins, which can
sequester and neutralize the antiapoptotic proteins. There are two models to explain
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the activation of the effector molecules BAX and BAK. According to the “direct
model,” BAX and BAK activation depends on the interaction with the so-called
BH3-only activators BID and BIM [5]. In contrast, “indirect model” suggests that
the activity of BAX and BAK is independent of the association with BH3-only
activators and instead the BH3-only proteins sequester antiapopotic BCL-2 proteins,
which inhibit BAX and BAK, which in turn releases BAX and BAK activity [81].
Some studies suggest that BCL-2 proteins may also regulate the integrity of the
lysosomal membrane. It was reported that BAX can permeabilize the lysosomal
membrane after treatment with STS [82] and TRAIL. The latter was shown to
induce a recruitment of multifunctional sorting protein phosphofurin acidic cluster
sorting protein-2 (PACS-2) on death receptor-5 (DR5)-positive endosomes, which
then in turn recruits BIM and BAX [83]. In addition, caspase-8 generated tBID was
reported to be able to permeabilize lysosomal membranes on its own. Phosphatidic
acid facilitates the insertion of tBID deeply into lipid bilayers, where it undergoes
homooligomerization and triggers the formation of highly curved nonbilayer lipid
phases [84].
LMP upstream of MOMP was observed also early after TNF treatment. It was
suggested to be mediated by sphingosine–cathepsin B interaction [85], caspase-8-
mediated cleavage of caspase-9 [86], or increased sphingosine generation [29].
Other studies suggested that also for TNF-α LMP occurs downstream of MOMP
and depends on mitochondrial ROS generation [78,79]. Similarly, late LMP that
occurs after caspase activation was shown to take place in extrinsic apoptotic
pathways initiated by ligation of TRAIL or Fas receptors [77,87,88]. In fibroblasts
and monocytes exposed to etoposide, ultraviolet light, FasL, or interleukin-3
(IL-3) deprivation, which represent stimuli that initiate intrinsic apoptotic pathway,
lysosomes were not directly perforated by Bax/Bak but by effectors downstream of
the apoptosome. Neither Bax nor Bak was localized to the lysosomes [80]. Probably
the most common mediator of LMP is ROS that have been generated in consequence
to mitochondrial destabilization and caspase activation. Critical for the generation of
mitochondrial ROS is caspase-3-mediated cleavage of the p75 subunit of complex I
of the electron transport chain [89].
In the execution phase of cell death, including apoptosis, necroptosis, and pyropto-
sis, cytosolic Ca2+ concentration increases [9,90,91]. This activates cytosolic lipases,
which can modify lipids in lysosomal membranes and thereby change their perme-
ability for ions and small metabolites, leading to osmotic lysis of lysosomes [92].
Moreover, increased ceramide generation may lead to aggregation and assembly of
NADPH subunits, whereby ROS are generated [93]. Increased calcium concentra-
tion was shown to generate H2O2 and thereby oxidative stress [94]. Ca
2+-mediated
activation of cPLA2 has also been involved in lysosomal membrane destabilization
induced by heavy metals [95] or 17-β-estradiol [96].
In neurons exposed to ischemia, LMP is postulated to occur with combined
action of calpains and ROS. Immediately after ischemia, cytosolic Ca2+ concen-
tration increases and activates μ-calpains. Upon reperfusion, hydroxyl radicals
generated within lysosomes through the Fenton reaction generate an oxidated
lipid 4-hydroxy-2-nonenal (HNE). This can in turn carbonylate proteins, including
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Hsp70.1. Carbonylated Hsp70.1 can be cleaved by μ-calpains. From the point
of Hsp70.1 inactivation, several mechanisms were proposed to contribute to cell
death [97]. Hypothetically, lysosomal membrane is destabilized by the increase in
sphingomyelin, whose degradation depends on Hsp70.1 enhanced activity of acid
SMase [98].
In addition, proteasome inhibitors [99] and microtubule stabilizing agents [100]
have been shown to mediate cell death via LMP, although detailed molecular signal-
ing has not been established.
For many compounds, the evidence that they can induce LMP is often not com-
pelling, even more challenging is the evaluation of the critical role of the putative
LMP for cell death. As mentioned earlier, targeting of LMP-inducing compounds
is not entirely specific for the endocytic pathway and potential effects on other cell
organelles should be investigated. When LMP is the result of complex molecular sig-
naling, the cause and the consequence relationship is considerably more complex and
therefore extremely challenging to decipher [101].
8.3.3 Signaling Downstream of LMP
In general, limited damage to lysosomes triggers apoptosis and an extensive one
results in necrosis [12–16]. In both cases, the signaling seems to be mediated by
lysosomal hydrolases and/or ROS. However, extensive LMP, which may occur after
an intense direct insult of lysosomes or in the execution phase of different cell death
modalities, leads to general hydrolysis and contributes to cell demise [13,102,103]
(Figure 8.2).
8.3.3.1 Lysosomal Cathepsins Lysosomal cathepsins, among them cysteine
cathepsins and aspartic cathepsin D, are the most common effector molecules associ-
ated with cell death signaling downstream of LMP [16]. These enzymes are the major
lysosomal proteases and among the smallest lysosomal hydrolases (25–30 kDa) that
often translocate to the cytosol during LMP. Cysteine cathepsins are members of
papain-like cysteine proteases. In humans, 11 cysteine cathepsins have been found,
including cathepsins B, C (dipeptidyl peptidase I, DPPI), F, H, K, L, O, S, V, W, and
X. They all share the same core structure and are all monomers of 30 kDa with the
exception of cathepsin C, which is a homotetramer. Cysteine cathepsins are synthe-
sized as inactive precursors and require acidic pH for proteolytic processing to active
forms, which usually takes place in late endosomes and lysosomes. The enzymes are
delivered to these organelles by the mannose 6-phosphate receptor-mediated protein
sorting. Cathepsins have a broad specificity for substrates, consistent with their
role of recycling enzymes, and exhibit considerable redundancy [104]. In contrast
to the aspartic cathepsin D, the catalytic mechanism of cysteine cathepsins is not
dependent on acidic pH. However, they are structurally unstable at neutral pH, which
makes their activity short lived. There are though considerable differences between
individual members in their half-life at neutral pH, ranging from a few minutes in the
case of CatL to a few hours for CatS [105–108]. Their activity can be prolonged by
binding to various ligands, including substrates, glycosaminoglycans (GAGs), and
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even inhibitors that may under special circumstances serve as cathepsin “reservoirs”
[106,107,109,110]. The endogenous inhibitors include cystatin C in the extracellular
space and stefins and serpins in the cytosol [16,111]. Interestingly, transcription
factor Stat3 upregulates cathepsins B and L and downregulates their cytosolic
inhibitor serpin SpiA2, which collectively promotes LMP-mediated apoptosis in
mammary epithelium [112]. The translocation of cysteine cathepsins from lysosomes
to the cytosol has been demonstrated by enzymatic activity or immunodetection
in the cytosolic fractions of cell extracts, or by immunolocalization in fixed cells
[113]. Their involvement in cell death signaling has also been demonstrated by using
specific synthetic inhibitors, gene knockdown or knockout systems [64,99,114].
8.3.3.2 Lysosomal Apoptotic Pathway Collectively, the proteolytic cell death sig-
naling by cathepsins is referred to as the lysosomal apoptotic pathway (Figure 8.3).
Initially in a cell-free system, it was established that cysteine cathepsins trigger apop-
tosis by a cleavage of the BIDmolecule rather than by a direct cleavage of executioner
caspases-3 and -7 [63,115]. In cell experiments, it was shown that LMP triggered by
hydroxychloroquine (HCQ) or LeuLeuOMe does not suffice to trigger caspase activa-
tion and that Bax/Bak-dependent MOMP is a critical step of LMP-induced cell death
[64,116]. The BID protein belongs to proapoptotic BH3-only BCL-2 proteins. It may
act as a direct activator of pore-forming effector molecules BAX and BAK or/and
indirectly promote their activity by sequestering antiapoptotic BCL-2 proteins [6]. It
contains an unstructured, the so-called bait loop, which is cleaved by several proteases
associated with cell death, including initiator caspase-8 [117], granzyme B [118],
and calpain [119]. Cysteine cathepsins can cleave mouse BID at several sites, most
notably at Arg65 [63]. These exact cleavage sites are not entirely preserved in the
human BID; however, similar cleavage fragments are generated [64]. Cathepsin D
also cleaves mouse BID in the bait loop, however at Trp48 [120]. A truncated form
tBID then translocates to the mitochondrial membrane via specific targeting medi-
ated by cardiolipin [121]. In the next step, tBID recruits soluble BAX and assists
homooligomerization of BAX or the membrane-resident BAK into pores spanning
the MOM. Upstream of MOMP, cathepsins not only proteolytically activate tBID but
also proteolytically inactivate or degrade antiapoptotic BCL-2 homologues BCL-2,
BCL-xL, and MIC-1, and thereby promote the activity of BAX and BAK proteins,
which target the integrity of mitochondria [64]. In this way, LMP is transmitted to
MOMP, which is critical for signaling in the intrinsic apoptotic pathway (Figure 8.3).
In addition to cytochrome c, other proapoptotic factors are translocated through the
pores in theMOM, among them SMAC/DIABLO that antagonizes and the serine pro-
tease HtrA2/Omi that degrades the inhibitors of apoptosis proteins (IAPs) [7], thereby
promoting caspase activity. Similarly, cysteine cathepsins can degrade XIAP [64],
thereby simultaneously promoting apoptosis upstream and downstream of MOMP.
Interestingly, tBID pathway is independent of p53 and so cancer cells with mutant
p53 remain sensitive for the lysosomal apoptotic pathway [122], which offers an
opportunity for therapeutic approaches [72].
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Figure 8.3 Lysosomal apoptotic pathway. Upon LMP, lysosomal cysteine cathepsins and
aspartic cathepsin D can be translocated to the cytosol, where they promote apoptotic sig-
naling upstream and downstream of MOMP by proteolytic activation of BID and degrada-
tion of antiapoptotic BCL-2 proteins and caspase inhibitor X-linked inhibitor of apoptosis
(XIAP) (bold arrows). Truncated BID (tBID) transmits LMP to MOMP via recruitment of
BAX and homooligomerization of BAX and BAK in the outer mitochondrial membrane (regu-
lar arrows) and/or sequestration of antiapoptotic BCL-2 proteins. Downstream ofMOMP (light
arrows), cytochrome c, which is translocated from the intermembrane space of mitochondria
into the cytosol, mediates the assembly of the apoptosome, which serves as a platform for
the activation of the initiator caspase-9. Caspase-9 then activates executioner caspases-3 and
-7. Additional proapoptotic factors are translocated through the pores in the MOM, includ-
ing SMAC/DIABLO that antagonizes and the serine protease HtrA2/Omi that degrades the
inhibitors of apoptotic proteins (IAPs), thereby promoting caspase activity.
8.3.3.3 Alternative Signaling For many compounds that induce cell death
via LMP, the signaling downstream of LMP is not understood. In some cases,
it was demonstrated that cell death is largely independent of lysosomal cathep-
sins [123,124]. In others, lysosomal cathepsins even seem to have a protective
role [125], which may be linked to the protective role of autophagy. Moreover,
even when lysosomal cathepsins seem to be involved, there may be considerable
differences in the execution phase in particular with regard to caspase activation.
Caspases may be activated, yet cell death cannot be prevented with caspase inhibitors
[124,126], which suggests that the cell has experienced severe caspase-independent
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injuries that cause metabolic imbalance [3]. Alternatively, caspases may not get acti-
vated at all, which suggests that cell death in such cases is nonapoptotic [127–129].
There are few mechanistic reports on BID-independent apoptotic signaling
pathways downstream of LMP. Oxidative stress induced by H2O2 or exogenous
iron loading induced LMP that leads to an increase in oxidative DNA damage
and p53-dependent Noxa expression, which in turn induces MOMP and eventual
activation of apoptosis signaling [130]. The involvement of p53 nuclear translocation
has also been shown upon oxysterol (oxidized derivatives of cholesterol)-mediated
LMP and cysteine cathepsin translocation to the cytosol [131].
Compared to apoptosis, pyroptosis has been established rather recently and thus
much less studied. In pyroptosis that is seemingly initiated by LMP, the mechanism
of NLRP inflammasome activation is not understood and the role of cysteine cathep-
sins seems controversial [101]. LMP and translocation of cysteine cathepsins into
the cytosol either appears essential [73,132,133], or LMP was observed to occur
downstream of inflammasome activation [103]. So far, ROS generated by phagosomal
NADPH have been identified as the only direct link between LMP and inflammasome
activation [74].
8.4 CONCLUSION
The map of cell death signaling has gained complexity with regard to the diversity
of distinct pathways and the cross talk between them. Lysosomes harbor numerous
hydrolases, which can promote cell death if released into the cytosol, similarly to
apoptotic factors contained in the intermembrane space of mitochondria. The poten-
tial of lysosomes to generate ROS seems to be another important factor involved in
both LMP itself and its downstream cell death signaling. LMP, which is a conse-
quence of a direct insult on lysosomes, can initiate lysosomal pathway of apoptosis,
necrosis, or pyroptosis. In addition, LMP that occurs downstream ofMOMP amplifies
cell death signaling likely in any cell death modality, including extrinsic and intrinsic
apoptosis, pyroptosis, and necroptosis. In the context of the role of LMP in cell death,
our understanding in particular of the effectors that signal cell death downstream of
LMP is modest. At present, proteolytic regulation of the BCL-2 proteins by cysteine
cathepsins and aspartic cathepsin D seems the predominant mechanism [134]; how-
ever, experimental data suggest that it is not the only one. Understanding the role
of LMP in cell death and the factors regulating it holds promise for an alternative
approach for drug delivery, therapeutic induction of cell death in cancer cells, or its
prevention in ischemic tissue.
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9.1 INTRODUCTION
The efficiency with which lysosomes receive, hydrolyze, and recycle substrates is a
vital aspect of cell homeostasis that becomes increasingly important during aging.
Substrate delivery to lysosomes occurs through several routes, including endocyto-
sis, macroautophagy, chaperone-mediated autophagy (CMA), and macroautophagy,
as summarized in Figure 9.1 and extensively reviewed elsewhere. As the only step
common to these pathways, lysosomes are vital determinants of the cell’s success in
maintaining quality control over its components and may be the compartment most
vulnerable to failure in neurodegenerative disease states [1]. Because postmitotic cells
such as neurons and cardiac myocytes have fewer options than dividing cells for
removing unwanted materials, they are particularly reliant on the lysosomal system.
Neurons are further challenged by their extreme geometric asymmetry that places
many compartments that sequester substrates at long distances from lysosomes, the
degradative compartments that are located mainly in cell bodies. Beyond these intrin-
sic limitations, cellular aging superimposes additional challenges to lysosome effi-
ciency. Indeed, declining efficiency of lysosomal-related degradation is believed to
be a cardinal mechanism underlying aging at the cell and organismal levels and one
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Figure 9.1 Major routes of substrate delivery to lysosomes. (a)Macroautophagy is character-
ized by the sequestration of structures targeted for degradation into double-membrane vesicles
called autophagosomes. Fully formed autophagosomes may first fuse with late endosomes to
form an amphisome before fusion with hydrolase-filled lysosomes, which causes degradation
of the inner limiting membrane releasing the hydrolases into the lumen of the created autolyso-
some. Introduction of a fully activated proton pump (V-ATPase) induces full acidification of
the autolysosomal lumen necessary to activate acid hydrolases for optimal digestion of sub-
strates. The resulting metabolites are transported into the cytoplasm and used for synthesis
of new macromolecules or as a source of energy. (b) During chaperone-mediated autophagy,
proteins carrying the pentapeptide KFERQ-like sequence are recognized by the Hsc70 chaper-
one, which then associates with the integral lysosomemembrane protein LAMP-2A, triggering
its oligomerization. This event leads to the translocation of the bound protein into the lyso-
some interior through a process that requires Hsc70. (c) Microautophagy involves “bulk” or
chaperone-mediated internalization and degradation of cytoplasmic substrates into late endo-
some/MVB or lysosomal compartments by a process of membrane invagination followed by
membrane scission to release the cargo into the lysosomal lumen for degradation. (d) Het-
erophagy involves the lysosomal degradation of plasmamembrane components and exogenous
substrates after they are internalized by bulk or receptor-mediated endocytosis. After selected
proteins are sorted to different cellular destinations or recycled to the plasma membrane,
proteins targeted for degradation are trafficked to late endosomes/MVB, which fuse with a
lysosome or with autophagosomes to effect degradation. (See color plate section for the color
representation of this figure.)
that promotes the emergence of late-onset neurodegenerative diseases characterized
by proteinopathy.
In this chapter, lysosomal system aging is discussed as a key factor in determining
the onset and progression of neurodegenerative diseases in late life. After briefly con-
sidering the dysfunction of lysosomes in nonneural tissues in the context of aging, we
review information on four late age-onset neurodegenerative diseases: Alzheimer’s
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disease (AD), Parkinson’s disease (PD) and related disorders, Lewy body disease,
and frontotemporal dementia (FD). In each of these disorders, lysosomal dysfunction
contributes critically to the functional decline and loss of neurons and to development
of the signature proteinopathies characterized in each of these disorders.
9.2 LYSOSOME FUNCTION IN AGING ORGANISMS
In familial forms of many common late age-onset degenerative diseases, pathogenic
misfolded proteins are produced continuously from an early age and often many
decades before the protein accumulates abnormally in the neuron or induces
evident cellular damage. This observation suggests that additional essential
disease-promoting factors emerge during the aging process. A likely vital contri-
bution of cellular aging to degenerative disease in late adulthood is diminished
proteostasis [2] and particularly a decline in the efficiency of the lysosomal system,
which is a well-established pathological hallmark of cellular aging [3–5]. At the
organismal and cellular levels, aging also involves a progressive loss of physiological
integrity through multiple pathways [4], including shortening of telomeres [6], accu-
mulation of extrachromosomal DNA [7] and oxygen-free radicals [8], and an altered
balance of cell cycle regulating factors [9] as well as alterations of insulin/mTOR
signaling, protein secretion, and epigenetic gene regulation [10]. In many of these
aspects of cell aging, progressive lysosomal degradative deficits can be implicated
as either a primary driving force or as a direct consequence of another aging-related
impairment. The close relationship between lysosomes and cellular aging is under-
scored by evidence that the dozen or so experimental manipulations known to extend
lifespan in a wide range of organisms share the property of increasing the activity
or efficiency of autophagy and lysosomal function [2,11]. Conversely, autophagy
impairment can induce a range of senescence-related changes in certain cells [12–14].
The activity of mTOR, a molecular rheostat that balances autophagy and protein
synthetic activities, is particularly critical in mediating lifespan extension and is
influenced by a broad array of signaling pathways, environmental and disease factors
[15,16]. Although mTOR and autophagy induction, and not lysosomes per se, are
usually the focus in longevity studies, mTOR activity and lysosome biogenesis are
cross-regulated by transcription factors, such as TFEB and TFE3, which modulate
the expression of genes encoding most lysosomal components and additional
components of the autophagosome machinery [2,17]. The upregulation of autophagy
flux via mTOR inhibition in lifespan extension models, therefore, includes major
changes in lysosomal function. Indeed, the lysosome and specifically the activity
of the lysosomal proton pump, V-ATPase, has recently been singled out in yeast as
a critical determinant of longevity [18–20] related to its control of lysosomal pH
and thus the hydrolytic capacity of lysosomes for clearing damaged mitochondria
and modified substrates generated during cellular aging. The mechanism involves
the amino acid sensing function of the lysosomal vacuole, which, in turn, regulates
mTOR activity [20]. During Ras-induced senescence, lysosomes spatially link
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Although a need for greater lysosome (and autophagy) capacity is expected in
cells as they age, evidence suggests that lysosome system efficiency and capacity
for clearing compromised organelles decline with age, which is considered funda-
mental to cellular aging. Mitochondrial turnover is entirely dependent on autophagy
(mitophagy) and adequate lysosomal hydrolytic capacity. Mitochondria in aging cells
become enlarged and less efficiently sequestered by mitophagy [22]. These enlarged
mitochondria have reduced inner membrane potential and produce ATP less effi-
ciently, making them more vulnerable to acute damage, which can then trigger mito-
chondrial membrane permeabilization and apoptosis or necrosis. In younger cells, an
efficient autophagic turnover of dysfunctional or damaged mitochondria counteracts
these structural changes. Conversely, in certain disease states, such as PD discussed
later, the expression of specific genes that regulate mitophagy is decreased and com-
pounds aging-related inefficiencies. Extensive nuclear changes that accompany cell
senescence, the state of irreversible cell cycle arrest, include the remodeling of chro-
matin and progressive loss of total histones, which are, in part, lysosome-dependent
processes. The autophagic-lysosomal degradation of chromatin released from nuclei
is believed to drive senescence by making cell cycle reentry less likely [10]. It could
be speculated that impaired lysosomal function, as seen in AD for example, promotes
the abortive attempts of neurons to reenter the cell cycle, which is associated with
neurodegeneration in this disease [23].
Beyond effects on specific organelles, cellular aging involves an increasing and
cumulative oxidative damage to cytosolic and membrane-associated proteins and a
rise in translational errors leading to larger synthesis of defective proteins [24–27].
Many of the covalent modifications of proteins common in aging such as oxidation,
glycation, phosphorylation, deamidation, carbonyl modification, and misfolding [28]
reduce the proteolytic susceptibility of the proteins to proteolysis [29]. Free oxygen
radicals, which accumulate with age, cross-link proteins through isopeptide bonds
and confer additional resistance to proteolysis. Moreover, disease-related gene muta-
tions promote misfolding and aggregation of specific pathogenic proteins or their
metabolites and thereby alter proteolytic susceptibility [30]. The cell’s primary line
of defense against these mounting aging- and disease-related substrate modifications
are mainly two proteolytic clearance systems, the ubiquitin proteasome system (UPS)
and the autophagic pathway [26,31–33]. These two systems act somewhat interde-
pendently as suggested by the shared use of overlapping families of adaptor proteins
such as ubiquitin and p62, which earmark substrates for elimination [34] and the ten-
dency of lysosomal degradation to become upregulated when proteasome activity is
inhibited [35,36].
The increased need for lysosomal degradation to clear the growing burden of
damaged constituents in aging cells is, unfortunately, not matched by an increased
degradative capacity because overall proteolysis actually declines with age in a wide
range of organisms and tissues. This decline is greatest for long-lived proteins, which
are most often lysosomal substrates, while declines in activity of the ubiquitin protea-
some pathway may be less marked [37,38], except in certain pathological states [39].
A third proteolytic capability of cells, the calpain–calpastatin system [40,41], may
selectively initiate turnover of certain proteins, but its capacity for only carrying out
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limited proteolysis results in the generation of protein fragments that must also be
cleared by lysosomes and the UPS. Notably, the activities of calpains increase in
most aging tissues [41,42], which may further contribute to an overburdening of the
two main clearance systems.
Besides effects on the proteolytic substrates, cell aging may also adversely impact
lysosomes directly. One manifestation of this impact, seen especially in postmitotic
cells, is an accumulation of the age pigment [43] lipofuscin within lysosomal
compartments, which is a hallmark of cell aging [44]. Lipofuscin content of cells
is linearly correlated with age in various organisms [45], although environmental
factors can independently affect net lipofuscin accumulation in a given organ-
ism [46]. Lipofuscin is an autofluorescent polymeric pigment composed of aldehyde
cross-linked protein fragments, oxidized lipids, carbohydrates, and trace amount of
metals, especially iron [47,48]. It is formed by the iron-catalyzed peroxidation of
decomposed lipids principally from vesicular organelles such as autophagocytosed
mitochondria and its presence reflects the impaired intralysosomal degradation of
these autophagic substrates under conditions of growing oxidative stress within
aging cells. Loss of lysosomal enzyme activity, as seen experimentally using
inhibitors of protease or acidification, increases the opportunity for lipid peroxida-
tion, and accelerates lipofuscin generation as well as other cardinal manifestations
of brain aging [5,49–51]. The influence of lipopigment accumulation on lysosomal
function was initially thought to be negligible, but further study has documented
lipofuscin-dependent decreases in activities of lysosomal cysteine proteases [48,52]
and, interestingly, also the proteasome [36].
Although the accumulation of lipofuscin in aging cells suggests dysfunctional
hydrolysis within lysosomes, reliable information on the hydrolytic efficacy of
lysosomes in living cells is still fragmentary and a better understanding is hampered
by the limitations of available methods to assess lysosomal activity in vivo. Hydro-
lase activities measured in vitro are a poor reflection of the total activities within
lysosomes in living cells. It is, therefore, difficult to interpret observations that the
in vitro activities of cathepsin D and certain lysosomal cysteine proteases may be
higher in aging rat liver [53] or in rat brain [54,55] and that in vitro β-galactosidase
activity may be elevated in aging human fibroblasts. Compensatory increases in
cathepsin protein expression in compromised lysosomes may yield higher activity
in vitro even though the in situ activity is lowered because of defective lysosomal
acidification [56] or other luminal lysosomal changes. Age-related changes in the
intralysosomal pH, levels of endogenous lysosomal cysteine protease inhibitors
(e.g., cystatins B and C) [57], membrane stability [58], or in myriad other possible
conditions within the intraluminal environment of the lysosome, may well explain
the overall decreased lysosomal activity in aging cells, although these possibilities
are yet to be fully investigated.
Another clear indication of the diminished function of aging lysosomes is the
striking decline in the activity of CMA seen in many cell types and tissues [59,60].
Underlying this decline are age-related changes in lysosomal membrane lipid com-
position that alter the dynamics and stability of LAMP-2A in lysosomes [60–62]
without changing transcription, synthesis, and lysosomal targeting of the LAMP-2A
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protein during lysosome biogenesis. The loss of LAMP-2A by degradation in the
lysosomal lumen reduces the ability of the lysosomes to bind and translocate sub-
strate proteins into the lumen [62]. Age-dependent declines in CMAmay be promoted
by increased oxidative stress and attempts to eliminate oxidatively damaged pro-
teins [63]. That these CMA deficits accelerate other aspects of the aging process is
shown by the improvement in the health span of aged mice [64] when an exogenous
copy of LAMP-2A is expressed in the liver.
9.3 LYSOSOMES AND DISEASES OF LATE AGE ONSET
In light of the adverse impact of aging on lysosome function, it is not surprising that
diseases that manifest at an old age would have a lysosomal component. Less well
appreciated is that in some of these disorders, the disease-related mechanism itself
helps to cripple the lysosomal system and also contributes significantly to primary
pathogenesis. This is particularly an emerging theme in recent conceptualizations of
neurodegenerative disease mechanisms. We first briefly consider a few examples of
lysosome-aging interactions in nonneural disorders and later discuss major neurode-
generative disorders that are most prevalent at advanced age in the following sections.
9.3.1 Cardiovascular Disease
Lipofuscin accumulates robustly within aging cardiac myocytes and other long-lived
postmitotic cells, like neurons, because it is neither degraded nor exocytosed effi-
ciently [5]. Along with lipofuscin accumulation, reflecting incomplete degradation
of autophagocytosed material, myocardial aging is characterized by the abnormal
accretion of lysosomal “waste” material, especially defective enlarged mitochondria.
Arising by oxidative damage and/or altered fission, these enlarged mitochondria
are believed to be autophagocytosed less efficiently than smaller ones, leading to
the progressive accumulation characteristic “giant” mitochondria in aged cardiac
myocytes [22].
Normal arteries express very low levels of cathepsins, but these proteases become
abundantly expressed and secreted in atherosclerotic vessels of elderly individuals
[65–67] stimulated in part by increased release of inflammatory cytokines [65,66,68].
Cysteine cathepsins K, L, and S contribute especially to the formation and progres-
sion of the atherosclerotic plaque and may influence its stability and thus thrombo-
genic potential [69]. The effect of cathepsins in atherosclerotic lesions is balanced
by the expression of endogenous cathepsin inhibitors, the cystatins, which normally
buffer protease activity, but the levels of cystatin C are reduced in atherosclerotic
lesions [70]. This situation likely contributes to increased degradation of the extra-
cellular matrix of the vessel, degradation of the elastic lamina, and formation of
larger plaques [71]. Lysosomal membrane permeabilization (LMP)-dependent apop-
tosis can be initiated in macrophages by lipids, including the oxidized lipoprotein
particles and oxysterols accumulating in lysosomes of the affected vessels [72] [73].
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Age-related macular degeneration (AMD), the leading cause of central vision
loss in the elderly in developed countries, is a progressive degenerative disease
involving multiple genetic and environmental factors impinging mainly on the
retinal pigment epithelium (RPE). AMD is a disease of aging, rising in incidence
exponentially 8- to 10-fold between ages 50 and 90 (https://nei.nih.gov/eyedata/
amd). Interestingly, the variant B mutation in cystatin C, a widely expressed lysoso-
mal protease inhibitor is associated with both AMD and Alzheimer’s disease [74]
and is one of several parallels that have been noted in these two disorders [75,76].
Links were recently suggested between mutations in the Npc1 and Npc2 gene
that cause Niemann–Pick type C (NPC), a lysosomal storage disease, and retinal
degeneration associated with marked AMD-like lipofuscin accumulation within
the RPE [77]. Age, genetics, diet, smoking, and many cardiovascular factors cause
aging-related functional changes in the RPE, choroid, and neural retina, and there
is increasing evidence that long-term oxidative stress, impaired autophagy clear-
ance, and inflammasome-mediated inflammation in the RPE are early pathogenic
events. Each RPE cell phagocytoses and digests the material produced by 30–50
overlying photoreceptor cells, which shed 10% of their mass daily. The intense and
continual phagocytic activity of RPE cells results in the progressive accumulation
of lipofuscin and other indigestible products in their lysosomal compartments [78].
Unlike lipofuscins found in other tissues, which are composed mainly of protein,
RPE lipofuscin consists predominantly of lipid-bisretinoids (LBs) and only 2%
protein [79]. Once N-retinylidene-N-ethanolamine (A2E) and other less abundant
bisretinoids are formed, they are refractory to all known lysosomal hydrolases and
progressively accumulate in the lysosomes of RPE cells [80,81]. The concept that
LB accumulation causes retinal degeneration is supported by evidence showing that
excessive LBs are toxic for cultured RPE cells [82,83], photoreceptors overlying
A2E-laden RPE become more susceptible to degeneration [84] and in Stargardt’s
disease, excessive accumulation of LBs precedes macular neurodegeneration [85].
Mice carrying null mutations in Abca4 and Rdh8, two genes linked to familial
forms of AMD, develop blindness, basal laminar deposits, and focal accumulations
of extracellular debris between the RPE and the Bruch membrane (drusen) [86].
Notably, beta cyclodextrins (β-CDs), which bind LBs and protect them against
oxidation, markedly reduce the LB content of RPE in the Abca4-Rdh8 double
knockout (DKO) mice model of AMD [87].
Lysosomes may be a convergence point of multiple factors contributing to AMD
pathogenesis. Iron-rich lysosomes are sensitive to oxidative stress, and diffusion
of peroxides into this compartment causes lipofuscin to form in normal aging
postmitotic cells. Iron contributes to the pathogenesis of AMD as a source of free
radicals that damage the tissue [88,89]. Iron levels increase normally with age in
the neural retina [90] [91,92]. When the greater abundance of iron observed in
vulnerable of AMD-affected eyes [93,94] is mimicked in an AMD mouse model,
the mice exhibit age-dependent retinal iron accumulation and retinal degeneration
with AMD features [95,96]. When the ARPE-19 cell model of AMD is exposed
to increased iron to mimic the iron accumulation with age, these cells display
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markedly decreased phagocytosis activity, interrupted cathepsin D processing, and
reduced cathepsin D activity [97]. As previously discussed, increased iron-catalyzed
free radical generation within lysosomes generates lipid peroxidation products,
such as 4-hydroxynonenal (HNE) and malondialdehyde (MDA), known to increase
lipofuscinogenesis and reduce autophagy activity in RPE cells [98] by directly
inhibiting autophagic sequestration of cytoplasmic material and by inactivating
lysosomal cysteine proteases via covalent binding to the active site, thereby creating
proteolysis-resistant substrates that become competitive protease inhibitors [99]. In
addition, A2-E is a potent inhibitor of the ATPase proton pump [100] and its accu-
mulation increases lysosomal pH and this inhibits lysosomal hydrolases. In support
of the importance of this effect, several approaches used to reacidify lysosomes,
including stimulating beta-adrenergic, A2A adenosine, and D5 dopamine receptors,
and targeting acidic nanoparticles to RPE lysosomes, have been shown to lower
lysosomal pH and improve degradation of outer segments within compromised RPE
cells from aged ABCA4(−/−) mice and other AMD models [101].
Finally, a number of AMD-associated insults may disrupt the integrity of RPE
lysosomes. For example, the lipofuscin component A2E has been shown to perme-
abilize RPE lysosomes via its detergent properties [102]. Destabilization of RPE
lysosomes induces NLRP3 inflammasome activation, which may contribute to AMD
pathology through the release of the proinflammatory cytokine IL-1β and through
caspase-1-mediated cell death, known as “pyroptosis” [103].
9.4 LYSOSOMES IN AGING-RELATED NEURODEGENERATIVE
DISEASES
Varying degrees of lysosomal-related pathology have been reported in most
major adult-onset neurodegenerative diseases, including AD [104,105], PD [106],
amyotrophic lateral sclerosis (ALS) [107,108], Huntington’s disease (HD) [109],
and several others [109]. Historically, the possible pathogenic significance of
this lysosomal pathology has been largely dismissed as generalized secondary or
end-stage responses of the lysosomal system to neuronal compromise. More recently,
however, with the emerging appreciation of lysosome and autophagy involvement in
neurodegenerative disease mechanisms, the concern is now increasing that modest
AV/lysosome changes in a disease tend to be overinterpreted as pathogenically
meaningful without performing adequate quantitative analytical assessments. Where
extensive quantitative analyses of this pathology have been carried out, as in AD,
for example, the findings strongly point to a disease process significantly involving
lysosomes, which has revealed important clues to the underlying pathobiology.
Compelling genetic evidence now links mutation-driven lysosome dysfunction to
the development of familial forms of multiple late-onset neurodegenerative diseases
[1,110,111] and to themechanism of neuronal cell death itself [112,113]. In a growing
array of aging-related neurodegeneration diseases, the suspected pathogenic protein
is often an integral or associated regulatory component of the lysosome or the larger
lysosomal network (e.g., autophagy or endosomal lysosomal pathway). In many of
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these cases, the disease mutation has also been shown to disrupt a critical function
of the lysosomal system. Equally compelling supporting evidence is the growing
number of instances in which the same lysosomal system gene can cause either a
neurodegenerative disease of late adult onset or a congenital lysosomal storage disor-
der (LSD), depending on the mutation or mutant gene dosage. In neurodegenerative
diseases characterized by signature patterns of proteinopathy, the pathogenic protein
is very frequently a known substrate of lysosomal mediated pathways (e.g., macroau-
tophagy or CMA) and its appearance as inclusions or aggregates is related in part to
a lysosomal effect induced by the protein. Finally, the striking therapeutic effects
achieved by modulating autophagy or lysosome efficacy in mouse models of major
late age-onset neurodegenerative diseases underscore the significance of lysosomal
system dysfunction as a pathogenic mechanism and as a target for future therapies.
We consider four major neurodegenerative diseases that develop with increased inci-
dence in old age (AD, PD, diffuse Lewy body diseases, and FD) and their earlier
onset familial variants as follows.
9.4.1 Alzheimer’s Disease (AD)
AD, the most common dementia and a disease involving widespread neuronal cell
death, increases exponentially in incidence after the age of 65, underscoring the
close relationship of pathogenesis to brain aging. Autosomal-dominant mutations
in one of three genes presenilin 1 (PS1), presenilin 2 (PS2), and amyloid precursor
protein (APP) (APP gene duplication in the case of Down syndrome), account for
less than 5% of AD cases. Risk in the remaining 95% of AD cases is influenced
substantially by the epsilon 4 allele of APOE and more modestly by a growing
number of other genes. AD is defined by the coexistence of two neuropathological
features: intraneuronal aggregates of the microtubule-associated protein tau (neu-
rofibrillary tangles) and extracellular lesions known as “senile or neuritic plaques,”
which are foci of degenerating or dystrophic axons and dendrites associated with
deposits of beta-amyloid peptide (Aβ), a cleavage product of APP able to form
amyloid fibrils and toxic Aβ oligomers. Equally characteristic of AD pathology,
however, are changes in the endosomal lysosomal system, beginning with very early
appearing disease-specific enlargement of early endosomes and increased lysosome
biogenesis and subsequently autophagy failure evidenced by profuse accumulation
of autophagic vacuoles (AVs), especially autolysosomes, in affected neurons.
Lysosomal dysfunction and enormously swollen dystrophic neurites containing
mainly AVs are widespread in affected brain regions and are highly character-
istic of neuropathology in AD compared to that in the several other adult-onset
degenerative diseases sufficiently studied. Such accumulations of autophagic and
endocytic “waste” in autolysosomes are, however, reminiscent of those seen in
some primary LSDs [114]. Notably, LSDs (e.g., NPC and mucopolysaccharidosis
type IIB [115,116]) are among the few disorders in which neurofibrillary tangles,
a hallmark lesion of AD, develop in some cases, along with other features of AD
pathology [117–120]. In NPC, for example, highly disease-selective abnormalities
of endosomes, elevated levels of the beta-site APP-cleaving enzyme (BACE) and
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BACE-cleaved carboxyl-terminal fragments of APP (βCTFs), and modest extracel-
lular Aβ deposition arise in the context of endosomal trafficking of cholesterol and
accumulation of unesterified cholesterol in late endosomes/lysosomes. Interestingly,
allele-selective influences of apolipoprotein E (APOE) genotype on pathology are
also seen in both NPC and AD [121].
Converging lines of evidence point to defective autolysosomal proteolysis is being
principally responsible for disruption of autophagy in AD. Enlarged substrate-laden
autolysosomes are the principal organelles in giant neuritic swellings [104], and
similar neuritic dystrophy and selective accumulation of AVs can be reproduced
by blocking lysosomal proteolysis pharmacologically or genetically in vitro or in
vivo (reviewed in Reference [122]). The morphological and functional deficits in
AD models that overexpress mutant APP develop lysosomal deficits, not unlike
those in the well-studied presenilin-1 loss-of-function models although different
mechanisms are likely involved (see below). The endosomal–lysosomal dysfunction
in these mouse models includes impaired axonal transport of selected cargoes,
increased amyloidogenesis, reduced amyloid clearance, and lowered survival of
neurons [122,123]. The pathologic significance of autophagy failure in AD is further
supported by evidence that selectively enhancing lysosomal proteolysis substantially
ameliorates AD-related pathologies (e.g., Aβ deposition, tau pathology), synaptic
dysfunction, and cognitive deficits in AD models [124–126]. This range of thera-
peutic effects has been seen in vivo in mouse AD models in which the endogenous
lysosomal cysteine protease inhibitors, cystatin C [124] or cystatin B, were deleted to
increase cysteine protease activation or cathepsin B was overexpressing or pharma-
cologically modulated to enhance lysosomal proteolysis [124,126–130]. Rapamycin
administration prior to development of AD pathology and presumably before lysoso-
mal failure delays the onset and diminishes the severity of the AD phenotype while
administration after the appearance of pathology has little beneficial effect high-
lighting the importance of lysosomal failure [127]. Although the mTOR inhibition
actions of rapamycin to induce autophagy may be a major factor in the preventative
effects, the additional effects of activating the transcriptional factors that regulate
lysosomal biogenesis, for example, TFEB, TFE3, are also likely to be important.
Although the known functions of the genes causing early-onset AD argue strongly
for a pathogenic role of APP and its metabolites in AD, the three autosomal-dominant
causative AD genes and many of the other genes that confer increased AD risk also
have direct or close functional relationships to the endosomal–lysosomal system,
which is notably also the organellar system most active in generating and clearing
APP metabolites [123]. Emerging evidence indicates that, independently of toxic
effects mediated by Aβ, the alterations of the key genes and many of the newly
identified genetic risk factors adversely alter lysosomal network function. Given that
endosomal–lysosomal and autophagic pathways are strongly implicated in both the
generation and clearance of Aβ and thus, the negative effects of AD genes on APP
processing and on lysosomal system function are mechanistically intertwined [123].
Key genetic risk factors and proteins linked to AD pathogenesis impair lysosome
function either directly (e.g., presenilins) or by altering processes upstream in
lysosomal pathways (e.g., APP), which requires aged and failing lysosomes to deal
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with a substantially greater burden of less digestible substrates, including Aβ, which
can further corrupt lysosome function.
The most direct genetic link between lysosomal dysfunction and AD pathogene-
sis are mutations of PS1, the most common cause of early-onset familial AD [131].
PS1, a ubiquitous protein with 9 transmembrane domains, exists in the endoplasmic
reticulum (ER) as a 65 kDa holoprotein and elsewhere as a cleaved two-chain cat-
alytic subunit of the gamma (γ)-secretase enzyme complex that mediates intramem-
branous cleavage of well over 25 different substrates [132,133]. Notable among its
actions is generation of Aβ from a carboxyl-terminal fragment of APP generated
by BACE-1 (ß-APP cleaving enzyme) [134]. PS1 mutations in AD confer loss of
function to γ-secretase [135] resulting in reduced levels of Aβ peptides [136,137]
and often, though not invariably, a modest increase in the proportion of a toxic 42
amino acid peptide (Aß42) prone to greater aggregation relative to a less toxic 40
amino acid form (Aß40) [133,135,138]. Although PS1 pathogenicity in AD is often
ascribed to this minor shift in Aβ42 and 40 and the promotion of Aβ oligomer-
ization, the evidence for this mechanism is correlational rather than direct. Addi-
tional or alternative explanations for pathogenicity of PS1 mutations have also been
sought [139] involving alternative actions of PS1 as a component of γ-secretase [140]
or via its secretase-independent roles as a holoprotein, which include disruption of
its roles in lysosomal acidification [141], Wnt signaling [142], and cellular calcium
regulation [143–145].
Mutations of PS1, which accelerate AD onset, considerably exacerbate lysosomal
system pathology in early-onset AD or mouse models of AD [146] and similar lyso-
somal pathology can be induced by deleting PS1 [141,147,148]. Exploring the basis
for these effects, Lee et al. [141] demonstrated that PS1 holoprotein acts as a chap-
erone in the ER for the V-ATPase V0a1 subunit, a six-pass transmembrane protein
(TMEM) core subunit of the proton pump principally responsible for full acidifica-
tion of lysosomes. While glycosylation at one candidate site on the V0a1 subunit
did not influence V-ATPase stability [149], recent studies (Lee, unpublished) have
shown that glycosylation failure at a second V0a1 site, an event normally facilitated
by PS1 holoprotein, leads to V0a1 protein instability and increased V-ATPase degra-
dation by ERAD before it can be delivered to lysosomes as earlier proposed [141].
In diverse cell types lacking PS1 and in fibroblasts from patients with AD-causing
PS1 mutations, the V0a1 subunit of the V-ATPase is poorly glycosylated [150] and is
associated with reduced assembly and function of the V-ATPase leading to a failure to
fully acidify lysosomes, which is a requirement for lysosomal protease activation and
autophagy [141,151] (Lee et al., 2014, submitted). The role of PS1 in lysosome acid-
ification has been confirmed in various systems [151–155], and recent evidence has
shown that normalizing lysosomal acidification fully reverses defective autophagy
and lysosome function in PS1-deficient cells [149].
The failure of lysosomal acidification under conditions of PS1 loss of function
has additional untoward effects on the signaling roles of lysosomes and lysosome
trafficking. Loss of PS1 holoprotein function has previously been implicated in medi-
ating γ-secretase-independent effects of AD-causing PS1 mutations (or PS1 deletion)
that dysregulate calcium homeostasis at the ER via multiple mechanisms [156–158].
 

148 THE LYSOSOME IN AGING-RELATED NEURODEGENERATIVE DISEASES
Lysosome mechanisms, however, have recently emerged as an additional important
factor driving calcium dysregulation. Although ER contains the largest stores of cel-
lular calcium [159], lysosomes are the second most abundant calcium store [160].
Abnormal efflux of calcium from lysosomes [149,161] via the TRPML1 calcium
channel is a major contribution to cytosolic calcium elevations in PS1-deficient cells
(Lee et al., submitted) and arises as a direct consequence of defective lysosomal
acidification. Notably, reversing calcium efflux abnormalities alone does not rescue
either acidification or autophagy deficits, whereas correcting lysosomal pH rescues
calcium and autophagy deficits indicating that lysosomal calcium dysregulation is
a secondary consequence of elevated pH. Although the lysosomal calcium efflux
abnormality in PS1-deficient cells does not drive autophagy/lysosomal abnormali-
ties, it does cause activation of calpains [162] and calcium effectors, such as pro-
tein kinases (e.g., cdk5, ERK 1/2), which potentially mediate tau hyperphosphory-
lation [162]. In addition, signaling that regulates endolysosomal compartments is
specifically impeded when lysosomal proteolysis is inhibited by blocking acidifica-
tion or directly inhibiting cathepsins, promoting the selective accumulation of these
organelles within axon swellings [163]. Local cytoskeletal protein hyperphosphory-
lation within dystrophic neurites also seen under these conditions [163] may involve
calcium release from accumulating deacidified autolysosomes.
Mutations of APP and APP gene duplication in the context of Down syndrome
cause AD in which severe autophagy neuropathology develops with a late age onset,
as seen in all forms of AD and in mouse models. In TgCRND8 mice overexpressing
human APP with two FAD mutations [126,164], florid autophagic-lysosomal pathol-
ogy includes strikingly enlarged autolysosomes containing incompletely digested
autophagic materials, including APP metabolites, membranous structures, and a
lipopigment component. Stimulating lysosomal proteolytic efficiency in TgCRND8
mice by deleting an endogenous inhibitor of lysosomal cysteine proteases (cystatin B)
prevents development of these pathological features, decreases extracellular amyloid
deposition, and ameliorates learning and memory deficits [126], supporting the
pathogenic significance of autophagic-lysosomal dysfunction, and specifically
deficient lysosomal proteolysis in AD. Similar therapeutic effects have also been
reported in another AD model of β-amyloidosis after overexpressing cathepsin B or
deleting cystatin C [124,130].
One likely contributor to the pathogenic actions of APP in all forms of AD, besides
Aβ, is the effect of the β-cleaved carboxyl-terminal fragment (βCTF) of APP on
the endosomal–lysosomal system. The earliest disease-specific pathologic change in
sporadic AD appearing before amyloid is deposited in the neocortex is the enlarge-
ment of Rab5- and Rab7-positive endosomes [165,166], and upregulated transcrip-
tion of genes related to endocytosis, such as Rab5, Rab7, and Rab4 [167]. Recruit-
ment to endosomes of the proteins encoded by these genes promotes fusion and
abnormal enlargement of early and late endosomes [105,165], pathological accel-
eration of endocytosis, and diverse additional deficits demonstrated in mouse mod-
els [165,167,168].
The same pathological endosomal response mediated by βCTF [168] is seen
in beginning decades before classical AD neuropathology in Down syndrome
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(trisomy 21), a cause of early-onset AD, attributed to an extra copy of App on the
trisomic region of chromosome 21 [169]. The downstream consequences of this
abnormal endocytic response include disrupted neurotrophin signaling, cholinergic
neuronal degenerative changes [170], and increased apoptotic signaling [171]. The
acceleration of endocytosis in cells of individuals with Down syndrome causes
increased protein and lipid accumulation in endosomes and slowed lysosomal degra-
dation of endocytic cargoes [165] as well as additional impairments of proteolysis
within lysosomes (Jiang et al., submitted). Rab5 activation and the endosomal
phenotype are exacerbated by both FAD mutations of APP [171] [172] and by
inheritance of the ε4 allele of APOE, an endocytic transporter of cholesterol and a
major genetic risk factor for late-onset AD [166] and by dietary cholesterol itself,
another suspected AD risk factor. By upregulating endocytosis, elevated dietary
cholesterol alone or overexpression of its receptor APOE (particularly APOE4)
elevate βCTF levels and also lead to increased delivery of Aβ1-42 to lysosomes
[173,174]. Expression in a hAPP mouse model of AD of an APOE ε4 allele, but not
the APOE ε3 allele, increases levels of intracellular Aβ in lysosomes, altering their
function and causing neurodegeneration of hippocampal CA1, entorhinal, and septal
neurons [175]. As in several AD mouse models, various lipid storage materials (e.g.,
cholesterol, sphingolipids) accumulate in endolysosomal compartments within cells
from individuals with Down syndrome. In several settings, these lipid accumulations
have been shown to promote lysosome deacidification [176–178] and to alter
the processing and clearance of APP and its metabolites [179]. Notably, chronic
administration of cyclodextrin, an agent that promotes clearance of cholesterol
from lysosomes, reduces amyloidogenesis and improves cognitive function in a
PS/APP mouse model [180]. Interestingly, among a very few additional pathological
conditions in which AD-like endosomal pathology develop is NPC, a disorder of
cholesterol homeostasis. Although less well characterized, a growing number of
AD risk genes for late-onset AD (e.g., BINI, CLU, PICALM, ABCA7, MS4A4A)
identified through genome-wide screens and association studies have direct links
to endocytic regulation in part because of the actions on these processes, APP
processing [181,182]. Thus, in sporadic AD and under conditions of increased
genetic and environmental AD risk, accelerated endocytosis mediated by Rab5
and βCTF seems to be a common pathway in AD leading to increased delivery of
substrates into degradative compartments.
Aβ peptide can be sequestered or generated from APP during autophagy [183]
although it is normally then degraded in lysosomes [184–186]. Although less
well studied as “Aβ degrading proteases” than the zinc metallopeptidase fam-
ily [187,188], cathepsins are now considered an important route for Aβ/amyloid
clearance [123,125,130] and human neurons may be particularly dependent on
this mechanism [189]. Among its various processing routes, tau also undergoes
lysosomal degradation by CMA upon hsc70 recognition of one of the two targeting
motifs in its C-terminus [190]. Mutant tau variants, however, abnormally bind to
LAMP-2A and are only partially internalized. The portion of the protein that gains
entry into the lysosomal lumen is trimmed, resulting in the formation of smaller
amyloidogenic tau fragments at the lysosomal membrane that oligomerize directly at
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the surface of lysosomes and may disrupt lysosomal membrane integrity and block
CMA of other substrates [190].
Slowed degradation of Aβ and other substrates within lysosomes encourages fur-
ther oxidation of substrates [191] and additional lysosomal dysfunction. In those
inheriting the ApoE4 risk allele, a unique proteolytic product of ApoE4, and not
ApoE3 or ApoE2, may be generated in lysosomes, which yields a “molten glob-
ule” structure that induces reactive intermediates and destabilizes lysosomal mem-
branes leading to lysosomal leakage and apoptosis [174]. Also, the expression of
ApoE4, but not the ApoE3 allele, increases levels of intracellular A-beta peptide (Aβ),
enlarges lysosomes and alters their morphology in a mouse AD model and causes
neurodegeneration of neurons typically vulnerable in AD [175]. Similarly, overex-
pression of human Aβ 42, but not Aβ 40, in Drosophila neurons induces age-related
autophagic/lysosomal dysfunction and neurotoxicity [192] believed to arise from
lysosomal membrane destabilization mediated directly by Aβ [193,194] or by incom-
pletely degraded oxidized autophagic substrates [191]. Neurons cannot dilute by cell
division any toxic protein buildup and are, therefore, particularly vulnerable to poten-
tially toxic, mutant, oxidized, and aggregated proteins and peptide fragments. Accu-
mulation of these substrates in lysosomes, promoted by increasing hydrolytic dys-
function, are conditions that may increase membrane permeability and release of
hydrolases into the cytoplasm, even from otherwise intact lysosomes [195]. A close
connection between lysosomal network dysfunction and mechanisms of neurodegen-
eration is well documented [114].
9.4.2 Parkinson’s Disease and Related Disorders
In PD, the death of neurons involves mainly the dopaminergic population in the
substantia nigra. These neurons develop signature Lewy body inclusions containing
fibrillar aggregates of α-synuclein (SNCA), a cytosolic protein that dynamically
interacts with membranes [196] and influences vesicle behavior, neurotransmission,
and synaptic plasticity [197]. Point mutations of the α-synuclein gene (PARK1
locus) are causative for an autosomal-dominant form of PD [198–203], and single
nucleotide polymorphisms (SNPs) in the SNCA gene increase PD susceptibil-
ity [204]. Additional families with multiplication (duplication or triplication) of
its allele (PARK4 locus) [205,206] suggest that even increased levels of normal
α-synuclein may be causal for PD or other synucleinopathies. Besides SNCA,
causative genes for PD include autosomal-dominant mutations in leucine-rich repeat
kinase (LRRK2) or glucocerebrosidase (GBA) or autosomal recessive mutations
of ATP13a2, VPS35, UCH-L1 (ubiquitin carboxy-terminal hydrolase-L1 Parkin),
PINK1, and DJ-1. For these last three recessive genetic disorders, the relationship
to the synucleinopathies is unclear since neuropathological reports are limited for
PINK1- and PARK7-related PD cases [207] and LBs are infrequent in the few
PARK2 cases studied. Nevertheless, PARK2 and PINK1 are known to regulate the
autophagy of mitochondria (mitophagy) [208].
Although they have relevant pathogenic effects on the lysosomal system and
potentially on other processes, most of the genes mutated in PD have an impact on
 

LYSOSOMES IN AGING-RELATED NEURODEGENERATIVE DISEASES 151
lysosomal α-synuclein clearance leading to its accumulation. α-Synuclein undergoes
various types of posttranslational modification [209–213], affecting its turnover and
oligomerization into putatively neurotoxic oligomers [196,210,214–216] that may be
released to propagate the pathological process in a prion-likemanner from one neuron
to neighboring neurons [200,217] possibly involving the endosomal–lysosomal path-
way [218]. α-Synuclein may be released by calcium-dependent exocytosis [219,220],
a phenomenon exacerbated by inhibition of lysosome function [221].
Most α-synuclein, especially overexpressed and misfolded aggregate-prone
forms, is degraded by macroautophagy, which is upregulated when CMA, the other
main degenerative pathway, becomes compromised in disease states [222,223].
Abnormal α-synuclein accumulation implicates lysosomal dysfunction as a primary
or secondary consequence of α-synuclein mishandling, which is reflected by an
accumulation of autolysosomes when either mutant or wild-type α-synuclein
is overexpressed [223,224]. Moreover, in rat PC12 cells, expression of mutant
α-synuclein can decrease lysosomal acidification [225] and slow lysosomal protein
turnover [226]. Interestingly, the characteristic α-synuclein aggregation of PD is
also a feature of Sanfilippo syndrome, a congenital LSD caused by α-N-acetyl-
glucosaminidase (NAGLU) gene mutations. An SNP in NAGLU was also associated
with PD risk [227]. The pathogenic importance of the lysosomal dysfunction induced
by α-synuclein overexpression can also be appreciated from the neuroprotection
provided by viral-mediated overexpression of transcription factor EB (TFEB),
LAMP2a, or Beclin-1 in rodent models of PD [223,228,229], which upregulate
different aspects of autophagy, including the lysosomal clearance steps.
Several other PD-related genetic factors have also been shown to disrupt lyso-
somal function and the general clearance of autophagic substrates. Loss-of-function
mutations of the lysosomal acid β-glucosidase gene (GBA) in the homozygous state
cause Gaucher disease, a congenital LSD leading to lysosomal accumulation of glu-
cocerebrosidase and reduced lysosomal content of ceramide. In heterozygous carriers
who are not affected developmentally by Gaucher disease, the samemutations greatly
increase the risk of developing PD [230,231]. A number of recent studies have high-
lighted a reciprocal relationship between α-synuclein and GCase. Synuclein levels
markedly increase in the presence of disease-associated mutations [232] due to pref-
erential resistance to lysosomal proteolysis [233] that may involve direct interaction
between α-synuclein and GCase [234]. The compromised lysosomal degradation and
neurodegeneration seen after deleting the gene encodingGCase inmice can be largely
prevented by overexpressing wild-type but not mutant forms of GCase [235].
A common property linking pathogenic actions of some mutant proteins in PD,
as well as several other neurodegenerative diseases, is their ability to disrupt CMA,
which is dysfunctional in both familial [226,236–238] and sporadic [236,239] PD.
CMA-targeting motifs are present in the majority of PD-related proteins, and the
two most commonly mutated proteins in patients with familial PD, α-synuclein and
LRRK2, are known to be degraded in lysosomes via CMA [226,236–239] as is a
third PD-related gene product, UCH-L1 [240]. Despite their normal chaperoned
delivery to the lysosomal membrane via cytosolic hsc70, pathogenic mutant variants
of α-synuclein, LRRK2, and UCH-L1 fail to reach the lysosomal lumen to be
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Figure 9.2 Genetic evidence strongly implicates the lysosomal network in the pathogenesis
of neurodegenerative disease. The diagram identifies selected neurological disorders in which
the pathogenic gene encodes a protein that plays a vital role in lysosomal network function-
ing. Mutations of the indicated genes are causative for familial forms of each disease and have
also been shown to disrupt lysosomal function directly or through malfunctions of another
compartment in the lysosomal network. Because of an extensive cross-talk among vesicular
compartments comprising the lysosomal network, a defect in any component of the various
pathways to lysosomes can potentially impede the efficiency of lysosomal digestion and sig-
naling. (See color plate section for the color representation of this figure.)
degraded by CMA [226,236] due to their aberrant association with LAMP-2A
[226,236,240]. LRRK2 mutant proteins show enhanced lysosomal binding in the
presence of other CMA substrates, which then interferes with the proper organization
of the active CMA translocon (Figure 9.2). The toxic interactions of α-synuclein
and LRRK2 mutants with the CMA transporter preclude not only their own degra-
dation but also inhibit the degradation of other CMA substrates and α-synuclein in
particular [226,236,240]. Wild-type α-synuclein modified by dopamine seems to
cause similar CMA dysfunction suggesting that this form of α-synuclein toxicity
applies to sporadic and familial forms of PD [241] and may partly explain the role
of environmental or cellular stressors (e.g., pesticides, oxidative stress) in develop-
mental PD [242]. Even in the absence of noticeable posttranslational modifications,
an increase in the cellular levels of either α-synuclein [226] or LRRK2 [236] beyond
a tolerable threshold, has very similar inhibitory effects on CMA activity. In fact,
these two proteins seem to potentiate each other’s toxic effect on CMA [236].
The most common autosomal-dominant form of PD and a familial variant that
closely resembles sporadic PD clinically [243] involves mutations of LRRK2. Similar
to SNCA, increased activity of this kinase associated with aggregate formation
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has been a prevailing hypothesis for mutant LRRK2-mediated toxicity [244–246],
although only a few LRRK2 mutations have been shown to enhance LRRK2 kinase
activity [244,247]. The range of pathogenic mutations identified along the molecule
have suggested other pathogenic effects of misfolded LRRK2, including disruption
of proteostasis [248]. Neurons ectopically expressing mutant LRRK2 develop a
PD-like cellular phenotype and degenerate at a rate predicted from the accumulated
level of diffuse mutant LRRK2 [249]. Additional findings suggest that LRRK2
levels are more important than kinase activity per se in predicting toxicity [249].
Overexpressing the C-terminus of Hsp70 interacting protein or downregulating
Hsp90, both of which interact with LRRK2, reduces mutant LRRK2-induced
toxicity in a kinase-independent manner. Interaction with either of these proteins is
associated with lower steady-state levels of mutant LRRK2 [250,251].
α-Synuclein may play a role in LRRK2-mediated toxicity by modulating LRRK2
levels. α-Synuclein accumulates in cells with elevated LRRK2 levels independently
of its kinase activity [252,253], and, in PD patients that have synuclein pathol-
ogy due to LRRK2 mutations [254], symptoms occur earlier if certain genetic
variants in the synuclein gene [255] are present along with the LRRK2 mutation.
In neurons ectopically expressing mutant LRRK, these levels are significantly
lower in the absence of α-synuclein. Because α-synuclein buildup disrupts protein
homeostasis pathways [226,256,257] and lowering α-synuclein levels enhances
them [257], synuclein accumulation may impede mutant LRRK2 clearance and
promote its toxicity. However, the increase in α-synuclein by LRRK2 is probably
insufficient to fully explain the range of mutant LRRK2 toxic effects, which
include dysfunction in vesicular trafficking, neurotransmitter release, cytoskeletal
dynamics, protein degradation [258], and mitochondrial dynamics [259,260]. The
range of possible LRRK2 functions is expanding [261], and roles in autophagy
and endosomal trafficking (via GTPase regulation) have been proposed as par-
ticularly relevant to pathogenesis [262,263]. Recently, three LRRK2 interactors
were identified that are risk factors for PD, including the small GTPase Rab7 (a
causative gene in Charcot–Marie–Tooth neuropathy), cyclin G-associated kinase,
and BCL2-associated athanogene (BAG5) [264]. Altered LRRK2 activity due to
PD-related mutations has been linked to defects in endosomal–lysosomal trafficking
[263] [265], lysosomal pH and calcium regulation [266] and CMA [236]. LRRK2
deletion in mice or siRNA knockdown in human cells prominently alters markers of
autophagy and the lysosomal pathway [267,268], suggesting a possible physiological
role in regulating autophagy [266,269], although the mechanisms are unclear. Inter-
estingly, LRRK2 inhibition has been shown to stimulate macroautophagy, suggesting
that two putative pathogenic LRRK2-related mechanisms may be interlinked [268].
Kufor-Rakeb syndrome, a neurodegenerative dementia, associated with early-
onset parkinsonism [270] is caused by mutations in the P5-type ATPase 13a2 gene
(ATP13a2) within the PARK9 PD susceptibility locus. ATP13a2 is a lysosomal
protein involved in heavy metal transport and possibly local lipid dynamics during
vesicle formation and membrane fusion [271] and in vitro studies show that mutant
proteins do not traffic correctly to the lysosome [272,273]. Loss of ATP13a2 in
cellular and animal models results in the accumulation of autophagosomes and
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lysosomes with reduced proteolytic activity possibly due to defective lysosomal
acidification [272,274,275]. Although the presence of α-synuclein aggregates or LB
has not yet been established in human cases [271], either knockout and knockdown
of ATP13a2 causes an accumulation of insoluble α-synuclein [276] [275,277], along
with NCL-like neuropathology [278], and induces neurotoxicity. Interestingly, in this
context, loss of ATP13A2 function is also associated with the LSD, neuronal ceroid
lipofuscinosis (NCL) in a strain of dogs and in at least one family [277,279,280].
Overexpression of ATP13A2 suppressed the toxicity of overexpressed α-synuclein
in animal and neuronal PD models [281].
Mutations in vacuolar protein sorting35 (VPS35) cause a parkinsonian syndrome
clinically similar to sporadic PD [282,283]. VPS35 is part of the retromer com-
plex mediating transport of endosomes back to the trans-Golgi and in the sorting of
receptors for hydrolases, thus affecting vacuole/lysosomal function and biogenesis.
Loss of function in VPS35 induces vacuolar/lysosomal abnormalities [284] includ-
ing acceleratingMPR turnover, impeding CatDmaturation, and inducing α-synuclein
accumulation [285]. Manipulating LRRK2 and a candidate gene for the PARK16
locus, RAB7L1, alters endosomal trafficking, linking to the previously reported func-
tion of VPS35 [265].
Hereditary spastic paraplegias (HSPs) are clinically and genetically heteroge-
neous neurological disorders characterized by length-dependent axonopathy of
corticospinal motor neurons, resulting in progressive spasticity and weakness of the
legs. Two nearly identical HSP gene variants, SPG15 and SPG11, exhibit distinctive
features of early-onset parkinsonism, cognitive impairment, white matter changes,
retinal abnormalities, and lens opacities. Although several different pathogenic
mechanisms have been suggested for these two autosomal recessive disorders
[286–288], pathogenic alterations in lysosomes or autophagy are favored in recent
studies [287,288]. Recent studies [289] show that the SPG15 protein spastizin and
SPG11 protein spatacsin play pivotal roles in autophagic lysosome reformation
(ALR), a pathway generating new lysosomes. Loss of spastizin or spatacsin results in
depletion of free lysosomes and accumulation of autolysosomes. Depletion without
affecting fusion of autophagosomes and lysosomes, as previously suggested [287], or
altering the acidic environment of autolysosome. However, ALR via lysosome tubu-
lation is significantly impaired, causing accumulation of autolysosomes [287] [288]
A mouse model of PD resulting from the exposure of the neurotoxin 1-methyl-4-
phenyl-1,2,3,6-tetrahydropyridine (MPTP) shows accumulation of autophagosomes
and an early decrease in lysosome number in dopaminergic neurons as a result of
lysosomal membrane destabilization and cytosolic release of cathepsins [290]. Mito-
chondrial dysfunction and oxidative stress induced by the neurotoxin MPTP is char-
acteristic of this well-characterized neurotoxin model of PD [291,292]. Lysosome
number drops in dopaminergic neurons very early after MPTP exposure, related in
part to LMP and in part due to Bax internalization within lysosomes [293]. Effects of
cytosolic release of cathepsins are partially prevented by cathepsin inhibitors. These
events and the secondary accumulation of autophagosomes and neurodegeneration
are attenuated by genetic or pharmacological activation of TFEB or rapamycin, both
of which increase lysosomal biogenesis [290] in addition to inducing autophagy.
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9.4.3 Diffuse Lewy Body Disease (DLB)
Another relatively common synucleinopathy is characterized by adult-onset demen-
tia, parkinsonism, and the presence of Lewy bodies (LBs) throughout the CNS
(central nervous system) and PNS (peripheral nervous system) and not infrequently
varying degrees of amyloid pathology [294]. Except for a few cases of familial aggre-
gation, DLB is generally considered a sporadic disorder. While the genetics of AD
and PD are generally not overlapping, a small number of reports suggest an involve-
ment of APOE (an AD risk factor) and GBA (a PD causative factor) as risk alleles
for the development of DLB [295–297]. In addition, two additional PD-related genes
were recently identified as DLB risk factors: SNCA involving a distinct risk haplotype
from PD and SCARB2, or lysosomal integral membrane protein 2 (LIMP2), which
is required for endolysosomal biogenesis and maintenance [298] and acts as a lyso-
somal receptor for GBA targeting [299]. While only a weak risk factor for PD [283],
LIMP2 seems to be a relatively strong risk factor for LBD. Localization of LRRK2
to enlarged endolysosomal compartment seen in PD is also seen in LBD [300].
9.4.4 Frontotemporal Lobar Degeneration (FTLD)
FTLD is the second most common dementia in people younger than 65 years and
25% of FTLD cases appear after this age [301]. A family history is positive in about
30–50% of FTLD cases [302,303]. In addition to cognitive impairment, motor dys-
function is often detected and may meet criteria for ALS in some of these cases [304],
reflecting mounting evidence that ALS and FTLD are at opposite ends of a single
disease continuum. The pathological hallmarks of the major subtype, FTLD-TDP,
are intracellular ubiquitin and TAR DNA-binding protein (TDP)-43 positive inclu-
sions [305,306], which distinguish this common variant from other FTLD types, such
as FTLD-tau, FTLD-FUS (fused in sarcoma) [307] or FTLD-DPR [308]. TDP-43,
a DNA- and RNA-binding protein involved in transcription and splicing, is hyper-
phosphorylated, proteolytically processed, and frequently mislocalized to the cyto-
plasm in FTLD-TDP [305,306,309]. Autosomal recessive loss-of-function mutations
in the progranulin (GRN) gene [310,311], which severely reduce tissue GRN levels
[312,313], account for up to 20% of familial FTLD-TDP cases [314,315] and are only
a rare cause of ALS [316]. Additional missense mutations reduce functional GRN
by impairing secretion or inducing premature degradation of the misfolded protein
[317–319]. Mutations of C9orf72, which induce DNA-repeat expansion, account for
another 20% of familial FTD TDP and 5–7% of the apparently sporadic FTLD cases.
Mutations of C9orf72, unlike GRN, are also a common cause of fALS.
Endolysosomal mechanisms are increasingly suspected in FTLD-TDP pathogene-
sis. As with synucleinopathies, the same gene (GRN) has been shown to cause either
FTLD or LSD. Although rare so far, homozygous mutations of GRN were identi-
fied in two siblings with dementia associated with an adult-onset form of NCL, a
family of childhood neurodegenerative diseases characterized by massive storage
of lipofuscin [320] and caused by recessive mutations in genes mainly involved in
lysosomal processing (PPT1, TPP1, CLN3, CLN5, CLN6, MFSD8, CLN8, CTSD,
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or DNAJC5) [305,320,321]. The clinical picture in these siblings, which included
retinopathy, seizures, and ataxia, contrasts with the FTLD-TDP phenotype due to het-
erozygous GRN mutations, where behavioral and cognitive impairments are rarely
accompanied by these additional features. Interestingly, progranulin-deficient mice
exhibit [313,322] pathobiochemical features of both GRN-associated FTLD-TDP
and NCL. Supporting the potential pathological overlap of FTLD and NCL are fur-
ther observations that mice lacking cathepsin D, Ctsd (−/−), a model for NCL, show
elevations of pathologically phosphorylated TDP-43 similar to those in mice lacking
Grn. Accompanying the neuronal storage of abnormal autofluorescent lipopigment
and characteristic ultrastructural features of NCL in GRN-deleted mice are elevated
levels of the NCL storage components saposin D and subunit c of mitochondrial ATP
synthase (SCMAS).
GRN-deleted mice have increased levels of TMEM 106B, a lysosomal protein
known as a risk factor for FTLD-TDP pathology [323–325] and a genetic factor that
confers risk for cognitive impairment in ALS controls (Ryan Vass). TMEM106B
variants that promote FTLD-TDP increase levels of TMEM106B mRNA and
protein [326], which can be demonstrated in GRN mutation carriers [324,327].
Moreover, microRNA-132, which represses TMEM106B expression [328], is halved
in FTLD-TDP, thus promoting pathologically high levels of TMEM106B. Evidence
suggests that TMEM106B and progranulin mechanisms are interrelated. Endoge-
nous neuronal TMEM106B colocalizes with progranulin in LAMP-1-positive late
endolysosomes [323–325] and TMEM106B overexpression increases intracellular
levels of progranulin. TMEM106B risk genotype correlates with age at onset
in GRN(_) FTLD-TDP [329], and both protein and mRNA for TMEM106B
are increased in expression and abnormally localized in neuronal processes in
GRN(_)FTLD-TDP cases.
The TMEM106B interactors, VPS11 and VPS13D, are known to participate in
endocytic vesicle maturation and in delivery to lysosomes [330–334] and molecular
interactions of TMEM106B with these and other endocytosis-related proteins may
contribute to the delayed degradation of endocytic cargoes when TMEM106B is
overexpressed [323]. Overexpression of TMEM106B in neurons inhibits lysosome
transport [323,324] and leads to accumulation of enlarged lysosomes in the cell soma.
Reduced TMEM106B not only increases the percentage of actively transported lyso-
somes but also impairs acidification of endolysosomes and mannose-6-phosphate-
receptor trafficking [335].
Further suggesting the involvement of lysosome in FTLD [336,337] are mutations
in the gene encoding valosin-containing protein (VCP, also known as p97) [338,339],
a conserved and highly abundant multifunctional protein and member of the class
II AAA ATPAse family (ATPases associated with diverse cellular activities) [340].
VCP is responsible for IBMPFD, a disorder characterized by disabling muscle
weakness, IBM-inclusion body myopathy, osteolytic bone lesions (Paget’s disease),
and FD [339]. VCP is considered an FTLD-related gene, due to its characteristic
language and/or behavioral dysfunction and FTLD-TDP D type pathology, which
features prominent ubiquitinated inclusions in multiple tissues. VCP mutations
are also responsible for autosomal-dominant fALS in an Italian family in which
 

LYSOSOMES IN AGING-RELATED NEURODEGENERATIVE DISEASES 157
other genetic causes of ALS were excluded in small percentages of other fALS
cases [341]. VCP regulates endolysosomal sorting of endocytosed ubiquitinated
cargoes [342] and VCP mutation is known to disrupt selective autophagy. VCP
depletion or the expression of IBMPFD-linked mutants of VCP in cell models
causes immature autophagosomes containing ubiquitinated substrates to accumulate
[336,343]. Mutations of CHMP2B (loss-of-function charged multivesicular body
protein – 2B), causing frontotemporal dementia linked to chromosome 3 (FTD3),
disrupt ESCRT machinery, impair amphisome formation, and lead to accumulation
of ubiquitin-positive aggregates in neurons.
C9orf72 expansion can cause FTLD-TDP, classical ALS, or combination of both
symptom complexes [344]. TDP-43 accumulates in neuronal and oligodendroglial
inclusions within various brain regions. Also observed specifically in C9orf72
expansion cases are ubiquitin/p62-positive, TDP-43 negative neuronal inclusions,
which contain dipeptide-repeat (DPR) proteins generated by unconventional
repeat-associated translation of C9orf72 transcripts [344,345]. C9orf72 interacts
with proteostasis molecules actin and ubiquilin-2, the latter involved in binding and
transporting ubiquitinated cargo to the proteasome and autophagosome [346,347].
Notably, mutations of UBQLN2 are present in rare cases of ALS with FTLD [347],
and SQSTM1 (p62) mutations have now been found in both ALS and FTLD
[348–350]. Similarly, rare ALS-associated mutations of another selective autophagy
receptor, OPTN, cause this protein to accumulate in TDP-43-positive neuronal
inclusions [351]. Collectively, these observations imply that a cluster of risk genes
for FTLD (and ALS), including C9orf72, may engage trafficking of cargoes for
delivery to the autophagosome and/or proteasome. In C9orf72 expansion disease,
nuclear RNA foci also form throughout the brain [344,345]. Wild-type C9orf72
interacts with ALS-related heterogeneous nuclear ribonucleoproteins, hnRNPA2/B1
and hnRNPA1, which shuttle continuously between the nucleus and cytoplasm and
accumulate in cytoplasmic SGs during cellular stress [352], as, for example, under
conditions of proteasome inhibition, raising the possibility that C9orf72 interference
with cargo delivery could trigger this response.
C9orf72 is believed to regulate aspects of endosomal and autophagic vacuole traf-
ficking [345]. Consistent with its predicted activity as a Rab guanine exchange factor
activity capable of activating Rab5, C9orf72 in neurons colocalizes with Rab pro-
teins (Rab1, Rab5, Rab7, and Rab11) and with LC3-positive vesicles implicated in
endocytic transport and autophagy and this colocalization increases in ALS patient
motor neurons. Depletion of C9orf72 inhibits internalization of TrkB receptor and
Shiga toxin transport from the plasma membrane to Golgi apparatus. Ectopic over-
expression of C9orf72 activates autophagy and its silencing attenuates autophagy
induction suggesting a role in regulating autophagy activation in response to ROS,
a well-established stimulus for autophagy induction and also for C9orf72 expression.
Genetic linkage in FTLD families with autosomal-dominant disinhibition,
dementia, parkinsonism, and amyotrophy was first demonstrated on chromosome
17q21 (FTDP-17) [353] and traced to missense or splice site mutations of the tau
(MAPT) gene, which disrupt the normal equimol proportions of tau isoforms with
either three or four repeat microtubule binding domains and drive aggregation into
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ubiquitinated tau inclusions within neurons and, in some cases, glia [354,355]. Tau
has a CMA-targeting motif and, as in other neurodegenerative diseases involving
misfolded and aggregated pathogenic proteins, mutant tau corrupts both its own
lysosomal luminal delivery but that of other substrates [190,226,236]. Lysosome
dysfunction, however, is unlikely to account for the entire phenotype in this disease,
given the number of other toxic gain of function effects of mutant tau on calcium
homeostasis and calpain activation, seen in this FTLD variant [162].
9.5 CONCLUSION
The past 5 years has witnessed a remarkable convergence of genetic and molecular-
biological data underscoring the broad importance of the lysosome and its interact-
ing compartments in the pathogenesis of late age-onset neurodegenerative diseases.
In view of the unique properties of neurons among other cell types, the heavy reliance
on efficient lysosomal clearance mechanisms is not surprising. Equally unsurprising
is the vulnerability to the lysosomal system impairments in postmitotic cells such as
neurons expected to survive over the lifetime of the organism. Lysosomal vulnera-
bility is magnified by aging, which adds further progressive impediments to efficient
substrate delivery and clearance at a period in life when increasing damage to proteins
and membranes may require an even greater capacity for quality control and clear-
ance. Understanding the critical role evidently played by the lysosomal system in cel-
lular aging and organismal lifespan is an important frontier of biology holding many
clues to neurodegenerative disease development and therapeutic strategies. Beyond
influences of aging, increasing numbers of genes responsible for forms of AD, PD,
and possibly other proteopathies have been shown to have specific and often direct
roles in regulating lysosomal function and causative genemutations in these disorders
are known to corrupt these functions. It may now be reasonable to view the realm of
degenerative lysosomal disorders as a continuum across the lifespan [114] with con-
genital disorders involving severe lysosomal dysfunction at one end and at the other
end, adult and late age-onset disorders involving milder, though still disease-selective
lysosomal dysfunction, which emerge as cellular aging adds a final set of insults to
the lysosome. Challenges lie ahead in identifying how to target the lysosomal net-
work effectively as a disease therapy; nevertheless, recent advances in this field are a
clear positive sign that the next decade will bring exciting progress toward this goal.
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10.1 INTRODUCTION
Cancer development and progression induces fundamental changes in lysosomes,
which in turn imposes profound effects in tumor invasion and metastasis and in sen-
sitivity to anticancer treatments. Enhanced lysosomal hydrolase activity, lysosome
trafficking, and extracellular secretion of lysosomal hydrolases (e.g., cathepsins and
heparanase) are important hallmarks of invasive cancer and are associated with its
metastatic capacity. On the other hand, lysosomal membrane permeabilization (LMP)
that often leads to lysosomal cell death (LCD) may be useful as an anticancer treat-
ment, provided that it is specially targeted toward cancer cells. In this chapter, we
present the most central cancer-associated alterations in the function and composi-
tion of lysosomes and discuss their importance for tumorigenesis and the possibilities
they may provide for the development of anticancer treatments.
10.2 LYSOSOMAL FUNCTION AND ITS IMPORTANCE FOR CANCER
DEVELOPMENT AND PROGRESSION
Lysosomes are membrane-bounded acidic organelles that are filled with powerful
hydrolytic enzymes. From their functional point of view, lysosomes can be described
as cellular recycling centers [1–3]. They receive material via endocytosis, autophagy,
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and phagocytosis, and their most basal function in cancer, as well as in healthy organ-
isms, is to degrade and destruct larger, unnecessary, worn out, and sometimes even
harmful cellular and extracellular components for the production of energy and build-
ing material. Accordingly, lysosomes compose an important source of cellular nutri-
ents and building blocks for rapidly dividing cancer cells.
Lysosomes are also contributing to cellular fate by functioning as specific end-
points of well-controlled degradation programs. For example, endocytic downregu-
lation of the epidermal growth factor receptor (EGFR/ErbB1) tyrosine kinase is an
important and tightly regulated process that is executed in lysosomes [4,5]. Its impair-
ment is associated to cancer, since the defective downregulation of EGFR can lead to
increased, uncontrolled signaling. In many cancers, EGFR signaling is facilitated and
one of themechanisms contributing to this is its cancer-associated increased recycling
and escape from lysosomal degradation [5]. Another example of lysosomes contribut-
ing to cell fate is the lysosome-mediated processing of chromatin that can contribute
to cellular senescence, proliferation arrest, and tumor suppression [6]. Thus, pro-
cesses that affect lysosomal function may have profound and multiple effects on the
cell fate.
In addition to downregulating important cellular processes and supporting cell
survival and growth by providing nutrients and building blocks, lysosomes and lyso-
somal hydrolases are also involved in tissue remodeling as for mammary gland invo-
lution [7,8], a process that can contribute to cancer progression. Moreover, invading
cancer cells can harness the cellular clearance mechanism called lysosomal exocy-
tosis to empty their digestive contents to the extracellular space [9–11]. Upon secre-
tion to extracellular space, lysosomal hydrolases can induce and facilitate invasion.
Numerous studies have shown that specific inhibition of lysosomal hydrolase activity
can significantly delay invasion and metastasis in various in vivo model systems as
reviewed earlier by us [11].
Lysosomes are central contributors of cancer development and progression. The
active involvement of lysosomes in these processes makes them attractive anticancer
therapy targets. Thus, understanding the lysosomal function and its alteration during
cancer development and progression can assist in the development of novel lysosome
based anticancer therapies.
10.3 CANCER-INDUCED CHANGES IN LYSOSOMAL FUNCTION
Cancer-induced changes in lysosomal function are summarized in Figure 10.1.
10.3.1 Increased Activity of Lysosomal Enzymes
Lysosomes contain over 50 hydrolases including proteinases, glycosidases, phos-
phatases, sulfatases, nucleases, and lipases. Since early 1950s, several studies have
reported increased activities of various lysosomal enzymes in solid tumors in com-
parison to their tissue of origin [12]. Especially, increased biogenesis and activity
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Figure 10.1 Cancer development induces changes in the lysosomal function. Normal,
healthy cells undergo dramatic changes that affect their lysosomal function upon transfor-
mation to cancer cells. Cancer development and progression induces lysosomal biogenesis
increasing the expression of various lysosomal hydrolases (gray). It alters the lysosomal mem-
brane integrity, sensitizing them to LMP and lysosomal leakage that can lead to LCD. It
additionally increases the size of lysosomes and alters their distribution in a manner where nor-
mally mostly perinuclear lysosomes adapt pericellular locations close to the invasive cellular
protrusions at the cell membrane, which allows them to secrete or exocytose their hydrolytic
contents by a process called “lysosomal exocytosis.” Upon reaching the extracellular space,
lysosomal hydrolases can induce cell growth, extracellular matrix degradation, invasion, angio-
genesis, and extracellular acidification. (See color plate section for the color representation of
this figure.)
of cathepsins, heparanase, acid ceramidase, and vacuolar-type ATPase have been
implicated in the progression of different types of cancers and linked to metastatic
disease and poor prognosis [11]. The increased activity of lysosomal hydrolases, such
as cathepsins and heparanase, is mostly resulting from their cancer-induced increased
gene expression and their pharmacological or genetic inhibition can hinder invasion
and metastasis in in vivo model systems [11]. Of these enzymes, cysteine cathepsin
B is the most studied and thus more is known about its regulation in cancer in com-
parison to the others. Oncogenic Ras, Src, and ErbB2 can increase cysteine cathepsin
mRNA and protein expression leading to increased hydrolase activity and increased
invasion [13–16]. Moreover, increased cathepsin B activity can sensitize cancer cells
to LMP and cathepsin B is also one of the most central mediators of LCD [17].
 
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10.3.2 Altered Lysosome Membrane Permeability
Oncogene-driven transformation alters lysosomal membranes and sensitizes them to
LMP. The sensitization is associated with increased cysteine cathepsin, especially
cathepsin B, activity [11,18]. This sensitization of lysosomalmembranes by cathepsin
B is most likely mediated by its intralysosomal digestion of the highly glycosylated,
lysosome-associated membrane proteins, which form a proteolyse protective glyco-
calyx shield of the inner lysosomal membrane [14,19]. Sensitized lysosomal mem-
branes have increased susceptibility for leakage, which can lead to LCD [18,20,21].
Accordingly, drugs that can specifically induce LMP in cancer cells are currently
considered as promising anticancer remedies.
Regulation of lysosomal membrane integrity is an important biological process,
which is not fully understood. In addition to cathepsin B, lysosomal membrane
proteins (LAMPs) and other glycosylated membrane proteins, lysosomal membrane
integrity is also regulated by lysosomal sphingomyelin catabolism, where increase
in the level of sphingomyelin or sphingosine has a destabilizing effect on lysosomal
membranes and increase in the activity of acid sphingomyelinase (ASM) has a stabi-
lizing effect [21]. Thus, a promising cancer therapeutic remedy could, for example,
involve ASM inhibition that would lead to the induction of LMP and LCD in cancer
cells [22]. LMP can also be induced by the inhibition of sphingosine kinase 1, an
enzyme that converts sphingosine into sphingosine-1-phosphate [23]. Interestingly,
cathepsin B can cleave sphingosine kinase 1 leading to its degradation [24], which is
likely to contribute to the oncogene-induced destabilization of lysosomal membranes.
10.3.3 Increased Lysosome Size
Lysosome size varies between 0.1 and 1.2 μm. Tumor cells have larger lysosomes
than noncancerous cells [9,14]. Lysosome size is regulated by a balance between
vesicle fusion and fission and can be reversibly altered by, for example, acidifying
the extracellular environment [9]. Acidification of the environment results in larger
lysosomal vesicles. This occurs more frequently in highly metastatic human breast
cancer cells than in less metastatic breast cancer cells or mammary epithelial cells [9].
Increase in the intracellular Ca2+ can trigger homotypic lysosomal fusion that can
lead to increase in the lysosome size. Similarly, deficient lysosome fission can give
rise to larger lysosomes. The absence of the Chediak–Higashi gene CHS1/Lyst gives
rise to enlarged lysosomes in a disease called Chediak–Higashi syndrome most likely
due to decreased rate of lysosome fission [25]. It is not fully known what causes the
increased lysosome sizes in malignant cancer cells beyond increased extracellular
acidification. Larger lysosomes have shown to be more sensitive for breakage [26].
Some LMP-inducing anticancer drugs increase lysosomal volume prior to inducing
cell death. For example, treatment of HeLa human cervical cancer cells with vin-
cristine, a widely used microtubule-destabilizing anticancer drug, induces increased
lysosome volume and LCD [27]. Similar observations have been reported already
40 years ago from studies where mouse mammary carcinoma cells were treated with
radiotherapy or chemotherapy (cyclophosphamide) resulting in increased lysosome
size and contents followed by degradative changes in the tumor cells [28,29].
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10.3.4 Altered Lysosome Trafficking – Increased Lysosomal Exocytosis
Cancer cells have altered lysosomal trafficking [9,14,30]. Oncogenic activation often
induces pericellular distribution of lysosomes leading to their accumulation to the
close vicinity of cell membrane at the invasive cellular protrusions, for example,
invadosomes. This is likely to be promoted by extracellular acidosis, which is typ-
ical for malignant cancer cells [31]. In noncancerous cells, lysosomal distribution
alters according to the nutritional status of the cells [32]. Normally, lysosomes cluster
around the nucleus in nutrient starvation conditions, and they move along micro-
tubules to a more peripheral location in nutrient-rich conditions [32].
In cancer cells, pericellular distribution of lysosomes enables them to exocytose
their highly hydrolytic contents into the extracellular space allowing the release of
lysosomal proteases and further acidification of the extracellular milieu. In turn, the
acidified extracellular milieu provides optimal conditions for lysosomal hydrolases.
There is a vast amount of evidence indicating that the lysosomal hydrolases (e.g.,
cathepsins and heparanase) have an important extracellular role in cancer progression
and are contributing to cancer invasion and metastasis [11,33,34].
10.4 CANCER-INDUCED CHANGES IN LYSOSOME COMPOSITION
Cancer-induced changes in lysosomal function are closely linked to changes in its
composition, as summarized in Figure 10.2. We describe in detail the most important
molecular changes affecting lysosomal components in connection to cancer in the
following sections.
10.4.1 Changes in Lysosomal Hydrolases
10.4.1.1 Cathepsins Cathepsins comprise three subgroups: aspartate cathepsins
(cathepsins D and E), cysteine cathepsins (cathepsins B, C, F, H, K, L, O, S, V/U/L2,
W, X/Z/Y), and serine cathepsins (cathepsins A and G). Cathepsins, like other lyso-
somal hydrolases, have optimal pH at 4.5 or lower. However, cathepsins can also
function in higher pH, which in some cases can change their functional parame-
ters such as substrate specificity. For example, cathepsin B, which is primarily an
exopeptidase in acidic lysosomal environment, will gain endopeptidase activity in
neutral pH [35,36]. Cysteine cathepsins are overexpressed in variety of tumor cells
and tumor associated cells such as fibroblasts, macrophages, osteoclasts, neutrophils,
mast cells, myoepithelial cells, T lymphocytes and endothelial cells, however the
diverse expression of cathepsins, tumor type and stage dependently, suggests for
variable roles for cathepsins during progression of different types of cancers [30].
Increased expression, activity, and secretion of cathepsins can enhance tumor growth,
angiogenesis, invasion, andmetastasis. Cathepsins, especially cathepsins B, L, and D,
are often overexpressed in cancer. In addition to cancer cells, cathepsin overexpres-
sion can also be detected in tumor-associated macrophages, leucocytes, fibroblasts,
osteoclasts, and in myoepitehlial and endothelial cells [11,30]. All cathepsin-targeted
cancer therapeutics aim at inhibiting its extracellular activity.
 
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Figure 10.2 Cancer induces changes in lysosomal composition. These include changes in
the expression levels and activity of several lysosomal hydrolases. Some of these changes are
“protumor” processes contributing to tumor growth, invasion, metastasis, and drug resistance,
and some of them are “antitumor” processes that sensitize lysosomes to LMP and LCD. (See
color plate section for the color representation of this figure.)
10.4.1.1.1 Cathepsin D Cathepsin D is an aspartate cathepsin that belongs to the
pepsin superfamily of proteases [37]. Increased levels of cathepsin D in human neo-
plastic tissues was first time reported almost 30 years ago [38]. Since then, numerous
studies have demonstrated increased cathepsin D expression in almost any type of
solid tumors, including neuroblastoma, glioma, melanoma, breast tumors, ovarian
and endometrial tumors, head and neck tumors, thyroid tumors, pancreatic tumors,
liver tumors, gastric, bladder, lung and colorectal carcinomas, and prostate tumors
in comparison to their tissue of origin [39,40]. Thus, several studies have identi-
fied positive correlation between cathepsin D levels and tumor size or grade, tumor
aggressiveness, metastasis, prognosis, degree of chemoresistance, and risk of recur-
rence [40,41]. Cathepsin D and especially its pro-form have been reported to act as
growth-stimulating autocrine growth factors for various cancer cells, as well as for
stromal cells. This function of cathepsin D is independent of its enzymatic activity
[39,41]. Activated cathepsin D can also promote invasion and metastasis upon secre-
tion to extracellular space and cathepsin D and its propeptide can induce activation
of the MAPK pathway and expression of various genes to enhance the secretion of
different cytokines [41–43]. The role of the protease inactive cathepsin D pro-form in
cancer progression challenges the development of cathepsin D targeting anticancer
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10.4.1.1.2 Cathepsin B Cathepsin B is a cysteine cathepsin and belongs to the
papain superfamily of proteases. In human colorectal and breast cancers, the expres-
sion of cathepsin B is increased in cancer cells as well as in the tumor-associated
cells such as macrophages and stromal fibroblasts [11,44,45]. Increased expression
and secretion of cathepsin B have also been reported in brain, lung, and prostate
cancers. In general, increased cathepsin B protein levels detected in immunohisto-
chemical staining correlate well with higher mRNA levels in cancer cells and tis-
sues, indicating a transcriptional upregulation of cathepsin B gene (CTSB) in various
cancers [46]. In tumors, cathepsin B expression is predominantly increased in the
tumor cells at the invasive front of the tumors [47,48]. Overexpression of oncogenic
Ras [14–16] or ErbB2 [13,14] can induce cathepsin B expression and activity. The
ErbB2-induced expression of CTSB is transcriptionally regulated, however indepen-
dently of the lysosomal biogenesis regulator transcription factor EB (TFEB) [13,49].
Instead, ErbB2 induces the myeloid zinc finger transcription factor 1 (MZF1), which
binds to an ErbB2-inducible enhancer element in the first intron of CTSB gene in
vivo. The ErbB2-mediated activity of MZF1 is regulated via an ErbB2-activated sig-
naling network consisting of PAK4, 5 and 6 cdc42bpβ, PKCα, and MAPK-ERK2
serine–threonine kinases as well as TGFβRI and 2 [13]. Interestingly, MAPK-ERK2
activity, which is essential for the ErbB2-induced activation of MZF1 and expres-
sion of CTSB, can inhibit the nuclear import of TFEB [50], further supporting the
observations that ErbB2 induces CTSB expression independently of TFEB [13]. In
malignant, highly invasive tumors overexpressed cathepsin B is often secreted into
the extracellular space where it associates with the tumor cell surface [16,51,52].
The active role of cathepsin B in cancer is strongly supported by murine models.
In the RIP1-Tag2/RT2 (RT2) pancreatic islet cell carcinogenesis model mice develop
multiple tumors in their pancreatic islets due to overexpression of oncogenic SV40
T-antigen in insulin producing ß-cells. These mice express high levels of cathepsin B
[33,53] and its genetic inactivation results in impaired tumor formation, angiogene-
sis, and invasiveness [53]. The suggested mechanism of how cathepsin B contributes
to increased tumor formation involves secretion of cathepsin B from tumor cells
and tumor-associated macrophages and cathepsin B-mediated direct cleavage of the
epithelial transmembrane protein E-cadherin as well as activation of the urokinase
plasminogen activator by cleavage of its propeptide [53,54]. In addition to activating
plasmin and various matrix metalloproteases, cathepsin B can also directly degrade
extracellular matrix by cleaving laminin, type VI collagen, and tenascin-C [55–57].
Similarly, Ctsb deficiency significantly delays the onset and growth of primary mam-
mary tumors as well as formation of lung metastases in murine mammary tumor virus
polyoma middle-T antigen (PyMT) transgenic mice and cathepsin B overexpression
in these mice promotes mammary tumor growth and metastasis [58,59]. In the PyMT
model, the expression of cathepsin B in the actual cancer cells rather than in the
stromal cells promotes tumor progression [60].
Since cathepsin B is overexpressed in various cancers and several studies show
beneficial effects of its inhibition by RNA interference or pharmacological com-
pounds in vitro and its genetic or pharmacological inhibition in vivo in mouse studies,
it is believed that targeting cathepsin B could have significant therapeutic effect [61].
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However, even though many compounds that can inhibit cathepsin B have been iso-
lated and developed, none of them have shown to be potential enough for clinics [61].
10.4.1.1.3 Cathepsin L Cathepsin L is ubiquitously expressed cysteine cathepsin
that is often overexpressed in human tumors [45]. It is capable of cleaving various
extracellular matrix proteins such as laminin, fibronectin, and collagens as well as
E-cadherin and proheparanase [53,62–65]. Several studies conclude that cathepsin
L plays an important role in cancer cell invasion and migration by decreasing
cell–cell adhesion and increasing extracellular matrix degradation [30,66]. Studies
elucidating the role of cathepsin L in angiogenesis have contradictory results,
suggesting that it is either angiogenesis promoting or not involved at all [65]. For
example, in glioma patients, cathepsin L expression is not associated significantly
with new vasculature of astrocytic tumors [67] but a cathepsin L-specific inhibitor
NapSul-Ile-Trp-CHO (NSITC) displays potent antiangiogenic activity in vitro in
chick chorioallantoic membrane and mouse Matrigel models of angiogenesis [68].
Crossing of an RT2 transgenic mice modeling pancreatic carcinoma with cathepsin
L knockout mice showed decreased tumor growth and invasiveness when compared
to the corresponding cathepsin B knockout mice. However, these mice showed no
signs of reduction in the angiogenic switch on the contrary to the corresponding
cathepsin B knockout mice [53]. It is to be noted that these pancreatic tumors
exhibited increased expression of several cathepsins and thus it is possible that some
other cathepsins were able to compensate the loss of cathepsin L [53].
In colorectal cancer, nuclear staining of cathepsin L increases and cytoplasmic
staining decreases with advancing tumor stage and is associated with poor progno-
sis [69]. Indeed, a short form of cathepsin L that lacks the signal peptide needed for
lysosomal targeting has been found in nucleus. There it cleaves histone H3 and spe-
cific transcription factors, such as the CCAAT-displacement protein/cut homeobox
(CDP/Cux), altering gene expression patterns and leading into delay in cell cycle
progression and contributing to oncogenic transformation [70–72]. Interestingly, Ras
transformation can increase both the production of short nuclear cathepsin L isoforms
and the cleavage of CDP/Cux [72].
Inhibition of cathepsin L can reverse cancer cell’s resistance to various chemother-
apeutic drugs. This is suggested to occur due to cathepsin L inhibition-mediated
stabilization and increased availability of cytoplasmic and nuclear targets includ-
ing estrogen receptor-α, Bcr-Abl, topoisomerase-II α, histone deacetylase 1, and the
androgen receptor [68,73].
However, contradicting to the beneficial role of cathepsin L inhibition in many
other types of cancers, inactivation of cathepsin L, for example, in mouse intestinal
epithelia promotes tumor progression [74]. Similarly, in mouse skin cancer models,
genetic inactivation of cathepsin L results in increased tumorigenesis [75,76]. Indeed,
cathepsin L has been found to be essential for the negative regulation of the growth
factor and growth factor receptor recycling in keratinocytes. Thus, its inhibition
will result in increased receptor levels at the plasma membrane as well as increased
levels of growth factors [77]. Moreover, transgenic overexpression of serine protease
inhibitor hurpin, also known as serpin, a specific inhibitor of cathepsin L, mainly
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expressed in skin epidermis, leads to increased skin cancer progression. Hurpin
overexpressing mouse skin undergoes less apoptosis than corresponding wild-type
skin upon exposure to UVB radiation [78], suggesting for a possible involvement of
cathepsin L in apoptosis regulation. Due to recent reports indicating that cathepsin
L deficiency can promote tumor progression, its usefulness as therapeutic target has
become questionable.
10.4.1.1.4 Cathepsin K Unlike cysteine cathepsins B and L that are expressed
ubiquitously, expression of cysteine cathepsin K is mainly restricted to skeleton and
particularly in osteoclasts, where it is the predominant cysteine cathepsin [79]. It
has a central role in osteoclastic resorption and inactivating mutants of the human
cathepsin K gene (CTSK) result in pycnodysostosis characterized by short stature,
skull deformities, and skeletal abnormalities [80]. Cathepsin K is expressed in
breast and prostate carcinomas and its expression is enhanced in bone metastases
of these cancers when compared to corresponding primary tumors [81–83]. Several
cathepsin K inhibitors (e.g., CKI, AFG-495, balicatib, and odanacatib) are devel-
oped to treat osteoporosis-associated bone loss [79,84,85]. Of these, for example,
CKI can reduce breast cancer–induced osteolysis and skeletal tumor burden in a
mouse experimental skeletal metastasis model [82]. However, most successful of
cathepsin K inhibitors, thus far, is odanacatib that is currently on phase III trial
as a treatment to reduce the risk of breast cancer–induced bone metastasis (http://
www.cancer.gov/drugdictionary). Interestingly, cathepsin K is also expressed in
melanoma where its expression correlates with advanced metastatic disease. Indeed,
pharmacological inhibition of cathepsin K with a rather unspecific cathepsin K
inhibitor Boc-I decreases melanoma cell invasion through the Matrigel basement
membrane matrix [86].
10.4.1.1.5 Additional Cysteine Cathepsins The expression of cysteine cathepsins
F, H, S, V (also known as L2 or U), and Z (also known as Y or X) is also increased in
cancer. In addition to cathepsins B and L, increase in the expression of cathepsins K
and V has been observed in breast carcinomas [83,87]. Furthermore, cathepsin V is
overexpressed in renal, ovarian, colorectal, and squamous cell carcinomas, cathepsin
S and Z expression is increased in prostate carcinoma, and expression of cathepsin Z
is increased in gastric cancers [88–90].
In a mouse RT2 model of pancreatic carcinoma, pancreatic tumors exhibit
increased expression of cathepsins C, S, H, and Z in addition to cathepsins B and
L and treatment of mice with a broad-spectrum pharmacological cell-permeable
cathepsin inhibitor led to delayed proliferation, angiogenic switch, tumor vascu-
larity, and invasion [91]. Genetic inactivation of cathepsin S in this model system
resulted in impaired tumor formation and angiogenesis, similar to the inactivation
of cathepsin B [53]. In the RT2 model, the absence of cathepsin B, L, or S resulted
in delayed tumor invasion [53]. E-cadherin, which is a suppressor of invasion, was
identified as a target for cathepsins B, L, and S but not C in these tumors, and
E-cadherin levels were well maintained in knockout RT2 pancreatic carcinomas
compared to the corresponding RT2 wild-type tumors [53].
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Increased expression of cathepsins B and Z is also detectable on the surface of the
cancer cells in the polyoma middle-T oncogene (MMTV-PyMT) induced mammary
breast carcinomas [58]. Genetic inactivation of cathepsin B or Z slightly delays the
appearance of tumors as well as lung metastases [92,93], but their combined inacti-
vation results in significant delay in tumor burden and reduction in the number and
size of metastases [92]. Cathepsin S, which is mainly expressed by endothelial cells,
can function in angiogenesis by degrading antiangiogenic, type IV collagen-derived
peptides and generating proangiogenic peptides by cleavage of laminin-5 [94].
10.4.1.2 Deregulation of Cystatins: Endogenous Cathepsin Inhibitors The
increased activity of cysteine cathepsins is often connected to the cancer-associated
deregulation of cystatins, which are endogenous cysteine cathepsin inhibitors [95].
There are four main cystatins (A, B, C, and M). They are epigenetically silenced in
breast, brain, lung, and pancreatic cancers, linking them to the increased activity of
cysteine cathepsins in these tissues [96]. The functional importance of cystatins in
cancer is demonstrated, for example, by an experimental human fibrosarcoma lung
metastasis model in which overexpression of cystatin C reduces metastasis [97] and
by in vitro invasion assays where overexpression of cystatin M or S can suppress
breast cancer and melanoma cell invasion [95,96].
10.4.1.3 Pharmacological Targeting of Cysteine Cathepsins Of all the cysteine
cathepsins, only inhibitors of cathepsin K, the osteoclast-specific cysteine cathepsin,
have reached the clinics. In most cases, often more than one cysteine cathepsin is
upregulated upon oncogene-driven cell transformation in vitro, in preclinical murine
cancer models as well as in human cancer. Their highly overlapping substrate speci-
ficities and prooncogenic functions in tumorigenesis suggest that their combined
inhibitionmight be required for efficient anticancer therapy. In line with this, the com-
bined inactivation of Ctsb and Ctsz in PyMT mice [92,93], treatment of mice with a
cell-permeable, broad-spectrum cysteine cathepsin inhibitor JPM-OEt was more effi-
cient than single depletions of Ctsb, Ctsl, or Ctss in reducing angiogenic switching in
the murine RT2 pancreatic carcinomamodel [33,53]. On the contrary, JPM-OEt is not
efficient in the PyMT murine mammary cancer model and fails to reduce metastasis
in a breast cancer bonemetastasis model in which the non-cell-permeable cathepsin B
inhibitor, CA-074, is effective [98,99]. This may be due to differences in the bioavail-
ability of these inhibitors in different tissues [99]. Another possible explanation is that
different cysteine cathepsins may still have unexplored opposing roles in some can-
cers. However, the currently available preclinical data is encouraging and supports
the continuation of the development of broad-spectrum cysteine cathepsin inhibitors
as cancer therapeutics [100]. However, more basic research on the function and local-
ization of individual cathepsins is needed to identify the optimal treatment modalities.
10.4.1.4 Heparanase Heparanase is an endo-β-d-glucuronidase and the most
important mammalian enzyme degrading heparan sulfate. Heparanase is processed
in lysosomes and late endosomes and in addition to these it is also active in extra-
cellular matrix. Cleavage of heparan sulfate side chains from the heparan sulfate
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proteoglycans by heparanase leads to the disassembly of the extracellular matrix and
is associated with tissue remodeling, cell movement, cancer progression, metastasis,
and angiogenesis [34]. Heparan sulfate binds and sequesters several growth factors,
cytokines, and chemokines into the extracellular matrix and cell surface and its
cleavage will therefore also increase their release and tissue availability [101,102].
Heparanase expression is induced in nearly all human cancers [103,104] and
increased heparanase activity correlates with the metastatic potential of tumor
cells, contributes to remodeling of the extracellular matrix and is associated with
neovascularization [105,106]. Cancer cells can secrete heparanase in response to
suitable stimulus such as ATP, ADP, and adenosine nucleotides with similar kinetics
than cathepsin D [107]. Heparanase is also found in the body fluids of patients with
metastatic cancer, indicating its secretion in vivo [108,109].
Heparan and its derivatives, sulfated oligoshaccarides suramin and suramin ana-
logues, have potent anti-metastatic activity in mouse models of metastatic cancers
[110–112]. Heparin itself is a close mimic of heparan sulfate and a natural heparanase
inhibitor. However, it is not clinically usable due to its potent anticoagulant activity.
Thus, heparin modifications have been largely used for the development of efficient
heparanase inhibitors [113]. These include SST0001, which is currently in Phase I/II
clinical trial for myeloma treatment [113]. Another heparin derivative is M402 that
is also currently in Phase I/II clinical trial in combination with gemcitabine against
metastatic pancreatic cancer [113]. The PI-88, a heparanase inhibitor with potent
antiangiogenic activity [114,115], is currently on Phase III clinical trial as “the adju-
vant treatment of subjects with hepatitis virus-related hepatocellular carcinoma after
surgical resection” (http://www.cancer.gov/drugdictionary). Moreover, an additional
heparan sulfate mimetic PG545 that is a potent heparanase and angiogenesis inhibitor
has shown to be promising when tested in preclinical murine cancer models [116] and
is now on Phase I clinical trial (http://www.cancer.gov/drugdictionary). All of these
heparanase inhibitors aim at inhibiting the extracellular heparanase activity.
10.4.1.5 Sialidase 1/Neuraminidase 1 Aberrant glycosylation is one of the typical
features of cancer cells. Changes in sialylation have been connected with the cancer
cell invasiveness and metastatic potential [117]. There are four types of mammalian
sialidases (Neu1, Neu2, Neu3, and Neu4). Of these, Neu1 is the predominant siali-
dase found in lysosomes [118]. When total sialidase activity is generally increased
in cancer, Neu1 activity is decreased and, for example, in rat 3Y1 fibroblasts trans-
formed with src or v-fos and mouse adenocarcinoma colon 26 cells, Neu1 expression
correlates negatively with the metastatic potential [117]. Ectopic expression of
Neu1 in human colon cancer HT-29 cells significantly decreases and its depletion
increases their potential to metastasize into liver in a mouse xenograft model. The
metastasis-suppressing function of Neu1 is mediated via sialylation of β4 integrin,
resulting in its decreased phosphorylation and signaling [119]. Moreover, Neu1 is
a negative regulator of lysosomal exocytosis, thus decreased Neu1 levels may con-
tribute to increased lysosomal exocytosis supporting its antimetastatic activity [120].
Excessive lysosomal exocytosis in Neu1-deficient cells can be inhibited by silencing
of lysosome-associatedmembrane protein 1 (LAMP1), suggesting that oversialylated
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LAMP1 is a key mediator of excessive exocytosis of lysosomal proteases in these
cells [120]. Increased sialylation of LAMP1 and lysosome-associated membrane
protein 2 (LAMP2) can be observed in some human cancers, and, for example, in
colorectal cancer it strongly correlates with the metastatic potential [121]. Because
sialylated LAMPs are essential for the lysosomal membrane stability [122], the
excessive sialylation of LAMPs may protect lysosomal membranes from destabi-
lization and thus enhance cancer cell survival. The fact that its inactivation promotes
cancer progression makes sialidase a challenging target for anticancer treatment.
10.4.2 Changes in the Lysosomal Membrane Proteins
10.4.2.1 Lysosomal Membrane Proteins LAMP1 and LAMP2 The most abun-
dant and the most studied lysosomal membrane proteins are LAMP1 and LAMP2.
Several less studied lysosomal membrane proteins exist whose role or changes in
cancer are not established and thus they are not discussed here [3,19,123]. LAMP1
and 2 are type-1 transmembrane proteins containing a large and heavily glycosylated
luminal domain and a short C-terminal cytosolic domain. Together they comprise
over 50% of the lysosomal membrane proteins and are essential for the maintenance
of the structural integrity of the lysosomal membranes [14,19].
Oncogenic transformation of fibroblasts decreases the levels of LAMPs on their
lysosomal membranes thus increasing their sensitivity to LMP and LCD [14]. The
glycosylated tails of LAMPs form a sugar coat called glycocalyx to the inner surface
of the limiting membrane protecting the lysosomal membrane from degradation by
lysosomal hydrolases [19]. LAMPs have shown to exhibit overlapping and distinct
functions in lysosomal trafficking and exocytosis, chaperone-mediated autophagy,
autophagosome–lysosome fusion, and cholesterol transport [19,120,124], all of
which may be affected when LAMP levels are altered.
10.4.2.2 V-ATPase Vacuolar-type H+ ATPase (V-ATPase) is a proton pump that is
associated with the membranes of endosomes, lysosomes, and secretory vesicles, and
it is also found at the plasma membranes of many cell types. V-ATPase is important
for the acidification of lysosomes and endosomes is also involved in the regulation
of the pH of the cytosol and possibly also of the extracellular space [125]. Its proper
function is necessary for the maintenance of the highly acidic pH of the lysosomal
lumen and for the maintenance of the calcium homeostasis in lysosomes [126,127].
In spite of the cancer-associated increase in acid production, the entire V-ATPase
complex does not seem to be upregulated in cancer cells. Instead, the increased
expression of specific subunits has been observed and is suggested to contribute to
altered pump activity. Thus, overexpression of the gene encoding for the V1 subunit
C (ATP6V1C1) in oral squamous carcinoma cells can enhance the pump activity
by promoting the assembly of V0 and V1 subcomplexes [128]. On the other hand,
the V0 subunit C (ATP6V0C) is upregulated in cisplatin-resistant cells [129]. The
expression pattern of the subunit isoforms can affect the subcellular localization
of the V-ATPase. The appearance of the V0 a3 isoform favors plasma membrane
localization of this type of V-ATPase [130], whereas the depletion of a3 isoform in
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highly invasive breast cancer or melanoma cells results in decreased cytosolic pH
and reduced invasiveness [131,132], thus making it less favorable for cathepsins
to function on the cleavage of the extracellular matrix to enhance invasion. The
expression of V-ATPases at the cell membrane is normally low but is, for example,
prominently increased in highly invasive MDA-MB-231 breast cancer cells in com-
parison to the less invasive MCF7 breast cancer cells [131,133], possibly through
increased lysosomal exocytosis. Inhibition of V-ATPase with bafilomycin A1, a
specific V-ATPase inhibitor, reduces the in vitro invasiveness of the MDA-MB-231
cells [131].
Several different V-ATPase inhibitors exist and they are known to induce pro-
grammed cell death, revert multidrug-resistant phenotype and induce cell cycle arrest
in cancer cells and decrease mouse xenograft tumor growth [125,134,135]. Perhaps
the most interesting of these are the benzolactone enamides that may even discrim-
inate between different V-ATPases and thus could be good basic compounds for
further development [136,137]. Moreover, benzolactone enamide RTA203 and taxol
can synergistically kill H1155 cancer cells at low doses [138], supporting the pos-
sible use of benzolactone enamide-based compounds in combinatory therapy. These
very potent V-ATPase inhibitors are however quite toxic, which limits their use in
the clinic. Due to this reason, well-tolerated inhibitors of H+/K+ ATPase, which is an
enzyme involved in proton secretion in the stomach (e.g., omeprazole and esomepra-
zole), have been suggested to be utilized instead. These are capable of inhibiting
V-ATPase and inducing LCD in vitro, a notion that has been supported by some
promising in vivo results [139–141].
10.5 MOLECULAR CHANGES INVOLVING LYSOSOMAL INTEGRITY
Oncogene-induced, decreased expression of LAMPs and increased expression and
activity of cysteine cathepsins, especially cathepsin B, can contribute to LMP by
sensitizing lysosomal membranes for leakage and rupture, as presented earlier in this
chapter. Moreover, cytoskeletal/cytosolic proteins, such as cytoskeleton-associated
motor proteins, protect lysosomes from LMP [142], and disruption of cytoskeleton
and cellular trafficking by microtubule-destabilizing drugs induces LMP [27,143].
There are additional, mainly cytosolic molecules that may contribute to lysosomal
stability [18,144,145]. One of these is the heat shock protein 70 (Hsp70) that can
promote cell survival by inhibiting LMP [146]. This occurs via Hsp70 binding to the
endolysosomal anionic phospholipid bis(monoacylglycero) phosphate (BMP), which
is an essential cofactor for lysosomal sphingomyelinmetabolism and has an important
role in the maintenance of lysosomal integrity [147].
10.5.1 Cancer-Associated Changes in Lysosomal Sphingolipid Metabolism
Sphingolipids modulate diverse physiological and pathological processes including
cell growth, cell death, autophagy, and angiogenesis [148]. Cancer-associated dysreg-
ulation of sphingolipid metabolism contributes to cancer progression and resistance
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Figure 10.3 Lysosomal sphingolipid catabolism. Sphingomyelin is an abundant structural
lipid of biological membranes. Acid sphingomyelinase catalyzes sphingomyelin into ceramide,
which is a membrane lipid that can be associated with lipid rafts and function as a signaling
molecule regulating cell death and autophagy. Acid ceramidase converts ceramide into sph-
ingosine, which is a soluble detergent that can also function as a signaling molecule. Finally,
sphingosine kinase phosphorylates sphingosine turning it into sphingosine-1-phosphate, a sol-
uble signaling molecule that can bind to cell surface receptor promoting cell survival and
autophagy.
to chemotherapeutics [149]. Sphingomyelinases and ceramidases are key enzymes
of sphingolipid catabolism (Figure 10.3). Human cells express several forms of these
enzymes with varying optimal pH. Here, we present only their lysosomal forms that
can function in low pH, that is, ASM and acid ceramidase (AC). They regulate the for-
mation and degradation of ceramide, one of the most studied sphingolipids. The vast
interest to ceramide in cancer owes to its capacity to induce programmed cell death
and inhibit cell proliferation [150]. Genetic inactivation of acid sphingomyelinase,
which is the major sphingomyelinase in lysosomes, protects mice against various
cellular stresses including ionizing radiation and treatment with cisplatin, assum-
ably due to deficient ceramide production, supporting the apoptosis-promoting role
of ceramide [151].
Sphingolipids and sphingolipid metabolites such as ceramide regulate cell sur-
vival with diverse mechanisms that are not completely understood. The proapoptotic
activity of ASM is mostly attributed to its localization to the plasma membrane
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in response to various stresses [152,153]. This induces generation of ceramide at
the plasma membrane contributing to the formation of ordered membrane domains
that can enhance death receptor function and lead to the induction of apoptosis
[151–153]. ASM activity is generally considered to negatively regulate cancer
progression, mainly due to the proapoptotic properties of ceramide [154,155].
Contrasting this, lysosomal ASM has an opposite effect on cell survival, since
its activity is necessary for the maintenance of the lysosomal membrane integrity
[22,144,147]. Another mechanism how ASM can positively contribute to cancer
progression is by ceramide-mediated activation of pre-pro cathepsin D resulting
in increased activity of cathepsin D [156]. Interestingly, a database search reveals
a highly significant cancer-associated reduction in the mRNA level of SMPD1
encoding for ASM in multiple studies of gastrointestinal, hepatocellular, salivary
gland, renal, and head and neck carcinomas. A modest but significant increase in
SMPD1 expression was found in single studies of hairy cell leukemia and smoldering
myeloma (www.oncomine.org). The decreased SMPD1 expression in several cancers
may contribute to the increased sensitivity of transformed cells to LCD pathways.
On the other hand, the SMPD1mRNA levels do not necessarily reflect the levels and
activity of ASM protein, which are further contributed by its stability, binding with
BMP and association with Hsp70 [146,147,157].
Lysosomal ceramide is degraded by AC to produce sphingosine, which diffuses
rapidly from lysosomes to cytosol and is converted to sphingosine-1-phosphate [158,
159]. Aberrant expression of AC has been attributed to several human cancers [160].
Inhibition of AC activity is expected to lead to increased ceramide levels, which can
stimulate programmed cell death. This has been verified with different cancer and
primary cell lines using various AC inhibitors such as N-oleoylethanolamine, B13,
and De-MAPP [160,161]. Although this data suggests that AC inhibition could be
a good cancer therapy strategy, it is to be noticed that the specificity of many of
these inhibitors toward AC in respect to, for example, other ceramidases remains
to be verified. In addition to survival, sphingolipid metabolism is also involved in
other cellular processes that are important in cancer including proliferation, cell cycle
progression, and inflammation, which have increased its interest as a potential cancer
therapy target [159].
10.5.2 Targeting Lysosomal Membrane Integrity
Cancer cells frequently escape from spontaneous and therapy-induced apoptosis
due to mutational defects in the caspase-dependent apoptosis pathways [162].
Thus, identification and utilization of caspase-independent cellular death programs
to selectively kill cancer cells have become increasingly important [17,163,164].
Cancer development and progression involves dramatic changes in the composition
and integrity of lysosomal membranes, which provides intriguing possibilities
for drug-induced LMP and LCD [14,17,22,165]. Several established anticancer
agents induce LCD [17]. These include DNA-damaging drugs camptothecin,
cisplatin, and etoposide [14,166,167]; microtubule targeting drugs discodermolide,
docetaxel, epothilone B, paclitaxel, and vincristine [27,143,168]; V-ATPase
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inhibitors omeprazole and bafilomycin A1 [139,169,170] among many others [17].
Interestingly, in all of these cases, LCD can be mediated by single cathepsins B, D,
or L, or their different combinations [17].
Recently, lysosomotropic detergents that specifically destabilize lysosomal mem-
branes in cancer cells have evolved as highly promising, potential anticancer remedies
[17,21]. These include siramesine [22,171,172], BAMLET [173], hydroxychloro-
quine [174], LeuLeuOMe [175], sphingosine [176], mefloquine [177], and SU11652
and sunitinib [178]. Recent work with siramesine has led to the identification of
a group of compounds, a subset of cationic amphiphilic drugs, which specifically
sensitize lysosomal membranes of cancer cells by a mechanism that involves direct
inhibition of ASM [22]. Interestingly, these compounds involve some feasible antide-
pressants and antiallergy remedies [22,179]. In addition to ASM inhibition, their
detergent-like activity and ability to induce the production of reactive oxygen species
is likely to further contribute to LMP and LCD [22]. Very exciting and promising
properties associated with these LCD-inducing agents are that they can also effi-
ciently kill multidrug-resistant cancer cells [17,22].
10.6 CONCLUSION
Lysosomes are packed with powerful hydrolases that upon release from the lysoso-
mal compartment can degrade the environment that they encounter. This imposes
opposing outcomes to cancer cells depending on where the lysosomes “leak,” thus
challenging the design of the lysosome targeting therapies. In principle, lysosomal
content that encounters the cytosol will most likely induce cell death and destruc-
tion of the cancer cell. On the contrary, leakage of lysosomal hydrolases into the
extracellular space can facilitate cancer cell invasion by degrading the extracellular
matrix. Thus, these two options provide two different possibilities to intervene. Con-
sequently, two types of promising anticancer therapy strategies involving lysosomes
are currently being explored: inhibition of extracellular lysosomal hydrolase activities
and induction of lysosomal permeabilization and leakage within cancer cells.
Long-term research on cysteine cathepsins and heparanase has led to the devel-
opment of several highly promising anticancer agents with a strategy to inhibit
invasion and metastasis by inhibiting the activity of these proteases [11,113,180].
Many of these are already in clinical trials. Moreover, recent identification of several
commonly used anticancer remedies as compounds that can induce cancer-specific
LMP [17] together with the identification of a widely used subset of cationic
amphiphilic drugs including tricyclic antidepressants, antihistamines, and calcium
channel blockers as direct ASM inhibitors capable of destabilizing lysosomal
membranes in cancer cells [22] has rapidly provided many novel and feasible
possibilities to intervene cancer progression by targeting lysosomes in cancer cells.
Especially, important and promising are the observations indicating that they can
target apoptosis-deficient cancer cells as well as those that have become multidrug
resistant [17,22,178]. Since cathepsins are important mediators of both invasion and




from cathepsin inhibition from those that would need full cathepsin activity for the
execution of cell death. One possible option could be to combine both processes:
the induction of cell death and the inhibition of invasion. This could, for example,
be achieved by combining LCD-inducing treatments with treatments that inhibit
lysosomal exocytosis. This would require more research on lysosomal exocytosis
and its regulation in cancer.
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THE GENETICS OF SPHINGOLIPID
HYDROLASES AND SPHINGOLIPID
STORAGE DISEASES
Edward H. Schuchman and Calogera M. Simonaro
Department of Genetics and Genomic Sciences, Icahn School of Medicine at Mount Sinai,
New York, NY, USA
11.1 INTRODUCTION AND OVERVIEW
Sphingolipids are a diverse group of over 100 bioactive lipids involved in many
aspects of cellular function (see Ref. [1–4] for recent reviews). They share a com-
mon sphingosine (2-amino-4-octadecene-1,3-diol) backbone, which may be linked
via an amide bond to a fatty acid (forming ceramide) or phosphorylated to form
sphingosine-1-phosphate. Ceramide itself also may be modified to form glycosph-
ingolipids, sphingomyelin, or ceramide-1-phosphate.
The metabolism of sphingolipids is complex and carefully regulated [5–7]. Abnor-
mal metabolism can have profound effects on cellular function, leading to enhanced
cell death, proliferation, and/or abnormal cell differentiation. In general, the synthe-
sis and breakdown of sphingolipids occurs in distinct cellular compartments. For
example, numerous enzymes contribute to the de novo synthesis of sphingolipids,
mostly found in the endoplasmic reticulum and Golgi apparatus. In contrast, the
breakdown of sphingolipids occurs primarily within endosomes and lysosomes by a
series of hydrolytic enzymes that function optimally at acidic pH. Hydrolysis of sph-
ingolipids also may occur in nonendosomal/lysosomal compartments, for example,
by enzymes located at the plasma membrane or within mitochondria. Overall, over
100 enzymes participate in the synthesis or breakdown of sphingolipids.
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Edited by Frederick R. Maxfield, James M. Willard and Shuyan Lu.
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Historically, most information concerning the importance of sphingolipids in
human disease stems from studies of the sphingolipid storage diseases [8]. These
disorders are each due to deficient function of one or more of the hydrolytic enzymes
found within the endosomal/lysosomal system, resulting in sphingolipid accumu-
lation [9]. Each of these diseases is inherited as a Mendelian trait (recessive or
X-linked), the cDNAs/genes encoding the respective enzymes have been isolated, and
many mutations causing the human diseases have been identified. In addition, genetic
abnormalities in several of these enzymes/genes have now been linked to more com-
mon diseases (e.g., Parkinson’s disease and beta-glucocerebrosidase) [10]. Table 11.1
lists the sphingolipid storage diseases and the respective enzymes involved.
This review focuses on the genetics of sphingolipid storage diseases and related
hydrolytic enzymes. Each of the diseases/enzymes will be briefly reviewed, with an
emphasis on the importance of genetic mutations in disease.
11.2 ACID CERAMIDASE DEFICIENCY: FARBER DISEASE
As with other lysosomal storage disorders, patients with Farber disease (also known
as Farber Lipogranulomatosis) may exhibit a wide variation of phenotypes ranging
from early-onset neurological forms to attenuated forms that lack neurological
involvement. A “triad” of clinical manifestations is typical of Farber disease, includ-
ing painful and progressively deformed joints, subcutaneous nodules, particularly
near joints, and progressive hoarseness due to laryngeal involvement [11]. About
half of the reported patients have neurological deficits [12], but this is likely to be
overrepresented since these patients are on the severe end of the spectrum and the
most likely to be diagnosed. Moreover, moderate and attenuated cases primarily
present as idiopathic juvenile arthritis and are seen by pediatric rheumatologists who
often have little or no knowledge of the disease.
Acid ceramidase (EC 3.5.1.23) was first identified and purified in the 1960s.
It was recognized as the enzyme deficient in Farber disease in the 1970s [13].
The full-length cDNAs and genes encoding AC have been isolated from humans,
mice, and other species. The human cDNA encodes a 395-amino-acid precursor
polypeptide, and the gene is located on chromosomal region 8p22. Of note, the
newly synthesized AC precursor is inactive and only assumes an active form after
N-glycosylation and the internal cleavage of a peptide bond, resulting in alpha and
beta subunits. Interestingly, this cleavage event is carried out by AC itself, and it
is therefore considered a “self-regulating” enzyme. In addition, AC associates with
other lipid hydrolases within lysosomes and other cell compartments, including acid
sphingomyelinase (ASM) (see Section 11.3). The importance of this multienzyme
complex on AC activity, as well as on sphingolipid metabolism in general, is not
clearly understood. Finally, full AC activity, at least in lysosomes, depends on the
expression of a sphingolipid activator protein (SAP-D), which is expressed by a
distinct gene (see Section 11.9).
Acid ceramidase is an “amidase” that hydrolyzes the amide bond between sphin-
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defined by the length of their fatty acid chains. While the substrate specificity of AC
is not entirely clear, ceramides with fatty acid chains shorter than 12 carbons can-
not be efficiently hydrolyzed by the enzyme in vitro. In vivo, it is likely that AC can
recognize and cleave ceramides of varying chain lengths. The ceramides that accu-
mulate in Farber disease patients are primarily found within lysosomes, leading to the
original designation of AC as a lysosomal enzyme. AC also has maximal activity at
lysosomal (acidic) pH, although it has been localized to sites other than the lysosomes
as well. It is therefore not entirely clear to what extent the biological activity of AC
depends on the acidic environment, and in fact a “reverse” ceramidase reaction has
been attributed to the enzyme at more neutral pH [14]. Numerous in vitro assays have
been developed for AC, and some can be used to diagnose Farber disease in cultured
cells from suspected patients, or prenatally using amniocytes or cultured chorionic
villi. However, due to the very hydrophobic nature of ceramides, it remains one of
the more difficult diagnostic enzyme assays to carry out.
To date, only about 100 Farber disease patients have been reported in the liter-
ature [15]. Several cases of hydrops fetalis due to acid ceramidase deficiency also
have been reported. Complete inactivation of the AC gene in mice leads to very early
embryonic lethality (four-cell stage), suggesting that severe mutations in the human
ASAH1 gene will lead to embryonic lethality as well [16]. Of note, mouse embryos
lacking AC can be rescued by the addition of recombinant AC (obtained from overex-
pressing Chinese hamster ovary [CHO] cells) to the culture media. Moreover, addi-
tion of recombinant AC to the culture media during in vitro fertilization (mouse,
bovine) enhances embryo production and quality, resulting in more live births [17].
Thus, AC is an essential enzyme required for very early mammalian develop-
ment. One explanation for the lethal phenotype in mice is that in the absence of this
enzymatic activity, early-stage embryos (four cells in mice) undergo apoptosis due to
ceramide accumulation. It should be recognized, however, that an additional conse-
quence of such AC “loss-of-function” during embryogenesis is reduced production of
sphingosine, which in turn is converted to S1P, an important mitogenic/proliferative
lipid. Thus, ACmutations also may reduce S1P production, contributing to the lethal-
ity as well. Indeed, embryos lacking AC can be partially rescued by S1P.
As noted earlier, the first relationship between AC and human disease arose from
studies on Farber disease. To date, over 25 mutations have been described in the
ASAH1 gene leading to Farber disease (e.g., see Ref. [15] for review and Ref. [18]).
Most are point mutations, although several splice variants leading to small deletions
have been described as well. To date, no patients have been found homozygous for
a complete loss-of-function mutation, likely because such individuals do not survive
embryonic development. Farber disease is inherited as an autosomal recessive disor-
der, and to develop the disorder mutations must be inherited on both ASAH1 alleles.
No reports of clinical findings in the parents of affected patients (obligate carriers)
have been published; however, such individuals are not usually followed by clinicians
and follow-up analysis is lacking.
Recently, a “knock-in” mouse model of Farber disease has been reported where a
specific human ASAH1 mutation (P361R) was expressed [19]. These animals exhib-
ited massive ceramide storage in tissues, a shortened lifespan, and an early-onset
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inflammatory profile typical of Farber disease patients. In addition, a conditional AC
knockout mouse has been developed, where AC can be inactivated at various stages
of development or in specific tissues [20].
In addition to Farber disease, a second rare genetic disorder – spinal muscular
atrophy with myoclonic epilepsy (SMA-PME) – was found to be due to AC
deficiency and mutations in the ASAH1 gene [21,22]. These patients exhibit massive
ceramide storage in motor neurons of the spinal cord and markedly reduced AC
activity in cultured cells, but have an otherwise distinct phenotype from Farber
disease patients. The molecular basis of this phenotypic heterogeneity is not
understood, but SMA-PME clearly represents a new sphingolipid storage disease
that might benefit from AC-mediate therapies.
Other than Farber disease and SMA-PME, which are due to the deficiency of AC,
constitutive overexpression of the AC gene occurs in many types of cancer [23,24].
This may promote tumorigenesis and/or metastasis due to overproduction of S1P
or may lead to chemoresistance due to an enhanced ability to hydrolyze proapop-
totic ceramide [2,25]. The molecular basis of AC overexpression in cancer has not
been studied extensively, but at least in some cases it appears to be due to elevated
transcription. Gain-of-function mutations also could explain this finding. A recent
report also showed that the ASAH1 gene was downregulated in a Chinese population
of schizophrenic patients and was associated with two single nucleotide polymor-
phisms in this gene [26]. Due to the central role that ceramide plays in cell signaling,
AC-related diseases may be more common than currently known since the enzyme is
essential for maintaining the proper balance between this lipid, sphingosine, and S1P.
Finally, it must be noted that several other ceramidase activities have been
described in humans, and at least four other genes have been cloned [27]. These
ceramidases are defined by their unique pH, subcellular location, and other biological
properties. These enzymes also play important roles in sphingolipid metabolism
and/or signaling and are likely to contribute to human disease pathogenesis. The
biology of the other ceramidases has been reviewed extensively elsewhere [27].
11.3 ACID SPHINGOMYELINASE DEFICIENCY: TYPES A AND B
NIEMANN–PICK DISEASE
Types A and B Niemann–Pick disease (NPD) result from mutations in the gene
(SMPD1) encoding ASM (EC 3.1.4.12) [28,29]. Patients with Type A NPD present
in early infancy with hepatosplenomegaly and failure to thrive and develop a rapidly
degenerative neurological phenotype that leads to death by 3 years of age. In contrast,
patients with Type B NPD have a later-onset disease and usually lack neurological
findings. Such individuals also frequently present with hepatosplenomegaly and
may have pulmonary involvement as well. Dyslipidemia (high LDL-C, low HDL-C,
and high triglycerides) is also common. Patients with Type B NPD may survive
into adulthood, although their lifespan is generally shortened by the disease. The
cause of death is unknown but may occur from complications related to liver
disease, trauma-induced bleeding episodes due to thrombocytopenia, early-onset
cardiovascular disease, or pulmonary disease.
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ASM was found to be deficient in Type A and B NPD patients in the late 1960s.
Although the enzyme had been discovered several years earlier in rat tissues, it was
not substantially purified until the late 1980s. The cDNAs and genes encoding human
and mouse ASM were cloned in the early 1990s. The human gene is located on chro-
mosome 11p15.1. Of interest, among genes encoding lysosomal enzymes, it is the
only one for which genomic imprinting has been described. This form of genetic
regulation is generally reserved for genes with important developmental roles.
Over 100 mutations have been found in the SMPD1 gene leading to Types A
or B NPD (http://www.hgmd.org). Of note, several of these mutations are common
within specific regions or ethnic populations, allowing genetic screening programs
to be established. Homozygosity for these mutations is required to develop NPD,
and it is inherited as an autosomal recessive trait. However, heterozygous carriers of
SMPD1 mutations may develop dyslipidemia and late-onset features of the disorder.
In part, the development of a phenotype in the carrier individuals may be related to
their imprinting status (i.e., whether the mutations are inherited from the mother or
father) [30]. Unlike acid ceramidase and several other sphingolipid hydrolases, ASM
does not require an exogenous activator protein to achieve full function. Thus, muta-
tions in the SAP gene (see Section 11.10) do not affect ASM activity or cause Types
A and B NPD. Of interest, the lysosomal lipid, bis(monacyl) phosphate, may activate
the enzyme in vitro and in vivo.
In addition to ASM, several other sphingomyelinases (nonacidic) exist in mam-
malian cells [31]. These are defined by their unique subcellular location or other
biochemical properties. At least four human genes have been isolated encoding
these sphingomyelinases. Definitive proof that mutations in the SMPD1 gene were
solely responsible for Types A and B NPD came from studies in the knockout mouse
model (ASMKO), where neutral and other sphingomyelinase activities were normal,
despite the fact that these animals completely lacked ASM and developed NPD-like
pathology and clinical features [32]. In addition, these early studies in the ASMKO
mice showed that the previously identified zinc-activated, serum form of ASM was
encoded by the same SMPD1 gene as lysosomal ASM [33]. It is now known that
ASM is, in fact, a zinc-requiring enzyme. The lysosomal form of the enzyme has
high levels of zinc bound and thus does not require exogenous zinc when measured
in vitro. In contrast, the serum form of the enzyme requires exogenous zinc in the
assay systems routinely used.
Another early finding in the ASMKOmouse was that ceramide, the product of sph-
ingomyelin hydrolysis by ASM, was also elevated in tissues of these animals. While
initially a surprising result, it is likely that the elevated ceramide derives from break-
down of the accumulating sphingomyelin in NPD tissues by other sphingomyeli-
nases. Sphingomyelin levels may be up to 30-fold above normal in the ASMKO
mice and ceramide two- to fivefold above normal. Most recently, sphingosine levels
also were found to be high in tissues from ASMKO mice, probably due to break-
down of the accumulating ceramide by ceramidases (Schuchman et al., unpublished
observations). Of interest, the degree of sphingosine accumulation in these animals
(>20-fold above normal) cannot be explained by ceramide alone, perhaps suggesting
some defect in converting sphingosine into S1P.
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The ASMKO mice develop a phenotype intermediate between Types A and B
NPD. They die prematurely at ∼6–8 months, secondary to neurological disease.
They have been extensively used to study the pathobiology of this disease and to
develop/evaluate new therapies. In particular, enzyme replacement therapy (ERT)
using recombinant ASM produced in CHO cells has been developed in the mouse
model [34], and a phase 1 clinical trial in adult patients with Type B NPD has been
completed (http://clinicaltrials.gov). Of interest, in the ASMKO mice, dose-related
toxicity was observed following ERT (which was not seen in healthy animals),
presumably due to rapid breakdown of the accumulating sphingomyelin to ceramide.
Toxicity could be prevented by pretreating the animals with low doses of enzyme
(“debulking” the accumulating sphingomyelin), followed by higher dose mainte-
nance therapy. Based on these findings, a second repeat dosing (phase 1b) clinical
was carried out in adult Type B NPD patients using a dose escalation scheme to
debulk the accumulating sphingomyelin. The findings revealed that the recombinant
ASM could be safely administered to these patients, resulting in significant clinical
improvements. A phase 2/3 clinical trial is now planned in adult patients and a
phase 2 study in children.
Beginning in the late 1990s, the ASMKOmice also were extensively used to inves-
tigate the role of ASM in cell signaling. This is the subject of several reviews and will
not be focused on in this chapter. However, it is now clear that ASM plays an impor-
tant role in stress-induced ceramide generation and apoptosis and that this occurs
through hydrolysis of sphingomyelin at the cell surface within lipid rafts [35]. How
ASM, which has an acidic pH optimum in vitro and functions within lysosomes, par-
ticipates in these processes has been the subject of much debate. It is now known
that after the induction of stress or developmental signals, ASM may be rapidly
translocated to lipid rafts at the cell surface. The mechanism underlying this rapid
translocation is not entirely clear, but phosphorylation within the ER/Golgi may be
responsible in part. It is also known that although ASM requires an acidic pH for opti-
mal activity in vitro, in vivo, it is capable of efficiently hydrolyzing sphingomyelin at
physiological pH. This highlights the complex biology of this and other sphingolipid
hydrolases, particularly in terms of pH, subcellular location, and other properties.
These observations on the ASMKO mice have also highlighted the important
role of ASM in human disease, beyond NPD [36–38]. Elevated ASM activity has
now been detected in numerous common diseases, including diabetes, Alzheimer
disease, cardiovascular diseases, pulmonary diseases, depression, and others. These
will also be reviewed elsewhere and not discussed further here. At the present time,
it is not known if the elevated ASM found in these diseases is due to an activating
genetic mutation, enhanced transcription, and/or posttranslational modification of
the enzyme.
11.4 BETA-GLUCOCEREBROSIDASE DEFICIENCY: GAUCHER
DISEASE
Gaucher disease, due to the deficient activity of acid beta-glucocerebrosidase (also
known as beta-glucosidase [E.C.#3.2.1.45]), is one of the most common sphingolipid
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storage disorders [128,129]. There are three clinical subtypes of Gaucher disease,
including an early-onset, neurological form (Type 2), an intermediate form (Type 3),
and a late-onset, nonneurological form (Type 1) [39,40]. All Gaucher patients
present with hepatosplenomegaly, but the progression of the disease and survival
are markedly different. For example, Type 3 children may only survive until 2–3
years of age, while Type 1 patients may survive into adulthood. If left untreated,
the hematological and bone lesions in Type 1 patients progress with age, seriously
limiting quality of life. A massively enlarged spleen and frequent bone fractures
may become common, requiring splenectomy, joint replacement, or other surgical
interventions [41,42]. Bleeding is also a common presenting feature of Gaucher
disease due to thrombocytopenia. Pulmonary involvement may similarly occur.
Of note, neoplastic disorders, particularly of the blood forming organs, are more
common in Gaucher disease patients than in the general population. These include
chronic lymphocytic leukemia, multiple myeloma, and Hodgkin and non-Hodgkin
lymphoma. The molecular basis of this increased cancer risk remains unknown [43].
All Gaucher patients are characterized by the presence of “Gaucher” cells in vari-
ous organs, lipid-filled cells derived from themonocyte/macrophage system. Gaucher
cells have a distinctive appearance by light microscopy and can be readily distin-
guished from cells of other sphingolipid storage disorders. Gaucher cells are dis-
tributed throughout the body wherever macrophages reside. The largest numbers are
found in the spleen, sinusoids of the liver, bone marrow, and lymph nodes.
The major accumulating lipid in Gaucher disease is N-acyl-sphingosyl-1-0-β-d-
glucoside (glucosylceramide, also known as glucosylcerebroside; GC). GC is widely
distributed in mammalian tissues in small quantities as a metabolic intermediate in
the synthesis and degradation of complex glycosphingolipids, such as gangliosides
or globoside. The deacylated form of GC, glucosylsphingosine, is not only normally
found in tissues but also accumulates in Gaucher disease cells. GC levels in plasma
may be 2- to 20-fold above normal.
The major site of GC turnover in cells is lysosome. Beta-glucocerebrosidase is
normally found in this organelle and functions optimally at an acidic pH. As with
the other lipid hydrolases, in vitro detection of this enzymatic activity can be diffi-
cult, and there have been various factors (lipids, protein, and sugars) shown to influ-
ence the assay systems. In vivo, sphingolipid activator-derived peptides, particularly
saposin (SAP) C, appear to be required for full enzymatic activity (see Section 11.10).
Nonacidic glucocerebrosidases also have been described and are encoded by distinct
genes. Whether these activities can be modifying factors for the Gaucher phenotype
has been the subject of much discussion but remains unclear.
The gene encoding beta-glucocerebrosidase (GBA1) has been mapped to chro-
mosome 1q21. It is ∼7 kb and contains 11 exons. Of note, a 5 kb “pseudogene”
is located immediately downstream from the GBA1 gene. This pseudogene has
maintained a high degree of homology with the functional gene and is transcribed.
However, the nucleotide changes within the pseudogene sequence prevent the
occurrence of a long open reading frame, precluding the possibility of expressing
an active beta-glucocerebrosidase [44]. Full-length cDNAs from many species also
have been obtained that can be used to express the active enzyme.
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Numerous mutations have been found in the GBA1 gene causing Gaucher
disease [45]. As described for NPD above, several common mutations are found
in specific populations, and DNA-based screening is now routinely carried out in
the Ashkenazi Jewish population [46]. Estimates of the Gaucher disease carrier
frequency in this population range from ∼1:10 to 1:25. Some of the mutations
also can be used to predict the occurrence of severe or mild Gaucher phenotypes,
assisting in family planning and genetic counseling.
Recently, mutations in the GBA1 gene also have been associated with the occur-
rence of Parkinson’s disease, although the precise relationship between the GBA1
gene, glucocerebrosidase activity, and Parkinson’s disease remains uncertain [47].
One of the first clues suggesting this linkage came from the small number of Gaucher
patients who exhibited Parkinson-like features, while stronger associations later came
from Gaucher relatives who were carriers for GBA1 mutations. Currently, heterozy-
gous GBA1 mutations are considered to be one of the most common genetic risk
factor for Parkinson’s disease [48].
A complete knockout mouse model for Gaucher was constructed and had an early
neonatal lethal phenotype, dying within 34 days after birth. These animals had mas-
sive GC storage, and while the cause of death was not entirely clear, skin abnormal-
ities were prevalent. Several knock-in models also have been constructed, and some
exhibited longer survival and later-onset GC storage in macrophages, more closely
resembling Gaucher disease patients [49,50].
Gaucher disease was the first sphingolipid storage disease for which ERT was
developed in the early 1990s, initially using beta-glucocerebrosidase purified from
placentae (Ceredase) and subsequently using recombinant enzyme produced in CHO
cells (Cerezyme) [51,52]. For nonneurological patients, ERT was life-changing,
resulting in reduction in spleen size and correction of the hematological abnormali-
ties. Bone disease has been much less responsive to ERT and remains a challenge in
the treatment of Gaucher disease, as does treatment of the brain disease [51]. Since the
introduction of Cerezyme, several other recombinant forms of GC also have become
available, and in general similar clinical responses have been observed. Another
treatment strategy currently available for some Gaucher patients uses small-molecule
inhibitors of GC synthesis (Miglustat) to slow the accumulation of this lipid [53,54].
The target of this inhibitor is the enzyme glucosylceramide synthase.
Of note, treatment of Gaucher patients by either ERT or with Miglustat should
elevate ceramide and could potentially result in ceramide-mediated toxicity. To date,
however, such toxicity has not been observed in animal models or patients. There are
several factors that might explain this observation. First, compared to sphingomyelin
in NPD, GC is generally found in small quantities in cells and is not a major struc-
tural component of cell membranes. Thus, accumulation of GC in Gaucher cells is
more exclusively found in the lysosomes than NPD and does not disrupt plasma
membrane structure and signaling to the same extent as sphingomyelin. In addition,
ceramide produced by ASM (compared to GC) is likely to remain within the cell
membrane. Finally, the ERT dose typically used to treat Gaucher patients (1.6mg/kg,
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11.5 GALACTOCEREBROSIDASE DEFICIENCY: KRABBE
DISEASE/GLOBOID CELL LEUKODYSTROPHY
Infantile globoid cell leukodystrophy (GLD), also known as Krabbe disease, is a
rapidly progressive, fatal neurological disease of infants [55]. The disease usually
begins between 3 and 6 months of life with symptoms that may include irritability
or hypersensitivity to stimuli. Patients rapidly exhibit severe mental and motor dete-
rioration and rarely survive beyond the second year [56]. Clinical manifestations in
classical GLD patients are limited to the nervous system. Blindness and deafness
are common, and peripheral neuropathy is almost always detectable. Patients with
later-onset forms of the disease, including adult-onset forms, may present with blind-
ness, spastic paraparesis, and dementia [57,58].
The presence of numerousmultinucleated globoid cells, almost total loss ofmyelin
and oligodendrocytes, and astrocytic gliosis in the white matter are the morphologic
basis of the disease. “Globoid cells” in Krabbe disease are enlarged macrophages
that contain undigested galactosylceramide and other lipids. Demyelination, axonal
degeneration, fibrosis, and histiocytic infiltration are also common in the peripheral
nervous system. Consistent with the myelin loss, the white matter is severely
depleted of all lipids, particularly glycolipids. Under normal circumstances, galacto-
sylceramide is present almost exclusively in the myelin sheath. The ratio of galacto-
sylceramide to sulfatide (3-0 sulfogalactosylceramide) is abnormally high in GLD.
The genetic cause of Krabbe disease is mutations in the gene encoding galac-
tocerebrosidase beta-galactosidase (GALC; E.C. #3.2.1.46). This lysosomal enzyme
normally degrades galactosylceramide to ceramide and galactose. It is postulated that
accumulation of a toxicmetabolite, psychosine (galactosylsphingosine), which is also
a substrate for the missing enzyme, leads to early destruction of the oligodendrocytes.
The total brain content of galactosylceramide is not increased in patients with Krabbe
disease, supporting this hypothesis. It should be noted that mammalian tissues contain
two genetically distinct lysosomal beta-galactosidases, GALC and GM1-ganglioside
beta-galactosidase (see Section 11.8). These two enzymes have overlapping substrate
specificities in vitro, which can present complications when attempting to make the
enzymatic diagnosis of Krabbe disease [59].
The human GALC gene has been mapped to chromosome 14q24.3-32.1, and
the genomic and/or full-length cDNA sequences have been cloned from multiple
species. The human cDNA encodes a 669 amino acid polypeptide with six potential
N-glycosylation sites. The fully glycosylated precursor polypeptide is ∼85 kDa and
is processed into ∼50 and 30 kDa subunits. To date, over 70 mutations in the GALC
gene have been identified in infantile and late-onset GALC-deficient patients (http://
www.hgmd.org). Most of these mutations are “private,” occurring in individual
families, but some may be commonly found in specific regions or ethnicities. Among
these, the most commonmutation occurs in patients of European ancestry and deletes
a large segment of the GALC gene. Several polymorphisms also have been found in
the GALC gene, and some of these may alter amino acids and thus potentially affect
the function of the GALC polypeptide, although not enough to cause GLD.
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In general, carriers of GALCmutations are considered clinically normal, although
one interesting report did show an association between the risk for primary open-
angle glaucoma and a heterozygous deletion of the GALC gene [60]. Another
interesting recent paper also showed that GALC contributed to the maintenance of
a functional hematopoietic stem cell niche, suggesting that genetic alterations in
the GALC gene may be associated with hematological conditions as well. Indeed,
hematopoietic stem cells retrieved from Twitcher mice (GALC deficient) had defects
in their frequency, proliferation, clonogenic potential, and engraftment.
As noted above, in 1972, Miyatake and Suzuki formulated a hypothesis to explain
the unusually rapid and complete destruction of oligodendrocytes in GLD. It was
known at that time that psychosine (galactosyl sphingosine), due to its free amino
group, was highly cytotoxic and that this lipid served as a substrate for GALC but not
GM1 beta-galactosidase. In the central nervous system (CNS), psychosine is primar-
ily formed within oligodendrocytes, the site of myelin synthesis, and this may explain
the selective destruction of these cells in GLD brains. Indeed, in the white matter of
brains from Krabbe patients, psychosine levels may be elevated up to 100-fold, while
galacotosylceramide levels are either normal or only elevated slightly.
GALC deficiency occurs in a number of naturally occurring animal models,
including mice, sheep, several breeds of dogs, and the rhesus monkey. The mouse
model, in particular (also known as the “Twitcher” mouse), has been exploited for
numerous therapeutic studies [61]. Affected mice develop clinical signs at ∼20 days,
with stunted growth, twitching, and hind leg weakness. By 40 days, they reach a
near-terminal stage. Twitcher mice have been treated by ERT, gene therapies, BMT
(bone marrow transplantation), and other modalities [62–64]. BMT, in particular,
may have positive therapeutic effects; however, all of the treated mice eventually
still died of characteristic pathological findings. Thus, this and the other available
therapies may slow the disease progress to some degree but not prevent it.
Since 2006, New York State in the United States has screened all newborns for the
occurrence of Krabbe disease. Pilot screening programs are now underway in other
states and parts of the world. This screening is accomplished byGALC activity assays
on dried blood spots, followed by DNA analyses. The rationale for this screening
program is that the early identification of infants with Krabbe disease will permit
early BMT and other therapeutic interventions, improving the quality of life [56].
However, since BMT has not been curative in the animal models, screening for severe
neurological disorders such as this remains controversial.
11.6 ARYLSULFATASE A DEFICIENCY: METACHROMATIC
LEUKODYSTROPHY
Metachromatic leukodystrophy (MLD) is an autosomal recessively inherited disor-
der in which desulfation of 3-0-sulfogalactosylsphingosine or 3-0-sulfogalactosyl
glycolipids is deficient. Among the accumulating glycolipids in MLD are sulfatide
(galactosylceramide-3-sulfate), lysosulfatide (i.e., similar to sulfatide but lacking
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the fatty acid in the ceramide moiety), lactosylceramide-3-sulfate, and others.
These sulfated glycolipids normally occur in the myelin sheaths in the central and
peripheral nervous systems, and, to a lesser extent, in visceral organs.
The clinical onset and severity of MLD is highly variable [65]. The late infantile
form is usually recognized in the second year of life and fatal in early childhood. The
juvenile form presents between age four and puberty; the adult form may occur at
any age after puberty. In both of the later-onset variants, gait disturbance and mental
regression are the earliest signs. In the childhood variants, other common signs are
blindness, loss of speech, quadriparesis, peripheral neuropathy, and seizures [66].
In 1963, Austin et al. reported the deficiency of arylsulfatase A (ASA, E.C. 3.1.6.8)
activity in MLD, also known as sulfatide sulfatase, and mutations in this gene (ARSA)
account for the vast majority ofMLD patients. There are also two other minor, genetic
causes of MLD. One is due to mutations in the gene (PSAP, see Section 11.9) encod-
ing the SAP, saposin B. Mutations in the saposin B encoding region of the PSAP gene
lead to deficient ASA activity, and a clinical picture indistinguishable from MLD.
In fact, these observations in MLD patients provided the first in vivo proof that such
SAPs were required for in vivo activity of this and other sphingolipid hydrolases. In
addition to ASA and SAP B mutations, patients with multiple sulfatase deficiency,
due to mutations in the gene encoding sulfatase-modifying factor 1 (SUMF-1), also
have a reduction in ASA and other sulfatase activities and develop features of MLD.
As with the other sphingolipid hydrolases, full-length genomic and cDNA se-
quences encoding ASA have been isolated from several species. The human ARSA
gene has been mapped to chromosomal region 22q13. It is a remarkably simple
gene and encompasses only 3.2 kb divided into eight exons. As noted above, almost
all cases of MLD are due to mutations in this gene, except for the rare cases of
PSAP or SUMF-1 mutations. The human ARSA gene encodes a 507 amino acid
polypeptide precursor that undergoes posttranslational modifications much like
other lysosomal enzymes (e.g., N-glycosylation). Also, as with all known eukaryotic
sulfatases, a formylglycine residue is substituted for a cysteine in human ASA. The
formylglycine residue is generated by oxidation of the thiol group to an aldehyde
by the enzyme SUMF-1. Mutations in the gene encoding this cysteine-modifying
enzyme lead to the synthesis of inactive sulfatases and are the cause for multiple
sulfatase deficiency [67].
Over 100 MLD-causing mutations have been described in the ARSA gene. The
most common mutation in patients with late-infantile MLD is a G to A transition
that eliminates the donor splice site at the start of intron 2 [68]. This causes a loss
of all ASA enzymatic activity, producing a severe early-onset phenotype. In contrast,
in adults with MLD the most frequent mutation is a C to T transition that results in
substitution of a leucine for proline in amino acid residue 426. Patients with this muta-
tion have a small amount of residual enzyme activity and therefore exhibit late-onset
MLD. Common mutations in specific populations have also been described.
Notably, there also are two mutations that cause “pseudodeficiency” of ASA
activity. The term “pseudodeficiency” reflects the fact that these mutations cause
severe reduction of ASA activity in vitro but do not result in MLD [69]. One of these
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mutations alters an N-glycosylation site, but this has no effect on enzyme function.
The other affects a polyadenylation site in the mRNA. The pseudodeficiency alleles
may be found in ∼3–8% of the normal population and, therefore, pose a diagnostic
challenge since the artificial in vitro assay systems may reveal very low ASA activity,
even though the individual is highly unlikely to develop MLD.
Alterations in the ARSA gene also have been linked with the occurrence of several
common diseases. For example, as early as 1991, Kappler et al. found that among
a small set of patients with multiple sclerosis (MS) there was a higher incidence of
the ASA pseudodeficiency alleles than in the general population [70]. In addition,
variants of the ASA protein and/or gene have been associated with depression and
alcoholism. MLD itself also has been associated with several psychiatric disorders,
and there is at least one report where polymorphisms in the genes encoding the sero-
tonin and dopamine pathways affected the MLD phenotype [71].
Other than humans, naturally occurring mutations causing MLD do not occur in
other species. ASA knockout mice have been constructed that exhibit a complete loss
of ASA activity and sulfatide storage in multiple organs [67]. While these animals
exhibit some neurological deficits, they do not develop the predicted severe pheno-
type ofMLD and live a near-normal lifespan. They also do not develop demyelinating
disease. Thus, these observations in the mouse suggest the existence of compensating
pathways in this species that do not exist in humans, perhaps providing a link to novel
therapies. Several therapies have been evaluated in the MLD knockout mouse model,
including BMT, ERT, and gene therapies [72,73]. BMT also has been extensively
used inMLD patients. While it is not effective in infantile cases, BMT is often recom-
mended for the later-onset cases [74,75]. However, the data supporting an improved
clinical outcome in the late-onset MLD cases are fragmented and incomplete, and it
is unclear whether the benefit outweighs the potential risks.
11.7 ALPHA-GALACTOSIDASE A DEFICIENCY: FABRY DISEASE
Fabry disease is inherited as an X-linked recessive trait, the only such X-linked
disease among the sphingolipid storage disorders [76,77]. Therefore, all males
(“hemizygotes”) carrying mutations in the Fabry gene (GLA) develop symptoms of
the disease although the severity may vary depending on the nature of the individual
mutation. Female heterozygotes who inherit one copy of the mutant gene on one
of their X chromosomes may also exhibit features of the disease depending on the
pattern of X-inactivation (“Lyonization”) that occurs in their individual tissues.
The gene responsible for Fabry disease encodes an enzyme, alpha-galactosidase A
(E.C.#3.2.1.22), that is required to hydrolyze glycosphingolipids with terminal
alpha-galactosyl moieties, predominately globotriosylceramide, and to a lesser
extent galabiosylceramide and blood group B substances. Affected males have
extensive deposition of these lipids in body fluids and in the lysosomes of endothe-
lial, perithelial, and smooth muscle cells of blood vessels. Deposition also occurs
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Clinical manifestations in classically affected hemizygotes with no detectable
alpha-galactosidase A activity include the onset during childhood or adolescence
of pain and paresthesias in the extremities, angiokeratomas in the skin and mucous
membranes, and hypohidrosis. Corneal and lenticular opacities also are early
findings. With increasing age, proteinuria, hyposthenuria, and lymphedema appear.
Severe renal impairment leads to hypertension and uremia. Death usually occurs in
adulthood from renal failure or from cardiac or cerebrovascular disease. Atypical
variant males with residual alpha-galactosidase A activity may be asymptomatic or
have late-onset disease. Heterozygous females may have an attenuated form of the
disease depending on the pattern of X-inactivation. They usually are asymptomatic
although can present with clinical disease as severe as hemizygous males.
As noted above, in Fabry disease glycosphingolipids with terminal alpha-d-
galactosyl residues are not properly broken down due to the alpha-galactosidase
A enzyme defect, and these lipids therefore accumulate in cells. The predominant
accumulating lipid is globotriaosylceramide (Gal(a1-4)Gal(a1-4)Glc(b1-1′)Cer).
Since alpha-galactosidase A is mostly found in lysosomes, the major site of lipid
accumulation is this organelle. Elevated globotriaosylceramide is found in most
tissues but predominantly in kidney.
Otherminor accumulating lipids include galabiosylceramide (Gala1-4)(Gal(b1-1′)
Cer) and the blood group B and P glycosphingolipids [79]. In human erythrocytes,
there are two neutral glycosphingolipids with terminal alpha galactosyl residues that
inhibit blood group B-specific hemagglutination. The structure of these blood group
B glycosphingolipids has been determined, and they are found at high levels in Fabry
patients. This raises an interesting and unique point about Fabry disease. Fabry
hemizygotes and heterozygotes who have blood groups B and AB accumulate four
glycosphingolipids, while those who are blood group A or O only accumulate two
(globotriaosylceramide and galabiosylceramide). A fifth neutral glycosphingolipid
that can accumulate in Fabry is the P1 blood group antigen, which also has terminal
alpha-galactosyl residues. The role of these individual blood types on the Fabry
phenotype is an interesting area of ongoing research.
In humans, there are two alpha-galactosidases (alpha-galactosidases A and B).
Fabry disease is caused by mutations in the gene (GLA) encoding the “A” type [80].
However, when measuring alpha-galactosidase activity in blood from Fabry patients
in vitro, classic hemizygotes may exhibit up to 25% of normal activity due to the
presence of the “B” form. Alpha-galactosidase B is encoded by a distinct gene
(NAGA) and is now known to be an alpha-N-acetylgalactosaminidase that recognizes
these moieties in glycoproteins, complex carbohydrates, and other molecules.
Because the artificial substrates routinely used to measure alpha-galactosidase
activity do not readily distinguish these enzymes, substantial misdiagnosis can occur
by simple enzyme testing.
The human gene encoding alpha-galactosidase A resides on chromosomal region
Xq22. It encompasses ∼12 kb and contains seven exons. The full-length human
cDNA contains a 1290 bp open reading frame that encodes an unglycosylated
 

ALPHA-GALACTOSIDASE A DEFICIENCY: FABRY DISEASE 223
precursor polypeptide of ∼48 kDa. As with most lysosomal hydrolases, there
are several N-glycosylation sites in the predicted polypeptide sequence and
the oligosaccharide chains undergo mannose-6-phosphate modifications, which
facilitates targeting of the enzyme to lysosomes. The mature, fully glycosylated
alpha-galactosidase A in lysosomes is ∼51 kDa. Genomic and cDNA sequences
encoding alpha-galactosidases have now been isolated from many species. An
unusual feature of most human alpha-galactosidase A cDNAs is the lack of a 3′
untranslated region. The polyadenylation signal sequence is often actually found in
the coding region, 12 bp from the termination codon, followed by a poly(A) tract.
The full-length cDNA encoding human alpha-galactosidase A had been used to
express and purify the recombinant enzyme from CHO cells. This enzyme was exten-
sively characterized and used in the Fabry disease mouse model to evaluate ERT.
Based on these results and after extensive clinical testing, a recombinant enzyme drug
(Fabrazyme) was approved for use in human Fabry disease patients in 2003. This
represents the second sphingolipid storage disorder for which ERT became avail-
able (Gaucher disease was the first). ERT in Fabry patients reduces pain, protein-
uria, and endothelial cell storage of glycolipids and improves the quality of life for
Fabry patients [81]. Since no naturally occurring animal model of Fabry disease has
been found, the preclinical evaluation of ERT was performed in a knockout mouse
model. These animals exhibit age-dependent glycosphingolipid storage, but few clin-
ical findings of Fabry disease. Since the approval of Fabrazyme several additional
recombinant alpha-galactosidases also have become available and are used for ERT
in Fabry patients (e.g., Replagal). The comparative efficacy and appropriate dosing
of these enzymes is a subject of ongoing debate, but suffice it to say clinical benefit
is provided by each of the enzymes currently being used.
Numerous mutations have been found in the GLA gene causing Fabry disease,
spread throughout the enzyme-coding region [82]. Several regulatory (promoter) and
splice site mutations also have been found. As noted above, the presence of one GLA
mutation in hemizygous males will cause disease, but the severity will depend on the
effect of this mutation on the residual alpha-galactosidase A activity. In female het-
erozygotes, because of X-inactivation some may develop disease [83]. It should be
noted that such “Fabry” females carrying single mutations will be essentially “mo-
saics” for alpha-galactosidase A, with some cells expressing the mutant allele and
others the normal allele (due to random inactivation of one X chromosome). Because
the enzyme can be released from cells at low levels (as with all lysosomal hydrolases),
and then taken up by neighboring cells, “cross-correction” of the lipid storage is pos-
sible. Aside from Fabry disease, there has been some evidence that mutations in the
GLA gene also may be a previously unrecognized cause of stroke. Indeed, newborn
screening programs have revealed that in some populations the incidence of GLA
mutations is unexpectedly high, suggesting that this gene/disease association should
be studied further as a potential risk factor for this and other common disorders of the
vasculature [84]. In the context of newborn screening, it is also important to recog-
nize that many individuals withGLA gene mutations may not develop clinical disease
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or perhaps may develop disease late in life. Thus, the very high estimates of Fabry
disease derived from these ongoing screening efforts may overestimate the number
of actual clinical cases.
11.8 BETA-GALACTOSIDASE DEFICIENCY: GM1 GANGLIOSIDOSIS
An inherited deficiency of lysosomal acid beta-galactosidase (E.C. 3.2.1.23) is
expressed as two clinically distinct diseases, GM1 gangliosidosis and Morquio B
disease [85–87]. GM1 gangliosidosis affects both neurological and somatic tissues,
occurring mainly in early infancy (type 1). Developmental arrest is usually observed
a few months after birth, followed by progressive neurologic deterioration and
generalized rigospasticity with sensorimotor and psycho/intellectual dysfunction.
As with many of the other neurodegenerative lysosomal storage diseases, cherry-red
maculae are common, as is facial dysmorphism, hepatosplenomegaly, and general-
ized skeletal dysplasia. Later-onset, juvenile, and adult forms of beta-galactosidase
deficiency have also been described (types 2 and 3, respectively). They are observed
as progressive neurologic diseases in childhood or in young adults. Dysmorphic
skeletal changes are less prominent or absent in these clinical forms. A protracted
course, mainly presenting as dystonia, is the major neurological manifestation in
adults with GM1 gangliosidosis.
Morquio B disease is clinically expressed as a generalized skeletal dysplasia with
corneal clouding, resulting in short stature, pectus carinatum, platyspondylia, odon-
toid hypoplasia, kyphoscoliosis, and genu valgum. There is no CNS involvement,
although spinal cord compression may occur at late stages of the disease. Intelligence
is normal and hepatosplenomegaly is not present.
In humans, two lysosomal enzymes are known to be responsible for the hydrolysis
of terminal beta-linked galactose residues at acidic pH in various glycoconjugates.
One is the enzyme being discussed here, beta-galactosidase (EC 3.2.1.23), and the
other is galactocerebrosidase (EC 3.2.1.46), whose primary substrates include galac-
tosylceramide, galactosylsphingosine, and other lipids. This is the enzyme deficient
in GLD (Krabbe disease) and was discussed in the Section 11.5. Beta-galactosidase
activity is severely deficient in cells and tissues from patients with both GM1
gangliosidosis and Morquio B disease, and both diseases are now known to be
due to genetic mutations in the same gene (GLB1) [88]. The primary substrates
for beta-galactosidase include galactose-containing oligosaccharides (e.g., keratan
sulfate) and GM1 ganglioside. The asialo derivative of GM1, GA1 ganglioside, may
also be a substrate for this enzyme.
As expected, tissues from patients with beta-galactosidase deficiency exhibit a
broad spectrum of accumulating galactose-containing macromolecules, including
GM1, GA1, and keratan sulfate. Gangliosides are normal components of plasma
membranes, concentrated in neuronal membranes, especially in the regions of nerve
endings and dendrites. GM1 is the major ganglioside in the brains of vertebrates.
Gangliosides display a broad spectrum of interactions and may act as binding
molecules for toxins and hormones, and are also involved in cell differentiation,
cell–cell interactions, and cell signaling.
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In the brains of patients with GM1 gangliosidosis, storage of GM1 is the most
prominent observation [89]. The accumulating GM1 has the same fatty acid com-
position, sugar composition and sequence, and glycosidic linkages as normal GM1.
Visceral organs also show storage of GM1 ganglioside but to a lesser degree. Also to
a lesser degree, GA1 ganglioside may accumulate in the brain of GM1 gangliosido-
sis patients, as do glycosylceramide, lactosylceramide, and GM2 ganglioside. White
matter shows chemical manifestations of myelin breakdown, include low proteolipid
protein, low total lipid, and the presence of esterified cholesterol [90].
Other than gangliosides, the other major storage molecule in beta-galactosidase-
deficient patients is keratan sulfate [91]. This glycosaminoglycan normally exists in
a proteoglycan linked with chondroitin sulfate. It is found primarily within connec-
tive tissues, particularly cartilage, explaining the skeletal dysplasia typical of many
beta-galactosidase-deficient patients. After proteolysis and release from the proteo-
glycan, free keratan sulfate chains are hydrolyzed by a series of exoenzymes, includ-
ing beta-galactosidase.
It should be noted that another protein, referred to as protective protein/cathepsin
A (PPCA), has been associated with both beta-galactosidase and another lyso-
somal hydrolase, neuraminidase, and stabilizes and in some cases activates the
enzymes [92]. A genetic deficiency of this protective protein results in combined
deficiency of beta-galactosidase and neuraminidase (galactosialidosis). The gene
encoding PPCA is distinct from both of these enzymes and will not be discussed
further here.
The gene encoding beta-galactosidase (GLB1) is located in chromosomal region
3p21.33. Genes encoding this enzyme also have been isolated from mice and several
other species. The full-length humanGLB1 cDNA encodes a 677 amino acid polypep-
tide with beta-galactosidase activity. Mutations in the GLB1 gene are responsible for
both GM1 gangliosidosis and Morquio B disease. As with other lysosomal diseases,
most are point mutations altering single amino acids, although small deletions, splice
site mutations, and other alterations also have been identified. To date, no correlation
has been made between the location or type of GLB1 mutations and the occurrence
of GM1 gangliosidosis or Morquio B disease.
The pathogenesis of beta-galactosidase deficiency is complex. GM1 ganglioside
stimulates neurite outgrowth, affects neuronal differentiation, and enhances the action
of nerve growth factor [93]. Golgi and electron microscopic studies of cortical neu-
rons from this and several other neurological lysosomal diseases exhibit large neural
processes (meganeurites), whichmay be explained by GM1 accumulation. The extent
of meganeurite development is related to the onset, severity, and clinical course of
the disease. In other studies, significant changes in neuronal connectivity were found
in the cerebral cortex of animals with beta-galactosidase deficiency, and cholinergic
function was altered as well. Phosphoinositol-specific phospholipase C and adenyl
cyclase activities were altered in the membranes of cerebral cortex from GM1 gan-
gliosidosis cats. In addition, the beta subunit of cholera toxin, which binds specifically
to GM1 in the outer leaflet of the cell membrane, was found to induce an increase of
calcium and manganese influx in N18 cells, and this has been associated with acti-
vation of an L-type voltage-dependent calcium channel. This channel has important
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implications for neural development, and its reliance on GM1 ganglioside is also
likely related to the pathogenesis of GM1 storage. These and other data suggest vari-
ousmorphologic andmetabolic aberrations occur in the brains of GM1 gangliosidosis
patients and animals, and can be linked to the biology of GM1.
Naturally occurring animal models of GM1 gangliosidosis have been reported in
cats, dogs, sheep, and calves. The cat model in particular has been studied in some
detail, and is a neurologic disorder with clinical, morphological, biochemical, and
genetic similarities to human GM1 gangliosidosis [94]. Affected kittens appear nor-
mal at birth, but tremors of the head and hind limbs are first noted at 2–3 months
of age, followed by generalized dysmetria and spastic quadriplegia. GM1 ganglio-
side and other galactose-containing oligosaccharides accumulate in the tissues of
affected animals. A genetic knockout of beta-galactosidase activity also has been
generated in mice by gene targeting [95]. Progressive and severe neurodegeneration
occurs in these animals, and GM1 and GA1 gangliosides accumulate in the brain.
Unlike patients, GA1 ganglioside may accumulate in beta-galactosidase deficiency
mice to a greater extent than GM1, which may be explained by the fact that there is a
unique neuraminidase in mice that converts GM1 to GA1. Skeletal dysplasia, which
is characteristic of patients with beta-galactosidase deficiency, does not occur in the
mice. This also is due to the unique metabolism of keratan sulfate in mice compared
to humans.
11.9 HEXOSAMINIDASE A AND B DEFICIENCY: GM2
GANGLIOSIDOSES
The GM2 gangliosidoses are a group of genetic disorders caused by excessive accu-
mulation of GM2 ganglioside and related glycolipids in lysosomes, mainly of neu-
ronal cells [96]. The general cause of GM2 gangliosidosis is deficient activity of
the enzyme beta-hexosaminidase (E.C. 3.2.1.30). The enzymatic hydrolysis of GM2
ganglioside by this enzyme requires that it be complexed with a substrate-specific
cofactor, the GM2 activator. There are two isozymes of beta-hexosaminidase, Hex A,
which is composed of alpha and beta subunits, and Hex B, which is composed of two
beta subunits. Hex A and B can only act on the GM2/GM2 activator complex.
Defects in any of three genes can lead to GM2 gangliosidosis, HEXA, which
encodes the alpha subunit of Hex A, HEXB, which encodes the beta subunit of Hex
A and Hex B, or GM2A, which encodes the GM2 activator protein [97]. Three clin-
ical forms of GM2 gangliosidosis occur from mutations in these genes: Tay–Sachs
disease and variants, resulting from mutations of the HEXA gene, and resulting in
deficient activity of Hex A; Sandhoff disease and variants, resulting from mutations
of the HEXB gene, and resulting in deficient activity of both Hex A and Hex B, and
GM2 activator deficiency, caused by mutations in the GM2A gene and character-
ized by normal Hex A and Hex B, but the inability to form a functional ganglioside
GM2/GM2 activator complex.
GM2 gangliosidosis can present with a wide spectrum of severity, ranging
from infantile-onset, rapidly progressive neurodegenerative disease culminating
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in death before age 4 years (classical Tay–Sachs and Sandhoff diseases and GM2
activator deficiency), to adult-onset, slowly progressive neurological conditions
compatible with long survival with little or no effect on intellect [98–101]. The
clinical phenotypes of the acute, infantile form of any of the three genetic GM2
gangliosidosis (HEXA,HEXB, orGM2Amutations) are essentially indistinguishable.
Affected infants generally appear normal at birth. The earliest signs of disease are
often mild motor weakness, beginning at 3–5 months of age. An exaggerated startle
response is also commonly observed at this early stage. Soon after, regression and
loss of already acquired mental and motor skills becomes obvious. The disease is
rapidly progressive and leads to death in early childhood.
As noted above, later-onset forms of GM2 gangliosidosis may also occur. The clin-
ical phenotype varies widely among these patients, and onset can occur at any time
from the late infantile period to adults. In general, in the later-onset cases involvement
of the deeper brain structures aremore prominent compared to the overwhelming gen-
eralized gray matter involvement in the infantile form. Manifestations include dys-
tonia, other extrapyramidal signs, such as ataxia, choreoathetoid movements, signs
of spinocerebellar degeneration, and ALS-like motor neuron involvement. Psychotic
manifestations are not uncommon as well. It should also be noted that in a small num-
ber of later-onset cases, mental capacity is well preserved, although severe dysarthria
often masks the preserved intelligence.
Similar to most lysosomal glycosidases, beta-hexosaminidase hydrolyzes a broad
spectrum of substrates. It is specific for only the terminal nonreducing sugar (Glc-
Nac or GalNac) in beta linkage. The primary substrates for Hex A and Hex B are
glycoproteins, oligosaccharides, glycosaminoglycans, and glycolipids, including the
ganglioside GM2when complexed with the GM2 activator protein. It should be noted
that a minor isoform composed of two alpha subunits (Hex S) also has been identified,
but the biochemical and clinical significance of this isoform remains unclear. Both
the alpha and beta subunits of beta-hexosaminidase possess an active site, although
dimerization is required for activity. The substrate specificity of the two subunits dif-
fers; however, the beta subunit prefers neutral, water-soluble substrates, while the
alpha subunit also hydrolyzes negatively charged substrates such as GM2 ganglio-
sides or glycosaminoglycans. The fact that mutations in theHEXA gene, in which the
Hex B isozyme (composed of two beta subunits) is normal, lead to accumulated GM2
ganglioside demonstrates that the preferred substrate for the alpha subunit is GM2.
However, as noted above, the Hex A isozyme can only hydrolyze GM2 if complexed
with the GM2 activator protein.
Mutations in the alpha subunit encoding the HEXA gene are therefore primarily
characterized by accumulation of GM2 ganglioside. Indeed, GM2 ganglioside is the
primary neuronal storage material in all three genetic causes, hence their grouping as
GM2 gangliosidoses. HEXA mutations are responsible for classical Tay–Sachs dis-
ease and the later-onset Tay–Sachs variants. The pathology of classical Tay–Sachs
disease has been described extensively. The brain is atrophic during the early stage,
but usually increases over time until death. Histological analysis shows classical neu-
ronal storage disease in essentially all neurons of the CNS and the peripheral nervous
system as well, including swollen retinal ganglion cells. The membranous storage
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bodies characteristic of Tay–Sachs disease upon electron microscopic examination
are composed of cholesterol, phospholipid, and GM2 ganglioside. Increased apop-
totic neurons have also been observed. The neuronal pathology in the acute or sub-
acute forms of Tay–Sachs disease is generally less severe than that in the infantile
form and tends to be more prominent in the hypothalamus, cerebellum, brain stem,
and spinal cord.
In the Sandhoff disease variants, due to mutations in theHEXB gene, the patholog-
ical and clinical findings are very similar to those of Tay–Sachs. However, yellowing
of the cerebral cortex and deeper structures has been documented in Sandhoff disease,
possibly due to accumulated asialoganglioside. Also, additional accumulation of sph-
ingoglycolipids with a terminal hexosamine residue and fragments of undigested
glycoprotein in systemic organs has been found. Patients with GM2A mutations are
indistinguishable from those with HEXA or HEXB mutations.
The HEXA gene, encoding the alpha subunit, is located within the chromosomal
region 15q23-q24. It is ∼35 kb in length and contains 14 exons. The HEXB gene,
encoding the beta subunit, is located at chromosomal region 5q13 and is ∼45 kb in
length that is divided into 14 exons. Analysis of these genes strongly suggests that
they arose from a common ancestor. They share a very common exon structure, and in
both genes the promoter activity resides within ∼150 bp of the initiating ATG codon.
Overall, the alpha and beta subunits share∼57% amino acid identity. TheGM2A gene
maps to chromosomal region 5q31.1-31.3. In addition, an evolutionarily related pseu-
dogene, GM2AP, maps to chromosome 3. The GM2A gene is ∼16 kb and contains
four exons.
Numerous mutations have been described in the HEXA gene responsible for
Tay–Sachs disease and its variants. Infantile Tay–Sachs disease occurs most com-
monly among individuals of Ashkenazi Jewish ancestry (carrier frequency ∼1:25),
and there are two mutations that are the most frequent; one is a 4 bp insertion in
exon 11, and the second is a donor splice site mutation in intron 11 [102]. Both
of these mutations result in severely deficient or absent HEXA mRNA expression,
leading to absent Hex A and Hex S activities. Another common HEXA mutation
causing infantile Tay–Sachs disease occurs in French Canadian patients and is due
to a deletion that extends from ∼2 kb upstream of the 5′ end of the gene into intron 1
[103,104]. This also results in the absence of Hex A mRNA and protein. Many
other mutations in the HEXA gene have been described causing classical Tay–Sachs
disease, effecting protein processing, catalytic activity, and/or mRNA processing. In
addition, mutations causing the later-onset forms are known, and generally result
in expression of HEXA mRNA and residual enzyme activity. An important HEXA
mutation is also known as the B1 variant, in which there is normal activity toward
the artificial substrates generally used to measure beta-hexosaminidase activity, but
no activity of the mutant enzyme toward GM2 ganglioside. Individuals with this
mutation pose a unique diagnostic challenge since they will appear enzymatically
normal but develop severe disease. Many mutations in the HEXB gene causing
Sandhoff disease and its variants also have been described. A much small number of
mutations in the GM2A gene are known. As noted above, the fact that mutations in
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this gene caused a severe clinical disease provided the first proof of the physiological
significance of the GM2/GM2 activator complex [105,106].
Naturally occurring mutations causing GM2 gangliosidosis have been described
in dogs, cats, and pigs [107–109]. In all species, abundant neuronal storage is the
major finding. Visceral storage is only found in the feline model, however. Mega-
neurite formation, which has been observed in human GM2 gangliosidosis patients,
occurs in dog and cat models. A number of groups also have independently generated
murine models of Tay–Sachs, Sandhoff, and GM2 activator deficiency in mice using
gene targeting strategies. In general, knockout of theHEXA gene in mice (Tay–Sachs
disease) results in a much milder neurological disease than predicted from the human
cases [110]. Mutations in the HEXB gene in mice results in a more severe phenotype,
with onset of clinical disease at ∼3 months associated with excessive neuronal GM2
storage [130]. Mutations in the GM2A gene of mice also resulted in a much milder
disease than predicted [111].
In part, the distinction between the mouse models and the human disorder are due
to the distinct degradation of GM2 ganglioside by these species [112]. In humans,
GM2 is degraded nearly exclusively by Hex A in collaboration with the activator
protein to yield the ganglioside GM3. In contrast, in mice GM2 can be degraded by
two different pathways. One is identical to the human pathway, and the second is
essentially unique to the mouse and is initiated by sialidase acting on GM2 to yield
GA2 ganglioside. The GA2 is then degraded by either Hex A with activator protein,
or to a lesser extent by Hex B. This explains the mild phenotype due to alpha subunit
mutations (HEXA), since the Hex B can act on the GA2 produced by sialidase. In
contrast, HEXBmutations result in deficiency of both enzymes and a complete block
of degradation.
11.10 SPHINGOLIPID ACTIVATOR PROTEINS
As discussed in the earlier sections, the lysosomal degradation of sphingolipids
requires small nonenzymatic glycoproteins, referred to as “SAPs” [113,114]. These
include the saposin proteins (SAPs A–D, and GM2 activator protein). There are two
genes responsible for these proteins. One isGMA2, which encodes the GM2 activator
protein and is located on chromosome 5 [115], and the other is PSAP, located on
chromosome 10 and encoding the saposin precursor protein and the individual SAPs
A–D, which are derived from proteolytic cleavage of the precursor [116]. The GM2
activator protein and resulting mutations (responsible for the “A/B” Tay–Sachs
variant) were discussed in the previous section and will not be discussed further here.
The PSAP gene encodes the SAP precursor protein (prosaposin), with a total
of 524 amino acids and 5 N-glycosylation sites [116]. There are four homologous
domains located within the precursor protein, each of ∼80 amino acids. A major
portion of the newly synthesized precursor is exported to the cell surface and then
imported into the lysosomal compartment, where it is processed to the mature SAP
A–D proteins. Notably, unlike most lysosomal proteins the prosaposin protein is
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transported to the lysosome via its interaction with the alternative receptor, sortilin
[117,118]. The occurrence of the nonprocessed SAP precursor in body fluids and
its neurotrophic properties indicates that its function may not be restricted to being
the precursor of the individual SAPs. For example, prosaposin has been found in
milk, serum, and seminal fluid, and treatment of cell lines with PSAP increased cell
survival and was antiapoptotic. Indeed, serum prosaposin levels are increased in
patients with advanced prostate cancer. Of interest is whether these effects of PSAP
on cell survival are a direct effect of the protein itself, or rather the effect on the
individual processed SAPs on the activation of the sphingolipid hydrolases.
In vitro, SAP-A stimulates beta-glucocerebrosidase (the enzyme deficient in
Gaucher disease) and beta-galactocerebrosidase (the enzyme deficient in Krabbe
disease) activities in the presence of detergents. SAP-B is a nonspecific glycolipid
binding protein that stimulates the hydrolysis of ∼20 or more glycolipids by different
enzymes in vitro, including the hydrolysis of sulfatide by ASA (the enzyme deficient
in MLD). SAP-C stimulates the in vitro activities of glucosyl- and galactosylcere-
brosidases, as well as sphingomyelin by ASM (the enzyme deficient in Types A
and B NPD) [119]. SAP-D is required for the degradation of ceramide by AC (the
enzyme deficient in Farber disease [120].
Analysis of mutations in the genes encoding the PSAP protein have provided
important insights into the role of the SAP proteins for the in vivo hydrolysis of sphin-
golipids and their relationship to human disease. Of note, a SAP precursor deficiency
was found in a child who died at 16 weeks andwhowas homozygous for a mutation in
the initiation codon of the PSAP gene. The complete absence of the precursor protein
and four resultant SAPs led to a generalized accumulation of ceramide, glucosylce-
ramide, galactosylceramide, sulfatide, lactosylceramide, digalactosylceramide, and
other sphingolipids. The symptoms of the disease resembled that of type 2 Gaucher
disease. Other point mutations within the region of the PSAP gene encoding SAP
B caused accumulation of sulfatide and some other sphingolipids, and a clinical
course resembling that of juvenile MLD. Mutations in the SAP-C region only led
to accumulation of glucosylceramide, similar to juvenile Gaucher disease [121]. No
sphingomyelin storage was observed in individuals with SAP-C mutations, and this
has been explained by the fact that there is a SAP-like domain within ASM that com-
pensates for the loss of SAP-C in these patients. Patients with mutations in the SAP-A
region of the PSAP gene resemble those with Krabbe disease (GLD), and accu-
mulate galactosylcerebroside within the CNS and peripheral nervous system [122].
There are no human patients with SAP-D mutations, but the requirement by AC for
SAP-D has been confirmed in vivo in mutant mice, who accumulate ceramides with
alpha-hydroxylated fatty acids mainly in the brain and kidney, and develop Purkinje
cell loss and defects in the urinary system [123,124].
A mouse model of SAP precursor deficiency has also been constructed by gene
targeting, and the clinical and biochemical features resembled that of the human dis-
ease [125]. Mice developed massive sphingolipid storage and neurological disease
by ∼20 days, and died by ∼35–38 days. Several knock-in models expressing specific
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Lysosomes are essential organelles for the physiological maintenance and viability
of all metazoan cells, with conserved functions in nutrient and ion homeostasis, cell
signaling, macromolecule turnover, and plasma membrane repair among others. The
complex physiology of multicellular organisms requires certain cell types to fulfill
needs that exploit some features of lysosomes but that are specialized for specific
functions – such as cell-mediated cytolysis by cytotoxic T lymphocytes (CTLs) or
regulated secretion of clotting factors, surfactants, or other specialized cargoes. Many
such cells have evolved to generate either modified forms of lysosomes or completely
distinct membranous structures to fulfill these functions. Such organelles are called
lysosome-related organelles (LROs), and are broadly defined as cell type-specific
compartments that share features of lysosomal or endosomal organelles but are func-
tionally and morphologically distinct. Since LROs are required for the physiology of
the organism but not for the viability of the cell that generates them, heritable defects
in the formation, composition, motility, or secretion of LROs often result in disease.
In this chapter, we briefly describe the variety of LROs that have been defined to
date in mammals and model organisms, relate recent insights into the biogenesis and
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secretion of a few model LROs and how these insights relate to disease, and end with
a focus on LROs of the immune system and perspectives for future investigation.
12.1 DIFFERENCES BETWEEN LROs AND SECRETORY GRANULES
LROs have been rather difficult to precisely define, even by experts in the field.
It is generally agreed that all LROs contain essential functional elements of
endolysosomal compartments, and the late endosomal/lysosomal tetraspanin CD63
has been raised as a potential common component of most, if not all, LROs (e.g., see
Refs [1–3]). This distinguishes LROs from classical regulated secretory granules,
such as the dense core granules of chromaffin cells or pancreatic β cells, in which
the functional components are derived exclusively from the secretory pathway.
However, the degree to which critical LRO components derive from the secretory
pathway varies. At one end of the spectrum, all protein components of melanosomes
that have been studied to date pass through endosomal compartments prior to arrival
at their destination. At the other end, the long vonWillebrand factor (vWF) polymers
of Weibel–Palade bodies (WPBs) assemble and bud from the Golgi and are joined by
endosome-derived factors such as the membrane proteins CD63 and P-selectin [4].
Most LROs are secretory organelles that release their contents upon cellular stimu-
lation; indeed, LROs have also been referred to as “secretory lysosomes” [5] based
largely on the behavior of LROs that double as the host cell’s lysosome, such as lytic
granules of CTLs and natural killer (NK) cells. However, this term belies the fact
that many LROs coexist with bona fide lysosomes in their host cells and that bona
fide lysosomes can also be secreted under certain conditions [6,7]. Moreover, not all
LROs are secreted. For example, notochord vacuoles function to provide structural
rigidity to the cells of the inner notochord layer [8], NOX2-containing LROs
fuse with nascent phagosomes [9,10], melanosomes in ocular pigment cells are
retained intracellularly, and it is not yet clear whether epidermal melanocytes secrete
melanin or whether their melanosome-enriched tips are engulfed by neighboring ker-
atinocytes [11,12]. Here we consider LROs as tissue-specific membranous structures
in which the origins of a substantial fraction of their components can be traced to the
endolysosomal system. Table 12.1 provides a list of compartments that conform to
this definition and that have been referred to as LROs or secretory lysosomes in the
literature. Electron micrographs of examples of these LROs are shown in Figure 12.1.
12.2 PHYSIOLOGICAL FUNCTIONS OF LROs
LROs fulfill a variety of functions within metazoans. Many LROs are found in
hematopoietic cells (Table 12.1 and Figure 12.1), and contribute to important func-
tions in innate or adaptive immunity. For example, the lytic granules of CTLs or NK
cells store pore-forming components such as perforin and cytolytic agents such as
granzymes; signal-dependent release of these components into the synapse between





















































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































Figure 12.1 Examples of LRO ultrastructure. Shown are transmission electron micrographs
(courtesy of G. Raposo, Insitut Curie and CNRS, Paris, France) of a few LROs described in
this chapter. (a) Melanosomes in a human melanoma cell line; (b) azurophilic granules from an
eosinophil; (c) cytolytic granules in a cytotoxic T cell; (d) MIIC from dendritic cells (immuno-
gold labeled for MHC-II); (e) a Weibel–Palade body in a human umbilical vein endothelial
cell. Raposo et al. [13]. Copyright 2007, Reproduced with permission of Elsevier.
Similarly, the azurophilic granules of eosinophils and the basophilic granules of
basophils and mast cells store effectors that are released upon cell stimulation to
damage extracellular microbes and activate proinflammatory pathways. Components
delivered to maturing phagosomes upon fusion with inhibitory NOX2 compartments




in neutrophils destroy internalized microbes and protect phagocytosed antigens
from degradation [15,16]. Stimulus-dependent secretion of a variety of LROs from
platelets (α granules and dense granules) and endothelial cells (WPBs) function
in hemostasis by providing factors that stimulate platelet adherence and thrombus
formation at sites of blood vessel damage [17,18]. Additional LROs in hematopoietic
cells serve nonsecretory roles, including the antigen processing compartments of
professional antigen presenting cells [19] and interferon regulatory factor 7 (IRF7)
signaling compartments in plasmacytoid DCs [20].
LROs are also found in nonhematopoietic cell types and fulfill unusual roles in
physiology. Melanosomes in pigment cells of the eye and skin function in the synthe-
sis and storage of melanin pigments to support photoprotection and visual develop-
ment [21]. Lamellar bodies within alveolar type 2 epithelial cells (not to be confused
with the lamellar bodies of the skin, which are distinct structures) function in the syn-
thesis, storage, and secretion of surfactant to facilitate lung plasticity [22]. Recently,
vacuoles within vertebrate notochords that provide turgidity for structural support
have been shown to have features of LROs [8], as do acrosomes in sperm – which
function in the penetration of the egg during fertilization [23]. LROs have also been
described in invertebrates, including the pigment granules within pigment cells of
the compound eyes of insects such as Drosophila melanogaster and the gut granules
within intestinal cells ofCaenorhabditis elegans. The latter serve as interestingmodel
systems for the biogenesis and maintenance of LROs.
12.3 LRO BIOGENESIS
LROs fall into two distinct subsets: those that correspond to traditional lysosomes
that have been functionally “accessorized” by the expression of tissue-specific con-
stituents and those that coexist with traditional lysosomes within their cell types [24].
Some LROs, such as cytolytic granules in CTLs and NK cells, are emerging as a
hybrid of these two subsets, in which traditional lysosomes that harbor lytic granule
components are further matured upon cellular stimulation by fusion with other endo-
cytic organelles [25]. The formation of nascent LROs in cells that generate them has
been a topic of interest for some time, in large part due to heritable diseases in which
the biogenesis of LRO subsets is impaired such as Chediak–Higashi syndrome (CHS),
Gray Platelet syndrome (GPS), and Hermansky–Pudlak syndrome (HPS). Here, we
illustrate several examples in which our understanding of LRO biogenesis is sub-
stantially mature and in which the products of the genes that are defective in these
diseases participate (Figure 12.2).
12.3.1 Chediak–Higashi Syndrome and Gray Platelet Syndrome
CHS is characterized by oculocutaneous albinism due to melanosome malformation,
bleeding diathesis due to platelet storage pool deficiency, severe immunodeficiency
due at least in part to defective cytolytic granules and neutropenia, and frequent neu-




















































Figure 12.2 Model for biogenesis of four vertebrate LROs. Shown are models for the bio-
genesis of immature (iMel) and mature (mMel) melanosomes (left, brown and gold), platelet
α granules (pink), lysosomes (violet), CTL LGs (gray), and WPBs (right, blue) relative
to endosomal and biosynthetic organelles. Golgi, trans-Golgi network (TGN), early endo-
somes, late endosomes/multivesicular bodies (MVBs), and lysosomes are indicated. Key
cargo molecules discussed in the text are noted in the same color as the LRO, and effec-
tors involved in biogenetic steps are labeled in black text. Arrows indicate relevant traffick-
ing pathways. Left, immature melanosomes (iMel) emerge from vacuolar domains of early
endosomes, and mature by cargo delivery from tubulovesicular domains of early endosomes
through AP-1-coated or AP-3-coated vesicles; recycling endosomal domains associated with
KIF13A and AP-1 migrate along microtubules toward maturing melanosomes for delivery of
some cargoes as indicated. BLOC-1 facilitates tubule-mediated transport; BLOC-2, BLOC-3,
RAB32, and RAB38 likely function downstream. Center left, platelet α granules derive in an
NBEAL2-dependent process from late endosomes within megakaryocytes, and receive both
biosynthetic and endocytic cargoes. Late endosomes in the same cells also fuse with lyso-
somes to deliver other cargoes. Center right, in CTLs and NK cells, immature LGs (iLGs)
also derive by fusion of late endosomes with dense core structures containing perforin and
granzymes. iLGs then fuse with recycling endosome-derived structures upon stimulation by
target cells to formmature LGs (mLGs). MUNC13-4 controls the fusion of RAB11-containing
exocytic compartments with RAB27A-containing iLG in a process that does not require a phys-
ical interaction betweenMUNC13-4 and RAB27A. In the final step, MUNC13-4 and RAB27A
cooperate in the docking of lytic granules to the plasmamembrane, to allow for granule content
secretion. Right, vWF forms long fibrous polymers in the TGN of endothelial cells. Nascent
immature WPBs (iWPBs) then bud off from the TGN encasing the vWF fibers likely with
membrane cargoes such as P-selectin. Other cargoes, such as CD63, are then delivered from
early endosomes in an AP-3-dependent manner. Marks et al. [24]. Copyright 2013, Repro-





lysosomes and/or LROs, whereas organelles of earlier endocytic compartments are
comparatively normal [29,30]. The defective gene in CHS and its beigemouse model,
CHS1, encodes a 3801-residue cytoplasmic protein called LYST [31,32]. How LYST
functions is still unknown. Although some data suggest that LYST positively regu-
lates fission from lysosomal fusion intermediates [33], themajority of data support the
view that mammalian LYST and its homologue in Dictyostelium discoideum, LvsB,
function as negative regulators of lysosome or LRO fusion [29,30,34], such that the
enlarged organelles in patient cells result from uncontrolled fusion.
LYST is a member of a small family of proteins with a conserved BEACH domain,
a pleckstrin homology domain that might engage phosphatidylinositides [35], and
WD domain repeats that are thought to form an interface for protein:protein interac-
tions (reviewed in Ref. [36]). Intriguingly, mutations in several other family members
also result in disease. In particular, mutations in the familymember neurobeachin-like
2 (NBEAL2) result in GPS, a syndrome characterized by the absence of α granules
in platelets [37–39]. Analyses of a mouse model of GPS suggest that NBEAL2 func-
tions during α granule formation within megakaryocytes (Figure 12.2, center panel)
and that loss of NBEAL2 correlates with uncontrolled release of α granule contents
and concomitant defects in megakaryocyte development [40].
12.3.2 Hermansky–Pudlak Syndrome
HPS is a genetically heterogeneous group of disorders characterized in all cases
by oculocutaneous albinism due to melanosome malformation in pigment cells and
by bleeding diathesis primarily due to an absence of dense granules in platelets.
Some HPS isoforms are also associated with a lethal lung fibrosis and/or immun-
odeficiency [41–43]. The ten genes that have been identified to date as defective
in HPS patients encode subunits of four multisubunit protein complexes – adaptor
protein (AP)-3 and Biogenesis of lysosome-related organelles complex (BLOC) -1,
-2 and -3 – that are thought to regulate membrane trafficking steps required for the
maturation of LROs, particularly, melanosomes, platelet dense granules, and alveo-
lar lamellar bodies (reviewed in Refs [24,43–46]). Mutations in orthologous genes
and several additional subunits of the same complexes result in a similar disorder in
mice, and orthologous complexes regulate the biogenesis of gut granules in C. ele-
gans [47–49] and ocular pigment granules in D. melanogaster [50–58]. In addition,
mutations in vacuolar protein sorting 33A (Vps33a) – encoding a SNARE-interacting
Sec1/Mun18 (SM) family member and a subunit of the homotypic fusion and protein
sorting (HOPS) tethering complex – and in Rab38 – encoding a tissue-restricted RAB
GTPase – underlie a similar disorder in rodents [59–63]. Mutations in genes encod-
ing additional HOPS subunits and orthologues of RAB38 underlie LRO defects in
invertebrates [47,49,64–67].
The products of all of these genes appear to regulate the delivery of cargoes
required for the maturation of LROs such as melanosomes. AP-3 is a member of
the heterotetrameric adaptor protein complexes that facilitate protein sorting into
transport carriers for post-Golgi trafficking in eukaryotes, and AP-3 specifically




HOPS complex facilitates homotypic fusion of the lysosome-like vacuole and fusion
of the vacuole with transport vesicles, and mammalian HOPS is thought to function
at multiple endocytic fusion events [70]. BLOC-3 has recently been shown to
function as a guanine nucleotide exchange factor (GEF) for RAB38 and the highly
related RAB32 GTPase [71]. The molecular functions of BLOC-1 and BLOC-2 are
less well understood, and how any of these proteins function during LRO biogenesis
is just beginning to unfold. Their function during melanosome biogenesis is best
understood (Figure 12.2, left panel) and is described in the following sections.
12.3.3 Melanosome Biogenesis
The pigment-storing organelles within melanocytes and developing retinal pigment
epithelia (RPE) have emerged as excellent models for LRObiogenesis due to an easily
identifiable morphology, a wealth of genetic variants, excellent cultured cell models,
and well-characterized cargoes [46,72]. Melanosomes in mammalian cells that make
predominantly black and brown eumelaninsmature through four distinct morphologi-
cal stages. The first two stages lack pigment but are characterized by development of a
fibrillar matrix uponwhichmelanins deposit in later stages [73]. Stage I melanosomes
are accessible to the endocytic pathway and correspond to vacuolar domains of early
endosomes with flat clathrin lattices on their cytoplasmic face and few intraluminal
vesicles [74] but differ from early endosomes in other cell types by their hyperacid-
ification and content of nascent amyloid fibrils that emerge from the intraluminal
vesicles [73–76]. These fibrils, composed of the pigment cell-specific premelanosome
(PMEL) protein (reviewed in Ref. [77]), elongate and assemble into sheets during
maturation of ellipsoidal stage II melanosomes [76]. As stage I melanosomes mature
into stage II, they become inaccessible to endocytic material [74]; how this occurs
concomitant with maturation of early endosomes to endocytic-accessible late endo-
somes is still not understood, but likely reflects fission of a common precursor. This is
suggested by the finding that distinct classes of intraluminal vesicles [78] are associ-
ated with distinct proteolytic fragments of PMEL destined either for lysosome-bound
late endosomes or stage II melanosomes [2].
Intriguingly, PMEL is synthesized as a transmembrane glycoprotein that becomes
proteolytically processed en route to and/or within stage I melanosomes [75,79–82]
to a lumenal fragment that has biophysical characteristics of amyloid [79,83]. PMEL
was the first described mammalian member of a family of “functional amyloid” pro-
teins that exploit the amyloid fold – commonly associated with neurodegenerative
diseases such as Alzheimer, Parkinson, and Creutzfeldt–Jakob diseases – for physio-
logical advantage [84]. A number of distinct domains within PMEL have amyloido-
genic capacity in vitro [85–89], but N-terminal domains appear to be most critical in
vivo [85,90]. How PMEL adopts an amyloid fold within melanosome precursors and
averts pathology is a subject of intensive investigation. Indeed, certain PMEL gene
mutations in animal hypopigmentationmodels are associated with amyloid forms that
are more detrimental than inactivating mutations for pigment accumulation and per-
haps for cell viability [91–95], suggesting that the process and/or timing of amyloid




12.3.4 HPS and Melanosome Maturation
Maturation of nonpigmented stage II melanosomes to pigmented stage III and IV
melanosomes requires the delivery of melanogenic enzymes (such as Tyrosinase
[TYR] and Tyrosinase-related protein-1 [TYRP1]), and membrane transporters (such
as OCA2 and ATP7A) that modify the lumenal environment to favor melanogenesis
(Figure 12.2, left panel). The delivery of these cargoes occurs by vesicular transport
from distinct domains of early endosomes and is regulated in part by BLOC-1,
BLOC-2, AP-3, and the RAB32 and RAB38 GTPases that are defective in HPS
models (reviewed in Ref. [46]). Except for the major cohort of TYR, most cargoes
analyzed to date absolutely require BLOC-1 for their export from vacuolar domains
of early endosomes toward melanosomes [96–99]. BLOC-1-dependent transport
occurs through tubular elements of the recycling endosome pathway [100] that are
“pulled” along microtubules by the kinesin-3 motor, KIF13A [101]. Thus, depletion
of KIF13A results in hypopigmentation and entrapment of BLOC-1-dependent
cargoes in enlarged early endosomes [100]. Recruitment of KIF13A and sorting of
many of these cargoes toward melanosomes requires AP-1, another member of the
clathrin-associated tetrameric adaptor family, which appears to play a dual role of
sorting adaptor for many melanosomal cargoes and recruiter of KIF13A [100].
How BLOC-1 functions in this pathway is not clear. BLOC-1 consists of eight
subunits, of which three and five, respectively, are encoded by genes that are
defective in HPS and its mouse models. A cohort of BLOC-1 associates with
AP-3 [102], and in neurons, BLOC-1 cooperates with AP-3 in the sorting of a
number of transmembrane cargoes into synaptic vesicles [103–105], but BLOC-1
functions to sort both AP-3-dependent and -independent cargoes in melanocytes
[97–99,106]. BLOC-1 interacts physically with a number of additional effectors that
might facilitate sorting, formation, or stabilization of transport carriers, or eventual
fusion of transport carriers with melanosomes. These include the SNARE proteins
syntaxin-13 and SNAP-25 [107–110], actin regulatory proteins such as Arp2/3
and WASH [111], phosphatidylinositol 4-kinase IIα [112], and a number of other
candidates identified by quantitative mass spectrometry analyses [113]. Moreover,
a BLOC-1-like complex in the yeast Saccharomyces cerevisiae is responsible
for recruiting the GTPase-activating protein for the master early endosomal Rab
GTPase, RAB5 [114], suggesting that mammalian BLOC-1 might participate in
RAB exchange to promote the formation of transport carriers. A low-resolution
rotary shadowed structure of recombinant BLOC-1 suggests that the complex
adopts a curvilinear shape [115], as expected for a protein that induces or stabilizes
membrane curvature on tubular transport intermediates [116].
BLOC-2 functions downstream of BLOC-1 and regulates the melanosomal deliv-
ery of a similar set of cargoes [97,102,117–119]. BLOC-2 binds a cohort of BLOC-1
in cells and, similar to BLOC-1, decorates tubular elements of the early endosomal
system [102]. Moreover, BLOC-2 appears to be an effector of RAB32 and RAB38,
with which it partially colocalizes on melanosomes or structures closely apposed to
melanosomes [120]. How BLOC-2 functions is not yet known. BLOC-2 consists of




variants and mouse models. The only clear structural domains in any of them are a
WD40 repeat in the HPS5 subunit [121] and a clathrin binding box that is capable
of engaging clathrin in vitro [122], but the functional relevance of these features is
not clear. When overexpressed in HeLa cells, the HPS6 subunit interacts with a com-
ponent of the dynein/dynactin complex [123], but whether this reflects a function of
intact BLOC-2 is not yet clear.
The genes that are disrupted in HPS are all ubiquitously expressed (albeit per-
haps at different levels in different cell types). How are then tissue-specific effects
observed? The answer likely lies at least in part in the collaboration of BLOC-1, -2,
-3 and AP-3 with tissue-restricted Rab GTPases. In particular, RAB32 and RAB38
play important roles in the biogenesis of melanosomes and other LROs. These two
Rab proteins localize in part to melanosomes and in part to presumed transport inter-
mediates in melanocytes [63,71,120], as well as to subsets of lamellar bodies in
alveolar type II cells [124] and of dense granule-like compartments in a megakary-
ocytoid cell line [125]. TYR and TYRP1 fail to be properly delivered to maturing
melanosomes upon simultaneous depletion of these two highly homologous RAB
proteins in immortalized mouse melanocytes and a humanmelanoma cell line [63,71]
or in RAB38-depleted RPE [61]. BLOC-3 – composed of two subunits, HPS1 and
HPS4, that are targeted by mutation in human and mouse HPS models – was recently
shown to function as a GEF i.e., activator) for these two RAB proteins [71]. Accord-
ingly, similar phenotypes were observed in a BLOC-3-depleted humanmelanoma cell
line [71] and in RPE and interfollicular skin melanocytes in mouse HPS1 and HPS4
models [126]. However, the lack of a similar phenotype in choroidal melanocytes or
hair follicle melanocytes from these same models [127] suggests that either an addi-
tional GEF must exist for RAB32 and RAB38 in these cells or the requirements for
RAB32/38 activation in these cells are more limited.
What do RAB32 and RAB38 do? In epidermal melanocytes, these two proteins
play partially redundant roles in cargo transport, although unique effects on some
cargoes have been observed specifically upon RAB32 knockdown [120]. Recent evi-
dence supports the view that both RAB GTPases, in their GTP-bound form, phys-
ically engage AP-1, AP-3, and BLOC-2, suggesting an important role throughout
cargo transfer to melanocytes [120], and to the myosin motor, Myosin Vc [128].
The latter effector apparently plays contrasting roles in melanosome biogenesis, as
knockdown of Myosin Vc with inhibitory RNA depletes cargoes such as TYRP1
from melanosomes but paradoxically enhances pigmentation. Part of the latter effect
seems to reflect a reduction in release of melanin that occurs constitutively in the
melanoma cell line used in this study [128], perhaps reflectingmelanin exocytosis. An
additional effector of RAB32 and RAB38 is VPS9-ankyrin-repeat protein (VARP),
a large scaffolding protein that also functions as a GEF for RAB21 and engages the
retromer complex and the closed conformation of the vSNARE, VAMP7/TI-VAMP,
through distinct binding sites [129–134]. Extinguished expression of VARP, VAMP7,
or retromer impairs melanosome protein transport [133,135,136]. The RAB32/38
binding site is dispensable for VARP recruitment to endosomes and for endosomal
recycling in nonmelanocytic cells [129] but is necessary for melanosomal protein




12.3.5 HPS and the Biogenesis of Other LROs
As predicted from the symptoms of HPS, BLOC-1, -2, and -3, AP-3 and RAB32/
RAB38 have important functions in the generation of other LROs besides
melanosomes. In patients and mouse models of all forms of HPS, platelets lack
detectable dense granules by whole mount electron microscopy and have reduced
storage pools of serotonin and adenine nucleotides [137–142]. In addition, platelets
from mouse HPS models and two HPS case studies show impaired secretion of α
granules and lysosomes, as well as of protein disulfide isomerase from the so-called
“T granules,” to low doses of agonists [143–145]; the α granule and T granule
secretion defects are secondary to impaired signaling due to loss of secreted dense
granule contents, but BLOC-1 and AP-3 likely regulate cargo delivery to lysosomes
since lysosome secretion from platelets lacking these complexes is intrinsically
impaired [143]. The result of all of these defects in HPS is impaired platelet
aggregation at sites of vascular damage [143,145,146], correlating with excessive
bleeding in patients (reviewed in Ref. [147]). RAB38-deficient rats also present with
bleeding diathesis due to absent dense granules [62,148], and depletion of RAB38
or RAB32 from a megakaryocytoid cell line resulted in reduced size and mobility of
dense granule-like compartments [125]. The cargoes that localize to dense granules
and that might be regulated by these components are not yet known but likely include
transmembrane transporters that pump calcium, adenine nucleotides, serotonin, and
polyphosphates into the dense granule lumen. Among the potential cargoes are the
vesicular serotonin transporter VMAT2 [125], the ABC transporter MRP4 [149], and
a member of the sugar–nucleotide transporter family, SLC35D3, which is depleted
in HPS model platelets [150] and which is the target of mutation in a mouse dense
granule storage deficiency [151].
HPS patients that lack BLOC-3 or AP-3 also present with a lethal lung fibro-
sis [147], and mouse models lacking many of the HPS complexes individually or
in combination have a distinct lung disorder [152,153] and heightened susceptibil-
ity to lung irritants [154,155]. This appears to result from defects in the formation
of lamellar bodies, the LROs of alveolar type II cells in which surfactant is synthe-
sized and stored, and correlates with lung disorders in HPS model mice [156–159].
In addition, RAB38-deficient rats present with progressive and severe lung fibro-
sis like BLOC-3-deficient HPS1 and HPS4 patients [62]. Consistently, RAB38 is
expressed in alveolar type II epithelial cells (AT2) [160] and RAB38-deficient cells
harbor abnormal surfactant levels and abnormally enlarged lamellar bodies [124,161].
The cargoes that are transported to lamellar bodies in an HPS-dependent manner are
not yet identified.
12.3.6 HPS and Neurosecretory Granule Biogenesis
Although not considered traditional LROs, certain synaptic vesicles in neuronal sub-
populations are also affected by HPS mutations. AP-3 regulates the formation of
synaptic vesicles from early endosomes in PC12 cells [162]. Neurons express unique
AP-3 β and μ chains, and only the AP-3B form that harbors these subunits func-




δ chain or the neuron-specific μ3B chain have neurological phenotypes, but HPS
type 2 (HPS2) patients and pearl mice with mutations in nonneuronal AP3B1 do not
[164,165]. Neuronal AP-3 deficiency leads to an imbalance in the composition of
synaptic vesicles in neurons, characterized by a depletion of cargoes such as the zinc
transporter ZnT3, the glutamate transporters Vglut1 and VGAT, the chloride chan-
nel ClC3, SNAREs such as VAMP2, and enzymes such as phosphatidylinositol (4)
kinase IIα [103,166–168]. Some of the same cargoes are also depleted in neurons
from BLOC-1-deficient mice [103,105,116], particularly in certain neuronal subpop-
ulations [104]. In particular, BLOC-1 mutations interfere with sorting to neurites and
nerve terminals [169]. These mutations are also associated with altered neurotrans-
mitter release and behavioral abnormalities inmice [170–172], and polymorphisms in
BLOC-1 subunit genes are associatedwith increased risk for schizophrenia in humans
(reviewed in Ref. [173]).
12.3.7 Weibel–Palade Body Biogenesis
HPS, CHS, and GPS clearly impact the formation of LROs for which cargoes are
derived exclusively from the endocytic pathway. However, not all LROs appear to
be formed via these pathways. A particularly well-characterized example is the for-
mation of WPBs in endothelial cells [174] (Figure 12.2, right panel). The primary
function of these elongated “cigar”-shaped organelles is to assemble vWF into large
polymers or fibers for agonist-induced secretion; the fibers then serve as a mech-
anism to recruit platelets and clotting factors to sites of endothelial cell damage
[175–177]. vWF polymers assemble in the Golgi complex following proteolytic mat-
uration of pro-vWF to the mature form [178,179]. Unlike PMEL in melanocytes,
vWF does not adopt an amyloid fold, but rather assembles into regularly spaced
helices that can extend up to 3–5 μm in length and that coalesce into paracrystalline
structures [180–182]. An exciting recent study showed that the length of the helices
is determined by the degree to which Golgi stacks assemble into the Golgi ribbon
in endothelial cells; “quanta” of vWF polymers within individual Golgi stacks are
assembled into longer polymers in the trans-Golgi network (TGN) within a Golgi
ribbon structure but remain as smaller quanta if ribbon formation is blocked [183].
The increased length of vWF polymers is required for optimum capture of platelets
at sites of vascular damage [183,184].
WPB precursors bud from the TGN in a process that requires clathrin and its adap-
tor AP-1 in an unconventional manner [185]. Rather than regulating cargo budding
into clathrin-coated vesicles, AP-1 and clathrin nearly completely coat the nascent
WPBs [185] (Figure 12.2, right panel). This likely provides a structural support for
the organelles during their formation or maturation but is not required to maintain the
shape of fully formed WPBs [185]. Once segregated from the Golgi, WPBs mature
by recruitment of additional membrane cargoes, such as P-selectin/CD62p and the
tetraspanin CD63, from the endosomal system [186]. Interestingly, recruitment of
CD63 requires AP-3, whereas the recruitment of P-selectin does not and relies on
targeting determinants in several topological domains [186]. P-selectin is thought to




vWF [187]. The RAB GTPase, RAB27A, is recruited to mature WPBs in a man-
ner that is dependent on the vWF cargo [188], where it facilitates vWF secretion in
response to secretagogues and regulates the degree of vWF polymerization released
into the extracellular space [189–191].
Smaller vWF polymers, P-selectin and the RAB27A-related GTPase, RAB27B,
are also major components of α granules in platelets, which have a distinct morphol-
ogy [192]. Whether this morphology reflects differing levels of vWF biosynthesis,
fractured Golgi elements in the megakaryocyte precursors, or another regulatory step
is not yet understood.
12.4 LRO MOTILITY, DOCKING, AND SECRETION
A number of diseases result from defects in LRO motility or secretion. Griscelli
syndrome types 1, 2, and 3 (GS1, GS2, and GS3) reflect defects in the intracellu-
lar transport of selected LROs due to mutations in the genes encoding Myosin VA,
RAB27A, and MLPH (Melanophilin), respectively [193]. A feature of each of these
diseases is cutaneous albinism due to defective positioning of mature melanosomes
within melanocytes and consequent failure to transfer melanosomes to keratinocytes
[194–201]. In melanocytes, RAB27A forms a tripartite complex with the linker pro-
tein, MLPH, and the processive actin motor, Myosin VA, that links melanosomes to
the peripheral actin cytoskeleton. This linkage captures melanosomes from bidirec-
tional movement along microtubules, in which minus-end-directed motions predomi-
nate; thus, loss of any of these components results in accumulation of melanosomes in
the pericentriolar region [202,203]. Myosin VA in this complex functions either as a
tether for melanosomes on peripheral actin [202,203] or to mediate long-range move-
ments toward the cell periphery [204]. The same RAB27A/MLPH/Myosin VA com-
plex impedes spontaneous secretion of immature WPBs from endothelial cells [190].
In RPE, RAB27A and MLPH associate with a distinct motor, Myosin VIIA, to facili-
tate motility of melanosomes into the apical processes that interdigitate with the outer
segments of photoreceptors [205,206].
GS3 (MLPH deficiency) is associated primarily with hypopigmentation, but
patients with GS1 and GS2 suffer from a number of additional symptoms. Defective
Myosin VA in GS1 is most often associated with neurological impairment due to
important roles of this myosin motor in neurons [207], particularly in the devel-
opment of dendritic spines [208]. The neuronal function of Myosin VA does not
require association with MLPH; consequently, some GS1 patients and dilute mouse
models with particular Myosin VA mutations present either with pigmentation or
neurologic defects, but not both [209,210].
GS2 (RAB27A deficiency) is not associated with neurological defects but rather
with immune defects and often with a hyperinflammatory syndrome referred to
as hemophagocytic lymphohistiocytosis (HLH) [199]. The latter is primarily due
to defects in cytolytic granule mobilization within CTLs [211,212]. When bound
to GTP, RAB27A engages numerous effectors that play roles in the maturation of
cytolytic granules and their positioning toward the immunological synapse (IS)
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in CTLs and NK cells [213,214]. These are further discussed in the following
text in the context of cytolytic granule maturation and secretion. RAB27A and its
effectors are also required for proper positioning and exocytosis of numerous other
LROs and non-LRO compartments, including mast cell granules [215], azurophilic
granules [216,217], tertiary and specific granules of neutrophils [218,219], and even
insulin-containing dense core secretory granules [220]. RAB27A and its homologue,
RAB27B, also regulate distinct steps in the release of exosomes [221], and RAB27B
controls dense granule release in platelets [222].
Other aspects in the regulation of LRO secretion have been discovered in the con-
text of hyperproliferative disorders of the immune system like that observed in GS2
and CHS patients. These are discussed as follows in the broader context of LROs in
adaptive and innate immunity.
12.5 LROs AND IMMUNITY TO PATHOGENS
LROs are particularly enriched within cells of the adaptive and innate immune sys-
tems, and diseases associated with their formation, positioning, or secretion lead to
immunodeficiency and often to hyperproliferative immune disorders. Investigations
into the etiology of these disorders has extended our understanding of general princi-
ples of LRO biogenesis and secretion, and raise interesting questions regarding how
LROs might be defined.
12.5.1 Cytolytic Granules
Directed secretion of the contents of CTL and NK cell cytolytic granules into the
synapse with target cells is necessary for antiviral immunity, cancer immunosurveil-
lance, and downregulation of immune responses. Hence, defects in cytolytic granule
biogenesis or secretion lead to heightened susceptibility to viral infection and cancer,
and often to the typically fatal hyperinflammatory disorder HLH. HLH is charac-
terized by an exacerbated yet ineffective immune response [223,224] in which aug-
mented cytokine secretion by CTLs and NK cells recruits and activates phagocytes;
these cells then produce additional cytokines, leading to a “cytokine storm” that sus-
tains inflammation and harms infiltrated tissues [225]. HLH is often observed in GS2
and CHS patients [199,226], but surprisingly only rarely in HPS2 patients, despite
impaired antiviral immunity [227].
Impaired cytolytic activity by CTLs in CHS, HPS2, and GS2 does not seem to
be due to abnormal composition of these granules. Perforin and granzyme are cor-
rectly localized to the lytic granules in AP-3-deficient CTLs [228] (but lysosomal
pools of perforin are reduced in NK cells, suggesting possible defects in NK cell
differentiation or in selective trafficking to granules [229]). The defect within CTLs
in CHS, HPS2, and GS2 resides primarily in the secretion of the granule contents.
In HPS2, granules are unable to efficiently engage and move along microtubules for
positioning at the IS and for subsequent polarized content secretion [228]. Move-




dynein [230]. Once the granules are polarized toward the microtubule organizing cen-
ter (MTOC), the MTOC moves toward the IS at the plasma membrane, ferrying the
associated cytolytic granules with it [230,231]. This step requires RAB27A in com-
plex with its effector, Slp3, and the kinesin-1 microtubule motor [232]. During this
process, the perforin-containing lytic granules fuse with polarized exocytic vesicles
that carry the recycling endosome-associated RAB11A [233] (Figure 12.2, center
panel). Fusion requires the RAB27A effector MUNC13-4 [233], which is discussed
later, and enables functional maturation of the perforin-containing granules for exo-
cytosis. Thus, the final transport step and docking at the IS are blocked in GS2 CTLs
[199,233]. Motility of effector-associated granules is also blocked in CHS [29]. The
polarization of the MTOC to the IS is tightly controlled by the strength of T-cell sig-
naling, at least in part via activation of the LCK tyrosine kinase [234], and requires
the dynein motor [230,235].
12.5.2 Familial Hemophagocytic Lymphohistiocytosis and Cytolytic Granule
Secretion
While HLH is observed together with pigmentation defects in CHS and GS2, HLH
can also manifest as a primary immunodeficiency disorder with mild or absent symp-
toms of oculocutaneous albinism. In this case, HLH is due to mutations in other
genes involved in the exocytosis of lytic granules and comprises a group of diseases
called familial HLH (FHL) [236]. The affected gene in FHL type 2 (FHL2) encodes
perforin, a cytolytic granule cargo that is the main effector of cytolytic activity in
target cells. By contrast, the affected genes in FHL types 3, 4, and 5 encode compo-
nents of the cytolytic granule secretory machinery: MUNC13-4 (defective in FHL3),
Syntaxin-11 (STX11; defective in FHL4) and syntaxin-binding protein-2 (STXBP2,
also referred to as MUNC18-2 in humans or Munc18-b in mice; defective in FHL5).
FHL types 3–5 are also associated with bleeding diathesis, which is caused by impair-
ment in agonist-stimulated release of α granules, dense granules, and lysosomes from
platelets [237–240]. This indicates that cytolytic granules and platelet LROs and lyso-
somes share mechanisms of exocytosis.
The RAB27A effector MUNC13-4 plays at least two distinct roles in cytolytic
granule release. First, as described above, MUNC13-4 controls the fusion of
RAB11-containing exocytic compartments with RAB27A-containing “immature”
lytic granules in a process that does not require a physical interaction between
MUNC13-4 and RAB27A [233]. Second, MUNC13-4 and RAB27A cooperate
in the docking of lytic granules to the plasma membrane, a necessary step in
secretion [241,242]. MUNC13-4 also binds directly to the SNARE complex con-
taining STX11 [237], and thus likely facilitates SNARE complex formation during
exocytosis.
STX11 is a member of the syntaxin family of SNARE proteins. SNAREs on
opposing membranes form a stable four-helix bundle that brings the membranes
into close apposition and thus drives their fusion [243]. STX11 is an unusual target
SNARE (tSNARE) protein in that it lacks a transmembrane helix, and instead is
tethered to the membrane by a lipid anchor [244,245]. In FHL4 patients (with
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mutations in STX11), lytic granule secretion in CTLs and NK cells is blocked,
indicating that an STX11-containing tSNARE complex mediates a fusion step
required for LRO exocytosis [246]. Recent findings suggest that STX11 functions
during the final exocytic step [247], but the localization of STX11 to intracellular
structures that lack RAB27A in CTLs and NK cells [246,248], and the finding that
CTL-dependent killing under certain circumstances in FHL4 patients is intact [248]
raises the possibility that STX11 might additionally – or instead – function in the
fusion of RAB11- and RAB27A-containing compartments to form mature granules.
The CTL deficiencies observed in FHL5 patients with mutations in STXBP2 are
similar to those of FHL4. Indeed, the MUNC18-2 product of the STXBP2 gene is a
member of the Sec1-Munc18 family of syntaxin “chaperones” that stabilizes STX11
and facilitates its SNARE complex formation [249]. In platelets, Munc18b facilitates
the formation of an STX11 complex with the Qbc SNARE SNAP-23 on the plasma
membrane and the R-SNARE VAMP8 on granule membranes to mediate fusion and
granule content release [237,239]. MUNC18-2 in CTLs and NK cells likely facili-
tates the formation of a similar complex to facilitate either maturation or exocytosis
of lytic granules. Intriguingly, a recent report identified a dominant negative mutant
of STXBP2 in an FHL5 patient that bound tightly to STX11 itself but impaired for-
mation of a four-helix bundle SNARE complex, suggesting that SNARE complex
assembly is indeed a key function for MUNC18-2 [250].
12.5.3 Azurophilic Granules
HPS2 patients suffer from recurrent bacterial infections, in part due to chronic
neutropenia [251]. The basis for neutropenia is not completely understood, but it
has been associated with impaired trafficking of elastase to azurophilic granules in
the absence of AP-3 [229,252,253]. Elastase is required for normal differentiation
of myeloid progenitors to mature neutrophils [254]. Consequently, HPS2 patients
show arrested maturation of neutrophil precursors at the promyelocyte stage [253].
However, neutrophil counts increase during infections, and recurrent infections
persist even upon treatment of patients with granulocyte-colony stimulating factor to
increase neutrophil numbers [255–257]. This suggests the presence of other immune
dysfunctions in these patients. Azurophilic granules are also required for neutrophil
bactericidal activity, and defective fusion of these granules with phagosomes has
been observed in CHS [258].
12.5.4 NADPH Oxidase-Containing LROs
Chronic granulomatous disease (CGD) is an immunodeficiency disorder in which
pigmentation is normal (and hence there is no defect in melanosome formation) but
in which a number of immune system LROs fail to function properly. Immunod-
eficiency is evidenced by recurrent respiratory, intestinal, and cutaneous bacterial
infections and delayed clearance of viruses [251]. These immune defects are
attributed to impaired activity of the “phagocyte-specific” NADPH oxidase (NOX2)




stored in “specific granules” in neutrophils or in less well-defined compartments
in macrophages that fuse with nascent phagosomes following phagocytosis of
large particles such as bacteria; there it generates reactive oxygen species that
are thought to damage the phagocytosed cargoes [259]. In DCs, gp91phox is also
stored within LROs that are mobilized to fuse with nascent phagosomes [10,260]
(Figure 12.3, left). These LROs have been called “inhibitory LROs” due to their
ability to limit acidification when recruited to phagosomes in phagocytes. The
reactive oxygen species generated by NOX2 capture protons in phagosomes and
therefore counteract the vacuolar ATPase activity in DCs, preventing acidification.
This activity limits the degradation of bacterial antigens within phagosomes to
preserve antigenic peptides [10]. DCs from patients and mouse models of CGD
show increased phagosomal acidification and impaired antigen cross-presentation
due to the defective recruitment of NOX2 to phagosomes, perhaps contributing to
impaired immune responses to infections [10,260]. Recruitment of inhibitory LROs
to phagosomes is mediated by RAB27A [261]; delayed recruitment of NOX2 to
nascent phagosomes in DCs in the RAB27A-deficient ashen mouse model of GS2
leads to increased acidification and consequently increased protein degradation and
impaired antigen cross-presentation to naïve CD8+ T cells [261].
12.5.5 IRF7-Signaling LROs and Type I Interferon Induction
Plasmacytoid DCs (pDCs) are a specialized DC subset that functions largely in
the production of type-I interferon (IFN) and plays an important role during viral
infections. The pDCs recognize viral DNA at least in part through endosomal
toll-like receptors (TLRs) including TLR7 and TLR9 [262]. TLR9 is activated
by proteolytic processing within endosomes and then signals through the adaptor
protein MyD88 via two bifurcating pathways. One pathway leads to NF-κB
activation and the production of proinflammatory cytokines. The other pathway
requires activation of the adaptor protein TNF receptor-associated factor 3 (TRAF3),
and leads to phosphorylation and activation of the transcription factor IRF7 to
stimulate production of type I IFN [263]. Interestingly, these two signaling cascades
are initiated in different compartments [20] (Figure 12.3, right). NF-κB activation
is initiated from a VAMP3-containing early endosomal compartment that lacks
the lysosomal-associated membrane protein 2 (LAMP2). By contrast, TRAF3 is
activated on a distinct LRO-like compartment that contains LAMP2 and to which
IRF7 is recruited [20]. Trafficking of TLR9 from endosomes to this IRF7 signaling
LRO requires AP-3 [20] and also likely BLOC-1 and BLOC-2 [264]. A potential
cargo of this pathway is SLC15A4 [264], a transporter recently shown to facilitate
cargo escape from phagosomes in conventional DCs [265]. The defective production
of type-I IFN by pDCs in the absence of AP-3 might contribute to the recurrent viral
infections observed in HPS2 patients.
12.5.6 MIICs: LROs or Conventional Late Endosome/Lysosomes?
The T-cell receptor on CD4+ lymphocytes recognizes antigenic peptides bound to
major histocompatibility complex class II (MHC-II) molecules on the surface of
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Figure 12.3 Model for LRO function in conventional DCs and pDCs. Left, LROs and phago-
some maturation in DCs. 1. Antigens captured by endocytosis or macropinocytosis enter
the endolysosomal system and are degraded to smaller peptides. Peptides encounter MHC-II
molecules as endosomes mature to late endosomes/MIICs and lysosomes. Antigen loading
mostly occurs within late endosomes/MIICs and lysosomes that are enriched in the regula-
tory component HLA-DM. From these compartments, peptide-loaded MHC-II molecules are
delivered to the cell surface (black straight arrow) for presentation to T cells. 2. Particulate
antigens captured by phagocytosis are degraded in phagosomes as the phagosomes mature.
Maturation is achieved by the acquisition of content (including MHC-II) from early and late
endosomes/MIICs and lysosomes by both direct fusion (open arrows) and vesicular transport
(turquoise arrows; dashed arrows indicate possible pathways for MHC-II transport that are not
yet confirmed). Antigen is loaded ontoMHC-II predominantly in late phagosomes. Phagosome
maturation is supported by autophagy (ATG; light violet) proteins, which might derive from
autophagosomes themselves or independently from the cytosol, and by signaling from pattern
recognition receptors (PRRs, black arrow) such as TLRs. PRRs such as TLR4 are delivered
to phagosomes from early endosomes in an AP-3-dependent manner (mauve dashed arrow).
From late phagosomes, peptide-loaded MHC-II is delivered to the cell surface either directly
(not shown) or via an intermediate tubular MHC-II storage compartment for presentation to
T cells (black straight arrow). Delivery to or from this compartment appears to be regulated
by PRR signaling from the phagosome (dashed black arrows). Right, IRF7 LROs and type I
IFN signaling in pDCs. TLR9 is trafficked from the biosynthetic pathway to VAMP-3-positive
early endosomes. Here TLR9 is cleaved and becomes competent for signaling to activate proin-
flammatory cytokine expression through NF-κB (NF-κB endosome). Cleaved TLR9 is then
targeted in an AP-3-dependent manner to a LAMP2-positive LRO (IRF7 LRO) harboring the
adaptor TRAF3. Here TLR9 signals through IRF7 to induce the transcription of type-1 inter-
feron genes. Adapted from Traffic 14:135–152, Mantegazza AR, Magalhaes JG, Amigorena S,
Marks MS, Presentation of phagocytosed antigen by MHC class I and II, 2013 and from Sci-
ence 329:1530–1534, Sasai M, Linehan MM, Iwasaki A, Bifurcation of toll-like receptor 9





antigen presenting cells, which include DCs, B lymphocytes, activated macrophages,
and a few other cell types [266]. In Epstein–Barr virus transformed B lymphocytes
and conventional DCs, MHC-II accumulates in multivesicular and multilaminar
compartments called MIICs that harbor lysosomal proteins such as CD63, LAMP1,
and cathepsins [267–269] as well as the antigen processing chaperones HLA-DM
and HLA-DO [270,271] (Figure 12.3, left). MIICs were historically described as
LROs due to the unusually uniform multilamellar electron dense morphology of
the “later” MIIC compartments [267] (Figure 12.1), which could be induced by
expression of MHC-II alone [272]. However, it is no longer clear whether MIICs
are true LROs or merely conventional late endosomes and lysosomes enriched in a
special cargo. Indeed, antigen processing and assembly withMHC-II has been shown
to occur in different MHC-II-containing compartments in APCs, including early and
late endosomes, lysosomes, and phagosomes [273]. Therefore, MIICs might not be
as clearly differentiated from conventional endolysosomes as once thought. On the
other hand, antigen processing compartments in DCs are particularly sensitive to
functional and morphological changes in response to signals from receptors such as
TLRs. For example, TLR stimulation of DCs leads to a reorganization of the MIICs
to a tubular morphology, favoring the delivery of peptide:MHC-II complexes to the
plasma membrane at the IS with T cells [274–277]. Tubular MIICs may coexist with
bona fide unstimulated lysosomes in DCs [276,277], and thus might more strictly
adhere to the LRO definition.
While MHC-II-dependent antigen presentation is impaired in CHS [278], it is
not generally disrupted in HPS [279,280] (although see the following section for a
unique exception in HPS2). However, AP-3 deficiency in HPS2 or its mouse models
causes impaired presentation of microbial lipid antigens on human CD1b molecules
or the mouse orthologue, CD1d [281–283]. CD1b binding to AP-3 is required for its
localization to MIICs in B cells and for appropriate sorting to the plasma membrane
[281–283]. This defect in antigen presentation, together with the defects described as
follows in phagosomal TLR activation and antigen presentation, may in part account
for the increased susceptibility to bacterial infections in HPS2.
12.5.7 Phagosomes and Autophagosomes as New Candidate LROs
Phagosomes are intracellular structures that surround large internalized particles
following their uptake through the specialized mechanism of phagocytosis. Based
on the definition of LROs as specialized cell-type specific organelles derived
from the endosomal system, one could argue that maturing phagosomes can be
considered to be LROs (Figure 12.3, left). We base this argument on the following
criteria: (i) Phagosomes are only generated in specific phagocytic cell types such
as macrophages, neutrophils, and DCs. (ii) Although they form by the unique
process of phagocytosis and thus do not strictly derive from endosomes, they
mature by continuously receiving input from the endosomal system [284,285].
(iii) Although they eventually fuse with lysosomes, they harbor unique cargoes
such as NOX2 and perform unique functions within the cell that differentiate
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them from conventional lysosomes. (iv) Maturing phagosomes fuse with other
phagocyte-specific LROs such as NOX2 positive LROs and MIICs, and coexist with
conventional lysosomes. (v) They harbor MHC molecules and provide peptides for
antigen presentation and thus behave functionally like autonomous MIICs [286].
(vi) At least in conventional DCs, TLR stimulation induces the extension of tubules
from maturing phagosomes that facilitate MHC-II presentation much like the
extension of tubules from endolysosomes. However, these tubules appear to function
in a different way from endolysosomal tubules and do not seem to drive surface
expression of MHC-II [287]. (vii) Finally, phagosome maturation is influenced by
AP-3 and is altered in models of HPS2. In conventional DCs, AP-3 facilitates the
recruitment of TLR4 and possibly other TLRs to maturing phagosomes, favoring
the MHC-II-dependent presentation of phagosomal antigens and TLR-dependent
proinflammatory cytokine stimulation [288]. Hence, in the mouse pearl model of
HPS2, the impaired capacity for MHC-II presentation and reduced proinflammatory
cytokine production from phagocytosed bacteria in DCs leads to reduced T-cell
activation and IFN-γ secretion [288]. These defects in DC performance likely
contribute to the recurrent bacterial infections observed in HPS2 patients even after
restoration of normal neutrophil counts [41].
Another degradative process that also converges with lysosomes and LROs is
macroautophagy. This process, generally referred to simply as autophagy, involves
the enclosure of intracellular components – including organelles – into a double-
membrane structure called the autophagosome. This structure ultimately fuses
with lysosomes for degradation of its contents [289,290]. Autophagosomes and the
machinery involved in their formation intersect LROs in a number of ways. Like
phagosomes, autophagosomes represent a source of peptides forMHC-II presentation
[291,292], and thus can feed into theMIIC pathway (Figure 12.3, left). As autophago-
somes mature, they also receive input from the endosomal system; indeed, compo-
nents involved in endosome maturation, such as the ESCRTs, are key components in
autophagosome maturation and fusion with lysosomes [293–295]. More recently, the
HOPS complex – which is required for the biogenesis of LROs such as melanosomes,
platelet dense granules and α granules, eye pigment granules in D. melanogaster and
gut granules in C. elegans, is required for autophagosome fusion with lysosomes
through an interaction with the autophagosomal SNARE syntaxin 17 [296,297].
Components of the autophagy pathway have also been implicated in the bio-
genesis of LROs. Depletion of a number of autophagy components in a human
melanoma cell line impairs pigmentation, and the lipidated form of LC3 might
associate with melanosomes of distinct stages [298,299]. Similarly, TLR-dependent
phagosome maturation in DCs involves recruitment of LC3 in a process requiring
the key regulators of autophagosome formation, ATG5 and ATG7 [300,301]. ATG5
and ATG7 have also recently been implicated in agonist-stimulated vWF release
from WPBs in epithelial cells, reflecting either storage of a cohort of vWF in
autophagosomes or contribution of these components in WPB biogenesis [302].
Thus, the formation of autophagosomal intermediates might play a more general





Over the last two to three decades, LROs have emerged as key effectors of metazoan
physiology and important models for subcellular compartmentation and function.
Analyses of LROs have provided insights into molecular mechanisms controlling
organelle formation, nonredundant protein sorting pathways, novel modes of secre-
tion, new physiological mechanisms, and the pathogenesis of a host of inherited
diseases. In addition, the unusual structural components of some LROs – such as the
fibrillar structures underlying melanosomes and WPBs – have given us insights into
unexpected areas such as the role of oligomer size in cell physiology and the control
of amyloid formation. Future studies will likely focus on integrating the “parts list”
that human diseases have provided for us to understand how different components of
biogenetic and secretory machinery function together to effect processes such as the
formation of transport intermediates or the exocytosis and expulsion of large cargoes.
Analyses of some of these processes within living organisms are likely to provide new
insights into considerations that are not typically addressed under culture conditions,
such as physical requirements of secretion of large cargoes against hemostatic pres-
sure (e.g., see Ref. [303]). At the same time, the exponential rise in the ability to define
geneticmutations in patients will provide a rich source of new information concerning
components required for LRO biogenesis, secretion and function and on how these
components might interact with each other. This information will in turn provide new
avenues for inexpensive diagnostic tools and therapies for LRO-related diseases.
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Within the cell, protein degradation is carried out by at least two mechanisms, the
proteasome and lysosome. For the degradation of larger molecules and organelles,
lysosome-dependent autophagy is the only mechanism available. Our understanding
of the role autophagy plays in disease pathology is reaching the point where therapeu-
tic modulation of autophagy in a number of diseases may be possible. This chapter
focuses on targeting lysosomal function to block autophagy in hopes of augmenting
the effectiveness of cancer therapy.
Autophagy can be subdivided into at least three forms: macroautophagy, microau-
tophagy, and chaperone-mediated autophagy. Each defined on the basis by the way
of the degradative material delivered to the lysosome [1–4]. Microautophagy is a
nonselective process that involves direct engulfment of cytoplasmic cargo by the
lysosomal membrane [5,6], while chaperone-mediated autophagy is selective for spe-
cific KFERQ-containing proteins through their interaction with heat shock cognate
70 (HSC70) and lysosome-associated membrane glycoprotein 2A (LAMP2A) [7,8].
Both microautophagy and chaperone-mediated autophagy directly deliver cytoplas-
mic components to the lysosomal compartment. In contrast, macroautophagy is the
most multifunctional and well-studied form of autophagy and consists of the gener-
ation of double-membraned autophagic vesicles known as autophagosomes, which
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sequester cytoplasmic material before delivering it to the lysosome for degradation.
For this reason, we refer to macroautophagy hereafter as autophagy.
Autophagy can also be described as canonical autophagy and noncanonical
autophagy. The molecular machinery of canonical autophagy is directed by a
number of autophagy-related (ATG) genes (see Table 13.1) as well as non-ATG
proteins such as phosphatidylinositol 3-kinase (PtdIns3KC3), p150 and activating
molecule in Beclin 1-regulated autophagy (AMBRA1). Although far less well
understood, noncanonical autophagy can occur in an ATG7- or ATG5-deficient
background [32] through the unconventional biogenesis of autophagosomes [33].
The observation of noncanonical autophagy complicates that view of autophagy
as a druggable target for therapy in human disease, since specific modulation of a
canonical autophagy protein may be compensated for by an increase in the activity
of noncanonical autophagy. One common denominator for all of the autophagy
programs is that ultimately they rely on lysosomal degradation.
Autophagy plays a critical role in a number of disease states, so it might make
sense to either induce or inhibit autophagy to treat disease depending on the cellular
context. While there is some evidence that autophagic cell death plays a role in spe-
cific human disease contexts, more studies have provided strong evidence indicating
autophagy can increase the survival of both normal andmalignant cells under stressful
conditions both in vitro and in vivo [34–36]. The critical role of autophagy in the sur-
vival of cancer cells is further underscored by its cell survival role in other biological
contexts. For instance, during organismal development, autophagy is needed for dif-
ferentiation, development, and survival [37]. The autophagy gene BECN1 (Beclin 1)
on chromosome 17q21, a human homologue of ATG6/VPS30 in yeast, is essential for
early embryonic development. Homozygous deletion ofBecn1 in mice results in early
embryonic lethality, whereas monoallelic deletion (Becn1 +/−) reproduces a com-
monly observed genotype in human cancers and results in the development of sponta-
neous malignancy in mice [38]. ATG5 and ATG7 are also essential autophagy genes;
complete knockout of either Atg5 or Atg7 in mice have indicated that these genes
are important for mammalian embryogenesis and survival during the early neonatal
starvation period [39–41] (see Chapter 5). Defective autophagy has been implicated
in many pathological conditions including neurodegeneration, cancer, heart disease,
and infectious disease [42–45].
Based on this potential role of autophagy as a survival pathway in many cell
contexts including advanced cancer cells, our group and others have focused on
inhibiting autophagy in the context of cancer therapy. This chapter first provides a
detailed description of the steps and stages of autophagy and the cellular regulators
of autophagy. Next, the evidence that autophagy is a tumor suppressor and tumor
promoting pathway in cancer cells depending on the cellular context is reviewed.
Finally, chemical and pharmacological inhibitors of autophagy, and their use in lab-
oratory experiments and early-phase clinical trials in cancer patients are reviewed.
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TABLE 13.1 Yeast Autophagy Genes and Mammalian Homologs
Yeast Mammal Major Function References
Atg1 Ulk1 and Ulk 2 Serine/threonine protein kinase [9,10]
Atg13 Atg13 ULK substrate [9,10]
Atg101 Atg13-binding protein [11]
Atg17 FIP200 (RB1CC1) Modulates response of autophagy [9]
Atg24 (Snx4) PtdIns(3)P-binding protein [12]
Atg6 (Vps30) Beclin 1 Component of PI3K complex [13]
Atg14 Atg14L Component of PI3K complex [14,15]
Vps34 PIK3C3 Kinase [13]
Vps15 PIK3R4 Component of PI3K complex [13]
Vps38 UVRAG Involved in activation and
maturation
[15]
Atg18 WIPI proteins Binds PtdIns(3)P and PtdIns(3,5)P2 [16]
Atg21 WIPI proteins Binds PtdIns(3)P and PtdIns(3,5)P2 [17]
Atg8 MAPLC3, GABARAP,
GATE-16, mATG8L
Ubiquitin-like conjugation system [18,19]





Cysteine protease that processes
Atg8/LC3
[21,22]
ATG5 Component of the
Atg12–Atg5–Atg16 complex
[23]
ATG7 Ubiquitin-activating (E1) enzyme [24]
ATG10 Similar to the E2
ubiquitin-conjugating enzyme
[25]






Atg9 mAtg9A and ATG9B Transmembrane protein, serves as a
lipid carrier
[27,28]
Atg12 Ubiquitin-like protein [23]
Ypt1 Rab1 Required for localization of Atg8 to
the PAS
[29]
Ypt7 Rab7 Small GTP-binding protein [30]
Sec18 NSF ATPase responsible for SNARE
disassembly
[31]
Abbreviations: Atg, autophagy related; ULK, Unc51-like kinase; FIP200, focal adhesion kinase (FAK)
family interacting protein of 200 kDa; RB1CC1, retinoblastoma 1-inducible coiled coil-1; Beclin 1. Bcl-2
interacting myosin/moesin-like coiled-coil protein 1; Vps, vacuolar protein sorting; UVRAG, UV irradi-
ation resistance-associated gene; WIPI, WD repeat protein interacting with phosphoinositides; GATE-16,
Golgi-associated ATPase enhancer of 16 kDa/GABARAPL2; GABARAP, gamma-aminobutyric acid
receptor-associated protein; LC3, microtubule-associated protein 1 light chain 3; TSC1/2, tuberous scle-
rosis complex 1/2; Ypt, yeast protein; PE, phosphatidylethanolamine.
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13.1 STAGES AND STEPS OF AUTOPHAGY
Autophagy consists of two stages. The proximal stage is characterized by the for-
mation of autophagosome (Steps 1–3 below), and the distal stage is defined by the
formation of autolysosome and degradation of vesicle contents (Steps 4–5 below).
At present, the proximal stage of autophagy is relatively well studied, whereas the
molecular mechanisms controlling the distal stage of autophagy remain poorly under-
stood. The whole process of autophagy proceeds through the following sequential
steps (Figure 13.1):
Step 1, Initiation: The initiation of autophagy begins by activation of the Atg1
complex, also known as the ULK complex, which is composed of the
mammalian Atg1 homologue Unc-51-like kinases 1 or 2 (mammalian Atg1
homologue Unc-51-like kinases 1 or 2, ULK1 and ULK2), the mammalian
autophagy-related 13 homologue (ATG13). 5′ adenosine monophosphate-
activated protein kinase (AMPK), and mammalian target of rapamycin
(mTOR) regulate autophagy through direct phosphorylation of ULK1 [9,10].
The tight regulation of ULK activity by intracellular energy and nutrient levels
is critical for autophagy initiation, and an activated ULK complex induces
autophagy by phosphorylating Beclin 1 and activating Vps34, a class III
PtdIns3KC3 [9–11,46].
Step 2, Nucleation: Nucleation of membrane that eventually becomes the
autophagic vesicle depends on the Beclin 1–Vps34–X complex, where X can
be ATG14L, Rubicon, Ambra, or others depending on the cellular and sub-
cellular context. Stimulation of this complex generates phosphatidylinositol-
3-phosphate (PI3P), which promotes autophagosomal membrane nucleation
arising from various sources in the cell, including plasma membrane [47],
mitochondria [48], endoplasmic reticulum (ER) [49], or the Golgi apparatus
[32]. ATG14L can directly interact with Beclin 1 and enhance VPS34 activity
to induce autophagosome membrane nucleation [50].
Step 3, Elongation and maturation: As the autophagic vesicle forms, elongation
and maturation require two ubiquitin-like conjugation systems. ATG12 is con-
jugated to ATG5 by ATG7 (an E1-like ligase) and ATG10 (an E2-like ligase)
enzymes. ATG5-ATG12 forms a complex with ATG16L, which participates
in maturation of the autophagosome. The second ubiquitylation-like reaction
involves the conjugation of the ubiquitin-like protein microtubule-associated
protein1 light chain 3 (LC3-I) to the lipid phosphatidylethanolamine (PE)
to form membrane-associated LC3-II through ATG7 and ATG3 (an E2-like
ligase). LC3-1 is generated from the cleavage of the precursor forms of LC3
by the cysteine protease ATG4. ATG5-ATG12 conjugation depends on Vps34
function, and is positively regulated by the small GTPase Rab5 [51]. ATG4
has a critical function by both processing LC3 precursors and deconjugating
LC3-PE. Once LC3 is integrated into the bilayer, it recruits cargo adaptor
 
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proteins (also known as autophagy receptors), such as p62, Nbr1, or NIX.
These proteins, in turn, recruit cargo from the cytoplasm (i.e., ubiquitinated
protein aggregates in the case of p62 and damaged organelles in the case of
NIX) to promote AV closure and maturation.
Step 4, Fusion and degradation: Once autophagic vesicles are formed and cargo is
engulfed the next step is fusion of the autophagosome with the lysosome. This
fusion event involves the trafficking of autophagosomes along microtubules
and fusion with the lysosome, forming the autolysosome. This process is not
well understood. What is known is that it is regulated by lysosomal membrane
proteins such as LAMP2, small GTPases such as Rab7, adaptor proteins such as
endosomal sorting complex required for transport (ESCRT) [11,52] and other
vesicular structures such as multivesicular bodies (MVBs) [52,53]. Within the
acidic environment of the autophagolysosome, the cytosolic cargo is degraded
via pH-dependent hydrolases.
Step 5, Recycling and autophagic lysosome reformation: The breakdown prod-
ucts of degradation within the autolysosome that include sugars, amino acids,
and nucleic acids are likely released back into the cytosol through permeases
such as Spinster [54]. AV components not exposed to lysosomal hydrolases are
recycled via a system involving multiple components of the outer membrane
such asATG9,ATG2,ATG18, andATG21. Alternatively, autophagosomesmay
also fuse with the plasma membrane and release their contents [55]. The fusion
of lysosomes and autophagosomes rapidly leads to depletion of free lysosomes
and thus a cellular mechanism is required for maintaining lysosome homeosta-
sis. Recent evidence indicates the presence of a lysosomal recyclingmechanism
after cargo degradation within the autolysosome [56].
13.2 INDUCTION OF AUTOPHAGY
Autophagy can be induced by many upstream signaling cascades. For instance,
as mentioned, mTORC1 [57] is a major controller of autophagy, and the intimate
connection between the lysosome and mTORC1 is being more appreciated. The
mTOR protein resides in mTORC1, which contains the regulatory-associated protein
of mTOR (Raptor), G protein beta subunit-like protein (GβL), and proline-rich
AKT/PKB substrate 40 kDa (PRAS40), which can regulate the mTOR substrate,
the ULK1/2 complex. In response to abundant nutrient supply and/or growth factor
activation, mTORC1 inhibits autophagy through inhibiting ULK1. Class I PI3K acti-
vates mTOR, and therefore inhibits autophagy [58]. Rapamycin inhibits mTORC1
and is therefore a powerful activator of autophagy. The ULK1 kinase complex
receives signals from the mTORC1 and controls the initiation of autophagy. Once
mTORC1 kinase activity is inhibited, the ULK1 complex is activated. MTORC1 is
bound to lysosomal membranes through the Ragulator complex [59]. MTORC1 has
associated proteins that act as sensors of amino acid concentrations in the cytoplasm
 
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Figure 13.1 Molecular signaling of macroautophagy.
as well as within the lysosomal lumen. This sensing mechanism is dependent on the
lysosomal H+-vacuolar ATPase [60]. Finally, mTOR signaling and MAPK signaling
coordinately regulate lysosomal biogenesis through control of key transcription
factors, such as transcription factor EB (TFEB) [61]. AMPK is another key regulator
of autophagy, and can do so by either downregulating mTORC1 signaling or through
direct phosphorylation and disinhibition of the ULK1 complex (see Section 13.6).
Other pathways that regulate autophagy include the unfolded protein response
(UPR)/endoplasmic reticulum stress (ER stress) response [62,63] and the regulation
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of autophagy through DNA damage and p53 at the transcriptional level. For instance,
the ER stress response gene activating transcription factor 4 (ATF4) induces LC3
gene expression [64], and p53 induces transcription of multiple ATG genes [65].
Throughout the process of autophagy, the lysosomal positioning tightly regulates
mTORC1 signaling and in turn regulates other signaling [66,67], which profoundly
influences autophagosome formation and autophagosome–lysosome fusion, as
well as autophagic flux by acting both at the proximal stage and the distal stages
of autophagy [68]. The translational significance of these molecular connections
is that therapeutic modulation in cancer with almost any drug will affect one or
more of these pathways upstream of autophagy. Therefore, the majority of cancer
therapeutics tend to activate autophagy [69–73].
13.3 STUDIES IN MOUSE MODELS UNRAVEL THE DUAL ROLES OF
AUTOPHAGY IN TUMOR BIOLOGY
Autophagy plays a complex and controversial role in oncogenesis and tumor progres-
sion. The dual function of autophagy in cancer, as both a tumor suppressormechanism
andmechanism of cell survival, has been widely recognized. Autophagy levels within
tumor cells and within cells within the tumor microenvironment may have a different
influence on early tumorigenesis, progression of established cancer, and the impact
of therapeutic interventions.
On the one hand, autophagy is a degradative process that was originally desig-
nated as type II programmed cell death [74]. Autophagy, if elevated or persistent
can lead to autophagic, apoptotic, or necrotic cell death due to depletion of cellular
components [75]. Autophagy can limit tumorigenesis through the elimination of
damaged proteins and dysfunctional organelles thus mitigating oxidative stress and
genomic instability that is characteristic of cancer cells [76]. These are, in general,
arguments that support the notion that autophagy should be promoted and not
inhibited in cancer cells.
In contrast, it is becoming clear that in later stages of tumor progression,
autophagy’s role as a garbage disposal and recycling plant enhance the survival of
cancer cells and engender therapeutic resistance to cancer therapies. In established
tumors, genetic suppression of autophagy significantly diminishes the ability of
cancer cells to withstand starvation and increases cell death in response to metabolic
stress [35].
In mice, homozygous deletion of Beclin 1 results in embryonic lethality, whereas
monoallelic loss of Becn1 (Becn1 +/−) leads to spontaneous tumorigenesis, iden-
tifying Beclin 1 as a haploinsufficient tumor suppressor protein [38,77]. BECN1 is
monoallelically deleted in 40–75% of sporadic human breast cancers and ovarian
cancers [78,79]. To date, Becn1 heterozygote mice are the only “autophagy-deficient”
mice that develop spontaneous malignant tumors. It is important to understand that
Becn1 heterozygote mice also have concurrently low levels of the tumor suppres-
sor p53, due to their common regulation by specific deubiquitinases [80]. It is also
important to note that the retained allele of Becn1 in Becn1 +/− cells is always wild
 
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type, and the protein expression of Beclin in Becn1 +/− cells can be equal to Becn1
+/+ cells if cells are stressed. Therefore, the relative “autophagy deficiency of the
Becn1 +/− model needs to be evaluated further. It is likely for this reason and others
that many studies have instead used genetic inhibition of Atg7 or Atg5 to render cells
“autophagy deficient.” Given the possibility of a noncanonical autophagy program
that is independent of Beclin, ATG5 or ATG7, there is concern that no model system
involving proliferating cells can be truly and completely autophagy deficient.
Despite its role in preventing early tumor development, once tumors are estab-
lished, tumor cell autophagy-related survival function can lead to tumor dormancy,
progression, and therapeutic resistance [81]. Cancer cells have high metabolic
demands due to increased cellular proliferation and a challenging microenvironment.
One of the first demonstrations of autophagy’s potential role as a cell survival mech-
anism in cancer cells came from studying the effects of growth factor withdrawal
in growth factor–dependent cancer cells defective in the apoptotic proteins Bax
and Bak. Growth factor withdrawal in Bax/Bak-deficient cells resulted in growth
arrest and cell death, but even after many weeks in culture, a subpopulation of cells
survived that were highly autophagic. If the growth factor was added back to the
medium, these cells would resume exponential growth. If the lysosomal inhibitor
chloroquine was added to cells undergoing autophagy, the cells would die providing
clear evidence that autophagy was promoting survival in these deprived cells [34].
These findings have been explored further in animal models. It is becoming
clear that cancers driven by mutations in the MAPK pathway are often “ad-
dicted” to autophagy. Cancer cells need high levels of autophagy to maintain
mitochondrial function for tumorigenesis and tumor growth in Kras-driven [82]
and BrafV600E-induced [83,84] non-small-cell lung cancer mouse models. Lack
of Atg5 or Atg7 in Kras-driven pancreatic cancer cells causes accumulation of
dysfunctional mitochondria upon nutrient starvation, impairing tumor growth.
Autophagy deficiency also impairs the tumorigenicity of KRAS-transformed cells
and human cancer cell lines with KRAS activation [82,85,86]. Similarly, autophagy
can oppose p53-mediated tumor suppression function and promote breast cancer
induced by partner and localizer of Brca2 (Palb2) loss [87]. Increased basal levels of
autophagy were detected in human pancreatic cancer cell lines and tumor specimens,
and autophagy can promote tumor cell growth by maintaining cellular energy
production. Inhibition of autophagy resulted in tumor regression and extended the
life span of nude mice harboring p53 mutant pancreatic xenografts [88]. In most of
these mouse model studies across tumor types, lack of Atg7 or Atg5 accelerated early
growth of premalignant cells but prevented or delayed the growth of aggressive and
metastatic late stage tumors (Table 13.2). The recurring theme in these studies is that
autophagy can be exploited by cancer cells to generate nutrients and energy during
various stresses, including the stress of maintaining a rapidly proliferative cancer.
13.4 CLINICAL STUDIES ON AUTOPHAGY’S DUAL ROLE IN
TUMORIGENESIS
Measurements of the expression of autophagy genes in cancer tissues and correlation
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on the role of autophagy in cancer. Numerous studies have looked at Beclin 1
expression and have come to conflicting views on the prognostic significance of
Beclin 1 expression in cancer tissues [92–96]. One study identified elevated levels
of LC3 puncta in the vast majority of advanced solid tumors [97]. High levels
of autophagy in melanoma tumors predicted poor response to chemotherapy and
shortened survival in melanoma [98]. On the other hand, one study has found that
promoter methylation and silencing of ATG5 was associated with more aggressive
features of primary melanoma [99], supporting the role of autophagy as a tumor
suppressor mechanism in early stages of malignancy. Additional work understanding
the significance of autophagy levels in normal, premalignant, and tumor tissue as
potential prognostic and predictive markers are sorely needed, but few methods that
can be used to measure autophagy are available for clinical specimens [100].
13.5 MOUSE MODELS PROVIDE THE RATIONALE FOR AUTOPHAGY
MODULATION IN THE CONTEXT OF CANCER THERAPY
The impact of autophagy inhibition, through RNAi targeting of essential autophagy
genes, or pharmacological inhibitors, on cancer therapy has been evaluated in
different tumor models, resulting in contrasting outcomes: prosurvival or prodeath,
depending on the specific context. Broadly speaking, silencing of some essential
autophagy genes, such as ATG3, ATG4B, ATG5, Atg6/BECN1, ATG7, ATG10, and
ATG12 has been found to increase cell death to a wide spectrum of therapeutic
stresses (detailed in Table 13.3). These data indicate that autophagy is generally
a survival mechanism for cancer cells especially for advanced tumor cells in
response to inherent stress or treatment-associated genotoxic and metabolic stress
[137,138], and considered a mechanism for acquired resistance of tumor cells to
chemotherapeutic agents. These studies have largely been conducted in vitro and
immunodeficient mouse models (xenograft tumors in nude mice). While most of
these studies have found that genetic or pharmacological autophagy inhibition
augments anticancer properties of a wide range of anticancer agents, more work
is needed in immunocompetent mouse models. At least one study has found that
genetic autophagy inhibition with Atg7 knockdown blunted antitumor immunity
elicited by chemotherapy in a syngeneic mouse flank tumor model [139]. In this
paper, the investigators found a role for autophagy in releasing ATP from damaged
cells, which serves as a key chemoattractant for cytotoxic T cells to enter the
tumor microenvironment. If this is true, then the therapeutic strategy that should
be pursued to augment existing cancer therapies is concurrent autophagy induction
rather than autophagy inhibition. Other groups have found the opposite role for
autophagy in tumor immunity. One group found that hypoxia-induced autophagy
can increase the granzyme B degradation thus alleviating natural killer cell-mediated
cell killing in breast cancer cell both in vitro and in vivo, while autophagy inhibition
by suppressing Beclin 1 can restore granzyme B level in vitro and induce tumor
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13.6 MULTIPLE DRUGGABLE TARGETS IN THE AUTOPHAGY
PATHWAY
There are multiple druggable targets in the autophagy pathways [141]. Autophagy
initiation is controlled by ULK1 complex, consisting of ULK1 or ULK2, FIP200,
ATG101, and ATG13. Activated mTORC1 inhibits autophagy by causing hyperphos-
phorylation of ATG13, reducing its interaction with ATG1/ULK1, and by controlling
phosphorylation of autophagy effectors such as the Beclin 1–Vps34 complex. The
kinase domain of ULK1 and ULK2 could be attractive targets for future drug devel-
opment. Proteomic studies investigating how inhibition of the mTORC1 pathway
affects the global features of autophagy control showed no large-scale changes in core
conjugation, lipid kinase, and recycling complexes. This finding implies that post-
translational modifications may be involved in AV accumulation when the autophagy
pathway is activated and may be a potential means to control autophagy [142].
AV nucleation represents a second major autophagy control point, involving
Vps34 and interacting partners Beclin 1 and p150. Beclin has become a candidate
for drug development for both autophagy inhibitors and autophagy promoters. As
described below, the specific and potent autophagy inhibitor (Spautin, described
below) was found to impact Beclin levels [80]. A novel fusion peptide called
tat-Beclin 1 was found to specifically activate Beclin [143,144] and could eventually
serve as a new class of specific autophagy inducers. Vps34 is a class III lipid
kinase, and existing chemical platforms have already identified numerous candidate
inhibitors of Vps34. For example, drugs that interfere with recruitment of Vps34
to membranes, including wortmannin and 3-methyladenine, are powerful proximal
inhibitors of autophagy.
ATG8 family proteins are central coordinators of proper AV membrane develop-
ment [145] and maturation and represent a third autophagy control point. LC3, the
most widely studied ATG8 family member, is cleaved by ATG4 and conjugated to PE
by an ATG7- and ATG3-dependent activation and transfer cascade. ATG4 is a cys-
teine protease, and efforts are underway to develop peptidomimetic inhibitors of its
protease activity [146,147]. ATG7 is an E2-like ligase, and at least one pharmaceu-
tical company is developing an ATG7 inhibitor [147]. LC3-PE conjugation is very
important for AV elongation and maturation including the cargo recruitment by the
cargo adaptor proteins, such as p62, Nbr1, and Nix, and the transfer of AV cargo
to lysosomes.
The main concern with inhibiting the targets stated earlier (ULK1, ATG7, and
ATG4) is that components of autophagy exhibit a high degree of redundancy. There
are five ULK homologues and four ATG4 homologues [148]. While ATG7 has no
genetic redundancy, the description of a noncanonical autophagy program [32] in
Atg7 −/− and Atg5 −/− cells suggests that autophagy is such a core function within
the cell, that in the absence of canonical autophagy signaling, the cell may recruit
other components of the endovesicular system to serve as the cargo collectors and
delivery system needed to maintain a clean intracellular environment.
Delivery and degradation of AV contents represents a fourth autophagy control
point. Because AVs and lysosomes move along microtubules, drugs that disrupt
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microtubules, such as nocodazole, colchicines, taxanes, and vinca alkaloids, inhibit
AV fusion with lysosomes, resulting in AV accumulation. Rab GTPases likely
play a role in vesicle maturation and fusion with lysosomes, but currently there
are no known chemical approaches that have provided clinical leads to targeting
Rab GTPases effectively. Lysosomes are acidic organelles, with their digesting
hydrolases dependent on low pH. Consequently, agents such as bafilomycin A1
or chloroquine derivatives, which disrupt the vacuolar H-ATPase responsible for
acidifying lysosomes, block autophagy in its final step, resulting in the accumulation
of AVs. In the following section, the available tool compounds to inhibit autophagy
in the laboratory are reviewed.
13.7 OVERVIEW OF PRECLINICAL AUTOPHAGY INHIBITORS AND
EVIDENCE SUPPORTING COMBINATIONWITH EXISTING AND NEW
ANTICANCER AGENTS
In laboratory studies, the inhibition of autophagy can be accomplished with a
number of tool compounds including 3-methyladenine (3-MA), selective and potent
autophagy inhibitor 1 (Spautin-1), bafilomycin A (Baf A) and CQ/HCQ. Table 13.3
provides a partial list of preclinical studies that demonstrate that chemical autophagy
inhibition enhances the efficacy of anticancer therapy. The literature has exploded
with these reports, so it is not possible to review every study in detail. What is
remarkable is that the synergy between autophagy inhibitors and anticancer agents
spans a wide variety of histotypes and holds true with a wide variety of anticancer
agents including alkylating agents, tyrosine kinase inhibitors, protease inhibitors,
HDAC inhibitors, angiogenesis inhibitors, proteasome inhibitor, and hormonal
therapy. One area of active research is to understand the mechanistic underpinnings
of how some of the synergistic combinations manifest. For instance, melanomas
that contains a point mutation in the BRAF proto-oncogene that encodes for BRAF
V600E is well known for resistance to chemotherapies and immunomodulating
therapies. PLX4032 is a selective BRAF inhibitor and, in clinical trials, has consis-
tently induced tumor responses in the majority of patients with BRAF V600E mutant
melanoma. However, duration of response has been limited due to the development
of acquired resistance. From our recent study, we found that after PLX4032 treatment
in melanoma cell lines, mutant BRAF bound the ER stress gatekeeper GRP78,
and the disassociation of GRP78 from the PKR-like ER-kinase (PERK) promoted
a PERK-dependent ER stress response. The ER stress subsequently activated
autophagy, which is responsible for survival and drug resistance. Combined BRAF
and autophagy inhibition promoted tumor regression in BRAFi-resistant xenografts.
Our data provide a rationale for combinational approaches targeting the resistance
pathway [123].
Understanding the mechanistic underpinnings of how cancer therapies initi-
ate autophagy provides a roadmap to multiple possible cancer drug-autophagy
inhibitor combinations. Much like our study in BRAF mutant melanoma, most of
the autophagy inhibition studies carried out in Table 13.3 use a lysosomotropic




because this approach is the most immediately translatable. One key point that needs
further research is needed to determine if proximal autophagy inhibition would be
more or less effective than distal autophagy inhibition. Toward the end, we next
review the characteristics and proximal autophagy inhibitors briefly and provide a
more extensive historical and mechanistic perspective on quinolines.
13.8 PROXIMAL AUTOPHAGY INHIBITORS
3-MA is a proximal autophagy inhibitor, which can prevent autophagic vesicle from
forming by inhibiting multiple forms of PI3 kinases includingVps34, a key enzyme
of the Beclin 1–Vps34 complex involved in the initiation of autophagosome for-
mation [149]. Preclinical studies have shown that 3-MA when given at millimolar
concentrations can enhance killing of cancer cells when combined with a variety of
therapeutic stresses, including alkylating agents, tyrosine kinase inhibitors, hormone
therapy, TNF-related apoptosis-inducing ligand (TRAIL), and photodynamic therapy
(Table 13.3). Given the high concentrations needed for 3-MA to block autophagy and
the promiscuity of the compound at these concentrations it is unlikely that a 3-MA
derivative will ever be suitable for in vivo or clinical testing.
Spautin-1 is a newly developed small-molecule inhibitor of autophagy [80],
which can promote the degradation of Beclin 1–Vps34 complexes through inhibiting
the ubiquitin-specific peptidases (USP)10 and USP13 that are responsible for
preventing Beclin 1 from undergoing proteasomal degradation. By inhibiting these
USPs, Spautin, therefore, induces degradation of beclin and thus inhibits autophagy.
Spautin-1 did not affect cell growth and survival of human breast cancer Bcap-37
cells under normal culture conditions but enhanced the cell death upon starvation.
Similarly, spautin-1 could induce the death of the ovarian cancer ES-2 and OVCAR-3
cells in glucose-free condition [80]. Another study shows that in confluent conditions,
in subclones of colon cancer cell line HCT16 engineered to harbor all 17 different
cancer-associated mutant p53, spautin-1 treatment increased the degradation of the
mutant p53 protein through increased chaperon-mediated autophagy (CMA) activity
that was produced by effective inhibition of macroautophagy. In addition, depletion
of mutant p53 expression due to macroautophagy inhibition sensitizes the death of
dormant cancer cells under nonproliferating conditions [150]. Spautin-1 selectively
induced cell death of mutant p53-expressing cancer cell lines under confluency but
not in dispersed growth conditions. In complete medium with unstressed cells, no or
little effect of spautin-1 on cell survival was detected in wild-type p53 or p53-null
cancer cells. Recently, one study has shown that Spautin can enhance tyrosine kinase
inhibitor imatinib-induced cell apoptosis in chronic myeloid leukemia [151].
13.9 QUINOLINES: FROM ANTIMALARIALS TO PROTOTYPICAL
DISTAL AUTOPHAGY INHIBITORS
Chloroquine and related quinolines, the prototypical lysosomotropic autophagy
inhibitors, were developed primarily as antimalarial drugs. Significant development
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of quinolines has taken place and continues to take place in the context of treating
malaria. Observations that many quinoline antimalarials inhibit autophagy in
mammalian cells have prompted development of the use of quinolines for treatment
of cancer and investigation of the role of autophagy in other processes.
Development of quinoline antimalarials began in earnest with the synthesis of
chloroquine in 1934. After the First World War, chloroquine, which was inexpensive
and highly effective, became the dominant monotherapy used against malaria [152].
However, resistance to chloroquine was first reported in 1961 (reviewed in
Ref. [153]) and quinoline resistance in general has become pervasive in Plasmodium
falciparum [154,155].
The most cited mechanism of action of quinolines in regard to their antimalarial
properties is that quinolines prevent the plasmodium species from successfully
sequestering hemin, a toxic byproduct of the organism’s digestion of hemoglobin. In
the erythrocytic stage of its life cycle, plasmodium species phagocytize hemoglobin,
which is delivered intracellularly to its acidic lysosome-like digestive vacuole,
where hemoglobin undergoes proteolytical degradation liberating amino acids.
Amino acids produced from the breakdown of hemoglobin are used as food, while
the iron-containing free hemin (protoporphyrin IX) resulting from this breakdown
poses a threat to the organism. Free hemin is prone to catalyzing Fenton reactions
that generate reactive oxygen species, which in turn causes lipid peroxidation
and bursting of the food vacuole [156]. Damage to the organism is prevented by
the biomineralization of the abundant hemin molecules into a harmless insoluble
crystal, hemozoin. Chloroquine and other quinolines are thought to interfere with
this biomineralization process by interacting directly with free hemin, preventing
sequestration of hemin in this crystal, leaving toxic quantities of hemin in solu-
tion [157]. While interference with hemin sequestration is considered to be the
canonical mechanism of action of aminoquinolines, the precise detailed mechanisms
by which quinolines inhibit hemin polymerization and promote the formation of
reactive oxygen species remains unsettled [158–160].
For decades, quinolines have been clinically useful for the treatment of malaria,
but since the 1960s [154], single agent quinolines for the treatment of malaria has
fallen out of favor due to emergence of plasmodium strains that have mutations in the
ABC-like drug efflux pump pfCRT (P. falciparum chloroquine resistance transporter)
and pfMDR (P. falciparummultidrug resistance transporter) [155,161]. Both of these
transporters remove quinolines from the organism’s digestive vacuole, themain site of
quinoline drug action. No other mutations in the parasite genome have been identified
definitely to explain the resistance to quinolines.
One byproduct of the extensive investigation of the use of quinolines in malaria
has been the investigation of the action of chloroquine on the vacuolar system
in mammalian cells as it was beginning to be described in the 1960s through the
1970s [162,163]. Chloroquine has been used in mammalian cell culture experiments
to improve DNA transfection efficiency [164], enhance antigen presentation for
immunology research [165], and increase the expression of specific proteins that
may be degraded through autophagy. For each of these experimental purposes,
chloroquine’s effects on autophagy and its intersection with each of the intended
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consequences was likely only partially appreciated, though the connection between
chloroquine and mammalian autophagy was made by Fedorko all the way back in
1967 [166]. While an autophagy-like pathway with multiple conserved autophagy
proteins (ATGs and others) exists in malaria [159], the common mechanism between
chloroquine’s activities in malaria and chloroquine’s ability to inhibit autophagy in
mammalian cells has not been established.
A definingmechanism of aminoquinolines is their ability to be concentrated within
the lysosome by a process known as lysosomotropism or proton trapping [163,167].
This process is general, and any weak base that is hydrophobic at cytosolic pH and
capable of diffusing into the lysosome will become concentrated there according to
its permeability, pKa, and the pHs of the two compartments. Chloroquine can be
concentrated several hundred- to several thousand-fold in the lysosome or digestive
vacuole [168–170] and the lysosomal compartment can represent the bulk of the cell’s
drug burden [171]. This partitioning can sequester compounds away from their site
of action, as with daunorubicin [172], and more generally the effect is exploited by
multidrug-resistant cancer cells to sequester toxic chemotherapeutics [173]. Alterna-
tively, if a compound not normally sequestered in the lysosome is appendedwith basic
amine groups, the compound will then be trapped within the lysosome [167,174].
Together, these effects confer the ability to target a compound to or away from the
lysosome, or render a compound unable to reach its intended target. Because of the
pivotal role of autophagy in multiple broadly diverse disorders and processes, espe-
cially cancer, and the measured successes of current upstream autophagy inhibitors,
the development of inhibitors that specifically target the final and indispensable stage
of autophagy – the lysosome – development of more effective lysosomal autophagy
inhibitors is critical.
Though quinolines have been thoroughly investigated in malaria, less has been
done in the context of understanding their mechanism of action as an autophagy
inhibitor in cancer cells. Due to their availability and favorable pharmacology, numer-
ous preclinical trials have established chloroquine and hydroxychloroquine as the
first potential autophagy inhibitors that should be tested in clinical trials. Hydroxy-
chloroquine, because of its safety and history of use in humans for treating maladies
ranging from malaria to rheumatoid arthritis, has been the focus of many ongoing
oncology clinical trials (reviewed in Section 13.10). However, despite the fact that
micromolar concentrations of chloroquine are the most reproducible means of mod-
ulating autophagy in vitro, concerns have been raised that clinically achieving micro-
molar concentrations with currently available quinolines may prove to be difficult
[175,176]. For this reason, more potent and specific inhibitors of autophagy that target
the lysosome are sorely needed.
13.10 SUMMARY FOR THE CLINICAL TRIALS FOR CQ/HCQ
Currently there are six trials involving HCQ combinations, five in human cancer
patients and one on dog cancer patients, that have completed enrollment and have
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been no recurrent dose-limiting toxicities identified and the maximal administered
dose of 1200mg HCQ per day in combination with different anticancer agents was
easily achieved. In most trials, grade 2 anorexia, nausea, fatigue, and diarrhea were
the most common side effects attributable to high-dose HCQ. Some of these clinical
trials have produced encouraging signs of activity [177–180]. The most encouraging
HCQ trial as far as antitumor activity is a phase I trial of temsirolimus and HCQ in
advanced melanoma patients. We have observed a 74% stable disease rate in contrast
to a 0% stable disease rate observed with temsirolimus alone in previous phase II
trial [180]. Some of the conclusions that can be drawn from this series of papers are
outlined as follows.
Autophagy modulation: These six clinical trials are the first deliberate attempt
to modulate autophagy therapeutically on cancer or any disease. Each trial
included a pharmacodynamic assay to determine if autophagy was indeed
modulated by an HCQ-containing therapeutic regimen. The conclusion was
that HCQ exposure in patients dictated whether or not autophagy inhibition
could be detected in patient tissues using mainly an electron microscopy-based
assay. Only patients with high HCQ exposure had detectable accumulation of
autophagic vesicles. Even in these patients, the degree of therapy-associated
autophagic vesicle accumulation was one- to twofold higher than the baseline
sample. These studies indicate that HCQ can modulate autophagy in patients,
and it is likely that more potent inhibitors are needed to block autophagy more
profoundly.
Dosing and concentration achieved: The highest concentration of HCQ achieved
in the blood was roughly 5000 ng/mL, which translates into 11.5 μM HCQ.
Concentrations in tumor may be 10- to 100-fold much higher. In all clinical
trials, HCQ concentration range is from 200 to 1200mg per day. In the dog
lymphoma trial [181], concentrations of HCQwere100-fold higher in the tumor
than in the plasma. This sort of tissue concentration may be critical if HCQ is
to have any future role in anticancer therapy.
Safety: The safety of adding HCQ to cancer regimens was established in mul-
tiple combinations and multiple malignancies. Further development of HCQ
combinations is now possible, and novel autophagy inhibitors can enter clini-
cal trials without an a priori assumption that blocking autophagy is too toxic.
Some HCQ combinations produced dose-limiting toxicities while others did
not. For instance, low-dose temozolomide without interruption [182] produced
more toxicity than high-dose temozolomidewith scheduled drug holidays [180]
when combined with HCQ.
Efficacy: While clinical responses were not a primary endpoint in some the stud-
ies, there were a number of remarkable clinical responses and prolonged stable
disease in patients with refractory cancers includingmyeloma,melanoma, renal
cell carcinoma, and colon cancer. These results suggest that autophagy inhibi-
tion could be an active therapeutic approach in a number of cancers. Future
preclinical studies should focus on identifying biomarkers that can predict sen-
sitivity to autophagy inhibitors.
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In a phase III randomized study of carmustine, radiation and low-dose chloro-
quine, (NCT00224978), CQ at 150 mg once daily combined with chemoradiation
improved the median survival after surgery from 11 months (SOC alone) to 24
months [183]. These results were not statistically significant but were nevertheless
provocative. However, in the adult brain tumor consortium phase I/II trial of temo-
zolomide, radiation, and hydroxychloroquine, no significant improvement in survival
was observed compared to historical controls. The lack of a survival benefit in our trial
may be related to lack of effective and consistent autophagy inhibition in this popu-
lation, as the dose of HCQ was lower, and the pharmacokinetic variability was high.
Biomarkers of autophagymodulation:Markers of autophagy inhibition and vesicle
accumulation were consistently more pronounced and observed in tumor tissue than
in PBMC. Therefore, EM-based measurement of autophagy in patient samples is fea-
sible in a clinical research setting. However, better markers of tumor cell autophagy
that can be clinically translated are sorely needed because following autophagy in eas-
ily accessible surrogate tissue does not fully reflect tumor autophagy. A significant
pharmacokinetic–pharmacodynamic interaction was discovered in multiple trials that
correlated HCQ exposure with autophagic vesicle accumulation in peripheral blood
mononuclear cells. The degree of autophagy inhibition (AV accumulation by EM)
achieved inmost patients was usually one- to twofold over baseline. Therefore, we are
intrigued to speculate that more potent autophagy inhibitors may produce more sub-
stantial clinical benefit. The pharmacokinetics of HCQ in cancer patients taking other
cancer drugs demonstrated a higher degree of variability across studies than in pre-
vious studies conducted for single agent hydroxychloroquine in rheumatoid arthritis
patients. The pharmacology of HCQ could hamper its utility as an effective anticancer
agent and improved pharmacology could be a focus for future autophagy inhibitors.
Selection of patients: As is typical for a first-in-class inhibitor, the patients that par-
ticipated in these first autophagy modulation studies were not preselected based on
a biomarker of sensitivity. If an enriched patient population within a specific malig-
nancy or based on a specific biomarker could be identified, and a significant incremen-
tal benefit of adding HCQ to existing cancer therapies is found in this subpopulation,
incorporation of this cheap well-studied drug into the cancer pharmacopeia could
have a remarkable impact on the burden of cancer care. This is especially true in
the developing world, where cancer rates are exploding, and the expense of cancer
therapy is poised to bankrupt economies.
13.11 DEVELOPING MORE POTENT ANTICANCER AUTOPHAGY
INHIBITORS
While other groups are developing potent and specific inhibitors of upstream compo-
nents of autophagy (as described earlier), further efforts to develop clinically useful
drugs that more effectively impair lysosomal function and therefore autophagy is a
focus of intense research. An underexploited avenue of elaboration on the quinoline
structure is the use of polyvalent quinolines that include two or more quinoline rings
with varying linkage, orientation, and substituents. The use of doubling or tripling
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structural motifs offers multiple advantages [184]. In the case of a target with multi-
ple binding sites, multimerismmay allowmultiple sites to be boundwith a single drug
molecule, promoting a cooperative like binding action, but within the same molecule,
which by virtue of multimerism is already present in close proximity. In the case of a
target that is undefined, the use of a flexible linker can allow the two active moieties
to conform the target without specific knowledge of how they should be positioned.
In the malarial literature, examples of bisquinolines already exist and have showed
some improvement over the activities of chloroquine in malaria [185–188]; however,
no dimeric chloroquines have been developed for clinical use.
Recently, our group synthesized a series of dimeric chloroquine analogues to eval-
uate the basic requirements for inhibiting autophagy inmammalian cancer cells with a
dimeric chloroquinemolecule (Figure 13.2)[189]. Compounds synthesized were cho-
sen to evaluate the activity of dimeric versus monomeric chloroquine compounds, the
importance of the 4-chloro substituent, and the effect of the linker joining the quino-
line rings, with HCQ serving as a reference compound to be improved upon. Lys01
was chosen as the first prototype to be investigated. Lys02 was designed to evaluate
the linker present in Lys02 but not be dimeric. Lys03 was chosen to confirm the neces-
sity of the 4-chloro group to the bisquinoline scaffold. Lys04 was chosen to evaluate


























Figure 13.2 Chloroquine and Lys-series autophagy inhibitors.
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When initially evaluated for ability to inhibit autophagy vial LC3-I/II immunoblot-
ting and proliferation viaMTT, all of the compounds (including hydroxychloroquine)
were active at some concentration. However, Lys01, which combined dimeric
4-chloroquinoline groups linked by an aminoalkyl group, was significantly more
active than all of the other compounds at inhibiting autophagy and proliferation in
cancer cells. Lys01 showed an approximately 10-fold improvement in the ability to
induce GFP-LC3 puncta formation than hydroxychloroquine. That the compound
was a distal autophagy inhibitor through the lysosome was confirmed using electron
microscopy and the bafilomycin clamp assay, and its ability to deacidify the lysosome
and cause lysosomal membrane permeabilization was confirmed using LysoTracker
red and acridine orange. Treatment of mouse xenografts with the soluble Lys01
Tris-HCl salt, Lys05 produced significantly greater antitumor activity compared to
hydroxychloroquine and significant reduction in tumor growth at doses as low as
10mg/kg over 14 days. In both treated tumor and cell fractions, Lys05 showed a
significantly greater ability to concentrate in the lysosome. Higher doses of 80mg/kg
induced toxicity in the form of apparent colonic pseudo-obstruction and Paneth cell
granule dysmorphia, a symptom set characteristic of Crohn’s disease patients with
inactivating polymorphisms in the essential upstream autophagy gene ATG16L1,
as well as mice hypomorphic for Atg16L1mice [190,191]. That the phenotype of
Lys05 treatment resembles the phenotype of a deficiency of an essential autophagy
protein [192] shows that Lyso5 has a profound effect on the autophagic system at
and beyond the lysosome.
Lys05 has shown that dimeric chloroquine compounds can have significantly
improved autophagy inhibiting activity in cancer than the clinically available
autophagy inhibitors and that there is significant room for the development of these
compounds. Mechanistic understanding of quinoline action across kingdoms will
continue facilitate understanding of the biology quinolines and their interaction with
the endovesicular system. Further exploitation of the structural diversity of dimeric
quinolines and allow for rationally designed and specifically targeted anticancer
autophagy inhibitors.
13.12 SUMMARY, CONCLUSION, AND FUTURE DIRECTIONS
Drug resistance has been the major barrier for the treatment of metastatic cancers,
and autophagy has emerged as a drug-resistance mechanism in clinic cancer therapies
[123,141]. Autophagy inhibition through genetic modification or pharmacological
inhibitors has been shown to sensitize cancer cells to different treatment modalities
in both preclinical animal models and clinic trials. However, the role autophagy
plays in cancer is complex and context-specific, our understanding of autophagy
in tumorigenesis and in cancer therapy is still incomplete and some key questions
remained unsolved.
Most cancer therapeutics induce autophagy, but the consequence of autophagy
induction is not very clear, and the sensitivity of tumor cells in response to autophagy
inhibition may depend on the genetic background and epigenetic modification.
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A better understanding of the mechanisms of autophagy in tumorigenesis and how
autophagy is regulated in tumor cells and inducted in cancer therapy can help identify
which tumor types are more “addicted” to autophagy, and more accurate and infor-
mative biomarkers are wanted to properly monitor the tumor autophagy status and
identify patients who can benefit from the autophagy inhibition treatment, and deter-
mine which drugs to combine with autophagy inhibition. More efforts are needed to
understand the following aspects to better guide the autophagy inhibition in clinical
cancer treatment:
1. The complex cross talk between autophagy and apoptosis, and other signals
or pathways. The interplay between apoptosis and autophagy is quite compli-
cated [193] and has not beenwell elucidated.Many signaling pathways induced
by cell-intrinsic stress regulate both autophagy and apoptosis. For example,
p53 can regulate both apoptosis and autophagy, and autophagy inhibition can
have both proapoptotic and antiapoptotic effect, and Bcl-2 family members
are dual regulators of apoptosis and autophagy, Bcl-2, Bcl-XL, Bcl-w, and
Mcl-1 can not only inhibit apoptosis but also inhibit autophagy, while proapop-
totic BH3-only proteins such as BNIP3, Bad, Noxa, and Puma can induce
autophagy [194]. Autophagy primarily acts as a protective mechanism that
may prevent cell death. There are complicated interaction between regulatory
elements of autophagy and apoptosis, for example, the inhibitory interaction
between BCL-2 and Beclin 1 and the interaction between LC3B and Fas. Sim-
ilarly, better understanding of the cross talk between autophagy and ER stress,
and the autophagy and DNA repair is also very helpful to target autophagy
inhibition in cancer treatment.
2. The interaction of autophagy with immune response to cancer. A large amount
of evidence has shown autophagy can profoundly influence the immune sys-
tems [195]. It is clear that autophagy plays a pivotal role in both the innate
immune responses and adaptive immune responses such as antigen presentation
and lymphocyte development [43,196–199]. Currently, most experiments have
generally been performed in xenograft models, thereby eliminating the involve-
ment of the immune system, while immunosurveillance plays very critical role
in cancer prevention and therapy, and it may also play a critical role in determin-
ing effectiveness of autophagy inhibition in chemosensitization or radiosensi-
tization. Autophagy can either increase anticancer immune responses induced
by chemotherapeutic agents in mice [139] or decrease tumor cell susceptibility
to NK cell-mediated lysis under hypoxia [140]. Moreover, chloroquine treat-
ment improves CD8 immunity during vaccination [165]. Many unanswered
questions remain to be tackled in the field of autophagy and immunity.
3. To develop specific and potent autophagy inhibitors. Currently, there are no
clinically available specific autophagy inhibitors. All preclinical reports and
clinical trials investigating pharmacological inhibition of autophagy have
used chloroquine or hydroxychloroquine, which interfere with lysosomal
function and block autophagy at a later stage. The capacity for sensitization
by chloroquine appears to be quite wide-ranging, with dramatic effects for
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some drugs/tumor models and modest or minimal effects in others. The
pharmacology of HCQ could hamper its utility as an effective anticancer agent
and improved pharmacology could be a focus for future autophagy inhibitors.
More specific and potent autophagy inhibitors are critical for the clinical
application of autophagy inhibition. However, autophagy inhibitors may be
toxic to normal tissue because of the autophagy’s cytoprotective role. There-
fore, the side-effect profile of these compounds needs to be closely monitored.
Besides inhibiting autophagy, CQ and HCQ may affect the tumor/cancer
therapy through other mechanisms. It will be important to establish whether
any anticancer activity of HCQ is due to autophagy impairment, as it may act
by other mechanisms [200].
4. Identify better markers of tumor autophagy and biomarkers for patients’ selec-
tion. Accurate and informative cancer biomarkers hold significant promise
for improvements in the selection of the most effective therapeutic strategies.
Better markers of tumor cell autophagy that can be clinically translated are
sorely needed, because currently although Beclin 1 by immunohistochemistry
as a measure of autophagy competence, and the measurement of AV number
directly by electron microscopy, LC3, and p62 levels as markers of autophagy
modulation, no autophagy marker fully reflects tumor autophagy. We need
better ways to assess and monitor autophagy in human patient samples
to determine which tumors are addicted to autophagy, and which tumors
will respond favorably to autophagy inhibitors. Future preclinical studies
should focus on identifying markers that can predict sensitivity to autophagy
inhibitors and best drugs to combine with autophagy inhibition. Proper
biomarkers are needed to identify the best subsets of patients can most benefit
from a specific treatment.
13.13 IN SUMMARY
Autophagy can both suppress tumorigenesis and promote the tumor cell growth in
established cancers. More studies are needed to better understand how autophagy is
regulated in tumor cells, the cross talk between autophagy and apoptosis, autophagy
and ER stress, autophagy and immune systems, and the specific mechanism by which
autophagy confers treatment resistance. An increased understanding of autophagy in
cancer is important for identifying better autophagy biomarker to detect which types
of tumor to be treated combined with autophagy intervention, which group of patients
can be most benefited from autophagy inhibition and developing most specific and
potent autophagy inhibitors, and eventually benefit the patients with the treatment.
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14.1 INTRODUCTION
Autophagy is a self-eating process by which long-lived proteins and organelles within
cells are delivered to lysosomes, ultimately degraded and recycled. This evolution-
arily conserved process plays a critical role in preserving cellular homeostasis and
maintaining a balance between synthesis and degradation/recycling under conditions
of changing nutrition or stress. At least three forms of autophagy have been identified,
including macroautophagy, microautophagy, and chaperone-mediated autophagy
(CMA). Among these subtypes, macroautophagy is the best characterized form
and the process involves autophagosomal sequestration of targets, which are then
delivered to lysosomes for degradation. Discovery of core autophagy-related genes
(Atgs) initiated a molecular-genetic era for autophagy research and a rapid expansion
of knowledge about autophagy. Many Atgs are involved in the multiple steps of
autophagosome formation, which include the initiation of a phagophore, elongation,
and closure of this structure, followed by the final maturation step, fusion of the
autophagosome with lysosomes. Current data suggest that membranes from multiple
organelle sources potentially contribute to autophagosome biogenesis, including
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mitochondria, endoplasmic reticulum, Golgi, plasma membrane, and nucleus. A
modest basal level of autophagy occurs under normal physiological conditions, but
its rate can be modulated by various stimuli. The best characterized mechanism of
autophagy regulation is through the canonical mTOR signaling pathways. When
mTOR1 activity is downregulated under conditions of nutrient depletion, autophagy
is induced by phosphorylation and activation of the ULK complex that initiates
phagophore formation. Additional pathways that act independently of mTOR
may also play a critical role in regulating autophagy. For instance, intracytosolic
calcium, cAMP, and 1,4,5-inositol trisphosphate (IP3) have been shown to modulate
autophagy [1,2]. Mounting evidence has revealed that autophagy is involved in
various physiological processes, including regulating nutrient supply essential for
survival and maintaining quality control of intracellular proteins and organelles. Mice
that lack autophagic activity due to a knockout of various Atgs die either in utero
or within 24 h after birth [3–5]. The vital role of constitutive autophagy maintaining
cellular/tissue homeostasis is supported by various conditional knockout studies. For
example, mice with a liver-specific knockout of Atg7 exhibit various liver lesions,
including hepatomegaly and hepatocyte hypertrophy [4], and mice lacking Atg5 in
cardiac muscle display cardiac hypertrophy and left ventricular dilation [6].
14.2 AUTOPHAGY IMPAIRMENT AND DISEASES
The link between autophagy and human disease was first demonstrated in studies
showing that decreased expression of beclin 1 (mammalian homolog of year Atg6)
contributes to the development or progression of human malignancies [7]. Recent
efforts have revealed the role of autophagy dysfunction in additional pathological
conditions such as aging and other aging-related diseases including neurodegenera-
tive disorders, metabolic diseases, cardiomyopathy, and age-related macular degen-
eration. Reduced degradation of proteins and organelles may contribute to accumu-
lation of damaged proteins and organelles and to the aging process. Both macroau-
tophagy and CMA become markedly less efficient during the aging process, which
contributes to malfunction of many biological processes [8] and may accelerate cell
aging itself [9]. Decreased hepatic autophagy has been observed in both genetic and
dietary mouse models of obesity and insulin resistance [10]. Surprisingly, restor-
ing autophagy by increasing Atg7 expression alone can counteract insulin resistance
and improve hepatic fat metabolism [10]. Impaired mitophagy (a specialized form
of macroautophagy for eliminating dysfunctional mitochondria) is believed to con-
tribute to cardiac aging [11]. Recent data also suggested that autophagy deficiency
is associated with age-related macular degeneration [12]. AMPK activator AICAR
can accelerate removal of protein aggregates and improve survival of retinal pig-
ment epithelial cells in this disorder. Because of their large expanses of dendritic
and axonal cytoplasm, neurons rely heavily on autophagy as evidenced by obser-
vations that the central nervous system (CNS) is usually the most severely affected
organ in various lysosomal storage disorders (LSDs) [13]. Indeed, mounting data
indicate a key role of impaired autophagy in a range of neurodegenerative conditions,
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such as AD (Alzheimer’s disease), PD (Parkinson’s disease), HD (Huntington’s dis-
ease), and ALS (amyotrophic lateral sclerosis). Behavioral defects, neuronal loss,
and abundant accumulation of polyubiquitinylated proteins were observed in mice
after conditional knockout of Atg5 or Atg7 [14,15] underscoring the role of basal
autophagy in the CNS and supporting the notion that compromised autophagy can
lead to neurodegeneration. A mechanism underlying disease pathogenesis of many
neurodegenerative diseases is the adoption of an abnormal conformation by certain
proteins, for example, Aβ (amyloid-β) and tau in AD, α-syn (α-synuclein) in PD,
and Htt (huntingtin) in HD [16], all of which are potential autophagy substrates.
Notably, neurons, cardiomyocytes, and retinal pigment epithelial cells are all termi-
nally differentiated postmitotic cells and cell division is not an available mechanism
to dilute accumulated waste. Efficient removal of damaged proteins or organelles by
autophagy is, therefore, particularly vital in these cells to preserve homeostasis dur-
ing aging and in disease. Not surprisingly, the brain, heart, and eyes are particularly
vulnerable to damage related to autophagy impairment.
14.3 AUTOPHAGY ENHANCER SCREENING
Given its pivotal role in multiple diseases, and especially neurodegeneration,
autophagy deficiency is an attractive therapeutic target. Effort has focused particu-
larly on identifying small molecules that can enhance autophagy, lower the burden
of toxic protein aggregates, and ultimately provide therapeutic benefit. Indeed,
autophagy upregulation is associated with beneficial effects on diverse disease-
associated phenotypes in cell, fly, worm, and mouse models [17]. For instance,
autophagy enhancement using mTOR inhibitors (e.g., rapamycin and analogs)
improves deficits in numerous neurodegeneration models, including AD, PD, HD,
and ALS [18]. Several researchers have conducted extensive compound screenings
to identify positive autophagy regulators, which has resulted in a range of interesting
chemical leads [19–21].
14.3.1 Methods for Monitoring Autophagy
As shown in Table 14.1, most investigators have used multiple methods to demon-
strate the steady-state accumulation of autophagosomes. Transmission electron
microscopy (TEM) was the first technology used to detect autophagosomes, the
morphological hallmark of autophagy. Despite limitations of this technology, TEM
is extremely informative and remains one of the most used methodologies to
monitor autophagy. Atg8/LC3 is currently the most widely used protein markers
of autophagosomes. LC3 is initially synthesized in an unprocessed form, which is
converted into an LC3-I form by removal of amino acids from the C terminus. Bound
principally to microtubules, LC3-I is modified to LC3-II upon PE-conjugation, which
becomes associated with the phagophore membrane. Changes in autophagosome
formation are commonly assessed by measuring the abundance of LC3-II onWestern
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antibodies using immunofluorescence (IF) labeling. An additional advantage of
an immunohistochemical approach is the capability to colocalize LC3 with other
organelle markers. LC3 tagged with a fluorescent protein such as GFP may be
introduced into cells to detect autophagosomes and has recently been used to assess
autophagy changes in animals in vivo [108]. Both endpoints (LC3-GFP puncta and
LC3 IF puncta) can be quantified with Image J or the high content imaging platform
for automatic image capturing and quantification. So far there is no specific dye to
stain autophagosomes although acridine orange is frequently used in the literature to
demonstrate development of acidic vesicular organelles (AVOs) as a surrogate marker
for autophagosome [78]. However, staining from acridine orange mainly reflects the
change of lysosome since this is a dye that accumulates in acidic lysosomes [109].
One challenge in screening for autophagy modulators is to discern enhancers from
inhibitors, both of whichmay increase the number of autophagosomes. All previously
mentioned methods reflect autophagosomes only in their static state rather revealing
information about the dynamic balance between autophagosome formation and clear-
ance (“autophagy flux”). Because increased autophagosome number can indicate
autophagy induction or failed autophagosome clearance (e.g., blocked fusion with
lysosomes or degradation by lysosomes), secondary assays are typically required to
further understand autophagy flux. Direct evidence of autophagy flux activity can be
obtained by measuring the degradation of long-lived proteins; however, this method
involves somewhat labor-intensive radiolabeling of the cells and subsequent separa-
tion of acid-soluble from acid-insoluble radioactivity. Its wide application is further
limited by the need to use inhibitors to establish specificity of proteolytic systems
involved, potential for released amino acids to be metabolized and low autophagic
activity of cells under certain conditions. The most common assay used in the liter-
ature is the determination of autophagosome formation rates by measuring levels of
LC3-II in the presence and absence of an inhibitor (e.g., chloroquine, bafilomycin
A, or proteases inhibitors) that blocks LC3 degradation. A rise in LC3-II levels in
the presence of inhibitors can therefore reflect autophagosome formation. While rel-
atively easy to apply once proper conditions of inhibitor concentration and incubation
time are established, this assay provides no information about the lysosomal steps of
autophagy (fusion and degradation). Therefore, this endpoint should not be consid-
ered as a reliable endpoint to evaluate autophagic flux. The substrate targeting protein,
p62 protein, also called sequestosome 1 (SQSTM1), binds to ubiquitinated proteins
facilitating their sequestration and ultimate delivery to lysosomes for degradation,
during which process p62 is also degraded. Since p62 accumulates when autophagy
is inhibited and its levels decrease when autophagy is induced, p62 turnover has
been used as a marker of autophagic flux. Special consideration needs to be taken
when using p62 data for autophagy enhancers since reduction of p62 synthesis by
poor cell health could confound the interpretation. A dose-dependent response can
certainly increase the confidence of the data interpretation using this assay. In addi-
tion, free GFP abundance relative to complete fusion of GFP-LC3 has also been used
as a marker to reflect autophagic flux [110]. GFP-LC3-containing autophagosomes
will be degraded after fusion with lysosomes. However, the free GFP moiety gen-
erated from the GFP-LC3 degradation is relatively resistant to proteolysis; hence,
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the appearance of free GFP to some extent reflects cargo delivery (GFP-LC3) from
the autophagosome to the lysosome and subsequent degradation. Caution must be
used, however, when conducting the GFP-LC3 cleavage assay as a determinant of
autophagic flux because GFP fragments can be further degraded and thus do not
accumulate when lysosomal acidity is high, for example, during starvation [111].
Recently, tandem mRFP/mCherry-GFP fluorescence microscopy has been particu-
larly designed to monitor flux. The principle of the assay is based on the differential
pH dependence of green and red fluorescent protein tags: GFP signal is typically
quenched in a strongly acidic environment while mRFP and mCherry remain fluores-
cent. This assay can be used in the format of single time point data, where an increase
of total red+green+ and red+green− vesicular compartments indicates autophago-
some formation (i.e., induction of autophagy) and an increase of red+green− com-
partments alone reflects successful autophagosome–lysosome fusion and lysosome
acidification associated with lysosomal clearance of autophagy substrate. Since the
autophagosome is a transient organelle existing for less than 10min before fusing
with the lysosome [112], evaluating the dynamic behavior of autophagosomes pro-
vides more critical information on autophagic flux than single time point data. Tan-
dem technology can be used to capture this dynamic behavior in real time and reveal
the rate of formation and clearance of autophagosomes over time. This technique
requires a high-resolutionmicroscope (e.g., confocal) with temperature and CO2 con-
trol to facilitate the kinetic monitoring. In addition, upregulation of Atgs (e.g., Atg5
andAtg7) has also been used as supporting evidence for autophagy activation [26,53].
However, most of the Atgs do not always show significant changes in mRNA and
protein levels when autophagy is induced and the extent of increase varies among
different cell and tissue types. More importantly, only induction of autophagy can be
concluded from the Atgs data and this assay still does not provide information about
the lysosomal degradation step.
14.3.2 Autophagy Enhancers Identified from Early Literature
Because of the potential of therapeutic benefits of autophagy enhancement,
large-scale screening for autophagy modulators has been carried out in various labs
[19–21,42]. There are many additional reports of fortuitously identified autophagy
enhancers/activators in the literature (Table 14.1). Compounds exhibiting autophagy
modulation activity are structurally and therapeutically diverse. Categorization of
these agents is mostly based on mechanism of action and inducers can be broadly
grouped as mTOR-dependent and mTOR-independent mechanisms. Compounds
work through the mTOR-dependent pathway include not only classic mTOR
inhibitors, such as rapamycin and torin 1, but also compounds from different
pharmacological classes, for example, calcium channel blockers (perhexiline and
verapamil), antiarrhythmics (amiodarone), and antiparasitics (niclosamide) [19].
Nevertheless, for a large number of compounds, the mechanism(s) by which they
modulate autophagy have yet to be identified.
Interestingly, many compounds (e.g., tamoxifen, amiodarone, and vera-
pamil) that are believed to be autophagy enhancers are basic lipophilic, which
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allows the compound to accumulate in acidic organelles (i.e., lysosome) by pH
partitioning [113]. Lysosomotropic compounds were recently shown to inhibit
autophagy by perturbing lysosomal function [114]. Historically, vinblastine, a
microtubule disruptor, was once believed to be an autophagy “enhancer” but later
identified to actually inhibit autophagosome–lysosome fusion. It may therefore
be prudent to reevaluate the classification of these basic lipophilic compounds as
autophagy enhancers.
Lysosomes are the final destination of autophagosomal substrates for degrada-
tion. Lysosomes are membrane-enclosed compartments filled with acid hydrolytic
enzymes (e.g., cathepsins) used to digest macromolecules and are found in the cytosol
of nearly all mammalian cells. For optimal activity of acid hydrolases, lysosomes
must maintain a low internal pH of about 4–5. The acidic pH in the lumen is achieved
by the vacuolar H+ ATPase, which uses the energy of ATP hydrolysis to pump H+
into the lysosome. The pH gradient between the lysosomal lumen and the cytosol
(pH≈ 7.2) can drive overaccumulation of basic lipophilic compounds via pH par-
titioning. Generally, lipophilic free bases can pass through the plasma membrane
and lysosome membrane; however, the majority will lose permeability and become
trapped inside lysosomes due to their protonation by the acidic lysosomal pH. For
instance, chloroquine, a well-known lysosomotropic compound, can easily reach con-
centrations in excess of 20mM inside lysosomes equal to a several hundred-fold
high level relative to that outside of the cells [113]. Two physicochemical proper-
ties, basic pKa (acid dissociation constant for the conjugate acid for the weak base)
and clogP (partition coefficient between octanol and water, representing membrane
permeability) both affect the accumulation by influencing the extent of lysosomal
trapping and regulating the kinetics of passive permeation. The compounds that accu-
mulate in lysosomes are classified as lysosomotropic agents. It was demonstrated
previously that compounds with certain physicochemical properties (basic pKa > 6.5
and clogP> 2) tend to be lysosomotropic [115]. To understand if physicochemical
properties could contribute to autophagy modulation by the compounds identified so
far, we evaluated relationships between physicochemical properties (i.e., basic pKa
and clogP) and autophagy modulation. Surprisingly, half of autophagy “enhancers”
fit into the profile of being basic with pKa > 6, in whichmajority of them are lipophilic
with clogP> 2 (Table 14.1 and Figure 14.1). It is noteworthy that commonly known
“autophagy enhancers” amiodarone and tamoxifen are located in the basic lipophilic
region (Figure 14.1)
It has been well established that lysosomotropic compounds can impair lysosome
function potentially through multiple mechanisms. Lysosomotropic compounds,
chloroquine and methylamine, increase lysosomal pH drastically (0.5–2.0 pH units)
after accumulation [116]. In addition, significant pH elevation by chloroquine is
observed in vivo [117]. In a previous study [115], lysosomotropic compounds
were shown to decrease staining of cells by Lysotracker, which requires low pH
to fluoresce. An increase in pH is expected to suppress lysosomal degradation
since most lysosome enzyme activities have acidic pH optima. An increase of pH
may also decrease the fusion capability of lysosomes in some cells as seen for
chloroquine [118] although pH dependence of lysosome fusion is not universally
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Figure 14.1 Correlation of physicochemical properties with autophagy screening: A scatter
plot showing the distribution of autophagy enhancers within the clogP-basic pKa physico-
chemical property space. A group of compounds clustered within the area (blue dotted square)
where the clogP was >2 and basic pKa was greater than 6. (See color plate section for the
color representation of this figure.)
observed [119]. Lysosomotropic compounds have also been shown to decrease
lysosomal enzyme activity. For instance, chlorpromazine and chloroquine inhibit the
lysosomal phospholipase A1 in vitro [120,121] and desipramine, chlorpromazine,
and chloroquine downregulate acid ceramidase [122]. Multiple lysosomotropic
compounds can redistribute the mannose 6-phosphate receptor from the trans-Golgi
network to endosomes and concomitantly increase the secretion of lysosomal
enzymes causing intracellular lysosomal enzyme levels to decline [123] further
exacerbating lysosomal dysfunction.
Given that lysosomal substrate degradation is an essential step of autophagy,
impairment of lysosomal function, by definition, impairs autophagy activity. Not
surprisingly, various lysosomotropic compounds have recently been shown to be
autophagy inhibitors [114]. Interestingly in the same study, transcription of plentiful
long-lived proteins, including cytoskeletal and extracellular matrix proteins, was
suppressed further suggesting that autophagic turnover of these proteins is hindered.
Notably, lysosomotropic compounds also impact other trafficking process (i.e.,
endocytosis and phagocytosis process) that delivers materials to lysosomes. The
lysosomotropic compounds chloroquine, tamoxifen, and verapamil decrease phago-
cytosis activity [124,125] and chloroquine is recognized as a clathrin-dependent
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endocytosis inhibitor [126]. Amiodarone impairs trafficking through late endosomes
and induces a Niemann–Pick C-like phenotype [127]. In addition, multiple cationic
amphiphilic compounds (e.g., amiodarone, fluoxetine, nortriptyline, and imipramine)
identified as “autophagy enhancers” are reported to induce phospholipidosis (PLD).
Although the toxicological impact of PLD is still debatable, it is believed to be
a drug-induced LSD characterized by the excess accumulation of phospholipids.
Multiple mechanisms are proposed to contribute to PLD including lysosomal
dysfunction via inhibition of lysosomal phospholipase enzyme activity or transport.
Basic pKa and clogP are important descriptors for in silico prediction of phospho-
lipidosis [128]. Taken together, the evidence supports the conclusion that compounds
with basic lipophilic properties have the propensity to impair lysosomal functions,
consequently hampering autophagy activity rather than boosting it.
The foregoing evidence on current autophagy enhancer screening assays raises
the critical question of whether they are sufficient to distinguish enhancers from
inhibitors. The most commonly used autophagy flux assay is LC3 assessment with
and without lysosome inhibitors. Compounds that increase LC3 abundance together
with lysosomal proteolysis inhibitor treatment, as compared to single agent effect
on LC3 in the absence of inhibitor, have often been interpreted as showing that the
compound increased “autophagic flux.” Autophagic flux in this context is a measure
of autophagosome formation and provides no information about the lysosomal
steps of autophagy. More appropriately, autophagic flux should reflect the activity
of the entire autophagic process from substrate sequestration through complete
substrate degradation. TFEB (transcription factor EB) stimulates the expression
of genes for lysosome biogenesis as well as many involved in autophagosome
formation and fusion of autophagosomes with lysosomes [129,130]. Recently,
TFE3, another family member of the microphthalmia-associated transcription factor
(MiTF) and TFE (miTF/TFE) families, was also shown to increase the expression
of the proteins involved in autophagy and lysosomal biogenesis [131]. Interestingly,
both transcriptional factors respond to lysosomal dysfunction, as shown by nuclear
translocation of both TFEB and TFE3 after chloroquine treatment [130,131]. Possi-
bly these transcriptional factors are activated as a compensatory feedback response
to overcome the lysosomal stress triggered by this lysosomal inhibitor, which
likely results in reduced signaling to the lysosomal amino acid sensing complex
that regulates TFEB phosphorylation and translocation. Further experiments are
required to confirm whether or not other basic lipophilic compounds trigger a similar
nuclear translocation of TFEB and TFE3 to increase the gene expression of the
protein involved in autophagosome formation and lysosomal biogenesis. In this
regard, LAMP1 expression is increased by the basic lipophilic compound imatinib
[63] and various autophagy genes (e.g., beclin 1, Atg5, or Atg7) are upregulated
by amiodarone, gefitinib, and compound C [26,46,53]. In addition, as observed
for chloroquine, multiple basic lipophilic compounds, including perhexiline, com-
pound C, siramesine, and imipramine, decrease mTOR signaling, suggesting that
nuclear translocation of TFEB and TFE3 may be occurring since mTOR activation
contributes to the cytosolic localization of these transcription factors [130,131].
It is therefore plausible that basic lipophilic compounds generally act similarly to
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the mechanism proposed for chloroquine, namely by decreasing mTOR activity,
triggering nuclear translocation of TFEB and TFE3, and ultimately inducing the
gene expression of lysosomal and autophagy genes as a feedback response to
the accumulation of substrates in autolysosomes, often referred to as “autophagic
stress.” Accordingly, activation of autophagy demonstrated by lysosomal inhibitor
assay might not be sufficient to identify effective autophagy enhancers. Similar
precautions need to be taken when interpreting the upregulation of autophagy
or lysosome genes as evidence of autophagy enhancement since basic lipophilic
autophagy inhibitors can activate those genes following lysosomal stress. Increased
expression of autophagy or lysosome genes may indicate initiation of autophago-
some or lysosome biogenesis but does not necessarily reflect increased autophagy
activity, which should be a measure of both autophagosome formation and clearance.
An additional assay previously used to support autophagy enhancement is mea-
surements of numbers of AVOs labeled by acridine orange. The development of
AVOs, a characteristic of autophagy [41,78], can be monitored by lysosomotropic
acridine orange, which selectively accumulates in acidic organelles, enabling quan-
titation of both number and size of lysosomes, although the lysosome expansion can
imply higher or lower lysosomal activity. Multiple lysosomotropic compounds, for
example, chloroquine that could perturb lysosomal functions have been shown to trig-
ger marked expansion of lysosomal volume [132,133]. In addition, lysosomal volume
expands in multiple lysosomal storage diseases, which are also associated with lyso-
somal dysfunction [134,135]. Reduction of lysosomal volume in these disease states
has been used as a phenotypic screening to identify the compounds that could improve
lysosomal function. [135,136]. Therefore, increase of AVOmight not be the appropri-
ate marker for identifying true autophagy enhancers due to the potential association
with lysosomal dysfunction.
Assays based on p62 turnover and the tandem-tagged GFP-mCherry-LC3 probe
can provide suitable appraisals of autophagy flux. Induction of autophagy by arsenic
trioxide has been demonstrated by TEM, IF staining with EGFP-LC3, and increased
LC3 in the presence of the lysosomal proton pump (vacuolar ATPase) inhibitor
bafilomycin A [30,137,138]. However, arsenic trioxide inhibited autophagy flux as
evidenced by the tandem-tagged GFP-mCherry-LC3 probe assay [139]. In this assay,
starved cells exhibit both yellow and red puncta but cells treated with arsenic trioxide
exhibited persistent yellow/orange puncta, similar to the effects of bafilomycin A,
indicating a block of autophagy flux. Arsenic also induced accumulation of p62
puncta, further indicating inhibition of autophagy flux. Although arsenic is not
basic lipophilic, lysosomal uptake of heavy metals is well documented [140,141].
Indeed, arsenic caused rapid destabilization of lysosomes [142], which might
underlie the negative effect of arsenic on autophagy. Thapsigargin, an inhibitor of
the ER SERCA calcium pump, has been frequently used as an autophagy inducer
[24,143], as reflected by increased LC3 in the presence of bafilomycin A [143];
however, in the tandem GFP-mCherry-LC3 assay, loss of GFP signal is delayed after
thapsigargin indicating impaired fusion of autophagosomes with lysosomes [144].
Fluoxetine, nortriptyline, and imipramine have all been classified as “autophagy
enhancers” based on earlier studies, but they were recently shown to increase p62
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protein abundance in a dose-dependent manner [114], supporting an inhibition of
autophagic flux.
Collectively, these findings suggest that many autophagy enhancers identified so
far might not represent true enhancers of autophagy flux. In particular, compounds
with basic and lipophilic moieties need to be evaluated very carefully due to their
high potential to disturb lysosomal function. Even compounds lacking a basic
lipophilic moiety may also perturb lysosome function as illustrated by arsenic
trioxide, which destabilized lysosomal membranes [142]. TRAIL triggers lysosomal
membrane permeabilization (LMP) via death receptor-5 [98]. LMP and relocation
of cathepsins contribute to the cell death by curcumin [47]. Pharmacological
inducers of ER stress, such as tunicamycin, have also been reported to associate with
LMP [103]. Notably, LMP has recently been shown to stimulate protein aggregate
formation in neurons [145]. In addition, oxidative stress or ER stress was associated
with multiple putative autophagy enhancers including amiodarone, apicidin, and
fluoxetine (Table 14.1). Compounds with liability of LMP, oxidative stress, or ER
stress are more likely to weaken their therapeutic benefit for conditions requiring
autophagy enhancement.
Since all membrane trafficking including autophagy, phagocytosis, and endocy-
tosis converge on lysosomes compounds that promote autophagy flux should not
compromise lysosomal function. For instance, chloroquine, a lysosomotropic com-
pounds that inhibit lysosomal function, is a well-known autophagy inhibitor and has
also been shown as an inhibitor for endocytosis and phagocytosis [124,126]. As we
discussed previously, many reported “autophagy enhancers” target lysosomes either
due to their lysosomotropic nature (e.g., amiodarone and latrepirdine) or by compro-
mising lysosomal membrane integrity (e.g., TRAIL). Analysis of other trafficking
processes, such as endocytosis and phagocytosis, could provide further certainty on
the lysosomal functions. In other words, if compounds shown to augment autophagy
perturb endocytic, phagocytic, or lysosomal functions, extra consideration should
be taken when classifying these compounds as “autophagy enhancers.” Especially
if “increased” autophagy is surmised on the basis of only elevated LC3 expression
with proteolysis inhibitors, increased expression of Atgs, or increased AVOs, this
“increase” may merely reflect a compensatory response to lysosomal dysfunction.
Therefore, evaluation of the general function of lysosomes could provide additional
supporting evidence for autophagy modulation.
14.3.3 mTOR Inhibitors
Mammalian target of rapamycin (mTOR) is a conserved serine/threonine protein
kinase that plays a significant role in cell growth, proliferation, and protein synthesis
by regulating the activities of factors such as 4E-BP1, S6K, and Akt. mTOR1 is also
a master negative regulator of autophagy by blocking the ULK1-ATG13-FIP200
complex. Various mTOR inhibitors were developed to enhance autophagosome
biogenesis and thereby promote clearance of aggregate-prone proteins. Notably,
genetic or pharmacological inhibition of TOR activity multiple model systems
is associated with life span extension [146–149], possibly through inhibitory
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effects on protein synthesis and stimulation of autophagy. Numerous studies show
that rapamycin can alleviate toxicity exerted by protein aggregates in a range of
neurodegeneration models (e.g., HD, PD, and AD) [150]. Surprisingly, rapamycin
was shown to induce pulmonary PLD demonstrated by lamella body formation using
EM (NDA 021083) indicating alteration of lysosomal function by mTOR inhibition.
In order to have a thorough understanding of mTOR inhibitors, we compared the
biological effects of TOR inhibitors (putatively to enhance autophagy induction),
like rapamycin, and lysosomotropic compounds, such as chloroquine (putatively to
block lysosomal degradation) (Table 14.2). Multiple endpoints such as vacuolation,
PLD, endocytosis, and phagocytosis inhibition were employed and unexpectedly,
mTOR inhibitors and lysosomotropic compounds, which supposedly have opposite
effects, behaved indistinguishably in all the endpoints that we compared. Lyso-
somotropic compounds are well known to cause cytoplasmic vacuolization [151]
after they accumulate in acidic organelles. The mTOR inhibitor, everolimus, also
induces cytoplasmic vacuolization in macrophages [152]. Large, clear vacuoles
by rapamycin were shown to be lysosomes that presumably had not returned to
normal size after proteolysis when autophagy is induced heavily due to mTOR
inhibition [153]. Although the biological meaning of vacuolization is not well
understood, the appearance of vacuoles in the brain is used as a typical hallmark
of neurodegeneration in Drosophila [154] and is observed in aged tissue [155].
Cytoplasmic vacuolization is also seen in various lysosomal storage diseases [156].
However, it is possible that vacuolation represents the enlarged lysosome that
is associated with increase in lysosomal function. Drug-induced PLD, which is
characterized by accumulation of phospholipid and drugs in lysosomes, are often
regarded as an acquired LSD [157]. Lysosomotropic compounds, which typically
contain a hydrophobic ring structure and a hydrophilic amine moiety, are best known
to trigger PLD [158]. As discussed earlier, the “autophagy enhancers” amiodarone
TABLE 14.2 Comparable Biological Effects from mTOR








Endocytosis inhibition + +
Phagocytosis inhibition + +
mTOR inhibition + +
TFEB nuclear translocation + +
LAMP1 upregulation + +
Increase Lysotracker staining + +
Immune response inhibition + +
Cancer therapy + +
Effects presented are not necessarily related to autophagy modulation.
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and tamoxifen are classic inducers of PLD [159] and mTOR inhibitors, including
everolimus, sirolimus, and temsirolimus [160], are all reported to induce PLD, sug-
gesting that they perturb lysosomal functions. Besides PLD induction, both mTOR
inhibitors and lysosomotropic compounds may also impair other aspects of mem-
brane trafficking, such as endocytosis and phagocytosis. Chloroquine is recognized
as a clathrin-dependent endocytosis inhibitor [126] and the phagocytosis of rod outer
segments is inhibited by chloroquine and tamoxifen in retinal pigment epithelial cell
cultures [124]. Azithromycin, a lysosomotropic antibiotic, delays sequestration of
receptor-bound transferrin and peroxidase–antiperoxidase immune complexes into
cell-surface endocytic pits and vesicles [161]. Although the mechanism is not clear,
mTOR may play a critical role in clathrin-mediated endocytosis [162], as suggested
by the ability of rapamycin to reduce albumin uptake [163]. Rapamycin also impairs
macropinocytosis and mannose receptor-mediated endocytosis of antigens by bone
marrow-derived DCs [164] and decreases phagocytosis of bacteria and apoptotic
cells [165].
Many lysosomotropic compounds, for example, niclosamide and imipramine
have been shown to lower mTOR1 activity [65,166], possibly attributable to lysoso-
mal dysfunction that reduces the generation of amino acids critical for the mTOR.
TFEB is a master regulator of lysosomal biogenesis and autophagy. Interestingly,
both mTOR inhibitor and lysosomotropic compounds can trigger TFEB nuclear
translocation [130,167], leading to the upregulation of a broad range of lysosomal
genes and increased lysosomal biogenesis [168,169]. Lysosomotropic compounds
can robustly increase lysotracker staining [132,170]. Similarly, both allosteric
mTOR inhibitor (rapamycin) [146] and catalytic inhibitors (PP242 and Torin1) [169]
also markedly increase lysotracker fluorescence intensity. Increased lysotracker
staining in these situations indicates increased numbers or size of lysosomal-related
compartments, which can potentially reflect both an attempted adaptive response
and a pathological phenomenon (lysosomal degradative impairment) as seen in
lysosomal storage diseases and aging.
Autophagy and autophagy proteins have multifaceted roles in the innate and adap-
tive immune responses, for example, antigen presentation and lymphocyte develop-
ment [171]. Surprisingly, with supposedly opposite actions on autophagy, both types
of agents (mTOR inhibitors and chloroquine) are shown to inhibit immune response.
Tor kinase has multiple effects on innate and adaptive immune responses. The mTOR
inhibitors sirolimus and everolimus block the response of T- and B-cell activation by
cytokines, which prevents cell-cycle progression and proliferation [172]. Rapamycin
has also been shown to suppress the mature dendritic cell function and decrease
the production of cytokine IFNγ produced by dendritic cells [173]. As noted ear-
lier, rapamycin has an inhibitory effect on dendritic cells endocytosis [164], which
could further decrease the immune response. The mTOR inhibitor (e.g., rapamycin)
has been used as an immunosuppressant to prevent transplant rejection. The efficacy
of the lysosomotropic compound hydroxychloroquine in the treatment of systemic
lupus erythematosus and rheumatoid arthritis has been well demonstrated [174,175],
and it has become a standard component of therapy for patients with these diseases.
Anti-inflammatory response by hydroxychloroquine could be ascribed to lysosomal
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dysfunction, which diminishes the formation of peptide–MHC protein complexes
required to stimulate CD4+ T cells and results in downregulation of the immune
response against autoantigenic peptides. Additional lysosomotropic compounds, for
example, fluoxetine and citalopram have also shown anti-inflammatory effects in
arthritis animal models [176].
In addition, both mTOR inhibitors and lysosomotropic compounds, such as
chloroquine, have been used in cancer therapy. Currently, rapamycin analog,
temsirolimus, has been used for the treatment of renal cell carcinoma and everolimus
for various cancer types [177]. Owing to their nature of autophagy inhibition,
lysosomotropic compounds, for example, chloroquine or, more commonly, hydrox-
ychloroquine in combination with other antitumor agents have been explored in
numerous oncology clinical trials [178]. Interestingly, the combination of hydroxy-
chloroquine with the mTOR inhibitor demonstrated an encouraging clinical outcome
in a phase I trial with advanced melanoma patients [179].
The unanticipated similarity between mTOR inhibitors and lysosomotropic com-
pounds further accentuate the challenge of autophagy enhancer screening, grant-
ing some of the effects could be attributed to pharmacological actions unrelated to
autophagy. Data interpretation of endpoints for autophagy screening needs to be con-
sidered carefully. In addition, the comparable biological effects raised a critical ques-
tion about the role of mTOR on lysosomal function. The ability of mTOR inhibitors
and lysosomotropic compounds to induce PLD and inhibit endocytosis and phago-
cytosis suggests that both classes of compounds may have a negative impact on
lysosomal functions. An increase of lysotracker staining from both types of agents
further supports this notion since a similar phenotype is often observed when lysoso-
mal functions is perturbed, for example, cells from LSD patients.
As discussed earlier, it is understandable as to why lysosomotropic compounds
have global negative impact on lysosomes. A negative impact of mTOR inhibitors is
seemingly more puzzling, given their ability to stimulate TFEB-mediated lysosomal
biogenesis. Recent findings, however, reveal positive roles of mTOR activity in traf-
ficking processes that lead to lysosomes and lysosomal function. Although the mech-
anisms have not been fully elucidated, mTOR activity may influence microtubule and
actin dynamics through the actions of ROCKs, which play a critical role in regulat-
ing actin polymerization and associated cytoskeletal rearrangements. mTOR inhibi-
tion by rapamycin abolishes ROCK-1 synthesis in macrophages thereby inhibiting
chemotaxis and phagocytosis [180]. Rapamycin slows microtubule polymerization
and lowers binding of Bik1P to microtubules [181]. mTOR hyperactivation seems
to disturb microtubule organization [182], suggesting that a proper mTOR activity
balance is important in this process. Disruption of the cytoskeleton obviously hin-
ders various trafficking processes, which prevents cargo delivery to lysosomes and
substrate degradation. Beyond these effects, mTOR activity is required to gener-
ate protolysosomal tubules and facilitate their maturation into functional lysosomes
under conditions of nutrition deprivation [183]. This process, described as autophagic
lysosome reformation (ALR), is observed after prolonged starvation and blocked
by rapamycin treatment. Similar phenomena such as ALR were also observed in
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phagosome maturation process where phagosomes and entotic vacuoles undergo a
fission process, which redistributes vacuolar contents into lysosomal networks [184].
mTOR inhibition slows down the shrinkage of phagosomes indicating that membrane
fission is regulated by mTOR. Recently, mTOR was also shown to positively reg-
ulate lysosomal ATP-sensitive two-pore Na+ channels, which modulate membrane
potential and may influence pH stability of lysosomes under certain cellular condi-
tions [185]. This finding underscores the reciprocal relationship between mTOR and
lysosomes in which amino acids generated during lysosomal proteolysis modulate
mTOR activity and, in turn, potentially regulate additional endosomal and lysosomal
functions via lysosomal ATP-sensitive two-pore Na+ channels and additional changes
in intralumenal pH and ion fluxes.
Although it has been demonstrated that phosphorylation of TFEB by mTORC1
contributes to the cytoplasmic location of TFEB [131,167,186], contradictory results
have also been reported, in which TFEB nuclear translocation was promoted by
mTORC1 activity [163]. The latter study employed an mTORC1 overactivation
model by knocking out tuberous sclerosis complex 2(TSC2), which negatively
regulates mTORC1. Statistically significant overrepresentation of lysosomal genes
and especially genes encoding vacuolar H+-ATPase (V-ATPase) was identified with
higher expression when mTOR was activated in Tsc2−/− cells, but low expression
in TSC2−/− with rapamycin treatment indicating V-ATPase genes were tightly
regulated by mTORC1. Interestingly, TFEB depletion downregulates V-ATPase
expression suggesting that this mTORC1-dependent V-ATPase upregulation requires
TFEB. TSC inactivation indeed promoted nuclear translocation of TFEB and this
was reverted by rapamycin treatment suggesting that TFEB nuclear localization is
mTORC1 dependent. The multiple roles of mTORC1 on various biological processes
(e.g., protein synthesis and cell growth) may well complicate the interpretation of
the net outcomes of mTORC1 modulation and its ultimate impact on autophagy.
It is plausible that mTORC1 might play varying roles in lysosomal function
under different physiological/pathological conditions. It is worth noting that the
substantial benefits of rapamycin in mouse models of different neurodegenerative
diseases may also derive from autophagy-independent therapeutic effects such as
rapamycin’s antiaging properties, reduced protein translation [18], or change in
immune responses. Further characterization of the role of mTORC1 especially
on late stages of autophagy, phagocytosis, and lysosomal function under diverse
conditions should provide a stronger mechanistic rationale for mTORC1 modulation
as a therapeutic approach to neurodegeneration.
14.4 OTHER AGENTS THAT BOOST AUTOPHAGY AND LYSOSOMAL
FUNCTIONS
As a promising therapeutic approach, autophagy enhancement has attracted exten-
sive research interest. Given the foregoing discussion about the negative impact on
lysosomal function by some of the current “autophagy enhancers” and the complex
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effects of mTOR inhibition on autophagy, further efforts are warranted for identifying
positive autophagy regulators especially the ones that increase autophagic substrate
clearance. Emerging evidence suggests lysosomal clearance defects as a mechanism
for various adult-onset neurodegenerative diseases, supported by findings on neu-
ronal cell death in LSDs [17]. When the lysosomal clearance process is impaired,
autophagy induction might exacerbate the pathology. As a result, the success of any
autophagy enhancer in a given condition may depend on relieving blockages in lyso-
somal clearance. Lysosomal function or general membrane trafficking as therapeutic
targets in neurodegeneration is relatively unexplored. Nonetheless, numerous thera-
peutic targets have been suggested to have positive effect, including cathepsin activity
enhancement, pH restoration, and increasing lysosomal stability [17].
14.4.1 HDAC Inhibition
Histone deacetylase inhibitors (HDAC inhibitors, HDACi) are a class of compounds
that interfere with the function of histone deacetylase, an enzyme with diverse bio-
logical effects owing to broad actions on gene transcription. HDACi clear the excess
accumulation of cholesterol and correct cholesterol storage defects in human NPC1
mutant cells [187]. HDACi have also been shown to correct the cellular phenotype
of cystic fibrosis [188]. How HDACi restore the phenotype is not thoroughly under-
stood and multiple mechanisms have been suggested in the literature. Proteostasis of
various misfolded proteins could potentially contribute to the efficacy observed since
HDACi increase expression and restore activity of NPC1, glucocerebrosidase, and
α1-antitrypsin [187,189], thereby promoting lysosomal function. Protein acetylation
may regulate autophagy and HDACi promote autophagy via acetylation of ULK1
and Atgs [190–192]. Moreover, increased tubulin acetylation by HDACi and subse-
quent recruitment of kinesin and dynein may also increase flux of vesicles during
autophagy [193]. Interestingly, HDAC6 inhibition rescues both anterograde and ret-
rograde transport [193,194]. Many studies have indeed demonstrated that HDACi can
ameliorate deficits in mouse models of a wide range of neurologic disorders including
HD, PD, AD, and ALS [195–198]. Many questions about HDAC inhibition, how-
ever, remain unanswered. For example, effects of HDACi on autophagy may be cell
type-specific since HDACi suppress autophagy in cardiomyocytes [199] but induce
autophagy in other cell types (e.g., skeletal muscle cell) [200]. Also, restoration of
protein function by HDACi may be selective: increased expression of NPC1 pro-
tein with dramatic correction of NPC phenotype is observed with HDACi treatment
using human fibroblast carrying NPC1 mutation; however, HDACi has no effect on
HDAC in an NPC2 mutant human fibroblast line [187]. Moreover, acetylation may
regulate autophagy in opposite directions: KAT2B regulates autophagy negatively,
whereas KAT5 upregulates autophagy [201]. Underlying mechanisms that contribute
to these different effects require additional studies. Functional substrate identification
could improve the druggability of HDACi and more selective HDACi could poten-
tially achieve greater efficacy with less toxicity.
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14.4.2 pH Restoration
Lumen acidity of lysosomes is critical not only for optimal lysosomal enzyme activ-
ity during autophagy but also for efficient membrane trafficking. Abnormal lyso-
somal pH could be a key aspect in diseases of accumulation. For example, prese-
nilin 1 mutations, which are the most common genetic form of early-onset familial
AD, elevate pH and reduce activation of cathepsins [202,203]. Even a few tenths
of a unit increase may be sufficient to reduce the activity of certain lysosomal pro-
teases, such as cathepsin D [204]. Restoring lysosomal pH could have broad ther-
apeutic benefits by enhancing degradation and vesicular trafficking [202]. Indeed,
acidic nanoparticles that were targeted to lysosomes of retinal pigment epithelium
cells in a model of macular degeneration produced a sustained lowering of lysosomal
pH and improved degradative activity [205]. Multiple signaling molecules, which
could potentially be therapeutic targets, play roles in regulating lysosomal pH. For
example, cAMP elevation can lower lysosome pH and restore cathepsin D activity
in fibroblasts from patients with familial AD due to a presenilin 1 mutation [203].
Phosphodiesterase PDE10A inhibition has also been shown to ameliorate striatal
and cortical pathology in an HD animal model, further supporting cAMP regula-
tion as a treatment approach for lysosomal accumulation diseases. Glycogen syn-
thase kinase-3 (GSK 3) has also attracted considerable interest in neurodegeneration
research. Among its multiple effects, inhibition of GSK3 restores lysosomal acidifica-
tion by rescuing impaired glycosylation and lysosomal delivery of the v-ATPase sub-
unit V0a1 in a presenilin 1/APP model of AD and consequently reducing β-amyloid
pathology [206].
14.4.3 TRP Activator
Mucolipin transient receptor potential channel 1 (TRPML1) is believed to be a Ca2+
and Fe2+ dually permeable cation channel [207], which predominantly resides in late
endosomes and lysosomes [208]. The critical role of TRPML1 in lysosomal function
is supported by the lysosomal storage disease mucolipidosis type IV, which is caused
by mutations in the geneMCOLN1 (codes for TRPML1). Increasing TRPML1 activ-
ity by its agonist is adequate to restore lysosomal degradative functions and pre-
vent abnormal lipid accumulation, possibly by controlling Ca2+-dependent lysosomal
trafficking [209]. In addition, TRPML1 might also facilitate H+ import and lyso-
somal pH acidification [210]. Both particle ingestion and lysosomal exocytosis are
inhibited by synthetic TRPML1 blockers and are defective in macrophages isolated
from TRPML1 knockout mice further supporting the positive role of TRPML1 in
membrane trafficking [211]. Although these findings support the therapeutic bene-
fit for LSDs, similar approaches might also be beneficial for other neurodegener-
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14.4.4 TFEB Overexpression/Activation
Since the discovery of TFEB, overexpression or activation of TFEB has become
an appealing therapeutic approach, especially targeting LSDs. TFEB overexpres-
sion has been shown to reduce glycosaminoglycans in mouse models of MSD and
MPSIIA [213] and glycogen load and lysosomal size in a Pompe disease model [214].
In the hepatic disease associated with alpha-1-anti-trypsin (AAT) deficiency, gene
transfer of TFEB increases clearance of the mutant AAT protein and corrects the
pathological phenotype in liver [215]. Remarkably, in anMPTP cellular model of PD,
TFEB overexpression reversed MPP+-induced lysosomal depletion and attenuated
MPP+-induced cell death [216]. More recently, TFEB has been shown to partially
block proteotoxicity by PGC1α in a mouse model of HD [217]. The therapeutic ben-
efits of TFEB may be attributed to its multiple biological functions as a multitasking
transcription factor. Increased lysosomal biogenesis, autophagy, and lysosomal exo-
cytosis by TFEB can collectively contribute to amelioration of toxicity exerted by
various pathogenic proteins. In addition, TFEB activation has been shown to enhance
folding, trafficking, and lysosomal activity of a destabilized glucocerebrosidase and
rescue the activity of a beta-hexosaminidase mutant [218], which could further con-
tribute to the efficacy of TFEB in LSD and neurodegenerative disorders. Obviously,
a small molecule approach to promote nuclear translocation could be a very powerful
approach to upregulate lysosomal function; however, additional caution needs to be
taken to discern the true TFEB enhancing agent from the molecules that induce TFEB
nuclear translocation after lysosomal stress (e.g., CQ) [167]. One potential caveat
for this approach is that pathogenic proteins released into the extracellular space by
TFEB upregulation might not be cleared adequately [219]. Reuptake of pathogenic
proteins such as α-synuclein and amyloid-β could seed the misfolding of their normal
conformers and promote prion-like spreading [16].
14.4.5 Lysosomal Efficiency
The function of lysosomes is critically dependent on soluble lysosomal hydrolases as
well as on lysosomal membrane integrity. Numerous promising therapeutic directions
have been evaluated to improve lysosomal efficiency. Enzyme replacement thera-
pies, which replace an enzyme in patients in whom that particular enzyme is defi-
cient, are quite successful for multiple LSDs, including Gaucher disease, Fabry dis-
ease, and Pompe’s disease. Genetic deletion of cystatin B, an endogenous lysosomal
cysteine protease inhibitor, enhanced multiple cathepsin activities, reduced abnor-
mal accumulations of amyloid-ß peptide, rescued autophagic-lysosomal pathology,
and restored normal cognition in a mouse model of AD [220]. Recently, the same
approach also promoted clearance of accumulated lipids in this disease model [221]
Similarly, genetic ablation of cystatin C in a similar mouse AD model significantly
decreased plaque load and restored normal synaptic plasticity [222]. Pharmacologi-
cal chaperone therapy has also proven effective in several models of LSDs [223]. In
principle, these reversible small molecule inhibitors bind to a target protein in the ER,
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stabilize its correct conformation, and thus enable a functional enzyme to traffic to
lysosomes. This principle can potentially apply to neurodegenerative diseases, such
as AD, to promote the folding and proper function of vATPase [202] or boost enzyme
activity to clear lipid storage that can impair lysosomal function [224].
Promoting lysosomal membrane stability can also have therapeutic benefit. LMP
impairs lysosomal function, accelerates protein aggregate formation, and contributes
to neuronal cell death [88,145,225]. Heat shock protein 70 (Hsp70) acts as a molecu-
lar chaperone to stabilize lysosomal membranes [136] and in recombinant form, was
able to enhance the enzymatic activity of endogenous mutated acid sphingomyeli-
nase and reverse lysosomal pathology in fibroblasts derived from Niemann–Pick dis-
ease. Calpains are abnormally activated in AD [226] and may act as a mediator of
LMP [227]. Calpain inhibitors have striking therapeutic effects in mouse models
of AD and several other neurological disorders [228–231]. The effects of calpain
inhibitors toward inducing autophagy and protecting against LMP, in addition to
reducing cytotoxicity of calpain overactivation, have created considerable excitement
around calpain inhibitor development.
14.4.6 MicroRNA
MicroRNAs (miRNAs), small noncoding RNAs ∼22 nucleotides in length have been
shown to regulate gene expression at the posttranscriptional and translational lev-
els. miRNAs guide the binding of the RNA-induced silencing complex to the target
mRNA via base-pair interactions with mRNA transcripts, resulting in target mRNA
degradation and/or translational inhibition. In general, each individual miRNA has
multiple target proteins. miRNAs play an important role in various biological pro-
cess, such as proliferation, differentiation, and apoptosis [232]. Recently, miRNAs
have been found to modulate mammalian autophagy. Proteins involved in multi-
ple steps of autophagy, such as induction, nucleation, and elongation, have been
shown to be targeted by various miRNAs [233,234]. For instance, miR181a atten-
uates autophagy through Atg5 [235]. Interestingly, an emerging role of miRNAs
in neurodegeneration has also been revealed. An exclusive group of miRNAs, such
as let-7 miRNAs, are expressed in brain [236]. Critical neuronal functions such as
plasticity and memory may be regulated by miRNAs [237] and global disruption of
miRNAs triggers neurodegeneration [238]. In Drosophila, loss of miR-34 triggers a
late-onset brain degenerative state, whereas miR-34 upregulation extends life span
and alleviates neurodegeneration by polyglutamine disease protein [239], providing
the evidence for involvement of specific miRNAs in neuronal functions. Notably, of
the multiple miRNAs that become dysregulated in neurodegenerative diseases [240],
many are involved in autophagy regulation [235]. Some miRNAs, such as miR-7,
have been shown to induce autophagy [241] and downregulate α-synuclein protein
expression through the 3-untranslated region (UTR) of α-synuclein mRNA [242],
both of which could contribute to the neuron protection. By contrast, miR-128 aggra-
vates α-synuclein toxicity by downregulating TFEB [243]. While miRNA research
is still in its infancy, the multitude of ways that miRNAs regulate autophagy and
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influence neurodegeneration suggest that miRNAmodulation could be a viable target
in the future treatment of neurodegeneration. A phase I clinical trial of miR-34 for
oncology has recently started and could provide a proof of principle for using miR-
NAs in the clinic. A major challenge for the clinical use of miRNAs in neurodegener-
ative disorders is the efficiency of delivery into the brain. Possibly intranasal delivery
could provide a noninvasive method of bypassing the blood–brain barrier to rapidly
deliver therapeutic agents [244]. Although multiple target modulation by miRNAs
provides therapeutic benefits, pathways, or targets, off-target adverse effects represent
another potential limitation. Ideally, miRNAs that are only associated with disease are
the optimal targets. Further understanding the role of miRNAs under pathological
conditions could provide the rationale for miRNA target selection.
14.5 CONCLUDING REMARKS
Mounting evidence supports the pathologic role of autophagy impairment and lysoso-
mal dysfunction in the development of neurodegeneration, which provides a strong
rationale for developing therapeutics to modulate autophagy by targeting steps in
autophagy substrate recognition and sequestration, and increasing the efficiency of
autophagy substrate clearance by modulating lysosome trafficking and hydrolytic
function. As promising as these therapeutic directions are, there is still a critical
need to understand the molecule mechanism of pathogenesis of neurodegeneration
and further decipher the complex regulation of membrane trafficking. For instance,
the existence of an autophagy protein interactome including over 400 interacting pro-
teins not only underscores the intricacy of autophagy regulation [245] but also reveals
an encouraging breath of druggable candidate targets for autophagy modulation. A
better understanding of this network could shed light on strategic interventions with
more specific therapeutic outcomes and fewer off-target effects. As we discussed ear-
lier, compounds of interest are not yet fully characterized, especially their dual effect
on both early and late stages of membrane trafficking. Positive effects on upstream
steps in autophagy (autophagy substrate recognition/sequestration) could be masked
by blockage at downstream steps of autophagy (e.g., lysosomal hydrolysis of sub-
strate) with an overall negative effect on autophagic substrate turnover as seen with
niclosamide [166]. Current screening paradigms can be further enhanced to better
understand the multiple biological effects of a compound. In particular, comprehen-
sive efforts are required to distinguish autophagy enhancers from inhibitors.
Another major barrier for compound characterization is the scarcity of tools to
measure their activity in vivo and establish drug efficacy. Most assay methods involve
static endpoints, which do not providemuch information on the kinetics of autophagic
substrate turnover. Novel techniques are especially needed to ideally evaluate the
various stages of autophagosome clearance and substrate degradation. These more
dynamic assessments of autophagy turnover will better establish target engagement
by a test compound and the development of surrogate biomarkers will enable new
approaches for noninvasive monitoring. Although genetically engineered animals are




efficacy of a therapy in preclinical models and success in clinical trials is still very
poor [246]. Improvements in disease modeling, study design, and standardization
across multiple models will be needed to enhance predictive power.
Additional important consideration for the application of autophagy augmenta-
tion strategies in a neurodegenerative disease setting is the stage of the disease. At an
early stage prior to a general failure of lysosomal function, enhancement of autophagy
could provide therapeutic benefit by reinstating normal autophagic rate to eliminate
the formation of aggregates. Conversely, in the late stage of the disease where lyso-
somal function has become markedly impaired, simple autophagy stimulation might
be not only ineffective but also detrimental. A better understanding of the molecu-
lar mechanisms of disease could obviously strengthen the foundation for therapeutic
strategies. Autophagy enhancement can act as a double-edged sword in neurodegen-
eration diseases. On the one side are the cytoprotective roles of increased autophagy;
however, on the other side, unchecked autophagy is a distinct mechanism for non-
apoptotic cell death in some neuropathological states, such as ischemia and exposure
to certain toxins [247].Similarly, LMP induces necrosis of neurons [227,248] and
upregulation of lysosomal activity conceivably might facilitate cell death through
cathepsin release.When boosting lysosomal activity, increasing lysosomalmembrane
stability might be necessary to minimize the potential for cellular damage. Balancing
beneficial and potential detrimental roles of autophagy regulationwill be an important
consideration in developing effective autophagy modulators.
Beyond the requirements for optimizing activity and selectivity of candidate ther-
apeutics, an additional challenge with drug development for neurodegeneration is
achieving sufficient bioavailability to the CNS from systemic administration due to
the blood–brain barrier. Interestingly, both basicity and lipophilicity can promote pen-
etration through the blood–brain barrier [249] and the CNS drugs have an average
clogP of 2.8 and an average basic pKa of 8.4 [250]. Because of their lysosomotropic
properties, potential lysosomal dysfunction by this type of autophagy modulator may
lessen the efficacy, as discussed before. The use of liposome or polymeric nanoparti-
cles could potentially facilitate drug entry in the brain [249]. Intranasal administration
is also an emerging area of investigation due to the rapid uptake of the drug, ease of
self-administration, and potential for frequent, chronic dosing [251].
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15.1 INTRODUCTION
Lysosomes are cellular organelles in which a variety of glycosphingolipids (GSLs),
glycosaminoglycans, glycoproteins, and oligosaccharides are degraded into simpler
substances that can be recycled or excreted from the cell. To metabolize these com-
plex biomolecules, a variety of hydrolases has evolved to function optimally at the
mildly acidic pH (∼5.5) of the lysosome. Disruption of any of these metabolic path-
ways can lead to accumulation of one or more substrates and emergence of the asso-
ciated disease pathology. Collectively, these diseases are known as lysosomal storage
disorders (LSDs), with currently more than 50 described [1]. The pathology associ-
ated with LSDs varies significantly depending on the deficient enzyme and accumu-
lated substrate(s). Interestingly, disease severity as well as organ involvement also
can be markedly different between individuals with the same LSD [2].
The current standard of care for several LSDs is enzyme replacement therapy
(ERT) in which a manufactured enzyme is infused on a weekly or biweekly basis.
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While ERT does improve clinical outcomes for many patients, immunological
responses, sometimes severe, and insufficient efficacy in key target tissues and
organs leave a significant unmet medical need for many patients. This is most
evident for those LSDs that involve CNS impairment since currently available ERTs
are unable to cross the blood–brain barrier (BBB), though brain-targeted ERTs are an
active area of preclinical research [3]. An alternative therapeutic approach for LSDs
is substrate reduction therapy (SRT). This treatment option relies on inhibition of a
key enzyme in the biosynthetic pathway of the accumulated substrate. A potential
advantage of this approach is the fact that the small-molecule enzyme inhibitor
has the potential to cross the BBB, and therefore addresses the CNS pathology
associated with the LSD that it is intended to treat. In the case of Gaucher disease
(GD), the side effect profile associated with the only approved SRT molecule,
N-butyl-deoxynojirimycin (NB-DNJ, miglustat, Zavesca™; Actelion, Allschwil,
Switzerland), has precluded its use in the vast majority of patients [4], though this
same molecule was recently approved to treat the CNS manifestations of another
LSD, Niemann–Pick type C disease (NPC) [5]. Second-generation SRT molecules
for GD are currently in clinical development [6].
Over the last half century, it has been recognized that accumulation of a particular
substrate(s) results from reduced activity of a specific lysosomal enzyme. To this end,
Brady et al. [7] recognized that for GD, the reduced enzymatic activity results from
mutations in the gene (GBA1) that encodes the lysosomal enzyme acid β-glucosidase
(GCase). Since that time, the connection between genetic mutations and virtually all
LSDs has been firmly established. While these mutations may be large deletions,
insertions, or premature stop codons, they are more often missense mutations that
involve a single amino acid change in the enzyme’s primary amino acid sequence.
These mutations are often outside the enzyme’s active site and in many cases lead to
the expression of a catalytically competent form of the enzyme. However, missense
mutations often result in an enzyme that is thermodynamically less stable than its
wild-type form; consequently, a substantially smaller quantity of enzyme is able to
fold properly and pass the quality control mechanisms of the endoplasmic reticulum
(ER) immediately after protein synthesis [8]. As a consequence, the majority of these
proteins are tagged for proteasomal degradation via the ER-associated degradation
(ERAD) pathway, which ultimately results in insufficient lysosomal activity [9].
Given the fact that the mutated enzymes associated with many LSDs are often
catalytically competent but unable to traffic to lysosomes, an alternative therapeutic
approach for LSDs involves the use of pharmacological chaperones (PCs). PCs are
small molecules that bind with high affinity and selectivity to increase the physical
stability of their otherwise unstable enzyme target, thereby improving cellular traf-
ficking from the ER to the lysosome [10,11]. In principle, there are many sites that
such small molecules could bind on their respective target; in practice, however, an
overwhelming majority of PCs bind to the active site of their target enzyme, gener-
ally with high specificity [10,11]. The idea of using a small molecule that binds to
an enzyme’s active site (by definition, an inhibitor) to increase total cellular enzy-
matic activity is counterintuitive; however, there are several reasons that account for




target enzyme in the neutral pH environment of the ER, and to dissociate in the acidic
environment of the lysosome. Consequently, reduced binding affinity at acidic pH is
an important property of many PCs. In addition, high concentrations of accumulated
substrate in the lysosome can compete with the PC for binding to the enzyme’s active
site, helping to drive kinetics toward substrate turnover rather than PC-mediated inhi-
bition. Finally, understanding the lysosomal half-life of the target enzyme relative
to the half-life of the small-molecule PC can aid in the development of adminis-
tration regimens and doses that allow for maximized substrate turnover [10,12,13].
While nonactive site PCs have the potential to greatly simplify the need to optimize
administration regimens as inhibition likely would not be present, the identification
of such compounds has proved challenging. However, Marugan and coworkers [14]
have recently made some progress with a series of molecules that seem to increase the
trafficking of GCase to the lysosome without inhibiting its catalytic activity. While
it is unclear if this series of compounds can also increase substrate turnover, it does
represent an important step in the identification of nonactive site PCs.
Chemical chaperones, such as dimethylsulfoxide or glycerol, are another class
of small molecules that also can bind and stabilize a variety of proteins [15].
However, these molecules are nonselective and have low potency; as such, they are
yet to reach clinical practice. Hence, chemical chaperones should not be confused
with PCs, which bind with high affinity to a specific target protein to stabilize its
three-dimensional conformation and permit proper trafficking through the secretory
pathway. Comprehensive reviews on the discovery/characterization, mechanism of
action, and medicinal chemistry aspects of PCs have been previously published
[10,11]. The remainder of this chapter therefore focuses on the select LSDs for
which specific PCs have been identified and moved through preclinical evaluation
and into clinical development.
15.2 FABRY DISEASE
Fabry disease (FD) is an X-linked LSD caused by mutations in the gene (GLA) that
encodes the lysosomal hydrolase α-galactosidase A (α-Gal A; EC 3.2.1.22) [16].
Deficiency of α-Gal A results in accumulation of neutral GSLs with terminal
α-galactose residues, primarily globotriaosylceramide (GL-3), in plasma and cells
of blood vessels, skin, heart, kidney, brain, and other tissues [16–19]. A deacylated
analog of GL-3, globotriaosylsphingosine (known as lyso-Gb3), is also elevated in
the plasma of Fabry patients by more than 10-fold compared to GL-3, and is an
important new indicator of FD [20–22]. High levels of plasma lyso-Gb3 correlate
with increased risk for cerebrovascular disease and left ventricular hypertrophy in
males and females with FD, respectively, and greater lifetime exposure to lyso-Gb3
has been positively correlated with disease severity [21].
The clinical manifestations of FD span a broad spectrum of severity and can
include progressive renal failure, cardiac disease, cerebrovascular disease, small-fiber
peripheral neuropathy, and skin lesions, among others [16,23]. Males with FD who
have little or no detectable α-Gal A activity are commonly referred to as “classic”
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Fabry patients and are most severely affected. If not treated, the life expectancy of
these patients is reduced and death usually occurs in the fourth or fifth decade of
life from renal failure, cardiac dysfunction, or stroke. Female Fabry patients may
be mildly symptomatic or as severely affected as classic males [24]. In addition,
many individuals with FD present with a later-onset form, and generally have higher
residual α-Gal A activity than classic males [25]. Furthermore, recent screening
studies suggest that there could be a large undiagnosed population of later-onset
Fabry patients [26–32].
The currently available treatment for FD is ERT, with two approved products:
Fabrazyme® (agalsidase beta; Genzyme, A Sanofi Company, Cambridge, MA),
which is available worldwide, and Replagal® (agalsidase alfa; Shire, Cambridge,
MA), available outside the United States only. Each is administered as a biweekly
infusion. These ERTs are generally well tolerated and in many patients lead to lower
levels of GL-3 in plasma, urine, and microvascular endothelium, stabilize kidney
function, and improve FD-related symptoms [33–38]. The reduction of plasma
lyso-Gb3 levels in response to ERT has also been demonstrated [20,39,40], although
Fabry males who developed neutralizing antibodies toward the infused enzyme had
significantly less reduction compared to males who did not [41].
PCs may serve as a new approach to the treatment of FD for some patients
[10,11,42–46]. The first PC investigated as a potential treatment for FD was galac-
tose, which is also the terminal residue of GL-3 and lyso-Gb3 that is removed by
α-Gal A. Incubation of male FD patient-derived lymphoblast cell lines with galactose
led to significantly greater cellular α-Gal A protein levels and enzyme activity for 7
of the 11 different mutant forms tested [43]. In a subsequent clinical case study, intra-
venous infusion of galactose (1 g/kg every other day) led to a significant improvement
in cardiac function in a male FD patient with severe myocardial disease [47]. After a
2-year treatment period, it was determined that the patient no longer required cardiac
transplantation, offering the first proof of concept for PC therapy in an LSD.
A few years later, Fan et al. [44,46] described the use of a natural substrate
mimetic, the iminosugar 1-deoxygalactonojirimycin (DGJ, AT1001, migalastat), as
a PC for α-Gal A. DGJ binds reversibly and selectively to the active site of α-Gal A
with high affinity [48]. Furthermore, DGJ increased the cellular levels and activity
of 49 of 75 different missense mutant forms of α-Gal A in cultured lymphoblasts or
fibroblasts derived from male FD patients [42,49–51]. Importantly, elevated GL-3
levels were also reduced in Fabry fibroblasts that showed increased α-Gal A levels
in response to DGJ incubation [42,49,51].
Initial preclinical in vivo studies with DGJ used a transgenic mouse model
(TgM/KO) that lacked the endogenous α-Gal A gene but expressed a human mutant
R301Q transgene driven by a β-actin promoter [52]. The R301Q mutant form of
α-Gal A has been identified in patients with both classic and late-onset FD, and
has shown increased levels and activity in FD patient-derived cell lines in response
to DGJ [49,53–56]. Following 1-week oral administration of DGJ, TgM/KO mice
showed significant increases in α-Gal A activity in the heart, kidney, spleen, and
liver at doses of 3 and 30mg/kg [52]. Subsequent studies using a different transgenic




α-Gal A promoter, also showed significant increases in α-Gal A activity in various
disease-relevant tissues [13]. Most importantly, a concomitant reduction of GL-3
levels in the skin, heart, and kidney following daily administration of DGJ for 4
weeks was shown; 24-week administration resulted in even greater reductions [13].
These in vivo studies also demonstrated that less-frequent administration (e.g.,
repeated cycles of 4 days with drug followed by 3 days without drug, or every
other day with drug (QOD) resulted in even greater GL-3 reduction compared
to daily administration, with reductions comparable to those obtained with once
weekly 1mg/kg agalsidase beta [13]. These data indicate that oral administration
of DGJ can increase α-Gal A activity and decrease GL-3 levels in disease-relevant
tissues of FD mice. Furthermore, they highlight the importance of identifying an
optimal administration regimen that allows sufficient time for DGJ clearance from
the lysosome in order to restore α-Gal A activity and enable maximum substrate
turnover. Taken together, the results of these preclinical studies indicate a potentially
positive effect on FD patients that express mutant forms of α-Gal A that can be
elevated by DGJ, and have supported moving DGJ into clinical investigations.
To this end, DGJ is the active component of an investigational new drug, migala-
stat hydrochloride (hereafter, migalastat; Amicus Therapeutics, Cranbury, NJ), that
is in development as a potential treatment for FD. In support of migalastat clinical
development, four Phase 1 studies in healthy volunteers were conducted to deter-
mine the pharmacokinetics, pharmacodynamics, safety, and tolerability of migalastat
HCl [57]. The pharmacokinetic profile of migalastat was dose-proportional between
25 and 2000mg, with a half-life of 3–4 h. No abnormal cardiac effects were observed.
Importantly, in amultiple ascending dose studywith repeat administration ofmigalas-
tat (50 or 150mg twice a day) over 7 days, increases in α-Gal A activity were observed
in both dose groups in white blood cell lysates on Days 5 and 7 [57]. Also noteworthy,
the increase over baseline persisted for an additional 7 days after the final adminis-
tration of DGJ. Hence, orally administered DGJ can bind and stabilize endogenous
wild-type α-Gal A in white blood cells of healthy volunteers, thus leading to greater
cellular α-Gal A levels. These data highlighted the key pharmacodynamic outcome
that supported the advancement of DGJ into Phase 2 clinical studies.
In two open-label Phase 2 studies, a total of nine male FD subjects was adminis-
tered 150mg of migalastat orally every other day (QOD) for up to 48 weeks (clini-
caltrials.gov: NCT00283959 and NCT00283933) [58]. Increases in α-Gal A activity
of at least 50% were seen in white blood cells, skin, and kidney in six of nine sub-
jects. Decreases in GL-3 levels were seen in the skin, urine, and/or kidney in these six
subjects. These six subjects all expressed mutant forms of α-Gal A that were elevated
following incubation with 10 μMmigalastat in a HEK-293 cell-based assay; the three
subjects who did not show a consistent response had mutant forms of α-Gal A that
did not respond to migalastat in the HEK-293 cell-based assay [56,58].
The selection of female FD subjects for PC therapy has been more challenging
than for male subjects. Changes in the biomarkers that have been used historically
to evaluate the effect of new treatments, such as GL-3 levels in plasma, urine, skin,
or kidney, are difficult to interpret in females, relative to males, since they generally
have lower GL-3 burden, and have different patterns of GL-3 accumulation due to
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X-linked mosaicism [24,59–61]. Thus, an open-label Phase 2 study in females (n= 9)
with symptomatic FD was conducted to evaluate the safety, tolerability, and pharma-
codynamic effects of migalastat (clinicaltrials.gov: NCT003045120) [62]. Migalastat
(50, 150, or 250mg QOD) was administered for 12 weeks, with extension to 48
weeks. The GLA mutation of each subject was retrospectively assessed for response
to migalastat based on the magnitude of the mutant α-Gal A response to 10 μM
migalastat in the HEK-293 cell-based assay described above [56,62]. Female subjects
with responsive mutant forms of α-Gal A tended to demonstrate a greater pharma-
codynamic response compared to female subjects with nonresponsive mutant forms.
The greatest declines in urine GL-3 were observed in three subjects with respon-
sive mutant forms who were administered 150 or 250mg migalastat; these three also
demonstrated reduced GL-3 inclusions in kidney peritubular capillaries. These results
suggested that migalastat potentially may be a novel genotype-specific therapy for FD
in patients with responsivemutant forms of α-Gal A, including heterozygous females.
Preliminary data from ongoing extension studies of four open-label Phase 2
migalastat clinical trials (the three studies described above, plus another that is
unpublished) are available (clinicaltrials.gov: NCT00526071) [63,64]. To date, 22
subjects received migalastat for over 3 years, of which 7 received migalastat for
over 4 years. Migalastat was generally safe and well tolerated, with encouraging
preliminary renal function data. In addition, a trend toward reduced urine protein
was observed in subjects with responsive mutant forms. Taken together, these results
suggested that further clinical investigation was warranted.
As such, migalastat has been investigated in two Phase 3 clinical studies. The first
was a double-blind, randomized, placebo-controlled study to evaluate the efficacy,
safety, and pharmacodynamics of 150mg QOD oral migalastat administration in
male and female FD subjects with the following characteristics: (i) treatment-naïve
or off ERT for at least 6 months, (ii) elevated urine GL-3 at screening, (iii) estimated
glomerular filtration rate (eGFR) ≥30mL/min/1.73m2, and (iv) express a mutant
form of α-Gal A that can be elevated in the presence of migalastat as determined
using a research-purpose HEK-293 cell-based assay (referred to as the “clinical trial
HEK assay”) (ClinicalTrials.gov: NCT00925301) [65]. Subjects were randomized
1:1 to receive either placebo or migalastat. The first 6 months of this study were
double-blind and placebo-controlled; thereafter, all remaining subjects received
migalastat for 6 months (open-label), followed by an optional 12-month extension.
The primary endpoint was the proportion of subjects (n= 67) that showed a ≥50%
reduction in kidney interstitial capillary (IC) GL-3 levels following migalastat
treatment using a novel quantitative histological scoring method [66]. The 6-month
results indicated that the primary endpoint was not met (p= 0.3, based on the
exact Cochran–Mantel–Haenszel test stratified by gender) [67]. Review of the
data revealed that many subjects had relatively low IC GL-3 levels, and that larger
decreases in IC GL-3 were observed with increasingly higher baseline IC GL-3 val-
ues in migalastat-treated subjects [68]. Furthermore, some subjects’ GLA mutations
were recategorized as “amenable” or “nonamenable” based on a GLP-validated form
of the HEK-293 cell-based assay (“GLP HEK assay”) that was completed before the




the number of inclusions per capillary (IPC) for subjects with amenable mutations
only during the 6-month double-blind phase, a statistically significant decrease in
the number of IPCs was seen in the migalastat group (n= 25) relative to the placebo
group (n= 21), which showed an increase in the number of IPCs. This effect was
durable, with similar findings at the 12-month time point. Kidney function, measured
by eGFR, also remained stable for up to 24 months of treatment. These results show
the ability of migalastat to reduce substrate (i.e., kidney IC GL-3), and to stabilize
renal function in subjects with GLA mutations that were determined to be amenable
in the GLP HEK assay.
The second Phase 3 trial is an ongoing randomized, open-label study to compare
the efficacy and safety of migalastat to that of ERT in subjects with FD and amenable
mutations (ClinicalTrials.gov: NCT01218659) [69]. The study enrolled 60 male and
female FD subjects with the following characteristics: (i) on ERT for ≥12 months,
with ≥3 months at the labeled dose and regimen, (ii) GLAmutation corresponding to
an amenable mutant form of α-Gal A as determined by the clinical trial HEK assay,
and (iii) eGFR ≥30mL/min/1.73m2. The study was designed to randomize sub-
jects 1.5:1 to treatment with migalastat or continued ERT for 18 months (i.e., n= 36
migalastat, n= 24 ERT), with those finishing the study offered an optional 12-month
migalastat extension. The primary outcome measures were renal function as assessed
by measured (iohexol) GFR and eGFR, with secondary outcome measures including
(i) renal function assessed by eGFR (based on a different methodology than used
for the primary endpoint) and 24-h urine protein, (ii) composite clinical outcome, as
assessed by time to occurrence of renal, cardiac, or cerebrovascular events, or death,
(iii) cardiac function, as assessed by echocardiography, and (iv) patient-reported out-
comes including pain and quality of life. Following randomization, 34 of 36 subjects
who switched to migalastat and 18 of 24 subjects who continued with ERT completed
the primary 18-month treatment period. Among subjects completing the 18-month
primary treatment period, 32 out of 34 in the migalastat group, and 16 out of 18 in
the ERT group had GLP HEK amenable mutations. In the migalastat group, 31 out of
32 subjects with GLPHEK amenable mutations elected to continue to receivemigala-
stat in the 12-month treatment extension, and in the ERT group, 15 out of 16 subjects
with GLP HEK amenable mutations elected to switch from ERT to migalastat for the
12-month treatment extension, which is ongoing.
15.3 GAUCHER DISEASE
GD is generally thought to be themost prevalent LSD and is caused by inheritedmuta-
tions in the gene (GBA1) that encodes acid β-glucosidase (GCase, glucocerebrosi-
dase; EC 3.2.1.45), the lysosomal enzyme responsible for removal of the terminal
β-linked glucose from glucosylceramide (GlcCer) to yield ceramide [70]. Mutations
in GCase result in reduced cellular enzyme activity and progressive accumulation
of GlcCer primarily within macrophages (Gaucher cells) of the liver, bone marrow,
and spleen. The typical clinical presentation of GD includes anemia, thrombocytope-
nia, hepatosplenomegaly, bone lesions, and in some cases, central nervous system
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(CNS) impairment [70]. GD without CNS involvement is classified as type I, while
neuronopathic GD is classified as type II (infantile acute) or type III (subacute). Over
200 mutations in GBA1 have been identified, though the two most prevalent mis-
sense mutant forms are N370S and L444P GCase [71]. The N370S mutant form has
approximately 30% of the cellular enzymatic activity relative to cells that express
wild-type GCase [72]. Patients homozygous or heterozygous for N370S GCase typ-
ically present with nonneuronopathic GD. In contrast, the L444P mutant form has
significantly less residual activity (10–12% of wild type); consequently, individuals
homozygous for the L444P mutation often present with CNS impairment that is asso-
ciated with type III disease. More than 70% of Gaucher patients within the Ashkenazi
Jewish population carry at least one N370S allele, while 38% of non-Jewish Gaucher
patients carry the L444P allele [71,73,74].
Currently, ERT and SRT are the only two approved treatment options for patients
with GD [75–79]. GD was the first LSD for which an ERT was available, with
the placental-derived Ceredase® (alglucerase) reaching clinical practice in 1988.
Ceredase was replaced with a recombinant form, Cerezyme® (imiglucerase),
in 2001; both ERTs are marketed by Genzyme. Several other ERTs have more
recently been approved for GD in various geographies, including velaglucerase alfa
(VPRIV®, Shire), and taliglucerase alfa (ELELYSO™, Pfizer, New York, NY and
Protalix, Carmiel, Israel). Treatment of GD with ERT is most effective against type
I disease, as well as the visceral manifestations of type II and III diseases, with
significant reductions in spleen and liver weights, as well as increases in platelet
counts and hemoglobin levels, typically observed [80–83]. The CNS manifestations
of type II and III GD do not respond well to ERT due to the inability of the exogenous
enzyme to cross the BBB [84].
As discussed, SRT drugs that are used to treat GD act as inhibitors of gluco-
syltransferase, the enzyme responsible for the synthesis of GlcCer, thereby leading
to reduced cellular levels of this substrate. Zavesca® (N-butyl-1-deoxynojirimycin
(NB-DNJ), miglustat) is currently the only approved SRT for mild-to-moderate type
I GD patients [78,79,85]. Unfortunately, many patients treated with Zavesca expe-
rience side effects that include diarrhea, weight loss, tremor, and peripheral neu-
ropathy [4]. Recently, another small molecule, orally available SRT drug, eliglustat
tartrate (Genzyme), has shown promise in Phase 2 and 3 studies for treatment of type
I GD [6]. As the therapeutic agents of SRT are small molecules, these drugs have
the potential for CNS access and treatment of the neurological aspects of GD. To
this end, Zavesca has been evaluated as a treatment for neuronopathic GD, though
no significant neurological benefit was seen in type III patients [86]. Unfortunately,
eliglustat tartrate does access the CNS, but is also a PgP substrate, which transports
eliglustat out of the brain, preventing significant drug levels from being achieved in
the CNS [87]. It is the hope that future drugs in this class may provide benefit to
patients with neuronopathic forms of GD, though the long-term effects of inhibiting
this natural biosynthetic pathway are not known.
PCs also have been proposed as a potential therapy for GD [88–90]. Since none
of the currently approved therapies address the CNS manifestations of GD, there is
also a hope that small-molecule PCs may provide treatment of the neuronopathic




activity of various mutant forms of GCase in cell lines derived from GD patients
have been evaluated as PCs. These molecules can be categorized as carbohydrate
mimetics (iminosugars, azasugars, or carbasugars), or noncarbohydrate compounds
identified by high-throughput screening initiatives [10,11]. From this collection,
two have advanced through preclinical animal studies and into early-stage clinical
development, namely isofagomine (IFG; AT2101; afegostat tartrate) and Ambroxol.
IFG is an azasugar that binds and inhibits both wild-type and mutant forms of
GCase, resulting in stabilization and increased cellular and lysosomal levels [91,92],
particularly for the N370S variant [92,93]. Similarly, the cellular levels of a number
of other missense mutant forms of GCase, including L444P, are also elevated
in response to incubation with IFG [92,94–96]. These encouraging in vitro data
supported the advancement of IFG into multiple preclinical animal studies. In the
first study, 4-week administration of IFG (3–30 mg/kg) led to statistically significant
increases in GCase activity in liver, spleen, lung, bone, and brain, as well as in liver
macrophages, in a mouse model homozygous for L444P GCase [96]. Furthermore,
increased lysosomal levels of L444P GCase were demonstrated in mouse liver
homogenates. More importantly, 6-month administration of approximately 8mg/kg
IFG to these mice modestly reduced liver and spleen weights, providing some
evidence of in vivo efficacy. In a second study using a GDmouse model homozygous
for V394L GCase that to some extent mimics neuronopathic forms of the disease,
increases in GCase protein levels and activity were demonstrated in peripheral
tissues and brain following daily administration of IFG [97]. Importantly, reduced
neuroinflammation and delayed onset of neurological disease were also noted,
with life spans increased by up to 18 days (∼35%). In a third study, the effects of
daily oral IFG administration were evaluated in three different mouse models, each
homozygous for a different variant of GCase (V394L, D409H, or D409V) [92].
In all models, increased GCase activity was observed in visceral tissues and brain
following administration of 30mg/kg IFG for up to 8 weeks. Finally, using transgenic
mice that express either the human N370S or L444P mutant forms of GCase, daily
subcutaneous administration of 20mg/kg IFG for 14 days resulted in consistently
elevated GCase levels in both spleen and liver, with modest increases in cerebrum
also noted in the L444P line [98]. These experimental results, as well as a clean
safety profile, led to the advancement of IFG into clinical studies.
In support of IFG clinical development, two randomized, double-blind Phase 1
studies in healthy volunteers were conducted by Amicus Therapeutics to determine
the pharmacokinetics, pharmacodynamics, safety, and tolerability of IFG [99]. In the
single ascending dose study, 8, 25, 75, 150, and 300mg IFG all showed good systemic
and dose-proportional plasma exposures. Mean plasma levels peaked at 3.4 h, and the
plasma elimination half-life was 14 h. In the multiple ascending dose study, 25, 75,
or 225mg IFG was administered daily for 7 days. On Day 7, the pharmacokinetic
behavior remained linear with dose, with no accumulation of IFG. In both studies,
IFG was generally well tolerated and treatment-emergent adverse events were mild;
no serious adverse events occurred.
In the multiple-dose healthy volunteer study, GCase activity in white blood cells
was measured on Days 1, 3, 5, and 7 during IFG administration and on Days 9, 14,
and 21 during the posttreatment washout period [10]. In all subjects receiving IFG,
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there was a marked increase in GCase levels during the treatment period, followed by
a decrease upon withdrawal of the drug, and a return to near baseline levels by Day
21. The increase in enzyme level was dose related, reaching approximately 3.5-fold
above baseline levels at the highest dose level. These results for the safety, pharma-
cokinetics, and preliminary pharmacodynamic effects in healthy volunteers supported
the further evaluation of IFG in patients for the treatment of GD.
As such, two Phase 2 clinical studies with IFG were initiated by Amicus Thera-
peutics. The first study evaluated the safety and pharmacodynamic effects of IFG in
type I GD subjects who discontinued ERT for the 4-week duration of the study (Clin-
icalTrials.gov: NCT00433147). Twenty-two women and eight men between the ages
of 18 and 63, representing 12 different mutations (including N370S and L444P) and a
9-year average duration of ERT treatment, were enrolled. IFG (25 and 150mg daily,
150mg 3 days on/4 days off, or 7 days on/7 days off) was generally well tolerated
at all dose levels evaluated, with no serious adverse events reported. GCase activ-
ity as measured in white blood cells was increased in 20 of the 26 subjects. Five of
the six subjects without a clear increase were in the lowest dose cohort or the cohort
that was administered IFG least frequently. As expected for a short-term study, the
levels of relevant markers of GD, including platelet counts, hemoglobin levels, Glc-
Cer levels, chitotriosidase activity, and pulmonary activation-related chemokine were
unchanged. The second Phase 2 study was a 6-month study designed to evaluate the
safety of IFG and its effect on parameters that are commonly abnormal in GD (Clin-
icalTrials.gov: NCT00446550). This study was also conducted in type I GD subjects
who had never received ERT. Two dose regimens of IFG (225mg 3 days on/4 days off
or 7 days on/7 days off) were studied. While all subjects experienced an increase in
the levels of GCase as measured in white blood cells, clinically meaningful improve-
ments in key measures of disease were observed in just 1 of the 18 subjects who
completed the study. Importantly, the white blood cell GCase levels attained in this
one subject following IFG treatment were close to those of healthy volunteers, which
was substantially greater than the magnitude of increase in all other subjects. While
the results suggested that treatment with IFG was generally well tolerated, with no
serious adverse events reported, Phase 3 studies were not pursued.
Ambroxol, an approved expectorant, was identified from a screen of 1040 FDA-
approved drugs by its ability to stabilize wild-type GCase against thermal denatura-
tion [95]. Ambroxol also showed pH-dependent affinity for GCase, with decreas-
ing inhibition at lysosomal pH values. In cell-based assays using patient-derived
cell lines homozygous for N370S, Ambroxol increased cellular GCase activity up
to twofold at a concentration of 60 μM, with evidence of increased lysosomal lev-
els; similar cellular effects were seen in a heterozygous cell line expressing F213I
and L444P GCase. Evidence was also provided for modest reductions in GlcCer lev-
els in patient-derived cells. In other in vitro studies, Ambroxol (at concentrations
up to 100 μM) elevated the cellular and lysosomal levels of multiple GCase mutants
in patient-derived cells expressing R120W, R131C, N188S, G193W, F213I, N370S,
L444P, and/or P415R [100,101]. In wild-type mice, Ambroxol was generally well
tolerated, with detrimental effects on water intake and body weight occurring in
the highest dose groups only [100]. Finally, N370S or L444P transgenic mice were
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subcutaneously administered 100mg/kg Ambroxol daily for 14 days, resulting in
consistently elevated GCase levels in both spleen and liver [98]. These results led
to the advancement of Ambroxol into a physician-sponsored study in GD patients.
This pilot study assessed the tolerability and efficacy of 150mg Ambroxol daily
in 12 subjects with symptomatic type I GD who were not on ERT, 11 of whom
were homozygous for the N370S allele [102]. Of the nine subjects that completed
the 6-month study, none showed deterioration in the measured GD-related param-
eters (e.g., body weight, hemoglobin levels, platelet counts, liver and spleen vol-
umes, and chitotriosidase activity), and three continued on therapy for an additional
6months. Over the 12-month course, these three subjects showed reductions in spleen
volumes (mean reduction approximately 15%) and chitotriosidase activity (mean
reduction approximately 40%), with stabilized hemoglobin levels and liver volumes.
Importantly, in one subject platelet counts also increased over 50%. Given these
promising results, follow-up placebo-controlled studies that include larger numbers
of GD subjects with more diverse genotypes, and potentially with CNS manifesta-
tions, are warranted.
15.4 GM2 GANGLIOSIDOSES (TAY–SACHS/SANDHOFF DISEASES)
The terminal sugar N-acetylgalactosamine, which is present on several GSLs as well
as various other oligosaccharides and glycoproteins, can be enzymatically removed in
the lysosome by β-hexosaminidase (β-Hex; EC 3.2.1.52). β-Hex is composed of two
subunits and can exist as a heterodimer comprised of α- and β-subunits (β-Hex A), or
as one of two homodimers, one containing two α-subunits (β-Hex S, which is excep-
tionally rare and whose function is not clearly understood) and the other containing
two β-subunits (β-Hex B). While most N-acetylgalactosamine-containing substrates
can be processed by either the β-Hex A or β-Hex B isoform, the ganglioside GM2
and several oligosaccharides can only be processed by β-Hex A. Mutations in either
gene result in GM2 gangliosidosis [103]. More specifically, mutations in the gene
that encodes the β-subunit primarily lead to accumulation of GM2 and result in an
LSD known as Tay–Sachs disease (TSD). In contrast, α-subunit mutations result in
decreased activity of both β-Hex A and β-Hex B, and the accumulation of multiple
GSLs. The resultant LSD is an equally or sometimes more severe form of GM2 gan-
gliosidosis known as Sandhoff disease (SD). Progressive neurodegeneration is the
primary pathology associated with both forms of GM2 gangliosidosis. As with many
LSDs, the infantile or early-onset form of the disease has the most severe pathol-
ogy with rapid neurodegeneration typically occurring at approximately 6 months of
age, with an overall lifespan of 4 years or less. The late-onset form typically tends to
present clinically in the second decade of life, again with progressive neurodegener-
ation over the next two to three decades. An intermediate juvenile form has also been
characterized, with life expectancies typically not beyond two decades. Currently,
there are no effective treatment options for GM2 gangliosidosis patients.
Pyrimethamine (PYR), an approved antimalarial drug, was identified as a potent
inhibitor of β-Hex from a screen of 1040 FDA-approved drugs [104]. In follow-up
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cell-based assays using 10 TSD and 7 SD patient-derived cell lines, PYR led to
significant increases in cellular and lysosomal β-HEX levels and activity in one cell
line with a β-subunit mutation (TSD) as well as all seven cell lines with α-subunit
mutations (SD). Consequently, escalating doses of PYR (maximum: 100mg/day)
administered orally in a single daily dose over a 16-week period were evaluated in
a Phase 1/2 open-label clinical study to determine tolerability and efficacy in the
treatment of late-onset GM2 gangliosidosis subjects [105]. A total of 11 subjects
were enrolled, 8 males and 3 females, aged 23–50 years. For the eight subjects that
completed the study, up to fourfold increases in β-Hex activity were observed in
white blood cell lysates at doses of 50mg per day or less, despite marked individual
variations in PYR’s pharmacokinetic profile. Unfortunately, significant side effects
(increased ataxia, lack of coordination, and seizures) were observed in most subjects
at doses of 75mg per day or higher and the trial was discontinued. These data
suggest that PYR can enhance β-Hex activity in peripheral cells of subjects with
late-onset GM2 gangliosidosis at doses lower than those that are associated with
adverse effects. Future studies will be necessary to determine the clinical efficacy of
PYR in TSD and SD patients.
15.5 POMPE DISEASE
Pompe disease (acid maltase deficiency, glycogen storage disease type II) is an
LSD caused by mutations in the gene (GAA) that encodes the lysosomal enzyme
acid α-glucosidase (GAA; EC 3.2.1.20) [106,107], the enzyme that hydrolyzes the
α1,4- and α1,6-glycosidic bonds of glycogen [108]. Deficiency in GAA activity
results in glycogen accumulation and deposition in the lysosomes of heart, skeletal
muscle, and other tissues [109]. GAA is synthesized as a 110 kDa immature
glycoprotein precursor in the ER and undergoes a series of proteolytic and N-glycan
processing events to yield the 95 kDa intermediate and the 76 and 70 kDa mature
isoforms [110–113]. This processing into the intermediate and mature forms occurs
in late endosomes and lysosomes, respectively [110], with the final mature isoforms
showing significantly increased affinity and activity toward glycogen compared to
the precursor forms [111,114]. Increasing the amount of mature, active GAA in
lysosomes is an important step toward increasing glycogen hydrolysis and reducing
substrate accumulation in this disease.
Pompe disease shows a broad phenotypic spectrum that ranges from the severe
infantile-onset form to more slowly progressing, later-onset forms. Infantile-
onset Pompe disease patients have little or no GAA activity, present with hypotonia,
cardiomegaly, and cardiorespiratory distress, and have a life expectancy of about
2 years [115]. Late-onset forms of the disease typically show some detectable
GAA activity, present in childhood or adulthood, and progress more slowly, with
musculoskeletal and pulmonary involvement leading to progressive weakness and
respiratory insufficiency [116]. Compared to an age- and gender-matched healthy
population, untreated late-onset Pompe patients have higher mortality rates [117],




Currently, ERT is the only approved treatment for Pompe disease, administered
as a biweekly intravenous infusion of recombinant human GAA (rhGAA; alglucosi-
dase alfa, marketed as Myozyme® and Lumizyme®, Genzyme-Sanofi). Treatment
with rhGAA improves cardiac function, motor skills, and life span in infantile-onset
patients [119–124] and leads to some improvements inmotor and respiratory function
in late-onset patients [125,126]. Despite the clinical benefits of ERT, the efficacy of
rhGAA may be limited by insufficient targeting and uptake into key disease-relevant
tissues, as well as poor tolerability due to sometimes severe immunogenic and ana-
phylactic reactions to the exogenous enzyme [124,126–132]. Thus, a clear unmet
medical need still exists for many Pompe patients.
Small-molecule PCs have been proposed as a potential alternative to ERT for
the treatment of Pompe disease [133–136]. Approximately 150 GAA mutations are
predicted to produce a full-length protein containing a single amino acid substitution.
However, these GAA mutants likely do not fold as efficiently or are less stable
compared to wild-type GAA and, therefore, are susceptible to premature degradation
via ERAD. It has been demonstrated that some mutant forms of GAA are responsive
to the PCs 1-deoxynojirimycin hydrochloride (DNJ, duvoglustat hydrochloride,
AT2220) and NB-DNJ, as evidenced by increased trafficking, maturation, and
activity [133,135]. To this end, Flanagan et al. [136] characterized the effects of
DNJ on 76 different mutant forms of GAA. A homology model of GAA was
also constructed using the crystal structure of a related eukaryotic α-glucosidase,
maltase-glucoamylase, to gain conformational insights into GAA and to map the
locations of the residues of the mutant forms of GAA responsive to DNJ. Given
the large number of pathogenic GAA mutants identified to date and the need to
determine which forms are amenable to PC therapy, this study provided additional
evidence and support for the continued evaluation of DNJ as a potential therapeutic
for Pompe disease. Mechanistically, DNJ has multiple modes of action during the
synthesis and maturation of mutant GAA, including increased specific activity
prior to proteolytic processing in lysosomes, facilitated export from the ER with
subsequent trafficking and processing through the secretory pathway to lysosomes,
and stabilization of the mature isoforms in lysosomes [12].
Furthermore, the in vivo effects of DNJ were tested in a new mouse model of
Pompe disease [12]. This mouse model expresses the human mutant GAA trans-
gene P545L on a Gaa knockout background (hP545L GAA Tg/KO) and shows low
GAA activity and elevated glycogen levels in disease-relevant tissues including heart,
diaphragm, multiple skeletal muscles, and brain. Daily oral administration of DNJ
to hP545L GAA Tg/KO mice resulted in significant and dose-dependent increases
in GAA activity with concomitant reduction in tissue glycogen levels; less-frequent
DNJ administration regimens (such as 4 days on drug followed by 3 days off, or 5
days on drug followed by 2 days off) resulted in even greater glycogen reduction
compared to daily administration. Collectively, these results provided support for the
evaluation of DNJ as a potential treatment for Pompe disease.
To date, five Phase 1 clinical studies have been completed in healthy adult vol-
unteers by Amicus Therapeutics, with single ascending DNJ doses ranging from 50
to 2500mg, and repeat-administration (up to 14 days) ascending doses ranging from
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50 to 2000mg. Across these studies, DNJ was generally safe and well tolerated at
all doses and was orally available with a plasma half-life of 4–5 h. There were no
drug-related serious adverse events in any of these studies, and no adverse events
were considered to be definitely or probably related to study treatment. In the mul-
tiple ascending dose study, all possibly related adverse events were mild in severity
and resolved spontaneously.
Following these Phase 1 studies, a Phase 2 study (ClinicalTrials.gov: NCT00688
597) was conducted in adult Pompe subjects. The subjects were to be enrolled
sequentially to one of three dosing cohorts: 2.5 g for 3 days followed by no drug for 4
days, 5 g for 3 days followed by no drug for 4 days, and 5 g for 7 days followed by no
drug for 7 days. This study was terminated after enrollment of three subjects at the
2.5 g dose level due to the occurrence of severe adverse events (muscle weakness)
in two subjects, which were judged to be drug related. Fortunately, these effects
were reversible over the 4–11 months following DNJ withdrawal. At this high dose
of DNJ, these adverse events were deemed to be due to sustained DNJ-mediated
inhibition of the low levels of endogenous GAA activity present in these subjects. A
follow-up Phase 1 study in healthy volunteers [137] was conducted to evaluate the
pharmacokinetics of DNJ in muscle of healthy volunteers after a single oral dose
of 100 or 1000mg. Following administration of 1000mg DNJ, the drug rapidly
appeared and remained in muscle for over 1 week at concentrations that were in
excess of its IC50 value for inhibition of GAA (approximately 20 nM at pH 5.2).
Muscle exposure to DNJ, as assessed by peak DNJ concentration, increased in an
approximately dose-proportional manner. DNJ levels in the muscle rapidly declined
to 1% of peak levels within 24 h after administration; the remainder was slowly
cleared with a terminal half-life of approximately 90 h [137]. Similar to other PCs,
DNJ is a reversible, competitive inhibitor that noncovalently binds to the active
site of GAA; hence, it is necessary to balance DNJ-mediated increases in GAA
stability and lysosomal levels with the potential for in situ GAA inhibition. The
pharmacokinetic profile of DNJ in human muscles suggests that the oral dose of
DNJ used in the Phase 2 study (2.5 g) was too high. Furthermore, the endogenous
GAA activity was quite low in these subjects (less than 1% of wild type), suggesting
that an appropriate balance between chaperoning and inhibition was not achieved,
resulting in prolonged inhibition of endogenous GAA activity, which may have led
to the clinically significant adverse, but reversible, muscle-related events in these
Pompe subjects. As such, reducing the dose and/or administration frequency of DNJ
in future clinical studies may avoid such adverse events.
15.6 PC-ERT COMBINATION THERAPY
As discussed earlier, ERT is used to treat several LSDs, often representing the only
approved therapy (with SRT for GD and NPC being the only exception). While
providing improved clinical outcomes, ERT in general has many limitations. The
infused enzymes tend to have short circulating half-lives, insufficient biodistribution
to some key cell types, tissues, and organs, and often elicit immunologic responses
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that adversely affect tolerability and efficacy. For instance, a recent study with Fabry
patients revealed that ERT provided only minimal improvement on cardiovascular
parameters, again underscoring the significant unmet medical need in LSDs [138].
PCs offer another approach to the treatment of these diseases, with the poten-
tial benefits of being noninvasive, well tolerated, and broadly biodistributed, includ-
ing the CNS. At the same time, PC therapy also has some limitations, especially
as PC monotherapy is only applicable for patients that express responsive mutant
forms of the enzymes. However, it was recently hypothesized and demonstrated that
PCs can improve the biochemical and pharmacological properties of the exogenous
enzymes used in ERTs through binding and stabilization, potentially opening up a
new approach for LSD treatment: combination therapy using PCs and ERTs together
for improved therapeutic activity.
One of the first examples of PC-ERT combination therapy was described in the
context of GD [139]. Incubation of recombinant human GCase (Cerezyme) with IFG
significantly increased the stability of the recombinant enzyme and increased cellu-
lar uptake into GD patient-derived cells to levels greater than those obtained with
enzyme alone. Parenti and coworkers [140] extended the findings on combination
therapy to the treatment of Pompe disease using the Gaa knockout mouse model.
Animals receiving an oral dose of NB-DNJ (4.3mg/kg) for 2 days prior to an intra-
venous (IV) infusion of rhGAA showed a significant increase in enzyme activity in
multiple disease-relevant organs as compared to those receiving ERT only, includ-
ing muscles that usually show little-to-no response to ERT alone. Furthermore, DNJ
prevented rhGAA denaturation and loss of activity at neutral pH and 37 ∘C in vitro.
In rats, oral coadministration of DNJ (3 or 30mg/kg), 60min prior to intravenous
infusion of rhGAA, increased the circulating half-life and overall exposure of the
enzyme by up to twofold. In Gaa knockout mice, four biweekly IV administrations
of rhGAA with oral coadministration of DNJ (30mg/kg) prior to ERT resulted in
a significant increase of up to 2.5-fold in GAA activity in disease-relevant tissues,
including skeletal muscles, compared to ERT alone. More importantly, PC coad-
ministration led to robust glycogen reduction in these same tissues, up to 2.6-fold
greater compared to ERT alone [141]. Similarly, increased enzyme stability and cel-
lular uptake and improved substrate reduction in an FD mouse model were observed
with DGJ in combination with recombinant human α-Gal A [142].
These promising preclinical results led to the initiation of several Phase 2 PC/ERT
coadministration clinical studies. In a Pompe Phase 2 study conducted by Amicus
Therapeutics (ClinicalTrials.gov: NCT01380743), subjects who had been on ERT
as their standard of care were orally coadministered a single dose of DNJ at 50,
100, 250, or 600mg 1 h prior to ERT infusion; GAA activities in plasma and muscle
were evaluated in comparison to administration of ERT alone. Similar to the findings
of the preclinical studies, the PC coadministration led to increased GAA activity in
plasma aswell as inmuscle. Dose-dependent increases in plasmaGAAexposure were
observed for all subjects, attaining 1.5- to 2.8-fold greater exposures compared to ERT
alone. In muscle biopsy samples taken on Day 3 or 7 after administration, increases
in total GAA activity were observed in 16 of 24 (67%) subjects with evaluable data.
While all DNJ doses evaluated showed some increase in plasma GAA activity, the
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lowest dose (50mg) was the least robust, while the highest dose (600mg) showed
the greatest effect on both plasma and muscle GAA levels [143]. In addition, another
clinical study based on the combination of NB-DNJ and rhGAAwas initiated in Italy
(Telethon foundation, trial GUP09017), and has similarly shown greater circulating
GAA levels in plasma with PC coadministration compared to ERT alone [144].
Finally, a Fabry Phase 2 study (ClinicalTrials.gov: NCT01196871) initiated by
Amicus Therapeutics explored a single oral coadministered dose of 150 or 450mg
DGJ 2 h prior to the infusion of ERT. Again, increased plasma exposures of α-Gal
A activity of 1.2- to 5.0-fold compared to ERT alone were seen in 22 of 23 subjects.
Both tested doses of DGJ led to greater total α-Gal A activity in Day 2 skin biopsies
in 19 of 23 (82.6%) subjects relative to ERT alone, with modest improvements still
noted in some Day 7 skin biopsies. Of the two DGJ doses tested, 450mg resulted in
greater increases of active α-Gal A enzyme levels in skin tissue [145].
These clinical studies extend preclinical observations and support the notion that
oral administration of a PC shortly before ERT infusion can stabilize the recombinant
enzyme in the circulation, protecting the infused proteins from denaturing and leading
to greater exposure and improved cellular uptake. These proof-of-concept studies lay
the foundation to further explore whether PC/ERT combination therapy can alter ERT
biodistribution and therapeutic efficacy in target tissues that respond poorly to ERT
alone. Furthermore, the stabilization by the PC also may reduce the immunogenicity
of the infused enzyme and thereby ameliorate the immune response elicited by many
ERTs. This could improve tolerability and safety, and further enhance therapeutic
outcomes in some patients. The synergism of an ERT combined with a PC offers a
new therapeutic option with promises for patients suffering with LSDs, especially
those who are unable to use PC monotherapy, or who do not get sufficient benefit
from ERT treatment alone.
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16.1 INTRODUCTION
The term “biologics” refers to a group of clinical therapies that employ biological
macromolecules, either as purified components, or in the context of biological
preparations, cells, and/or tissues that are intended to modify the health and well-
being of patients based on the inherent biological structure and function of the
therapeutic. In the United States, the responsibility for approval and use of biologics
lies with the United States Food and Drug Administration (FDA). The FDA
provides a list of classifications of biologics that includes Allergenics, Blood and
Blood Products, Cellular and Gene Therapy Products, Tissue and Tissue Products,
Vaccines, and Xenotransplantation (use of nonhuman biologics in humans). Among
these major classes, only biologics related to Cellular and Gene Therapy Products
are likely to require endosomal escape for full activity. Of interest, as of January
2015, 9 of the 10 approved products in this category included live human cells
while the 10th is a live mycobacterium for use as a vaccine, none of which require
endosomal escape (US Food and Drug Administration Vaccines, Blood & Biologics:
Cellular and Gene Therapy Products; http://www.fda.gov/biologicsbloodvaccines/
cellulargenetherapyproducts/ApprovedProducts/default.htm; viewed on 01/30/15).
Therefore, while a tremendous amount of research has gone into the development
of intracellular therapies that will require endosomal escape, the benefits of that
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research remain to be realized, and the difficulties surrounding intracellular delivery
of large molecules can certainly be identified as one of the factors delaying the
development of these therapies. Among the therapies in the pipeline, gene therapy
holds tremendous promise for correction of genetic defects as well as in vivo
production of therapeutic proteins. Despite the fact that the first approved human
gene therapy trial was conducted in the United States in 1990 [1], there remain
no FDA-approved gene therapies as of the writing of this chapter (US Food and
Drug Administration Vaccines, Blood & Biologics: Cellular and Gene Therapy
Products; http://www.fda.gov/biologicsbloodvaccines/cellulargenetherapyproducts/
default.htm; viewed on 01/30/15). Nonetheless, the role of intracellular therapeutics,
involving nucleic acid-based drugs as well as other macromolecules, is expected to
grow rapidly in coming years. In particular, the recent focus on the development
of small interfering RNA (siRNA) technology has pushed the development of new
solutions to passing the plasma membrane [2–4].
Biologics, as a group of therapeutic agents, have unique challenges in terms of
preparation and delivery. Compared with small molecules, biologics require specific
formulations that preserve their complex molecular structure, are limited in terms
of routes of administration due to tissue barriers, and have unique pharmacokinetic
and pharmacodynamics profiles based on their interactions with other biologic
molecules in the patient [5]. Thus, it is not surprising that delivery of biologics to
the cytosol of a target cell raises a new set of issues. While small molecules typically
rely on organic phase partitioning or use of pumps or channels to enter the cytosol,
the larger, more complex biologic drugs must find other ways to cross the membrane
and gain access to the cytosol.
This chapter addresses common strategies for delivering biologics past the endo-
somal membrane and into the cytosol. The major routes for biologic delivery from
the endosome are summarized in Table 16.1. The majority, but not all, mechanisms
for leaving the endosome involve disruption of the endosomal membrane. Major
mechanisms for disrupting the endosomal are summarized in Figure 16.1. This
review focuses on biologics that must escape from endosomes to be active. For some
biologics, the site of action is within the endosomal–lysosomal system and does not
require passage across a membrane. For example, exogenous delivery of lysosomal
enzymes to treat lysosomal storage diseases does not require crossing a membrane
and is not addressed here. As noted here, the vast majority of biologics are either in
cellular form or constitute vaccines, and thus not relevant to this topic, vaccines that
are meant to enter the endosomal processing pathway of antigen-presenting cells but
that do not escape, or molecules that act primarily in the blood or on the cell surface
such as therapeutic antibodies (e.g., Herceptin or Avastin) or clotting factors that
act extracellularly and, thus, do not require endocytosis to reach their site of action.
These classes of biologics are not addressed in this chapter.
16.2 ENDOSOME CHARACTERISTICS
The first step in developing strategies for endosomal escape during delivery of




TABLE 16.1 Examples of Natural or Engineered Endosomal Escape for Delivery of













peptides derived from HA2
[9–12]
HIV gp41 [13] A peptide derived from HIV
gp41 retains endosomolytic
activity and enhances
siRNA and plasmid DNA
delivery [14,15]
Flock house virus capsid protein
autocleavage product [16]
Adenovirus protein VI [17]




Hepatitis A virus VP4 [23]
Human rhinovirus VP1 [24] A peptide from the human









Insertion of hydrophobic domains
Reovirus μN1 [33–35]
Murine polyoma virus VP2 [36]
Human rhinovirus VP4 [37]
Poliovirus VP4a [38]
Acid-catalyzed phospholipase
Adeno-associated virus VP1 [39]
Canine parvovirus VP1 [40,41]
B19 VP1 [42]













honey bee venom was
combined with a plasmid in
a nanohydrogel-enhanced
plasmid delivery [43]
Proton sponge effect Production of small pores that could admit K+ ions









Membrane fusion Peptide-induced membrane fusion
Dengue virus glycoprotein E [52]
Ebola virus glycoprotein [53,54]
SARS coronavirus [55] [56]






head groups to positive
head groups by protonation
of carboxyl groups [3]
Alternative endocytic
trafficking
Retrograde secretory pathway trafficking







aPoliovirus appears to use more than one strategy for endosomal escape.
bSince bacterial escape from phagosomes is complex, mechanistic contributions of bacterial proteins listed












Figure 16.1 Endosomal escape pathways. Delivery of macromolecular biologic drugs to the
cytosol requires passage across at least one membrane barrier. The endosome membrane rep-
resents a convenient point of transit to the cytosol due to the fact that the characteristic, rapid
acidification of the endosome provides a useful environmental trigger to deploy molecules that
might otherwise be cytotoxic. At the same time, the endosome is a confined space where the
environment can be manipulated and close apposition to the membrane is guaranteed. (a) Rup-
ture of the endosomal membrane can be accomplished by membrane-lytic molecules such as
amphipathic helices that display a series of positively charged R groups on one side of the helix
facilitating interaction with negatively charged lipid head groups. The resulting disruption to
the lipid bilayer can result in pore formation or larger fissures, sufficient to release endosomal
contents to the cytosol including viral particles with a diameter up to 80 nm and bacteria with
short-axis diameters up to 0.5 μm. The amphipathic helices are potentially cytotoxic and, thus,
are stored in an inactive form as part of either the capsid (e.g., adenovirus), in the membrane
of an enveloped virus (e.g., influenza virus), or within a bacterium (e.g., Listeria). Typically,
the deployment of helices is linked to acidification of the endosome and activation of either a
viral protease, such as the L3/p23 protease of adenovirus, or an endosomal protease as in the
case of influenza virus HA2 or listeriolysin O.When an enveloped virus utilizes a pH-triggered
insertion of an amphipathic helix into the endosomal membrane, the insertion can be coupled
with a conformational change in the helix-bearing membrane protein to enhance the fusion of
the viral membrane and the endosomal membrane. (b) Endosomal membrane rupture can also
be accomplished by osmotic lysis via the proton sponge effect. The formation of a particle that
includes a high concentration of functional groups that convert from neutral to proton-accepting
moieties at slightly acidic pH, for example, secondary or tertiary amino groups, results in fix-
ation of protons in association with weak bases inside of the endosome. As a result, far more
protons are pumped into the endosome to achieve a drop in pH. Themassive influx of protons is
accompanied by chloride counterions resulting in a locally high osmolarity. An influx of water
by osmosis then elevates the interior pressure in the endosome resulting in lysis of the mem-
brane. The high transfection efficiency of polyethylenimine (PEI) has been attributed to the
proton sponge effect. Other weak bases such as histidine residues can also generate osmotic
lysis of endosomes. (c) Membrane fusion can also contribute to the delivery of biologics to
the cytosol across the endosomal membrane. Membrane fusion occurs when using cationic
liposomes or lipoplexes due to the locally high number of positive charges in close apposi-
tion to the inner leaflet of the endosomal membrane. While acidification is not required for
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and phagocytic trafficking pathways to lysosomes. Relevant parameters include
compartment size and pH as well as the kinetics of formation and maturation of
endosomal compartments, the dichotomy between the flow of membrane versus fluid
contents within the endosomal pathway, and the complement of lytic enzymes found
in these compartments. Several detailed reviews of these topics are available [65–67].
Several distinct pathways exist for entry into the endocytic or phagocytic
pathways [65]. Endocytic pathways include both clathrin-mediated endocytosis
and clathrin-independent endocytosis, both of which involve the invagination of
membrane from the plasma membrane creating vesicles of approximately 100 nm in
diameter. There do not appear to be any markers of nonclathrin-mediated endocytosis
that are distinct from the clathrin pathway, suggesting that clathrin-independent
endocytosis may be simply a consequence of a particular set of conditions rather
than a distinct pathway with unique molecular control. Both classes of endocytic
vesicles rapidly (<3min) acidify to a pH of approximately 6.0 and then fuse with a
larger organelle, the sorting endosome. Sorting endosomes are larger than endocytic
vesicles and feature a tightly controlled pH in the range from 5.9 to 6.0. Residence
time for components of the sorting endosome depends on whether the cargo adheres
to the membrane or is present in the fluid phase. Ligands for cell surface receptors
either remain bound to their receptor or detach from their receptor as pH decreases.
Membranous components including receptors and bound ligands return to the cell
surface while fluid-phase components including released ligands and other materials
that may have entered endosomes by diffusion during endocytosis remain associated
with the sorting endosome until the sorting endosome matures to become a late
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endosome. Due to this dichotomy in routing at the sorting endosome, residence time
depends on fractionation. Membrane-bound components reside in sorting endo-
somes for approximately 2.5min, while fluid-phase components leave the sorting
endosome with a half-life of 8min. Membrane-bound components, in general, are
trafficked to recycling endosomes before returning the plasma membrane while late
endosomes ultimately fuse with primary lysosomes where the internal pH decreases
to 5.0–5.5 and a host of hydrolytic enzymes are activated. A subset of the hydrolytic
enzymes are encountered earlier in the endocytic pathway, with cathepsins, type II
transmembrane serine proteases, furin, and other preprotein convertases having been
reported in sorting endosomes [68–70].
Caveolae, smaller invaginations of the plasma membrane having a characteristic
“flask” shape, represent an important plasma membrane specialization that plays a
critical role in cell signaling and appear to serve as an alternative site of internal-
ization for a subset of ligands and receptors [71]. Caveolae have a distinct protein
coat, often including caveolin, and serve as sites for accumulation of aggregated,
lipid-anchored proteins on the cell surface. Ligands that are internalized via caveolae
enter the endocytic sorting system and are likely to encounter similar conditions as
those internalized by endocytosis.
While phagocytosis accomplishes the same mission as endocytosis, that is, bring-
ing a cargo into the cell with a surrounding envelope comprised of plasma mem-
brane, the process is structurally and functionally distinct from endocytosis [72].
Phagocytosis is normally restricted to a set of cells in the immune system including
macrophages, dendritic cells, and neutrophils. These cells play key roles in internal-
ization of bacteria and other pathogens, hydrolytic degradation of those pathogens,
and antigen presentation [73]. The process of phagocytosis in macrophages and neu-
trophils is not directly relevant to the general topic of endosomal or lysosomal escape,
and thus is not discussed in detail here. However, a related process occurs in a larger
variety of cells that normally do not exhibit endocytosis where a certain group of
pathogens induce phagocytic entry of the pathogen to the cytosol by escape from
phagocytic compartments to establish colonization of the cytosol [74]. These species
(include the trypanosomes, which are eukaryotic protists, as well as several genuses
of bacteria, including Shigella, Listeria, Rickettsia, and Francisella) are able to gain
access to the cytosol by breaching a phagosome membrane and, thus, are of interest
to a discussion of delivery of biologics to the cytosol.
In summary, the design of mechanisms to enable escape of biologics from endo-
somes after internalization must be cognizant of the rate of acidification, size of the
compartment, presence of potentially catalytic and/or hydrolytic enzymes, and resi-
dence time in that compartment prior to encountering a new set of conditions.
16.3 DELIVERY OF NATURE’S BIOLOGICS: LESSONS ON
ENDOSOMAL ESCAPE FROM PATHOGENS
Nature has been a consistent contributor as a starting point for engineering. In
seeking solutions to problems, a careful consideration of nature often points toward
a reasonable, well-tested solution. In the case of endosomal escape, nature does
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not disappoint. Viruses, bacteria, and toxins have all been observed to escape
from endosomes.
16.3.1 Viruses
Viruses provide, perhaps, the richest set of examples for molecular solutions to
the problem of endosomal escape. While some viruses are capable of fusing with
the plasma membrane, many viruses depend on endosomal escape mechanisms to
deliver their genetic payload to the cytoplasm, with the ultimate target being either
the cytoplasm, for some RNA genome-containing viruses, or the nucleus, for DNA
genome-containing viruses or for those viruses that utilize reverse transcriptase
to create a DNA genome from an RNA genome. In both cases, the endosomal
membrane must be breached as an initial step in infection.
Viruses, in general, fall into two categories: enveloped and nonenveloped viruses.
Enveloped viruses are formed by budding from an infected cell. Budding is an exo-
cytic process during which viral proteins, host cellular proteins, and a small portion
of host plasma membrane are collected around the viral core (nucleocapsid). In con-
trast, nonenveloped viruses simply contain a protein shell, or capsid, that encases their
genetic material. The encounter of enveloped viruses and nonenveloped viruses with
the endosomal membrane, while fundamentally different, can share similar molecular
mechanisms for escape.
The most prevalent shared mechanism is the requirement for a pH trigger. Many
viruses that escape from endosomes require acidification of the endosome as part
of the triggering mechanism for escape. Influenza virus hemagglutinin protein was
the first protein for which the lytic activity was unambiguously assigned [6,7]. This
requirement has been experimentally documented by demonstrating that infection of
target cells is inhibited in the presence of molecules that inhibit endosome acidifica-
tion. Endosome acidification can be prevented through the use of weak bases such as
ammonium chloride or chloroquine that enter acidic compartments as neutral com-
pounds before acting as weak bases and associating with protons at low pH where the
charged molecule becomes trapped [75]. Alternatively, ionophores such as monensin
A1 can be used to prevent the acidification of endosomes by exchanging protons with
other monovalent cations across the endosome membrane [76]. Finally, acidification
of endosomes can be blocked through the use of inhibitors of the vacuolar-type H+
ATPase, such as bafilomycin A1 [77]. In the presence of these agents, the infection
of many viruses is reduced or delayed.
Further investigation into the mechanism of the pH trigger has revealed several
different models. The hemagglutinin 2 (HA2) protein from the influenza virus, an
enveloped virus, was shown to undergo proteolytic cleavage mediated by ubiquitous
endosomal proteases, such as furin [78] or preprotein convertase-6 [79]. Proteolytic
modification reveals an amphipathic helix that is capable of insertion into a biological
membrane. Upon association of a sufficient number of helices with the membrane,
the endosomal membrane is effectively destabilized and the virus is able to escape to
the cytosol. Several models of membrane destabilization by amphipathic helices have
been proposed [80]. Membrane destabilization results from the interaction of positive
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amino acid side chains (largely lysine and histidine) with negatively charged head
groups of lipids. Two models, the barrel-stave model and the carpet model, describe
insertion of the amphipathic helices into membranes following binding to the lipid
head groups and can result in disruptions ranging from pore formation to membrane
solubilization. Relevant to the role of amphipathic helices in endosomal escape, low
pH enhances the ability of amphipathic helices to disrupt membranes [81]. In the case
of enveloped viruses, membrane destabilization can lead to membrane fusion. Three
models for membrane fusion exist: Class I, Class II, and Class III, which generally
involve peptide–peptide interactions leading to the formation of hairpins that drive
the fusion process [82].
Similar amphipathic peptides have also been implicated in endosomal escape
mediated by other viral proteins [83]. In addition to influenza virus, proteins from
other enveloped viruses including HIV gp41 [13] and the γ fragment of Flock
house virus capsid protein [16], as well as nonenveloped viruses such as adenovirus
protein VI [17], bluetongue virus VP5 [18], rotavirus VP7 [84], rotavirus NSP4 [20],
poliovirus VP1 [21,22], and human rhinovirus VP1 [24] have also been implicated
in endosomal escape via an amphipathic alpha helix.
While the involvement of an amphipathic alpha helix is a common mechanism
found among viruses, other lytic systems are also employed. The reovirus μN1
[33,34], murine polyomavirus VP2 [36], hepatitis A virus VP4 protein [23], and
human rhinovirus VP4 protein [37] use the insertion of a myristoylated proteins into
the endosomal membrane to create pores that could permit translocation of viral
RNA to the cytosol. Of interest, poliovirus also contains a myristoylated protein,
VP4, suggesting that the poliovirus escape route might combine more than one
endosomal exit strategy [38].
In contrast, four parvoviruses including adeno-associated virus [39], canine par-
vovirus [40,41], and B19 and porcine parvovirus [42] use a very different strategy.
The VP1 proteins of these viruses contain a phospholipase A2 (PLA2) enzyme activ-
ity. After entry into the endosome, the PLA2 activity is thought to destabilize the
inner leaflet of the endosomal membrane leading to membrane rupture and capsid
escape. Finally, flaviviruses such as dengue virus use the acidic environment of the
endosome to induce a conformational change in an envelope protein (glycoprotein E
in dengue virus) exposing a series of hydrophobic peptide loops that can insert into
the membrane inducing fusion of the viral envelope and organelle [85].
Viruses may harbor additional mechanisms and/or control points for endosomal
escape beyond those discussed above. For example, in the case of adenovirus, the
acid dependence of the escape is mediated by the L3/p23 protease. Upon exposure to
an acidic environment, L3/p23 cleaves a second protein, protein VI [17]. Protein VI
is present in hundreds of copies just under the facets of the viral capsid [86]. A prote-
olytic cleavage of protein VI reveals the amphipathic helix that is ultimately respon-
sible for destabilizing the endosomal membrane [17,87]. Similar to adenovirus, the
mammalian reovirus is the beneficiary of a proteolytic trigger wherein the μ1 pro-
tein is cleaved in the endosome to reveal the myristoylated μ1N fragment [33–35].
In the case of dengue virus, the fusion loops of glycoprotein E are not active in the
early endosome where they are revealed. Instead, fusion is delayed until the virus
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encounters the late endosome where the loops interact with anionic lipids as cofac-
tors for fusion [52]. Although the precise molecular events of endosomal escape by
Ebola virus, a flavivirus, are not known, they bear some resemblance to that of dengue
virus. Both dengue virus and Ebola virus are activated by proteases during entry. For
Ebola virus, members of the cathepsin cysteine protease family prime the glycopro-
tein for interaction with cellular membranes [88,89]. Although Ebola virus infection
does not require low pH, cathepsin activity is enhanced at low pH, but the fusion
event, similar to that of dengue virus, does not occur in early endosomes. Instead,
the cleaved Ebola virus glycoprotein binds to the Niemann–Pick C protein leading to
membrane fusion and late endosomal escape [53,54]. Finally, the SARS coronavirus
shares a similar strategy to Ebola in that it employs a proteolytically activated fusion
protein with multiple, bundled alpha helices, but, like reovirus, a posttranslationally
added lipid molecule helps to guide the fusion reaction [55,56].
16.3.2 Bacteria, Protozoa, and Fungi
Some bacteria and lower eukaryotic cells have developed mechanisms to escape from
the endolysosomal system to avoid hydrolytic enzymes and to take safe harbor in the
cytoplasm of host cells. The escape problem for these pathogens is literally magni-
fied relative to viruses since viruses are typically less than 500 nm in their largest
dimension, with all nonenveloped viruses being less than 100 nm in diameter [90],
a property that enables uptake by endocytosis. In contrast, bacteria are hundreds to
thousands of nanometers in diameter while protozoa and fungal cells are larger. For
most cells, engulfment by a eukaryotic phagosome leads to degradation and death,
but a select group of pathogens live within eukaryotic host cells where they have
developed extraordinary means of avoiding their own demise.
Phagosomes are large, often on the order of microns in diameter, and require
actin-dependent extension of the plasmamembrane, intracellular signaling, and inter-
action with endosomes and lysosomes within the cell to engulf, internalize, acidify,
and hydrolyze a cargo [91]. The maturation of the phagosome includes a period
during which membrane can be exchanged with early endosomes and recycling endo-
somes, although the contents of the phagosome remain in a single compartment.
The phagosome first acquires the GTP-binding protein, rab5, which is known for
its roles in directing membrane trafficking events in endocytic systems, but the regu-
lation and, perhaps, the function of phagosomal rab5 appears to be distinct from that
of endosomal rab5, suggesting common functions but a clear delineation between
the trafficking pathways [92]. Eventually, rab5 is exchanged for rab7 and matura-
tion concludes with accumulation of lysosomal markers such as lysosomal-associated
membrane protein 1 (LAMP-1) and LAMP-2 in the compartment due to fusion with
primary lysosomes [92].
While some bacteria, protozoans, or fungi modify the phagosome to create a viable
environment, others escape to the cytosol [74], and these methods of escape are rel-
evant to this discussion. The mechanisms of phagosomal escape are as varied as
observed earlier for viral escape from endosomes. Species of Shigella, Listeria, Rick-
ettsia, Francisella, Burkholderia, and Cryptococcus genuses have developed unique
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solutions to this problem. In each case, the effectors of escape have been investigated.
In some cases, the mechanisms are quite complex and involve multiple proteins or
even multiple protein complexes. Among these, the bacterial secretion systems are
often involved. Gram-negative bacteria are characterized by seven distinct secretion
systems that enable bacteria to facilitate delivery of large molecules across mem-
branes [93]. Inmore than one case, elements of these systems do double duty enabling
escape of the entire organism from the phagosome.
Recent data on the escape mechanism for Francisella tularensis illustrate the com-
plexity with which bacteria escape from phagosomes. The ability of Francisella to
cause disease is dependent upon escape from the endosome. Escape from the phago-
some has been genetically mapped to a group of genes known as the Francisella
pathogenicity island, which itself is a conserved part of type 6 secretion systems.
Among the genes encoded in this domain, some gene products create a pore through
which other pathogenicity island proteins can be secreted into host cells. To give a
sense of the complexity in this system, some proteins, such as IglI, have been impli-
cated in pathogenicity [94]. IglI is a protein that is secreted by Francisella into the
cytoplasm of the host cell and requires the presence of VgrG to accomplish secre-
tion. In contrast, VgrG, another protein that is secreted, does not require any other
protein in the pathogenicity island to accomplish secretion [94]. VgrG appears to be
a key protein since oligomers of VgrG can create holes in membranes [45]. Other
members of the pathogenicity island are also required for phagosome escape, despite
the fact that their roles appear to be in secretion. DotU mutants do not escape from
phagosomes [45], and IglE, a palmitylated outer membrane protein, is also required
for both secretion and escape [95]. It is not clear where the line between secretion
and endosomal escape is drawn.
Shigella flexneri is another Gram-negative human pathogen that begins its colo-
nization by entry into macrophages or epithelial cells by phagocytosis followed by
escape from the phagosome. Similar to several of the other pathogenic intracellular
bacteria, Shigella enters cells and then spreads from cell to cell by a nonphago-
cytic mechanism. This discussion focuses on the initial escape from the phagosome.
Shigella relies on two proteins, IpaB and IpaC, to form a 2.5 nm pore, far too small
to permit escape of an intact bacterium [44]. These pores likely admit potassium ions
that disrupt the phagosomemembrane, since a separatemodel using IpaB alone is able
to cause endosomal disruption [96]. While IpaB and IpaC are integral membrane pro-
teins, a soluble protein, IpaD facilitates their role in pore formation [97,98]. The same
proteins are involved in a type 2 secretion system that enables cell-to-cell spread of
the bacteria. Separating the mechanical role of the Ipa proteins in phagosome escape
compared with intercellular spread is complex.
Listeria monocytogenes, a Gram-positive bacteria, is able to escape from
phagolysosomes in macrophages with expression of bacterial phospholipases and
listeriolysin O, a pore-forming protein of the cytolysin family that initially opens
holes of 20–30 nm that appear to expand over time, eventually allowing release of
the entire bacterium into the cytosol of the host cell. The initial activity requires
proximity triggers in a similar manner to many of the viruses described earlier.
Activation of host calpain proteases by high Ca2+ ion concentrations, the presence
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of a pH-activated reductase activity, and host cell cholesterol are keys to initiation
of Listeria escape [25,26,99]. The involvement of a host protease to initiate escape
is reminiscent of the pH trigger that initiates adenovirus or influenza virus escape.
Recall that low pH triggers both endogenous furin to activate influenza virus hemag-
glutinin protein and the adenovirus L3/p23 protease. Listeria escape also resembles
adenovirus and influenza virus in that the main actor, listeriolysin O, contains an
amphipathic helix [27]. Of interest, Listeria fails to infect neutrophils, despite the
phagocytic potential of that cell type. Arnett et al. [100] showed that neutrophils avoid
infection due to the fact that neutrophil metalloproteinase-8 lyses listeriolysin O.
Staphylococcus aureus is the organism responsible for the cytolytic, methicillin-
resistant Staphylococcus aureus (MRSA) infections of skin. This same organism
is also capable of escape from endosomes. In this case, the pathogen synthesizes
a series of toxins that either individually or cooperatively have the ability to lyse
cholesterol-containing membranes [101,102].
The escape of Gram-negative Rickettsia species from phagosomes was initially
thought to be due to Rickettsial PL2, an enzyme that is required for infection of tar-
get cells [103]. However, Walker et al. [104] later showed that under conditions that
inhibited the bacterial enzyme, there was no difference noted in the proportion of bac-
teria that escaped from phagosomes by electron microscopic observation. Therefore,
while it is tempting to propose that phospholipase enzyme plays a role in escape from
endosomes as it does in some parvoviruses, it appears that the enzyme plays a role in
a different aspect of infection such as internalization from the cell surface.
Perhaps the most unusual escape route is shared by Cryptococcus neoformans,
a fungal pathogen, and two species of yeast, Candida albicans and Candida krusei.
C. neoformans use a nonlytic method of escape from the endosome, termed vomo-
cytosis [105]. Vomocytosis involves secretion of phospholipase B1, [106], and while
it at first appears to use a comparable mechanism to the parvoviruses-PLA2 activity
and Rickettsia secretion of PLA2 discussed previously, the end result of vomocy-
tosis permits phagosome escape without causing lysis of the organelle. Vomocytosis
also exhibits a unique, inverted, two-stage pH dependence wherein acidification must
occur, perhaps to trigger the process to begin, while inhibition of acidification ulti-
mately enhances the end result [74].
16.3.3 Toxins
Organisms in every kingdom have evolved variety of toxic molecules that provide
offensive capability for overcoming prey or defensive properties that reduce the like-
lihood of predation. Toxins can take the form of a number of different biological
molecules from small molecule metabolites to genetically encoded peptides. In the
latter case, the large size and relative hydrophilicity of the molecules require that the
toxin carry a mechanism for translocating across the plasma membrane in order to
access the vulnerable cellular machinery in the cytoplasm. Pseudomonas exotoxin A,
for example, is produced by the Pseudomonas bacterium and, upon entry to the cyto-
plasm, poisons cells by interrupting the process of protein translation by catalyzing
ADP ribosylation of an elongation factor. In order to enter the cytoplasm, the exotoxin
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requires three functions: cell surface binding, translocation from the endosome to the
cytosol, and enzymatic activity. The three functions are compartmentalized in the
structure of the exotoxin, with domain II enabling escape from endosomes [107].
Domain II contains a series of positively charged arginine residues, and site-directed
mutagenesis of either one of two critical Arg residues can knock out the translo-
cation activity of Pseudomonas exotoxin [108]. The presence of the Arg residues
might lead to the conclusion that the exotoxin utilizes a membrane disruption strat-
egy similar to that described for cationic liposomes. However, replacement of the
Arg residues with other basic amino acids did not restore activity, and translocation
of the exotoxin exhibited two other distinctions from a general membrane disruption
strategy: exotoxin translocation was demonstrated to be a saturable process and was
dependent on the presence of Ca2+ ions suggesting that a defined molecular interac-
tion rather than a general chemical reaction was occurring in the endosome [108,109].
Subsequent characterization revealed that Pseudomonas exotoxin exemplified a class
of molecules that escaped from endosomes without disrupting membranes. Instead,
the exotoxin exhibited the ability to stay within membrane-bound organelles as it
adopted a rather unorthodox intracellular trafficking pathway that takes the toxin from
endosomes to the trans-Golgi apparatus to the Golgi apparatus and finally to the endo-
plasmic reticulum – a retrograde trip through the secretory pathway [60]. During this
translocation, the exotoxin interacts with both protein disulfide isomerases (PDIs)
and the endosomal protease furin, both of which change the structure of the toxin
by releasing the C-terminal catalytic domain from the N-terminal targeting domain.
Finally, by virtue of an endogenous RDEL peptide, the toxin rides from the Golgi
to the endoplasmic reticulum where it escapes to the cytosol via the Sec61p peptide
transporter, a protein complex designed to rid the endoplasmic reticulum ofmisfolded
proteins [110].
The example of Pseudomonas exotoxin A is but one of many naturally occurring
cytotoxic molecules that have been commandeered due to their potential for inducing
death of tumor cells in clinical settings. Gilabert-Oriol et al. [61] recently reviewed
the topic and include an exhaustive list of toxins that have been targeted for anti-
cancer purposes. Notably, diphtheria toxin [60], cholera toxin [62], ricin [111], and
Shiga toxin [64] all use substantially the same route to escape the endosomes and
gain access to the cytosol.
16.4 ENDOSOMAL ESCAPE USING ENGINEERED SYSTEMS
Much of what is known about engineered endosomal escape has been derived from
the field of gene therapy in which the cargo is a large, hydrophilic macromolecule
such as DNA or RNA, and the goal is delivery to the cytosol or even to the nucleus
of the target cell. As a result, methods for breaching the barrier presented by the
plasma membrane are in demand. In the case of nucleic acid delivery, designs for
gene delivery vectors have often borrowed ideas from nature’s gene delivery vec-
tors, namely, viruses. A description of engineered endosome escape systems will,
therefore, intermittently introduce new chemical and material science applications
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interspersed with virus-inspired designs. In retrospect, the two are sometimes difficult
to separate, but it should suffice to say that one of the principal tenets of gene deliv-
ery was the requirement to form small condensed particles containing the polyanionic
nucleic acid. Naturally, polycations were an early solution to this problem and were
introduced in the form of polymeric polycations as well as cationic liposomes that
simulated polycations by virtue of their sequestration into a lipid bilayer [112]. In both
cases, the clustered positive charges and clustered negative charges happily formed
the requisite small, <100 nm, condensed particles, and with assistance from targeting
molecules that conferred high-affinity binding to the cell surface, could lead to uptake
of those particles via endocytosis. Having gained entry into cells, the next stage of
design was to exit the endosome before the contents of the endosome encountered
the hydrolytic environment of the lysosome. As it turned out, the very same polymers
and lipids used for condensing nucleic acids were also amenable to modification to
enhance endosomal escape.
16.4.1 Peptides and Polymers
Among the first polymers to be used for condensation of DNAwas polyethylenamine
or PEI, a very simple polymer containing a repeating structure that has secondary
amino groups separated by ethyl group [113]. PEI’s efficiency as a gene delivery
vehicle has been attributed to its ability to lyse endosomes. The proposed mechanism
by which PEI lyses endosomes is known as the proton sponge effect [46]. This effect
is predicated on the presence of functional groups that can accept protons only when
the pH drops well below neutral. Secondary and tertiary amines are ideal for this role
since they do not become proton acceptors until the pH falls to approximately 6, the
pH found in endosomes. In contrast, primary amines would be fully protonated at a
neutral pH as they entered the endosome, and thus, would have no further capacity to
absorb protons. Following this logic, the multiple secondary amino groups in PEI are
available to bind protons that are pumped into the endosome by the vacuolar ATPase.
However, far more protons are required to acidify the endosome due to the effective
buffering provided by the PEI, so a second phenomenon begins to occur. Chloride
ions, passively following the protons into the endosome down a charge gradient,
begin to raise the local osmotic pressure inside of the endosome, finally resulting in
rupture of the endosome and release of the contents. Some reports have questioned
the mechanism proposed by the proton sponge effect based on an absence of dis-
cernable effect on lysosomes in PEI-transfected cells [114], but the efficiency of PEI
along with the relatively long time required for endocytic cargo to access lysosomes
suggests that PEI complexes may accomplish their escape from endosomes by the
proton sponge effect well before the encounter with lysosomes becomes an issue.
Now, 20 years after it was introduced for the delivery of macromolecular biologics
to the cytosol of target cells, PEI remains an active area of research with well over
100 PubMed-listed articles on PEI- or modified-PEI-mediated drug delivery having
been published in 2014 alone.
Using the same proton sponge logic, other polymers incorporating weak bases
with the potential to protonate at endosomal pH values have been incorporated into
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cationic polymers to accomplish DNA packaging and delivery. The proton sponge
effect helps to explain why a dendrimer made of branched polylysine is far more
effective in gene delivery than a linear polylysine polymer [48]. Polyamidoamine
(PAA), an early polymer that achieved success in gene transfer with low toxicity, is
also thought to utilize the proton sponge effect [47]. Another prominent entity that has
been incorporated into gene-transfer carriers to take advantage of the proton sponge
effect has been the amino acid, histidine, which contains a secondary amine in its imi-
dazole ring. As in the case of secondary and tertiary amines in the other polymers,
histidine remains uncharged at neutral pH but can become protonated below pH 6.
The well-known biochemistry of amino acids and their polymerization into peptides
has facilitated the incorporation of histidine residues into a wide variety of molecules
ranging from histidine-containing peptides [49] to histidylated polymers [115] to his-
tidylated lipids [116]. A more complete description of histidine-containing peptides
has been provided by Martin and Rice [50].
Other peptides (amino acid polymers) have been utilized in endosomal escape sys-
tems, but rather than relying on osmotic lysis of the endosome, some peptide-based
strategies have utilizedmembrane fusion ormembrane-lytic strategies, reminiscent of
the solutions developed by viruses or bacteria using similar tools. Recall that several
viruses made use of amphipathic alpha helices to induce membrane disruption. Both
the HA2 protein from influenza virus and protein VI from adenovirus exhibited this
property [6,17]. Not surprisingly, the amphipathic helix from the HA2 protein has
been incorporated into engineered drug delivery vectors for accessing the cytosol.
Both Subbarao et al. [9] and Wagner et al. [10] used the HA2 protein as a starting
point for developing a set of potential fusogenic peptides to enhance the delivery of
DNA into cells. While the native HA2 peptide showed the ability to lyse membranes
with a gradient of increasing lytic activity as the pH decreased from 7 to 4.5 [10], the
engineered peptides exhibited no lytic activity at pH 7 andmaximal activity below pH
5.5 [9,10]. By focusing the lytic activity only at acidic pH, the engineered peptides
were less likely to cause damage to target cells. This example is an elegant demon-
stration of the principle that while nature has provided a wide array of biologically
active molecules for us to discover, we should continue to use our own knowledge to
attempt to bend those molecules to address our needs.
Before leaving the topic of peptides, a note should be made about cell-penetrating
peptides. These peptides belong to a unique class of peptide that has a seeminglymag-
ical ability to translocate across phospholipid bilayers, breakingmany of the rules that
we learn in introductory biology class [117,118]. Many of these peptides were dis-
covered in natural settings such as the Tat protein of human immunodeficiency virus I
[119] or the Antennapedia protein that was identified in studies of fruit fly develop-
ment [120]. Not only can these peptides translocate themselves across membranes,
but, when conjugated to other large, hydrophilic molecules, these small adducts can
drag much larger hydrophilic molecules across membranes. Translocation of biolog-
ics including siRNA and full biologically active proteins has been accomplished by
conjugation of the bioactive molecule with cell-penetrating peptides [121,122]. How-
ever, since there is no requirement for entry into endosomes, the topic is beyond the
scope of this review.
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16.4.2 Lipids
Just as cationic polymers provide a very useful strategy for cytosolic delivery of
polyanionic nucleic acids, cationic lipids have also been employed in nucleic acid
delivery. Lipids, however, have a feature that sets them apart from polymers, and that
is the natural formation of a container through the arrangement of the hydrophobic
tails into a lipid bilayer and, ultimately, into the bag-like liposome that has a natural
ability to sequester a payload. As a result, liposomes can also be employed to deliver
other biologics such as antibodies or enzymes [123,124]. But for any of these pay-
loads, the critical problem remains delivery to the cytosol, so the same set of barriers
and similar solutions are employed.
Liposomes have the added advantage that the investigator controls the compo-
nents of the liposome since liposomes are typically synthesized from stock solutions
of lipids in organic solvents that are mixed to create the overall lipid formula, dried
to a thin film under vacuum, and then hydrated to create multilamellar liposomes. In
order to create unilamellar liposomes, a shear force is typically applied [124]. When
hydrated in the presence of large molecular solutes, such as biologics, the solutes
are often trapped within the layers of the liposome. Alternatively, the cargo can be
combined with the liposome after the lipid bilayers have formed. The latter strategy is
commonly used to combine cationic liposomes with DNA, and the term for the result-
ing complex structure is a “lipoplex” [125]. The structure and activity of lipoplexes
has been studied at great length, such that sophisticated structure–activity relation-
ships can now be identified and associated with the commonly observed lamellar or
hexagonal packing of DNAwith cationic lipids [125]. The cationic liposomes include
a mixture of cationic lipids and the so-called “colipids,” which are lipids with zwitte-
rionic head groups that enhance the ability of liposome bilayer to fuse with endosomal
or plasmamembranes during delivery of cargo to the cytoplasm [57]. Recent evidence
points to the geometry of the colipid (conical vs cylindrical) as well as the neutral net
charge as being determining factors in driving fusion in endosomes [58]. In fact, the
composition of cationic lipids and colipids can be chosen to enhance fusion events
in the endosome [59], just as peptide chemistry can be designed to favor membrane
lysis in a specified pH range as we saw earlier.
Toita et al. [43] employed a unique strategy for changingmembrane lipid geometry
after internalization. By packaging plasmid DNAwith PLA2 in a carbohydrate-based
cationic hydrogel, these authors were able to demonstrate enhanced delivery of DNA
to target cells. The use of PLA2 in this context recalls the use of PLA2 by viruses to
achieve endosomal disruption, as described earlier.
Liposomes, like polymers, are amenable to modification. Following nature’s lead,
several groups have incorporated fusogenic or lysogenic molecules from pathogens
into lipid-based drug delivery systems. Provoda [28] incorporated variations on the
listeriolysinO protein to enhance liposome-mediated delivery of a tumor-killing toxin
to cancer cells while Lorenzi and Lee [29] used listeriolysin O to enhance plasmid
delivery. In the same manner that the delivery properties of the HA2 proteins have




mutagenesis to develop a highly efficient version of listeriolysin O that is effective in
far smaller doses.
16.4.3 Other Chemical and Physical Strategies
The issue of delivery of biologics to the cytosol is such an important problem that it
has sparked the imagination of many scientists. While the major endosomal escape
strategies have been reviewed earlier, there remains an array of interesting strategies
that may yet take center stage. Some of these strategies include ultrasound-induced
delivery of drugs to cells via induction of microbubbles, also known as sonopo-
ration [126], photochemical internalization [127], photothermal endosome disrup-
tion [128], and lipid emulsions [129], all of which have been used to deliver macro-
molecules to the cytoplasm through an endocytic route. Perhaps the most exciting
new technology involves exosomes, which can either be naturally occurring plasma
membrane-bound vesicles released from cells that can carry bioactive molecules,
such as micro-RNAs, to other cells and are being examined for potential roles in
understanding and perhaps treating conditions related to oncology, infectious disease,
regenerative medicine, and a host of other settings [130–132]. One key to utilizing
exosomes for drug delivery may lie in virally engineered exosomes with a specific
drug delivery goal in mind [133]. Evidence is mounting that exosomes are taken into
cells by endocytosis before they fuse with the endosomal membrane to escape [134].
16.5 CONCLUSION
Based on the discussion of natural and engineered endosomal escape systems
above, it is clear that a variety of successful strategies exist for delivering large
macromolecules to the cytoplasm of target cells. More importantly, the fact that
replication-deficient forms of these pathogens routinely employ a number of these
systems during successful delivery of genes to cells without appreciable cytotoxicity
implies that the delivery can be accomplished without irreparable harm to the target
cell. Therefore, we can look forward to a time when a range of biologics including
siRNA molecules, full-length genes, or even therapeutic proteins can be developed
for deployment to the cytosol of cells. However, a very practical consideration should
not be overlooked: many of the natural and/or engineered systems for delivery of
biologics to the cytosol discussed above involve full-length foreign proteins, foreign
peptides, or foreign polymers. Use of foreign proteins is obviously a problem for
drug delivery since the administration of a foreign protein will almost certainly
initiate an acquired immune response leading to humoral immunity against any
therapeutic agent bearing the foreign protein. As a result, readministration of the
therapy will be difficult if any foreign proteins are exposed on the surface of a
therapeutic particle. While peptides, in general, are not as immunogenic as larger
proteins, it should also be kept in mind that the use of peptides derived from foreign
proteins as discussed above does not really constitute delivery of peptides per se.
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Rather, as envisioned in engineered systems, the peptides will be part of a larger
particle that combines a therapeutic cargo as well as the packaging for that cargo.
Therefore, the peptides will not escape detection of the immune system but will be
seen by the immune system as part of a pathogen-sized particle. Even polymers
used in engineered systems run the risk of evoking an immune response. Recall
that the immune system can respond to antigens as small as a dinitrophenol hapten
when conjugated with an appropriate carrier. In order to fool the immune system,
it is likely that use of self-peptides will be preferred to the use of foreign peptides
and that a shielding system or transient immunosuppression will be required to
prevent exposure of engineered particles during transit to the site of action. These
are not simple problems to solve. The immune system has successfully thwarted the
widespread implementation of gene therapy strategies for more than two decades.
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17.1 INTRODUCTION
Antibody–drug conjugates (ADCs) are emerging therapeutic modalities that utilize
the specificity of antibodies to deliver chemotherapeutic drugs directly to tumors with
the promise of maintaining antitumor efficacy while minimizing nontumor toxicities.
With improved tumor targeting, ADCs are strategically designed to increase the ther-
apeutic index of a given chemotherapeutic drug. The lysosome is a key organelle
central to the biology of ADCs. In this chapter, we discuss the cellular biology that
impacts ADC efficacy and design a strategy as well as propose the lysosome as an
antitumor target for novel ADC development.
With ever-increasing interest in precision medicine and targeted therapy, in the
past decade, there has been an explosion in the development of therapeutic biologics,
including naked antibodies and ADCs. Many of the targets for these therapeutic
entities are located on the plasma membrane with the target epitopes exposed to
the extracellular space. Therapeutic naked antibodies bind to their target antigen
and presumptively inhibit their function (e.g., reduced ligand binding and partner
interactions) [1–3]. For example, trastuzumab (Herceptin) is a therapeutic antibody
targeting the receptor tyrosine kinase human epidermal growth factor receptor 2
(HER2) and is Food and Drug Administration (FDA)-approved to treat HER2+
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breast cancer. The antibody component of ADCs also binds extracellular epitopes
of plasma-membrane-bound antigens. However, in order to achieve the therapeutic
effect of ADCs, the target antigen must also internalize into the cell. First, we discuss
the mechanisms that mediate internalization of plasma-bound antigens.
17.2 RECEPTOR INTERNALIZATION
Molecules can be internalized through multiple mechanisms, including clathrin-
mediated endocytosis (CME) or clathrin-independent mechanisms such as phago-
cytosis, macropinocytosis, and caveolin-dependent endocytosis (Figure 17.1) [4,5].
The internalization of cell surface receptors provides ADCs with a target-specific
entry point [4,5]. CME is a strikingly complex process involving the recruitment of
a series of both adaptor and accessory proteins, along with a clathrin polymer lattice
to both the proximal phospholipids of the membrane and the intracellular segment
of the receptor [6]. Adaptor proteins serve to target receptors for endocytosis.
Sequencemotifs in the cytoplasmic domains of transmembrane proteins are known
to recruit different adaptor proteins; this allows segregation and packaging of their
internalized cargo into coated vesicles. Similar motifs, including tyrosine-based and
dileucine-based sorting signals, can mediate sorting of transmembrane proteins to
endosomes and lysosomes and facilitate direct segregation of lysosomal proteins at
the trans-Golgi network (TGN) [7,8]. In addition, small RABGTPases play a key role
in controlling the different sorting fates of cargoes in endosomal compartments [9].
The best characterized adaptor protein is adaptor complex 2 (AP2), which binds
to short, linear tyrosine- and dileucine-based sequences on the cytoplasmic tails of
receptors [10].
AP-2 plays a key role in clathrin-coated vesicle (CCV) formation and function,
being responsible for the assembly of clathrin triskelia at the plasma membrane
and selection of cargo receptors that are internalized by forming CCVs [11–13].
Upon receptor internalization, clathrin begins to polymerize, causing membrane
rearrangement and the formation of intracellular vesicles [14]. This intracellular
vesicle is released from the plasma membrane via GTP-dependent proteins, such
as the large GTPase, dynamin (Dyn), which hydrolyzes GTP to remove the vesicle
from the plasma membrane [15–17]. After the internalized vesicles are released
from the plasma membrane, they continue to fuse with each other in the cytoplasm
to form the intracellular organelle known as the early endosome (EE) [18].
Fusion of these vesicles is crucial to the physiology of the endosome and regulates
the vesicle maturation from the EE into the late endosome (LE). The EE is surrounded
by a complex and compartmentalized system of proteins within the cytoplasm that
function to regulate the intracellular distribution of all internalized cargo. Within the
EE, internalized receptors and their ligands are subjected to segregation into sepa-
rate intracellular trafficking pathways, resulting in receptor recycling or degradation.
In one scenario, internalized receptors discharge their ligands in EEs and recycle back
to the cell surface. Examples of receptors that traverse this pathway are the transfer-























Figure 17.1 Internalization pathways mediating ADC uptake. (a) Clathrin-mediated endo-
cytosis (CME) originates with adaptor proteins targeting receptors for internalization by
forming clathrin-coated vesicles (CCVs), followed by membrane rearrangement and the
formation of intracellular vesicles. These intracellular vesicles are released and fuse to
form the early endosome. (b) Caveolae-mediated endocytosis is initiated by caveolae, a
lipid raft containing sphingolipids, cholesterol, and caveolin proteins. Cargoes contained in
caveolin-coated vesicles traffic to the caveosome, an intermediate compartment, en route to
the early endosome. (c) Macropinocytosis mediates nonspecific uptake of soluble antigens.
Intake is an actin-dependent process mediated by plasma membrane projections that give rise
to macropinosomes, large endocytic vesicles (>1 μm). (See color plate section for the color
representation of this figure.)
 
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Figure 17.2 ADC receptor-mediated internalization. (1) The ADC binds to the antigen
on the plasma membrane, then the complex internalizes into the early endosome. (2) The
ADC/antigen complex navigates through vesicle maturation from the early endosome into the
LE, where the pH is reduced from 6 to 5. (3) The ADC can then be delivered to the lysosome,
where the pH is further reduced to 4, eventually targeted for degradation. (4) Alternatively, the
ADC can release its antigen and recycle back to the cell surface. (See color plate section for
the color representation of this figure.)
the maturing endosome and eventually be delivered to the lysosome for degradation
(Figure 17.2). Instances of receptors that utilize this pathway include the epidermal
growth factor receptor (EGFR) [4,21] and the gamma aminobutyric acid (GABAA)
receptor [22]. The precise mechanisms governing the specificity of sorting and choice
of distinct trafficking paths for various cargoes remain unknown.
By the time the EE matures to become the LE, the lumen of the organelle becomes
highly acidic and the recycling of cargo back to the plasma membrane ceases. A
family of proteins called the endosomal sorting complexes required for transport
(ESCRT) facilitates the internalization of transmembrane proteins within the LE
membrane into the lumen to form multivesicular bodies (MVBs).
Mammalian ESCRTs have been implicated in diverse cellular processes including
MVB biogenesis, cytokinesis, viral budding, and autophagy. The primary function of
ESCRT counterparts is to downregulate signaling receptors among other membrane
proteins. Protein sorting into the internal vesicles of MVBs is regulated by the four
endosomal sorting complexes required for transport, ESCRT-0, -I, -II, and -III [23].
Notably, the main function of complexes 0–II is to perform sorting by recognizing
ubiquitin-tagged membrane proteins in the endocytic pathway and mediate the mem-
brane involution of those proteins into MVBs. The ESCRT-III and Vps4 complexes
expedite the completion of cargo sorting, deubiquitination, and induction of mem-
brane curvature for vesicle formations [23]. Specifically, ESCRT-III complexes are
only transiently assembled on endosomes and facilitate recruitment of deubiquitina-




localizes to the endosomal membrane via phosphatidylinositol-3-phosphate (PI3P)
binding. This complex contains ubiquitin- and clathrin-binding domains that aid in
the recognition, binding, and clustering of ubiquitylated proteins tagged for degrada-
tion [24]. ESCRT-I and -II cooperate with neighboring functional oligomeric units
to further facilitate cargo sorting and membrane involution [25]. Finally, Vps4 disas-
sembles the complex to complete the formation of intraluminal vesicles (ILVs). ILVs
fuse with lysosomes to deliver the processed contents and the remaining molecules
are degraded in the lumen by acid hydrolysis [23].
Next, we outline the strategic design of ADCs and the mechanisms that drive
receptor-ADC internalization.
17.3 ANTIBODY–DRUG CONJUGATES
There are four components to consider when designing successful ADCs, a mono-
clonal antibody (mAb) specifically targeting tumor-associated cell surface antigens,
a cytotoxic chemotherapeutic payload, and a chemical linker that attaches and sta-
bilizes the payload onto the mAb (Figure 17.3). Lysosomal biology has helped to
delineate how mAbs exploit receptor internalization and act as transporters for cyto-
toxic payloads, by delivering them to the cancer cell microenvironment. Keeping in
mind, each antigen may utilize different intracellular sorting pathways. In addition,
effective ADCs are reliant on both linker release and payload delivery to the lysoso-
mal compartment of the targeted cells [26].
ADC efficacy is dependent on its binding to the tumor-associated antigen (TAA)
followed by receptor internalization to guarantee delivery of the cytotoxic payload
inside the tumor cell. Often, targets that internalize have the capability of also
trafficking to the lysosome. Therefore, selection of the appropriate ADC target is a
critical component of any successful ADC development program. In general, several





Figure 17.3 ADC structure. Antibody–monoclonal antibody (mAb) that specifically targets
tumor-associated cell surface antigens. Linker – attaches and stabilizes payload to the mAb,
releases cytotoxic payload within the target cell. Cytotoxic payload – highly potent cytotoxic
agent. For example, those causing DNA damage or microtubule disruption. (See color plate
section for the color representation of this figure.)
 
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membrane, relative levels of overexpression in malignant tissues compared with
normal counterparts, rates of antigen internalization, and the intracellular trafficking
dynamics of internalized receptors. Interestingly, the level of TAA expression needed
for an efficacious ADC is dependent on the ADC payload. Programs that utilize
less potent payloads, such as microtubule inhibitors, should have TAA expressed at
sufficiently high density to ensure delivery of cytotoxic payload to tumor cells. ADCs
with more toxic DNA-damaging agents, for example, Mylotarg® (calicheamicin
payload) can be delivered with a relatively low TAA copy number [27,28].
Advances in antibody engineering have exploited differences between the envi-
ronments of the extracellular and endosomal space. Despite the route that the target
antigen follows after internalization, antibody engineering can modify the intracellu-
lar trafficking dynamics. Engineered antibodies can improve lysosomal localization
thereby ensuring the ADC/antigen complex is dissociated in the endosome, allow-
ing the ADC to independently traverse endosomal sorting pathways regardless of
its receptor. In two separate studies, scientists have altered the intracellular route of
antibody trafficking by designing antibodies with high-affinity binding for the extra-
cellular target at neutral pH and low-affinity binding for the receptor within the acidic
EE [29,30]. Both studies utilized a histidine scanning approach, in which histidine
residues were introduced in critical areas of the antibody. This screen selected for
mutations that disrupt antibody binding at a low pH environment without affecting
binding at neutral pH. Histidine residues were prioritized based on the fact that they
show pKa values of 6.0, and thus these histidine residues become protonated in pH
environments below 6.0, causing disruption of antibody binding. In both cases, this
approach was used to identify the antibody that can dissociate from its receptor within
the EE and enter the recycling pathway while its target antigen underwent lysosomal
degradation. This yielded an antibody capable of escaping lysosomal degradation,
leading to an increase in the serum half-life and efficacy of the therapeutic [29,30]. In
recent studies, a similar method was used to generate anti-IL6 neutralizing antibod-
ies with a range of pH dependencies for binding [31]. Following uptake into the cell,
anti-IL-6 antibodies bind antigens with higher affinity at near-neutral pH (relative to
acidic endosomal pH). After ADC uptake, the complex is expected to release antigen
within the endosome, with concomitant antibody recycling and exocytosis occurring
in FcRn-expressing cells. In the acidic pH of the endosome, the cytokine dissociated
from the engineered antibody and trafficked to the lysosome, thus decreasing its level
in the circulation, while the anti-IL-6 antibody was recycled out of the cell [31].
Linker-payloads are additional factors affecting ADC efficacy whereby the
intracellular drug release from the antibody is accomplished through the disruption
of the chemical linker between the antibody and cytotoxic payload. Therefore,
ADC efficacy can be directly impacted by linker choice. Early-generation ADCs
relied on the use of nonproteolytically cleavable linkers such as hydrazone, or
disulfide-based linker approaches [32]. Hydrazone linkers are stable at a neutral
pH but are cleaved within the low pH environment of intracellular endosome
and lysosome compartments. Proteolytically cleavable linkers, such as the pep-
tide linker valine-citrulline-p-aminobenzyl carbamate (vc), are designed to be




internalization [33]. Noncleavable linkers, such as thioether- or amide-based linkers,
have been utilized more recently and are intended to retain stability throughout the
plasma and most of the intracellular space. Current evidence suggests that the early
and LEs provide a highly reductive environment and contain sufficient proteases to
process both cleavable types of linkers [34,35]. Nonetheless, one study has disputed
this notion and has shown that the endosomes are in fact highly oxidative in nature,
thereby limiting the cleavage of disulfide-based linkers [36]. This finding suggested
the possibility that using disulfide linkers may result in reduced antitumor activity in
some situations. Interestingly, payloads attached through disulfide linkers can form
lipophilic drug metabolites after cleavage in the lysosome [37]. These metabolites
have the ability to cross membranes and contribute to the bystander killing effect
when effluxed out of tumor cells. Such approaches may be beneficial when targeting
tumors with heterogeneous antigen expression, but, at the same time, can result in
higher levels of undesirable toxicity. Another study has shown that the specific sites
on which the linker-payload is conjugated onto the antibody can influence stability
of a proteolytically cleavable linker [38].
One of the most common linkers across the ADCs in clinical trials is the aforemen-
tioned vc-linker. Brentuximab vedotin (Adcetris®, SGN-35), a currently approved
ADC, is an anti-CD30-auristatin conjugate that incorporates a peptide cleavable
vc-linker conjugated to monomethyl auristatin E (MMAE) [39]. In Brentuximab
vedotin, the vc-linker is conjugated via a cysteine sulfhydryl group on the antibody
to the maleimide functionality on the linker. Upon internalization of the ADC into
the endosomes and lysosomes, the amide bond between the citrulline residue and the
p-aminobenzyl carbamate portion of the linker is cleaved by lysosomal proteases [33].
Self-elimination of the p-aminobenzyl carbamate group, which is important to spa-
tially separate the drug from the site of enzymatic cleavage, releases free MMAE in
the tumor cell. While ADCs with cleavable linkers tend to show good efficacy, the
nature of a cleavable linker generates certain liability due to potential extracellular
cleavage of the payload and the resultant off-target toxicity. As a consequence,
some recent ADCs have been designed to possess linkers that are not cleavable by
conventional mechanisms, such as thioether or amide bonds [40]. While this creates
an ADC that is highly stable in the extracellular environment, the use of such a linker
requires that the ADC be routed to the lysosomal compartment of the cell, where
the antibody is completely degraded, liberating the linker-payload. The payload is
then released from the lysosome into the cytosol, where it elicits cytotoxic activity.
However, some targets are not delivered to the lysosomal compartment at a sufficient
concentration and are instead recycled back to the plasma membrane, making it
challenging to develop ADCs with a noncleavable linker against such targets.
The development of novel cytotoxic payloads with optimized potency and
appropriate linker compatibility remains an important goal in ADC development.
Early-generation ADCs contained payloads that provided little antitumor activity due
to the lack of potency (e.g., methotrexate, doxorubicin, and vinblastine) [41–46]. As
a result, newer ADCs have incorporated highly potent cytotoxic agents that interfere
with microtubule dynamics or cause irreversible disruptions in DNA integrity. Usage
of highly potent microtubule-disrupting agents has become widely adopted due to
 
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the efficacy observed against rapidly dividing cells, which provides an additional
mechanism for tumor selectivity. Compared to conventional spindle poison cytotox-
ics, DNA-damaging agents are less dependent on cell cycle progression to induce
apoptosis, a property that may be advantageous when targeting malignant cells that
are not rapidly proliferating. Significant efforts are underway to develop new and
more tumor-selective linker-payloads.
Lysosomal sequestration should be considered when developing novel payloads
for ADC platforms. The concept of pH partitioning has been well described for
payloads linked by amine residues [47]. When payloads exist in a pure basic form,
they are capable of free diffusion across membranes. For example, when a small
molecule exhibits a pKa value of 7–8, it exists predominantly in the free base form
in the cytosol. However, if this molecule crosses into organelles with acidic lumens,
such as endosomes and lysosomes, the molecule exists primarily in an ionized or
protonated form potentially producing a membrane impermeable molecule that
subsequently traps the molecule inside the organelle. This is believed to be one
of the reasons why tumors develop resistance to drug therapy [47]. Lysosomal
sequestration has been described for molecules such as sunitinib [48]. In addition, it
has been suggested that lysosomal sequestration of molecules can occur through the
presence of multidrug transporters, such as P-glycoprotein (Pgp), in the lysosomal
membrane [49]. In this case, cytotoxic agents are pumped out of the cytoplasm into
the lysosomal compartment by Pgp, where they are subsequently ionized within the
lysosome, rendering them ineffective agents. This mode of sequestration has been
described for molecules such as doxorubicin, daunorubicin, and vinblastine [49].
To date, lysosomal sequestration has not been reported for ADC payloads. Novel
payload development strategies should be considered to reduce potential issues of
lysosomal sequestration. Therefore, developing payloads or agents that interfere
with the integrity of the lysosomal compartment is an attractive option to consider
in preclinical studies with future ADCs [50]. Disruption of lysosomes can lead to
autophagic cell death, resulting in the release of detrimental lysosomal proteases
into the cytoplasm. Bafilomycin A, salicylihalamide A, and concanamycin A are
interesting examples of natural products that disrupt the lysosomes. These agents
inhibit vacuolar ATPase (vATPase), which maintains the proton gradient across the
lysosomal membrane [51–54]. Accordingly, inhibition of this vATPase impedes the
ability of lysosomes to acidify, which can result in cell death.
17.4 MECHANISMS OF RESISTANCE TO ADCs
The efficacy and duration of any chemotherapeutic regimen is dictated by the innate
resistance of cancer cells to a therapy or the acquisition of resistance following drug
exposure and resistant cell population selection. Multiple ADCs have entered clinical
development, yet little data is available that describes the molecular mechanisms
of resistance that emerges within this drug class. Published clinical data for acute
myeloid leukemia (AML) suggests patients that initially responded but eventually




Pgp or multidrug resistance (MDR1) [55,56]. As Mylotarg’s payload is a known sub-
strate for MDR1, the mechanism of resistance in Mylotarg refractory patients could
be due to efflux of payload out of leukemic cells [57,58]. However, published data
about clinical resistance to other FDA-approved ADCs (i.e., Adcetris or Kadcyla®)
are lacking. Recently, several studies have reported the acquisition of resistance to
trastuzumab-based ADCs in in vitro models. The first study showed that chronic
treatment of HER2+ cell lines with Kadcyla resulted in the emergence of resistant
cell populations with varying mechanisms of resistance [59]. Mechanisms of resis-
tance observed in this study included the compensatory expression of neuregulin-1,
MDR1 protein overexpression, HER2 protein downregulation, and changes in
mitogen-activated protein kinase (MAPK) family signaling. A second study revealed
that cyclical treatment of HER2+ cell lines with a trastuzumab-maytansinoid ADC,
which is structurally similar to Kadcyla, yielded resistant cell lines. The observed
resistance was mediated by payload drug efflux through overexpression of multidrug
resistance protein 1 (MRP1) and HER2 protein downregulation [60]. Whether these
mechanisms of resistance translate from in vitro models to the clinic in HER2+
breast cancer patients remain to be seen.
Interestingly, the aforementioned class of lysosomal-targeted payloadsmay be fur-
ther attractive to develop given that some analogs do not appear to be substrates for
drug efflux proteins. The classical models of drug resistance mediated by MDR1- or
MRP1-induced drug efflux use HL60/Vinc and HL60/Adr cell lines [61]. Marquardt
and Center revealed a regulatory role for vATPase in the inhibition of drug efflux in
these cell models. Surprisingly, bafilomycin A, a vATPase inhibitor, appears not to
be a substrate for MDR1 [61]. This sets the stage for proposing the appealing com-
bination of vATPase inhibitors with the payload classes of current clinical ADCs.
17.5 SUMMARY
With the promise of targeting chemotherapeutic drugs specifically to tumors, ADCs
effectively increase the therapeutic index of conventional chemotherapeutic com-
pounds by increasing efficacy while decreasing toxicities inmany cases. ADCs utilize
TAAs, receptor internalization, and intracellular trafficking through the endolyso-
somal pathway to deliver their cytotoxic payloads to tumor cells while protecting
nontumor cells from drug exposure. Using antibody targeting as a platform, we can
reconsider compounds previously thought to be too toxic, such as the lysosomal
inhibitors described herein, as exciting new strategies for ADC development and
patient treatment regimens going forward.
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18.1 INTRODUCTION
It is well known that certain low-molecular-weight, weakly basic drugs become
highly concentrated in acidic intracellular organelles including lysosomes. Substrates
for this accumulation are routinely referred to as being lysosomotropic, and themech-
anism for accumulation is known as ion trapping or pH partitioning. Lysosomotropic
drugs have been shown to reach concentrations within lysosomes that are more than
1000 times greater than in the cytosol or extracellular space at steady state. This
chapter reviews the mechanism by which lysosomal trapping occurs and the drug-
and cell-related factors that influence the process. The chapter also examines some of
the techniques used to assess lysosomal trapping in cultured cells. Subsequent discus-
sions focus on the therapeutic implications associated with lysosomal drug seques-
tration. As discussed, the lysosomal sequestration of drugs can impact the extent of
interaction with intracellular targets. Toward this end, lysosomotropic behavior of
drugs has been purposefully exploited in an effort to increase drug potency and selec-
tivity. Moreover, the sequestration of drugs in lysosomes can have a profound impact
on the pharmacokinetic properties of drugs. Specifically, lysosomotropic drugs
often have large volumes of distribution and, therefore, long elimination half-lives.
Lysosomes: Biology, Diseases, and Therapeutics, First Edition.
Edited by Frederick R. Maxfield, James M. Willard and Shuyan Lu.




424 CONSEQUENCES OF AMINE-CONTAINING DRUG SEQUESTRATION IN LYSOSOMES
Finally, the chapter reviews instances where it has been shown that one drug is
capable of influencing the lysosomal accumulation of a secondarily administered
drug, establishing the basis for a new type of pharmacokinetic drug–drug interaction.
18.2 LYSOSOMAL TRAPPING OVERVIEW
For over a century, light microscopy studies have revealed that certain low-molecular-
weight dyes known as vital stains are able to selectively stain cellular compartments
of living cells. Vital stains that were thought to specifically stain lysosomes were first
described in the literature in the mid-19th century and originally included weakly
basic molecules such as neutral red and acridine orange (see Figure 18.1) [1,2].
In the mid-1970s, de Duve [3], a Nobel laureate, credited with the initial char-
acterization of lysosomes, and his colleagues wrote an elegant theoretical commen-
tary on the mechanism for weakly basic drug accumulation in lysosomes. In their
commentary, they referred to the substrates for lysosomal accumulation as lysoso-
motropic agents. The authors argued that in order for ion trapping in lysosomes to
occur, a weakly basic drug must be relatively membrane permeable when it is union-
ized and relatively membrane impermeable when ionized. Under these conditions,
the driving force for lysosomal sequestration is based on the preferential ionization
of weakly basic drug that occurs inside the acidic lysosomes due to the low lysosomal
pH (see Figure 18.2). This relatively low pH (approximately pH 4.5) is maintained
by the vacuolar proton ATPase [4]. The activity of vacuolar proton ATPase is there-
fore central to the ion trapping phenomenon, and inhibitors of this enzyme have been































Figure 18.2 Diagram illustrating the pH partitioning-based mechanism for accumulation of
weakly basic drugs (B) in the acidic lysosomes. The equation at the bottom of the figure rep-
resents the lysosome to extracellular space steady-state concentration ratio for a base. The
dissociation constant for the conjugate acid of the weak base is denoted as Ka and [H
+] is the
proton concentration (subscript E represents extracellular and L represents lysosomal). The
ratio of permeabilities of the ionized base to that of the unionized base in the lysosomal lipid
bilayer is denoted by the α term.
In their commentary, de Duve and his colleagues derive an equation relating the
steady-state concentration ratio of a weakly basic drug inside lysosomes compared to
the extracellular space (see Figure 18.2). According to this equation, the maximum
possible concentration ratio for a weakly basic substance in lysosomes (relative to
the extracellular space) is equal to the ratio of the hydrogen ion concentration in
lysosomes relative to the fluid surrounding the cells. For example, if the extracellular
pH was 7.4 and the pH of lysosomes was 4.4, the maximal lysosomal concentration
ratio would be 1000. According to de Duve’s derivations, there are two drug-related
terms that can theoretically influence the steady-state accumulation of weakly basic
drugs in lysosomes. The first variable is the weak base pKa, and the second is termed
alpha (𝛼), which represents the ratio of permeabilities of the weakly basic drug across
the lysosomal lipid bilayer in its ionized and unionized forms.
The pKa of the weakly basic drug is predicted to impact the steady-state lysosomal
accumulation ratio. Molecules with pKa values of 6 or below were not considered
to be lysosomotropic because they would not extensively ionize in lysosomes. Low
pKa molecules can never reach the maximal steady-state accumulation ratio of 1000.
Molecules with pKa values of 8 or greater can theoretically achieve 1000-fold higher
levels in lysosomes relative to the extracellular space. However, molecules with very
high pKa values will start to become less lysosomotropic in a therapeutically relevant
timescale because they are predicted to take exceedingly long times to reach steady
state. Specifically, the permeation rate was predicted to decrease by a factor of 10
for each 1-unit increase in drug pKa. Interestingly, de Duve’s theoretical calculations
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predict that the time to reach one-half of steady state for molecules with a pKa of 12
would be over 11∕2 years. In contrast, bases with pKa values near 7 are predicted to
take 10min to reach one-half steady-state levels.
Duvvuri et al. [6] later quantitatively tested the theoretical predictions of de Duve
and colleagues in cultured cells. Using a series of weakly basic structural isomers
that varied in pKa from 4 to 9, the authors experimentally investigated the influ-
ence of pKa on lysosomal accumulation. Consistent with theoretical predictions, the
authors reported that molecules with pKa values below 6 were not appreciably lyso-
somotropic. The molecule with a pKa value of 9 had the greatest degree of lysosomal
accumulation.
As a consequence of extensive entrapment of drugs, the lysosomes can take on a
vacuolated appearance. Using vacuolization as a readout for lysosomotropic behav-
ior, early work by Ohkuma and Poole [7] investigated how weak base structure influ-
ences lysosomal accumulation. Collectively, with few exceptions, both theoretical
and experimental approaches support the notion that most lysosomotropic agents will
have optimal pKa values between 7 and 10.
As previously mentioned, the term alpha (𝛼) refers to the ratio of the permeability
coefficients across the lysosomal lipid bilayer for the ionized base divided by that of
the unionized base [3]. This term can theoretically vary from zero to one. Molecules
with an alpha value of zero, meaning the ionized base is completely impermeable,
will be the most lysosomotropic and will reach a theoretical maximal steady-state
ratio of accumulation dictated by the pH differential. However, as the alpha parameter
increases in magnitude, the maximal steady-state accumulation ratio of a drug in the
lysosomes significantly decreases. For example, a drug with an alpha value equal
to 1 will have equal membrane permeability regardless of ionization. Under these
circumstances, extensive protonation of the drug in lysosomes would not slow the rate
of diffusion back to the cytosol. A theoretical relationship illustrating the combined
influence of pKa and alpha on lysosomal trapping is shown in Figure 18.3.
Duvvuri et al. [8] have experimentally estimated alpha values for a series of drugs
and model compounds and correlated this value with the experimentally measured
lysosome-to-cytosol concentration ratio obtained in cell culture experiments. As
a proxy for lysosomal membrane permeability, which is difficult to measure, the
authors measured the octanol/water partition coefficients for drugs as a function of
pH. Estimates for the logD of the ionized and unionized species were obtained, and
the ratio of these values was used to obtain alpha. As anticipated, it was found that
compounds with lower alpha values accumulated to a greater extent in lysosomes
relative to compounds with higher alpha values. The authors also examined how
alpha correlated with mitochondrial versus lysosomal accumulation of weakly
basic drugs. They found that molecules with low alpha values accumulated almost
exclusively in lysosomes, whereas molecules with high alpha values accumulated
within mitochondria. It was noted that the alpha parameter for a given drug appeared
to correlate with the degree of charge delocalization present in the molecule.
Weak bases with fixed localized positive charges tended to have very low alpha
values, whereas those with delocalized charges tended to have higher alpha values
near 1. The relationship between charge delocalization and alpha was attributed to
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Figure 18.3 Theoretical relationship between weak base pKa and the alpha permeability
parameter. The relationships were derived using the equation shown in Figure 18.2, with indi-
cated values for alpha.
differences in how tightly the molecules bind water, which subsequently relates to
the energy required to pass into a nonpolar lipid-like environment.
The relative lipophilicity (i.e., logP) does not influence the predicted steady-state
accumulation ratios for weakly basic drugs. However, it will most definitely influ-
ence the time to reach steady state and the propensity to exhibit lysosomal trap-
ping in a therapeutically relevant timescale. As a consequence, most experimentally
observed lysosomotropic substrates tend to be relatively lipophilic and have logP
values greater than 1 [9].
18.3 TECHNIQUES TO ASSESS LYSOSOMAL TRAPPING
For therapeutic reasons that are discussed below, there is a keen interest in under-
standing how drugs localize and distribute within the cells and tissues of our body.
Toward this end, a number of assays and approaches have been described over the
years. These approaches have been more extensively reviewed elsewhere [10,11],
and the reader should refer to these examples for more details. The purpose of this
section is to give the reader a brief overview of the different techniques used and some
of the associated strengths and weaknesses.
By far, the simplest approach is to utilize fluorescence microscopy on cultured
cells that have been exposed to a drug that is intrinsically fluorescent. The anti-
cancer drug daunorubicin is highly fluorescent, and, as a consequence, numerous
publications have examined the intracellular distribution of this drug in cultured
cells [12–14]. Unfortunately, most drugs are not sufficiently fluorescent to allow
for this technique. However, extensive structure–localization relationship studies
with regard to lysosomal accumulation have been conducted using weakly basic
fluorescent compounds that are not drugs per se. For example, Horobin and
 
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colleagues [15,16] have compiled correlations between intracellular distribution and
physical and structural properties of a variety of fluorophores. Similarly, Rosania
and coworkers [17,18] have employed results from such studies to develop models
and simulations that describe lysosomal accumulation of weak bases.
Microscopic detection methods that do not rely on fluorescence have also been
investigated. Recently, Fu et al. [19] described the use of hyperspectral stimulated
Raman scattering microscopy to examine the intracellular localization and concen-
trations of tyrosine kinase inhibitors and chloroquine in cultured cells. The authors
were able to show that the weakly basic drug imatinib accumulated in lysosomes at
concentrations that were approximately 1000-fold higher than extracellular levels.
The authors provided evidence that the drugs accumulated in lysosomes to an extent
greater than ion trapping theory would have predicted and that this was, for some
drugs, due to precipitation within lysosomes. The authors also used this method to
show that chloroquine administration decreases lysosomal accumulation of imatinib
and that this could provide the basis for the positive therapeutic advantages of taking
two drugs simultaneously. Although the current limit of detection for drugs in cells
described in this manuscript was quite high (approximately 1–2mM), it was com-
mented that improvements in the instrumentation and techniques such as deuterium
labeling of drugs can be expected to increase sensitivity.
It is also possible to isolate lysosomes from cultured cells or tissues in an effort
to quantify lysosome and drug association. The purification can either occur before
or after the cells have been exposed to drug. In the former scenario, the test drug is
added to the isolated lysosomes, and the degree of accumulation is assessed either
directly or indirectly. For example, Ishizaki et al. [20] have used highly purified rat
liver lysosomes to study the mechanism for imipramine accumulation and have also
studied the ability of other basic molecules to compete with imipramine uptake.
Andrew et al. [21] developed an indirect approach to assess the permeability of
weakly basic drugs across the lysosomal lipid bilayer using an unpurified cell lysate.
The assay was based on the measured ability of a test drug to protect lysosomes from
osmotic pressure-induced rupturing, which is directly related to the propensity for a
test drug to permeate across the lipid bilayer of the isolated lysosomes. The readout
for lysosomal rupturing involved testing for release of free lysosomal enzymes into
the cell lysate. The advantages of this approach are that lysosomes need not be puri-
fied, and the test drug needs no special properties or tags. Accordingly, this approach
is amenable to relatively high-throughput analysis, and the authors have used this
method to demonstrate a strong correlation between hydrogen bonding capacity and
lysosomal membrane permeability.
A unique analytical approach for evaluating the accumulation of fluorescent com-
pounds into acidic organelles, such as lysosomes, was described by Arriaga and
coworkers [22]. The authors utilized capillary electrophoresis with laser-induced flu-
orescence with dual-channel detection to identify lysosomes containing fluorescent
nanospheres that were preloaded into lysosomes using an endocytic uptake-based
pulse-chase technique. Selecting organelles possessing both nanospheres and dox-
orubicin fluorescence allowed them to specifically determine the content of the drug
in lysosomes without potential interference from other organelles in which the drug
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could associate. The authors were able to identify heterogeneity among lysosomes
in their doxorubicin content, an observation not readily achievable using alterna-
tive techniques.
Duvvuri et al. [23] describe an approach whereby living cells are incubated, in a
pulse-chase manner, with magnetic dextran particles to allow them to be specifically
localized in lysosomes. The cells were subsequently incubated with a test drug and
then lysed so that the lysosomes could be isolated using magnetic chromatography.
The drug associated with the isolated lysosomes was then quantified using
conventional strategies including high-performance liquid chromatography-mass
spectrometry/mass spectrometry (HPLC-MS/MS). Similar to other studies, the
authors show that model drugs including quinacrine accumulated in lysosomes to
levels much greater than simple ion trapping theory would predict.
Lemieux et al. [9] have developed an approach for evaluating lysosomal sequestra-
tion that is amenable to high-throughput screening formats. The main principle of the
method involves a competition between the test drug and the fluorescent basic amine
probe LysoTracker Red (LTR) in cultured cells. The authors show that drugs that are
cationic and amphiphilic decrease LTR fluorescence in a dose-dependent manner,
presumably by increasing lysosomal pH. The authors use this assay to establish that
lysosomotropism occurs more readily for drugs with a high logP. This general assay
format was further examined by Nadanaciva et al. [24], and they were able to estab-
lish that lysosomotropic drugs identified in the assay generally had C logP> 2 and a
basic pKa between 6.5 and 11. This same assay format was more recently applied to
an immortalized hepatocyte cell line [25].
18.4 INFLUENCE OF LYSOSOMOTROPISM ON DRUG ACTIVITY
Mammalian cells are highly compartmentalized, and drug targets are typically local-
ized in discrete intracellular organelles as opposed to being evenly distributed across
all intracellular compartments. How a drug distributes within a human cell can have a
profound impact on its activity and side effect profile. Knowledge regarding the total
amount of drug associated with a cell cannot by itself allow one to accurately predict
the likelihood of experiencing a therapeutic effect. Instead, the most relevant piece
of information to know would be the free concentration of the drug that exists in the
local microenvironment that immediately surrounds the intended drug target.
Hypothetically speaking, if a drug distributed evenly across the entire cell and
all of its compartments, one would anticipate activity at some dose, but the propen-
sity for off-target effects would also be high. This is due to the drug having a high
degree of interaction with unintended cellular components. However, if a scenario
is considered where the drug has the propensity to specifically concentrate within
the organelle containing the target, one would anticipate this causing an increase in
the potency. In addition, the propensity for unintended off-target interactions would
be minimized. The most unfavorable scenario would be realized if the drug were to
exclusively concentrate in some discrete organelle that did not contain the target. In
this scenario, the drug would have no activity, and off-target effects would be the
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only possible effects. Our understanding of these various scenarios is increasing and
is spurring efforts in the design and development of drugs with known and optimized
intracellular distribution in order to maximize potency and reduce side effects.
According to the previous discussion, lysosomotropic behavior of a drug can
potentially increase or decrease therapeutic activity. In instances where the drug
target is inside the lysosomes, the lysosomotropic behavior would be expected to
increase potency; when the target is outside the lysosomes, the sequestration of
drugs in lysosomes could decrease the availability of the drug to interact with its
target and decrease activity.
There are examples in drug discovery where the lysosomotropic behavior of a
drug was not recognized or exploited in the initial drug design, but later studies have
revealed that the sequestration serendipitously contributed to the therapeutic activity.
The most well-known example is the lysosomotropic antimalarial drug chloroquine
(see Figure 18.4). This drug was originally synthesized in the 1930s and is recognized
to have potent antimalarial properties [26]. It is now believed that the antimalar-
ial effects are attributed to inhibition of hemozoin biocrystallization in the digestive
vacuole of the malarial parasite that resides in the red blood cells. The digestive vac-
uole is lysosome-like in its function and the low pH facilitates drug accumulation in
this space, thus maximizing the effectiveness of the drug. Other weakly basic anti-
malarials such as mefloquine and quinine (see Figure 18.4) are also thought to show
increased therapeutic efficacy from the sequestration in the digestive vacuole but are
not believed to be sequestered as extensively as chloroquine [27].
In the late 1970s, Firestone and colleagues, to our knowledge, were the first group
to publish on the purposeful exploitation of lysosomotropic behavior in the design of
low-molecular-weight drugs. In their work, the scientists synthesized and evaluated a
series of long-chain alkyl amines as potential anticancer agents [28,29]. The authors
selected amines with intermediate pKa values in the range of 5–8, such as imidazole
and morpholine, which had varied alkyl chain length (see Figure 18.5).
These agents were designed to accumulate in lysosomes by ion trapping and





























Figure 18.5 Example of lysosomotropic detergent investigated by Firestone and colleagues.
the agents would acquire surfactant properties that would lead to the selective
permeabilization of the lysosomal membrane, which would precipitate the death of
the cell. The authors provided several compelling pieces of evidence that the agents
were indeed acting as lysosomotropic detergents. First, cell fractionation studies
showed that the drugs were specifically accumulating in fractions rich in lysosomes.
Cellular cytotoxicity studies revealed a sharp sigmoidal dose–response relationship,
which is consistent with the requirement for the formation of detergent micelles. In
addition, the drugs were toxic only to cells that had lysosomes and were not toxic to
those that did not contain lysosomes (i.e., red blood cells). Finally, cell death was
preceded by lysosomal vacuolization, led to an increase in lysosomal pH, and was
associated with the release of lysosomal contents.
In a later work, Dubowchick and colleagues also rationally incorporated lysoso-
motropic features in a series of molecules that were designed to increase the luminal
pH of endosomes and lysosomes. Such agents were hypothesized to have potential
utility in the reversal of anticancer multidrug resistance that was mediated through
increased lysosomal ion trapping of weakly basic anticancer drugs [30,31]. In addi-
tion, it was suggested that such agents could be effective against some viruses that
exploit the low pH of lysosomes to facilitate entry in the cell cytosol to allow for
subsequent replication [32]. The molecules were designed and optimized to be mem-
brane active and capable of transporting protons across lipid bilayers resulting in
the dissipation of the lysosomal pH gradient (see Figure 18.6 for a depiction of the
strategy). The efficiency of proton transfer was optimized by designing hydrophobic
nitrogenous bases that would have the tendency to remain embedded in the lysoso-
mal lipid bilayer while mediating the proton transfer from the lumen of lysosomes to
the cytosol. Toward this end, the authors identified a lipophilic imidazole-containing
molecule that had the best ability to neutralize lysosomal pH in cells grown in culture
and had physicochemical properties evaluated in in vitro tests that were consistent
with the aforementioned mechanism of action in proton transfer (see Figure 18.6 for
structure). This molecule also showed activity in reversing anticancer drug resistance
and in the inhibition of influenza virus replication [33].
There are numerous examples whereby known lysosomotropic agents have been
shown to interfere with endosomal/lysosomal trafficking and function. This is an
important consideration from a potential toxicological point of view; however, this
is the focus of a separate chapter and is not further discussed here. Interestingly,
these otherwise potentially negative effects have been proposed to have poten-
tial relevance in the treatment of various diseases. For example, lysosomotropic
agents have been shown to decrease the escape of viruses and other endocytosed
membrane-impermeable toxins from late endosomes and lysosomes [34–38].
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Figure 18.6 (a) Diagram of proposed lysosomal proton transfer mechanism. (b) Structure of
lysosomotropic proton transfer reagent.
Similarly, there exists work that suggests that lysosomotropic amines can suppress
major histocompatibility complex (MHC) class II antigen presentation [39] and
decrease iron release from lysosomes [40]. Lysosomotropic amines have also been
used to help decrease the exocytosis of anticancer drugs that are sequestered in lyso-
somes as a means to reverse the anticancer drug-resistance mechanism, as was previ-
ously described [41–44]. The mechanism by which lysosomotropic amines decrease
lysosomal egress/function in the previous applications is not completely understood.
One explanation is that the amines transiently increase the pH of lysosomes through
a buffering effect. In this way, the drugs could decrease the activity of lysosomal
hydrolases and this could lead to a buildup of undigested materials, which can inter-
fere with lysosomal trafficking. Another possibility is that the lysosomotropic amines
could directly modify lysosomal membranes such that fusion and fission events
required for the vesicle-mediated trafficking could become impaired. Consistent with
the latter notion, the weakly basic drug primaquine has been shown to impair budding
events at the Golgi, which also has an acidic lumen relative to the cell cytosol [45].
It is well known that most anticancer agents can be classified as being weakly
basic and therefore presumably lysosomotropic. However, the therapeutic advantage
of lysosomal trapping, if any, in the treatment of cancer is not immediately obvious
because most anticancer drug targets are not localized within the lysosomes, and trap-
ping in this space would be anticipated to decrease interactions with the drug targets,
as previously discussed. Recently, it has been proposed that the weakly basic nature
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of anticancer drugs contributes to the selective toxicity of the drugs against cancer
cells. A number of studies have demonstrated that many cancer cells have defective
acidification of lysosomes for reasons that have not been fully elucidated [46–49].
Based on this difference in lysosomal pH between normal and many cancer cells, it
was hypothesized that lysosomotropic behavior of a cancer drug with extralysosomal
targets could enhance the selective toxicity of the drug toward a cancer cell compared
to a normal cell with normally acidified lysosomes. In other words, weakly basic
anticancer agents that are exquisite substrates for lysosomal trapping would achieve
very low concentrations in the cell cytosol and nucleus of normal cells and thus have
reduced capacity to interact with targets and exert cytotoxic effects. Alternatively,
when the lysosomotropic cancer drug is present in cancer cells with elevated lysoso-
mal pH, the lysosomotropic drug would be relatively less concentrated in lysosomes
and would exist to a greater degree in the cell cytosol and nucleus. According to this
proposed mechanism, the lysosomotropic anticancer agent would possess increased
selectivity against tumor cells compared to nonlysosomotropic anticancer agents (see




























Figure 18.7 Overview of intracellular distribution-based anticancer drug targeting platform.
(See color plate section for the color representation of this figure.)
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The initial evaluations of these hypotheses were conducted in cultured cells that
had variable lysosomal pH and with model anticancer agents that were derivatives
of geldanamycin, a prototypic inhibitor of the molecular chaperone heat shock pro-
tein 90 (Hsp90). Geldanamycin is amenable to diverse chemical derivatization at the
17-position with little effect on binding to Hsp90 [50]. It was therefore possible to
synthesize inhibitors that had variations at the 17-position that made them either
weakly basic (i.e., lysosomotropic) or neutral (nonlysosomotropic). The selectivity
of the drugs was measured by taking the ratio of the IC50 cytotoxicity value for a
given drug in cells with low (normal) pH divided by the corresponding value in cells
with elevated lysosomal pH (i.e., cancer cells). These studies reveal that weakly basic
inhibitors had additional selective toxicity toward cells with elevated lysosomal pH,
a characteristic that was not the case for nonlysosomotropic inhibitors [51]. Further
investigation of this hypothesis was completed in non-tumor-bearing mice with and
without elevated lysosomal pH, again using lysosomotropic and nonlysosomotropic
Hsp90 inhibitors [52]. In this study, it was found that mice with elevated lysosomal
pH were far more susceptible to the toxic effects of lysosomotropic Hsp90 inhibitors.
As a control, nonlysosomotropic inhibitors had toxicities that did not vary with alter-
ations in lysosomal pH. More recently, a more extensive series of Hsp90 derivatives
were synthesized with variable pKa in the 17-position, and it was shown that the
degree of selectivity toward tumor cells increased as the pKa was changed to values
that were most conducive to lysosomal trapping [53].
Kang et al. [54] have similarly exploited this difference in lysosomal pH between
normal cells and cancer cells to aid in the development of fluorescent probes that
could selectively identify cancer cells. The authors have developed a fluorophore
(3,6-bis-(1-methyl-4-vinylpyridinium)carbazole diiodide (BMVC)), whose quantum
yield increases by 100-fold when bound to DNA. The authors show that in normal
cells these lysosomotropic fluorophores are not particularly fluorescent because they
are trapped in lysosomes and are unavailable to bind to DNA. However, in cancer
cells with elevated lysosomal pH, the fluorophores escape the lysosomes and bind
with mitochondrial and/or nuclear DNA and become highly fluorescent.
Prostate cancer cells, similar to many other cancer cell types, have alterations in
their ceramide metabolism that influence the ability of the cell to undergo apoptosis.
This has led investigators to target this pathway in the development of a novel class of
anticancer agents. Ceramide metabolism occurs in the acidic lysosomes, and this has
prompted the evaluation of inhibitors with lysosomotropic properties [55–57]. Specif-
ically, LCL204, a lysosomotropic analog of a nonlysosomotropic parent inhibitor
(B13), was evaluated in cancer cells and was shown to have superior potency relative
to the parent drug. As expected, the lysosomotropic inhibitor also had greater cel-
lular accumulation relative to the parent molecule. Evidence suggests that LCL204
was able to transiently increase lysosomal pH immediately after exposure, but this
alone was not believed to be responsible for the activity. Instead, the authors pro-
posed that the drug also needed to destabilize the lysosomal membrane such that
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Lysosomotropic properties have also been optimized in the development of drugs
used to treat osteoporosis [58]. The lysosomal protease cathepsin K is involved in the
process of bone reabsorption, and efforts are underway to develop potent and specific
inhibitors against this enzyme. Falgueyret and colleagues have synthesized and
evaluated inhibitors of cathepsin K with varying degrees of lysosomotropic proper-
ties [58,59]. Interestingly, molecules with lysosomotropic properties had far greater
activity in whole cell enzyme occupancy assays compared to activity evaluations
conducted with isolated enzymes. Fortuitously, these compounds were inherently
fluorescent, and their cellular distribution could be monitored using two-photon
confocal fluorescence microscopy. Microscopic evaluations demonstrated that
compounds localized in lysosomes, as was confirmed with colocalization studies
with the lysosomal vital stain LTR. The lysosomotropic inhibitors of cathepsin
K also had much improved pharmacokinetic properties in rats (see the following
section for more details). The lysosomotropic inhibitors had high tissue-to-plasma
concentration ratios in organs rich in lysosomes including liver, lungs, and kidneys.
In addition, the half-life of lysosomotropic inhibitors was sevenfold longer than that
of nonlysosomotropic inhibitors. One noteworthy obstacle with this approach was
that basic cathepsin K inhibitors were also concentrated in the lysosomes of cells
other than osteoclasts, and lysosomotropism tended to enhance their potential for
off-target interactions with other members of the cathepsin family in these cells (i.e.,
cathepsin B, S, and L) [60].
The same principle in lysosomal targeting of cathepsin K inhibitors was addition-
ally evaluated in a structure called the hemivacuole. The osteoclast resorbs bone by
forming a ring in close contact with the bone surface within the confines of which
it secretes protons and lysosomal enzymes, thus forming an extracellular digestive
hemivacuole. In this hemivacuole, the mineral component of bone is dissolved
by protons, and the organic component is digested by cathepsin K. Interestingly,
lysosomotropism was shown to occur in the hemivacuole surrounding the osteo-
clast [61]. This space was shown to be capable of trapping lysosomotropic drugs,
thereby increasing their potency and prolonging their duration of action relative to
nonlysosomotropic inhibitors that had equal binding affinity to cathepsin K.
18.5 INFLUENCE OF LYSOSOMAL TRAPPING
ON PHARMACOKINETICS
Shortly after lysosomotropic behavior of drugs grew to be appreciated in the litera-
ture, it became apparent that it could provide the driving force for large tissue accu-
mulation and, subsequently, a large volume of distribution and long half-life [62,63].
In other words, lysosomotropic drugs had very large tissue-to-plasma concentration
ratios, and this was particularly the case in tissues that had a high abundance of lyso-
somes such as the liver, lungs, and kidneys.
In an attempt to quantitatively describe the contribution of lysosomal trapping on
volume of distribution, a hypothetical scenario will be employed (see Figure 18.8).
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Figure 18.8 Hypothetical example illustrating the potential influence of lysosomotropism on
the apparent volume of distribution of a drug. See text for details.
In this example, the volume of distribution will be comparatively approximated for a
nonlysosomotropic drug and a lysosomotropic counterpart. For the lysosomotropic
drug, it will be assumed that its steady-state concentration in the lysosomes is 1000
times greater than extracellular concentrations. We will assume that both drugs are
dosed to achieve the same steady-state plasma concentration (i.e., 1mg/L). The
equation for the volume of distribution (VD) is given by the following equation:




This equation states the VD is equal to the volume of the plasma (VP) plus the
volume of the tissues (VT) multiplied by the ratio of the free fraction of the drug in
the blood (fUB) and the free fraction of the drug in the tissues (fUT). For the sake of
simplicity, we will assume that the drug does not physically bind to anything in the
body (i.e., free fraction in the blood and tissues are both equal to one). Under these
circumstances, the total volume of distribution for the nonlysosomotropic drug would
be equal to the volume of plasma plus the volume of tissues, which is approximately
42 L for an average 70 kg person.
In this scenario, the nonlysosomotropic drug will distribute evenly throughout
the body, while the lysosomotropic drug will be concentrated within the lysosomes.
Accordingly, it is clear that the volume of distribution will be greater for the lysoso-
motropic drug relative to the nonlysosomotropic counterpart (i.e., 42 L). In order to
quantitatively estimate the volume of distribution for the lysosomotropic drug, one
needs estimates for both the volume of the lysosomes in the body and the concentra-
tion of drug in the lysosomal compartment.
To estimate the volume of the lysosomes in the body, it is necessary to know the
number of cells in the body, the average volume of a cell, and the percent of the cell
volume comprised by lysosomes. It will be assumed that the body has some 15 trillion
cells with an average volume of 3.4× 10−9 cm3, a value which is the volume estimate
of the average human liver cell. Using these values, we arrive at a total cell volume
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estimate of 51 L. Assuming that lysosomes take up 1% of the total volume of a cell,
the volume of lysosomes in an average human body is approximately 0.51 L in total.
This estimation can be rounded to 0.5 L.
In order for the physical volume of the lysosomes to be factored into the total
body volume of distribution, the concentration of drug must be the same inside the
lysosomes as it is in the plasma. To equalize concentrations, the apparent volume
of the lysosomes must be increased by 1000-fold. Accordingly, the apparent lyso-
somal volume is now 500L. Using these assumptions, one would anticipate that the
total volume of distribution for the lysosomotropic drug would be 542 L, which is
approximately 10 times greater than the value obtained with an identical nonlysoso-
motropic counterpart.
Such alterations in the volume of distribution of a drug will translate into changes
in the elimination half-life for a drug. The half-life of a drug is referred to as a depen-
dent pharmacokinetic parameter that is dictated by the independent pharmacokinetic





According to this relationship, one would predict that a 10-fold increase in vol-
ume of distribution would translate into a 10-fold increase in half-life, assuming no
differences in clearance. Collectively, the aforementioned scenario is only hypothet-
ical and relies on a number of assumptions; nevertheless, it illustrates the impact that
lysosomal trapping could have on a drug by influencing pharmacokinetic parameters
including the volume of distribution and half-life.
In the preceding theoretical example, it was assumed that the concentration of
drugs in lysosomes at steady state would be 1000 times greater than extracellular
concentrations. Assuming that lysosomes constitute 1% of the total cell volume and
that a drug does not bind with anything in the cell, one could predict that total cellu-
lar concentrations of a lysosomotropic drug might be approximately 10 times greater
than extracellular or plasma concentrations. Interestingly, when quantified through
experimental means, Duvvuri and Krise [23] have shown that lysosomal trapping
occurs to a much larger extent than pure pH-partitioning theory would predict. This
is further supported by the work of MacIntyre and Cutler [62]. Performing in vitro
and in vivo studies in rats, and using typical therapeutic levels of chloroquine, the
authors found tissue-to-plasma accumulation ratios of approximately 800. The work
goes on to show that this sort of accumulation occurred as a result of lysosomal trap-
ping. Furthermore, the accumulation ratio was constant at varying concentrations of
chloroquine, but this accumulation ratio decreased greatly when the concentration of
chloroquine was raised. This last observation likely occurs due to the tendency of high
concentrations of chloroquine to raise lysosomal pH [62]. Cramb’s [64] work shows
similar results. In this work, the lysosomotropic drug propranolol, when adminis-
tered at therapeutically relevant concentrations, exhibits a concentration in cultured
cells that is 1000-fold greater than in extracellular media. Cramb posits that lysoso-
mal trapping could allow for a continuation of drug activity even after therapy ceases
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abruptly [64]. A fourth study by Ishizaki et al. [20] takes a look at the accumulation of
imipramine in isolated lysosomes and finds that accumulation is approximately 140
times greater than would be predicted through pH-partitioning theory. The authors
attribute this finding to either the binding of the drug to lysosomal resident molecule,
the aggregation of the drug, or a combination of both of these two scenarios. The
scientists conclude that these basic drugs, upon sequestration and binding within the
lysosome, shift the equilibrium to favor the entry of further drug molecules [20].
Taking these studies into consideration, it is plausible that lysosomal trapping might
have even greater implications on volume of distribution and half-life of drugs than
was contemplated in the previous theoretical example.
The lysosomal trapping phenomenon can occur unevenly in the various cells and
tissues comprising the body. A study by Rodgers and colleagues examined the major
factors governing the distribution of lysosomotropic β-blockers in vivo. These drugs
are weakly basic, and the studies found that distribution into the lungs was more
prevalent than distribution into other tissues, especially with lipophilic β-blockers.
Lysosomal trapping is given as the cause of this observation, since lung tissues contain
large numbers of lysosomes. In addition to lysosomal sequestration, the researchers
suggest phospholipid binding and pulmonary phospholipidosis, occurring when the
breakdown of phospholipids is impaired by the lysosomotropic drugs, as potential
reasons for this phenomenon [65].
Hung et al. [66] have examined and modeled the disposition kinetics of several
cationic drugs in isolated perfused rat liver preparations. The predictions of these
scientists hold that the unbound concentrations of drugs in tissues are over seven
times greater than the perfusate concentrations for lysosomotropic drugs such as
propranolol. Conversely, the ratio is one-to-one for a nonlysosomotropic drug such
as antipyrine.
A drug having a large volume of distribution can be viewed beneficially in that
it may have a long half-life, thereby allowing for a prolonged dosage interval in a
multiple dose setting. However, it is also possible that lysosomal trapping could be
viewed negatively from a drug development standpoint, particularly if the tissue bind-
ing is strong enough to result in undetectable plasma concentrations. Along this line,
Gong et al. [67] have demonstrated that lysosomotropic melanocortin receptor ago-
nists were effectively trapped in the lysosomes of the liver after oral administration
and that this limited their detection in the plasma. Counterparts with less affinity for
lysosomes were more easily detectable in the plasma. Ultimately, this work suggests
that there needs to be some sort of balance of lysosomotropic properties to achieve
success in drug development.
18.6 PHARMACOKINETIC DRUG–DRUG INTERACTIONS INVOLVING
LYSOSOMES
Given the aforementioned implications of lysosomal trapping on the pharmacokinet-
ics of a drug, it is important to consider possible scenarios whereby the administra-
tion of one drug (i.e., perpetrator of the interaction) to a patient could influence the
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lysosomal accumulation of a second (i.e., victim of the interaction). Conceptually,
such interactions could happen in one of three general ways. The first possibility is
that a perpetrator drug could in some way modify the steady-state accumulation of
a victim by either changing lysosomal pH or altering the binding of the victim with
some component of lysosomes. In a second scenario, the steady-state concentration
of a drug in the lysosomes remains constant, but a perpetrator drug, by some means,
is able to modify the volume of the lysosomal compartment. Finally, it is possible
that a perpetrator drug could modify the permeability characteristics of the lysosomal
membrane, and this could impact retention of the victim drug.
Daniel et al. [68,69] have investigated drug–drug interactions involving lyso-
somes whereby one lysosomotropic drug could increase lysosomal pH and therefore
decrease the accumulation of a second lysosomotropic drug that was coadministered
or administered secondarily. Lysosomotropic antidepressant and antipsychotic drugs
were the subject of the studies and were administered simultaneously either in
vivo or to isolated tissues in relatively high concentrations. Moreover, the authors
demonstrate that the perpetrator drug caused a shift in the in vivo disposition of
victim drugs. Specifically, the victim drugs were shown to decrease in concentration
in tissues high in lysosomes (i.e., lungs, liver, and kidneys) and increase in those that
have lower abundance of lysosomes (i.e., heart, skeletal muscle, and brain) [69]. It
is important to note that this type of interaction is unlikely to have profound clinical
implications. Clinically, lysosomotropic drugs would not be administered at the
doses required to cause an elevation in lysosomal pH. If a drug-induced elevation in
lysosomal pH were to occur, it would likely be very short lived.
More recently, alternative mechanisms for drug-drug interactions involving lyso-
somes that may have more widespread therapeutic relevance have been considered.
Such interactions are focused on the longer term effects that drugs can have on
lysosome structure and function that would occur at therapeutically relevant drug
concentrations. As previously discussed, under most therapeutic settings most drugs
would not be expected to significantly raise lysosomal pH. Funk and coworkers
have shown that numerous weakly basic drugs from a variety of therapeutic classes
can cause an appreciable increase (two- to threefold) in the apparent volume of
the lysosomes in a concentration- and time-dependent manner, without impacting
lysosomal pH [70]. In these conditions, the presence of the first drug can dramatically
increase the cellular accumulation of a secondarily administered lysosomotropic
drug. The authors investigated the mechanism for this effect and have shown it to be
due to changes in the vesicle-mediated trafficking associated with lysosomes [71].
Specifically, the amine-containing drugs that perpetrate the interaction do so by
increasing the flux of membrane and volume into the lysosomes through the
induction of autophagy. In addition, the perpetrating amines have also been shown to
decrease the efficiency of vesicle-mediated flux out of the lysosomes. More recently,
Logan et al. [72] have examined the structure–activity relationship of drugs that
perpetrate this effect and have found that both the propensity to be lysosomotropic
and having a capacity to intercalate within lipid bilayer membranes are important.
So far, this drug interaction pathway has not been extensively studied in animals or
humans. However, it is postulated that future studies pertaining to this drug–drug
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interaction pathway involving lysosomes could shed light on a novel basis for
variability in drug pharmacokinetics.
Working with cultured cells, Kornhuber and colleagues have demonstrated that
weakly basic, lysosomotropic drugs such as amitriptyline do not alter the lysosomal
pH or lysosomal volume but instead work to increase the permeability of the lipid
membrane of the lysosome. When lysosomotropic perpetrator drugs were adminis-
tered concurrently with LTR, they caused a decrease in its fluorescence, suggestive of
a displacement of LTR from the lysosomes. This finding fits in with these researchers’
prediction that the lysosomotropic drug has increased the permeability of the lysoso-
mal membrane, allowing for increased diffusion of LTR out of the lysosome [73].
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19.1 INTRODUCTION
All eukaryotic cells contain an elaborate array of membrane compartments including
the endoplasmic reticulum (ER), Golgi cisternae, the trans-Golgi network (TGN),
endosomes, lysosomes, mitochondria, various types of secretory vesicles, and the
plasma membrane. The compartments are highly dynamic, and vesicular trafficking
is an essential cellular process delivering cargo from one compartment to another.
Lysosomes are single membrane-enclosed compartments filled with acid hydrolytic
enzymes (e.g., cathepsins) that digest macromolecules and organelles from both
external and internal origins via endocytosis, phagocytosis, and autophagy degrada-
tion pathways. For the optimal activity of the acid hydrolases, lysosomes require the
maintenance of a low internal pH of about 4–5. Central to their role as metabolic
regulators, recent compelling evidence has indicated that lysosomes play a critical
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role in nutrient sensing and signaling pathways that are involved in cell metabolism
and growth. For instance, the kinase complex mammalian target of rapamycin
complex 1 (mTORC1), a master controller of cell and organism growth, needs to
be translocated onto the lysosomal surface to exerts its activity [1]. In this review,
we discuss how perturbation of lysosomes by pharmaceuticals and other chemical
substances can impact membrane trafficking and other biological processes that
potentially can lead to cell injury and a variety of organ toxicities.
19.2 COMPOUNDS THAT IMPACT LYSOSOMAL FUNCTION
The list of compounds that can impact lysosomal function is steadily growing and
can be classified into two main categories. One is associated with lysosomal accu-
mulation by either passive permeation or active transport, while the other involves
pharmacological inhibition of certain targets required for lysosomal function and/or
the trafficking process. Collectively, these compounds are referred to as lysosomal
toxicants.
19.2.1 Lysosomotropic Compounds
For many decades, it has been known that weakly basic lipophilic (also known as
cationic amphiphilic) compounds can accumulate in acidic organelles, including
lysosomes. Nobel laureate and discoverer of lysosomes, de Duve et al. [2] wrote an
elegant commentary discussing the concept of lysosomotropism, a mechanism for
accumulation, and the potential link to toxic side effects of pharmaceuticals. The
acidic pH (≈4.5) in the lysosomal lumen is achieved by the vacuolar H+ ATPase,
which uses the energy of ATP hydrolysis to pump H+ into the lysosome. The pH
gradient between the lysosomal lumen and the cytosol (≈7.4) drives hyperaccumula-
tion of basic lipophilic compounds via pH partitioning. Generally, the lipophilic free
bases are believed to easily traverse lipid bilayers becoming trapped in the acidic
environment of the lysosome due to ionization, which decreases the permeability
of the compound. Large amounts of basic lipophilic compounds can accumulate in
lysosomes. For instance, chloroquine, a well-known lysosomotropic compound, can
easily reach a concentration in excess of 20mM inside lysosomes yielding a ratio
several 100-fold higher than outside of the cells [2]. Similarly, after 2 h incubation
with amiodarone, the intracellular drug concentration can reach millimolar levels,
which is 500-fold higher than the initial extracellular concentrations [3].
Two physicochemical properties, basic pKa (acid dissociation constant for the
conjugated acid of the weak base) and clogP (partition coefficient between octanol
and water, representing membrane permeability) affect the drug accumulation by
influencing the extent of lysosomal trapping and regulating the kinetics of passive
permeation, respectively [2] (see Chapter 18). Since lysosomotropism is driven
by physicochemical properties, its occurrence will not be restricted to a specific
chemical or drug class. The physicochemical property distribution of close to 1500
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marketed drugs is shown in Figure 19.1 (compounds and property information
were downloaded from DrugBank [4]). A significant portion of marketed drugs
(651) carry a basic moiety (basic pKa > 6) and close to 400 of them are basic
and lipophilic (clogP> 1.5). Hypothetically, all these basic lipophilic drugs could
accumulate in lysosomes by pH partitioning, potentially impacting lysosomal
function. As illustrated in Table 19.1, a variety of drugs from multiple indications
(analgesic, antiarrhythmic, antibiotics from different classes, antihypertensive,
and antineoplastic) contain a basic moiety and most of them are lipophilic with
clogP> 2. It is noteworthy that numerous central nervous system (CNS) drug classes
(antipsychotics, selective serotonin reuptake inhibitor, and tricyclic antidepressants)
are basic and lipophilic, fitting the lysosomotropic profile. Indeed, CNS drugs have
been reported to have an average clogP of 2.8 and an average basic pKa of 8.4, both
of which contribute to the blood–brain barrier (BBB) penetration [5].
Interestingly, compounds that are either not basic or lipophilic can also accu-
mulate inside lysosomes. For instance, basic but polar aminoglycoside antibiotics
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Figure 19.1 Property distribution of approved drugs. A scatter plot showing the distribution
of approved (including withdrawn ones) small molecules drugs within the clogP-basic pKa





TABLE 19.1 Basic Compounds in Multiple Drug Classes
Indication Class Drugs clogP Basic pKa




Opioid Tapentadol 2.96 9.6
Dezocine 3.23 9.67
Dextromethorphan 3.49 9.85
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TABLE 19.1 (Continued)
Indication Class Drugs clogP Basic pKa
Ketolid Telithromycin 5.37 7.65

















Protease inhibitor Indinavir 2.81 7.37
Nelfinavir 4.72 8.18
Saquinavir 3.16 8.47












Ganglionic blocker Mecamylamine 2.37 10.88























































lysosomal accumulation has been demonstrated for multiple aminoglycoside
antibiotics [6], specifically in the kidney proximal tubule cells [7] and sensory hair
cells of the inner ear [8]. Rather than passive permeation, specialized uptake trans-
porters and endocytosis is utilized by those polar molecules to transport themselves
into lysosomes [9]. The major transport of aminoglycosides into proximal tubule
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cells involves interaction with acidic, negatively charged phospholipid-binding
sites at the level of the brush border membrane. The megalin receptor, a scavenger
receptor with broad tissue distribution, including the cochlea of the inner ear [10]
and apical surface of polarized epithelial cell membranes facing the proximal tubule
[11], has been shown to contribute to the aminoglycoside accumulation in these
tissues [12].
Another chemical class that is not associated with the basic lipophilic properties
but is lysosomotropic involves heavy metals such as arsenic, cadmium [13,14], and
platinum-containing compounds (e.g., cisplatin) [15]. Cadmium and arsenic are
environmental toxicants, and cisplatin is one of the most widely used antitumor
drugs. Similar to aminoglycoside antibiotics, various membrane transporters have
been shown to be involved in heavy metal uptake. Cellular uptake of cisplatin is
mediated, at least in part, by transport proteins including the copper transporters 1
and 2 (Ctr1 and Ctr2), the P-type copper-transporting ATPases ATP7A and ATP7B,
the organic cation transporter 2 (OCT2), and the multidrug extrusion transporter 1
(MATE1) [16]. Similarly, arsenic is transported into mammalian cells via multiple
pathways including the aquaglyceroporins (AQP3, AQP7, AQP9, AQP10), the
glucose permeases (GLUT1, GLUT2, GLUT5), and the organic anion transporting
polypeptides (OATPB, OATPC) [17]. The major pathway for cadmium uptake
by kidney proximal tubule cells involves the endocytosis of cadmium complexes
followed by binding to the high-affinity metal-binding protein metallothionein [18].
Cadmium may also be transported into cells via zinc and/or copper transporters [19].
Interestingly, various metal transporters are located on the lysosomes and play a
role in metal import/export from lysosomes [20]. The proton-coupled divalent metal
transporter DMT1, for example, is expressed exclusively in endosomes/lysosomes
and transports cadmium into lysosomes [21]. The exact mechanism of lysosomal
sequestration of heavy metals and what lysosomal transporters are involved needs to
be further investigated.
19.2.2 Nonlysosomotropic Compounds
Lysosomal accumulation is not the only mechanism by which xenobiotics can
impact the lysosomal pathway. Lysosomal toxicants can also affect lysosomal
function via pharmacological inhibition of molecular targets involved in lysosomal
regulation. Bafilomycin A (Baf A) and concanamycin, for example, can block
lysosomal acidification through selective inhibition of the V-type ATPase [22]. The
ionophores monensin and nigericin, which mediate the exchange of H+ and Na+, can
also increase the pH of lysosomes [23]. Evidently, inhibition of various cathepsins
can disrupt lysosomal proteolysis. Microtubule disruptors, such as paclitaxel and
vincristine, can impair lysosomes by disrupting microtubule-dependent trafficking.
Bacterial proteins such as staphylococcal a-toxin and anthrax toxin have been shown
to impact lysosomal function by disrupting lysosomal membrane integrity [24,25].
Recently, it was shown that botulinum neurotoxins (BoNTs, serotypes A–G) and
tetanus neurotoxin (TeNT) induce perturbations of the fusogenic SNARE (soluble




which could impact the fusion of lysosomes with other vesicles. In addition,
tumor necrosis factor-related apoptosis-inducing ligand (TRAIL) was observed to
trigger lysosomal change after binding to death receptor 5 via recruitment of the
proapoptotic proteins Bim and Bax to the lysosomes [26].
19.3 CELLULAR CONSEQUENCES
Lysosomes are kinetic organelles and have an intimate link with the endocytic
apparatus, phagocytosis, and autophagy, which deliver materials to lysosomes for
degradation and recycling. Lysosomes are not the only acidic organelles; early
endosomes, late endosomes, phagosomes, and autolysosomes all have a differing
degrees of luminal acidity and thus are targets for accumulation of basic lipophilic
xenobiotics. For simplicity, our discussions primarily focus on lysosomal changes
and vesicular trafficking.
19.3.1 Effect of Drugs on pH and Lysosomal Volume
Accumulation of high concentrations of basic compounds in lysosomes can increase
the luminal pH. The lysosomotropic compounds, chloroquine andmethylamine, were
shown to increase lysosomal pH drastically (0.5–2.0 pH units) after accumulation
in vitro [27], and in the case of chloroquine, in vivo [28]. The LysoTracker probes
consist of a fluorophore linked to a weak base that is only partially protonated at neu-
tral pH. This allows LysoTracker probes to freely permeate cell membranes enabling
them access to the luminal regions of acidic organelles in live cells. Similar to other
lysosomotropic compounds, low pH is required for the lysosomal accumulation and
subsequent detection of LysoTracker® probes. In a previous study using H9C2 cells,
basic lipophilic compounds were shown to decrease the staining of LysoTracker Red
DND-99 (LTR) after 4 h of treatment, indicating an increase in lysosomal pH [29].
The drugs used in this study were from multiple drug classes and pharmacologi-
cal actions including antidepressants, antipsychotics, and anticancer, indicating the
increase in pH is related to their physicochemical properties rather than specific phar-
macological target inhibition. Indeed, clustering analysis demonstrated that com-
pounds possessing a clogP> 2 and a basic pKa between 6.5 and 11 were associated
with the increase in pH [29]. These data are consistent with the observation from a
different publication using Fa2N-4 cells in which the decrease in LTR fluorescence
was associated with basic and lipophilic compounds [30]. An increase in pHwould be
expected to decrease the lysosomal degradation capability since acidic pH is optimal
for lysosomal enzyme activity. In addition, an increase in pH can decrease the fusion
capability of lysosomes [31], and in fact, chloroquine has been shown to decrease the
fusion between autophagosome and lysosome [32]. Besides basic lipophilic com-
pounds, vacuole ATPase inhibitors, such as Baf A, can also inhibit the acidification
of lysosomes, resulting in decreased LTR staining [33].
Interestingly, pH increase by basic lipophilic compounds is only a short-term




exposure [34]. Consistent with a reversal of the pH change, prolonged exposure of
numerous basic lipophilic drugs significantly increases the cellular accumulation
of LTR [35,36], indicating an increase in lysosomal volume and normalization
of luminal pH. A fourfold increase in lysosomal volume was estimated based on
both the lysosomal pH and amount of LTR accumulated after 24 h exposure of
imipramine [34]. One plausible reason for the increase in lysosomal volume could be
due to an adaptive change by increasing lysosomal biogenesis with basic lipophilic
compounds. For example, increases in lysosome-associated membrane protein 2
(LAMP-2) staining was observed in vivo with multiple basic lipophilic drugs [37]
and marked lysosome-associated membrane protein 1 (LAMP-1) increase was
observed in vitro with chloroquine treatment [38]. Transcription factor EB (TFEB)
is a master transcription factor for lysosomal biogenesis [39] and TFEB nuclear
translocation was triggered by chloroquine treatment, which could explain in part the
increase in lysosomal volume [40]. TFEB also potentially plays a role in reversing
the pH change via upregulation of vATPase [39].
A second reason for an increase in lysosomal volume is accumulation of
undigested substrate in lysosomes. Lysosomal volume expansion by imipramine
can be reversed by exposing cells to hydroxypropyl-β-cyclodextrin, which reduces
lysosomal cholesterol burden, suggesting elevation in lysosomal cholesterol content
contributes to the lysosomal volume increase [34]. Similar lysosomal changes
were also observed for compounds that impact lysosomes via nonaccumulative
process. For instance, increases in the acidic compartment and LAMP-2-positive
vesicles were observed following vincristine treatment [41]. Interestingly, cells
derived from patients with lysosomal storage diseases (LSDs) are often associated
with an increase in LTR staining [34,42], implying the increase in LTR by compound
treatment is indicative of lysosomal dysfunction. Hence, decreased LTR staining is
a common approach as a phenotypic screen for LSDs drug discovery [42], which
further supports this notion.
19.3.2 Effects on Lysosomal Enzymes
Besides the pH change, lysosomotropic compounds have demonstrated effects on
lysosomal enzyme activity, either directly or indirectly. Chlorpromazine and chloro-
quine have demonstrated inhibition of lysosomal phospholipase A1 in vitro [43,44],
as well as downregulation of acid ceramidase that was not caused by decreased tran-
scription [45]. Furthermore, multiple lysosomotropic compounds have demonstrated
the ability to redistribute the mannose 6-phosphate (M6P) receptor from the TGN to
endosomes and concomitantly increase the secretion of lysosomal enzymes resulting
in a decline of mature intracellular lysosomal enzyme levels [46]. Since the majority
of enzymes delivered to lysosomes require the M6P receptor, the redistribution of
the receptor by lysosomotropic compounds could dysregulate a range of lysosomal
enzymes. Reduction of lysosomal enzyme activity (either due to alterations of pH, or
by direct or indirect inhibition) could contribute to lysosomal dysfunction. Paradox-
ically lysosomotropic cathepsin K inhibitors were shown to increase other cathep-




Alzheimer’s disease (AD) presumably due to a compensatory protective response
[48,49]. It is therefore conceivable that lysosomal toxicants can also trigger upregu-
lation of lysosomal cathepsins to offset the lysosomal dysfunction. Long-term impact
of lysosomal toxicants on lysosomal enzymes needs to be evaluated further.
19.3.3 Lysosomal Substrate Accumulation
One of the critical functions of lysosomes is to break down all types of biological
polymers including proteins, nucleic acids, carbohydrates, and lipids. Changes in
pH or enzymatic activity by basic lipophilic compounds may decrease lysosomal
degradation capacity, triggering accumulation of various substrates. One of the best
characterized examples of this is the excessive accumulation of phospholipid, for
example, phospholipidosis (PLD), induced by lysosomotropic compounds. The
hallmark feature of PLD is the characteristic lamellar bodies that are visible by
transmission electron microscopy [50] (see Chapter 20). An in silico model for
PLD prediction proposed by [51] describes a simple method based on both pKa
of the most basic center and clogP value of the molecules. Interestingly, besides
basic lipophilic compounds, polar aminoglycoside antibiotics, which carry a basic
moiety, are also associated with PLD [52]. Lysosomal hydrolysis contributes
to the mobilization of lipid droplet-associated cholesterol [53] and cholesterol
accumulation is associated with lysosomal dysfunction. For instance, a mutation in
NPC1 resulting in the accumulation of cholesterol in late endosomes or lysosomes
leads to the autosomal recessive disease Niemann–Pick disease type C (NPC). The
basic lipophilic compounds U18666A, clomiphene, and terconazole have been used
to produce the NPC phenotype (cholesterol accumulation) experimentally [54,55].
Moreover, accumulation of lipofuscin, which is an intralysosomal waste material
consisting of various components such as protein, lipid, carbohydrates, metals, and
autofluorescent pigment [56] has been observed in postmitotic cells associated with
aging, lysosomal protease inhibitors, and chloroquine treatment [57,58].
Excessive accumulation of various substrates triggers severe lysosomal dysfunc-
tions exemplified by LSDs. While the majority of LSDs are a consequence of the
deficiency of a single enzyme required for the metabolism of lipids or glycoproteins,
lysosomotropic compounds may affect multiple lysosomal activities. In addition,
lysosomotropic agents including ammonium chloride, chloroquine, methylamine,
doxorubicin, and the lysosomal enzyme inhibitor E64D, cause ferritin accumulation
[59], which prevents the redistribution of iron to vital cellular processes and triggers
cellular damage as a result.
19.3.4 Lysosomal Membrane Permeabilization (LMP) and Cell Death
Lysosomal membrane integrity, as measured by acridine orange leakage, can be
compromised by excessive compound accumulation [60,61]. Subsequent leakage
of large amounts of lysosomal acid hydrolases following lysosomal membrane
disruption leads to cellular toxicity through apoptotic mechanisms [62–65]. In




hydrolytic enzymes released into the cytosol, is dose dependent and may induce
sublethal damage, apoptosis, or necrosis depending on the exposure level and
duration [66]. This dose-related differential outcome has been demonstrated by the
lysosomotropic agent O-methyl-serine dodecylamide hydrochloride (MSDH), in
which apoptosis accompanied by caspase-3 activation occurred at <50 μM while at
>75 μMnecrosis occurred and was associated with more extensive lysosomal rupture
[67]. Tamoxifen also exhibited a similar toxicity profile in which high concentration
(10 μM) caused extensive necrosis while apoptotic-like cell death was observed at
lower concentrations [68]. The close connection between lysosomal accumulation
and cell death is further demonstrated by the observation that Baf A pretreatment of
cells can rescue the toxicity caused by certain basic lipophilic compounds [69].
The intimate relationship between lysosomes and mitochondria in the execution
of apoptosis is emphasized in the lysosomal–mitochondria axis theory of apoptosis,
where released lysosomal enzymes trigger mitochondria permeability transition and
apoptosis via the Bcl-2 family (e.g., bax and BAD) [70] (see Chapter 8). Lysosomal
membrane permeabilization has also been reported to initiate a caspase-independent
cell death pathway [71] as well as the release of iron that can catalyze the formation
of highly reactive hydroxyl radicals leading to oxidative stress-induced apoptosis or
necrosis [72].
19.3.5 Membrane Trafficking Changes
Lysosomes are the central hub for membrane trafficking including endocytosis,
autophagy, and phagocytosis. Lysosomal dysfunction from xenobiotic effects on
pH, enzymatic activity, substrate accumulation, and/or impairment of membrane
integrity could lead to disruption of various trafficking pathways associated with
lysosomes.
19.3.5.1 Autophagy Perturbation Autophagy refers to the catabolic process in
eukaryotic cells that delivers cytoplasmic material to lysosomes for degradation.
This highly conserved process is involved in the clearance of long-lived proteins and
damaged organelles. Vinblastine (a microtubule inhibitor), leupeptin (a lysosomal
protease inhibitor), and the lysosomotropic amines propylamine and chloro-
quine are all capable of inhibiting autophagy in various model systems [73,74].
Microtubule-associated protein light chain 3 (LC3) is an ubiquitin-like protein
required for the formation of autophagosomal membranes. During autophagy, a
cytosolic form of LC3 (LC3-I) is conjugated to phosphatidylethanolamine to form an
LC3-phosphatidylethanolamine conjugate (LC3-II), which is recruited to autophago-
somal membranes. Detection of LC3 by immunoblotting or immunofluorescence
has become a reliable method for monitoring autophagy. Several lysosomotropic
compounds have been shown to increase LC3 staining, indicating the modulation
of autophagy [75]. The concentration-dependent increase in the abundance of
the autophagy substrate, sequestosome 1 (SQSTM1/p62, hereafter referred to as
p62) by these compounds supports the hypothesis that the increase in LC3 was




downregulation of extracellular matrix and cytoskeletal gene transcription by these
compounds also indicate ineffective turnover of long-lived proteins, supporting the
notion of autophagy inhibition. Further evidence of this hypothesis is demonstrated
by the finding that the lysosomotropic detergent siramesine decreases the colo-
calization of LC3-positive vesicles with LAMP-2-positive vesicles, indicating the
impairment of autophagosomal fusion with lysosomes [76]. Conversely, many basic
lipophilic compounds such as amiodarone [77], tamoxifen [78], amitriptyline [79],
verapamil [80], and dimebon [81] have been proposed as autophagy stimulators
based on their ability to increase LC3. Because of their basic lipophilic properties,
these compounds have the propensity to accumulate in lysosomes [29].
One common assay format employed to study autophagy flux is to evaluate
the effect on LC3-II abundance with test compound in the presence of protease
inhibitors (e.g., E64d) or Baf A. An increase of LC3-II abundance with the combi-
nation treatment relative to the test compound alone is indicative of increased flux
through the autophagy process. However, this assay only measures the initial stage of
autophagosome formation without the evaluation of the degradation step. Recently,
it was shown that lysosomotropic compounds (e.g., chloroquine) induce lysosomal
stress and, consequently, provokes TFEB nuclear translocation [40], which could
drive expression of autophagy genes leading to the induction of autophagy. It is
possible that the increase of LC3-II caused by these basic lipophilic compounds is
due to the adaptive increase in autophagy by TFEB nuclear translocation. Ultimately,
downstream lysosomal dysfunction inflicted by lysosomotropic compounds would
tend to block autophagy [75]. Other types of membrane trafficking perturbation
discussed later further supports the notion of global lysosomal dysfunction.
19.3.5.2 Impairment of Endocytosis/Phagocytosis Endocytosis is an energy-
consuming process by which cells take up extracellular molecules (such as pro-
teins) by engulfing them. There are various mechanisms of endocytosis such as
clathrin-mediated, caveolae, and macropinocytosis. Phagocytosis is a special form of
endocytosis in which large particles are taken up via the phagosome. The endocytic
pathway consists of distinct membrane compartments, which internalize molecules
from the plasma membrane and then either recycle them back to the surface, as in
early endosomes and recycling endosomes, or designate them for degradation, as in
late endosomes and lysosomes. Lysosomes are the last compartment of the endocytic
pathway and their dysfunction by lysosomal toxicants can negatively impact the
endocytic process and various endocytic compartments.
Indeed, numerous lysosomal toxicants are known to impact various stages
and compartments of endocytosis and are routinely used to study the endocytic
process. For example, direct evidence for recycling came from the observation that
the process can be inhibited by basic compounds, including chloroquine, NH4Cl,
methylamine, and ionophores, such as monensin [82]. Many receptors are recycled
and return to the plasma membrane after ligand dissociation. Lysosomal toxicants
have been shown to prevent recycling of receptors for LDL [83], transferrin [84],
epidermal growth factor, and macroglobulin [85]. Instead of returning to the plasma




to the pH elevation of acidic compartments and inhibition of the dissociating of
the ligand from the receptor [86] or perturbation of the clathrin lattice assembly.
Indeed, chloroquine is recognized as a clathrin-dependent endocytosis inhibitor
[87]. In addition, using an in vitro macrophage model, monensin and chloroquine
were shown to inhibit transfer to lysosomes of endocytosed macromolecules [88].
Azithromycin, a lysosomotropic antibiotic, delayed sequestration of receptor-bound
transferrin and peroxidase–antiperoxidase immune complexes into cell-surface
endocytic pits and vesicles [89].
Virus entry relies on either membrane fusion or endocytosis and, intriguingly, the
viral entry has been shown to be impacted by lysosomotropic compounds. Ebola
viruses enter the cell by a macropinocytic-like process after attachment to the cell
surfaces [90], and multiple lysosomotropic compounds, including U18666A and
clomiphene, were shown to inhibit Ebola virus entry and infection. Chloroquine and
NH4Cl also demonstrated more than a 50% reduction of HCV infectivity. Recently,
another lysosomotropic compound, amiodarone, has been shown to inhibit the entry
of the hepatitis C virus [91]. Together these data strongly support the inhibition of
endocytosis by lysosomal toxicants.
19.3.5.3 Phagocytosis Basic lipophilic local anesthetics, dibucaine, tetracaine,
and procaine, have been shown to exert a reversible inhibition of phagocytosis
of opsonized sheep red blood cells using mouse peritoneal macrophages [92].
Interestingly, the potencies of these local anesthetics for inhibition of phagocytic
uptake were proportional to their logP, indicating the critical role of this physic-
ochemical property in inhibiting phagocytosis. Retinal pigment epithelium (RPE)
is one of the most phagocytotically active cell types. Chloroquine has been shown
to decrease the uptake of rhodamine-labeled dextran in retinal pigment epithelial
cells [38], suggesting disruption of the phagocytic pathway. The basic lipophilic
compounds tamoxifen, toremifene, and chloroquine were also shown to decrease the
uptake of FITC-labeled rod outer segments [93] in retinal pigment epithelial cells
in vitro, further supporting the notion of inhibiting phagocytosis by lysosomotropic
xenobiotics.
19.3.5.4 Exocytosis Exocytosis involves the transport of intracellular vesicles
to the plasma membrane of the cell where vesicular fusion results in the delivery
of membrane and protein to the cell surface, as well as secretion of the vesicular
contents. It is well established that increases in lysosomal pH result in lysosomal
exocytosis, with enhanced secretion of preformed hydrolases [46,94–96]. Chloro-
quine not only stimulated the release of porphyrins from yeast [97] but also enhanced
the exocytosis of MTT formazan, which accumulates in the endosomal/lysosomal
compartment [98]. Similarly, exocytosis of lysosomal contents was also observed
from skeletal muscle in vivo following chloroquine treatment [99]. The association
of increased exocytosis with lysosomal dysfunction is further supported by the find-
ings in lysosomal storage and aging-related diseases. Lysosomal storage materials
have been found in extracellular fluids, blood, and urine in some LSDs patients,




different neurodegenerative diseases, including AD, Parkinson’s disease (PD), and
Huntington’s disease (HD), share one common feature: abnormal accumulation
and aggregation of disease-specific proteins that form either intracellular inclusions
or extracellular aggregates, presumably by excessive lysosomal exocytosis. For
instance the truncated, misfolded, and oxidatively modified α-synuclein forms
appear to be enriched in the vesicular fraction and to be preferentially secreted [102].
Chloroquine has been shown to increase nuclear translocation of TFEB during
lysosomal stress [40], promoting lysosomal exocytosis by increasing the pool of
lysosomes in the proximity of, and promoting fusion with, the plasma membrane
[103]. Besides the role of TFEB, Ca2+ release also contributes to the regulation of
exocytosis. The lysosomotropic agent glycyl-l-phenylalanine-naphthylamide (GPN)
evoked robust increases in the intracellular Ca2+ concentration and triggered release
of β-hexosaminidase within 5min of exposure, demonstrating the characteristic
ruffling of the plasma membrane associated with exocytosis [104]. Ca2+ release
from the lysosome in this case is believed to play a role in the immediate increase in
exocytosis.
19.3.6 Other Cellular Impacts
Due to the central role of lysosomes in membrane trafficking, organelle homeostasis
critically relies on effective lysosomal function. Membrane trafficking perturbation
due to lysosomal dysfunction subsequently impacts other organelles. In addition, the
intriguing discovery that activation of mTORC1 requires lysosomal recruitment in
response to amino acid concentrations [105] positions these degradation organelles as
a new hub for signaling transduction. However, how xenobiotics affect cell signaling
via lysosomes is yet to be investigated.
19.3.6.1 Mitochondria The intimate relationship between lysosomes and
mitochondria is twofold. First, as discussed earlier, released cathepsins can destabi-
lize mitochondria, promote cytochrome c release, and ultimately induce apoptosis.
Second, autophagic delivery to lysosomes is the major degradative pathway in mito-
chondrial turnover, which is critical for mitochondrial quality control [106]. This
special form of mitochondrial degradation by autophagy is referred to as mitophagy.
Mitochondrial abnormalities would be an expected outcome of drug-induced lysoso-
mal dysfunction and the persistence of dysfunctional mitochondria has indeed been
observed with multiple LSDs [107]. Abnormal mitochondria were also observed
in multiple autophagy knockout studies further strengthening this critical role of
autophagy [108]. The number of mitochondria and GFP-LC3 colocalized puncta
increased in the presence of lysosomal inhibitors such as chloroquine or E64 D
plus pepstatin A [109]. Accumulation of damaged mitochondria by lysosomotropic
compounds could certainly lead to cellular perturbations.
19.3.6.2 Endoplasmic Reticulum The ER has a role in folding and modifying
proteins, and secreting proteins via the secretory pathway. Elevated levels of mis-




LSD patients, indicating a role for lysosomes in maintaining of ER homeostasis
[110]. The autophagy process has been shown to degrade sequestered ER within
autophagosomes [111], for instance, autophagy-deficient T lymphocytes demonstrate
abnormal expansion of ER and impaired calcium influx [112]. Induction of autophagy
during ER stress [113,114] is believed to serve as a protective mechanism against
cell death. Presumably, an autophagy defect due to lysosomal dysfunction induced
by lysosomal toxicants could exacerbate the ER stress and enhance cytotoxicity.
The lysosomotropic kinase inhibitors, imatinib and flavopiridol, have been associated
with ER stress resulting from perturbation of autophagy and lysosomal membrane
permeabilization [61] [115].
19.3.6.3 Oxidative Stress Several reports have associated reactive oxidative
species (ROS) with lysosomotropic agents [116–119]. Interestingly, in situ imaging
showed ROS production was present within 1 h of exposure to the lysosomotropic
antibiotic gentamicin [120]. The links between autophagy dysregulation and
increases in oxidative stress are evident by mouse lysosomal protein knockout
studies and autophagy inhibitors [108]. These studies demonstrate the accumulation
of oxidized ubiquitinated proteins and dysfunctional mitochondria. Mitochondria
are a major site of ROS generation from multiple sites along the respiratory chain
[121], and accumulation of damaged mitochondria due to lysosomal function
impairment likely contributes to the increase of oxidative stress. Interestingly,
lysosomes are susceptible to oxidative stress and an increase in oxidative stress can
act as an amplifying loop to further destabilize the lysosomal membrane [122,123].
Antioxidant treatments have demonstrated that prevention of ROS production at least
partially rescued cell death caused by lysosomal permeabilization [120]. Lysosomes
are rich in redox-active iron due to degradation of iron-containing macromolecules
and the lysosomal iron has been shown to play a role in exacerbating the effects
of ROS via the Fenton reaction, in which an extremely reactive hydroxyl radical is
formed during hydrogen peroxide oxidization of iron [124].
19.3.6.4 Signaling Modulation Besides membrane trafficking and degradation,
lysosomes have a critical emerging role as a signaling hub, particularly for nutrient
sensing and cellular metabolism. mTORC1 needs to be recruited to the lysosomal sur-
face to exert its kinase activity [105]. Interestingly, it is the level of amino acids inside
the lysosomal lumen that controls mTORC1 docking on the lysosomal surface and
subsequent activation.Multiple protein complexes, including RagGTPase, raptor and
regulator, are involved in the mTORC1 translocation. p62, a substrate for autophagy,
has been shown to bind to raptor, becoming an integral part of the mTORC1 complex
and facilitating mTORC1 translocation to the lysosomal surface upon amino acid
stimulation [125]. Furthermore, activation of mTORC1 inhibits both autophagy and
lysosome biogenesis [126,127].
Lysosomal toxicants may affect signaling molecules via lysosomes in several
ways. First of all, inadequate lysosomal degradation may decrease free amino
acid generation, impeding mTORC1 activation. Indeed, a decrease in mTORC1




mucopolysaccharidosis type I, Fabry disease, and aspartylglucosaminuria [128],
but also observed after treatment with several lysosomotropic compounds (e.g.,
chloroquine [40], amiodarone [129], and imipramine [130]. In addition, p62 has been
shown to regulate various other signal transduction pathways (Nrf2, NF-κB, caspase
8, and ERK1) through specific protein interactions [131]. As was discussed before,
increases in p62 are typically associated with lysosomal dysfunction and autophagy
deficiency, and this increase could modulate multiple signaling molecules. A
noncanonical mechanism of Nrf2 activation by autophagy deficiency due to
direct interaction between Keap1 and p62 has recently been proposed [132,133].
Essentially, p62 interacts with the Nrf2-binding site on Keap1, a component of
Cullin-3-type ubiquitin ligase for Nrf2. When p62 accumulates due to autophagy
deficiency, it competes with the interaction between Nrf2 and Keap1, resulting in sta-
bilization of Nrf2 and transcriptional activation of Nrf2 target genes. Lysosomotropic
compounds were clearly shown to induce multiple Nrf2-regulated genes such as
glutamate–cysteine ligase and glutathione-S-transferase, indicating Nrf2 activation
[75]. Remarkably, arsenic inhibits autophagic flux and activates the Nrf2-Keap1 path-
way in a p62-dependent manner since Nrf2 activation by arsenic is diminished when
p62 is knocked down [134]. In addition, activation of NF-κB has been observed in an
autophagy-suppressed Atg7 knockout model accompanied by accumulation of p62
[135], whereas knockout of p62 suppressed NF-κB signaling, indicating a critical role
of p62 in the regulation of NF-κB. The lysosomotropic compounds chloroquine and
imatinib mesylate were indeed shown to induce NF-κB in astroglial cells and pan-
creatic islet cells, respectively [136,137]. However, whether the increase in NF-κB
is generic for all lysosomotropic compounds and whether the effect is dependent on
p62 needs to be further investigated. p62 also promotes the full activation of caspase
8 with subsequent triggering of apoptosis [138], and suppresses ERK1 signal during
adipogenesis [139]. More recent data showed autolysosomal sequestration of active
RhoA was via p62 and negative regulation of RhoA signaling activity by constitutive
autophagy [140]. Overall, lysosomal changes and p62 accumulation due to autophagy
deficiency from lysosomal toxicant treatment could set off a chain of altered signaling
molecules, which in turn can further impact a variety of biological processes.
In conclusion, we propose a multifaceted model (Figure 19.2) in which lysosomal
toxicants, either by accumulation or disturbance of lysosome function, not only
induce cell death due to lysosomal membrane permeabilization but also impair
lysosomal function. These functional changes can result in the perturbation of
multiple membrane trafficking pathways including autophagy, endocytosis, phago-
cytosis, and possibly exocytosis enhancement. Besides the lysosomal change, other
organelles such as mitochondria and ER could be damaged due to deficiency of
autophagy, which subsequently leads to oxidative stress. Furthermore, multiple
signal transduction processes including mTORC1, ERK1, Nrf2, and NFκB are
modulated by lysosomal dysfunction due to the increase of p62 abundance resulting
from autophagy deficiency. The pathophysiological consequences of modulating
those signaling molecules by lysosomal toxicants needs to be further deciphered.
Thus far, the focus has been on the impact of small molecules on lysosomes.
However, nanotechnology is currently an area of intense scientific interest due to a
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Figure 19.2 Biological impacts of the lysosomotropic compounds. Compounds can perturb
lysosome functions either by accumulation inside the lysosomes or direct inhibition of various
lysosomal functions (e.g., decrease of lysosomal enzyme activity). Lysosomal membrane per-
meabilization can trigger cell death. In addition, lysosomal dysfunction can tamper membrane
trafficking pathways including autophagy, endocytosis, phagocytosis, and exocytosis. Multiple
signal transduction processes including MTORC, ERK1, Nrf2, and NFκB can also be modu-
lated by lysosomal dysfunction due to the increase of p62 abundance resulting from autophagy
deficiency. (See color plate section for the color representation of this figure.)
wide variety of potential applications in biomedical, optical, and electronic fields,
and various nanoparticles have been shown to be trapped inside the lysosomes and
disrupt lysosome function including LMP and inhibition of autophagy [141,142].
Thus, lysosomal dysfunction could be an emerging toxicological mechanism for
both small molecules and nanomaterials.
19.4 IMPAIRED LYSOSOMAL FUNCTION AS A MECHANISM FOR
ORGAN TOXICITY
A number of cellular processes can be affected by lysosomal dysfunction that can
ultimately lead to organ toxicity as illustrated in LSDs. Pathological manifestations
in LSDs as a result of lysosomal defects strongly indicate that a similar mechanism
could contribute to organ toxicity resulting from xenobiotics that perturb lysoso-




cardiac, kidney, skeletal muscle, and hepatocyte are impacted by LSDs [107]. As
will be discussed later, a number of organ toxicities have been associated with lyso-
somal dysfunction. Obviously, many mechanisms discussed previously such as LMP,
blocking of membrane trafficking, impacted organelle function, and modulation of
signaling molecules elicited by lysosomal toxicants could contribute to target organ
toxicity. Furthermore, one critical point that needs to be taken into consideration is
that many lysosomotropic compounds have higher volume of distribution [143] and
tissue exposure in general is higher than systemic plasma exposure, especially in the
organs that are known to have abundant lysosomes such as liver, lung, and kidney.
Indeed in animal studies, chloroquine concentrations in the liver, spleen, kidney, and
lung were found to be 700–1600 times the concentration in plasma after 1 month
of administration at 40mg/kg/day [144]. Even in the heart, which has low lysosomal
content, chloroquine concentrations were 200 times over plasma levels. Higher tissue
drug exposure can certainly increase the risk of organ toxicity. Remarkably, simply
lowering the pKa can result in decreased tissue exposure and lower liver toxicity [145]
supporting the role of lysosomal accumulation in xenobiotic-induced toxicity.
19.4.1 Liver Toxicity
More than 900 drugs, toxins, and herbs have been reported to cause liver injury.
Different mechanisms such as reactive metabolite formation, oxidative stress, and
mitochondrial impairment have been proposed to contribute to the pathogenesis of
drug-induced liver injury. The involvement of the lysosomal pathway in liver toxicity
has been suggested by numerous studies. Oral drugs are absorbed by the gastrointesti-
nal system and enter the liver via the hepatic portal vein prior to systemic circulation.
Thus, the liver typically receives the highest maximal drug exposures relative to
other tissues. These high maximal exposures coupled with the lysosomal trapping of
basic lipophilic drugs often leads to drug accumulation in the liver. For example, the
lysosomotropic compounds amiodarone and chloroquine have been shown to have
significantly higher levels in liver tissue compared to the plasma [146,147]. Many
basic lipophilic compounds, such as amiodarone, chloroquine, and perhexiline, are
indeed associated with hepatic morphologic effects, which include marked lysosomal
changes described as lamellar lysosomal inclusions [148].
As discussed previously, nonbasic xenobiotics can affect the lysosomal pathway
via a nonaccumulation mechanism. The cathepsin B–mitochondria apoptotic path-
way has been demonstrated to play a critical role in hepatocyte apoptosis and liver
injury induced by TNFα [149,150]. Either genetic knockout or pharmacological
inhibitors of cathepsin B can mitigate the liver damage. Interestingly, acetaminophen,
overdose of which is the most frequent cause of drug-induced liver failure in the
United States, can also increase the lysosomal membrane instability as demon-
strated by the release of cathepsin B from lysosomes [151]. In addition, lysosomal
iron mobilization into mitochondria has been shown as a contributing factor to
acetaminophen-induced hepatotoxicity [152,153]. Hepatotoxicity is also one of the
adverse reactions caused by diclofenac, an arylacetic nonsteroidal anti-inflammatory
drug (NSAID). Involvement of LMP and lysosomal/mitochondrial cross talk induced
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by reactive oxygen species (ROS) formation contributes to diclofenac hepatotoxicity
[154]. It is noteworthy that the lysosomal pathway also contributes to liver injury
in pathological conditions such as cholestasis and hepatic lipotoxicity [155,156].
Using a bile duct-ligated mouse model, both genetic and pharmacologic inactivation
of cathepsin B reduces liver injury, inflammation, and hepatic fibrogenesis during
cholestasis, indicating a role for lysosomes in liver damage [155]. Similarly, in a
dietary murine model of nonalcoholic fatty liver disease and hepatic steatosis, liver
injury was mitigated by the genetic and pharmacologic inactivation of cathepsin
B [156]. Moreover, the loss of Atg7 in the adult liver leads to hepatomegaly and
accumulation of abnormal organelles in hepatic cells [157]. Histological analysis
revealed disorganized hepatic lobules and cell swelling in the ATG7-deficient liver.
These findings support the physiological role of the autophagy/lysosome pathway
in the maintenance of liver homeostasis and lend credence to the involvement of
xenobiotic disruption of this pathway in liver injury.
19.4.1.1 Heart The heart is low in lysosomal mass and in general does not
accumulate lysosomotropic xenobiotics to levels measured in the liver [144].
However, cardiomyocytes can be very sensitive to tissue homeostasis perturbation
due to membrane trafficking impairment. Cardiac muscle is characterized by
a predominantly aerobic metabolism and consequently ROS are continuously
generated [158]. Efficient removal of damaged cellular structures by the lysosomal
pathway, particularly autophagy, is critical to the maintenance of the cardiac myocyte
homeostasis. Indeed, controlled cardiac-specific deficiency of autophagy-related
homolog 5 (Atg5) in adult mice led to cardiac hypertrophy, left ventricular dilation,
and contractile dysfunction [159]. The findings could be due to the long-lived
postmitotic nature of the cardiac myocytes, in which autophagy plays an important
role in the quality control of proteins and organelles. Diminished lysosomal function
has been associated with heart disease and aging as evidenced by accumulation of
the age pigment lipofuscin in the lysosomal compartment and extralysosomal waste
accumulation [160]. Danon disease in humans is a well-characterized example of
how lysosomal dysfunction by LAMP-2 deficiency can lead to heart failure [161].
The classical lysosomal inhibitors chloroquine and hydroxychloroquine have
been associated with cardiac adverse effects (more commonly cardiac conduction
block) with long-term treatment. Electron microscopy analysis of myocardial
samples from patients revealed large lysosomes and myelin figures [162], which is
consistent with perturbed autophagy. Another lysosomotropic compound, isopro-
terenol, is a β-adrenergic agonist that induces myocardial infarction and triggers
decreased stability of lysosomal membranes. This is reflected by lowered activities of
β-glucuronidase and cathepsin D in the lysosomal fraction [163], linking lysosomes
in the cardiac toxicity.
Imatinib mesylate (Gleevec) inhibits the catalytic activity of Bcr-abl and is
the first targeted therapy approved for the treatment of Ph+CML. Despite its
breakthrough success in the treatment of CML, imatinib treatment has been
implicated in the development of congestive heart failure [164]. There have been




oncogene 1 (c-Abl) kinase and the observed cardiac findings. Through the use of
RNA interference technology and kinase-inactive chemical analogs of imatinib, a
lack of association between c-Abl inhibition and in vitro cardiomyocyte toxicity
was demonstrated [69]. Instead, the toxic effects of imatinib were related to the
compound’s physicochemical properties. Imatinib and its kinase-inactive analogs are
basic lipophilic compounds that accumulate in lysosomes and interrupt autophagy.
The vacuolar-type H(+)-ATPase inhibitor Baf A inhibits the lysosomal acidification
[165] and consequently prevents accumulation of basic compounds in lysosomes.
The in vitro cytotoxicity of both imatinib and kinase-inactive analogs was shown to
be rescued by Baf A, further supporting the contribution of the lysosomal accumula-
tion in imatinib-induced cardiac toxicity. The in vivo findings from imatinib-treated
spontaneous hypertensive rats further support this hypothesis. In the imatinib-treated
rat, aggregated lysosomes and nonfusion vacuoles were detected in the cytoplasm of
severely atrophic myocytes, indicative of autophagy disruption [166]. Interestingly,
myocyte lesions were more severe in spontaneous hypertensive rats than in normal
Sprague Dawley rat. Similarly, when cardiac-specific deficiency of Atg5 occurs
early in cardiogenesis between embryonic day 7.5 and 8, no cardiac phenotype
was observed under baseline conditions. However, cardiac dysfunction and left
ventricular dilatation developed 1 week after treatment with pressure overload [159],
suggesting the role of autophagy in response to this type of cardiac stress. As drug
treatment gradually triggers lysosomal dysfunction and autophagy interruption,
adaptive changes take place to maintain the basal function. This adaptive response
can be compromised by the stress of pressure overload leading to greater sensitivity
to autophagy disruption. Alternatively, autophagy disruption may limit the adaptive
response to the pressure overload, resulting in the same net effect on cardiac function.
As a result, utilizing a stress model might increase the sensitivity for identification
of cardiac toxicants, especially those that trigger autophagy disruption.
The clinical use of the antineoplastic drug doxorubicin (DOX) is limited by its
cumulative dose-dependent propensity to cause irreversible degenerative cardiomy-
opathy and congestive heart failure [167,168]. The mechanism of cardiotoxicity
by DOX involves oxidative stress, mitochondrial dysfunction, and apoptosis.
Interestingly, DOX is a basic lipophilic compound and has been shown to become
trapped insides lysosomes [169] affecting lysosomal morphology and enzyme
activity [170]. Recently, dysregulation of autophagy has been shown to play a
contributing role in DOX-induced cardiotoxicity [171]. Using GFP-LC3 transgenic
mice, acute DOX cardiotoxicity is associated with impaired autophagic functions
demonstrated by an increase of GFP-LC3 puncta, and accumulation of LC3-II and
p62 [171]. Interestingly, starvation, which is the most extensively studied condition
that induces autophagy, can at least partially restore autophagosome formation and
is cardioprotective against DOX-induced cardiotoxicity.
19.4.2 Kidney Toxicity
Cisplatin, aminoglycoside antibiotics, and cadmium have been extensively studied
for their nephrotoxic effects on proximal tubule epithelial cells [14,172,173].
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Lysosomal acid phosphatase staining has shown that proximal tubules are rich in
lysosomes, while in distal tubules and glomerular cells, lysosomes are relatively
sparse [174]. The local abundance of lysosomes in the proximal tubule could explain
in part drug-induced kidney injury as a result of xenobiotic accumulation in the
lysosomes. Functionally, proximal tubular epithelial cells have an extensive apical
endocytotic apparatus that is critical for the reabsorption and degradation of proteins
that traverse the glomerular filtration barriers [175] and endosomal acidification
has been shown to be critical for this physiological function of proximal tubule
cells [176]. Therefore, lysosomal disruption could adversely affect proximal tubule
function. It has been demonstrated that cisplatin [177], aminoglycosides [178], and
cadmium [14] can accumulate in proximal tubule cells, localizing in lysosomal
vacuoles. Ultrastructural alterations in proximal tubular cells following aminoglyco-
side treatment span from enlargement of lysosomes and progressive deposition of
polar lipids at low doses to lysosomal rupture and extensive mitochondrial swelling
at higher doses [179]. Apoptosis induced by gentamicin in LLC-PK1 cells (pig
kidney epithelial cells) involves the permeabilization of lysosomes followed by
subsequent activation of the mitochondrial apoptosis pathway [180], indicating
the critical role of LMP in the mitochondrial change and cell death. In addition,
gentamicin has been shown to decrease the activity of cathepsins B and L in
proximal tubules after in vivo treatment, which could reduce renal protein catabolism
[181]. Cisplatin has also been shown to increase lysosome fragility [182] and
accumulation of autophagosome-associated LC3 [173]. In addition, cisplatin also
inhibits uptake of fluorescein-isothiocyanate (FITC)-albumin, a receptor-mediated
endocytosis marker [183]. Ulinastatin can protect the kidney from gentamicin and
cisplatin-induced toxicity, possibly through its lysosomal membrane-stabilizing
effect [182].
Remarkably, both gentamicin and cisplatin are highly polar compounds with
clogP values of −1.7 and −2.19, respectively. Compounds with this range of polarity
typically do not cross lipid membranes by passive diffusion. Electron microscopic
analysis demonstrated that aminoglycosides are localized in claritin-coated pits,
endocytic compartments, and lysosomes in the proximal tubular cells, indicating the
involvement of an endocytic pathway of accumulation [184]. Megalin, a multiligand,
endocytic receptor abundantly expressed in the renal proximal tubule, has been
associated with kidney tubular cell uptake of aminoglycosides [185], and renal
accumulation of gentamicin can be decreased by competition with another megalin
ligand [184]. This suggests an alternative route for basic compound accumulation
in lysosomes besides permeation. It is noteworthy to mention that megalin is also
expressed in the marginal cells of the stria vascularis of cochlear duct of the ear. Both
aminoglycosides and cisplatin are known for their nephro- and ototoxicity, further
highlighting the role of megalin in the uptake of these polar molecules. In fact,
nonsynonymous single-nucleotide polymorphisms of the megalin gene have been
shown to impact the individual susceptibility toward cisplatin-induced ototoxicity
[186]. Clinically, the susceptibility of the kidney to these two compounds may be
enhanced when administered by the IV route as this route bypasses absorption




large volume of blood flow to the kidney increases the accessibility of these drugs to
the kidney as well.
19.4.3 Retinal
The retina is a thin layer of light-sensitive neural tissue that lines the back of the eye.
The retina is highly structured with multiple intricate layers responsible for convert-
ing of visible light into the electrochemical signals interpreted by the brain as vision.
The RPE is a specialized monolayer epithelium that forms the outermost layer of
the retina and is positioned between the neuroretina and choroid. The RPE performs
multiple functions including nutritional transport, light absorption, and retinoid
metabolism [187,188]. RPE cells are differentiated with numerous long microvilli
on the apical side facing the photoreceptor outer segment. One RPE cell supports
30–50 photoreceptors, which shed ∼5% of their outer segment mass daily [189]. The
shredded discs are phagocytosed into the RPE and digested within phagolysosomes.
RPE cells are considered one of the most active phagocytic cell types, making
them particularly susceptible to membrane trafficking perturbation due to lysosomal
dysfunction. Not surprisingly, cathepsin D-deficient mice have membrane-bound
compartments containing granular osmiophilic deposits in the RPE, which leads to
progressive retinal layer thinning and loss of cone and rod cells [190]. The critical
role of the lysosome in retinal homeostasis is also corroborated by the LSDs, such
as mucopolysaccharidoses (MPS). MPS is due to iduronate-2-sulfatase deficiency
and characterized by the defective breakdown of glycosaminoglycans (GAGs).
GAG deposition within the retinal pigment epithelial cells and in the photoreceptor
matrix leads to progressive photoreceptor loss, retinal degeneration, and dysfunction
of the remaining photoreceptors [191]. In addition, in the mouse model of Npc1
(Niemann–Pick type C) deficiency, accumulation of lipofuscin in the RPE layer
and degeneration of photoreceptors was observed [192]. Many lysosomotropic
compounds including amiodarone, imipramine, clomipramine, chlorphentermine,
and chloroquine have been shown to induce retinal lipidosis [193]. In long-term
treatments with chloroquine (10 months) in rats, complete destruction of the outer
segments of photoreceptors is indeed observed [194]. Recently, a correlation among
the physicochemical properties, lysosomal dysfunction in vitro, and retinal lesion in
vivo was established, demonstrating the critical role of physicochemical properties
in the xenobiotics-induced retinal toxicity [195].
19.4.4 Peripheral Neuropathy
Neurons are especially dependent on the membrane trafficking due to their complex,
highly polarized, elongated structure, and active trafficking for synaptic activity.
Anterograde axonal transport delivers cargo from the cell body toward distal
terminals to maintain synaptic function, whereas retrograde axonal transport helps
clear toxic components from nerve terminals and deliver distal trophic signals to
the soma. LC3-positive autophagosomes have been shown to undergo exclusive
retrograde movement and rapidly obtain the endolysosomal markers Rab7 and
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LAMP1 [196]. In addition, signaling endosomes containing neurotrophic factor
receptor signaling complexes and their retrograde transport is critical to deliver the
signals from distal points to the cell body [197]. Axonal transport deficits have
emerged as a contributing factor in multiple neurodegenerative diseases such as
AD and PD [198,199]. Recent data has suggested that impairment of membrane
trafficking could be, in part, the cause for drug-induced peripheral neuropathy.
Taxanes, including paclitaxel, docetaxel, and cabazitaxel, stabilize GDP-bound
tubulin in the microtubule, whereas plant alkaloids, such as vinblastine, vincristine,
and vinorelbine, prevent formation of microtubules. All of these drugs that perturb
microtubule dynamics are associated with peripheral neuropathy [200], predomi-
nately of sensory neurons. Microtubule-targeting drugs have demonstrated inhibition
of axonal transport [201], which translates into length-dependent neuropathies
after cumulative exposure. In addition, peripheral neuropathy also develops during
platinum drug treatment including cisplatin, carboplatin, and oxaliplatin [200] due to
perturbed lysosomal function demonstrated with the disrupted aggresome-autophagy
pathway [202].
Lysosomotropic aminoglycosides have long been reported to cause peripheral
neuropathy, and nerve biopsies have revealed an association with lysosomal abnor-
malities [203,204]. Recently, a new peripheral neuropathy warning has been issued
by Food and Drug Administration (FDA) for the fluoroquinolone class of antibiotics
including ciprofloxacin, levofloxacin, moxifloxacin, norfloxacin, ofloxacin, and
gemifloxacin (http://www.fda.gov/Drugs/ DrugSafety/ucm365050.htm). Fluoro-
quinolones are basic drugs for which lysosomal accumulation has been demonstrated.
It is fairly sensible to assume that lysosomal dysfunction and membrane trafficking
perturbation play a significant role in those peripheral neuropathies. However,
additional studies are needed to further strengthen the link. Remarkably, platinum
drugs, aminoglycosides, and fluoroquinolones antibiotics are more hydrophilic than
typical lysosomotropic compounds [205]. The potential effects of hydrophilicity on
their mechanism of toxicity warrant further investigation.
19.4.5 Muscle Toxicity
Similar to the other postmitotic tissues, skeletal muscle is also vulnerable to
dysfunctional organelles and accumulation of aggregation-prone proteins. There-
fore, these degradation systems need to be carefully regulated in muscle cells. Indeed,
excessive or defective activity of autophagic lysosomes or ubiquitin-proteasomes
leads to detrimental effects on muscle homeostasis [206]. A growing number
of studies have linked abnormalities in the regulation of these two pathways to
myofiber degeneration and muscle weakness. The concept linking lysosomal failure
or membrane trafficking perturbation to skeletal muscle toxicity is further supported
by evidence from genetic diseases and a range of mouse knockout studies. Danon
disease, an X-linked dominant disorder resulting from a mutation in the lysosomal
protein LAMP-2 is characterized by cardiomyopathy and myopathy [207]. Extensive
accumulation of autophagosomes in muscle was observed in LAMP-2-deficient




in skeletal muscle of mice induces myofiber degeneration and muscle loss [209].
In addition, autophagy-deficient muscles are extremely weak compared to muscles
from control animals.
Multiple lysosomotropic drugs, such as chloroquine and hydroxychloroquine, are
associated with lysosomal storage myopathy, where storage of curvilinear bodies
within the lysosomes and autophagic vacuolation with phospholipid inclusion has
been demonstrated [210]. Amiodarone has been associated with myopathy in humans
and mouse models, demonstrating proximal muscle weakness with diffuse myalgia
[211] and autophagic vacuolation and phospholipid inclusions, respectively [212].
Antimicrotubule drugs such as colchicines and vincristine have also been reported to
causemyopathy [213,214], which, in the case of colchicine, causes a vacuolar myopa-
thy with accumulation of lysosomes and autophagic vacuoles without necrosis [215].
19.4.6 Tumorigenesis
Autophagy has paradoxical roles in the initiation and progression of cancer.
In established tumors, autophagy might provide a survival advantage for tumor
cells under metabolic stress. The emerging hypothesis is that autophagy can be
a safe guardian of the genome and provide an antitumorgenesis function, at least
during initiation. Hypothetically, lysosomal toxicants could block the autophagy
process, subsequently triggering mitochondrial dysfunction leading to an increase in
oxidative stress that consequently elicits DNA damage and genetic instability. Thus,
lysosomal perturbation and autophagy inhibition could play a role in drug-induced
tumorigenesis. This notion was supported by a variety of autophagy gene deletion
studies. The first evidence to show a link between autophagy and tumorigenesis was
established in 1999, when the ATG gene beclin 1 was discovered as a candidate
tumor suppressor [216]. A single copy loss of beclin-1 in the heterozygous knockout
mice increases the frequency of spontaneous malignancies in the lung and liver
and accelerates the development of hepatitis B virus-induced premalignant lesions
[217]. Besides beclin-1, other autophagy gene knockouts (e.g., Bif-1, atg5, and atg7)
have also been reported to lead to tumors [135,218]. Nrf2, a transcription factor
that controls the expression of antioxidant and cytoprotective genes, was recently
suggested to have an oncogenic function. In liver-specific autophagy-deficient mice,
Nrf2 activation via p62 contributes to the development of hepatocellular carcinoma
[219].
High incidences of cancer in various organs such as skin, lung, bladder, liver,
and kidney have been associated with chronic exposure to inorganic arsenic from
contaminated drinking water [220]. Multiple mechanisms including changes in DNA
methylation and generation of ROS [221,222] have been proposed for the mechanism
of arsenic-related carcinogenicity. In a notable study, arsenic was shown to block
autophagy, resulting in accumulation of p62, sequestration of Keap1 in autophago-
somes, and prolonged Nrf2 activation [134], similarly to autophagy-deficient mice.
Interestingly, Nrf2 overexpression has been associated with many cancer types
[223,224]. As a major regulator of cytoprotective responses, the Nrf2 pathway
has also been demonstrated to be hijacked by cancer cells, resulting in intrinsic
 

IMPAIRED LYSOSOMAL FUNCTION AS A MECHANISM FOR ORGAN TOXICITY 469
or acquired chemoresistance [225,226]. Although further studies are required, the
noncanonical activation of Nrf2 due to autophagy impairment could be part of a
novel mechanism for arsenic carcinogenicity.
Besides arsenic, other heavy metals can potentially employ the same pathway for
carcinogenicity. Cadmium is classified as a human carcinogen [227] and can trig-
ger a lysosomal membrane permeabilization-dependent necrosis pathway [228]. It
is possible that autophagy deficiency induced by cadmium can also activate Nrf2,
leading to cancer. Zebrafish larvae exposed to cadmium indeed showed an increase
in glutathione-S-transferase glutamate–cysteine ligase catalytic subunit, heme oxy-
genase 1, and peroxiredoxin 1 mRNA levels indicative of Nrf2 activation [229].
19.4.7 General Considerations for Organ Toxicity
In this review, we only touch upon a limited set of organ toxicities but other organs
such as thyroid and the immune system can also be impacted by lysosomal toxicants.
There are a number of factors that need to be considered when dealing with toxicity
related to lysosomal dysfunction.
1. Although the lysosome was discovered more than 50 years ago and the concept
of lysosomotropism has been well established, the mechanistic link to toxic-
ity has been overshadowed by the vast research effort focusing on PLD. The
link between lysosomal dysfunction and organ toxicity discussed in this review
is largely based on the information from LSDs, genetic modulation models,
and lysosomal changes inflicted by xenobiotics. There are many gaps in the
knowledge of the molecular pathways tying lysosomal perturbation to organ
toxicity that requires further investigation. It is plausible that certain cells or
organs are more susceptible to the particular cellular change due to lysosome
dysfunction. For instance, phagocytosis inhibition could be more detrimen-
tal for retinal epithelial cells than liver cells, while cardiomyocytes may be
more susceptible to autophagy inhibition based on their respective specific
physiological functions.
2. Clearly not all lysosomal toxicants have the same in vivo toxicity profile.
Dose and duration certainly can dictate the degree of lysosomal dysfunction
thus resulting in different toxicity manifestations. More importantly, the tissue
distribution could significantly contribute to the organs impacted. Although
various analyses have been conducted to determine the correlation between
physicochemical properties with lysosomal accumulation in vitro, further
investigations are required to understand the translation to tissue accumulation
in vivo. Asymmetrical tissue accumulation are often observed with xenobiotics
and it is reasonable to assume that orally administered compounds with
higher lipophilicity will result in higher relative liver concentrations due to
the first-pass effects and fast permeation. This scenario may lead to decreased
exposure in the other organs, while less lipophilic xenobiotics may have a bet-
ter chance of accumulating in the other organs. Development of sophisticated




certainly help uncover the relationship between physicochemical properties
and tissue distribution, in hopes of predicting organ toxicity. However, it is
more complex and challenging when considering the contribution of active
transport in the model. The other convoluting factor is that adaptive responses
will occur when cells or tissues are challenged with lysosomal toxicants.
As was discussed earlier, lysosomal and autophagy genes can be upregulated
by lysosomal toxicants. The ultimate physiological outcome will be deter-
mined by the net effects of the negative impact by the xenobiotic and adaptive
response within the cells. In other words, an adequate adaptive response
may spare some tissues from detrimental consequences, while inadequate
adaptation might result in the toxicity in others. The possibility that different
tissues are equipped with differing capabilities to respond to lysosomal insults
warrants further investigation.
3. The occurrence of organ toxicities are a function of duration and dose, and some
may only manifest following long-term exposure due to the protective adaptive
response and dependence on interactions with other stressors, as was observed
with cardiotoxicity from chloroquine. To some extent, the occurrence of organ
toxicity mimics the progressive aging process. This presents a challenge for
early detection of toxicity in drug development since longer term studies are
not conducted until the later stages of development. The intriguing discovery
that atg5 knockout mice only showed rapid and dramatic declines in cardiac
function with pressure overload [159] suggests the value of using stress models
in toxicity screening. It is conceivable that, at basal conditions, cells or tissues
can maintain normal function with a certain degree of lysosomal dysfunction,
particularly with some level of adaptive response, while additional stress can
sway the delicate balance toward a pathophysiological perturbation. This con-
cept can also offer some explanation for the occasional discrepancy between
preclinical studies and clinical outcome. In general, young healthy animals are
used in the preclinical studies, while patients in the clinical setting may carry
various levels of lysosomal dysfunction (disease- or age-related) prior to drug
exposure. As a result, a greater incidence or severity of toxicity, or a different
toxicity profile altogether may be revealed in the clinical situation. Alternative
animal models, like those under particular stress or with preexisting lysosomal
dysfunction, could offer additional value in predicting clinical toxicity.
4. Toxicities triggered by impairment of lysosomal functional are potentially
reversible. For instance, PLD is reversible after cessation of fluoxetine
treatment and reversibility of fulminant amiodarone-induced hepatitis has
also been shown for some cases [230]. While the degree of damage can
determine the potential for reversibility, it is possible that certain dosing
regimens could prevent toxicity from occurring. Further investigation on the
tissue pharmacokinetics during the dosing and recovery phases may shed
light on an innovative dosing regimen design that avoids toxicity. Growing
evidence has demonstrated the benefit of various therapeutic approaches,
such as antioxidants or compounds that increase the lysosomal membrane




amiodarone toxicity [231,232]. In addition, gallic acid and lycopene have
been shown to ameliorate isoproterenol-induced cardiotoxicity by preserving
the integrity of the lysosomal membrane, presumably due to their free radical
scavenging and antioxidant properties [163,233]. The concept of increasing
stability of the lysosomal membrane to ameliorate toxicity is further supported
by the finding that HSP70 can revert Niemann–Pick disease-associated
lysosomal pathology by stabilizing lysosomes through binding to anionic
phospholipid bis(monoacylglycero)phosphate [234]. Recently, curcumin has
been shown to promote exosomes/microvesicles secretion that attenuates
lysosomal cholesterol traffic impairment [235], indicating the potential of
curcumin as a remedy for lysosomal dysfunction. However, curcumin was
also reported to trigger LMP and apoptosis [236]. Further research in this
area is needed to identify and characterize a genuine antidote. Appropriate
combination of drugs and antidotes may well attenuate or diminish certain
toxicity associated with lysosomal dysfunction.
5. Mechanisms of toxicity can be multifactorial. In this review, we focused
on how a compound’s impact on lysosomal function can lead to toxicity.
However, other organelles (e.g., mitochondria) or biological processes can also
be simultaneously disturbed by these same compounds further contributing
to the manifestation of toxicity. Nefazodone, which was withdrawn from the
US market in 2004 due to hepatotoxicity, has been studied extensively. As
expected with a basic pKa of 7.65 and clogP of 4.09, nefazodone has been
shown to increase lysosomal content staining [35]. It was also demonstrated
that nefazodone profoundly inhibited mitochondrial respiration in isolated rat
liver mitochondria and in intact HepG2 cells [237]. Potentially, both mecha-
nisms can contribute to the hepatotoxicity observed for nefazodone given the
potential for interaction between the two pathways. Lysosomal dysfunction
can aggravate the mitochondria function by perturbing efficient mitochondria
turnover. This can lead to mitochondrial dysfunction-elicited ROS production
that could further induce lysosomal membrane permeabilization. Compounds
with multiple impacts on organelles or biological processes may carry a higher
risk of toxicity.
19.5 CONCLUDING REMARKS
Growing evidence suggested that lysosomal dysfunction and membrane trafficking
perturbation not only contribute to aging and aging-related diseases but also serve
as unique emerging mechanisms for xenobiotic-induced toxicities. Lysosomal toxi-
cants can disrupt lysosomal function either via accumulation, direct damage to the
lysosome, or indirectly by vesicular trafficking perturbation. Lysosomal dysfunction
not only impacts all membrane trafficking pathways that converge on lysosomes
but also modulates various signal transduction molecules, both of which can impair
various cellular biological functions, consequently contributing to the development




research, has progressed noticeably, research efforts aimed at understanding the link
between the lysosomal pathway and toxicity are still in imperative need. A molecular
comparison among the toxicities arising from lysosomal toxicants, aging-related
diseases, including neurodegeneration, and genetic lysosomal dysfunction could
serve as a valuable model in understanding disease pathology related to lysosomal
dysfunction.
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20.1 INTRODUCTION
Drug development is inherently difficult, since most, if not all drugs carry some risk
of an adverse event (AE). AEs vary in clinical importance, incidence, pathogenesis,
and predictability. The AEs may result from pharmacodynamic activity, operation of
collateral physiologic homeostatic systems, off-target direct cytotoxicity, or be due
to other biochemical lesions. Drug-induced phospholipidosis (DIPL) is essentially a
lysosomal storage disorder provoked by a variety of pharmacodynamically diverse
drugs, usually cationic amphiphilic drugs (CADs). The lesion is characterized by the
intracellular accumulation of tissue phospholipid–drug complexes. Not always dis-
ruptive, the location and pathological significance of the deposits vary, reminiscent of
the hereditary lysosomal storage diseases. These complexes form concentric lamellar
membranous vesicles that are diagnostic of DIPL [1–3]. The amphiphilic region of the
molecule can enter the phospholipid bilayer of the plasma membrane, and the com-
plex deposits in the lysosome during phagocytosis, pinocytosis, or plasma membrane
∗This chapter reflects the views of the authors and should not be construed to represent FDA’s views or
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recycling. The subsequent acidification of the lysosome traps the phospholipid–drug
complex. Although the inclusions typically dissipate upon drug withdrawal, DIPL
represents a concern in risk assessment, and biomarkers are being sought for routine
phospholipidosis assessment.
20.2 FDA INVOLVEMENT
FDA deliberation of the safety implications of positive nonclinical toxicity finding
of an investigational new drug (IND) escalated after 1962 when the Food and Drug
Act was passed by the US Congress. It required the Food and Drug Administration
(FDA) to evaluate and approve pharmaceuticals based on evidence of safety as well
as efficacy [4]. Since then, an increasing understanding of mechanisms of toxicologic
pathology and organ dysfunction has afforded more reliable forecasting of risk of an
AE in target patient populations. This can be attributed in part to the evolution and
continued refinement of tests for toxicologic histopathology, safety pharmacology,
and organ dysfunction that the FDA relies on to identify the safety margins and mini-
mize the risk of an AE in a clinical trial [5], enabling increased safety of first-in-man
trials [6]. Nevertheless, the safety implications of some toxicologic lesions that are
encountered in preclinical trials remain contentious. This includes DIPL, especially
when there is important collateral histopathology and organ dysfunction. However,
DIPL, even when isolated, should be monitored, especially in drugs that will be pre-
scribed to patients to long-term therapeutic use.
Toxicologic phospholipidosis was identified in the late 1960s as the cause of the
lethal hepatotoxicity associatedwith use of coralgil and perhexiline [1], and it remains
problematic. DIPL can be a regulatory issue even when encountered in IND trial at
suprapharmacodynamic dosages due to the absence of validated biomarkers and the
uncertainty of the toxicological significance. In 2004, the Center for Drug Evalu-
ation and Research (CDER) of the FDA established the Phospholipidosis Working
Group (PLWG) [7] after contentious findings of DIPL in nonclinical IND programs,
and the absence of clinical information on its consequences, prevalence, and time
course. There also had been no uniform regulatory review policy given the lack of
consensus as to whether DIPL was an adaptive or toxic response [8] and, its safety
implications, especially absent any other collateral histopathology. Clearly, this phe-
nomenon required further study to enable informed and uniform regulatory responses
because it is not infrequently observed during IND development [9,10]. The PLWG
has considered the importance of the pathogenesis of DIPL primarily from a regula-
tory perspective.
Until recently, DIPL has been poorly understood. A big step in clarifying the
collateral effects of DIPL occurred when Sawada et al. [11] reported that 12 phospho-
lipidotic compounds altered the expression of genes controlling lysosomal phospho-
lipase, lysosomal enzyme transport, and phospholipid and cholesterol biosynthesis.
Real-time polymerase chain reaction analysis showed that expression of the 12 gene
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markers covaried with lysosomal lamellar myelin body formation. The affected lyso-
somes and/or endosomes accumulated phospholipids in a complex with the inducing
drug ormetabolite [1,12–16], leading to the signaturemultilamellar vesicles and lead-
ing to the cellular effects of DIPL.
20.3 AUTOPHAGY AND DIPL
Several drugs involved with DIPL have also been shown to be involved in autophagy,
including rapamycin, for which the mammalian target of Rapamycin (mTOR)
received its name. Conceivably, some consequences of DIPL likely depend on
the extent of disruption, if any, of pathways that control autophagy. Studies of the
activity of the lysosome, the primary target of DIPL, have elucidated autophagy as
a homeostatic catabolic process in which the cell clears old organelles and dysfunc-
tional proteins synthesized in the cell, thereby preserving cardiac, neuronal, and
other cell function [17–23]. These studies have revealed signaling pathways cardinal
to cell cycling that help determine whether cells are quiescent and differentiated or
apoptotic. The process of autophagy is additionally regulated by cell conditions such
as starvation or stress. Multiple pathways control autophagy, and the processes of
internalization of exogenous or plasma membrane-bound targets, and protein traffic
within the cell [20] could be perturbed by lipidosis.
Many drugs that cause DIPL are useful for investigating the regulation of
autophagy and apoptosis. Compounds that regulate autophagy and apoptosis such as
rapamycin, tamoxifen, and gentamicin also induce DIPL. The mTOR is an important
protein in the autophagy cascade [18,24]. Binding of rapamycin, a CAD, to the
mTOR complex inhibits autophagy [24]. Rapamycin can block neurodegeneration
through its actions on mTOR [25]. Other inducers of autophagy cause clearance of
mutant proteins such as β-amyloid and prevent neurodegeneration [18]. Tamoxifen
induces autophagy and causes cell death in cultured retinal pigment epithelial and
photoreceptor cells [26], while chloroquine inhibits autophagy in a cell line with
retinal pigment epithelial properties and causes cell death [27]. The pathways
controlling autophagy should be studied further, and CADs are strong candidates for
manipulating such pathways.
20.4 EARLY EXPERIENCEWITH LETHAL DIPL
In the late 1960s, multiple hepatic deaths and hospitalizations of patients in Japan
treated with the coronary vasodilator coralgil (4,4′-diethylaminoethoxyhexestrol)
brought DIPL to the attention of regulatory agencies [28–30]. Electron microscopy
of liver tissue revealed the signature lamellar myeloid bodies in lysosomes [8,30].
Bis(monoacylglycerol)phosphate, that is, lysobisphosphatidic acid (BMP) and acyl
phosphatidylglycerol were recovered from coralgil-treated patients. The lesions and
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symptoms were noted to resemble those of patients with Niemann–Pick type C
(NP-C), a heritable disorder of phospholipid metabolism [30]. Subsequently, use of
perhexiline maleate (a vasodilator prescribed for angina pectoris) and telithromycin
(Ketek) were restricted because of the risk of liver toxicity and phospholipidosis
[16,31]. DIPL may also underlie the toxicity of several other drugs. For example,
the quinolone-type antimalarial drugs carry a risk of important neurotoxicity [32]
and myotoxicity [33]. Amiodarone labeling has a boxed warning of the risk of lethal
pulmonary toxicity.
20.5 CLINICAL AND NONCLINICAL EXPRESSIONS OF DIPL
20.5.1 Clinical
The clinical expression and context of DIPL may vary markedly. For example,
although foamy alveolar macrophages and cytoplasmic lamellar bodies are promi-
nent features of amiodarone-induced pneumonitis, their presence alone may not
distinguish the toxic from the asymptomatic patients [34,35], and their role in the
pathogenesis of the pulmonary lesions in these cardiac patients remains uncertain.
Some phospholipidotic compounds such as the antihistamine loratadine have few
toxic manifestations other than the lipidosis, as in the case of the asymptomatic
cardiac patients with amiodarone-induced DIPL. Obviously, such variations may
confound the evaluation of phospholipidosis as a risk factor and cause difficulty
in assessing the importance of DIPL. The genetic lysosomal storage diseases, for
example, NP-C disease also varies incidence and clinical importance of the liver and
spleen lesions.
Response to a particular CAD is qualitatively and quantitatively unpredictable, and
forecasting clinical or veterinary risk of organ dysfunction, or asymptomatic tissue
involvement, remains tenuous. Currently, it is not possible to predict the major target
organ for DIPL. In the importantly involved organs, compromised function can reflect
biochemical reactions beyond any concurrently altered phospholipid traffic. For
example, a phospholipidotic molecule such as gentamicin may inhibit both protein
synthesis and phospholipid degradation in a target tissue. Gentamicin is a nephrotoxic
aminoglycoside that accumulates in lysosomes, the Golgi complex, and mitochon-
dria in the renal cortex of the rat and disrupts function of these organelles early in
the time course of the nephrotoxicity [36]. As in the rat, gentamicin-associated DIPL
manifests in both the inner ear and kidney in humans, and deafness and kidney failure
can be caused by exposure to this antibiotic. In some cases, phospholipidosis does
not obviously underlie clinical disease. In NP-C disease, a hereditary lysosomal lipid
storage disorder, respiratory distress is associated with depressed protein expression
in alveolar macrophages. Although foamy concentrically laminated macrophages can
be present in the lung, spleen, and liver of the NP-C patient, overt collateral pathology
(alveolar proteinosis) can be confined to the lung at the time of biopsy [37]. Accord-
ingly, for both DIPL and hereditary phospholipidosis, associated collateral pathology




Drug accumulation and associated organ dysfunction in DIPL generally are
reversible when drug treatment is discontinued, as with gentamicin nephrotoxicity.
20.5.2 Nonclinical
In nonclinical trials, DIPL is often multiorgan and not isolated, that is, it is associ-
ated with excess nonphospholipidotic histopathology. In an analysis of 419 internal
toxicology reports of 46 proprietary phospholipogenic and 62 nonphospholipogenic
compounds tested in 1- to 4-week studies in the rat and dog, AstraZeneca (London,
UK) reported that half of the phospholipogenic compounds targeted three or more
organs [35]. Furthermore, the phospholipogenic drugs were more likely to be asso-
ciated with other histopathology than the nonphospholipogenic compounds in all
organs, with significantly higher frequencies of liver necrosis, alveolitis, and pneu-
monitis, and lymphocytolysis in the thymus, lymph nodes, and spleen [35]. Analysis
of nonclinical studies submitted to the FDA CDER showed that the lowest observed
adverse effect level (LOAEL) for phospholipidosis was highly correlated with the
LOAEL for the appearance of nonlipidotic histopathological lesions [38]. Therefore,
the appearance of phospholipidosis may be associated with other histopathological
findings in nonclinical studies.
20.6 PHYSICAL CHEMISTRY
Phospholipidotic activity is predictable based on physicochemical criteria [39],
though the target organ is not. Most compounds that cause DIPL are CADs that have
a positively charged primary, secondary, or tertiary amine group associated with an
amphiphilic region that typically is incorporated into a ring structure [40]. DIPL may
be predicted from the acid dissociation constant (pKa) and logarithm of the partition
coefficient between n-octanol and water (clogP), an index of hydrophobicity [40].
Molecular modeling programs are used to calculate physicochemical properties from
structural motifs [39]. The likelihood that a drug with pKa > 8 and clogP> 1 will
concentrate in the lysosomes by pH partitioning and induce DIPL in vivo is increased
when ([pKa]
2 + [clogP]2)≥ 90 [39]. Sensitivity and specificity are 80% in several
models [39]. Modifications to the formula may increase predictive potential, and
incorporation of Bayesian methods increases sensitivity to 93% [41] and specificity
to 80%. Applying quantitative structure–activity relationship (QSAR) to the FDA
database of 385 compounds that provoked DIPL and the 358 compounds that did
not provoke DIPL yielded 5 false positives and 38 false negatives [42]. However, 6
of the 38 false negative compounds were amphiphilic; therefore, in that data set, 32
non-CADs provoked DIPL [42]. Based on this database and distribution of amines,
more than 90% of the compounds that induced DIPL were CADs. Not surprisingly,
metabolic transformation that appreciably affects cationic amphiphilic properties
also affects phospholipidotic activity [43].
CADs have physicochemical properties that promote access to the cell cyto-
plasm [44], enabling access to the cell membrane, and promoting intracellular
sequestering. The ionization pKa would enable these molecules to be charged,
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and thus to be trapped, in the acidic interior of the lysosome [45]. One practical
application of this property is in the design of drugs for central nervous system
(CNS) activity. Cationic amphiphilic compounds cross the blood–brain barrier, and
are not extruded by transporters. CADs that are pharmacologically active could be
candidates for neurologic and psychiatric therapies. Indeed, lysosomal sequestering
of CNS drugs is a well-known phenomenon, and not always accompanied by central
lipidosis [46]. Nevertheless, DIPL in the CNS is a major concern, especially when
irreversible, because DIPL occurring in nerves resembles the pathology of some
severe genetic sphingomyelin storage disorders such as NP-C [46]. Neurotoxicity
can be a problem with antimalarial drugs such as mefloquine that can achieve CNS
concentrations that are effective against resident parasites, but that may also cause
lipidosis and neurologic AEs [46].
20.7 QUANTITATIVE STRUCTURE–ACTIVITY RELATIONSHIP (QSAR)
QSAR screening is used to forecast toxicity as well as targeted pharmacodynamic
activity in drug development [47]. The QSAR programs for predicting DIPL com-
plement those for carcinogenicity, reproductive toxicity, genetic toxicity, and QT
prolongation, and, together, are a valuable recourse ancillary to FDA safety assess-
ment [40]. QSAR involves algorithms that deconstruct the primary structure of com-
pounds and identify compounds that fit a common pharmacophore. Phospholipidotic
compounds are especially amenable to QSARmodeling because they share relatively
well-defined and discrete structural and physicochemical features.
Model building for QSAR-based predictions of DIPL has been evolving at the
FDA [9,42]. The FDA PLWG has created a large database of compounds that vary
in phospholipidotic activity by using the FDA and literature databases, and by solic-
iting FDA reviewers for candidate compounds [35,42]. This provided a composite
database of 750 compounds, including 385 that provoked DIPL in at least one species.
From this robust data set, QSAR models were developed, using different commercial
algorithms that performed with 80% sensitivity and specificity. The early predic-
tive models had high concordance with published or experimental results, compar-
ing favorably to commercially available predictive tools. Modifications have since
resulted in an increase in sensitivity and specificity to 84% and 80% [41].
Pharmaceutical companies have used QSAR models for DIPL activity and human
ether-à-go-go-related gene (hERG) channel interaction to complement in vitro assay
systems in forecasting potential IND safety issues [47]. The utility of such mod-
eling depends on accounting for factors that affect activity in vivo. For example, a
QSAR analysis of CNS drugs that had cationic amphiphilic properties generated dis-
proportionately more false positives, in part because the expected therapeutic plasma
concentrations may not have been attained [41]. It has been suggested that perhexi-
line, a phospholipidotic antianginal drug, be returned to use if patients are screened




in patients with such a deficiency. However, loratadine and ketoconazole are more
likely to be phospholipidotic because metabolism leads to the usual oxidation to the
phospholipidotic metabolite [43], making it less hydrophobic.
The continuing refinement of QSAR platforms for both targeted pharmacody-
namic activity and lipidotic activity should help further both the synthesis and selec-
tion of promising drug candidates devoid of lipidotic activity. This is aided by the fact
that many physicochemical features of a drug that predispose to DIPL are indepen-
dent of the pharmacophore that mediates pharmacodynamic activity, and capacity for
lipidosis may be independent of pharmacologic activity. Lysosomotropic drugs, for
example, chloroquine, can be viewed as converging in the lysosome [3], but diverg-
ing, markedly, in pharmacologic activity. Exceptions would include nanoparticles and
nonorganic compounds without potent or specific pharmacodynamic activity that also
accumulate in the lysosome [44].
Many of the hERG channel blockers have a positive charge on one end of the
molecule and hydrophobic regions on the other end [50,51], recalling CADs and
their association with DIPL. The QSAR for predicting hERG channel interference
is sophisticated and includes van der Waals surface forces and hydrogen bonding.
However, hERG channel blockers and CADs have similar behavior. To block the
hERG channel, a compoundmust readily cross the plasmamembrane [3] to access the
interior of the cell, similar to CAD-like compounds. Therefore, the correspondence
in physicochemical properties between compounds affecting lysosome behavior and
hERG channel traffic, and the overlap between the hERG and DIPL pharmacophores
[38,51] forecast the possibility of concurrent phospholipidosis and QT prolongation.
This association is further probed below (see Section 20.12).
20.8 TOXICOGENOMICS
Changes in gene expression associated with lipid accumulation are being evaluated
as markers of DIPL. Gene chip microarray technologies have been used to examine
such changes in response to a phospholipidotic challenge [11,52]. In a hepatic cell
line (HepG2) exposed to 12 compounds provoking DIPL, alterations in gene expres-
sion most correlated with lamellar myelin-like body formation changes were found
in those genes regulating phospholipid and cholesterol metabolism and lysosomal
enzyme transport [11].When combined with histopathology andmeasures of cell and
organ function, such aDNAmicroarray technique could identify early sensitivemark-
ers of DIPL and determinewhether DIPL is a primary pathogenic factor or an adaptive
response. From these studies, a profile of similarities between NP-C and phospholipi-
dosis has been observed in regard to cholesterol transport that may define common
features of disorders of lysosomal storage function. The early studies on DIPL in
Japan noted a link between the increase in BMP levels in the liver and a concomitant
increase in cholesterol levels [28]. These studies have begun to clarify the processes
and systems underlying the toxic lysosomal disruption induced by phospholipidosis.
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20.9 FLUORESCENCE, DYE, AND IMMUNOHISTOCHEMICAL
METHODS FOR SCREENING
Fluorescent compounds and dyes such as Nile red and nitrobenzoxadiazole (NBD)
have been used in vitro for the rapid examination of cell cultures as indicators of
phospholipidosis, and these fluorophores may enable the rapid detection and quan-
tification of DIPL [15,53–55]. The dye methods may enable the quantification of
signal level but may be confounded by signal artifacts. In contrast, immunostaining
methods, for example, for lysosomal proteins, provide a specific signal, depending on
the choice of antibody target. Lysosomes have several specific surface markers that
enable identification and characterization of the organelle. The lysosome-associated
membrane proteins 1 and 2 (LAMP-1 and LAMP-2) are specific to the lysosome and
comprise 50% of the surface membrane proteins of lysosomes [56]. There is func-
tional overlap between LAMP-1 and LAMP-2, but knockouts of LAMP-1 have little
effect. LAMP-2 knockouts cause accumulation of lysosomes and Danon disease, and
the double knockout is lethal to the embryo [56]. Use of LAMP-2 antibody immunos-
taining and costaining with anti-adipophilin antibodies may enable the differentiation
of phospholipidosis from lipidosis with nonphosphorylated lipids [57,58]. Therefore,
immunostaining is a simple and effective method to determine the presence of phos-
pholipidosis without recourse to electron microscopy.
20.10 FDA DATABASE AND QSAR MODELING
As mentioned, FDA pharmacologists have revisited the issue of DIPL, and its effect
on drug development due to at least 50 INDs had caused the lesions [8]. A data set
was created from information in NDA and IND submissions, using published meth-
ods [35]. At present, 384 compounds that caused DIPL in animals have afforded an
examination of the physicochemical characteristics of CADs and QSAR analyses of
such [41,42]. QSAR modeling is further described in the following sections.
20.11 LINKING PHOSPHOLIPIDOSIS AND OVERT TOXICITY
DIPL may be linked to symptomatic organ dysfunction such as arrhythmias. How-
ever, a causal relation is difficult to confirm [37], in part because of the difficulty of
diagnosing DIPL in humans. Absent validated biomarkers, electron microscopy is
the only recourse [8]. Therefore, evidence of DIPL linked with damage is typically
observed only in catastrophic occurrences, for example, hepatotoxicity of coralgil. Its
use in Japan led to over 100 deaths and many more hospitalizations. This provided
an early link between a drug and DIPL [13,29,30,37] and also raised the possibility
of BMP as a biomarker of liver damage [37]. Another coronary vasodilator indicated
for angina pectoris, perhexiline, caused nonalcoholic steatohepatitis (NASH), simi-
lar to coralgil [59], along with neuropathy. These occurrences raised much concern.
That caution continues to this day with the recent limitations placed on the use of
telithromycin (Ketek) after the observation of DIPL and NASH [31].
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Preclinical studies can be more forthcoming than clinical trials in probing for
dose-related DIPL and its role in the pathogenesis of any histopathology beyond
lipidosis, and any organ dysfunction. In IND toxicology studies, all animals dying
spontaneously or killed in extremis or at the study end are subjected to gross and
microscopic examination of tissues. If evidence of DIPL such as foamy macrophages
is observed, further examination with electron microscopy can be done to confirm
DIPL. An association has been observed between the appearance of DIPL in tissues
and histopathological findings such as necrosis, apoptosis, and/or hypertrophy [35].
Tissues vary in susceptibility to DIPL, but there is enough evidence of colocalization
of such conditions to suggest that DIPL may have a pathogenic role in the expression
of other concurrent histopathology.
The lung, liver, and lymphoid tissue are the most susceptible to DIPL; based
on tissue distribution of phospholipidosis in the 134 rat and 42 dog studies [35]
that comprise the FDA database (Figure 20.1). These organs may be sentinel organs
where the drug–lipid complex collects, but the lesions can present anywhere in the
body, and predicting the target tissue in animals or man is not possible. In dogs,
the most frequent target organ is the liver followed by the lung and lymphoid tis-
sue. In rats and dogs, coexpression of DIPL and nonlipidotic histopathology has
been investigated systematically [35]. Reevaluation of the behavior of phospholi-
pogenic and nonphospholipogenic compounds (AstraZeneca) showed significantly
higher frequencies of liver necrosis, alveolitis/pneumonitis, and lymphocytolysis in
lymphoid tissue associated with the typically multiorgan systemic lipidosis, at a lower






































































Figure 20.1 Comparison of dog (42 studies) and rat (134 studies) tissue distributions of
drug-induced phospholipidosis from investigational new drug (IND) and new drug application
(NDA) submissions to the USFDA from pharmaceutical companies [38]. GI, gastrointestinal;
PLD, phospholipidosis. (See color plate section for the color representation of this figure.)
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PLD presence versus toxicity























Figure 20.2 Relation between lowest observed drug-induced phospholipidosis (DIPL) dose
and the lowest observed adverse effect level (LOAEL) toxicity dose in nonclinical studies
submitted to the USFDA by pharmaceutical companies. A total 53 different studies were used
to generate the graph [38]. LOEL, lowest observed effect level; PLD, phospholipidosis.
plasma exposure than in nonlipidotic animals. From the FDA DIPL database, there
was good correlation (R2 = 0.96) between the dosage that caused DIPL and the overt
LOAEL for the drugs tested (Figure 20.2) [38]. These two results are evidence of a
link between the appearance of DIPL and other histopathological damage.
20.12 PHOSPHOLIPIDOSIS AND QT INTERVAL PROLONGATION
Forecasting cardiovascular safety issues, including an important delay in cardiac ven-
tricular repolarization, is an important goal in safety pharmacology testing of an IND.
Prolonging the corrected QT (QTc) interval by altering hERG and/or other ion chan-
nel trafficking may cause Torsades de pointes (TdP) and sudden cardiac death. There-
fore, early testing for QTc interval prolongation is required because hERG channel
blockade may be proarrhythmic in some patients [5]. Proarrhythmia has led to the
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postmarketing discontinuation of potentially beneficial drugs because cardiac risk
outweighed potential benefit.
The pharmacophore similarities in QSAR models for phospholipidosis and QT
prolongation suggest that CADs that provoke DIPL may also carry risk of TdP
although many drugs that caused phospholipidosis in preclinical animal toxicology
studies are not potent inhibitors of the hERG potassium current, at least in vitro.
A review of the Arizona Center for Education and Research on Therapeutics
database [60] showed that 44% of 28 drugs that increased QT interval and thus
the risk of TP were also associated with DIPL in animal studies (Table 20.1). This
was not unexpected because 69% of more than 100 approved drugs in our database
that provoked DIPL also prolonged QT (Table 20.2) usually by blocking the hERG
TABLE 20.1 Selection from the Combined List of Drugs that Prolong QT
and/or cause Torsades de Pointes (TDP) [54]
Generic Name Brand Name Phospholipidosis
Amiodarone Cordarone®, Pacerone® Yes


















Methadone Dolophine®, Methadose® Yes
Pentamidine Pentam®, Nebupent® Yes
Pimozide Orap® No
Probucol Lorelco® No
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TABLE 20.2 From the USFDA database of 95 Approved New Drug
Applications (NDAs) that have Drug-Induced Phospholipidosis (DIPL)










































Dutasteride 5-α-reductase inhibitor No
Ebastine Antihistamine Yes
Erythromycin Antibiotic Yes
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TABLE 20.2 (Continued)










Lansoprazole Proton pump inhibitor No
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TABLE 20.2 (Continued)















Varenicline tartrate Antismoking Yes
Verapamil Antihypertensive No
channel [38,51]. Some of these compounds may affect the hERG channel by other
mechanisms, for example, inhibiting protein trafficking. For example, pentamidine
does not block the hERG channel directly, but at 10 μM, a level achieved in
antiparasitic therapy, it inhibits hERG channel trafficking [61,62]. In contrast, the
DIPL-inducing and QTc-prolonging drug aclarubicin, an anthracycline antineoplas-
tic drug, is an inhibitor of the vacuolar-type adenosine triphosphatase (V-ATPase)
that is part of the proton pump mechanism in lysosomes [63]. Such activities may
facilitate accumulation of the anthracycline and inhibit phospholipase activity in the
lysosome by inhibiting lysosomal acidification. Accordingly, there are multiple ways
to interfere with endosomal/lysosomal functions, which are important not only for
clearing endocytosed materials coming from the cell surface but also for transporting
hERG channels and other materials from the Golgi apparatus to the cell surface
or other locations in the cell. Culprit drugs also might disrupt lysosomal recycling
of misfolded or incorrectly made proteins along with blocking cellular organelle
recycling [23].
20.13 DIPL MECHANISMS
Multiple pathogenic mechanisms have been proposed for DIPL. Early studies on
DIPL examined the role of lysosomal phospholipases in the pathogenesis of DIPL. It
was hypothesized that the causative drug interfered with the activity of the phospho-
lipases (sphingomyelin phosphodiesterase, lysosomal phospholipase A2 [LYPLA2],
and lysosomal phospholipase A1) or that the CAD had increased cholesterol biosyn-
thesis via the lanosterol synthase pathway, leading to accumulation of phospholipids




cells, splenomegaly, and phospholipidosis [65]. However, it has been argued that
phospholipase inhibition is not a factor in DIPL as BMP is still excreted from cells
and is subsequently observed in the serum and urine [37]. Since BMP is produced by
phospholipase A2 action, increased synthesis of the former would not be expected
if inhibition of phospholipase was a constant or important factor in phospholipi-
dosis [37]. Evidence has been accumulating for the direct binding of the causative
drug to a phospholipid such as the phospholipids present in l-α-dipalmitoyl phos-
phatidylcholine vesicles. Such binding distinguishes several CADs that cause DIPL
from quinidine, which does not bind to phospholipids [66]. The phospholipidotic
and antimalarial activities of chloroquine may occur from blocking the V-ATPase
and associated increase in pH in the parasitic and host cell organelle, with associ-
ated indirect inhibition of acidic phospholipase and other activities requiring low pH
[67]. Procainamide also blocks V-ATPase and raise lysosomal pH [24]. Pentamidine
inhibits hERG protein trafficking in cells [61] but does not inhibit phospholipases.
20.14 TREATMENT
There are no approved treatments for DIPL, likely because it is usually reversible
upon drug withdrawal, and the need may not arise if DIPL is detected early. It is not
clear how a clinical trial could be acceptably designed to test for reversal of DIPL,
rather prevention might be more feasible. Gentamicin DIPL causes apoptosis of renal
tubules [68] that can be blocked by polyaspartic acid [69]. Vitamin E can also inhibit
apoptosis induced by 7-ketocholesterol, an inducer of phospholipidosis [70]. DIPL
caused by amiodarone is also reduced by vitamin E treatment [71], an antioxidant
also reported to inhibit the formation of DIPL and multilamellar vesicles associated
with desipramine and other CADs [72]. These isolated reports are encouraging, but a
systematic study of the effects of these compounds on DIPL is needed to determine
whether polyaspartic acid and vitamin E may be therapeutic or prophylactic in DIPL.
While it is not clear how DIPL would be treated other than recourse to prompt
drug withdrawal, it is clear that CADs possess useful properties for developing drugs
for treating CNS or other indications. Some CADs are valuable pharmacotherapeu-
tics that can readily cross plasma membranes to reach targets in the cell interior. This
property also enables such compounds to cross the blood–brain barrier, which is oth-
erwise a major obstacle to the development of new centrally acting drugs [46,73–76].
The use of CADs for selectively promoting autophagy may afford new therapies for
aging, neurodegeneration, and cancer [18–21,23,26,27,70,77].
20.15 DISCUSSION
Although the pathogenesis of DIPL is increasingly understood and the propensity for
causing these lesions is now relatively predictable [64], the forecasting of important
sequelae is not [9]. The safety implications remain obscure, and DIPL is not eas-
ily addressed in the development and regulation of an IND. At the beginning of the
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modern era of drug development in the late 1960s and early 1970s, regulators were
confronted with deaths and severe hepatic injury associated with DIPL and elevated
levels of circulating BMP [28–30,37]. There is also a concern that lipidotic drugs
might be associated with cardiac arrhythmias due to QTc prolongation, hERG pro-
tein trafficking, or other effects related to endosome/lysosome complexes. At present,
DIPL, when encountered in a toxicology study, cannot be dismissed without further
investigation, especially if associated with cardiac arrhythmias, neuronal toxicity, or
liver, lung, kidney, or cardiac parenchymal injury.
There is concern in the pharmaceutical industry when DIPL is encountered, or
likely to be encountered, given the problems in early detection and the potential clini-
cal importance. Ongoing research addressing multiple aspects of DIPL, and an earlier
and easier diagnosis, reflects the importance of DIPL to industry and to regulators
[1,11,15,35,37,39,45,47,54,55,70,76,78–82]. The issue has driven QSAR and other
machine learning technologies for in silico prediction of phospholipidosis [35,42,45].
Such forecasting is important considering, for example, the overlap between hERG
channel blockade and phospholipidosis [38,51]. Research has prompted develop-
ment of rapid in vitro methods for cell culture and assays for phospholipid binding
[15,53–55,66,74,78,81] and validation of their ability to predict DIPL. Toxicoge-
nomic studies to evaluate responding genes [11], and immunohistochemical methods
of identifying DIPL definitively [28,57,58], have helped to identify the lipidosis with-
out recourse to TEM. A reliable urine or blood test would provide an important
alternative to the definitive, but less convenient, current diagnostic procedure and
would resolve the present difficulty in recognizing DIPL in the clinic.
DIPL and hereditary lysosomal storage disease both vary widely in clinical impor-
tance. Concern over DIPL is, of course, greater when there is additional nonphospho-
lipidotic histopathology and important overt sequelae. The FDA phospholipidosis
database (Figure 20.2) and the AstraZeneca database, with its spectrum of histo-
logic lesions from toxicology studies, shows a close association between DIPL and
excess nonphospholipidotic lesions [35]. However, DIPL provoked in animals by
some compounds such as loratadine may occur absent other concurrent histopathol-
ogy. However, even the risk of isolated DIPL with loratadine depends on the extent
of metabolic conversion to the less lipidotic desloratadine metabolite [43].
The lysosomal storage disease NP-C, and DIPL, not only share the hallmark mul-
tilamellar vesicles and disrupted cholesterol transport, but both can be devastating in
their extreme expressions. Even patients with nonlethal NP-C and DIPL may present
with important hepatotoxicity, neuropathy, and myopathy. Elevated serum and urine
levels of BMP are a feature of both NP-C and amiodarone-induced DIPL [37].
Patients with DIPL present with variable organ damage, for example, chloroquine
myopathy, perhexiline neurogenic muscle atrophy, 4,4′-diethylaminoethoxyhexestrol
hepatotoxicity, and gentamicin nephrotoxicity, evidence that DIPL and parenchymal
injury involve those organ(s) where there is a critical level of drug accumulation and
lysosomal disruption.
There are several practical approaches to balancing the potential benefits versus
risks of CADs. Regulatory agencies, including the FDA, approve drug doses that




history) versus adverse effects [83]. The initial doses for human phase 1 trials in
healthy subjects are based primarily on safety margins for positive findings in pre-
clinical toxicity studies; the incidence and severity of AEs in clinical trials would
limit the maximum recommended human dose. Drugs occasionally must be adminis-
tered based on milligram per kilogram or milligram per square meter when there is a
relatively small therapeutic index. As with any condition that does not have a conve-
nient validated biomarker, it may be difficult to establish the relation between DIPL
and the study drug and whether organ dysfunction precedes or follows the appearance
of DIPL.
Covert off-target toxicities can be difficult to detect and evaluate unless toxicity is
an expected extension of pharmacodynamic activity, for example, systemic toxicity of
corticosteroids [73,75]. Although QSAR and physicochemical analysis of lipophilic-
ity and amphiphilicity may be reassuring when they predict a low risk of DIPL, when
the latter is observed in animal safety studies, it may be an unexpected off-target event
and imprudent to dismiss. The important lipophilicity and amphiphilicity compo-
nents of the determinants of in vivo toxicity may be receptor-mediated, a consequence
of nonspecific accumulation, or a detergent effect [75]. Drug discovery projects are
heavily populated with cationic amphiphilic amines, which are common pharma-
cophores for histamine, muscarinic, and adrenal receptors. As exposure-toxicity
data sets and other lipidotic pharmacophore domains are accumulated, the risks of
developing DIPL may become clarified, and DIPL may be avoided. Extensive DIPL
and other histopathological lesions may not be colocated or obviously associated;
therefore, these additional data sets and focused mechanistic studies may identify
the collateral pharmacodynamic activity that may cause collateral injury.
With the availability of QSAR and in vitro screening methods [80], the poten-
tial risk of developing DIPL may be assessed early in drug development. However,
safety margins cannot be determined until after the start of clinical studies and the
establishment of clinical dose ranges. When development of DIPL is predicted from
QSAR or in vitro testing, the risk should be verified in preclinical toxicology stud-
ies that should determine propensity, safety margin, severity, and reversibility. Tis-
sues that show DIPL should be monitored for signs of collateral histopathology,
and the clinical relevance of histologic lesions such as liver or lung dysfunction or
electrocardiographic changes adjudicated. There may be a link between severity of
DIPL, AEs, and QTc interval prolongation by direct or indirect (protein trafficking)
mechanisms.
Although BMP level may not be monitored in animal toxicity trials, except for
cause, elevated levels would suggest its use in monitoring clinical studies. Early indi-
cations of DIPL from in silico or in vitro assayswould indicate whether BMPmonitor-
ing may be useful in animal or clinical trials. A preclinical assay of protein trafficking
(hERG-Lite assay, ChanTest, Cleveland, OH) may be advisable for DIPL-positive
compounds. The possibility should be considered that metabolites may be more lipi-
dotic than the parent compound, even though this may be uncommon [43]. It is
important to evaluate lung, liver, brain, and lymph node parenchymal cells, resident
tissue macrophages, and bile duct cells, and this evaluation may be a basis for classi-
fying and monitoring DIPL according to organ systems most commonly involved. As
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with any toxicologic pathology, targets may be specific to species, organ, and CAD,
and a reliable biomarker is needed that would be species- and organ-independent.
Monitoring in the clinic with BMPwould be advisable as an early sentinel for the col-
lateral tissue damage, especially when there is important tissue damage in nonclinical
toxicology studies and elevated BMP level. This may be important especially when
a small safety margin exists for phospholipidotic versus targeted pharmacodynamic
activity. Clinicians who oversee trials of CADs may benefit from having a biomarker,
knowing the affected organ systems in animal studies and focusing on those systems.
Recommendations are available for assessment of potential toxicity of DIPL and QT
prolongation and protein trafficking [80] (Figure 20.3).
Although it may be difficult to develop a drug that may induce DIPL, there
is much potential for therapeutic benefit. CADs are increasingly recognized as
inhibitors and inducers of autophagy [27] and processes linked to aging [19], cancer
[77], Alzheimer’s disease [84], and neurodegenerative disease [21,22,25]. The
physicochemical properties of CADs enable these drugs to access the interior of
the cell and facilitate passage across the blood–brain barrier [3], which may not be
achievable with other drugs. The multimodal study by Mesens et al. [85] provides an
example of additional ways to characterize a CAD compound. With the potential for
this group of compounds, Figure 20.4 offers a flowchart of steps and considerations


















Figure 20.3 Relation between phospholipidosis, QT prolongation, protein trafficking effects,
and adverse events. The QT-only group had adverse events that were significant but on target
(i.e., related to the mechanism of action of drugs). The phospholipidosis-only group had mild
adverse events. The overlap groups had significant, off-target adverse events associated with
their use [38]. (See color plate section for the color representation of this figure.)
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Figure 20.4 Flow chart for pharmaceutical development. When drug-induced phospholipi-
dosis (DIPL) is predicted from in silico studies or in vitro assays, animal studies are used to
evaluate DIPL. When DIPL is confirmed, it may be monitored with BMP and associated with
tissue toxicity that may or may not be reversible. The BMP may be monitored clinically to
assess potential drug toxicities.
All drugs have AEs that may or may not be dose related. Regulatory agencies
understand the potential for AEs and use risk/benefit profiles in decision-making.
Together with sponsors, regulatory agencies implement a Risk Evaluation and Miti-
gation Strategy (REMS) when it is necessary to ensure that the benefit of a drug or
biological product will justify the risk. Multiple reports suggest that vitamin E and
polyamino acids may decrease adverse symptoms of amiodarone [69–72], a phos-
pholipidotic antiarrhythmic drug with major toxicity that restricts its usage. It would
be important to know whether vitamin E and polyamino acids improved the safety of
amiodarone without reducing its utility in atrial fibrillation.
20.16 FUTURE DIRECTIONS AND RECOMMENDATIONS
• Increase use of BMP as a biomarker in nonclinical and clinical trials of drugs
that induce phospholipidosis.
• Further develop strategies to treat or prevent phospholipidosis, for example,
vitamin E and polyamino acids versus amiodarone lung toxicity.
• Increase awareness of the importance of metabolism, and genetic variations of
patients, in the expression of phospholipidosis.
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• Further investigate the association between phospholipidosis and autophagy/
apoptosis.
• Develop new therapeutic uses for CADs.
REFERENCES
[1] Shikata T, Kanetaka T, Endo Y, Nagashima K. Drug-induced generalized phospholipi-
dosis. Acta Pathol Jpn 1972;22(3):517–531.
[2] Nonoyama T, Fukuda R. Drug-induced phospholipidosis – pathological aspects and its
prediction. J Toxicol Pathol 2008;21(1):9–24.
[3] Vitovic P, Alakoskela JM, Kinnunen PK. Assessment of drug-lipid complex formation by
a high-throughput Langmuir-balance and correlation to phospholipidosis. J Med Chem
2008;51(6):1842–1848.
[4] Temple R. Policy developments in regulatory approval. Stat Med 2002;21(19):
2939–2948.
[5] Bass AS, Vargas HM, Valentin JP, Kinter LB, Hammond T, Wallis R, Siegl PK,
Yamamoto K. Safety pharmacology in 2010 and beyond: survey of significant events
of the past 10 years and a roadmap to the immediate-, intermediate- and long-term future
in recognition of the tenth anniversary of the Safety Pharmacology Society. J Pharmacol
Toxicol Methods 2011;64(1):7–15.
[6] Karsh LI. A clinical trial primer: historical perspective and modern implementation. Urol
Oncol 2012;30(4 suppl):S28–S32.
[7] Berridge BR, Chatman LA, Odin M, Schultze AE, Losco PE, Meehan JT, Peters T, Von-
derfecht SL, Society of Scientific and Regulatory Policy Committee Working Group.
Phospholipidosis in nonclinical toxicity studies. Toxicol Pathol 2007;35(2):325.
[8] Reasor MJ, Hastings KL, Ulrich RG. Drug-induced phospholipidosis: issues and future
directions. Expert Opin Drug Saf 2006;5(4):567–583.
[9] Reasor MJ, Kacew S. Drug-induced phospholipidosis: are there functional conse-
quences? Exp Biol Med 2001;226(9):825–830.
[10] Shayman JA, Abe A. Drug induced phospholipidosis: an acquired lysosomal storage dis-
order. Biochim Biophys Acta 2013;1831(3):602–611.
[11] Sawada H, Takami K, Asahi S. A toxicogenomic approach to drug-induced phospholipi-
dosis: analysis of its induction mechanism and establishment of a novel in vitro screening
system. Toxicol Sci 2005;83(2):282–292.
[12] Kodavanti UP, Mehendale HM. Cationic amphiphilic drugs and phospholipid storage
disorder. Pharmacol Rev 1990;42(4):327–354.
[13] Blohm TR. Drug-induced lysosomal lipidosis: biochemical interpretations. Pharmacol
Rev 1978;30(4):593–603.
[14] Lüllmann H, Lüllmann-Rauch R, Wassermann O. Lipidosis induced by amphiphilic
cationic drugs. Biochem Pharmacol 1978;27(8):1103–1108.
[15] Monteith DK, Morgan RE, Halstead B. In vitro assays and biomarkers for drug-induced
phospholipidosis. Expert Opin Drug Metab Toxicol 2006;2(5):687–696.
[16] Farrell GC. Drugs and steatohepatitis. Semin Liver Dis 2002;22(2):185–194.





[18] Gustafsson AB, Gottlieb RA. Recycle or die: the role of autophagy in cardioprotection.
J Mol Cell Cardiol 2008;44(4):654–661.
[19] Rajawat YS, Hilioti Z, Bossis I. Aging: central role for autophagy and the lysosomal
degradative system. Ageing Res Rev 2009;8(3):199–213.
[20] Mehrpour M, Esclatine A, Beau I, Codogno P. Overview of macroautophagy regulation
in mammalian cells. Cell Res 2010;20(7):748–762.
[21] Renna M, Jimenez-Sanchez M, Sarkar S, Rubinsztein DC. Chemical inducers of
autophagy that enhance the clearance of mutant proteins in neurodegenerative diseases.
J Biol Chem 2010;285(15):11061–11067.
[22] Eskelinen EL, Illert AL, Tanaka Y, Schwarzmann G, Blanz J, Von Figura K, Saftig P.
Role of LAMP-2 in lysosome biogenesis and autophagy. Mol Biol Cell 2002;13(9):
3355–3368.
[23] Shanware NP, Bray K, Abraham RT. The PI3K, metabolic, and autophagy networks:
interactive partners in cellular health and disease. Annu Rev Pharmacol Toxicol 2013;
53:89–106.
[24] PastorMD, García-Yébenes I, Fradejas N, Pérez-Ortiz JM,Mora-Lee S, Tranque P,Moro
MA, Pende M, Calvo S. mTOR/S6 kinase pathway contributes to astrocyte survival dur-
ing ischemia. J Biol Chem 2009;284(33):22067–22078.
[25] Bové J, Martinez-VicenteM, VilaM. Fighting neurodegeneration with rapamycin: mech-
anistic insights. Nature Reviews. Neuroscience 2011;12(8):437–452.
[26] Cho KS, Yoon YH, Choi JA, Lee SJ, Koh JY. Induction of autophagy and cell death by
tamoxifen in cultured retinal pigment epithelial and photoreceptor cells. Invest Ophthal-
mol Vis Sci 2012;53(9):5344–5353.
[27] Yoon YH, Cho KS, Hwang JJ, Lee SJ, Choi JA, Koh JY. Induction of lysosomal dilata-
tion, arrested autophagy, and cell death by chloroquine in cultured ARPE-19 cells. Invest
Ophthalmol Vis Sci 2010;51(11):6030–6037.
[28] Matsuzawa Y, Yamamoto A, Adachi S, Nishikawa M. Studies on drug-induced lipidosis.
VIII Correlation between drug accumulation and acidic phospholipids. J Biochem 1977;
82(5):1369–1377.
[29] Akeda S. A study on the lipidosis induced by a coronary vasodilator, 4,4’-diethylamino-
ethoxyhexestrol dihydrochoride. Mie Med J 1972–1973;22:65–96.
[30] Kasama K, Yoshida K, Takeda S, Akeda S, Kawai K. Bis-(monoacylglyceryl)phosphate
and acyl phosphatidylglycerol isolated from human livers of lipidosis induced by
4,4’-diethylaminoethoxyhexestrol. Lipids 1974;9(4):235–243.
[31] Bolesta S, Roslund BP. Elevated hepatic transaminases associated with telithromycin
therapy: a case report and literature review. Am J Health Syst Pharm 2008;65(1):37–41.
[32] Casado E, Gratacós J, Tolosa C, Martínez JM, Ojanguren I, Ariza A, Real J, Sanjuán A,
Larrosa M. Antimalarial myopathy: an underdiagnosed complication? Prospective longi-
tudinal study of 119 patients. Ann Rheum Dis 2006;65(3):385–390.
[33] Myers JL, Kennedy JI, Plumb VJ. Amiodarone lung: pathologic findings in clinically
toxic patients. Hum Pathol 1987;18(4):349–354.
[34] Kennedy JI, Myers JL, Plumb VJ, Fulmer JD. Amiodarone pulmonary toxicity. Clinical,
radiologic, and pathologic correlations. Arch Intern Med 1987;147(1):50–55.
[35] Barone LR, Boyer S, Damewood JR Jr, Fikes J, Ciaccio PJ. Phospholipogenic pharma-
ceuticals are associated with a higher incidence of histological findings than nonphospho-




508 LYSOSOMES AND PHOSPHOLIPIDOSIS IN DRUG DEVELOPMENT AND REGULATION
[36] Sundin DP, Sandoval R, Molitoris BA. Gentamicin inhibits renal protein and phos-
pholipid metabolism in rats: implications involving intracellular trafficking. J Am Soc
Nephrol 2001;12(1):114–123.
[37] Tengstrand EA, Miwa GT, Hsieh FY. Bis(monoacylglycerol)phosphate as a non-invasive
biomarker to monitor the onset and time-course of phospholipidosis with drug-induced
toxicities. Expert Opin Drug Metab Toxicol 2010;6(5):555–570.
[38] Willard JM. 2010. Phospholipidosis: data mining, modeling and laboratory research.
United States Food and Drug Administration Web site. Available at http://www.fda.gov/
downloads/AdvisoryCommittees/CommitteesMeetingMaterials/Drugs/Advisory
CommitteeforPharmaceuticalScienceandClinicalPharmacology/UCM210798.pdf.
Accessed 2015 June 29.
[39] Pelletier DJ, Gehlhaar D, Tilloy-Ellul A, Johnson TO, Greene N. Evaluation of a pub-
lished in silico model and construction of a novel Bayesian model for predicting phos-
pholipidosis inducing potential. J Chem Inf Model 2007;47(3):1196–1205.
[40] Kruhlak NL, Choi SS, Contrera JF, Weaver JL, Willard JM, Hastings KL, Sancilio
LF. Development of a phospholipidosis database and predictive quantitative structure–
activity relationship (QSAR) models. Toxicol Mech Methods 2008;18(2–3):217–227.
[41] Choi SS, Kim JS, Valerio LG Jr, Sadrieh N. In silico modeling to predict drug-induced
phospholipidosis. Toxicol Appl Pharmacol 2013;269(2):195–204.
[42] Orogo AM, Choi SS, Minnier BL, Kruhlak NL. Construction and consensus performance
of (Q)SAR models for predicting phospholipidosis using a dataset of 743 compounds.
Mol Inform 2012;31(10):725–739.
[43] Goracci L, Ceccarelli M, Bonelli D, Cruciani G. Modeling phospholipidosis induction:
reliability and warnings. J Chem Inf Model 2013;53(6):1436–1446.
[44] Kaufmann AM, Krise JP. Lysosomal sequestration of amine-containing drugs: analysis
and therapeutic implications. J Pharm Sci 2007;96(4):729–746.
[45] Zhang X, Zheng N, Rosania GR. Simulation-based cheminformatic analysis of organelle-
targeted molecules: lysosomotropic monobasic amines. J Comput Aided Mol Des 2008;
22(9):629–645.
[46] Mesens N, Steemans M, Hansen E, Verheyen GR, Van Goethem F, Van Gompel J.
Screening for phospholipidosis induced by central nervous drugs: comparing the pre-
dictivity of an in vitro assay to high throughput in silico assays. Toxicol In Vitro 2010;
24(5):1417–1425.
[47] Valerio LG Jr. In silico toxicology models and databases as FDA Critical Path Initiative
toolkits. Hum Genomics 2011;5(3):200–207.
[48] Gardiner SJ, Begg EJ. Pharmacogenetic testing for drug metabolizing enzymes: is it hap-
pening in practice? Pharmacogenet Genomics 2005;15(5):365–369.
[49] Inglis S, Stewart S. Metabolic therapeutics in angina pectoris: history revisited with per-
hexilene. Eur J Cardiovasc Nurs 2006;5(2):175–184.
[50] Seierstad M, Agrafiotis DK. A QSARmodel of hERG binding using a large, diverse, and
internally consistent training set. Chem Biol Drug Des 2006;67(4):284–296.
[51] Sun H, Xia M, Shahane SA, Jadhav A, Austin CP, Huang R. Are hERG channel blockers
also phospholipidosis inducers? Bioorg Med Chem Lett 2013;23(16):4587–4590.
[52] Cunningham ML, Lehman-McKeeman L. Applying toxicogenomics in mechanistic and




[53] van de Water FM, Havinga J, Ravesloot WT, Horbach GJ, Schoonen WG. High con-
tent screening analysis of phospholipidosis: validation of a 96-well assay with CHO-K1
and HepG2 cells for the prediction of in vivo based phospholipidosis. Toxicol in Vitro
2011;25(8):1870–1882.
[54] Kasahara T, Tomita K, Murano H, Harada T, Tsubakimoto K, Ogihara T, Ohnishi S,
Kakinuma C. Establishment of an in vitro high-throughput screening assay for detecting
phospholipidosis-inducing potential. Toxicol Sci 2006;90(1):133–141.
[55] Bhandari N, Figueroa DJ, Lawrence JW, Gerhold DL. Phospholipidosis assay in HepG2
cells and rat or rhesus hepatocytes using phospholipid probe NBD-PE. Assay Drug Dev
Technol 2008;6(3):407–419.
[56] Eskelinen EL. Roles of LAMP-1 and LAMP-2 in lysosome biogenesis and autophagy.
Mol Aspects Med 2006;27(5–6):495–502.
[57] Obert LA, Sobocinski GP, Bobrowski WF, Metz AL, Rolsma MD, Altrogge DM, Dun-
stan RW. An immunohistochemical approach to differentiate hepatic lipidosis from hep-
atic phospholipidosis in rats. Toxicol Pathol 2007;35(5):728–734.
[58] Asaoka Y, Togashi Y, Imura N, Sai T, Miyoshi T, Miyamoto Y. Immunohistochemistry
of LAMP-2 and adipophilin for phospholipidosis in liver and kidney in ketoconazole-
treated mice. Exp Toxicol Pathol 2013;65(6):817–823.
[59] Larrain S, Rinella ME. A myriad of pathways to NASH. Clin Liver Dis 2012;16(3):
525–548.
[60] Luo D. Ultracytochemical observation on lysosome of hair cells in kanamycin ototoxic
guinea pigs [in Chinese]. Zhonghua Er Bi Yan Hou Ke Za Zhi 1990;25(5):281–282, 318.
[61] Dennis AT, Wang L, Wan H, Nassal D, Deschenes I, Ficker E. Molecular determi-
nants of pentamidine-induced hERG trafficking inhibition. Mol Pharmacol 2012;81(2):
198–209.
[62] Kuryshev YA, Ficker E,Wang L, Hawryluk P, Dennis AT,Wible BA, BrownAM,Kang J,
ChenXL, Sawamura K, ReynoldsW, RampeD. Pentamidine-induced longQT syndrome
and block of hERG trafficking. J Pharmacol Exp Therap 2005;312(1):316–323.
[63] Bravo-Cuellar A, Balercia G, Levesque JP, Liu XH, Osculati F, Orbach-Arbouys .
Enhanced activity of peritoneal cells after aclacinomycin injection: effect of pretreat-
ment with superoxide dismutase on aclacinomycin-induced cytological alterations and
antitumoral activity. Cancer Res 1989;49(6):1578–1586.
[64] Lowe R, Mussa HY, Nigsch F, Glen RC, Mitchell JBO. Predicting the mechanism of
phospholipidosis. J Chemoinform 2012;4:2. DOI: 10.1186/1758-2946-4-2.
[65] Hiraoka M, Abe A, Lu Y, Yang K, Han X, Gross RW, Shayman JA. Lysosomal phospho-
lipase A2 and phospholipidosis. Mol Cell Biol 2006;26(16):6139–6148.
[66] Joshi UM, Kodavanti PR, Coudert B, Dwyer TM, Mehendale HM. Types of interac-
tion of amphiphilic drugs with phospholipid vesicles. J Pharmacol Experim Therap
1988;246(1):150–157.
[67] Morissette G, Lodge R, Marceau F. Intense pseudotransport of a cationic drug mediated
by vacuolar ATPase: procainamide-induced autophagic cell vacuolization. Toxicol Appl
Pharmacol 2008;228(3):364–377.
[68] El Mouedden M, Laurent G, Mingeot-Leclercq MP, Taper HS, Cumps J, Tulkens PM.
Apoptosis in renal proximal tubules of rats treated with low doses of aminoglycosides.
Antimicrob Agents Chemother 2000;44(3):665–675.
 

510 LYSOSOMES AND PHOSPHOLIPIDOSIS IN DRUG DEVELOPMENT AND REGULATION
[69] Kishore BK, Lambricht P, Laurent G, Maldague P, Wagner R, Tulkens PM. Mechanism
of protection afforded by polyaspartic acid against gentamicin-induced phospholipidosis.
II. Comparative in vitro and in vivo studies with poly-l-aspartic, poly-l-glutamic and
poly-d-glutamic acids. J Pharmacol Exp Therap 1990;255(2):875–885.
[70] Vejux A, Guyot S, Montange T, Riedinger JM, Kahn E, Lizard G. Phospholipido-
sis and down-regulation of the PI3-K/PDK-1/Akt signalling pathway are vitamin E
inhibitable events associated with 7-ketocholesterol-induced apoptosis. J Nutr Biochem
2009;20(1):45–61.
[71] Card JW, Racz WJ, Brien JF, Massey TE. Attenuation of amiodarone-induced pul-
monary fibrosis by vitamin E is associated with suppression of transforming growth
factor-beta1 gene expression but not prevention of mitochondrial dysfunction. J Phar-
macol Exp Therap 2003;304(1):277–283.
[72] Scuntaro I, Kientsch U, Wiesmann UN, Honegger UE. Inhibition by vitamin E of
drug accumulation and of phospholipidosis induced by desipramine and other cationic
amphiphilic drugs in human cultured cells. Br J Pharmacol 1996;119(5):829–834.
[73] Lounkine E, Keiser MJ, Whitebread S, Mikhailov D, Hamon J, Jenkins JL, Lavan P,
Weber E, Doak AK, Côté S, Shoichet BK, Urban L. Large-scale prediction and testing
of drug activity on side-effect targets. Nature 2012;486(7403):361–367.
[74] Hanumegowda UM, Wenke G, Regueiro-Ren A, Yordanova R, Corradi JP, Adams SP.
Phospholipidosis as a function of basicity, lipophilicity, and volume of distribution of
compounds. Chem Res Toxicol 2010;23(4):749–755.
[75] Price DA, Blagg J, Jones L, Greene N, Wager T. Physicochemical drug properties asso-
ciated with in vivo toxicological outcomes: a review. Expert Opin Drug Metab Toxicol
2009;5(8):921–931.
[76] Ratcliffe AJ. Medicinal chemistry strategies to minimize phospholipidosis. Curr Med
Chem 2009;16(22):2816–2823.
[77] Mathew R, Karantza-Wadsworth V, White E. Role of autophagy in cancer. Nature
Reviews. Cancer 2007;7(12):961–967.
[78] Zhou L, Geraci G, Hess S, Yang L, Wang J, Argikar U. Predicting phospholipidosis:
a fluorescence noncell based in vitro assay for the determination of drug-phospholipid
complex formation in early drug discovery. Anal Chem 2011;83(18):6980–6987.
[79] Naisbitt DJ, Ruscoe JE, Williams D, O’Neill PM, Pirmohamed M, Park BK. Dis-
position of amodiaquine and related antimalarial agents in human neutrophils: impli-
cations for drug design. Journal of Pharmacology and Experimental Therapeutics
1997;280(2):884–893.
[80] Chatman LA, Morton D, Johnson TO, Anway SD. A strategy for risk management of
drug-induced phospholipidosis. Toxicol Pathol 2009;37(7):997–1005.
[81] Kuroda Y, SaitoM. Prediction of phospholipidosis-inducing potential of drugs by in vitro
biochemical and physicochemical assays followed by multivariate analysis. Toxicol in
Vitro 2010;24(2):661–668.
[82] Smith DA, van de Waterbeemd H, Walker DK. Pharmocokinetics and metabolism in
drug design. In: Mannhold R, Kubinyi H, Folkers G, editors. Methods And Principles




[83] United States Food and Drug Administration. 2005. Guidance for industry: premarket-
ing risk assessment. Available at http://www.fda.gov/downloads/RegulatoryInformation/
Guidances/UCM126958.pdf.
[84] Barnett A, Brewer GJ. Autophagy in aging and Alzheimer’s disease: pathologic or pro-
tective? J Alzheimers Dis 2011;25(3):385–394.
[85] Mesens N, Desmidt M, Verheyen GR, Starckx S, Damsch S, De Vries R, Verhemeldonck
M, Van Gompel J, Lampo A, Lammens L. Phospholipidosis in rats treated with amio-
darone: serum biochemistry and whole genome micro-array analysis supporting the lipid






acid ceramidase (AC), 93, 183, 194, 195
deficiency, 210–213
downregulation of, 453
acidic vesicular organelles (AVOs), 325
acid sphingomyelinase (ASM), 90, 92, 93, 118,





adaptor complex 2 (AP2), 410
adenomatous polyposis coli (APC), 38





Alzheimer’s disease see Alzheimer’s
disease (AD)




Parkinson’s disease and related disorders see
Parkinson’s disease (PD)
Lysosomes: Biology, Diseases, and Therapeutics, First Edition.
Edited by Frederick R. Maxfield, James M. Willard and Shuyan Lu.
© 2016 John Wiley & Sons, Inc. Published 2016 by John Wiley & Sons, Inc.
alpha-galactosidase A deficiency, 221–224
Alzheimer’s disease (AD), 20, 109, 454, 467




hAPP mouse model, 149
lysosomal dysfunction, 145–147
mutations of PS1, 147
pathogenesis of, 457–458
ambroxol, 365–367
aminoglycoside antibiotics, 447, 450–451, 467
amiodarone, 326, 329, 446, 456, 460, 462, 466,
468, 490, 501, 505
amitriptyline, 440, 456
β-amyloid, 489
amyloid precursor protein (APP), 145–149
amyotrophic lateral sclerosis (ALS), 20, 144, 317
anthracycline antineoplastic drug, 500
anthrax toxin, 451










antibody–drug conjugates (ADCs) (Continued)
linker-payloads, 414–415
mechanisms of resistance, 416–417
receptor-mediated internalization, 410–412
structure, 413
therapeutic effect of, 410
anticancer agents, 195, 196, 288, 295, 297, 302,
430, 432–434
anticancer drugs, 184, 427, 431–433
antihistamine loratadine, 490
antimicrotubule drugs, 468
antineoplastic drug doxorubicin (DOX), 464
antioxidant vitamin E, 470–471
antipyrine, 438
α1-antitrypsin (ATZ), 110
apoptosis, 116, 117, 121–125, 127
and DIPL, 489
by gentamicin, 465
vitamin E inhibits, 501
Arizona Center for Education and Research on
Therapeutics database, 497
arsenic, 451, 469





autolysosomes, 7, 13, 18–20, 54, 145, 151, 154,
282, 283, 330, 452
autophagic lysosomal reformation (ALR), 8,
18–19, 154, 334–335












dual function in cancer see cancer therapy,
autophagy inhibition in
elongation and maturation, 282–283
enhancers screening see screening methods,
autophagosomes
forms of, 315
fusion and degradation, 283
HDAC inhibition, 336
impairment and diseases, 316–317
induction, 283–285
initiation, 282
literature reports, 317–324, 326
lysosomal efficiency, 338–339






























beclin-1, 22, 56, 151, 282, 288, 468





CHS and GPS, 244, 246






bis(monoacylglycero)phosphate (BMP), 89, 118
BMT (bone marrow transplantation), 219
botulinum neurotoxins (BoNTs), 451
brentuximab vedotin, 415
cadmium, 451, 464, 469












cancer-induced changes, in lysosomal function
and composition
altered lysosomal trafficking, 185
altered lysosome membrane permeability, 184
cathepsins see cathepsins
heparanase, 190–191
increased lysosome size, 184
lysosomal hydrolases, increased activity of,
182–183
lysosomal membrane proteins LAMP1 and
LAMP2, 192
sialidase 1/neuraminidase 1, 191–192
sphingolipid metabolism, 193–195
targeting lysosomal membrane integrity,
195–196
V-ATPase, 192–193
cancer therapy, autophagy inhibition in
clinical studies, 286, 288




mouse model studies, 285–287
multiple druggable targets, 291–292
preclinical studies, 288–290, 292











cargo adaptor proteins, 291
casein kinase 1 (CK1), 38
caspase-dependent apoptosis pathways, 195
β-catenin, 38, 44
cathepsin B, 183–185, 187–190, 193
cathepsin K, 66, 189, 190, 435, 453
cathepsins, 124–125, 327, 445
cationic amphiphilic drugs (CADs), 489–494,
497, 500–502, 504, 506
caveolae-mediated endocytosis, 410, 411
cell death signaling, 127
LMP in see lysosomal membrane
permeabilization (LMP) in cell death
modalities, 116–117






drugs effects on pH and lysosomal volume,
452–453
LMP and cell death, 454–455
on lysosomal enzyme activity, 453–454
membrane trafficking changes see trafficking
pathways
substrate accumulation, 454
Center for Drug Evaluation and Research
(CDER), 488
central nervous system (CNS), 89, 90, 109, 155,
219, 316, 363, 447, 492
ceramide, 65, 90, 92, 93, 118, 194, 195, 209, 210,
212, 213, 215, 230, 434
CeredaseⓇ (alglucerase), 364
CerezymeⓇ (imiglucerase), 364
chaperone-mediated autophagy (CMA), 8, 12,
137, 138, 293, 315
Chediak–Higashi syndrome (CHS), 184, 244, 246
chemical chaperones, 359
chloroquine (CQ), 286, 293–295, 298, 299, 301,
327, 328, 332–334, 428, 430, 437, 446,
452–458, 460, 462, 463, 466, 468, 470
chlorphentermine, 466
chlorpromazine, 338
cholesterol, 89, 95, 118, 119
cholesteryl ester storage disease, 89
chronic granulomatous disease (CGD), 255
chylomicrons, 90
ciprofloxacin, 121, 467
cisplatin, 194, 195, 451, 464, 465
clathrin-coated vesicle (CCV)
formation by AP-2, 410
clathrin-independent transport route, 10






Coordinated Lysosomal Enhancement And
Regulation (CLEAR), 103
C9orf72 mutation, 155, 157
cristae, 52














cytotoxic T lymphocytes (CTLs), 64–65, 239
Danon disease, 463, 467
daunorubicin, 416, 427
death-inducing signaling complex (DISC), 116
Delta-like 4 (DLL-4), 42
delta/serrate/Lag2 (DSL), 41






differential centrifugation techniques, 1
Diffuse Lewy Body Disease (DLB), 155
dimebon, 456
dimethylsulfoxide, 359
dipeptide-repeat (DPR) proteins, 157
dipeptidyl-β-naphthylamides, 121
direct membrane lysis, 120
disheveled (Dvl) proteins, 38
disulfide linkers, 415
DNA-damaging drugs, 195
DNA microarray technique, 493
N-dodecylimidazole, 120
doxorubicin, 416, 428, 429
Drosophila, 17, 18, 36




clinical expression and context of, 490–491
in CNS, 492
collateral effects of, 488–489
comparison of dog and rat tissue distributions,
495–496
FDA database and QSAR modeling, 494
FDA involvement, 488–489
lethal, 489–490
linked with overt toxicity, 494–496
lowest observed vs. toxicity LOEL, 496










USFDA database of approved NDAs, 497–500
dye methods, 494
dysfunction, lysosme
cellular impacts see cellular impacts, lysosomes
lysosmotropic compounds, 446–451
mechnaism for organ toxicity see organ toxicity
nonlysosomotropic compounds, 451–452
early endosomes (EEs), 7, 9, 11, 37, 101, 115,
145, 245, 247, 248, 250, 257, 391, 392,
410–412, 452, 456
E-cadherin, 187–189
eliglustat tartrate (Genzyme), 364
endocytic pathways, 10–12, 22, 63, 71, 115, 118,
119, 121, 124, 247, 251, 388, 389, 412, 456,
465
endocytic recycling compartment (ERC), 89
endogenous cysteine cathepsin inhibitors, 190
endoplasmic reticulum (ER), 9, 10, 13, 54, 147,
209, 282, 284, 316, 358, 395, 445, 458–459
endosomal escape pathways, biologics delivery,
383–384
bacteria, 392–394
endosome characteristics, 384, 388–389
engineered endosomal escape, 385–386,
395–399
fungi, 392–394





endosomal sorting complex required for transport
(ESCRT), 34–37, 39, 41, 42, 44, 89, 283, 412
engineered endosomal escape
chemical and physical strategies, 399
description of, 395–396
lipids, 398–399
peptides and polymers, 396–397
enzyme replacement therapy (ERT), 215, 217,
219, 221, 223, 357
eosinophils, 75, 243









exocytosis, 457–458 see also lysosome exocytosis
exosomes, 35, 39, 41–44, 253, 399
FabrazymeⓇ, 360
Fabry disease (FD), 338, 460





GLP HEK assay, 362–363
male patient, 359–360
migalastat clinical trials, 361–362
in vivo studies, 360–361
Fabry Phase 2 study, 372
Farber disease, 210–213
fast/direct recycling pathway, 11





Food and Drug Administration (FDA), 383, 384,
467, 488
Francisella tularensis, 393
free fatty acids (FFAs), 110
Frizzled (Fz) receptors, 38, 40










α-galactosidase A (α-Gal A), 359
gallic acid, 471
gamma aminobutyric acid (GABAA), 412
gangliosides, 216, 224–227












gentamicin, 489–491, 501, 502
globoid cell leukodystrophy (GLD), 218–219
globotriaosylceramide (GL-3), 359
globotriaosylsphingosine ( lyso-Gb3), 359







glycogen synthase kinase (GSK3), 35, 38, 39, 44
glycoproteins, 357
glycosaminoglycans (GAGs), 124, 357, 466
glycosphingolipids (GSLs), 92, 93, 357
Gly-Phe-β-naphthylamide, 121
GM2-activator protein (GM2-AP), 92
GM2 gangliosidoses, 226–229, 367–368
GM1 gangliosidosis, 224–226
GPI-anchored receptor (GPIHBP1), 89
Gray Platelet syndrome (GPS), 244, 246
Griscelli syndrome GS2 (RAB27A
deficiency), 252
Griscelli syndrome GS3 (MLPH deficiency), 252
growth hormone receptor (GHR), 11
GTPase-activating protein (GAP), 106
guanosine exchange factor (GEF), 11
half-life of drugs, 437, 438
heat shock cognate 70 (HSC70), 279
heat shock protein 70 (Hsp70), 339
helix–loop–helix transcription factors, 103
hemagglutinin 2 (HA2) protein, 390
hemophagocytic lymphohistiocytosis (HLH), 252
heparanase, 190–191
hereditary spastic paraplegias (HSPs), 22, 154
Hermansky–Pudlak syndrome (HPS)
BLOC-1,-2,-3 and AP-3, 250
and melanosome maturation, 248–249
neurosecretory granule biogenesis, 250–251
RAB32/RAB38, 250
HEXA gene, 226–229
hexosaminidase A and B deficiency, 226–229




histone deacetylase 6 (HDAC6), 57







sphingolipid storage diseases see sphingolipid
storage diseases
TFEB and cellular clearance, 106–111
human ether-à-go-go-related gene (hERG)
channel, 492, 493, 496, 497, 500–502
Huntington’s disease (HD), 109
Huntingtin (htt), 317
pathogenesis of, 457–458
hydroxychloroquine (HCQ), 125, 196, 295, 298,
300, 301, 333–334, 468
4-hydroxynonenal (HNE), 144
hypoxia-inducible factor-1 (HIF-1), 56
imatinib, 329, 428, 460, 463, 464
imidazole, 397, 430




1,4,5-inositol trisphosphate (IP3), 316
intracytosolic calcium (cAMP), 316
intraluminal vesicles (ILVs), 8, 9, 11, 33, 34, 42,
44, 413 see also multivesicular bodies
(MVBs), sorting onto ILVs
intralysosomal waste material, 454





late endosomes (LEs), 7, 9, 11, 20, 410
late endosomes and lysosomes (LE/Ly), 1, 17, 87,
89, 91–94, 96
LC3-interacting region (LIR), 16
leucine-rich repeat kinase (LRRK2), 20, 150–155
LeuLeuOMe, 121, 125, 196
levofloxacin, 467
ligand-independent Deltex-dependent pathway, 41
lipid-bisretinoids (LBs), 143, 154
lipids, 87
and autophagy, 94–95
endocytic uptake of lipoproteins, 87–91
engineered endosomal escape, 398–399
hepatocytes and macrophages, 90
hydrolysis in LE/Ly, 87, 91–93
metabolic regulation, 95–96
lipofuscin, 120, 141–144, 155, 454, 466




low-density lipoprotein (LDL), 67
cholesterol, 91
receptor, 88–89, 91
lowest observed adverse effect level (LOAEL)
PLD nonclinical studies, 491
toxicity vs. PLD LOEL, 496
LSDs see lysosomal storage disorders (LSDs)
lycopene, 471
lysobisphosphatidic acid (LBPA), 37, 89, 489
lysosomal acid lipase, 89, 90, 94, 95
lysosomal apoptotic pathway, 125–126
lysosomal integral membrane protein 2
(LIMP2), 155
lysosomal integral membrane proteins (LIMPs),
91, 118
lysosomal membrane permeabilization (LMP),
142, 454–455
lysosomal membrane permeabilization (LMP) in
cell death, 117–118
characteristics, 118–119
direct insult vs. molecular signaling, upstream
of, 121–124
direct membrane lysis, 120
mechanisms, 119
minor destabilization, 117




signaling downstream see signaling
downstream pathways, LMP
lysosomal membrane proteins, 10, 101, 184,
192–193, 283
lysosomal storage disorders (LSDs), 1, 316
ERT, 357–358
Fabry disease, 359–363
Gaucher disease see Gaucher
disease (GD)
increased LTR staining, 453




TFEB and cellular clearance, 106–109
lysosomal trapping
assessment techniques, 427–429
β-blockers in vivo distribution, 438









theoretical relationship between pKa and alpha,
426–427
vital stains, 424
volume of distribution, 423, 435–437
weakly basic drug, 424–425
lysosome-associated membrane glycoprotein 2A
(LAMP2A), 279
lysosome-associated membrane protein 1
(LAMP1), 191–192




lysosome exocytosis, 104, 107–109, 182, 183,
185, 191, 193, 197, 337, 338, 457, 458
calcium-dependent exocytosis, 76
cortical actin in, 71–72
extracellular degradation, 66–68
fusion with plasma membrane, 75
lysosome-related organelle, 64–65
lysosome-related organelles maturation, 69–70
membrane repair, 65–66
occurrence, 63
plasma membrane repair see plasma membrane
proteins delivery into cell surfaces, 68
role, 76
schematic representation, 68–69
source of membrane, 66
lysosome-related disorders (LSDs), 9, 18–20
lysosome-related organelles (LROs), 239–240
azurophilic granules, 255




familial HLH and cytolytic granule secretion,
254–255
IRF7-signaling and IFN induction, 256
MIICs, 256–258
motility, docking, and secretion, 252–253
NADPH oxidase-containing, 254–256
in nonhematopoietic cell types, 244
perspectives, 260
phagosomes and autophagosomes, 258–259
physiological functions, 240–244





biosynthetic transport routes, 10
cellular recycling centers, 181
digestion, 1, 2, 88, 152
endocytic pathways, 10–12
function in aging organisms, 139–142
history, 2–4
lipophilic compounds accumulation, 446
morphology, 445
neurodegeneration and links to autophagy, 20
role in cellular processes, 101, 102
role in nutrient sensing and signaling
pathways, 445–446
lysosomotropic compounds
aminoglycoside antibiotics, 447, 450–451
amiodarone, 446
approved drugs, property distribution
of, 446–447
autophagy screening, 327–338
biological impacts of, 460, 461
cadmium and arsenic, 451
chloroquine, 446












proton transfer mechanism, 431, 432
selective against tumor cells, 433
LysoTracker staining, 300, 327, 333, 334, 429,
440, 452
macroautophagy, 7, 9, 12, 13, 137, 138, 145, 151,
153, 282, 284, 293, 315, 316 see also
autophagy
macrolipophagy, 110
macrophages, 65–66, 69, 76, 91, 94, 95, 117, 121,
142, 185, 187, 216–218, 256, 332, 334, 337,
365, 389, 393, 457, 490, 495, 503
macropinocytosis, 42, 257, 333, 410, 411, 456
magnetic chromatography, 429
major histocompatibility complex class II
(MHCII), 68, 256–258
malondialdehyde (MDA), 144
mammalian target of rapamycin (mTOR)











mechanistic target or rapamycin complex 1
(mTORC1), 95, 104–107
mediated by the calcium channel mucolipin-1
(MCOLN1), 106
mefloquine, 196, 430, 492
melanocytes, 64, 71, 72, 240, 247–249, 251, 252
melanosomes, 35, 64, 70, 72, 247–249
metabolic syndrome, 110
metachromatic leukodystrophy (MLD), 219–221
3-methyladenine (3-MA), 292, 293
methylamine, 327, 452, 454, 456
1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine
(MPTP), 154
MHC class II compartments (MIICs), 68,
256–258





microRNAs (miRNAs), 36, 42, 109, 339–340
microscopic detection methods, 428
microtubule, 291–292
-associated protein light chain 3, 56, 282
dependent movement, 69, 71
-destabilizing anticancer drug, 184, 193
disruption, 413
inhibitors, 414, 455
in lysosome transport, 70–71
stabilizing agents, 124
targeting drugs, 195






fundamental role of, 51
structure, 52
mitochondrial outer membrane (MOM), 116
mitochondrial outer membrane permeabilization
(MOMP), 116, 127
Bax/Bak-dependent, 125
LMP upstream of, 123
upstream and downstream of, 125, 126
mitochondrial permeability transition (MPT), 53
mitochondrial-processing protease (MPP), 56






monensin, 451, 456, 457
monoclonal antibody (mAb), 413




mucopolysaccharidosis type I, 460
multidrug resistance (MDR1), 417
multiple sulfatase deficiency (MSD), 109
multivesicular bodies (MVBs), 8, 11, 89,
283, 412
multivesicular bodies (MVBs), sorting onto ILVs
downregulating EGFR signaling, 35–38
electron micrograph, 33, 34
ESCRT machinery, 34
intercellular Notch signaling, 39–44
maturation process, 33
upregulating Wnt signaling, 38–40
Munc13– 4, 74, 245, 254
muscle toxicity, 467–468
Mycobacterium tuberculosis, 65–66, 76






necroptosis, 116, 117, 121–123, 127
nefazodone, 471
neurodegeneration with Brain Iron Accumulation
(NBIA), 21–22
neurodegenerative disease, 20, 109–110, 338 see
also Alzheimer’s disease (AD); Parkinson’s
disease (PD)
neutrophils, 64, 72, 74–76, 185, 244, 253, 255,
256, 258, 259, 389, 394
new drug applications (NDAs), 495, 498
niclosamide, 326, 333, 340
Niemann–Pick disease, 2, 18, 339
type C, 89, 93, 143, 358, 454, 466, 490,
492, 502
types A and B, 213–215
Nile red dye, 494
nitrobenzoxadiazole (NBD), 494
NOD-like receptors (NLRs), 117
nonalcoholic steatohepatitis (NASH), 494
nonlysosomotropic compounds, 451–452










off-target effects, 340, 429
ofloxacin, 467
N-oleoylethanolamine, 195













osmotic lysis, 119–121, 123, 387, 397
osteopenia, 66
outer mitochondrial membrane (OMM) proteins,
54, 56, 57
paclitaxel, 195, 451, 467
Parkinson’s disease (PD), 20, 109, 467
ATP13a2, 153–154
autosomal-dominant form, 150
death of neurons, 150
disrupt by CMA, 151–152
exposure of MPTP, 154
lysosomal degradation, 151
mutations of LRRK2, 152–153
pathogenesis of, 457–458
α-synuclein, 150–151, 317
vacuolar protein sorting35, 154
perhexiline, 326, 329, 462, 488, 492–494
perhexiline maleate, 490
P-glycoprotein (Pgp), 416, 417
phagocytosis, 1, 42, 66, 76, 102, 104, 115, 144,
182, 256–258, 331, 333–335, 389, 393, 410,
445, 452, 455–457, 461, 487
phagophore, 7, 315
biogenesis, 14
electron micrograph of, 13
elongation, 14
formation, 15, 16, 316
growing, 15
phagophore assembly site (PAS), 8
phagosomes, 76, 243, 255–259, 335,
392–394, 452
phosphatidylcholine, 91, 501
phosphatidylethanolamine (PE), 15, 91, 282, 455
phosphatidylglycerol (PG), 94, 489
phosphatidylinositol 4-kinases (PI4Ks), 19
phosphatiylinositol-3-phosphate (PtdIns3P), 15,
22
phosphoinositide 3,4,5 triphosphate (PIP3), 74, 75
phospholipase A2 (PLA2) enzyme, 391
phospholipidosis (PLD), 454
autophagy enhancers, 329
drug development and regulation see
drug-induced phospholipidosis (DIPL)
Phospholipidosis Working Group (PLWG), 488
pH-partitioning theory, 437, 438
pigment cell-specific premelanosome (PMEL)
protein, 247
PI4KIIIβ knockdown cells, 19
plasmacytoid DCs (pDCs), 256, 257
plasma membrane, 10, 11, 13, 15, 33, 90, 95, 195,
209, 282, 316, 389, 487
gangliosides, 224
lysosome fusion with, 75
repair mechanisms, 65–66, 76
tethering of lysosomes, 72–75






Pompe disease (PD), 18, 109, 338, 368–371




proprotein convertase subtilisin/kexin type 9
(PCSK9), 91
protolysosomes, 18, 19
proton sponge effect, 121
PSAP gene, 220, 229, 230
Pseudomonas exotoxin, 394–395
pyrimethamine (PYR), 367–368
pyroptosis, 116, 117, 121–123, 127, 144
quantitative structure–activity relationship




Rab27, 72, 74, 75
Rab27a, 42, 64, 72, 74, 245, 252–256
Rab7-interacting lysosomal protein (RILP), 70, 71





reactive oxidative species (ROS), 52, 56, 117, 119,
121–124, 127, 157, 459, 463, 468, 471
real-time polymerase chain reaction analysis, 488
receptor tyrosine kinases (RTKs), 33–36, 39,
44, 409
recycling endosomes (REs), 7, 9, 16, 70, 245, 248,
389, 392, 456
renal cell carcinoma (RCC), 110, 297, 334
ReplagalⓇ, 223, 360
retinal pigment epithelium (RPE), 72, 143, 247,
457, 466
Rickettsia species, 394
Risk Evaluation and Mitigation Strategy
(REMS), 505
salicylihalamide A, 416
Sandhoff disease (SD), 226–229, 367
screening methods, autophagosomes
Atg8/LC3, protein marker, 317






membrane trafficking process, 331
mTOR inhibitors, 331–335







selective and potent autophagy inhibitor 1
(Spautin-1), 292, 293
sequestosome 1 (SQSTM1/p62), 16. 157, 325,
455, 459, 460, 464
serpin, 125, 188
Shigella flexner, 393
sialidase 1/neuraminidase 1, 191–192
signaling downstream pathways, LMP
BID-independent apoptotic signaling
pathways, 127
lysosomal apoptotic pathway, 125–126
lysosomal cathepsins, 124–127
siramesine, 196, 329, 456
SLC38A9, 106
slow/indirect recycling pathway, 11
small interfering RNA (siRNA) technology, 384
Soluble NSF Attachment REceptor (SNARE)
proteins, 75
sorting nexins (SNXs), 12
spermatids, 75
sphingolipid activator proteins (SAPs), 92, 210,
229–230
sphingolipids, 104, 118, 149, 209, 411
catabolism, 93, 194













Types A and B NPD, ASM deficiency, 213–215
sphingomyelin (SM), 90, 92, 93, 118, 124, 184,
194, 209, 214, 215, 230, 492, 500
sphingosine, 93, 118, 123, 184, 194–196, 209,
210, 212–214
spinal muscular atrophy with myoclonic epilepsy
(SMA-PME), 213
Spinster, 18, 283




SU11652, anticancer remedy, 196
substrate reduction therapy (SRT), 358, 364, 370
sunitinib, 196, 416
synaptotagmin-like protein 1 (Slp1), 72, 74–75
α-synuclein (SNCA), 20, 109, 151–154, 317, 338,
339, 458
tamoxifen, 326–328, 333, 455–457, 489
target SNAREs (t-SNAREs), 75
taxanes, 292, 467
Tay–Sachs disease (TSD), 2, 226–229, 367–368
telithromycin (Ketek), 490
tetanus neurotoxin (TeNT), 451
therapeutic naked antibodies, 409
thioether-or amide-based linkers, 415
toll-like receptors (TLRs), 117, 256–259
toremifene, 457
Torsades de pointes (TdP), 496, 497
toxicogenomics, 493












transcription factor EB (TFEB), 16, 95, 139, 146,
151, 154, 187, 284, 329, 330, 333, 335, 338,
453, 456, 458
transcription factor EB (TFEB), cellular clearance
activation on cellular mechanisms, 107, 108











subcellular regulation by phosphorylation,
104–105
transferrin receptor (TfR), 33, 410
trans-Golgi network (TGN), 10, 11, 15, 245, 251,
410, 445, 453
transient receptor potential calcium channel
MucoLipin subfamily member 1 (TRPML1),
106, 148, 337
trastuzumab (Herceptin), 409
Trypanosoma cruzi, 65, 72, 76
tuberous sclerosis complex 2(TSC2), 335
tubular lysosome, 71
tumor-associated antigen (TAA), 413, 414, 417
tumorigenesis, 181, 188, 190, 213, 285–288,
300–302, 468–469
tumor necrosis factor-related apoptosis-inducing
ligand (TRAIL), 116, 123, 293,
331, 452
tunicamycin, 331
type-I interferon (IFN), 256, 257
Types A and B Niemann–Pick disease (NPD),
213–215
ubiquitin-binding adaptor protein 62
(p62/SQSTRM1), 57
ubiquitin proteasome system (UPS), 140, 141
UCH-L1 (ubiquitin carboxy-terminal
hydrolase-L1 Parkin), 150, 151
ulinastatin, 465
Uvrag, autophagy-associated protein, 22
vacuolar protein sorting35 (VPS35), 20, 154
vacuolar-type adenosine triphosphatase




valosin-containing protein (VCP), 156–157
velaglucerase alfa (VPRIVⓇ), 364
verapamil, 326, 328, 456
very low-density lipoproteins (VLDLs), 88–89
vesicular SNARE (v-SNARE) VAMP-7, 75
Vici syndrome, 21
vinblastine, 327, 416, 455, 467




adenovirus protein VI, 391







safety of amiodarone, 505
treatments for DIPL, 501
WIPI (WD-repeat protein interacting with
phosphoinositides), 14, 15
































Figure 2.1 Schematic drawing depicting the endocytic and autophagy pathways to the lyso-
somes. Note: Refer to page 8 for full caption.
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Figure 3.4 Intercellular Notch signaling mediated by ligand-bearing exosomes. Note: Refer





















Figure 5.2 Schematic of mechanisms involved in lysosome exocytosis. Note: Refer to


















Figure 6.1 Schematic diagram of lipoprotein and lipid droplet degradation by lysosomes.
















Figure 7.1 Central role of lysosomes in key cellular processes.
Figure 7.2 Systems biology approach used to discover the CLEAR network. Note: Refer to












































Figure 7.4 TFEB activation on cellular mechanisms that lead to cellular clearance.





































































































ALS – Alsin, C9orf72,
ALS – CHMP2B
Frontotemporal dementia – CHMP2B, p97/VCP
ALS, FTD – p97/VCP, p62, OPTN






Hereditary spastic paraplegia – Spg4, Spartin
Charcot–Marie tooth type 2B – rab 7,
                      FIG4, and SH3TC2
ALS, MND, CMT – dynein, dynactin complex
Frontotemporal dementia –TMEM106B, GRN
Hereditary spastic paraplegia – Spg15, Spg11
LSDs (juvenile/adult forms): e.g.,
•  Niemann–Pick Type C
 •   Mucopolysaccharidosis  IIIB, IIB
 •   Gaucher’ s (GBA)          Parkinson’ s
•  Neuronal ceroid lipofuscinosis)           PD (ATPase13a2), ?FTP (GRN)
 •   Chediak–Higashi (CHS/LYST)            PD/dementia
AD – Presenilins 1, 2
Parkinson’ s Disease – ATPase 13A2, ATP6AP2
LRRK2,  α-synuclein, GBA, VPS35
ApoE ε4   (high risk)
Figure 9.2 Genetic evidence strongly implicates the lysosomal network in the pathogenesis















Figure 10.1 Cancer development induces changes in the lysosomal function. Cancer devel-
opment and progression induces lysosomal biogenesis increasing the expression of various
lysosomal hydrolases. It alters the lysosomal membrane integrity, sensitizing them to LMP
and lysosomal leakage that can lead to LCD. Note: Refer to page 183 for full caption.
 




















Figure 10.2 Cancer induces changes in lysosomal composition. These include changes in






















































































































Figure 12.3 Model for LRO function in conventional DCs and pDCs. Left, LROs and phago-
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Figure 14.1 Correlation of physicochemical properties with autophagy screening: a scatter
plot showing the distribution of autophagy enhancers within the clog P-basic pKa physico-






































































































Figure 19.2 Biological impacts of the lysosomotropic compounds. Note: Refer to page 461
for full caption.






































































Figure 20.1 Comparison of dog (42 studies) and rat (134 studies) tissue distributions of
drug-induced phospholipidosis from investigational new drug (IND) and new drug applica-
tion (NDA) submissions to the USFDA from pharmaceutical companies [38]. Note: Refer to




















Figure 20.3 Relation between phospholipidosis, QT prolongation, protein trafficking effects,
and adverse events. Note: Refer to page 504 for full caption.
